PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
27541079-5	2016	RESULTS: Salivary concentrations of IL-17A and IL-23 were elevated significantly in patients with LP compared with controls and patients with GP.	leucylproline	98-100	interleukin 17A	Homo sapiens	36-42
27541079-9	2016	CONCLUSION: Elevated salivary IL-1beta concentrations are related to GP, whereas distinct elevation and reduction profiles of IL-17A and IL-23 are detected in saliva of patients with LP and GP.	leucylproline	183-185	interleukin 17A	Homo sapiens	126-132
27888992-3	2016	IL-17 is associated with neutrophilic inflammation, steroid resistance and severe asthma, but its importance in the association between asthma and obesity is unknown.	Steroids	52-59	interleukin 17A	Homo sapiens	0-5
27916100-7	2016	The serum 25-OH-VitD was positively correlated with serum C3, negatively correlated with serum IL-17A and 24 hour urine protein excretion, but not obviously correlated with serum IFN-alpha2, IL-6 and IL-10.	25-oh-vitd	10-20	interleukin 17A	Homo sapiens	95-101
27916100-8	2016	Conclusion The serum 25-OH-VitD decreases in Chinese patients newly diagnosed with SLE and it is negatively correlated with serum IL-17A.	25-oh-vitd	21-31	interleukin 17A	Homo sapiens	130-136
27729129-9	2016	The level of IL-17 mRNA was significantly higher in patients who did than did not undergo T&A (p < 0.05).	t&amp	90-95	interleukin 17A	Homo sapiens	13-18
27909978-5	2016	Further experiments showed the increased IL-17 was probably secreted by peritoneal macrophages when exposed to dextran sulfate sodium (DSS).	Dextran Sulfate	111-133	interleukin 17A	Homo sapiens	41-46
27909978-5	2016	Further experiments showed the increased IL-17 was probably secreted by peritoneal macrophages when exposed to dextran sulfate sodium (DSS).	Dextran Sulfate	135-138	interleukin 17A	Homo sapiens	41-46
27904655-1	2016	BACKGROUND: Up-regulated cyclic adenosine 5"-monophosphate response element modulator alpha (CREMalpha) which can inhibit IL-2 and induce IL-17A in T cells plays a critical role in the pathogenesis of systemic lupus erythematosus (SLE).	cyclic adenosine 5"-monophosphate	25-58	interleukin 17A	Homo sapiens	138-144
27820818-0	2016	Increased Serum Levels of IL-17A and IL-23 Are Associated with Decreased Vitamin D3 and Increased Pain in Osteoarthritis.	Cholecalciferol	73-83	interleukin 17A	Homo sapiens	26-32
27820818-5	2016	A significant positive correlation was found between the serum levels of IL-17A and IL-23 using WOMAC pain scores and vitamin D3 serum levels.	Cholecalciferol	118-128	interleukin 17A	Homo sapiens	73-79
27694494-6	2016	AEA-treated keratinocytes showed reduced an induction of IFN-gamma-producing TH1 and IL-17-producing TH17 cells, and these effects were reverted by pharmacological inhibition of CB1 Further analyses identified mammalian target of rapamycin as a proinflammatory signaling pathway regulated by CB1, able to promote either IL-12 and IL-23 release from keratinocytes or TH1 and TH17 polarization.	anandamide	0-3	interleukin 17A	Homo sapiens	85-90
27146815-9	2016	IL-17A had positive correlations with LDL cholesterol and IL-33 and negative correlations with ADAMTS1, ADAMTS5, and ADAMTS9.	Cholesterol	42-53	interleukin 17A	Homo sapiens	0-6
27717877-7	2016	Treatment with 1,25(OH)2D3 resulted in significant up-regulation of IL-4, IL-10, arginase activity, and p-STAT6 and, conversely, down-regulation of IFN-gamma, IL-17 and NO production levels, as well as p-STAT4.	,25(oh)2d3	16-26	interleukin 17A	Homo sapiens	159-164
27552197-2	2016	We aimed to compare expression of IL-17 in bronchial airways between atopic and nonatopic asthmatics, with/without inhaled corticosteroid (ICS) use and to identify its major cellular source.	Iron-Sulfur-Molybdenum Cluster With Interstitial Carbon	139-142	interleukin 17A	Homo sapiens	34-39
27746637-1	2016	BACKGROUND: Interleukin-17A (IL-17A) is mainly secreted from Th17 cells that are activated by various stimuli including CpG oligodeoxynucleotide, a Toll-like receptor 9 (TLR9) ligand.	Oligodeoxyribonucleotides	124-144	interleukin 17A	Homo sapiens	12-27
27746637-1	2016	BACKGROUND: Interleukin-17A (IL-17A) is mainly secreted from Th17 cells that are activated by various stimuli including CpG oligodeoxynucleotide, a Toll-like receptor 9 (TLR9) ligand.	Oligodeoxyribonucleotides	124-144	interleukin 17A	Homo sapiens	29-35
27328392-0	2016	Role of podoplanin in the high interleukin-17A secretion resulting from interactions between activated lymphocytes and psoriatic skin-derived mesenchymal cells.	podoplanin	8-18	interleukin 17A	Homo sapiens	31-46
27328392-15	2016	Podoplanin contributes largely to this massive IL-17 secretion.	podoplanin	0-10	interleukin 17A	Homo sapiens	47-52
27614264-8	2016	In addition, 1,25(OH)2D3 also suppressed pro-inflammatory cytokines (INF-gamma and IL-17A) but promoted anti-inflammatory cytokine (IL-10) secretion in ITP patients.	Calcitriol	13-24	interleukin 17A	Homo sapiens	83-89
27264458-0	2016	A combination of dexamethasone and anti-IL-17A treatment can alleviate diesel exhaust particle-induced steroid insensitive asthma.	Steroids	103-110	interleukin 17A	Homo sapiens	40-46
28167485-8	2016	Th17 cells, CD4+ CD25+ Foxp3+ cells and their secretory proteins IL-17, TGF-beta and transcription factors were significantly increased in AL patients.	Aluminum	139-141	interleukin 17A	Homo sapiens	65-70
27725127-0	2016	Vitamin D modulates different IL-17-secreting T cell subsets in multiple sclerosis patients.	Vitamin D	0-9	interleukin 17A	Homo sapiens	30-35
26553320-10	2016	Compared with the monoculture, MMP-1, MMP-3, interleukin (IL)-1beta, IL-6, IL-17, and IL-21 in supernatant of cocultures were markedly elevated after treatment with nicotine.	Nicotine	165-173	interleukin 17A	Homo sapiens	75-80
27207443-6	2016	Additionally, the serum and saliva levels of IL-6, IL-17A, and NO were higher in the pSS patients, compared with the NCs.	pss	85-88	interleukin 17A	Homo sapiens	51-57
27257938-6	2016	Global HI increased the number of myeloperoxidase positive cells in the mucosa, upregulated mRNA levels of interleukin (IL)-1beta and IL-17 in gut tissue and caused T-cell invasion in the intestinal muscle layer.	hi	7-9	interleukin 17A	Homo sapiens	134-139
27575486-10	2016	Additionally, 15d-PGJ2-SLN increased IL-10 levels and reduced IL-1beta as well as IL-17 in peritoneal fluid.	15d-pgj2-sln	14-26	interleukin 17A	Homo sapiens	82-87
27552197-4	2016	IL-17 expression was correlated with atopy and inflammatory cell counts (EPX, NP57, CD3, CD4, CD8, CD20, CD68), taking ICS use and smoking into account.	Iron-Sulfur-Molybdenum Cluster With Interstitial Carbon	119-122	interleukin 17A	Homo sapiens	0-5
27746865-12	2016	The frequency of IL-17 producing CD4+ T cells in patients with active TB was lower than LTB subjects (P<0.05).	Terbium	70-72	interleukin 17A	Homo sapiens	17-22
27746865-13	2016	CONCLUSION: The results of the present study might suggest that IL-17 and IL-23 play critical roles in the immune response against TB.	Terbium	131-133	interleukin 17A	Homo sapiens	64-69
27002656-0	2016	Sphingosine kinase 1/sphingosine-1-phosphate regulates the expression of interleukin-17A in activated microglia in cerebral ischemia/reperfusion.	sphingosine 1-phosphate	21-44	interleukin 17A	Homo sapiens	73-88
27411590-3	2016	URI-induced DNA damage in hepatocytes triggers inflammation via T helper 17 (Th17) lymphocytes and interleukin 17A (IL-17A).	uri	0-3	interleukin 17A	Homo sapiens	99-114
27411590-3	2016	URI-induced DNA damage in hepatocytes triggers inflammation via T helper 17 (Th17) lymphocytes and interleukin 17A (IL-17A).	uri	0-3	interleukin 17A	Homo sapiens	116-122
27224264-10	2016	Finally, we observed that the deubiquitinase inhibitor vialinin A could down-regulate retinoic acid receptor-related orphan receptor-gammat expression and decrease IL-17A level in TAO patients.	vialinin A	55-65	interleukin 17A	Homo sapiens	164-170
26749555-1	2016	BACKGROUND & AIMS: The pro-inflammatory cytokine IL-17 plays a crucial role in liver diseases associated with hepatic fibrosis and increased risk of cancer development.	Adenosine Monophosphate	12-15	interleukin 17A	Homo sapiens	53-58
27448598-10	2016	RESULTS: We found that RES is capable of inducing a dose-dependent inhibition of IL-1alpha, IL-6 and TNF-alpha production in vitro and can down regulate the expression of IL-17 at both mRNA and protein levels in HTLV-1 infected cells.	Resveratrol	0-3	interleukin 17A	Homo sapiens	171-176
27468622-5	2016	Pearson correlation analysis was used to analyze the relationships between expression of IL-17 in the airway and lung parenchyma and forced expiratory volume in 1 second/predicted value (FEV1%pred), carbon monoxide diffusion amount accounting for the percentage of the expected value (DLCO%pred), COPD assessment test (CAT) score, body mass index (BMI).	Carbon Monoxide	199-214	interleukin 17A	Homo sapiens	89-94
27129092-9	2016	BP exposure increases Langerhans cell migration, and increases IL-5, IL-13, and IL-17 levels when lymph node cells were re-challenged with Ova.	Benzopyrenes	0-2	interleukin 17A	Homo sapiens	80-85
27034404-1	2016	IL-6 and IL-23 (IL-6/23) induce IL-17A (IL-17) production by a subpopulation of murine and human neutrophils, resulting in autocrine IL-17 activation, enhanced production of reactive oxygen species, and increased fungal killing.	Reactive Oxygen Species	174-197	interleukin 17A	Homo sapiens	40-45
27034404-7	2016	Taken together, these observations indicate that the regulation of activity of IL-17-producing neutrophils by JAK/STAT inhibitors impairs reactive oxygen species production and fungal killing activity but also blocks elastase and gelatinase activity that can cause tissue damage.	Reactive Oxygen Species	138-161	interleukin 17A	Homo sapiens	79-84
27747518-5	2016	OBJECTIVES: The interleukin (IL)-17 pathway has recently been attributed a critical role in the pathogenesis of spondyloarthritides.	spondyloarthritides	112-131	interleukin 17A	Homo sapiens	16-35
27512288-1	2016	[Purpose] The effects of vitamin D on the circulating levels of IL-17 and IL-13 were investigated in patients with diabetic peripheral neuropathy, patients with diabetes mellitus type 2 without neuropathy, and healthy controls.	Vitamin D	25-34	interleukin 17A	Homo sapiens	64-69
27512288-10	2016	[Conclusion] Vitamin D is a potential modifiable risk factor for diabetic peripheral neuropathy and may regulate inflammatory mediators, e.g., IL-17 and IL-13.	Vitamin D	13-22	interleukin 17A	Homo sapiens	143-148
27450011-8	2016	From the calculation of diagnostic performance for differentiating active TB patients from QFT-positive patients, among the measured values, the value of IL-17 TB Ag tube with the cut-off value set to <=0.82 (AUC 0.742) showed sensitivity, specificity, positive predictive value, and negative predictive value of 69.2%, 97.5%, 96.4%, and 76.5%, respectively.	Terbium	74-76	interleukin 17A	Homo sapiens	154-159
27450011-9	2016	DISCUSSION: Among TB suspects, IL-17 TB Ag response had the highest ability to distinguish active TB followed by IP-10 TBAg-Nil response and the IL-17/IFN-gamma-TB Ag response combination improved the detection response.	Terbium	18-20	interleukin 17A	Homo sapiens	31-36
27450011-9	2016	DISCUSSION: Among TB suspects, IL-17 TB Ag response had the highest ability to distinguish active TB followed by IP-10 TBAg-Nil response and the IL-17/IFN-gamma-TB Ag response combination improved the detection response.	Terbium	37-39	interleukin 17A	Homo sapiens	31-36
27450011-9	2016	DISCUSSION: Among TB suspects, IL-17 TB Ag response had the highest ability to distinguish active TB followed by IP-10 TBAg-Nil response and the IL-17/IFN-gamma-TB Ag response combination improved the detection response.	Terbium	37-39	interleukin 17A	Homo sapiens	31-36
27450011-10	2016	Differentiating active TB is best done using IL-17 as a biomarker, with IP-10 and IL-10 being potential useful.	Terbium	23-25	interleukin 17A	Homo sapiens	45-50
27020669-0	2016	Potassium supplementation inhibits IL-17A production induced by salt loading in human T lymphocytes via p38/MAPK-SGK1 pathway.	Potassium	0-9	interleukin 17A	Homo sapiens	35-41
27020669-0	2016	Potassium supplementation inhibits IL-17A production induced by salt loading in human T lymphocytes via p38/MAPK-SGK1 pathway.	Salts	64-68	interleukin 17A	Homo sapiens	35-41
27020669-3	2016	Thus, we explored the effects and underlying molecular mechanism of high salt and potassium supplementation on IL-17A production in T lymphocytes.	Salts	73-77	interleukin 17A	Homo sapiens	111-117
27020669-3	2016	Thus, we explored the effects and underlying molecular mechanism of high salt and potassium supplementation on IL-17A production in T lymphocytes.	Potassium	82-91	interleukin 17A	Homo sapiens	111-117
27020669-6	2016	In the participants, IL-17A levels in plasma and in peripheral blood mononuclear cells (PBMC) were significantly increased after a high-salt diet, which was dramatically reversed when potassium was supplemented.	Salts	136-140	interleukin 17A	Homo sapiens	21-27
27020669-6	2016	In the participants, IL-17A levels in plasma and in peripheral blood mononuclear cells (PBMC) were significantly increased after a high-salt diet, which was dramatically reversed when potassium was supplemented.	Potassium	184-193	interleukin 17A	Homo sapiens	21-27
27020669-7	2016	In Jurkat cells, the addition of 40 mM NaCl markedly enhanced IL-17A production and the expression of phosphorylated p38/mitogen-activated protein kinase (MAPK) and its downstream target, serum/glucocorticoid-regulated kinase (SGK)1, whereas combined treatment with additional 2 mM KCl significantly decreased them.	Sodium Chloride	39-43	interleukin 17A	Homo sapiens	62-68
27020669-8	2016	Respective inhibition of p38/MAPK and SGK1 suppressed IL-17A expression induced by NaCl, and KCl inhibited IL-17A production induced by specific activator of p38/MAPK.	Sodium Chloride	83-87	interleukin 17A	Homo sapiens	54-60
27020669-8	2016	Respective inhibition of p38/MAPK and SGK1 suppressed IL-17A expression induced by NaCl, and KCl inhibited IL-17A production induced by specific activator of p38/MAPK.	Potassium Chloride	93-96	interleukin 17A	Homo sapiens	107-113
27020669-9	2016	We conclude potassium supplementation has a blocking effect on IL-17A production in T lymphocytes induced by salt loading.	Potassium	12-21	interleukin 17A	Homo sapiens	63-69
27020669-9	2016	We conclude potassium supplementation has a blocking effect on IL-17A production in T lymphocytes induced by salt loading.	Salts	109-113	interleukin 17A	Homo sapiens	63-69
27350635-7	2016	RESULTS: The mean absorbance of 10 out of the 12 studied cytokines showed reduction after the therapy with rapamycin including IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IFN-gamma and TNF-alpha.	Sirolimus	107-116	interleukin 17A	Homo sapiens	172-177
26980802-7	2016	Experiments with naive CD4(+) T cells, activated in the presence of Th1/Th17 conditions and absence of DCs, indicated that retinoic acid inhibited IFN-gamma and IL-17 expression on T cells.	Tretinoin	123-136	interleukin 17A	Homo sapiens	161-166
27450011-7	2016	RESULTS: In comparing the differences significant differences in TB Ag tube response of IL-17 and IP-10, and "TB Ag - Nil" response of IL-10 and IP-10 were evident between the active TB and non-active TB groups.	Terbium	65-67	interleukin 17A	Homo sapiens	88-93
27246981-6	2016	In addition, VEGF binding pathway, a druggable target by tyrosine kinase inhibitors such as sorafenib, was mutated at a higher frequency among Asians (13% vs. 2%); while the negative regulation of IL17 production, involved in inflammation and autoimmunity, was mutated only in EAs (12% vs. 0).	Sorafenib	92-101	interleukin 17A	Homo sapiens	197-201
27338729-0	2016	Interaction among activated lymphocytes and mesenchymal cells through podoplanin is critical for a high IL-17 secretion.	podoplanin	70-80	interleukin 17A	Homo sapiens	104-109
26814615-6	2016	Our results support further the therapeutic role in pSS of RTX that, despite its B cell specificity, appears able to also hamper IL-17-producing T cells in this disease.	pss	52-55	interleukin 17A	Homo sapiens	129-134
26780754-8	2016	Additionally, PEMF treatment significantly diminished IL-1alpha-induced gene expression of IL-17A (33%, p=.01) and MMP2 (24%, p=.006) in NP cells and NFkappaB (11%, p=.04) in AF cells.	pemf	14-18	interleukin 17A	Homo sapiens	91-97
27012776-7	2016	However, Tregs cocultured with M(IL-4 + butyrate) produced less IL-17A than Tregs cocultured with M(IL-4).	Butyrates	40-48	interleukin 17A	Homo sapiens	64-70
27012776-8	2016	These data illustrate the importance of butyrate, a microbial-derived metabolite, in the regulation of gut immunity: the demonstration that butyrate promotes phagocytosis in M(IL-4)s that can limit T-cell production of IL-17A reveals novel aspects of bacterial-host interaction in the regulation of intestinal homeostasis.	Butyrates	140-148	interleukin 17A	Homo sapiens	219-225
26701127-5	2016	In the colon of mice with dextran sulphate sodium-induced colitis and in patients with CD, only IL-36alpha, gamma and IL-38 were induced at relatively low levels and correlated with IL-1beta and IL-17A.	dextran sulphate sodium	26-49	interleukin 17A	Homo sapiens	195-201
27176825-0	2016	Increased Th17 cells and IL-17A exist in patients with B cell acute lymphoblastic leukemia and promote proliferation and resistance to daunorubicin through activation of Akt signaling.	Daunorubicin	135-147	interleukin 17A	Homo sapiens	25-31
27176825-10	2016	Additionally, IL-17A promoted resistance to daunorubicin via activation of Akt signaling and the PI3K/Akt inhibitor LY294002 or perifosine almost completely rescued daunorubicin-induced cell death in B-ALL cells.	Daunorubicin	44-56	interleukin 17A	Homo sapiens	14-20
27176825-10	2016	Additionally, IL-17A promoted resistance to daunorubicin via activation of Akt signaling and the PI3K/Akt inhibitor LY294002 or perifosine almost completely rescued daunorubicin-induced cell death in B-ALL cells.	Daunorubicin	165-177	interleukin 17A	Homo sapiens	14-20
27176825-11	2016	CONCLUSIONS: Our findings suggest that elevated Th17 cells secrete IL-17A by which promotes the proliferation and resistance to daunorubicin in B-ALL cells through activation of Akt signaling.	Daunorubicin	128-140	interleukin 17A	Homo sapiens	67-73
27152519-9	2016	Further, patients with successful ARBE treatment featured enhanced levels of Th17-cell specific cytokine IL-22 and immunoregulatory cytokine IL-10 as well as reduced serum levels of TNF-alpha and MCP-1, but enhanced levels of IL-17A, in contrast to patients that did not reach remission after ARBE treatment.	arbe	34-38	interleukin 17A	Homo sapiens	226-232
27041081-6	2016	Both forms of vitamin D reduced the expression of pathogenic Th17 markers and their secretion of pro-inflammatory cytokines (IL-17A, IFN-gamma).	Vitamin D	14-23	interleukin 17A	Homo sapiens	125-131
27269887-12	2016	Corticosteroids such as fluticasone propionate and dexamethasone, but not salmeterol, partially suppressed the IL-17A and TNF-alpha-induced IL-8 production.	Fluticasone	24-46	interleukin 17A	Homo sapiens	111-117
27269887-12	2016	Corticosteroids such as fluticasone propionate and dexamethasone, but not salmeterol, partially suppressed the IL-17A and TNF-alpha-induced IL-8 production.	Dexamethasone	51-64	interleukin 17A	Homo sapiens	111-117
26654345-3	2016	In this study, the associations between salivary 8-OHdG and IL-17 levels and clinical and microbial parameters before and after non-surgical treatment are investigated.	8-ohdg	49-55	interleukin 17A	Homo sapiens	60-65
26654345-13	2016	CONCLUSIONS: There was a strong association between salivary 8-OHdG and IL-17 levels and periodontitis.	8-ohdg	61-67	interleukin 17A	Homo sapiens	72-77
27375717-0	2016	Serum IL-17 & eotaxin levels in asthmatic patients with allergic rhinitis.	Adenosine Monophosphate	13-16	interleukin 17A	Homo sapiens	6-11
27038884-0	2016	IL-17A induces chromatin remodeling promoting IL-8 release in bronchial epithelial cells: Effect of Tiotropium.	Tiotropium Bromide	100-110	interleukin 17A	Homo sapiens	0-6
27038884-1	2016	AIMS: IL-17A plays a key role in the persistence of airway inflammation, oxidative stress, and reduction of steroid-sensitivity in COPD.	Steroids	108-115	interleukin 17A	Homo sapiens	6-12
27038884-8	2016	KEY FINDINGS: IL-8 and IL-17A levels were higher in ISS from COPD patients and HSs than from HCs.	ISS	52-55	interleukin 17A	Homo sapiens	23-29
27038884-8	2016	KEY FINDINGS: IL-8 and IL-17A levels were higher in ISS from COPD patients and HSs than from HCs.	hepatic stimulator substance	79-82	interleukin 17A	Homo sapiens	23-29
27038884-11	2016	IL-17A depletion in ISS and the IKKalpha silencing in 16HBE significantly increased the nuclear levels of HDAC2, reduced Ac-His H3 (k9), and promoted IL-8 synthesis in stimulated 16HBE.	ac-his	121-127	interleukin 17A	Homo sapiens	0-6
26928603-6	2016	TSH was negatively and FT4 was positively correlated with IL-17 (p=0.016 for TSH and p=0.004 for FT4) and IL-23 (p<0.001 for TSH and p=0.003 for FT4) levels.	Thyrotropin	0-3	interleukin 17A	Homo sapiens	58-63
26951799-4	2016	We demonstrate that ATP acting via the P2X7 receptor pathway promotes a Th17 polarizing microenvironment with high levels of IL-1beta, IL-6, and IL-17 in VAT explants from lean donors.	Adenosine Triphosphate	20-23	interleukin 17A	Homo sapiens	145-150
27073858-15	2016	Ibuprofen modulated the immune response as measured by narrowed range of observed Il-13, Il-17 and IFN-gamma gene expression in mediastinal lymph nodes.	Ibuprofen	0-9	interleukin 17A	Homo sapiens	89-94
26723502-0	2016	Sodium channel gammaENaC mediates IL-17 synergized high salt induced inflammatory stress in breast cancer cells.	Salts	56-60	interleukin 17A	Homo sapiens	34-39
26723502-3	2016	In this report, using three breast cancer-related cell lines, we determined the molecular basis of the potential synergistic inflammatory effect of sodium chloride (NaCl) with interleukin-17 (IL-17).	Sodium Chloride	148-163	interleukin 17A	Homo sapiens	176-190
26723502-3	2016	In this report, using three breast cancer-related cell lines, we determined the molecular basis of the potential synergistic inflammatory effect of sodium chloride (NaCl) with interleukin-17 (IL-17).	Sodium Chloride	148-163	interleukin 17A	Homo sapiens	192-197
26723502-4	2016	Combined treatment of high NaCl (0.15M) with sub-effective IL-17 (0.1 nM) induced enhanced growth in breast cancer cells along with activation of reactive nitrogen and oxygen (RNS/ROS) species known to promote cancer.	Sodium Chloride	27-31	interleukin 17A	Homo sapiens	59-64
26723502-4	2016	Combined treatment of high NaCl (0.15M) with sub-effective IL-17 (0.1 nM) induced enhanced growth in breast cancer cells along with activation of reactive nitrogen and oxygen (RNS/ROS) species known to promote cancer.	reactive nitrogen	146-163	interleukin 17A	Homo sapiens	59-64
26723502-4	2016	Combined treatment of high NaCl (0.15M) with sub-effective IL-17 (0.1 nM) induced enhanced growth in breast cancer cells along with activation of reactive nitrogen and oxygen (RNS/ROS) species known to promote cancer.	Oxygen	168-174	interleukin 17A	Homo sapiens	59-64
26723502-4	2016	Combined treatment of high NaCl (0.15M) with sub-effective IL-17 (0.1 nM) induced enhanced growth in breast cancer cells along with activation of reactive nitrogen and oxygen (RNS/ROS) species known to promote cancer.	Radon	176-179	interleukin 17A	Homo sapiens	59-64
26723502-4	2016	Combined treatment of high NaCl (0.15M) with sub-effective IL-17 (0.1 nM) induced enhanced growth in breast cancer cells along with activation of reactive nitrogen and oxygen (RNS/ROS) species known to promote cancer.	ros	180-183	interleukin 17A	Homo sapiens	59-64
26883061-6	2016	In activated CD4(+) T cells re-stimulated through CD3 and ICOS, IC87114 inhibited Akt and Erk activation, and the secretion of IL-2, IL-4, IL-17A, and IFN-gamma better than A66.	IC 87114	64-71	interleukin 17A	Homo sapiens	139-145
26883061-7	2016	The p110alpha/delta inhibitor ETP-46321, or p110alpha plus p110delta inhibitors also inhibited IL-21 secretion by differentiated CD4(+) T follicular (Tfh) or IL-17-producing (Th17) helper cells.	ETP-46321	30-39	interleukin 17A	Homo sapiens	158-163
26883061-8	2016	In vivo, therapeutic administration of ETP-46321 significantly inhibited responses to protein antigen as well as collagen-induced arthritis, as measured by antigen-specific antibody responses, secretion of IL-10, IL-17A or IFN-gamma, or clinical symptoms.	ETP-46321	39-48	interleukin 17A	Homo sapiens	213-219
26959879-5	2016	Flurbiprofen also significantly stimulated the postoperative IFN-f and IL-17 production, but inhibited the immunosuppressive IL-10 and TGF-beta levels.	Flurbiprofen	0-12	interleukin 17A	Homo sapiens	71-76
26928603-6	2016	TSH was negatively and FT4 was positively correlated with IL-17 (p=0.016 for TSH and p=0.004 for FT4) and IL-23 (p<0.001 for TSH and p=0.003 for FT4) levels.	Thyrotropin	77-80	interleukin 17A	Homo sapiens	58-63
26566627-6	2016	We showed an inhibition of angiogenesis and tumor progression when JSI-124 was treated with IL-17A in the cells and xenografts in an animal model and suggested that targeting the Stat pathway with JSI-124 could derive an effective therapeutic target for gastric cancers and could be a promising drug in gastric cancer treatment.	jsi	67-70	interleukin 17A	Homo sapiens	92-98
26943962-0	2016	Immunomodulation by vitamin D in multiple sclerosis: More than IL-17.	Vitamin D	20-29	interleukin 17A	Homo sapiens	63-68
27151015-7	2016	RESULTS: The serum levels of IL-17, IL-6 and TGF-beta between two groups before treatment were not significantly different (P > 0.05), but after treatment, thier levels in two groups decreased, moreover the levels of the observation group was significantly lower than that in control group (P < 0.05).	thier	159-164	interleukin 17A	Homo sapiens	29-34
26999594-3	2016	Recently, it was shown that the IL-23/ IL-17 axis plays a deciding role in the pathogenesis of human psoriasis, as well as in the mouse model of IMQ-induced psoriasis-like skin disease.	Imiquimod	145-148	interleukin 17A	Homo sapiens	39-44
26606373-3	2016	We have shown that the enzyme cyclooxygenase-2 (COX-2) and its prostanoid products, prostaglandin E2 (PGE2 ) in particular, are key contributors in in vitro models of infectious exacerbation; however, the impact of IL-17A was not known.	Dinoprostone	102-106	interleukin 17A	Homo sapiens	215-221
26988982-6	2016	RESULTS: Our results showed that IL-17A increased COX2 expression and PGE2 production via the activation of MAPKs, including p38 kinase and Jun N-terminal kinase (JNK).	Dinoprostone	70-74	interleukin 17A	Homo sapiens	33-39
26988982-7	2016	Moreover, IL-17A-induced COX2 and PGE2 production was shown to rely on p38/c-Fos and JNK/c-Jun activation in an AP-1-dependent manner.	Dinoprostone	34-38	interleukin 17A	Homo sapiens	10-16
26988982-8	2016	CONCLUSION: In summary, our results indicate that IL-17A enhances COX2 expression and PGE2 production via the p38/c-Fos and JNK/c-Jun signalling pathways in NP cells to mediate IVD inflammation.	Dinoprostone	86-90	interleukin 17A	Homo sapiens	50-56
26854023-0	2016	A Binding Site on IL-17A for Inhibitory Macrocycles Revealed by Hydrogen/Deuterium Exchange Mass Spectrometry.	Hydrogen	64-72	interleukin 17A	Homo sapiens	18-24
26854023-0	2016	A Binding Site on IL-17A for Inhibitory Macrocycles Revealed by Hydrogen/Deuterium Exchange Mass Spectrometry.	Deuterium	73-82	interleukin 17A	Homo sapiens	18-24
26606373-0	2016	IL-17A increases TNF-alpha-induced COX-2 protein stability and augments PGE2 secretion from airway smooth muscle cells: impact on beta2 -adrenergic receptor desensitization.	Dinoprostone	72-76	interleukin 17A	Homo sapiens	0-6
26606373-3	2016	We have shown that the enzyme cyclooxygenase-2 (COX-2) and its prostanoid products, prostaglandin E2 (PGE2 ) in particular, are key contributors in in vitro models of infectious exacerbation; however, the impact of IL-17A was not known.	Prostaglandins	63-73	interleukin 17A	Homo sapiens	215-221
26606373-3	2016	We have shown that the enzyme cyclooxygenase-2 (COX-2) and its prostanoid products, prostaglandin E2 (PGE2 ) in particular, are key contributors in in vitro models of infectious exacerbation; however, the impact of IL-17A was not known.	Dinoprostone	84-100	interleukin 17A	Homo sapiens	215-221
26606373-4	2016	METHODS AND RESULTS: We address this herein and show that IL-17A induces a robust and sustained upregulation of COX-2 protein and PGE2 secretion from airway smooth muscle (ASM) cells.	Dinoprostone	130-134	interleukin 17A	Homo sapiens	58-64
26405064-0	2016	Effects of Fluticasone Furoate on Clinical and Immunological Outcomes (IL-17) for Patients With Nasal Polyposis Naive to Steroid Treatment.	fluticasone furoate	11-30	interleukin 17A	Homo sapiens	71-76
26606373-7	2016	Instead, TNF-alpha-induced COX-2 upregulation is subject to regulation by the proteasome, and IL-17A acts to increase TNF-alpha-induced COX-2 protein stability as confirmed by cycloheximide chase experiments.	Cycloheximide	176-189	interleukin 17A	Homo sapiens	94-100
26405064-0	2016	Effects of Fluticasone Furoate on Clinical and Immunological Outcomes (IL-17) for Patients With Nasal Polyposis Naive to Steroid Treatment.	Steroids	121-128	interleukin 17A	Homo sapiens	71-76
26405064-8	2016	The IL-17A/F expression was higher in nonallergics with high neutrophil counts and was inclined by steroids.	Steroids	99-107	interleukin 17A	Homo sapiens	4-10
26606373-8	2016	In this way, IL-17A acts to amplify the COX-2-mediated effects of TNF-alpha and greatly enhances PGE2 secretion from ASM cells.	Dinoprostone	97-101	interleukin 17A	Homo sapiens	13-19
26606373-9	2016	CONCLUSION: As PGE2 is a multifunctional prostanoid with diverse roles in respiratory disease, our studies demonstrate a novel function for IL-17A in airway inflammation by showing for the first time that IL-17A impacts on the COX-2/PGE2 pathway, molecules known to contribute to disease exacerbation.	Dinoprostone	15-19	interleukin 17A	Homo sapiens	140-146
26606373-9	2016	CONCLUSION: As PGE2 is a multifunctional prostanoid with diverse roles in respiratory disease, our studies demonstrate a novel function for IL-17A in airway inflammation by showing for the first time that IL-17A impacts on the COX-2/PGE2 pathway, molecules known to contribute to disease exacerbation.	Dinoprostone	15-19	interleukin 17A	Homo sapiens	205-211
26606373-9	2016	CONCLUSION: As PGE2 is a multifunctional prostanoid with diverse roles in respiratory disease, our studies demonstrate a novel function for IL-17A in airway inflammation by showing for the first time that IL-17A impacts on the COX-2/PGE2 pathway, molecules known to contribute to disease exacerbation.	Prostaglandins	41-51	interleukin 17A	Homo sapiens	140-146
26606373-9	2016	CONCLUSION: As PGE2 is a multifunctional prostanoid with diverse roles in respiratory disease, our studies demonstrate a novel function for IL-17A in airway inflammation by showing for the first time that IL-17A impacts on the COX-2/PGE2 pathway, molecules known to contribute to disease exacerbation.	Prostaglandins	41-51	interleukin 17A	Homo sapiens	205-211
26606373-9	2016	CONCLUSION: As PGE2 is a multifunctional prostanoid with diverse roles in respiratory disease, our studies demonstrate a novel function for IL-17A in airway inflammation by showing for the first time that IL-17A impacts on the COX-2/PGE2 pathway, molecules known to contribute to disease exacerbation.	Dinoprostone	233-237	interleukin 17A	Homo sapiens	140-146
26606373-9	2016	CONCLUSION: As PGE2 is a multifunctional prostanoid with diverse roles in respiratory disease, our studies demonstrate a novel function for IL-17A in airway inflammation by showing for the first time that IL-17A impacts on the COX-2/PGE2 pathway, molecules known to contribute to disease exacerbation.	Dinoprostone	233-237	interleukin 17A	Homo sapiens	205-211
26751989-9	2016	IL-17 was present in the ADDE, LDDE, and combined groups.	ldde	31-35	interleukin 17A	Homo sapiens	0-5
27021094-1	2016	We studied the ability of melatonin in physiological and pharmacological concentrations to induce and/or regulate differentiation of T cells producing IL-17 (Th17).	Melatonin	26-35	interleukin 17A	Homo sapiens	151-156
27021094-3	2016	Melatonin induced the synthesis of IL-17A by intact T cells, but had little effect on activated cells.	Melatonin	0-9	interleukin 17A	Homo sapiens	35-41
26637231-15	2016	The baseline serum IL-17 levels were significantly higher in patients with PA than in the control group (p = 0.001).	Protactinium	75-77	interleukin 17A	Homo sapiens	19-24
27026043-9	2016	Levels of IL-17, TNF-alpha and lymphocyte proliferation in the atorvastatin treatment group were significantly lower than the control group.	Atorvastatin	63-75	interleukin 17A	Homo sapiens	10-15
26429410-4	2016	The deduced LycIL-17A/F1 and 3 had four cysteine residues conserved in teleost IL-17A/F1 and 3 homologues and shared a domain similar to the B chain of human IL-17F.	Cysteine	40-48	interleukin 17A	Homo sapiens	15-30
26794805-8	2016	RESULTS: Compared to vehicle control or mono-treatments, the effect of calcipotriol/betamethasone combination was significantly better in inhibiting the secretion of IL-17A and TNF-alpha in psoriatic skin.	calcipotriene	71-83	interleukin 17A	Homo sapiens	166-172
26794805-8	2016	RESULTS: Compared to vehicle control or mono-treatments, the effect of calcipotriol/betamethasone combination was significantly better in inhibiting the secretion of IL-17A and TNF-alpha in psoriatic skin.	Betamethasone	84-97	interleukin 17A	Homo sapiens	166-172
26845700-8	2016	RESULTS: Exposure to IL-17 and TNF-alpha enhanced expression of the Zn-importer ZIP-8, regardless of the concentration of Zn in the culture medium.	Zinc	68-70	interleukin 17A	Homo sapiens	21-26
26845700-11	2016	CONCLUSION: IL-17/TNF-mediated inflammation enhanced the intracellular Zn uptake by synoviocytes, further increasing inflammation.	Zinc	71-73	interleukin 17A	Homo sapiens	12-17
26334689-3	2016	RESULTS: We found significant associations between Hcy levels and increased expression of IL-17 and TGF-beta among SCA patients, and a positive significant correlation between Hcy and soluble vascular cellular adhesion molecules (sVCAM).	Homocysteine	51-54	interleukin 17A	Homo sapiens	90-95
26909479-1	2016	OBJECTIVE: The objective of the present study was to investigate the effect of vitamin A supplementation on serum Th17 (IL-6, IL-17, IFNgamma) and Treg (TGF-beta, IL-10) related cytokines in obese and non-obese women.	Vitamin A	79-88	interleukin 17A	Homo sapiens	126-131
26909479-7	2016	The mean concentrations of IL-17 and TGF-beta were significantly decreased after vitamin A supplementation in non-obese and obese women respectively.	Vitamin A	81-90	interleukin 17A	Homo sapiens	27-32
26909479-9	2016	CONCLUSIONS: The results of the present study showed for the first time that vitamin A supplementation reduces serum concentrations of IL-17 and TGF-beta in reproductive age women.	Vitamin A	77-86	interleukin 17A	Homo sapiens	135-140
26600259-5	2016	SUMMARY: Steroid resistant severe asthma with predominant bronchial neutrophilic inflammation could benefit from IL-17 targeted therapies.	Steroids	9-16	interleukin 17A	Homo sapiens	113-118
26429410-5	2016	The deduced LycIL-17A/F2 possessed the unique arrangement of six cysteine residues as teleost IL-17A/F2 (except Fugu IL-17A/F2) and higher vertebrate IL-17A and F, and shared a domain similar to the D/E chain of human IL-17A.	Cysteine	65-73	interleukin 17A	Homo sapiens	15-24
26429410-5	2016	The deduced LycIL-17A/F2 possessed the unique arrangement of six cysteine residues as teleost IL-17A/F2 (except Fugu IL-17A/F2) and higher vertebrate IL-17A and F, and shared a domain similar to the D/E chain of human IL-17A.	Cysteine	65-73	interleukin 17A	Homo sapiens	15-21
26454413-12	2016	In the same way, stimulating IS CD4(+) T cells in the presence of rIL-37 inhibited IL-17 production both in asthma patients and HC.	ril-37	66-72	interleukin 17A	Homo sapiens	83-88
26558536-6	2016	Amino acids (AAs) also regulate IL-17 expression by being the energy source for Th17 cells, and by activating mTORC1 signaling.	Amino Acids	13-16	interleukin 17A	Homo sapiens	32-37
26830368-13	2016	The mechanism of IL-17A-triggered NLRP3 activation and subsequent IL-1beta secretion was found to involve the generation of reactive oxygen species.	Reactive Oxygen Species	124-147	interleukin 17A	Homo sapiens	17-23
26735612-4	2016	Furthermore, melatonin enhances splenic interleukin (IL)-10 expression in regulatory T cells by inducing IL-27 expression in the splenic DC; it also suppresses the expression of IFN-gamma, IL-17, IL-6, and CCL20 in the CNS and inhibits antigen-specific T cell proliferation.	Melatonin	13-22	interleukin 17A	Homo sapiens	189-194
26781085-9	2016	The ability of hydrocortisone to inhibit IL-17 and IL-22 production by MBP-specific CD4(+) T cells was inversely related to the number of active brain lesions.	Hydrocortisone	15-29	interleukin 17A	Homo sapiens	41-46
26742425-0	2016	IL-17A up-regulates expression of endothelial tissue factor in liver cirrhosis via the ROS/p38 signal pathway.	Reactive Oxygen Species	87-90	interleukin 17A	Homo sapiens	0-6
26742425-8	2016	Taken together, our data show that enhanced expression of endothelial TF, which plays an important role in coagulopathy and splenic vein remodeling in liver cirrhosis, is induced by IL-17A in a ROS dependent manner.	Reactive Oxygen Species	194-197	interleukin 17A	Homo sapiens	182-188
26742425-7	2016	Cirrhotic serum and IL-17A stimulated TF expression in HUVECs, which was reduced by blockade of IL-17A, p38, and reactive oxygen species (ROS).	Reactive Oxygen Species	113-136	interleukin 17A	Homo sapiens	20-26
26742425-7	2016	Cirrhotic serum and IL-17A stimulated TF expression in HUVECs, which was reduced by blockade of IL-17A, p38, and reactive oxygen species (ROS).	Reactive Oxygen Species	138-141	interleukin 17A	Homo sapiens	20-26
26789270-7	2016	Tbeta4 activation with a Tbeta4 peptide attenuated the H2O2-induced production of NO and PGE2 and up-regulated iNOS, COX-2, and osteoclastogenic cytokines (TNF-alpha, IL-1beta, IL-6, IL-8, and IL-17) as well as reversed the effect on RANKL and OPG in PDLCs.	Hydrogen Peroxide	55-59	interleukin 17A	Homo sapiens	193-198
26884302-5	2016	Of these, only the difference between IL-17A levels reached statistical significance (2.1 pg/mL vs. 1.8 pg/mL, respectively; p < 0.001).	Adenosine Monophosphate	128-131	interleukin 17A	Homo sapiens	38-44
26781963-0	2016	Transcriptome profiling unveils the role of cholesterol in IL-17A signaling in psoriasis.	Cholesterol	44-55	interleukin 17A	Homo sapiens	59-65
26781963-6	2016	Here, we demonstrate that during IL-17A signaling total cholesterol levels were elevated, which in turn resulted in the suppression of genes of cholesterol and fatty acid biosynthesis.	Cholesterol	56-67	interleukin 17A	Homo sapiens	33-39
26781963-6	2016	Here, we demonstrate that during IL-17A signaling total cholesterol levels were elevated, which in turn resulted in the suppression of genes of cholesterol and fatty acid biosynthesis.	Cholesterol	144-155	interleukin 17A	Homo sapiens	33-39
26781963-6	2016	Here, we demonstrate that during IL-17A signaling total cholesterol levels were elevated, which in turn resulted in the suppression of genes of cholesterol and fatty acid biosynthesis.	Fatty Acids	160-170	interleukin 17A	Homo sapiens	33-39
26781963-7	2016	We found that accumulation of cholesterol was essential for IL-17A signaling as reduced total cholesterol levels by methyl beta cyclodextrin (MBCD), significantly decreased IL-17A induced secretion of CCL20, IL-8 and S100A7 from the keratinocytes.	Cholesterol	30-41	interleukin 17A	Homo sapiens	60-66
26781963-7	2016	We found that accumulation of cholesterol was essential for IL-17A signaling as reduced total cholesterol levels by methyl beta cyclodextrin (MBCD), significantly decreased IL-17A induced secretion of CCL20, IL-8 and S100A7 from the keratinocytes.	Cholesterol	30-41	interleukin 17A	Homo sapiens	173-179
26781963-7	2016	We found that accumulation of cholesterol was essential for IL-17A signaling as reduced total cholesterol levels by methyl beta cyclodextrin (MBCD), significantly decreased IL-17A induced secretion of CCL20, IL-8 and S100A7 from the keratinocytes.	Cholesterol	94-105	interleukin 17A	Homo sapiens	60-66
26781963-7	2016	We found that accumulation of cholesterol was essential for IL-17A signaling as reduced total cholesterol levels by methyl beta cyclodextrin (MBCD), significantly decreased IL-17A induced secretion of CCL20, IL-8 and S100A7 from the keratinocytes.	Cholesterol	94-105	interleukin 17A	Homo sapiens	173-179
26781963-7	2016	We found that accumulation of cholesterol was essential for IL-17A signaling as reduced total cholesterol levels by methyl beta cyclodextrin (MBCD), significantly decreased IL-17A induced secretion of CCL20, IL-8 and S100A7 from the keratinocytes.	methyl-beta-cyclodextrin	116-140	interleukin 17A	Homo sapiens	60-66
26781963-7	2016	We found that accumulation of cholesterol was essential for IL-17A signaling as reduced total cholesterol levels by methyl beta cyclodextrin (MBCD), significantly decreased IL-17A induced secretion of CCL20, IL-8 and S100A7 from the keratinocytes.	methyl-beta-cyclodextrin	116-140	interleukin 17A	Homo sapiens	173-179
26781963-8	2016	To our knowledge this study for the first time unveils that high level of intracellular cholesterol plays a crucial role in IL-17A signaling in keratinocytes and may explain the strong association between psoriasis and dyslipidemia.	Cholesterol	88-99	interleukin 17A	Homo sapiens	124-130
26392196-7	2016	RESULTS: The newly developed cytokine secretion assay consists of anti-IL-22 and anti-IL-17A catch antibodies, which via biotin-streptavidin interaction are bound to the biotinylated surface of the target cell, and anti-IL-22 and IL-17A detection antibody labelled with a fluorescent dye, which detects cytokines bound to these catch antibodies.	Biotin	121-127	interleukin 17A	Homo sapiens	86-92
26392196-7	2016	RESULTS: The newly developed cytokine secretion assay consists of anti-IL-22 and anti-IL-17A catch antibodies, which via biotin-streptavidin interaction are bound to the biotinylated surface of the target cell, and anti-IL-22 and IL-17A detection antibody labelled with a fluorescent dye, which detects cytokines bound to these catch antibodies.	Biotin	121-127	interleukin 17A	Homo sapiens	230-236
26553345-0	2016	Benzoxazepines Achieve Potent Suppression of IL-17 Release in Human T-Helper 17 (TH 17) Cells through an Induced-Fit Binding Mode to the Nuclear Receptor RORgamma.	benzoxazepines	0-14	interleukin 17A	Homo sapiens	45-50
26666485-7	2016	Pretreatment with Poly(IC) dose-dependently inhibited SEB-induced IL-5, IL-13 and IL-17A, but not IFN-gamma production.	poly	18-22	interleukin 17A	Homo sapiens	82-88
27383847-9	2016	Overexpression of p65 NF-x03BA;B significantly suppressed TC-induced decrease of TNFalpha, IL-17A and IL-23 expression and keratinocyte proliferation, indicating that HO-1-mediated downregulation of NF-x03BA;B was involved in the anti-psoriatic effect of TC.	Technetium	58-60	interleukin 17A	Homo sapiens	91-97
29874433-6	2016	This paper presents a research panel of five SNP, which are hereditary factors for violations processes of innate immunity: CD14-159 C> T (rs2569190); TNFa -308 G> A (rs1800629); IL17A -197 G> A (rs2275913); TLR2 Arg753GIn G> A (rs5743708); TLR4 Asp299Gly A> G (rs4986790).	arg753gin	222-231	interleukin 17A	Homo sapiens	185-190
27777963-7	2016	High post-NAC tumour levels of FOXP3+ T cells, IL-10, and IL-17 were associated with a failed pCR.	nac	10-13	interleukin 17A	Homo sapiens	58-63
26390837-0	2016	Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases.	cova322	34-41	interleukin 17A	Homo sapiens	75-81
27774460-5	2016	Our results showed both increased frequency and activation (indicated by higher expression of ICOS, PD-1, HLA-DR, and Ki-67 and increased production of IL-21, IL-17, and IFN-gamma) of cTfh cells in psoriasis patients.	ctfh	184-188	interleukin 17A	Homo sapiens	159-164
27294162-7	2016	The placental extravillous layer of the MGH showed high levels of IL-4, IL-6, IL-10, IL-17, and IFN-gamma and low levels of IL-1beta and IL-8, whereas the placental villous layer contained high levels of IL-17 and IFN-gamma.	mgh	40-43	interleukin 17A	Homo sapiens	85-90
27294162-7	2016	The placental extravillous layer of the MGH showed high levels of IL-4, IL-6, IL-10, IL-17, and IFN-gamma and low levels of IL-1beta and IL-8, whereas the placental villous layer contained high levels of IL-17 and IFN-gamma.	mgh	40-43	interleukin 17A	Homo sapiens	204-209
26390837-4	2016	Based on the marketed anti-TNF antibody adalimumab, we generated the bispecific TNF/IL-17A-binding FynomAb COVA322.	cova322	107-114	interleukin 17A	Homo sapiens	84-90
26390837-6	2016	COVA322 was characterized in detail and showed a remarkable ability to inhibit TNF and IL-17A in vitro and in vivo.	cova322	0-7	interleukin 17A	Homo sapiens	87-93
26390837-7	2016	Through its unique mode-of-action of inhibiting simultaneously TNF and the IL-17A homodimer, COVA322 represents a promising drug candidate for the treatment of inflammatory diseases.	cova322	93-100	interleukin 17A	Homo sapiens	75-81
26903715-8	2016	In contrast, the Th17 cytokines IL-17, IL-22, and IL-26 showed a significant disruption of the epithelial barrier, evidenced by a loss of TEER, increased paracellular permeability of FITC-dextrans, and discontinuous ZO-1 immunolocalisation.	fluorescein isothiocyanate dextran	183-196	interleukin 17A	Homo sapiens	32-37
26678745-6	2015	The results revealed that acarbose at the dose of 500 mg/kg/day attenuated the incidence and severity of arthritis and the expression of proinflammatory cytokines, including TNF-alpha, IL-6 and IL-17 in the paw tissues.	Acarbose	26-34	interleukin 17A	Homo sapiens	194-199
27298519-0	2016	Autocrine Acetylcholine, Induced by IL-17A via NFkappaB and ERK1/2 Pathway Activation, Promotes MUC5AC and IL-8 Synthesis in Bronchial Epithelial Cells.	Acetylcholine	10-23	interleukin 17A	Homo sapiens	36-42
27298519-8	2016	IL-17A is involved in the IL-8 and Muc5AC production promoting, via NFkappaB and ERK1/2 pathway activation, the synthesis of ChAT, and the related activity of autocrine ACh in bronchial epithelial cells.	Acetylcholine	169-172	interleukin 17A	Homo sapiens	0-6
27098148-6	2016	Pretreatment with a nuclear factor-kappaB (NF-kappaB) inhibitor (PDTC) or PI3K/AKT inhibitor (LY294002) was proven to abolish the promoting effect of IL-17A on the invasion ability of colorectal cancer cells and upregulation of MMP-2/9.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	94-102	interleukin 17A	Homo sapiens	150-156
26729099-1	2015	Human leukocytic antigen-B27 heavy chain (HLA-B27 HC) has the tendency to fold slowly, in turn gradually forming a homodimer, (B27-HC)2 via a disulfide linkage to activate killer cells and T-helper 17 cells and inducing endoplasmic reticulum (ER) stress to trigger the IL-23/IL-17 axis for pro-inflammatory reactions.	Disulfides	142-151	interleukin 17A	Homo sapiens	275-280
27127346-1	2016	OBJECTIVE: To study the effects of low-dose and long-term treatment with erythromycin on IL-17 and IL-23, in peripheral blood and induced sputum, in patients with stable chronic obstructive pulmonary disease (COPD).	Erythromycin	73-85	interleukin 17A	Homo sapiens	89-94
26396142-6	2015	Mechanistic studies have shown that calcitriol-active form of vitamin D-influences inflammatory processes involved in cancer progression, including the enzyme cyclooxygenase 2, the NF-kappaB pathway, and the expression of the cytokines TNFalpha, IL1beta, IL6, IL8, IL17, and TGFbeta1.	Calcitriol	36-46	interleukin 17A	Homo sapiens	265-269
26667768-6	2015	Positive correlations between the frequency of CD4+CD45RO+IL-17+IFN-gamma- T-cells and serum LDL-C (P=0.007), triglyceride (P=0.02), and systolic (P=0.001) and diastolic (P=0.009) blood pressures (BP) were found.	Triglycerides	110-122	interleukin 17A	Homo sapiens	58-63
26667768-7	2015	The frequency of CD4+CD45RO+IL-17-IFN-gamma- T-cells, which was higher in controls than patients, showed negative correlations with the serum LDL-C (P=0.01) and triglyceride (P=0.02) levels and systolic (P=0.003) and diastolic (P=0.01) BPs.	Triglycerides	161-173	interleukin 17A	Homo sapiens	28-33
25919006-7	2015	Individually, IL-17A and IL-25 enhanced contractility of human bronchial smooth muscle induced by methacholine or carbachol.	Methacholine Chloride	98-110	interleukin 17A	Homo sapiens	14-20
25919006-7	2015	Individually, IL-17A and IL-25 enhanced contractility of human bronchial smooth muscle induced by methacholine or carbachol.	Carbachol	114-123	interleukin 17A	Homo sapiens	14-20
25919006-8	2015	IL-17A had more pronounced effects on methacholine-induced contractility in bronchial rings from donors with asthma compared with donors without asthma.	Methacholine Chloride	38-50	interleukin 17A	Homo sapiens	0-6
26396142-6	2015	Mechanistic studies have shown that calcitriol-active form of vitamin D-influences inflammatory processes involved in cancer progression, including the enzyme cyclooxygenase 2, the NF-kappaB pathway, and the expression of the cytokines TNFalpha, IL1beta, IL6, IL8, IL17, and TGFbeta1.	Vitamin D	62-71	interleukin 17A	Homo sapiens	265-269
26543364-14	2015	CONCLUSION: The MTX-LNC were better than the MTX solution at reducing proinflammatory cytokines and T-cell-derived cytokines such as interferon-gamma and interleukin-17A.	Methotrexate	16-19	interleukin 17A	Homo sapiens	154-169
26581714-9	2015	At 30 days, the lumbar spinal cords of glibenclamide-treated WT/EAE and Abcc8-/-/EAE mice showed significantly fewer invading immune cells, including leukocytes (CD45), T cells (CD3), B cells (CD20) and macrophages/microglia (CD11b), and fewer cells expressing pro-inflammatory cytokines (TNF-alpha, IFN-gamma, IL-17).	Glyburide	39-52	interleukin 17A	Homo sapiens	311-316
26456334-5	2015	Mechanistically, cPTH stimulates conventional T cell production of TNFalpha (TNF), which increases the differentiation of IL-17A-producing Th17 cells via TNF receptor 1 (TNFR1) signaling in CD4(+) cells.	cpth	17-21	interleukin 17A	Homo sapiens	122-128
26043025-0	2015	Simvastatin Suppresses Airway IL-17 and Upregulates IL-10 in Patients With Stable COPD.	Simvastatin	0-11	interleukin 17A	Homo sapiens	30-35
26043025-10	2015	CONCLUSIONS: Simvastatin reversed the IL-17A/IL-10 imbalance in the airways and reduced sputum macrophage but not neutrophil counts in patients with COPD.	Simvastatin	13-24	interleukin 17A	Homo sapiens	38-44
26447633-5	2015	Creatinine concentrations 12, 24, 36, 48, and 60 months after transplantation were significantly higher in recipients with the rs2275913:A>G IL17A GG genotype (GG vs. GA + AA: p = 0.03, p = 0.004, p = 0.006, p = 0.03, p = 0.04, respectively).	Creatinine	0-10	interleukin 17A	Homo sapiens	144-149
26467057-7	2015	The anti-inflammatory effect of TCE was mediated via reduction of the pro-inflammatory cytokines such as: IL-1beta, TNF-alpha, IL-6, and IL-17; the frequency of IL-17-producing T cells; and the production of chemokines such as RANTES.	Trichloroethylene	32-35	interleukin 17A	Homo sapiens	137-142
26467057-7	2015	The anti-inflammatory effect of TCE was mediated via reduction of the pro-inflammatory cytokines such as: IL-1beta, TNF-alpha, IL-6, and IL-17; the frequency of IL-17-producing T cells; and the production of chemokines such as RANTES.	Trichloroethylene	32-35	interleukin 17A	Homo sapiens	161-166
26453305-0	2015	TRAF5-mediated Lys-63-linked Polyubiquitination Plays an Essential Role in Positive Regulation of RORgammat in Promoting IL-17A Expression.	Lysine	15-18	interleukin 17A	Homo sapiens	121-127
26209886-4	2015	The PBMC treatment with PHA plus nicotine produced a significant decrease of IL-1beta e IL-17 both as transcript and as protein, confirming that the PBMC of the patients respond to the cholinergic stimulation more than PBMC of HD.	Nicotine	33-41	interleukin 17A	Homo sapiens	88-93
25652035-14	2015	Ex vivo DMP stimulation was associated with a predominant Th2 response in allergic donors, and minor reactivity of T cells producing IFNI3, IL17 and IL10.	dmp	8-11	interleukin 17A	Homo sapiens	140-144
26505478-7	2015	Comprehensive chemokine analysis showed that, compared with poly(I:C) alone, co-stimulation of BEAS-2B cells with IL-17A and poly(I:C) strongly induced production of such neutrophil chemoattractants as CXC chemokine ligand (CXCL)8, growth-related oncogene (GRO), and CXCL1.	Poly I	60-66	interleukin 17A	Homo sapiens	114-120
26505478-7	2015	Comprehensive chemokine analysis showed that, compared with poly(I:C) alone, co-stimulation of BEAS-2B cells with IL-17A and poly(I:C) strongly induced production of such neutrophil chemoattractants as CXC chemokine ligand (CXCL)8, growth-related oncogene (GRO), and CXCL1.	Carbon	0-1	interleukin 17A	Homo sapiens	114-120
26505478-7	2015	Comprehensive chemokine analysis showed that, compared with poly(I:C) alone, co-stimulation of BEAS-2B cells with IL-17A and poly(I:C) strongly induced production of such neutrophil chemoattractants as CXC chemokine ligand (CXCL)8, growth-related oncogene (GRO), and CXCL1.	Poly I-C	60-68	interleukin 17A	Homo sapiens	114-120
26505478-11	2015	IL-17A promoted stabilization of CXCL8 mRNA in BEAS-2B cells treated with poly(I:C).	poly	74-78	interleukin 17A	Homo sapiens	0-6
26461825-6	2015	IL-17A IHC staining was performed using 4 mum paraffin skin sections.	Paraffin	46-54	interleukin 17A	Homo sapiens	0-6
29879337-2	2015	The Th7 pathway corresponds to polarization of CD4 naive cells towards Thi 7 cells (produ- cing predominantly IL-17 and IL-22) under the influence of IL-23, completing the IL-23IThJ 7 axis.	2-acetyl-4(5)-tetrahydroxybutylimidazole	71-74	interleukin 17A	Homo sapiens	110-115
26242299-3	2015	OBJECTIVE: We sought to Determine the mechanism by which 17beta-estradiol (E2) and progesterone (P4) increase IL-17A production.	Estradiol	57-73	interleukin 17A	Homo sapiens	110-116
26242299-3	2015	OBJECTIVE: We sought to Determine the mechanism by which 17beta-estradiol (E2) and progesterone (P4) increase IL-17A production.	Progesterone	83-95	interleukin 17A	Homo sapiens	110-116
26489621-4	2015	In this study, we aimed to explore whether and how the important inflammatory cytokine IL-17 is associated with MPTP opening in platelets activation by using MPTP inhibitor cyclosporine-A (CsA).	Cyclosporine	173-187	interleukin 17A	Homo sapiens	87-92
26489621-4	2015	In this study, we aimed to explore whether and how the important inflammatory cytokine IL-17 is associated with MPTP opening in platelets activation by using MPTP inhibitor cyclosporine-A (CsA).	Cyclosporine	189-192	interleukin 17A	Homo sapiens	87-92
26489621-9	2015	However, CsA attenuated these effects triggered by IL-17.	Cyclosporine	9-12	interleukin 17A	Homo sapiens	51-56
26418032-6	2015	Inhibition of the TLR3, TLR/TIR-domain-containing adaptor-inducing interferon beta (TRIF), NF-kappaB, and IRF3 pathways decreased the polyI:C- and IL-17A/polyI:C-induced G-CSF and IL-8 mRNA expression.	Poly I	154-159	interleukin 17A	Homo sapiens	147-153
26524034-7	2015	The percentage of Th17 cells, the mRNA expression of RORgammat and the plasm IL-17 levels in patients with response to thalidomide were statistically lower than those in patients before treatment (P < 0.05).	Thalidomide	119-130	interleukin 17A	Homo sapiens	77-82
26283408-4	2015	In general, breast milk arachidonic acid (AA) levels were inversely correlated with the production of IL-10 (r -0.25; P=0.004), IL-17 (r -0.24; P=0.005), IL-5 (r -0.21; P=0.014) and IL-13 (r -0.17; P=0.047), whereas EPA was positively correlated with the counts of blood regulatory T-cells and cytotoxic T-cells and decreased T-helper cell counts.	Arachidonic Acid	24-40	interleukin 17A	Homo sapiens	128-133
26418032-7	2015	Comparing the levels of mRNA induction between co-treatment with IL-17A/polyI:C and treatment with polyI:C alone, blocking the of NF-kappaB pathway significantly attenuated the observed synergism.	Poly I-C	72-79	interleukin 17A	Homo sapiens	65-71
26418032-7	2015	Comparing the levels of mRNA induction between co-treatment with IL-17A/polyI:C and treatment with polyI:C alone, blocking the of NF-kappaB pathway significantly attenuated the observed synergism.	Poly I-C	99-106	interleukin 17A	Homo sapiens	65-71
26418032-8	2015	In western blotting analysis, activation of both NF-kappaB and IRF3 was observed in treatment with polyI:C and co-treatment with IL-17A/polyI:C; moreover, co-treatment with IL-17A/polyI:C augmented IkappaB-alpha phosphorylation as compared to polyI:C treatment alone.	Poly I-C	99-106	interleukin 17A	Homo sapiens	173-179
26418032-8	2015	In western blotting analysis, activation of both NF-kappaB and IRF3 was observed in treatment with polyI:C and co-treatment with IL-17A/polyI:C; moreover, co-treatment with IL-17A/polyI:C augmented IkappaB-alpha phosphorylation as compared to polyI:C treatment alone.	Poly I	99-104	interleukin 17A	Homo sapiens	173-179
26418032-8	2015	In western blotting analysis, activation of both NF-kappaB and IRF3 was observed in treatment with polyI:C and co-treatment with IL-17A/polyI:C; moreover, co-treatment with IL-17A/polyI:C augmented IkappaB-alpha phosphorylation as compared to polyI:C treatment alone.	Poly I-C	136-143	interleukin 17A	Homo sapiens	129-135
26418032-8	2015	In western blotting analysis, activation of both NF-kappaB and IRF3 was observed in treatment with polyI:C and co-treatment with IL-17A/polyI:C; moreover, co-treatment with IL-17A/polyI:C augmented IkappaB-alpha phosphorylation as compared to polyI:C treatment alone.	Poly I-C	136-143	interleukin 17A	Homo sapiens	173-179
26232645-10	2015	Administration of bilirubin reduced mean linear intercept and mean alveoli area, increased mean alveoli number, reduced macrophage, neutrophil and TNF-alpha content of BALF, and increased BALF and serum IL-10 level, but lowered local and systemic CCL2, CXCL2, CXCL8 and IL-17 levels.	Bilirubin	18-27	interleukin 17A	Homo sapiens	270-275
26418032-8	2015	In western blotting analysis, activation of both NF-kappaB and IRF3 was observed in treatment with polyI:C and co-treatment with IL-17A/polyI:C; moreover, co-treatment with IL-17A/polyI:C augmented IkappaB-alpha phosphorylation as compared to polyI:C treatment alone.	Poly I-C	136-143	interleukin 17A	Homo sapiens	129-135
26418032-8	2015	In western blotting analysis, activation of both NF-kappaB and IRF3 was observed in treatment with polyI:C and co-treatment with IL-17A/polyI:C; moreover, co-treatment with IL-17A/polyI:C augmented IkappaB-alpha phosphorylation as compared to polyI:C treatment alone.	Poly I-C	136-143	interleukin 17A	Homo sapiens	173-179
26418032-9	2015	Collectively, these findings indicate that IL-17A and TLR3 activation cooperate to induce proinflammatory responses in the airway epithelium via TLR3/TRIF-mediated NF-kappaB/IRF3 activation, and that enhanced activation of the NF-kappaB pathway plays an essential role in synergistic induction after co-treatment with IL-17A and polyI:C in vitro.	Poly I-C	329-336	interleukin 17A	Homo sapiens	43-49
26400516-4	2015	The pro-inflammatory cytokine IL-17, which is produced by T-helper 17 (Th17) cells, has been reported to be involved in the glucose metabolism and pathogenesis of diabetes via the induction of low-grade inflammation.	Glucose	124-131	interleukin 17A	Homo sapiens	30-35
26368822-6	2015	Of these, three tetraazacyclic compounds can potently inhibit RORgammat activity, and suppress Th17 differentiation and IL-17 production.	tetraazacyclic compounds	16-40	interleukin 17A	Homo sapiens	120-125
26360050-9	2015	Treatment with metformin inhibited the expression of interleukin (IL)-17, p-STAT3, and p-mTOR.	Metformin	15-24	interleukin 17A	Homo sapiens	53-72
26360050-12	2015	CONCLUSIONS: Metformin attenuates IBD severity and reduces inflammation through the inhibition of p-STAT3 and IL-17 expression.	Metformin	13-22	interleukin 17A	Homo sapiens	110-115
26386144-7	2015	In contrast, the low levels of CD4(+)IL-17(+) cells in overweight and obese T2D patients showed a positive correlation with glucose and HbA1c.	Glucose	124-131	interleukin 17A	Homo sapiens	37-42
25772594-0	2015	Distinct endotypes of steroid-resistant asthma characterized by IL-17A(high) and IFN-gamma(high) immunophenotypes: Potential benefits of calcitriol.	Steroids	22-29	interleukin 17A	Homo sapiens	64-70
26188623-0	2015	Vitamin D supplementation up-regulates IL-6 and IL-17A gene expression in multiple sclerosis patients.	Vitamin D	0-9	interleukin 17A	Homo sapiens	48-54
26188623-3	2015	The aim of this study was to investigate the vitamin D effects on the expression level of IL-6 and IL-17A in peripheral blood mononuclear cells (PBMCs) of multiple sclerosis (MS) patients.	Vitamin D	45-54	interleukin 17A	Homo sapiens	99-105
26188623-5	2015	Significant up-regulation of IL-6 and IL-17A gene expression was shown under vitamin D treatment.	Vitamin D	77-86	interleukin 17A	Homo sapiens	38-44
25772594-9	2015	Oral calcitriol, compared with placebo, therapy of the patients with SR asthma significantly improved dexamethasone-induced IL-10 production in vitro while suppressing dexamethasone-induced IL-17A production.	Calcitriol	5-15	interleukin 17A	Homo sapiens	190-196
25772594-9	2015	Oral calcitriol, compared with placebo, therapy of the patients with SR asthma significantly improved dexamethasone-induced IL-10 production in vitro while suppressing dexamethasone-induced IL-17A production.	Dexamethasone	168-181	interleukin 17A	Homo sapiens	190-196
25905982-5	2015	RESULTS: Tacrolimus significantly and SRL modestly inhibited interferon (IFN)-gamma (Th1) and IL-17 (Th17)-producing cells.	Tacrolimus	9-19	interleukin 17A	Homo sapiens	94-99
26232431-5	2015	During immunization with peptide in CFA, cholesterol-modified p40 siRNA generated p40-deficient, IL-10-producing DCs that prevented IL-17/Th17 and IFN-gamma/Th1 responses.	Cholesterol	41-52	interleukin 17A	Homo sapiens	132-137
26232431-6	2015	Only cholesterol-modified p40-siRNA established protective immunity against experimental autoimmune encephalomyelitis and suppressed IFN-gamma and IL-17 expression by CNS-infiltrating mononuclear cells without inducing regulatory T cells.	Cholesterol	5-16	interleukin 17A	Homo sapiens	147-152
26312063-8	2015	Twenty-three significantly differentially expressed cytokines were detected, among which three cytokines, interleukin (IL)-17, macrophage inflammatory protein (MIP)-1alpha, and MIP-1beta, with the largest Gini scores were identified by RF, and further evaluated for their significant changes in serum levels.	gini	205-209	interleukin 17A	Homo sapiens	106-125
26168736-3	2015	Some patients, while receiving azithromycin, (re)develop increased airway neutrophilia, which we hypothesize to result in worse outcome and to be regulated by an IL-17-independent mechanism.	Azithromycin	31-43	interleukin 17A	Homo sapiens	162-167
26198928-0	2015	Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial.	Vitamin D	20-29	interleukin 17A	Homo sapiens	40-54
26198928-4	2015	OBJECTIVE: This study assessed the effect of oral high dose vitamin D intake on IL-17 levels in MS patients in a double blind randomized clinical trial.	Vitamin D	60-69	interleukin 17A	Homo sapiens	80-85
26198928-12	2015	The multiple linear regression analysis indicated that the consumption of vitamin D3 was positively and significantly associated with the logarithm of IL-17 measures (beta=1.719; p=0.002 and R2=0.91), adjusted by EDSS scores.	Cholecalciferol	74-84	interleukin 17A	Homo sapiens	151-156
26198928-13	2015	CONCLUSION: IL-17 levels showed significant change in RRMS patients after receiving high dose vitamin D3 for 12weeks.	Cholecalciferol	94-104	interleukin 17A	Homo sapiens	12-17
25904179-10	2015	When exposed to IL-1beta, poly:IC or IL-17, patient and control primary human keratinocytes produced AMPs in similar amounts.	adenosine 5'-phosphorothioate	101-105	interleukin 17A	Homo sapiens	37-42
25890878-4	2015	Importantly, recent studies showed that several pro-atherogenic factors including cholesterol, oxidized low-density lipoprotein and fatty acids regulate the production of IL-17 and IL-17-promoting cytokines from innate and adaptive immune cells.	Cholesterol	82-93	interleukin 17A	Homo sapiens	171-176
25890878-4	2015	Importantly, recent studies showed that several pro-atherogenic factors including cholesterol, oxidized low-density lipoprotein and fatty acids regulate the production of IL-17 and IL-17-promoting cytokines from innate and adaptive immune cells.	Cholesterol	82-93	interleukin 17A	Homo sapiens	181-186
25890878-4	2015	Importantly, recent studies showed that several pro-atherogenic factors including cholesterol, oxidized low-density lipoprotein and fatty acids regulate the production of IL-17 and IL-17-promoting cytokines from innate and adaptive immune cells.	Fatty Acids	132-143	interleukin 17A	Homo sapiens	171-176
25890878-4	2015	Importantly, recent studies showed that several pro-atherogenic factors including cholesterol, oxidized low-density lipoprotein and fatty acids regulate the production of IL-17 and IL-17-promoting cytokines from innate and adaptive immune cells.	Fatty Acids	132-143	interleukin 17A	Homo sapiens	181-186
25880879-7	2015	IL-22R1 expression on PBMC of pSS was functional, as its stimulation with recombinant IL-22 significantly up-regulated the expression of STAT-3, IL-17 and IL-22.	pss	30-33	interleukin 17A	Homo sapiens	145-150
25904179-12	2015	This presumably leads to activation of keratinocytes and neutrophil influx, and further amplification of inflammation by IL-17 (from neutrophils and mast cells) and epidermal AMP production leading to chronic histamine-independent neutrophilic urticarial dermatosis.	Histamine	209-218	interleukin 17A	Homo sapiens	121-126
25648880-7	2015	Glomerular IFN-gamma and IL-17 staining grades correlated with the urinary protein/creatinine ratio (r = 0.62, p = 0.02 and r = 0.507, p = 0.016, respectively).	Creatinine	83-93	interleukin 17A	Homo sapiens	25-30
25747940-6	2015	In vitro, we also evaluated the effect of beclomethasone dipropionate (BDP) on T1/ST2, IL-31 and IL-17A expression in CD3(+)T-cells from PBMC of AAR (n=6).	Beclomethasone	71-74	interleukin 17A	Homo sapiens	97-103
25904071-9	2015	The main finding was a significant decrease in CD8(+) IL-17(+) T cells in skin-derived cells from calcipotriol-treated skin, which was further supported by the absence of CD8(+) IL-17(+) T cells in immunohistochemical staining of calcipotriol-treated skin.	calcipotriene	98-110	interleukin 17A	Homo sapiens	54-59
25904071-0	2015	The Vitamin D Analogue Calcipotriol Reduces the Frequency of CD8+ IL-17+ T Cells in Psoriasis Lesions.	Vitamin D	4-13	interleukin 17A	Homo sapiens	66-71
26181372-9	2015	In CD4+ T helper cells, sodium lactate also induces a switch towards the Th17 subset that produces large amounts of the proinflammatory cytokine IL-17, whereas in CD8+ T cells, lactic acid causes the loss of their cytolytic function.	Sodium Lactate	24-38	interleukin 17A	Homo sapiens	145-150
26154409-0	2015	IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells.	lmw-e	109-114	interleukin 17A	Homo sapiens	0-6
26154409-5	2015	Accordingly, IL-17A and IL-17E promoted resistance to Docetaxel and failed to induce apoptosis as previously reported for IL-17E.	Docetaxel	54-63	interleukin 17A	Homo sapiens	13-19
26108267-7	2015	Treatment with DMF could significantly decrease IL-17, GM-CSF, and IL-22 mRNA levels in the PBMCs of patients.	Dimethyl Fumarate	15-18	interleukin 17A	Homo sapiens	48-53
25904071-11	2015	Our findings show that the vitamin D analogue calcipotriol reduces the frequency of CD8(+) IL-17(+) T cells in psoriasis lesions concomitant with clinical improvement.	Vitamin D	27-36	interleukin 17A	Homo sapiens	91-96
25904071-0	2015	The Vitamin D Analogue Calcipotriol Reduces the Frequency of CD8+ IL-17+ T Cells in Psoriasis Lesions.	calcipotriene	23-35	interleukin 17A	Homo sapiens	66-71
25904071-2	2015	The aim of this study was to investigate the effect of calcipotriol on the frequency of CD4(+) and CD8(+) T cells and innate lymphoid cells (ILC) and their production of IL-17A, IFN-gamma and IL-22 in psoriasis lesions in patients with chronic plaque psoriasis.	calcipotriene	55-67	interleukin 17A	Homo sapiens	170-176
25904071-11	2015	Our findings show that the vitamin D analogue calcipotriol reduces the frequency of CD8(+) IL-17(+) T cells in psoriasis lesions concomitant with clinical improvement.	calcipotriene	46-58	interleukin 17A	Homo sapiens	91-96
26072707-5	2015	Hence, we propose that therapeutically targeting either TLR2 or IL17 in bronchial epithelia, in the context of morphine, can restore inflammatory homeostasis.	Morphine	111-119	interleukin 17A	Homo sapiens	64-68
26107738-3	2015	Moreover, whether vitamin D treatment of DCs regulates their ability to promote differentiation of IL-17-/IL-22-producing T cell subsets, such as Th17 and Th22 cell, is not known.	Vitamin D	18-27	interleukin 17A	Homo sapiens	99-104
26072707-0	2015	Morphine compromises bronchial epithelial TLR2/IL17R signaling crosstalk, necessary for lung IL17 homeostasis.	Morphine	0-8	interleukin 17A	Homo sapiens	47-51
26942065-0	2016	Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells.	ibrutinib	0-9	interleukin 17A	Homo sapiens	19-24
26072707-4	2015	Morphine inhibits the early IL17 release and interaction between Act1 and MyD88, leading to decreased pathogenic clearance and sustained inflammation.	Morphine	0-8	interleukin 17A	Homo sapiens	28-32
26942065-6	2016	Further, ibrutinib-treated DCs promoted T cell proliferation and enhanced IL-17 production upon co-culture with nylon wool enriched T cells.	ibrutinib	9-18	interleukin 17A	Homo sapiens	74-79
26942065-7	2016	Taken together, our results indicate that ibrutinib modulates TLR-4 mediated DC activation to promote an IL-17 response.	ibrutinib	42-51	interleukin 17A	Homo sapiens	105-110
25786687-3	2015	CT, mmCT, and dmLT strongly enhanced IL-17A and to a lesser extent IL-13 responses, but had little effect on IFN-gamma production or cell proliferation.	mmct	4-8	interleukin 17A	Homo sapiens	37-43
26039416-7	2015	IL-17A neutralization protected barrier integrity and improved survival in morphine-treated animals.	Morphine	75-83	interleukin 17A	Homo sapiens	0-6
25986991-10	2015	These results suggest that the anti-inflammatory action of Pae is attributable to its regulation of IL-17/IL-10 secretion and Treg expression.	peoniflorin	59-62	interleukin 17A	Homo sapiens	100-105
26019446-8	2015	An efficient strategy for IBD therapy is represented by the combination of IL-17A and IL-17F in acute IL-17A knockout TNBS-induced colitis, and also definite decrease of the inflammatory process in IL-17F knockout, DSS-induced colitis have been observed.	Trinitrobenzenesulfonic Acid	118-122	interleukin 17A	Homo sapiens	75-81
26019446-8	2015	An efficient strategy for IBD therapy is represented by the combination of IL-17A and IL-17F in acute IL-17A knockout TNBS-induced colitis, and also definite decrease of the inflammatory process in IL-17F knockout, DSS-induced colitis have been observed.	Trinitrobenzenesulfonic Acid	118-122	interleukin 17A	Homo sapiens	102-108
25948100-5	2015	The levels of interferon-gamma (IFN-gamma) and interleukin-17 (IL-17) secreted by T cells stimulated with PMA and ionomycin were also determined by flow cytometry.	Tetradecanoylphorbol Acetate	106-109	interleukin 17A	Homo sapiens	47-61
25948100-5	2015	The levels of interferon-gamma (IFN-gamma) and interleukin-17 (IL-17) secreted by T cells stimulated with PMA and ionomycin were also determined by flow cytometry.	Tetradecanoylphorbol Acetate	106-109	interleukin 17A	Homo sapiens	63-68
25948100-5	2015	The levels of interferon-gamma (IFN-gamma) and interleukin-17 (IL-17) secreted by T cells stimulated with PMA and ionomycin were also determined by flow cytometry.	Ionomycin	114-123	interleukin 17A	Homo sapiens	63-68
25559144-4	2015	However, TNF-alpha also decreased poly(I:C)-induced production of interleukin (IL)-12 and IL-23 by MoDCs, which correlated with their diminished capacity to stimulate cellular proliferation, interferon-gamma and IL-17 production by allogeneic CD4(+)T cells in co-culture.	Poly I-C	34-43	interleukin 17A	Homo sapiens	212-217
25933188-7	2015	In tandem with increased CD4+IL17A+ T-cells upon EAP induction, prophylactic treatment with an anti-IL17 antibody one-day prior to EAP induction prevented the onset of pelvic pain.	phosphorylethanolamine	49-52	interleukin 17A	Homo sapiens	29-34
25933188-7	2015	In tandem with increased CD4+IL17A+ T-cells upon EAP induction, prophylactic treatment with an anti-IL17 antibody one-day prior to EAP induction prevented the onset of pelvic pain.	phosphorylethanolamine	49-52	interleukin 17A	Homo sapiens	29-33
25592248-6	2015	Lastly, we observed that IFN-gamma and IL-17 production by ex vivo re-stimulated dLNs cells is greatly increased during rejection, which it turns depends on RA synthesis, as shown in experiments using a specific RALDH inhibitor.	Tretinoin	157-159	interleukin 17A	Homo sapiens	39-44
25833686-4	2015	IL-17A increased 2-12 times the amounts of phospholipids, cholesterol, triglycerides, and cholesteryl esters in DCs.	Phospholipids	43-56	interleukin 17A	Homo sapiens	0-6
25833686-4	2015	IL-17A increased 2-12 times the amounts of phospholipids, cholesterol, triglycerides, and cholesteryl esters in DCs.	Cholesterol	58-69	interleukin 17A	Homo sapiens	0-6
25833686-4	2015	IL-17A increased 2-12 times the amounts of phospholipids, cholesterol, triglycerides, and cholesteryl esters in DCs.	Triglycerides	71-84	interleukin 17A	Homo sapiens	0-6
25833686-4	2015	IL-17A increased 2-12 times the amounts of phospholipids, cholesterol, triglycerides, and cholesteryl esters in DCs.	Cholesterol Esters	90-108	interleukin 17A	Homo sapiens	0-6
25833686-8	2015	Besides this foamy phenotype, IL-17A induced a mixed macrophage-DC phenotype and expression of the nuclear receptor NR1H3/liver X receptor-alpha, previously identified in the context of atherosclerosis as the master regulator of cholesterol homeostasis in macrophages.	Cholesterol	229-240	interleukin 17A	Homo sapiens	30-36
25965695-11	2015	The RNA microarray revealed a psoriasis-like gene expression-profile in the Imiquimod treated group, and highlighted several resveratrol dependent changes in relevant genes, such as increased expression of genes associated with retinoic acid stimulation and reduced expression of genes involved in IL-17 dependent pathways.	Resveratrol	125-136	interleukin 17A	Homo sapiens	298-303
25965695-12	2015	Quantitative PCR confirmed a resveratrol dependent decrease in mRNA levels of IL-17A and IL-19; both central in developing psoriasis.	Resveratrol	29-40	interleukin 17A	Homo sapiens	78-84
25965695-13	2015	CONCLUSIONS: Resveratrol ameliorates psoriasis, and changes expression of retinoic acid stimulated genes, IL-17 signalling pathways, IL-17A and IL-19 mRNA levels in a beneficial manner, which suggests resveratrol, might have a role in the treatment of psoriasis and should be explored further in a human setting.	Resveratrol	13-24	interleukin 17A	Homo sapiens	106-111
25965695-13	2015	CONCLUSIONS: Resveratrol ameliorates psoriasis, and changes expression of retinoic acid stimulated genes, IL-17 signalling pathways, IL-17A and IL-19 mRNA levels in a beneficial manner, which suggests resveratrol, might have a role in the treatment of psoriasis and should be explored further in a human setting.	Resveratrol	13-24	interleukin 17A	Homo sapiens	133-139
25379698-8	2015	IL-17 serum levels were directly correlated (r = 0.39, p = 0.02) with disease duration while a significant inverse correlation was detected between IL-17 levels and MMT scores (r = -0.4, p = 0.02).	mmt	165-168	interleukin 17A	Homo sapiens	148-153
25786687-3	2015	CT, mmCT, and dmLT strongly enhanced IL-17A and to a lesser extent IL-13 responses, but had little effect on IFN-gamma production or cell proliferation.	dmlt	14-18	interleukin 17A	Homo sapiens	37-43
25769677-3	2015	duIL-17F is predicted to encode 166 amino acids, including a 26-amino acid signal peptide, a single N-linked glycosylation site, and six cysteine residues that are conserved in mammalian IL-17.	Cysteine	137-145	interleukin 17A	Homo sapiens	2-7
25769677-4	2015	duIL-17F shares 77.5% amino acid sequence identity with chicken IL-17F (chIL-17F), 37-46% with corresponding mammalian homologues, and 53.5% with the previously described duck IL-17A (duIL-17A).	duil	0-4	interleukin 17A	Homo sapiens	176-182
25769677-4	2015	duIL-17F shares 77.5% amino acid sequence identity with chicken IL-17F (chIL-17F), 37-46% with corresponding mammalian homologues, and 53.5% with the previously described duck IL-17A (duIL-17A).	duil	184-188	interleukin 17A	Homo sapiens	176-182
25616369-3	2015	The results of such a study revealed for the first time that NFkB induced miR-2909 RNomics is crucial for the regulation of RelA translocation within human PBMCs exposed to high glucose thereby enabling these epigenetically programmed cells to tailor immune response involving genes coding for CCL5; IFN-gamma and IL-17.	Glucose	178-185	interleukin 17A	Homo sapiens	314-319
25867469-2	2015	Ursolic acid (UA) is a pentacyclic triterpenoid with anti-inflammatory and immunomodulatory properties, especially inhibiting IL-17.	ursolic acid	0-12	interleukin 17A	Homo sapiens	126-131
25867469-2	2015	Ursolic acid (UA) is a pentacyclic triterpenoid with anti-inflammatory and immunomodulatory properties, especially inhibiting IL-17.	ursolic acid	14-16	interleukin 17A	Homo sapiens	126-131
25867469-2	2015	Ursolic acid (UA) is a pentacyclic triterpenoid with anti-inflammatory and immunomodulatory properties, especially inhibiting IL-17.	triterpenoid TP-222	35-47	interleukin 17A	Homo sapiens	126-131
25860963-0	2015	Polycyclic aromatic hydrocarbons reciprocally regulate IL-22 and IL-17 cytokines in peripheral blood mononuclear cells from both healthy and asthmatic subjects.	Polycyclic Aromatic Hydrocarbons	0-32	interleukin 17A	Homo sapiens	65-70
25860963-5	2015	We hypothesized that PAH might affect, through their effects on AhR, IL-17 and IL-22 production in allergic asthmatics.	Polycyclic Aromatic Hydrocarbons	21-24	interleukin 17A	Homo sapiens	69-74
25860963-8	2015	Diesel exhaust particle (DEP)-PAH and Benzo[a]Pyrene (B[a]P) stimulation further increased IL-22 but decreased IL-17A production in both groups.	Polycyclic Aromatic Hydrocarbons	30-33	interleukin 17A	Homo sapiens	111-117
25860963-8	2015	Diesel exhaust particle (DEP)-PAH and Benzo[a]Pyrene (B[a]P) stimulation further increased IL-22 but decreased IL-17A production in both groups.	Benzo(a)pyrene	38-52	interleukin 17A	Homo sapiens	111-117
25860963-10	2015	Among PBMCs, PAH-induced IL-22 expression originated principally from single IL-22- but not from IL-17- expressing CD4 T cells.	Polycyclic Aromatic Hydrocarbons	13-16	interleukin 17A	Homo sapiens	97-102
25853810-0	2015	Nitric oxide sustains IL-1beta expression in human dendritic cells enhancing their capacity to induce IL-17-producing T-cells.	Nitric Oxide	0-12	interleukin 17A	Homo sapiens	102-107
25708600-6	2015	RESULTS: Niclosamide reduced the secretion of IL-1beta, IL-6, IL-8, IL-17A and IFN-gamma from TNF-alpha-induced RA FLS in a dose-dependent manner.	Niclosamide	9-20	interleukin 17A	Homo sapiens	68-74
25354724-9	2015	Dexamethasone and cyclosporin A significantly reduced IL-17 and IFN-gamma production in PBMCs and dexamethasone up-regulated IL-10 production in activated PBMCs from healthy subjects.	Dexamethasone	0-13	interleukin 17A	Homo sapiens	54-59
25605871-7	2015	In addition, IL-17 restoration attenuated S. aureus-induced dermatopathology and improved bacterial clearance defects in EtOH-fed mice.	Ethanol	121-125	interleukin 17A	Homo sapiens	13-18
25605871-8	2015	Taken together, the findings show, in a novel model system, that the EtOH-induced increase in S. aureus-related injury/illness corresponds with defects in the IL-23/IL-17 inflammatory axis and poor PMN accumulation at the site of infection and draining LNs.	Ethanol	69-73	interleukin 17A	Homo sapiens	165-170
25434365-10	2015	Administration of multi-dose parecoxib may diminish the increase in postoperative IL-2, IFN-gamma and IL-17 levels, and suppress the excessive production of IL-4, IL-10 and TGF-beta.	parecoxib	29-38	interleukin 17A	Homo sapiens	102-107
25203937-6	2015	IL-6, IFNgamma, and IL-17A levels were significantly reduced after methylprednisolone treatment (p = 0.02, 0.03, and 0.03, respectively) in Severe Persistent Asthma (SPA) and in Moderate Persistent Asthma (MPA), (p = 0.007, 0.01, and 0.007, respectively).	Methylprednisolone	67-85	interleukin 17A	Homo sapiens	20-26
25203937-8	2015	CONCLUSION: Methylprednisolone downregulated IL-6, IL17A, and IFNgamma, but not IL-22, in stimulated PBMCs from asthmatic children indicating that methylprednisolone has no effect on IL-22 production by PBMCs.	Methylprednisolone	12-30	interleukin 17A	Homo sapiens	51-56
25583575-4	2015	In an activation assay of the Il17a promoter using Jurkat cells, these compounds enhanced the RORalpha- or RORgamma-mediated activation of the Il17a promoter at concentrations of 1 x 10(-6)M to 1 x 10(-5)M. In mammalian two-hybrid assays, the four isoflavones enhanced the interaction between the RORalpha- or RORgamma-ligand binding domain and the co-activator LXXLL peptide in a dose-dependent manner.	Isoflavones	248-259	interleukin 17A	Homo sapiens	30-35
25583575-4	2015	In an activation assay of the Il17a promoter using Jurkat cells, these compounds enhanced the RORalpha- or RORgamma-mediated activation of the Il17a promoter at concentrations of 1 x 10(-6)M to 1 x 10(-5)M. In mammalian two-hybrid assays, the four isoflavones enhanced the interaction between the RORalpha- or RORgamma-ligand binding domain and the co-activator LXXLL peptide in a dose-dependent manner.	Isoflavones	248-259	interleukin 17A	Homo sapiens	143-148
25354724-9	2015	Dexamethasone and cyclosporin A significantly reduced IL-17 and IFN-gamma production in PBMCs and dexamethasone up-regulated IL-10 production in activated PBMCs from healthy subjects.	Cyclosporine	18-31	interleukin 17A	Homo sapiens	54-59
25384921-14	2015	In addition, we also determined that BMI was negatively correlated with BMD; IL-17A was positively correlated with serum calcium.	Calcium	121-128	interleukin 17A	Homo sapiens	77-83
26045845-1	2015	UNLABELLED: We conduct a case-control study to explore the possible association between IL-17 gene polymorphisms and development of TB.	Terbium	132-134	interleukin 17A	Homo sapiens	88-93
25614225-8	2015	Citrulline levels below the median at day +7 were associated with higher spontaneous production of IL-6 and TNF-alpha as well as higher in vitro stimulated production of IL-17A at day +21.	Citrulline	0-10	interleukin 17A	Homo sapiens	170-176
25542095-7	2015	While TGF-beta and IL-17 showed a positive and negative correlation, respectively, with fasting and postprandial glucose levels and glycated hemoglobin (HbA1c), IL-9 showed positive correlation with urea and microalbuminuria.	Glucose	113-120	interleukin 17A	Homo sapiens	19-24
25849622-2	2015	Cytokines such as the gp130 family member Oncostatin M (OSM) can act synergistically with Th2 cytokines (IL-4 and IL-13) to modulate lung cells, however whether IL-17A responses by HASMC can be altered is not known.	hasmc	181-186	interleukin 17A	Homo sapiens	161-167
26087561-1	2015	OBJECTIVE: To observe the effect of shikonin on the proliferation of human keratinocytes induced by IL-17 and secretion of chemokines, in order to discuss the mechanism of Shikonin in the treatment of psoriasis.	shikonin	36-44	interleukin 17A	Homo sapiens	100-105
26087561-6	2015	RESULT: Shikonin (2,1 mg x L(-1)) could distinctly inhibit HaCaT cell proliferation induced by IL-17A, with statistical difference (P < 0.01).	shikonin	8-16	interleukin 17A	Homo sapiens	95-101
26087561-8	2015	CONCLUSION: Shikonin could inhibit HaCaT cells proliferation induced by IL-17 and secretion of relevant cytokines and recruit leukocytes by inhibiting chemokines, so as to show the effect in treating psoriasis.	shikonin	12-20	interleukin 17A	Homo sapiens	72-77
26045995-11	2015	We found that BAY 11-7028 abrogated IL-17-induced ZEB1 expression, cell migration, and EMT, thus confirming that NF-kappaB is required for IL-17 to induce these aggressive phenotypes in lung cancer cells.	bay 11-7028	14-25	interleukin 17A	Homo sapiens	36-41
26045995-11	2015	We found that BAY 11-7028 abrogated IL-17-induced ZEB1 expression, cell migration, and EMT, thus confirming that NF-kappaB is required for IL-17 to induce these aggressive phenotypes in lung cancer cells.	bay 11-7028	14-25	interleukin 17A	Homo sapiens	139-144
25485537-11	2015	After inactivating Notch signal by DAPT, Th17 cells and Th17/Treg ratio were dose dependently decreased and accompanied by the reduction of IL-17 in culture supernatants and RORgammat mRNA expression in ITP patients.	dapt	35-39	interleukin 17A	Homo sapiens	140-145
25499021-0	2015	Exopolysaccharides from Cyanobacterium aponinum from the Blue Lagoon in Iceland increase IL-10 secretion by human dendritic cells and their ability to reduce the IL-17+RORgammat+/IL-10+FoxP3+ ratio in CD4+ T cells.	exopolysaccharides	0-18	interleukin 17A	Homo sapiens	162-167
25499021-8	2015	A reduced frequency of IL-17(+)RORgammat(+) T cells was observed when co-cultured with EPS-Ca-exposed DCs and a tendency towards increased frequency of FoxP3(+)IL-10(+) T cells, resulting in a lower IL-17(+)RORgammat(+)/FoxP3(+)IL-10(+) ratio.	eps-ca	87-93	interleukin 17A	Homo sapiens	23-28
25499021-8	2015	A reduced frequency of IL-17(+)RORgammat(+) T cells was observed when co-cultured with EPS-Ca-exposed DCs and a tendency towards increased frequency of FoxP3(+)IL-10(+) T cells, resulting in a lower IL-17(+)RORgammat(+)/FoxP3(+)IL-10(+) ratio.	eps-ca	87-93	interleukin 17A	Homo sapiens	199-204
25256809-8	2015	T-cell receptor (TCR) activation of PBMCs and nickel (Ni(2+) ) treatments of human dermal microvascular endothelial cells (HDMECs) were performed resulting in IL-4, IL-6, IL-8 and IL-17 production.	Nickel(2+)	54-60	interleukin 17A	Homo sapiens	180-185
25149761-2	2015	Interleukin 17A (IL-17A) is considered an important component in host defense against Candida infections and is modulated by Candida-induced impairment of tryptophan-kynurenine metabolism.	Tryptophan	155-165	interleukin 17A	Homo sapiens	0-15
25149761-2	2015	Interleukin 17A (IL-17A) is considered an important component in host defense against Candida infections and is modulated by Candida-induced impairment of tryptophan-kynurenine metabolism.	Tryptophan	155-165	interleukin 17A	Homo sapiens	17-23
25149761-2	2015	Interleukin 17A (IL-17A) is considered an important component in host defense against Candida infections and is modulated by Candida-induced impairment of tryptophan-kynurenine metabolism.	Kynurenine	166-176	interleukin 17A	Homo sapiens	0-15
25149761-2	2015	Interleukin 17A (IL-17A) is considered an important component in host defense against Candida infections and is modulated by Candida-induced impairment of tryptophan-kynurenine metabolism.	Kynurenine	166-176	interleukin 17A	Homo sapiens	17-23
25149761-8	2015	The statistically significant association between IL-17A and kynurenine levels and candidemia suggests their potential as biomarkers for anticipation of invasive candidiasis.	Kynurenine	61-71	interleukin 17A	Homo sapiens	50-56
24980460-13	2015	Adaptive immune system activation occurred only partially: IL-23p19 and IL-22 were similarly overexpressed in Aldara-treated and lesional psoriatic skin, but IL-17A and IL-12p40 were significantly underexpressed in Aldara-treated skin compared with lesional psoriatic skin.	Imiquimod	215-221	interleukin 17A	Homo sapiens	158-164
25552541-10	2015	Antisense oligonucleotide treatment caused dose-responsive induction of the IL23RDelta9 mRNA and interfered with in vitro differentiation of human Th17 cells, reducing their expression of the signature Th17 cytokines IL-17A and IL-17F.	Oligonucleotides	10-25	interleukin 17A	Homo sapiens	217-223
25485537-13	2015	We also present evidence that the effect of DAPT inhibition on the Th17 cell response was associated with downregulation of RORgammat and IL-17 transcription using human in vitro polarization.	dapt	44-48	interleukin 17A	Homo sapiens	138-143
25707687-9	2015	As for the other investigated markers, only hsCRP (r = 0.672, p < 0.001) and IL-17 (r = 0.296, p < 0.005) correlated closely with CDEIS.	cdeis	136-141	interleukin 17A	Homo sapiens	80-85
25078944-8	2015	Fungal cell-wall polysaccharides were stronger innate inflammatory cytokines inducers, while extracellular polysaccharides demonstrated a higher capacity to modulate cytokine responses of IONO+PMA induced production of IL-17.	Polysaccharides	107-122	interleukin 17A	Homo sapiens	219-224
25078944-8	2015	Fungal cell-wall polysaccharides were stronger innate inflammatory cytokines inducers, while extracellular polysaccharides demonstrated a higher capacity to modulate cytokine responses of IONO+PMA induced production of IL-17.	iono+pma	188-196	interleukin 17A	Homo sapiens	219-224
25078944-11	2015	All of the polysaccharide fractions tested induced IL-17 production at different concentration levels.	Polysaccharides	11-25	interleukin 17A	Homo sapiens	51-56
25652865-4	2015	RESULTS: The number of IL-17-producing cells (per 105 gammadeltaT cells) in anti-TCRgammadelta combined with CK group was significantly higher than that in the anti-TCRgammadelta group.	cyanogen chloride	109-111	interleukin 17A	Homo sapiens	23-28
25652865-5	2015	Meanwhile, the IL-17-producing gammadeltaT cell number in anti-TCRgammadelta combined with anti-CD28 group was lower than that in the anti-TCRgammadelta combined with anti-CD28 and CK group.	cyanogen chloride	181-183	interleukin 17A	Homo sapiens	15-20
25652865-6	2015	The IL-17-producing gammadeltaT cell number of anti-TCRgammadelta combined with anti-CD28 and CK group was significantly higher than that in anti-TCRgammadelta combined with CK group, and that in MTB-HAg combined with anti-CD28 and CK group was significantly lower than that in anti-TCRgammadelta combined with anti-CD28 and CK group, but higher than that in MTB-HAg combined with anti-CD28 group.	cyanogen chloride	94-96	interleukin 17A	Homo sapiens	4-9
25652865-6	2015	The IL-17-producing gammadeltaT cell number of anti-TCRgammadelta combined with anti-CD28 and CK group was significantly higher than that in anti-TCRgammadelta combined with CK group, and that in MTB-HAg combined with anti-CD28 and CK group was significantly lower than that in anti-TCRgammadelta combined with anti-CD28 and CK group, but higher than that in MTB-HAg combined with anti-CD28 group.	cyanogen chloride	174-176	interleukin 17A	Homo sapiens	4-9
25652865-6	2015	The IL-17-producing gammadeltaT cell number of anti-TCRgammadelta combined with anti-CD28 and CK group was significantly higher than that in anti-TCRgammadelta combined with CK group, and that in MTB-HAg combined with anti-CD28 and CK group was significantly lower than that in anti-TCRgammadelta combined with anti-CD28 and CK group, but higher than that in MTB-HAg combined with anti-CD28 group.	cyanogen chloride	174-176	interleukin 17A	Homo sapiens	4-9
25652865-6	2015	The IL-17-producing gammadeltaT cell number of anti-TCRgammadelta combined with anti-CD28 and CK group was significantly higher than that in anti-TCRgammadelta combined with CK group, and that in MTB-HAg combined with anti-CD28 and CK group was significantly lower than that in anti-TCRgammadelta combined with anti-CD28 and CK group, but higher than that in MTB-HAg combined with anti-CD28 group.	cyanogen chloride	174-176	interleukin 17A	Homo sapiens	4-9
25652866-11	2015	In POCD group, serum IL-6, IL-17, MCP3 and MPIF-1 levels at 4 hours postoperatively were higher when compared with ones at 1 day preoperatively.	pocd	3-7	interleukin 17A	Homo sapiens	27-32
25707687-10	2015	The correlation of the markers with CDAI was also significant, though weaker, with r = 0.518 for hsCRP (p < 0.001) and r = 0.296 for IL-17 (p < 0.05).	cdai	36-40	interleukin 17A	Homo sapiens	136-141
26273599-5	2015	Markedly decreased levels of IL-17, retinoid-related orphan receptor C (RORc), and MMP-3 mRNA expression were also observed in IL-6-induced RASFs in the presence of T-614 or MTX compared with those in its absence.	T 614	165-170	interleukin 17A	Homo sapiens	29-34
26273599-5	2015	Markedly decreased levels of IL-17, retinoid-related orphan receptor C (RORc), and MMP-3 mRNA expression were also observed in IL-6-induced RASFs in the presence of T-614 or MTX compared with those in its absence.	Methotrexate	174-177	interleukin 17A	Homo sapiens	29-34
26451144-10	2015	In vivo and in vitro studies showed a downregulation of NGAL, IL-17, IL-6, IL-1beta, TNF-alpha, and IFN-gamma after paricalcitol administration (p < 0.0001).	paricalcitol	116-128	interleukin 17A	Homo sapiens	62-67
26279438-9	2015	Phosphorylation of STAT3 was identified mainly at the tyrosine in position 705 (Y705), and the Y705F mutants attenuated IL-17-mediated STAT3 activation.	Tyrosine	54-62	interleukin 17A	Homo sapiens	120-125
26862311-8	2015	RESULTS: Administration of low doses of curcumin (0.1 and 1 microg/ml) could decrease Th17 percentages (p = 0.000 and p = 0.000 compared to control), reduce IL-17A productions (p = 0.000 and p = 0.000 compared to control), increase Treg percentages (p = 0.001 and p = 0.000 compared to control), and increase TGF-beta1 productions (p = 0.001 and p = 0.000 compared to control) on CD4+ T cells of SLE patients.	Curcumin	40-48	interleukin 17A	Homo sapiens	157-163
25815027-7	2015	The levels of IL-17 and Th17 were significantly higher in both DHLI and SKYD groups than in healthy control group and higher in DHLI than in SKYD group (P < 0.05).	dhli	63-67	interleukin 17A	Homo sapiens	14-19
25815027-7	2015	The levels of IL-17 and Th17 were significantly higher in both DHLI and SKYD groups than in healthy control group and higher in DHLI than in SKYD group (P < 0.05).	dhli	128-132	interleukin 17A	Homo sapiens	14-19
25480564-5	2015	We found an increased ratio of IFN-gamma/IL-17 expression in Th17 cells in children with advanced beta cell autoimmunity, which correlated with HbA1c and plasma glucose concentrations in an oral glucose tolerance test, and thus impaired beta cell function.	Glucose	161-168	interleukin 17A	Homo sapiens	41-46
25480564-5	2015	We found an increased ratio of IFN-gamma/IL-17 expression in Th17 cells in children with advanced beta cell autoimmunity, which correlated with HbA1c and plasma glucose concentrations in an oral glucose tolerance test, and thus impaired beta cell function.	Glucose	195-202	interleukin 17A	Homo sapiens	41-46
25720383-5	2015	Here, we show that HPV16.E7 protein expression as a transgene in skin is associated with enhanced IL-17A production by macrophages exposed to DNCB.	Dinitrochlorobenzene	142-146	interleukin 17A	Homo sapiens	98-104
26504859-12	2015	Zn potently reduced IL-17 production in a dose-related fashion; however it did not exert any toxic effects.	Zinc	0-2	interleukin 17A	Homo sapiens	20-25
25720383-7	2015	Further, blockade of either IL-17A or arginase activity alleviates DNCB-induced hyperinflammation through reduced recruitment of neutrophils, as a consequence of decreased CXCL1 and CXCL5 chemokine production.	Dinitrochlorobenzene	67-71	interleukin 17A	Homo sapiens	28-34
25720383-8	2015	Thus, our findings suggest that increased IL-17A expression by macrophages in E7-expressing skin exposed to DNCB promotes arginase-1 induction and contributes directly to the observed hyperinflammation.	Dinitrochlorobenzene	108-112	interleukin 17A	Homo sapiens	42-48
26504859-16	2015	CONCLUSIONS: This study demonstrates that Zn modulates IL-17 expression and provides a rationale for evaluating this compound as a supplementary agent in the treatment of chronic HCV.	Zinc	42-44	interleukin 17A	Homo sapiens	55-60
24557630-8	2015	The induction of RANKL was observed when IL-17 was added in combination with 1,25-dihydroxyvitamin D3 and prostaglandin E2, well-known inducers of RANKL, although the exact mechanism of this synergistic effect remains unclear.	Calcitriol	77-101	interleukin 17A	Homo sapiens	41-46
25323532-11	2015	Serum IL-17 levels were positively correlated with total bilirubin (TBIL), alanine aminotransferase (ALT) and Child-Pugh grade, and were negatively correlated with albumin.	Bilirubin	57-66	interleukin 17A	Homo sapiens	6-11
24557630-8	2015	The induction of RANKL was observed when IL-17 was added in combination with 1,25-dihydroxyvitamin D3 and prostaglandin E2, well-known inducers of RANKL, although the exact mechanism of this synergistic effect remains unclear.	Dinoprostone	106-122	interleukin 17A	Homo sapiens	41-46
26199466-8	2015	Lower IL-17A concentrations synergized with NO donor nitroprusside.	Nitroprusside	53-66	interleukin 17A	Homo sapiens	6-12
26111958-5	2015	RESULTS: Significantly higher plasma levels of IL-12p70, IL-23, IL-27, IFN-gamma and IL-17A were observed in cITP patients than in controls (p < 0.01), and after HD-DXM treatment, these levels decreased significantly (p < 0.01).	citp	109-113	interleukin 17A	Homo sapiens	85-91
26199466-6	2015	The effect of IL-17A (0.1-1 ng/mL) was sensitive to the iNOS-selective inhibitor aminoguanidine and undetectable in iNOS-/- bone-marrow.	pimagedine	81-95	interleukin 17A	Homo sapiens	14-20
26278415-0	2015	All-trans-retinoic acid modulates nitric oxide and interleukin-17A production by peripheral blood mononuclear cells from patients with Alzheimer"s disease.	Tretinoin	0-23	interleukin 17A	Homo sapiens	51-66
25323532-11	2015	Serum IL-17 levels were positively correlated with total bilirubin (TBIL), alanine aminotransferase (ALT) and Child-Pugh grade, and were negatively correlated with albumin.	Bilirubin	68-72	interleukin 17A	Homo sapiens	6-11
25469293-2	2015	In esophageal carcinoma patients undergoing thoracic surgery, TEA combined with general anesthesia during surgery and subsequent postoperative patient-controlled epidural analgesia (PCEA) may improve plasma cortisol (Cor), interleukin (IL)-6 and IL-17 levels and helper T-cell differentiation.	tea	62-65	interleukin 17A	Homo sapiens	246-251
27407219-7	2015	RESULTS: In patients with aSpA, elevated serum concentration of IL-10, IL-15, IL-17 and IL-23 was detected.	aspa	26-30	interleukin 17A	Homo sapiens	78-83
24792332-6	2015	We suggest that the treatment with MTX and MP could ameliorate RA disease activity by normalizing the distribution/imbalance of Th17/Treg and indicate a new regulatory role of IL-17(+) cells in RA patients.	Methotrexate	35-38	interleukin 17A	Homo sapiens	176-181
25790671-0	2015	[Effect of Sanhuang Yilong Decoction combined MTX on the expression of serum IL-1, IL-6, and IL-17 in rheumatoid arthritis patients of accumulated dampness-heat syndrome].	Methotrexate	46-49	interleukin 17A	Homo sapiens	93-98
26124839-8	2015	ATRA-pretreated MSCs significantly decreased not only the vital pathogenic cytokine in AS, tumor necrosis factor-alpha (TNF-alpha), but also AS-boosting factors interleukin-17 (IL-17A) and interferon-gamma (IFN-gamma).	Tretinoin	0-4	interleukin 17A	Homo sapiens	177-183
25790671-1	2015	OBJECTIVE: To study the effect of bitter-cold herbs easing dampness method (BCHEDM) plus Sanhuang Yilong Decoction (SYD) combined with methotrexate (MTX) on expression levels of interleukin-1 (IL-1), IL-6, and IL-17 in rheumatoid arthritis (RA) patients of accumulated dampness-heat syndrome (ADHS).	Methotrexate	149-152	interleukin 17A	Homo sapiens	210-215
25790671-9	2015	CONCLUSION: SYD combined MTX could play roles of improving inflammatory indices within 2 weeks, and inhibiting the expression of IL-1, IL-6, and IL-17 within 4 weeks.	Methotrexate	25-28	interleukin 17A	Homo sapiens	145-150
25385822-0	2014	Chloroquine promotes IL-17 production by CD4+ T cells via p38-dependent IL-23 release by monocyte-derived Langerhans-like cells.	Chloroquine	0-11	interleukin 17A	Homo sapiens	21-26
25551434-4	2014	In the present study, we investigated the effect of IL-17A on the SSc patient-derived DVSMCs.	dvsmcs	86-92	interleukin 17A	Homo sapiens	52-58
25551434-5	2014	METHODS: DVSMCs from patients with SSc and healthy subjects were incubated using IL-17A or serum derived from patients with SSc.	dvsmcs	9-15	interleukin 17A	Homo sapiens	81-87
25551434-7	2014	The protein phosphorylation of signalling pathways in the process of IL-17A-mediated DVSMC activation was investigated and validated by specific signalling pathway inhibitor.	dvsmc	85-90	interleukin 17A	Homo sapiens	69-75
25551434-8	2014	RESULTS: IL-17A and serum from patients with SSc could promote the proliferation, collagen synthesis and secretion, and migration of DVSMCs.	dvsmcs	133-139	interleukin 17A	Homo sapiens	9-15
25551434-9	2014	IL-17A neutralising antibody could inhibit the IL-17A-induced activation of DVSMCs.	dvsmcs	76-82	interleukin 17A	Homo sapiens	0-6
25551434-9	2014	IL-17A neutralising antibody could inhibit the IL-17A-induced activation of DVSMCs.	dvsmcs	76-82	interleukin 17A	Homo sapiens	47-53
25551434-10	2014	Additionally, IL-17A induced the activation of extracellular-regulated protein kinases 1/2 (ERK1/2) in DVSMCs, and ERK1/2 inhibitor could block the IL-17A-elicited activation of DVSMCs.	dvsmcs	103-109	interleukin 17A	Homo sapiens	14-20
25551434-10	2014	Additionally, IL-17A induced the activation of extracellular-regulated protein kinases 1/2 (ERK1/2) in DVSMCs, and ERK1/2 inhibitor could block the IL-17A-elicited activation of DVSMCs.	dvsmcs	103-109	interleukin 17A	Homo sapiens	148-154
25551434-10	2014	Additionally, IL-17A induced the activation of extracellular-regulated protein kinases 1/2 (ERK1/2) in DVSMCs, and ERK1/2 inhibitor could block the IL-17A-elicited activation of DVSMCs.	dvsmcs	178-184	interleukin 17A	Homo sapiens	14-20
25551434-10	2014	Additionally, IL-17A induced the activation of extracellular-regulated protein kinases 1/2 (ERK1/2) in DVSMCs, and ERK1/2 inhibitor could block the IL-17A-elicited activation of DVSMCs.	dvsmcs	178-184	interleukin 17A	Homo sapiens	148-154
25551434-11	2014	CONCLUSIONS: Our results suggested that IL-17A derived from patients with SSc might induce the proliferation, collagen synthesis and secretion, and migration of DVSMCs via ERK1/2 signalling pathway, raising the likelihood that IL-17A and ERK1/2 might be promising therapeutic targets for the treatment of SSc-related vasculopathy.	dvsmcs	161-167	interleukin 17A	Homo sapiens	40-46
25551434-11	2014	CONCLUSIONS: Our results suggested that IL-17A derived from patients with SSc might induce the proliferation, collagen synthesis and secretion, and migration of DVSMCs via ERK1/2 signalling pathway, raising the likelihood that IL-17A and ERK1/2 might be promising therapeutic targets for the treatment of SSc-related vasculopathy.	dvsmcs	161-167	interleukin 17A	Homo sapiens	227-233
25385822-5	2014	Importantly, CHQ-treated MoLC promoted IL-17A secretion by CD4(+) T cells and elevated RORC mRNA levels, whereas IFN-gamma release was reduced.	Chloroquine	13-16	interleukin 17A	Homo sapiens	39-45
25308129-6	2014	Pristimerin-treated rats exhibited a reduction in the pro-inflammatory cytokines (IL-6, IL-17, IL-18, and IL-23) and the IL-6/IL-17-associated transcription factors (pSTAT3 and ROR-gammat), coupled with an increase in the immunomodulatory cytokine IL-10.	pristimerin	0-11	interleukin 17A	Homo sapiens	126-131
25331548-0	2014	Lactose inhibits regulatory T-cell-mediated suppression of effector T-cell interferon-gamma and IL-17 production.	Lactose	0-7	interleukin 17A	Homo sapiens	96-101
25463121-11	2014	Change in 25(OH)D and IL-17 levels were independent predictors of the change in FMD measurements following vitamin D replacement.	Vitamin D	107-116	interleukin 17A	Homo sapiens	22-27
25449852-5	2014	Circulating Th1, Th2 and Th17 effector cells were identified by intracellular staining for IFN-gamma, IL-4 and IL-17, respectively, upon in vitro stimulation with PMA and calcium ionophore.	Tetradecanoylphorbol Acetate	163-166	interleukin 17A	Homo sapiens	111-116
25022448-9	2014	In conclusion, polymorphisms in IL6, TNF, IL10, IL17A and IFNG are associated with susceptibility to cSSSIs.	csssis	101-107	interleukin 17A	Homo sapiens	48-53
24919524-6	2014	Finally, both cell proliferation and IL-17 release by CD4(+) and, mainly, CD8(+) T cells from patients with MS were less sensitive to hydrocortisone inhibition than control group.	Hydrocortisone	134-148	interleukin 17A	Homo sapiens	37-42
25520943-0	2014	AZD5363 Inhibits Inflammatory Synergy between Interleukin-17 and Insulin/Insulin-Like Growth Factor 1.	capivasertib	0-7	interleukin 17A	Homo sapiens	46-60
25520943-9	2014	AZD5363 inhibited the synergy between IL-17 and insulin/IGF1 through reducing phosphorylation of GSK3alpha and GSK3beta by inhibiting Akt function.	capivasertib	0-7	interleukin 17A	Homo sapiens	38-43
25520943-10	2014	These findings imply that the cooperative crosstalk of IL-17 and insulin/IGF1 in initiating inflammatory responses may be alleviated by AZD5363.	capivasertib	136-143	interleukin 17A	Homo sapiens	55-60
24919524-7	2014	Interestingly, IL-6R signalling blockade restored the ability of hydrocortisone to inhibit both T-cell proliferation and IL-17 production.	Hydrocortisone	65-79	interleukin 17A	Homo sapiens	121-126
25016929-5	2014	RESULTS: Both, post-treatment absolute counts of CD4+IL17+ cells in peripheral blood and IL-17 levels in EBC decreased significantly (post-treatment CD4+IL17+ mean 2.418 +- 0.414 cells/mul versus pre-treatment 3.202 +- 0.507 cells/mul, p = 0.036 and post-treatment IL-17 mean levels 7.16 +- 0.47 pg/ml versus pre-treatment 9.32 +- 0.47 pg/ml, p < 0.001, respectively).	NSC638702	105-108	interleukin 17A	Homo sapiens	89-94
25466265-6	2014	RESULTS: Dexamethasone caused variable inhibition of cytokines; 1 muM inhibited IL-10 and IL-17 by 50% or lower, while inhibition > 50% was observed for IL-2, IL-13 and IFNgamma.	Dexamethasone	9-22	interleukin 17A	Homo sapiens	90-95
25346207-8	2014	Patients with pSS had a high number of CD4(+)/IL-17A(+) and IL-19(+) T cells and a lower percentage of IL-24(+) cells (P < 0.05).	pss	14-17	interleukin 17A	Homo sapiens	46-52
25192396-6	2014	We also found diminished intracellular formation of IL-17, and diminished IL-17 responses to both group B streptococci (GBS) and Escherichia coli.	gbs	120-123	interleukin 17A	Homo sapiens	74-79
25427574-2	2014	The IL-17 superfamily, which mediates cross-talk between the adaptive and innate immune systems, has been associated with diminished responses to steroids.	Steroids	146-154	interleukin 17A	Homo sapiens	4-9
25089799-7	2014	Bcl3 expression is regulated by bortezomib (BZ)-mediated proteasome inhibition, and BZ inhibits Bcl3 recruitment to its target promoters, resulting in decreased expression of cIAP1 and cIAP2, but increased expression of IL-8 and IL-17.	Bortezomib	84-86	interleukin 17A	Homo sapiens	229-234
25385601-3	2014	Pharmacological inhibition with KD025 or siRNA-mediated inhibition of ROCK2, but not ROCK1, significantly diminished STAT3 phosphorylation and binding to IL-17 and IL-21 promoters and reduced IFN regulatory factor 4 and nuclear hormone RAR-related orphan receptor gammat protein levels in T cells derived from healthy subjects or rheumatoid arthritis patients.	KD025	32-37	interleukin 17A	Homo sapiens	154-159
24962673-5	2014	Here, we investigated the levels of IL-17 and frequencies of IL-17-producing cells responding to mKatG in sarcoidosis patients with different prognosis.	mkatg	97-102	interleukin 17A	Homo sapiens	61-66
24962673-10	2014	Patients with Lofgren"s syndrome had a higher frequency of IL-17-producing cells responding to mKatG in BAL fluid compared to patients without Lofgren"s syndrome (P < 0 05).	mkatg	95-100	interleukin 17A	Homo sapiens	59-64
25162311-10	2014	We summarize and discuss the implications of IL-17 in the induction of neutrophilic airway inflammation, steroid insensitivity, the epithelial cell profile, and airway remodeling.	Steroids	105-112	interleukin 17A	Homo sapiens	45-50
24668555-4	2014	Vitamin D inhibits IFN-gamma and IL-17 production while inducing regulatory T cells.	Vitamin D	0-9	interleukin 17A	Homo sapiens	33-38
25128460-9	2014	[25(OH)D3]-treated DCs significantly inhibited IL-17 production [P=0.002] and decreased the percentage of CD4(+)IL-17(+) [P=0.007] in young asthmatics.	Calcifediol	1-9	interleukin 17A	Homo sapiens	47-52
25128460-9	2014	[25(OH)D3]-treated DCs significantly inhibited IL-17 production [P=0.002] and decreased the percentage of CD4(+)IL-17(+) [P=0.007] in young asthmatics.	Calcifediol	1-9	interleukin 17A	Homo sapiens	112-117
24981072-8	2014	The levels of galectin-3 were correlated positively with the values of CRP, FIB, IgG or IL-17 in patients with pSS.	pss	111-114	interleukin 17A	Homo sapiens	88-93
25042748-10	2014	TH2/TH17 cell counts and IL-17 production correlated with PC20 for methacholine, eosinophil counts, and FEV1.	Methacholine Chloride	67-79	interleukin 17A	Homo sapiens	25-30
25279717-4	2014	Also, 1,25(OH)2D3 and TX527 treatment inhibit the production of effector cytokines IFN-gamma, IL-9, and IL-17.	Calcitriol	6-17	interleukin 17A	Homo sapiens	104-109
25279717-4	2014	Also, 1,25(OH)2D3 and TX527 treatment inhibit the production of effector cytokines IFN-gamma, IL-9, and IL-17.	inecalcitol	22-27	interleukin 17A	Homo sapiens	104-109
24882215-0	2014	Dopamine favors expansion of glucocorticoid-resistant IL-17-producing T cells in multiple sclerosis.	Dopamine	0-8	interleukin 17A	Homo sapiens	54-59
24803294-4	2014	We examined the utility of andrographolide, a diterpenoid lactone extracted from the Chinese herb Andrographis paniculata, an anti-inflammatory agent for CRSwNP treatment by evaluating interleukin (IL)-6 and IL-17 production and monitoring T helper 17 (Th17) differentiation of peripheral blood mononuclear cells (PBMCs) isolated from 20 Chinese CRSwNP patients and 11 control subjects.	andrographolide	27-42	interleukin 17A	Homo sapiens	208-213
24803294-6	2014	Andrographolide significantly inhibited IL-6 and IL-17 production, suppressed p-Stat3 expression, and inhibited Th17 differentiation of PBMCs in vitro.	andrographolide	0-15	interleukin 17A	Homo sapiens	49-54
25016235-6	2014	Compared to naive platelet supernatants, APS had a higher level of various cytokines, such as IL8, IL17, PDGF and VEGF.	aps	41-44	interleukin 17A	Homo sapiens	99-103
25244643-8	2014	SB203580 also inhibited the expression of MMP-2/-9 and increased the expression of E-cadherin in IL-17A-stimulated NPC-039 and CNE-2Z cell lines.	SB 203580	0-8	interleukin 17A	Homo sapiens	97-103
25250801-9	2014	In addition, treatment of cervical cancer cells with the pharmacological p38/NF-kappaB signal pathway inhibitors, SB203580 and PDTC, potently restored the roles of invasion and upregulation of MMPs induced by IL-17A.	SB 203580	114-122	interleukin 17A	Homo sapiens	209-215
25107440-11	2014	Moreover, the DTC analysis showed in addition that IL-17 may be correlated with CRS reactions, although this correlation has not yet been corroborated in the literature.	3-cresol	80-83	interleukin 17A	Homo sapiens	51-56
25509254-15	2014	CONCLUSION: QHR combined Mesalazine could synergically enhance the effect and effectively inhibit intestinal inflammation through down-regulating the expression of IL-17.	Mesalamine	25-35	interleukin 17A	Homo sapiens	164-169
25255099-3	2014	Immunization with Cy3 conjugates induces a rapid Cy3-specific gammadelta T cell IL-17 response.	cy3	18-21	interleukin 17A	Homo sapiens	80-85
25255099-3	2014	Immunization with Cy3 conjugates induces a rapid Cy3-specific gammadelta T cell IL-17 response.	cy3	49-52	interleukin 17A	Homo sapiens	80-85
24993316-6	2014	At the present time whether a TB vaccine would work better if it targeted one specific T cell subset rather than another is as yet completely unknown, and this is now further complicated by new evidence that suggests other subsets such as IL-17 secreting CD4 T cells and cells with stem cell-like qualities may also play important roles.	Terbium	30-32	interleukin 17A	Homo sapiens	239-244
24419155-0	2014	Calcipotriol increases hCAP18 mRNA expression but inhibits extracellular LL37 peptide production in IL-17/IL-22-stimulated normal human epidermal keratinocytes.	calcipotriene	0-12	interleukin 17A	Homo sapiens	100-105
24419155-4	2014	However, the effect of calcipotriol on the mRNA expression/production of human cathelicidin antimicrobial protein (hCAP18) and LL37 peptide by IL-17A/IL-22-stimulated keratinocytes remains controversial.	calcipotriene	23-35	interleukin 17A	Homo sapiens	143-149
24419155-7	2014	Calcipotriol increased hCAP18 mRNA expression in IL-17/IL-22-stimulated keratinocytes.	calcipotriene	0-12	interleukin 17A	Homo sapiens	49-54
25228547-6	2014	Proangiogenic effects of IL-17 on CECs was determined by proliferation assays with a water-soluble tetrazolium cell proliferation reagent kit, wound healing migration assays, and tube formation assays using basement membrane matrix.	Water	85-90	interleukin 17A	Homo sapiens	25-30
25228547-6	2014	Proangiogenic effects of IL-17 on CECs was determined by proliferation assays with a water-soluble tetrazolium cell proliferation reagent kit, wound healing migration assays, and tube formation assays using basement membrane matrix.	Tetrazolium Salts	99-110	interleukin 17A	Homo sapiens	25-30
25228547-12	2014	The PI3K inhibitor wortmannin suppressed CEC migration, cytoskeleton rearrangement, and upregulation of activated Rac1 and RhoA induced by IL-17.	Wortmannin	19-29	interleukin 17A	Homo sapiens	139-144
25141009-0	2014	IL-17A induces Pendrin expression and chloride-bicarbonate exchange in human bronchial epithelial cells.	Chlorides	38-46	interleukin 17A	Homo sapiens	0-6
25141009-0	2014	IL-17A induces Pendrin expression and chloride-bicarbonate exchange in human bronchial epithelial cells.	Bicarbonates	47-58	interleukin 17A	Homo sapiens	0-6
25141009-6	2014	Functional studies using live-cell fluorescence to measure intracellular pH demonstrated that IL-17A induced chloride-bicarbonate exchange in HBE cells that was not present in the absence of IL-17A.	Chlorides	109-117	interleukin 17A	Homo sapiens	94-100
25141009-6	2014	Functional studies using live-cell fluorescence to measure intracellular pH demonstrated that IL-17A induced chloride-bicarbonate exchange in HBE cells that was not present in the absence of IL-17A.	Bicarbonates	118-129	interleukin 17A	Homo sapiens	94-100
25097034-0	2014	Calmodulin and PI(3,4,5)P3 cooperatively bind to the Itk pleckstrin homology domain to promote efficient calcium signaling and IL-17A production.	phosphoinositide-3,4,5-triphosphate	15-26	interleukin 17A	Homo sapiens	127-133
24554396-7	2014	Re-stimulation with unspecific stimuli (PMA and ionomycin) generated a mixed Th1 (CD4(+)/IFN-gamma(+)) and Th17 (CD4(+)/IL-17(+)) phenotype in comparison with the vehicle-matched group.	Ionomycin	48-57	interleukin 17A	Homo sapiens	120-125
25108437-8	2014	Pretreatment of PMNs with U0126 mostly inhibited the anti-apoptosis effect of IL-17 at 5 mug/L on PMNs of TB patients and normal subjects.	U 0126	26-31	interleukin 17A	Homo sapiens	78-83
24893702-8	2014	Stratified analyses indicated that a significantly increased risk of GCA associated with the IL17A rs3819024 A > G polymorphism was evident among male patients, patients who drank alcohol or those who never smoked.	Alcohols	183-190	interleukin 17A	Homo sapiens	93-98
24845870-0	2014	Vitamin A supplementation reduces IL-17 and RORc gene expression in atherosclerotic patients.	Vitamin A	0-9	interleukin 17A	Homo sapiens	34-39
24845870-2	2014	The purpose of this study was to evaluate the effect of vitamin A supplementation on expression of Th17 cells-related IL-17 and RORc genes in atherosclerotic patients.	Vitamin A	56-65	interleukin 17A	Homo sapiens	118-123
24845870-8	2014	In atherosclerotic patients, vitamin A supplementation resulted in significant decrease in IL-17 gene expression by 0.63-fold in fresh cell, 0.82-fold in PHA-activated cells and 0.65-fold in ox-LDL-activated cells (P < 0.05 for all).	Vitamin A	29-38	interleukin 17A	Homo sapiens	91-96
25038765-0	2014	Interleukin-17 Indirectly Promotes M2 Macrophage Differentiation through Stimulation of COX-2/PGE2 Pathway in the Cancer Cells.	Dinoprostone	94-98	interleukin 17A	Homo sapiens	0-14
25038765-6	2014	The conditional medium obtained from the cancer cells contained prostaglandin E2, the levels of which were increased by IL-17 treatment.	Dinoprostone	64-80	interleukin 17A	Homo sapiens	120-125
25038765-9	2014	CONCLUSION: The results of this study suggest that IL-17 indirectly promotes M2 macrophage differentiation through stimulation of the COX-2/PGE2 pathway in the cancer cells, thus IL-17 plays an indirect role in regulating the tumor immune microenvironment.	Dinoprostone	140-144	interleukin 17A	Homo sapiens	51-56
25038765-9	2014	CONCLUSION: The results of this study suggest that IL-17 indirectly promotes M2 macrophage differentiation through stimulation of the COX-2/PGE2 pathway in the cancer cells, thus IL-17 plays an indirect role in regulating the tumor immune microenvironment.	Dinoprostone	140-144	interleukin 17A	Homo sapiens	179-184
24664971-6	2014	Nevertheless, the secretion of IL-17A was increased by DMOG and reduced by YC-1 under Th17-skewing conditions in a dose- dependent manner.	dimethyloxallyl glycine	55-59	interleukin 17A	Homo sapiens	31-37
24635166-5	2014	The frequencies of Th22, IL-22(+) Th17 and Th17 cells and the concentrations of IL-22 and IL-17 were reduced in response to the drugs methylprednisolone, cyclophosphamide and hydroxychloroquine for 4 weeks in the majority of SLE patients.	Methylprednisolone	134-152	interleukin 17A	Homo sapiens	90-95
24635166-5	2014	The frequencies of Th22, IL-22(+) Th17 and Th17 cells and the concentrations of IL-22 and IL-17 were reduced in response to the drugs methylprednisolone, cyclophosphamide and hydroxychloroquine for 4 weeks in the majority of SLE patients.	Cyclophosphamide	154-170	interleukin 17A	Homo sapiens	90-95
24635166-5	2014	The frequencies of Th22, IL-22(+) Th17 and Th17 cells and the concentrations of IL-22 and IL-17 were reduced in response to the drugs methylprednisolone, cyclophosphamide and hydroxychloroquine for 4 weeks in the majority of SLE patients.	Hydroxychloroquine	175-193	interleukin 17A	Homo sapiens	90-95
24253487-3	2014	METHODS: The relationship between serum IL-17A and estradiol levels was studied in 72 postmenopausal women and 22 premenopausal women.	Estradiol	51-60	interleukin 17A	Homo sapiens	40-46
24306678-4	2014	RESULTS: IHC statistical analysis showed that the expression level of IL-17- and IL-23p19-positive cells significantly increased in CP-OLP group compared with that in CP (P < 0.01) and OLP groups (P < 0.05), showing intense staining reaction in local lamina propria lesions.	cp-olp	132-138	interleukin 17A	Homo sapiens	70-75
24978193-7	2014	In non-smokers but not in smokers ATPgammaS increased the release of IL-17.	adenosine 5'-O-(3-thiotriphosphate)	34-43	interleukin 17A	Homo sapiens	69-74
24711661-5	2014	Mechanistically, we could show that ruxolitinib impaired differentiation of CD4(+) T cells into IFN-gamma- and IL17A-producing cells, and that both T-cell phenotypes are linked to GVHD.	ruxolitinib	36-47	interleukin 17A	Homo sapiens	111-116
24811173-5	2014	In addition, CaeA significantly suppressed the number of Th1 and Th17 cells, as supported by a decreased percentage of CD4(+)/IFN-gamma(+) and CD4(+)/IL-17(+) cells, respectively.	caerulomycin A	13-17	interleukin 17A	Homo sapiens	150-155
25058997-1	2014	BACKGROUND: Interleukin-17A (I-17A)-producing CD4+T helper cells have been implicated in allergic inflammation; however, the role of IL-17A in allergic rhinitis (AR) patients with different degrees of atopy and airway reactivity to methacholine (Mch) has not been examined.	Methacholine Chloride	232-244	interleukin 17A	Homo sapiens	12-27
24905806-6	2014	Pretreatment with helenalin, a nuclear factor-kappaB (NF-kappaB) inhibitor, was proved to abolish the promoting effect of IL-17A on the invasion ability of GC cells and upregulation of MMP-2 and MMP-9.	helenalin	18-27	interleukin 17A	Homo sapiens	122-128
25058997-2	2014	OBJECTIVES: To explore IL-17A-producing CD3+CD4+T cells in peripheral blood of patients with persistent AR and assess the degree of atopy, eosinophil count (Eo count), and bronchial hyper-responsiveness (BHR) to methacholine.	Methacholine Chloride	212-224	interleukin 17A	Homo sapiens	23-29
25058997-1	2014	BACKGROUND: Interleukin-17A (I-17A)-producing CD4+T helper cells have been implicated in allergic inflammation; however, the role of IL-17A in allergic rhinitis (AR) patients with different degrees of atopy and airway reactivity to methacholine (Mch) has not been examined.	Methacholine Chloride	232-244	interleukin 17A	Homo sapiens	29-34
25058997-1	2014	BACKGROUND: Interleukin-17A (I-17A)-producing CD4+T helper cells have been implicated in allergic inflammation; however, the role of IL-17A in allergic rhinitis (AR) patients with different degrees of atopy and airway reactivity to methacholine (Mch) has not been examined.	Methacholine Chloride	246-249	interleukin 17A	Homo sapiens	12-27
25058997-1	2014	BACKGROUND: Interleukin-17A (I-17A)-producing CD4+T helper cells have been implicated in allergic inflammation; however, the role of IL-17A in allergic rhinitis (AR) patients with different degrees of atopy and airway reactivity to methacholine (Mch) has not been examined.	Methacholine Chloride	246-249	interleukin 17A	Homo sapiens	29-34
24441101-5	2014	Transcription and secretion of IFN-gamma, IL-17, and IL-22 were increased in alpha-NAC-stimulated PBMCs.	alpha-nac	77-86	interleukin 17A	Homo sapiens	42-47
24861949-6	2014	A significant correlation (r = 0.78, p = 0.001) was observed between EBC levels of IL-6 and IL-17; IL-17 was also correlated to EBC levels of the VEGF (r = 0.83, p < 0.001) and TNF-alpha (r = 0.62, p = 0.014).	NSC638702	69-72	interleukin 17A	Homo sapiens	92-97
24861949-6	2014	A significant correlation (r = 0.78, p = 0.001) was observed between EBC levels of IL-6 and IL-17; IL-17 was also correlated to EBC levels of the VEGF (r = 0.83, p < 0.001) and TNF-alpha (r = 0.62, p = 0.014).	NSC638702	128-131	interleukin 17A	Homo sapiens	99-104
24629073-10	2014	How omeprazole induces this inflammatory response is unclear, but may include direct effects by IL-17 expressing CD4+ cells on renal tubular cells.	Omeprazole	4-14	interleukin 17A	Homo sapiens	96-101
24347461-0	2014	Defective IL-10 expression and in vitro steroid-induced IL-17A in paediatric severe therapy-resistant asthma.	Steroids	40-47	interleukin 17A	Homo sapiens	56-62
24347461-7	2014	Dexamethasone regulated the balance between PBMC IL-10 and IL-13 production, increasing IL-10 secretion (p<0.001) and decreasing IL-13 (p<0.001) but unexpectedly enhanced IL-17A production in all groups-most strikingly in the STRA cohort (p<0.001).	Dexamethasone	0-13	interleukin 17A	Homo sapiens	177-183
24347461-8	2014	The inclusion of the active form of vitamin D, 1alpha,25-dihydroxyvitamin D3, in culture enhanced dexamethasone-induced IL-10 (p<0.05) without marked effects on IL-13 or IL-17A production.	Vitamin D	36-45	interleukin 17A	Homo sapiens	173-179
24347461-11	2014	Conversely, steroids enhanced IL-17A levels, and therefore any steroid-sparing properties of vitamin D may have additional benefit in STRA.	Steroids	12-20	interleukin 17A	Homo sapiens	30-36
24347461-11	2014	Conversely, steroids enhanced IL-17A levels, and therefore any steroid-sparing properties of vitamin D may have additional benefit in STRA.	Steroids	12-19	interleukin 17A	Homo sapiens	30-36
24570184-8	2014	Besides, IL17A inhibits H2O2-induced cell apoptosis.	Hydrogen Peroxide	24-28	interleukin 17A	Homo sapiens	9-14
23889803-8	2014	In the triamcinolone group, levels of IL-6, IL-17, IP-10, platelet-derived growth factor (PDGF)-AA and VEGF were reduced significantly (p=0.012, p<0.001, p<0.001, p=0.015, and p<0.001, respectively).	Triamcinolone	7-20	interleukin 17A	Homo sapiens	44-49
24782182-5	2014	We also examined the effect of the forced expression of the molecule on retinoic acid receptor-related orphan nuclear receptor gammat (RORgammat)-induced IL-17A production in CD4+ T cells and on RORgammat-induced IL-17A promoter activation.	rorgammat	135-144	interleukin 17A	Homo sapiens	154-160
24529390-8	2014	Hemicholnium-3 reduced the percentage of ACh+IL-17A+, ACh+IL-22+, and ACh+RORgammat+ while it did not affect FOXP3+ expression in CD3+PBT-cells from cultured PBMC from COPD patients.	hemicholnium-3	0-14	interleukin 17A	Homo sapiens	45-51
24549402-9	2014	Serum IL-35, IL-6 and IL-17 levels were positively correlated with total bilirubin and international normalized ratio, and negatively correlated with albumin.	Bilirubin	73-82	interleukin 17A	Homo sapiens	22-27
24583150-7	2014	The levels of serum IL-17A and IFN-gamma in steroid group and serum TNF-alpha in alcoholic group were significantly higher than those in the HC.	Steroids	44-51	interleukin 17A	Homo sapiens	20-26
24236690-7	2014	In addition, the TGF-beta1/IL-17 ratio was also markedly increased in patients with HBV-LC, especially in nonsurvival and decompensated liver cirrhosis patients, and positively correlated with total bilirubin, Child-Pugh, and model of end-stage liver disease scores.	Bilirubin	199-208	interleukin 17A	Homo sapiens	27-32
24683191-10	2014	IL-17 expression was increased in CD4(+) lupus T cells (SLE: 3.62 +- 0.66%, HC: 2.29 +- 0.27%; p = 0.019), which was suppressed by rapamycin (control: 3.91 +- 0.79%, rapamycin: 2.22 +- 0.60%; p < 0.001).	Sirolimus	131-140	interleukin 17A	Homo sapiens	0-5
24317395-3	2014	Here we characterized IL-17-producing immune cells over time, using two established in vivo models of human skin inflammation that share many histological features with psoriasis, i.e., leukotriene B4 application and tape-stripping.	Leukotriene B4	186-200	interleukin 17A	Homo sapiens	22-27
24485875-10	2014	RESULTS: Our results indicate that sirolimus exerts prolonged suppression of lymphocyte proliferation and decreased interleukin 17A that lasts up to 48 h after drug withdrawal.	Sirolimus	35-44	interleukin 17A	Homo sapiens	116-131
24172846-7	2014	CS extracts directly activated mouse and human dendritic cells (DC) and airway epithelial cells (AECs) to trigger interferongamma and/or IL-17 production by iNKT cells, an effect ablated by the anti-oxidant N-acetylcystein.	Cesium	0-2	interleukin 17A	Homo sapiens	137-142
24482023-10	2014	IL-17 immunostaining correlated with proteinuria, requirement for pulse steroids, and SLEDAI renal score, and negatively with GFR.	Steroids	72-80	interleukin 17A	Homo sapiens	0-5
24694060-3	2014	FINDINGS: Using anti-CD3 antibody-stimulated human peripheral blood mononuclear cell cultures, we observed that Hsp90 inhibition by non-toxic concentrations of the geldanamycin derivative 17-DMAG significantly blocked T cell proliferation, reduced IFN-gamma and IL-17 expression on CD4+ T lymphocytes, and arrested secretion of proinflammatory IFN-gamma, TNF-alpha, and IL-17, cytokines characteristic of Th1 and Th17 cells, respectively.	geldanamycin	164-176	interleukin 17A	Homo sapiens	262-267
24694060-3	2014	FINDINGS: Using anti-CD3 antibody-stimulated human peripheral blood mononuclear cell cultures, we observed that Hsp90 inhibition by non-toxic concentrations of the geldanamycin derivative 17-DMAG significantly blocked T cell proliferation, reduced IFN-gamma and IL-17 expression on CD4+ T lymphocytes, and arrested secretion of proinflammatory IFN-gamma, TNF-alpha, and IL-17, cytokines characteristic of Th1 and Th17 cells, respectively.	geldanamycin	164-176	interleukin 17A	Homo sapiens	370-375
24694060-3	2014	FINDINGS: Using anti-CD3 antibody-stimulated human peripheral blood mononuclear cell cultures, we observed that Hsp90 inhibition by non-toxic concentrations of the geldanamycin derivative 17-DMAG significantly blocked T cell proliferation, reduced IFN-gamma and IL-17 expression on CD4+ T lymphocytes, and arrested secretion of proinflammatory IFN-gamma, TNF-alpha, and IL-17, cytokines characteristic of Th1 and Th17 cells, respectively.	17-(dimethylaminoethylamino)-17-demethoxygeldanamycin	188-195	interleukin 17A	Homo sapiens	262-267
24694060-3	2014	FINDINGS: Using anti-CD3 antibody-stimulated human peripheral blood mononuclear cell cultures, we observed that Hsp90 inhibition by non-toxic concentrations of the geldanamycin derivative 17-DMAG significantly blocked T cell proliferation, reduced IFN-gamma and IL-17 expression on CD4+ T lymphocytes, and arrested secretion of proinflammatory IFN-gamma, TNF-alpha, and IL-17, cytokines characteristic of Th1 and Th17 cells, respectively.	17-(dimethylaminoethylamino)-17-demethoxygeldanamycin	188-195	interleukin 17A	Homo sapiens	370-375
24824706-3	2014	In contrast, ghrelin in a concentration typical of trimester I-II of pregnancy reduces the number of IL-17-producing cells, but stimulated the formation of T-regulatory cells.	Ghrelin	13-20	interleukin 17A	Homo sapiens	101-106
24419251-5	2014	RESULTS: The IL-17A, IL-6, IL-22 and IFN-gamma were significantly reduced in a dose response after simvastatin treatment (50 muM, p = 0.0005; p < 0.0001; p < 0.02; p = 0.0005, respectively).	Simvastatin	99-110	interleukin 17A	Homo sapiens	13-19
24419251-6	2014	The IL-17A and IL-6 cytokines were also significantly reduced in lower concentrations of simvastatin (10 muM) compared to controls (p = 0.018; p = 0.04) and compared to the standard drug (p = 0.007; p = 0.0001).	Simvastatin	89-100	interleukin 17A	Homo sapiens	4-10
24419251-7	2014	The results also showed that only RA patients with severe disease (DAS28 >5.1 and CDAI >22) had poor response to simvastatin in reducing cytokines levels, mainly for IL-17A and IL-22 cytokines (p = 0.03; p = 0.039, respectively).	Simvastatin	119-130	interleukin 17A	Homo sapiens	172-178
24521871-5	2014	Our results showed that shikonin significantly inhibited IL-17-induced VEGF mRNA and protein expression in HaCaT cells and the secretion of VEGF by HaCaT cells, inhibited IL-17-induced IL-17R, pJAK2 and pSTAT3 expression, while up-regulated the expression of SOCS1 in HaCaT cells.	shikonin	24-32	interleukin 17A	Homo sapiens	57-62
24521871-5	2014	Our results showed that shikonin significantly inhibited IL-17-induced VEGF mRNA and protein expression in HaCaT cells and the secretion of VEGF by HaCaT cells, inhibited IL-17-induced IL-17R, pJAK2 and pSTAT3 expression, while up-regulated the expression of SOCS1 in HaCaT cells.	shikonin	24-32	interleukin 17A	Homo sapiens	171-176
24338253-0	2014	The effects of vitamin D on allergen-induced expression of interleukin-13 and interleukin-17 in cord blood CD4+T cells.	Vitamin D	15-24	interleukin 17A	Homo sapiens	78-92
24338253-5	2014	After allergens stimulation, CD4+T cells showed an increase of IL-13 and IL-17 production, while cultured in the presence of 1,25-(OH)2D3 displayed a statistically significant down-regulation of allergen-induced expression of IL-13 and IL-17 in CD4+T cells.	Calcitriol	125-137	interleukin 17A	Homo sapiens	236-241
23451767-8	2014	There were significant positive correlation between serum IL-17, IL-23, TNF-alpha and disease activity assessed by cumulative UAS for 7 days before blood sampling.	Phenindione	126-129	interleukin 17A	Homo sapiens	58-63
24192715-0	2014	Targeting PKC in human T cells using sotrastaurin (AEB071) preserves regulatory T cells and prevents IL-17 production.	sotrastaurin	37-49	interleukin 17A	Homo sapiens	101-106
24192715-8	2014	Moreover, in both circulating and dermal psoriatic Treg, prone to rapid induction of IL-17, sotrastaurin enhanced Foxp3 expression and prevented IL-17A and IFNgamma production even when stimulated in the presence of the helper T 17-enhancing cytokines IL-1beta or IL-23.	sotrastaurin	92-104	interleukin 17A	Homo sapiens	85-90
24192715-8	2014	Moreover, in both circulating and dermal psoriatic Treg, prone to rapid induction of IL-17, sotrastaurin enhanced Foxp3 expression and prevented IL-17A and IFNgamma production even when stimulated in the presence of the helper T 17-enhancing cytokines IL-1beta or IL-23.	sotrastaurin	92-104	interleukin 17A	Homo sapiens	145-151
24516202-6	2014	In addition, TMP778, but not TMP776, inhibited IL-17A production in both human and mouse gammadelta T cells.	TMP778	13-19	interleukin 17A	Homo sapiens	47-53
24516202-7	2014	IL-23-induced IL-17A production was also blocked by TMP778 treatment.	TMP778	52-58	interleukin 17A	Homo sapiens	14-20
24308966-0	2014	High glucose driven expression of pro-inflammatory cytokine and chemokine genes in lymphocytes: molecular mechanisms of IL-17 family gene expression.	Glucose	5-12	interleukin 17A	Homo sapiens	120-125
24308966-6	2014	High glucose induced gene profiling in Jurkat T-lymphocytes showed significantly increased expression of 64 proinflammatory genes including IL-6 and IL-17A and most of these genes were Nuclear Factor (NF)-kappaB and AP-1 regulated.	Glucose	5-12	interleukin 17A	Homo sapiens	149-155
24308966-7	2014	RT(2)-PCR array results suggested the transcriptional activation of IL-17 and its downstream signaling in Jurkat T-lymphocytes upon high glucose treatment.	Glucose	137-144	interleukin 17A	Homo sapiens	68-73
24308966-12	2014	These results show that IL-17 cytokines are induced by high glucose via key signaling pathways leading to lymphocyte activation and relevant to the pathogenesis of diabetic complications like atherosclerosis.	Glucose	60-67	interleukin 17A	Homo sapiens	24-29
24548422-7	2014	Elevated levels of TNF-alpha, interleukin (IL)-6, IL-1beta, interferon (IFN)-gamma and IL-17 were observed during DSS exposure phase which restored to the normal level after DSS removal.	Dextran Sulfate	114-117	interleukin 17A	Homo sapiens	87-92
23929359-7	2014	In addition, a p38 mitogen-activated protein kinase (MAPK) inhibitor (SB203580) inhibited IL-17A-induced increase of the migration and MMP-1 upregulation of PDL fibroblasts.	SB 203580	70-78	interleukin 17A	Homo sapiens	90-96
23929359-9	2014	A nuclear factor kappaB (NF-kappaB) inhibitor (pyrrolidine dithiocarbamate) also suppressed the cell migration and MMP-1 expression enhanced by IL-17A.	pyrrolidine dithiocarbamic acid	47-74	interleukin 17A	Homo sapiens	144-150
24383677-4	2014	There was a direct correlation between IL-17A and glutamate levels; IL-17A levels were also associated with the neutrophil expansion in CSF and blood-brain barrier disruption.	Glutamic Acid	50-59	interleukin 17A	Homo sapiens	39-45
24505477-6	2014	Dietary arginine or glutamine supplementation had significant (P<0.05) influence on the clinical and biochemical parameters (T-SOD, IL-17 and TNF-alpha) in colitis model.	Arginine	8-16	interleukin 17A	Homo sapiens	135-140
24505477-6	2014	Dietary arginine or glutamine supplementation had significant (P<0.05) influence on the clinical and biochemical parameters (T-SOD, IL-17 and TNF-alpha) in colitis model.	Glutamine	20-29	interleukin 17A	Homo sapiens	135-140
24808367-3	2014	Following UVR, extracellular ATP leads to an increase in CD69 expression, proliferation, and IL-17 production, and to changes in DETC morphology.	Adenosine Triphosphate	29-32	interleukin 17A	Homo sapiens	93-98
24441101-6	2014	As IL-17 was significantly upregulated by alpha-NAC, we assessed signal transduction in PBMCs and found signal transducer and activator of transcription 3 phosphorylation in alpha-NAC-stimulated cells.	alpha-nac	42-51	interleukin 17A	Homo sapiens	3-8
24441101-6	2014	As IL-17 was significantly upregulated by alpha-NAC, we assessed signal transduction in PBMCs and found signal transducer and activator of transcription 3 phosphorylation in alpha-NAC-stimulated cells.	nac	48-51	interleukin 17A	Homo sapiens	3-8
24441101-8	2014	Inhibition of IL-23 p19 led to lower amounts of IL-17 in the PBMC supernatants after alpha-NAC stimulation.	alpha-nac	85-94	interleukin 17A	Homo sapiens	48-53
24342887-13	2014	Further, tofacitinib treatment twice per day significantly decreased the conjunctival expression of IL-17A and significantly increased the conjunctival expression of FoxP3.	tofacitinib	9-20	interleukin 17A	Homo sapiens	100-106
24345576-0	2014	The role of interchain disulfide bond in a recombinant human interleukin-17A variant.	Disulfides	23-32	interleukin 17A	Homo sapiens	61-76
23924903-0	2014	Propionibacterium acnes Induces an IL-17 Response in Acne Vulgaris that Is Regulated by Vitamin A and Vitamin D.	Vitamin A	88-97	interleukin 17A	Homo sapiens	35-40
24313624-0	2014	Oral vitamin D increases the frequencies of CD38+ human B cells and ameliorates IL-17-producing T cells.	Vitamin D	5-14	interleukin 17A	Homo sapiens	80-85
24313624-7	2014	Following cholecalciferol intake, the frequencies of circulating CD38 expressing B cells were significantly increased and IFN-gamma+ , and/or IL-17+ CD4+ T helper cells were decreased.	Cholecalciferol	10-25	interleukin 17A	Homo sapiens	142-147
24238999-0	2014	Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model.	Cannabidiol	55-66	interleukin 17A	Homo sapiens	0-15
24238999-0	2014	Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model.	anandamide	71-81	interleukin 17A	Homo sapiens	0-15
24238999-5	2014	IL-17A incubation caused significant mucosal epithelial and crypt damage which were attenuated following hydrocortisone treatment, and also reduced following anandamide or cannabidiol incubation.	Hydrocortisone	105-119	interleukin 17A	Homo sapiens	0-6
24238999-5	2014	IL-17A incubation caused significant mucosal epithelial and crypt damage which were attenuated following hydrocortisone treatment, and also reduced following anandamide or cannabidiol incubation.	anandamide	158-168	interleukin 17A	Homo sapiens	0-6
24238999-5	2014	IL-17A incubation caused significant mucosal epithelial and crypt damage which were attenuated following hydrocortisone treatment, and also reduced following anandamide or cannabidiol incubation.	Cannabidiol	172-183	interleukin 17A	Homo sapiens	0-6
23924903-0	2014	Propionibacterium acnes Induces an IL-17 Response in Acne Vulgaris that Is Regulated by Vitamin A and Vitamin D.	Vitamin D	102-111	interleukin 17A	Homo sapiens	35-40
23924903-8	2014	Together, our data demonstrate that IL-17 is induced by P. acnes and expressed in acne lesions and that both vitamin A and D could be effective tools to modulate Th17-mediated diseases such as acne.	th17	162-166	interleukin 17A	Homo sapiens	36-41
24428928-9	2014	RESULTS: IL-17 producing T cell percentage of AR group was significantly higher: 2.59 +- 1.32 than in controls 1.24 +- 0.22, (p = 0.001).	Argon	46-48	interleukin 17A	Homo sapiens	9-14
24362892-4	2014	Autocrine activity of IL-17A and its receptor induced the production of reactive oxygen species (ROS), and increased fungal killing in vitro and in a model of Aspergillus-induced keratitis.	Reactive Oxygen Species	72-95	interleukin 17A	Homo sapiens	22-28
24362892-4	2014	Autocrine activity of IL-17A and its receptor induced the production of reactive oxygen species (ROS), and increased fungal killing in vitro and in a model of Aspergillus-induced keratitis.	Reactive Oxygen Species	97-100	interleukin 17A	Homo sapiens	22-28
24473142-6	2014	However, Th1 in ND AML patients and IL-17 in ND, Non-CR or CR AML patients was significantly decreased compared with controls.	Chromium	53-55	interleukin 17A	Homo sapiens	36-41
24428928-12	2014	Serum IL-17 levels in AR group were significantly higher (5.10 +- 4.40) pg/ml than in controls (3.46 +-1.28) pg/ml, (p = 0.04).	Argon	22-24	interleukin 17A	Homo sapiens	6-11
24232001-5	2014	Pre- and coadministration of paeoniflorin significantly reduced the severity of colitis and resulted in downregulation of several inflammatory parameters in the colon, including the activity of myeloperoxidase (MPO), the levels of TNF-alpha and IL-6, and the mRNA expression of proinflammatory mediators (MCP-1, Cox2, IFN-gamma, TNF-alpha, IL-6, and IL-17).	peoniflorin	29-41	interleukin 17A	Homo sapiens	350-355
25054133-6	2014	In those subjects with depressive symptoms, IL-17 was associated with higher LPH (rho = 0.518, P = 0.023) and lower IL-10 (rho = -0.484, P = 0.036), but not in those without.	Lipid Peroxides	77-80	interleukin 17A	Homo sapiens	44-49
26155114-2	2014	Zymosan injection at the ankle joint caused swelling and coincided with histological joint alterations and IL-17A expression in areas with cell infiltrates.	Zymosan	0-7	interleukin 17A	Homo sapiens	107-113
26155114-7	2014	The administration of IL-17 in ZIO increased paw thickness, enlarged the blood Ly6G(+) pool, elevated CD11b expression and decreased apoptosis.	ly6g	79-83	interleukin 17A	Homo sapiens	22-27
26155135-3	2014	The results showed that both DEX and CsA dose-dependently inhibited the production of eleven cytokines: interleukin (IL)-2, IL-4, IL-5, IL-6, IL-13, IL-17, interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF).	Dexamethasone	29-32	interleukin 17A	Homo sapiens	149-154
26155135-3	2014	The results showed that both DEX and CsA dose-dependently inhibited the production of eleven cytokines: interleukin (IL)-2, IL-4, IL-5, IL-6, IL-13, IL-17, interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF).	Cyclosporine	37-40	interleukin 17A	Homo sapiens	149-154
25345512-9	2014	We integrated these data with known pathways using Ingenuity Pathway Analysis tool and found following common pathways associated with all three diseases to be most affected; epithelial adherens junction signaling, remodelling of epithelial adherens junctions, role of BRCA1 in DNA damage response, sphingomyelin metabolism, 3- phosphoinositide biosynthesis, acute myeloid leukemia signaling, type I diabetes mellitus signaling, agrin interactions at neuromuscular junction, role of IL-17A in arthritis, and antigen presentation pathways.	3- phosphoinositide	325-344	interleukin 17A	Homo sapiens	483-489
25056541-5	2014	Here we demonstrate that the frequency of Th17 and Th1 cells along with the relevant cytokines IL-17, IFN-gamma and corresponding transcriptional factors RORC, T-bet were all decreased following LXR activation by the agonist GW3965.	GW 3965	225-231	interleukin 17A	Homo sapiens	95-100
25651714-5	2014	RESULTS: The results indicate a lower expression of IL-17A, IL-17E, and IL-17F in PMNs and B lymphocytes of pa- tients with B-cell chronic lymphocytic leukemia compared to cells of healthy subjects.	Protactinium	108-110	interleukin 17A	Homo sapiens	52-58
25812351-10	2014	These effects of morphine and cannabinoids T cell suppression were accompanied by elevation of IL-10 level and concomitant reduction in IL-17 secretion from cultured CD4+ T cells.	Morphine	17-25	interleukin 17A	Homo sapiens	136-141
25812351-10	2014	These effects of morphine and cannabinoids T cell suppression were accompanied by elevation of IL-10 level and concomitant reduction in IL-17 secretion from cultured CD4+ T cells.	Cannabinoids	30-42	interleukin 17A	Homo sapiens	136-141
25332518-5	2014	The most pronounced effect of CC-LPMC-CM on peripheral CD4(+) T cells was a trend towards increased production of IL-17A and IL-10.	cc-lpmc-cm	30-40	interleukin 17A	Homo sapiens	114-120
25524382-3	2014	RESULTS: Trichophytin or candidin, or both, stimulated the production of regulatory cytokines (TGF-beta and/or IL-10), accompanied or not by stimulation of production of cytokines associated with the Th1 response (TNF-alpha, IL-12 and IFN-gamma), but without stimulation of Th2 cytokines (IL-5 and IL-13) and IL-17, by peripheral blood mononuclear cells of most allergic and nonallergic individuals.	candidin	25-33	interleukin 17A	Homo sapiens	309-314
24316750-7	2013	We further established that recombinant IL-17A recruits the MAPK pathway by upregulating phosphorylated ERK1/2 in human breast cancer cell lines thereby promoting proliferation and resistance to conventional chemotherapeutic agents such as docetaxel.	Docetaxel	240-249	interleukin 17A	Homo sapiens	40-46
24367714-8	2013	Surprisingly, patients treated with methylprednisolone had no difference in the expression levels of HFMD-associated biomarkers instead had slightly increased levels of IL-17A, which was not associated with the occurrence of HFMD.	Methylprednisolone	36-54	interleukin 17A	Homo sapiens	169-175
24340045-4	2013	Multicolour fluorescence analysis of IL-17-expressing peripheral blood mononuclear cells (PBMC) revealed larger proportions of IL-17(+)CD3(-) non-T cells in RA patients than in healthy controls (constitutive, 13.6% vs. 8.4%, and after stimulation with PMA/ionomycin 17.4% vs. 7.9% p < 0.001 in both cases).	Tetradecanoylphorbol Acetate	252-255	interleukin 17A	Homo sapiens	37-42
24340045-4	2013	Multicolour fluorescence analysis of IL-17-expressing peripheral blood mononuclear cells (PBMC) revealed larger proportions of IL-17(+)CD3(-) non-T cells in RA patients than in healthy controls (constitutive, 13.6% vs. 8.4%, and after stimulation with PMA/ionomycin 17.4% vs. 7.9% p < 0.001 in both cases).	Ionomycin	256-265	interleukin 17A	Homo sapiens	37-42
24060907-5	2013	Our study demonstrated that apigenin inhibited OVA-induced increases in Raw and eosinophil count; interleukin (IL)-6, TNF- and IL-17A levels were recovered.	Apigenin	28-36	interleukin 17A	Homo sapiens	127-133
23680281-14	2013	PGE2 was also positively correlated with Th17 proportion (r=0.539, p=0.001), and IL-17 concentration (r=0.500, p=0.003).	Dinoprostone	0-4	interleukin 17A	Homo sapiens	81-86
23732752-5	2013	Moreover, IL-17 and TNF synergistically inhibited pigmentation-related signaling and melanin production, and induced keratinocyte production of beta-defensin 3, an antagonist for melanocortin 1 receptor.	Melanins	85-92	interleukin 17A	Homo sapiens	10-15
24257035-4	2013	We systematically investigated the effect of three antidepressant drugs, citalopram, escitalopram and mirtazapine, on secretion of cytokines IL-1beta, IL-2, IL-4, IL-6, IL-17, IL-22 and TNF-alpha in a whole blood assay in vitro, using murine anti-human CD3 monoclonal antibody OKT3, and 5C3 monoclonal antibody against CD40, to stimulate T and B cells respectively.	Mirtazapine	102-113	interleukin 17A	Homo sapiens	169-174
24257035-7	2013	Escitalopram decreased IL-17 levels.	Citalopram	0-12	interleukin 17A	Homo sapiens	23-28
24033914-10	2013	Our data support our hypothesis and suggest that melatonin may be used to dampen IL-17-mediated inflammation that is enhanced by the increased levels of insulin and IGF1 in obesity.	Melatonin	49-58	interleukin 17A	Homo sapiens	81-86
23765637-0	2013	In vitro effects of IL-17 on angiogenic properties of endothelial cells in relation to oxygen levels.	Oxygen	87-93	interleukin 17A	Homo sapiens	20-25
23765637-1	2013	The aim of this study has been to elucidate how different oxygen levels impact the effects of Interleukin-17 (IL-17) on angiogenic properties of endothelial cells.	Oxygen	58-64	interleukin 17A	Homo sapiens	94-108
23765637-1	2013	The aim of this study has been to elucidate how different oxygen levels impact the effects of Interleukin-17 (IL-17) on angiogenic properties of endothelial cells.	Oxygen	58-64	interleukin 17A	Homo sapiens	110-115
23765637-5	2013	When cultured at 20% O2 , IL-17 stimulated proliferation, migration and tubulogenesis, whereas a hypoxic environment did not affect their migration and proliferation, but increased their survival and tubulogenic properties.	Oxygen	21-23	interleukin 17A	Homo sapiens	26-31
23765637-8	2013	At 20% O2 , IL-17 did not alter their proliferation,but inhibited migration and stimulated tubule formation.	Oxygen	7-9	interleukin 17A	Homo sapiens	12-17
23765637-11	2013	Thus the effects of IL-17 on the angiogenic properties of endothelial cells depend on both the cell line used and the oxygen concentration.	Oxygen	118-124	interleukin 17A	Homo sapiens	20-25
24940514-3	2014	Consistent with this, we have recently shown that IL-17A increases human and murine platelet response to ADP.	Adenosine Diphosphate	105-108	interleukin 17A	Homo sapiens	50-56
24007780-5	2013	Following vitamin D loading at 3 months, the relationships between some of the cytokines changed (TNF-alpha and MCP-1: r=0.38, p=0.017, IL-1beta and IL-17: r=0.3, p=0.06).	Vitamin D	10-19	interleukin 17A	Homo sapiens	149-154
24033914-0	2013	Insulin and IGF1 enhance IL-17-induced chemokine expression through a GSK3B-dependent mechanism: a new target for melatonin"s anti-inflammatory action.	Melatonin	114-123	interleukin 17A	Homo sapiens	25-30
24033914-2	2013	The objective of this study was to test a hypothesis that insulin and IGF1 enhance IL-17-induced expression of inflammatory chemokines/cytokines through a glycogen synthase kinase 3beta (GSK3B)-dependent mechanism, which can be inhibited by melatonin.	Melatonin	241-250	interleukin 17A	Homo sapiens	83-88
24033914-6	2013	Melatonin inhibited Akt activation, thus decreasing P-GSK3B at serine 9 (i.e., increasing GSK3B activity) and subsequently inhibiting expression of Cxcl1 and Ccl20 that was induced either by IL-17 alone or by a combination of insulin and IL-17.	Melatonin	0-9	interleukin 17A	Homo sapiens	191-196
24033914-6	2013	Melatonin inhibited Akt activation, thus decreasing P-GSK3B at serine 9 (i.e., increasing GSK3B activity) and subsequently inhibiting expression of Cxcl1 and Ccl20 that was induced either by IL-17 alone or by a combination of insulin and IL-17.	Melatonin	0-9	interleukin 17A	Homo sapiens	238-243
24192564-8	2013	NC and pSS freshly isolated DN T cells produce consistent amounts of IL-17 (67.7+-5.6 in NC vs 69.2+-3.3 in pSS).	pss	7-10	interleukin 17A	Homo sapiens	69-74
24192564-8	2013	NC and pSS freshly isolated DN T cells produce consistent amounts of IL-17 (67.7+-5.6 in NC vs 69.2+-3.3 in pSS).	pss	108-111	interleukin 17A	Homo sapiens	69-74
24179731-4	2013	Patients with IIH had highly elevated IL-2, IL-4, IL-10, IL-17 and IFNgamma in the CSF compared to patients with multiple sclerosis or non-organic/non-inflammatory neurological conditions.	4-(7-Chloro-1,3-Benzoxazol-2-Yl)-2,6-Diiodophenol	14-17	interleukin 17A	Homo sapiens	57-62
24179731-8	2013	We conclude that IIH is associated with elevated levels of IL-17 and IL-2 in the CSF, suggesting the involvement of these cytokines in disease pathogenesis.	4-(7-Chloro-1,3-Benzoxazol-2-Yl)-2,6-Diiodophenol	17-20	interleukin 17A	Homo sapiens	59-64
23969332-0	2013	Beclomethasone dipropionate and formoterol reduce oxidative/nitrosative stress generated by cigarette smoke extracts and IL-17A in human bronchial epithelial cells.	Beclomethasone	0-27	interleukin 17A	Homo sapiens	121-127
24146856-7	2013	Lipopolysaccharide (LPS), muramyl dipeptide (MDP), tumour necrosis factor (TNF), and Interleukin (IL)-4 induced gp96-expression, while IL12, IL-17, IL-23 and interferon (IFN)-gamma were not effective indicating that Th1 and Th17 cells are probably not involved in the induction of gp96.	Acetylmuramyl-Alanyl-Isoglutamine	26-43	interleukin 17A	Homo sapiens	141-146
24043897-7	2013	Along with the decreased production of other proinflammatory cytokines (IFN-gamma, TNF-alpha, and IL-2), we found that CT could directly enhance the IL-17A production through a cAMP-dependent pathway.	Cyclic AMP	177-181	interleukin 17A	Homo sapiens	149-155
23969332-0	2013	Beclomethasone dipropionate and formoterol reduce oxidative/nitrosative stress generated by cigarette smoke extracts and IL-17A in human bronchial epithelial cells.	Formoterol Fumarate	32-42	interleukin 17A	Homo sapiens	121-127
23969332-2	2013	We investigated whether recombinant human IL-17A (rhIL-17A), in combination with cigarette smoke extracts (CSE), increases the levels of inducibile nitric oxide synthase (iNOS), reactive oxygen species, nitrotyrosine (NT) and the activation of signal transducer and activator of transcription 1 (STAT-1) in normal human bronchial epithelial cells (16HBE).	Reactive Oxygen Species	178-201	interleukin 17A	Homo sapiens	42-48
23969332-8	2013	16HBE treated with BDP or formoterol alone partially suppressed the effect of IL-17A or CSE on ROS, NT, and STAT-1 activation.	16hbe	0-5	interleukin 17A	Homo sapiens	78-84
23969332-8	2013	16HBE treated with BDP or formoterol alone partially suppressed the effect of IL-17A or CSE on ROS, NT, and STAT-1 activation.	Beclomethasone	19-22	interleukin 17A	Homo sapiens	78-84
23969332-8	2013	16HBE treated with BDP or formoterol alone partially suppressed the effect of IL-17A or CSE on ROS, NT, and STAT-1 activation.	Formoterol Fumarate	26-36	interleukin 17A	Homo sapiens	78-84
23969332-8	2013	16HBE treated with BDP or formoterol alone partially suppressed the effect of IL-17A or CSE on ROS, NT, and STAT-1 activation.	Reactive Oxygen Species	95-98	interleukin 17A	Homo sapiens	78-84
23969332-8	2013	16HBE treated with BDP or formoterol alone partially suppressed the effect of IL-17A or CSE on ROS, NT, and STAT-1 activation.	3-nitrotyrosine	100-102	interleukin 17A	Homo sapiens	78-84
23800789-0	2013	The IL17A and IL17F loci have divergent histone modifications and are differentially regulated by prostaglandin E2 in Th17 cells.	Dinoprostone	98-114	interleukin 17A	Homo sapiens	4-9
23800789-1	2013	Prostaglandin E2 (PGE2), IL-23 and IL-1beta are implicated in inflammatory bowel disease susceptibility, likely in part by modulating IL-17 producing CD4(+) T helper (Th17) cells.	Dinoprostone	0-16	interleukin 17A	Homo sapiens	134-139
23800789-1	2013	Prostaglandin E2 (PGE2), IL-23 and IL-1beta are implicated in inflammatory bowel disease susceptibility, likely in part by modulating IL-17 producing CD4(+) T helper (Th17) cells.	Dinoprostone	18-22	interleukin 17A	Homo sapiens	134-139
23800789-2	2013	To better understand how these three mediators affect Th17 cell memory responses, we characterized the gene expression profiles of activated human peripheral CD4(+) effector memory T cells and sorted Th17 memory cells from healthy donors concurrent with IL17A mRNA induction mediated by PGE2 and/or IL-23 plus IL-1beta.	Dinoprostone	287-291	interleukin 17A	Homo sapiens	254-259
23800789-3	2013	We discovered that PGE2 and IL-23 plus IL-1beta differentially regulate Th17 cytokine expression and synergize to induce IL-17A, but not IL-17F.	Dinoprostone	19-23	interleukin 17A	Homo sapiens	121-127
23800789-5	2013	The addition of PGE2 to IL-23 plus IL-1beta only enhances IL-17A expression as mediated by the PGE2 EP4 receptor, and promotes a switch from an IL-17F to an IL-17A predominant immune response.	Dinoprostone	16-20	interleukin 17A	Homo sapiens	58-64
23800789-5	2013	The addition of PGE2 to IL-23 plus IL-1beta only enhances IL-17A expression as mediated by the PGE2 EP4 receptor, and promotes a switch from an IL-17F to an IL-17A predominant immune response.	Dinoprostone	16-20	interleukin 17A	Homo sapiens	157-163
23782487-9	2013	In patients with detectable IL-17 concentrations on admission, 78% of those who received NAC vs. 44% of those who received placebo had undetectable levels by day 3-5 (P = 0.042), and the mean decrease in IL-17 concentrations between admission and late samples was significantly greater in patients who received NAC vs. placebo (P = 0.045).	Acetylcysteine	89-92	interleukin 17A	Homo sapiens	28-33
23782487-9	2013	In patients with detectable IL-17 concentrations on admission, 78% of those who received NAC vs. 44% of those who received placebo had undetectable levels by day 3-5 (P = 0.042), and the mean decrease in IL-17 concentrations between admission and late samples was significantly greater in patients who received NAC vs. placebo (P = 0.045).	Acetylcysteine	89-92	interleukin 17A	Homo sapiens	204-209
23782487-10	2013	CONCLUSIONS: N-acetylcysteine (NAC) may improve transplant-free survival in patients with non-acetaminophen ALF by ameliorating the production of IL-17, which is associated with progression of hepatic encephalopathy and poor outcome.	Acetylcysteine	13-29	interleukin 17A	Homo sapiens	146-151
23782487-10	2013	CONCLUSIONS: N-acetylcysteine (NAC) may improve transplant-free survival in patients with non-acetaminophen ALF by ameliorating the production of IL-17, which is associated with progression of hepatic encephalopathy and poor outcome.	Acetylcysteine	31-34	interleukin 17A	Homo sapiens	146-151
24035274-4	2013	Via IP binding, the PGI2 analogue decreased the proportion of Tregs and Foxp3 mRNA expression but increased the percentage of Th17 cells, RORC mRNA and IL-17A production.	Epoprostenol	20-24	interleukin 17A	Homo sapiens	152-158
24069246-4	2013	Here we demonstrated that Poly I:C treatment triggered IL-17A production from hepatic gammadeltaT cells.	Poly I-C	26-34	interleukin 17A	Homo sapiens	55-61
24358684-6	2013	Vitamin D inhibits IL-6, IL-17 and IL-23 secretions which are crucial in Th1 and Th17 differentiation and also decreases proinflammatorical cytokine production.	Vitamin D	0-9	interleukin 17A	Homo sapiens	25-30
24069246-5	2013	Neutralizing IL-17A by monoclonal antibodies reduced Poly I:C-induced intrahepatic inflammatory responses and the liver injury through decreased accumulation, activation and cytolytic activity of NK cells in the liver.	Poly I-C	53-61	interleukin 17A	Homo sapiens	13-19
24069246-7	2013	Finally, our findings demonstrated a pathological role of IL-17A and gammadeltaT cells in Poly I:C-induced acute hepatitis, which provides novel insights into viral infection-induced hepatitis and may serve as potential target in clinic immunotherapy against these disease.	Poly I-C	90-98	interleukin 17A	Homo sapiens	58-64
23850622-1	2013	The aim of this study was to maximize the yield of the production of mono-PEGylated anti-interleukin-17A (anti-IL-17A) antibody fragments using large (>= 20 kDa) polyethylene glycol (PEG) chains.	Polyethylene Glycols	165-184	interleukin 17A	Homo sapiens	111-117
23850622-1	2013	The aim of this study was to maximize the yield of the production of mono-PEGylated anti-interleukin-17A (anti-IL-17A) antibody fragments using large (>= 20 kDa) polyethylene glycol (PEG) chains.	Polyethylene Glycols	74-77	interleukin 17A	Homo sapiens	111-117
23908180-9	2013	A significantly higher level of IL-17 was observed in the supernatants of naive T cells and monocytes stimulated with LPS or PGN in BD patients as compared with controls.	pgn	125-128	interleukin 17A	Homo sapiens	32-37
23886473-5	2013	Citalopram was able to strongly reduce the frequency of IL-4- and IL-2-producing cells triggered by CD3 stimulation, but exhibited a less pronounced effect on IL-17-producing cells.	Citalopram	0-10	interleukin 17A	Homo sapiens	159-164
23908180-10	2013	Upon stimulation with R848 or PolyI:C, the levels of IL-17 in the supernatants of naive T cells and monocytes and IL-23 levels in the supernatants of monocytes were not different between BD patients and controls.	Poly I-C	30-37	interleukin 17A	Homo sapiens	53-58
24185279-6	2013	Gene expression alterations of IL-17 were assessed following challenge with testosterone and 17beta-estradiol under simulated inflammatory conditions (+-IL-1beta).	Testosterone	76-88	interleukin 17A	Homo sapiens	31-36
24008730-7	2013	SAA-treated BMDC that were serum starved for 48 h remained capable of presenting antigen and induced OTII CD4(+) T cells to secrete IL-17A, IL-17F, IL-21, IL-22, and IFNgamma in the presence of ovalbumin.	bmdc	12-16	interleukin 17A	Homo sapiens	132-138
24008730-8	2013	IL-17A, IL-17F, IL-21, and IFNgamma production occurred even when the CD4(+) T cells were treated with dexamethasone (Dex), whereas glucocorticoid treatment abolished cytokine secretion by T cells cocultured with untreated serum-starved BMDC.	Dexamethasone	103-116	interleukin 17A	Homo sapiens	0-6
24008730-8	2013	IL-17A, IL-17F, IL-21, and IFNgamma production occurred even when the CD4(+) T cells were treated with dexamethasone (Dex), whereas glucocorticoid treatment abolished cytokine secretion by T cells cocultured with untreated serum-starved BMDC.	Dexamethasone	118-121	interleukin 17A	Homo sapiens	0-6
22993227-8	2013	Surprisingly, patients with strong IL-17A expression tended to experience less relapses, and required significantly shorter treatment periods (median 25 vs 44 weeks to achieve <10 mg prednisone/day, p=0.0079).	Prednisone	186-196	interleukin 17A	Homo sapiens	35-41
24185279-6	2013	Gene expression alterations of IL-17 were assessed following challenge with testosterone and 17beta-estradiol under simulated inflammatory conditions (+-IL-1beta).	Estradiol	93-109	interleukin 17A	Homo sapiens	31-36
23957337-2	2013	IL-17 plays an important role in T cell-dependent inflammatory response that occurs in allergic asthma, it could act as a potent activator of inducible nitric oxide synthase (iNOS) to amplify FeNO levels.	feno	192-196	interleukin 17A	Homo sapiens	0-5
23857601-3	2013	Thus, we have investigated the role of IL-17A in GCTBs.	gctbs	49-54	interleukin 17A	Homo sapiens	39-45
23857601-8	2013	RESULTS: In GCTBs, we detected abundant levels of IL-17A, which were associated with tumor extension and grade.	gctbs	12-17	interleukin 17A	Homo sapiens	50-56
23857601-12	2013	In addition, IL-17A stimulated in vivo tumor growth and the extent of angiogenesis in GCTBs.	gctbs	86-91	interleukin 17A	Homo sapiens	13-19
23857601-13	2013	CONCLUSION: IL-17A stimulates the progression of GCTBs and might represent a useful candidate marker for progression and as a therapeutic target for GCTBs.	gctbs	49-54	interleukin 17A	Homo sapiens	12-18
23857601-13	2013	CONCLUSION: IL-17A stimulates the progression of GCTBs and might represent a useful candidate marker for progression and as a therapeutic target for GCTBs.	gctbs	149-154	interleukin 17A	Homo sapiens	12-18
23957337-10	2013	Serum IL-17 levels were positively correlated with FeNO (rho = 0.74; P < 0.01), negatively correlated with C-ACT (rho = -0.63; P < 0.01) in asthmatics.	feno	51-55	interleukin 17A	Homo sapiens	6-11
23817641-5	2013	Higher (p < 0.05) concentrations of IL-6, IL-17 and MCP-1 were found in lipopolysaccharide-stimulated PBMC from RA patients compared to controls.	PBMC	105-109	interleukin 17A	Homo sapiens	45-50
23944193-12	2013	Postictal IL-17A levels in the CSF were significantly elevated compared to interictal patients and patients with IIDDs.	iidds	113-118	interleukin 17A	Homo sapiens	10-16
24034921-8	2013	1,25-(OH)2D3 inhibits the expression of IL-13 and IL-17, suggesting that vitamin D intake may provide protective effects in the development of atopy-predisposing immune responses in early life.	Calcitriol	0-12	interleukin 17A	Homo sapiens	50-55
23818717-8	2013	In the whole cohort and the vitamin D-insufficient group, serum 25(OH)D was inversely associated with IL-17 (log IL-17; beta = -0.83, p = 0.04; beta = -0.63, p = 0.004, respectively) by univariate analysis, which persisted after adjustment for season, and in multivariate analysis after adjustment for confounders (log IL-17; beta = -0.74, p = 0.04; beta = -0.53, p = 0.02).	Vitamin D	28-37	interleukin 17A	Homo sapiens	102-107
23818717-11	2013	Maintaining normal serum vitamin D levels may protect against IL-17-mediated inflammation and vascular dysfunction in RA.	Vitamin D	25-34	interleukin 17A	Homo sapiens	62-67
23947692-2	2013	On immune system, imatinib has antiproliferative activity and immunomodulatory effects in lymphocytes, macrophages, mast cells and dendritic cells with abrogating multiple signal transduction pathways involved in pathogenesis of autoimmune diseases e.g. inhibiting IFN-gamma, TNF-alpha, IL-1beta and IL-17 pro-inflammatory cytokines and MMPs secretion.	Imatinib Mesylate	18-26	interleukin 17A	Homo sapiens	300-305
24034921-8	2013	1,25-(OH)2D3 inhibits the expression of IL-13 and IL-17, suggesting that vitamin D intake may provide protective effects in the development of atopy-predisposing immune responses in early life.	Vitamin D	73-82	interleukin 17A	Homo sapiens	50-55
23991206-0	2013	LDL cholesterol modulates human CD34+ HSPCs through effects on proliferation and the IL-17 G-CSF axis.	Cholesterol	4-15	interleukin 17A	Homo sapiens	85-90
23991206-14	2013	Finally, the HSPC mobilizing cytokine G-CSF (r(2)=0.0683, p < 0.05), and its upstream regulator IL-17 (r(2)=0.0891, p < 0.05) both correlated positively with LDL cholesterol, while SDF-1 levels were not significantly affected.	Cholesterol	168-179	interleukin 17A	Homo sapiens	99-104
23991206-15	2013	CONCLUSIONS: Our findings support a model where LDL cholesterol levels positively correlate with CD34+ HSPC levels in humans through effects on the levels of G-CSF via IL-17 promoting mobilization of HSPCs, and by direct effects of LDL cholesterol on HSPC proliferation.	Cholesterol	52-63	interleukin 17A	Homo sapiens	168-173
23918362-3	2013	We observed that poly(I:C)-induced IRF3 activation in CD8 T cells represses IL-17 expression in a type I IFN-independent fashion.	Poly I-C	17-26	interleukin 17A	Homo sapiens	76-81
23683514-0	2013	Enhanced production of IL-17A in patients with severe asthma is inhibited by 1alpha,25-dihydroxyvitamin D3 in a glucocorticoid-independent fashion.	Calcitriol	77-106	interleukin 17A	Homo sapiens	23-29
24034921-0	2013	[1,25-(OH)2D3 inhibits lipopolysaccharide-induced expression of interleukin-13 and interleukin-17 in cord blood CD4+T cells].	Calcitriol	0-13	interleukin 17A	Homo sapiens	83-97
24034921-1	2013	OBJECTIVE: To study the effect of 1,25-(OH)2D3 on lipopolysaccharide (LPS)-induced expression of interleukin-13 (IL-13) and interleukin-17 (IL-17) in cord blood CD4(+)T cells, providing theoretical basis for clinical reasonable application of vitamin D and prevention of asthma and allergic diseases.	Calcitriol	34-46	interleukin 17A	Homo sapiens	124-138
24034921-1	2013	OBJECTIVE: To study the effect of 1,25-(OH)2D3 on lipopolysaccharide (LPS)-induced expression of interleukin-13 (IL-13) and interleukin-17 (IL-17) in cord blood CD4(+)T cells, providing theoretical basis for clinical reasonable application of vitamin D and prevention of asthma and allergic diseases.	Calcitriol	34-46	interleukin 17A	Homo sapiens	140-145
24034921-6	2013	When co-stimulation of 1,25-(OH)2D3 with LPS, levels of IL-13 and IL-17 in the culture supernatant and mRNA expression of IL-13 and IL-17 in the cord blood CD4(+)T cells decreased compared with LPS-stimulated alone group (P<0.05), but remained higher than the blank group (P<0.01).	-(oh)2d3	27-35	interleukin 17A	Homo sapiens	66-71
24034921-6	2013	When co-stimulation of 1,25-(OH)2D3 with LPS, levels of IL-13 and IL-17 in the culture supernatant and mRNA expression of IL-13 and IL-17 in the cord blood CD4(+)T cells decreased compared with LPS-stimulated alone group (P<0.05), but remained higher than the blank group (P<0.01).	-(oh)2d3	27-35	interleukin 17A	Homo sapiens	132-137
23951170-9	2013	Few sputum cytokine concentrations changed in response to dexamethasone IL-17 and IFNalpha increased in smokers, CCL4 increased in never smokers and CCL5 and CXCL10 reduced in ex-smokers with asthma.	Dexamethasone	58-71	interleukin 17A	Homo sapiens	72-77
23752063-10	2013	IL-17 was significantly correlated with TBUT (R = -0.22, P = .012) and Schirmer I test (R = -0.36, P = .027) scores in the SS group.	tbut	40-44	interleukin 17A	Homo sapiens	0-5
23778260-2	2013	In this study, T-cell proliferation and IL-17 production were less sensitive to hydrocortisone (HC) inhibition in MS patients than healthy individuals, mainly in CD8(+) compartment.	Hydrocortisone	80-94	interleukin 17A	Homo sapiens	40-45
23242600-7	2013	In contrast, all-trans retinoic acid treatment generates regulatory T cells that retain the capacity to secrete IL-17.	Tretinoin	23-36	interleukin 17A	Homo sapiens	112-117
23242600-8	2013	However, combined use of rapamycin and all-trans retinoic acid abolishes IL-17 production and confers a specific chemokine receptor homing profile upon regulatory T cells.	Sirolimus	25-34	interleukin 17A	Homo sapiens	73-78
23242600-8	2013	However, combined use of rapamycin and all-trans retinoic acid abolishes IL-17 production and confers a specific chemokine receptor homing profile upon regulatory T cells.	Tretinoin	49-62	interleukin 17A	Homo sapiens	73-78
23683514-3	2013	OBJECTIVE: We sought to investigate the production of the TH17-associated cytokines IL-17A and IL-22 in culture in patients with moderate-to-severe asthma defined on the basis of their clinical response to steroids and the susceptibility of this response to inhibition by steroids and the active form of vitamin D, 1alpha,25-dihydroxyvitamin D3 (1,25[OH]2D3).	Steroids	206-214	interleukin 17A	Homo sapiens	84-90
23683514-3	2013	OBJECTIVE: We sought to investigate the production of the TH17-associated cytokines IL-17A and IL-22 in culture in patients with moderate-to-severe asthma defined on the basis of their clinical response to steroids and the susceptibility of this response to inhibition by steroids and the active form of vitamin D, 1alpha,25-dihydroxyvitamin D3 (1,25[OH]2D3).	Steroids	272-280	interleukin 17A	Homo sapiens	84-90
23683514-3	2013	OBJECTIVE: We sought to investigate the production of the TH17-associated cytokines IL-17A and IL-22 in culture in patients with moderate-to-severe asthma defined on the basis of their clinical response to steroids and the susceptibility of this response to inhibition by steroids and the active form of vitamin D, 1alpha,25-dihydroxyvitamin D3 (1,25[OH]2D3).	Vitamin D	304-313	interleukin 17A	Homo sapiens	84-90
23683514-3	2013	OBJECTIVE: We sought to investigate the production of the TH17-associated cytokines IL-17A and IL-22 in culture in patients with moderate-to-severe asthma defined on the basis of their clinical response to steroids and the susceptibility of this response to inhibition by steroids and the active form of vitamin D, 1alpha,25-dihydroxyvitamin D3 (1,25[OH]2D3).	Calcitriol	315-344	interleukin 17A	Homo sapiens	84-90
23683514-9	2013	Treatment with 1,25(OH)2D3 with or without dexamethasone significantly reduced both IL-17A and IL-22 levels.	Calcitriol	15-26	interleukin 17A	Homo sapiens	84-90
23683514-9	2013	Treatment with 1,25(OH)2D3 with or without dexamethasone significantly reduced both IL-17A and IL-22 levels.	Dexamethasone	43-56	interleukin 17A	Homo sapiens	84-90
23624523-12	2013	Higher frequency of IL-17-positive TICI might persist in recurrent tumor tissues of chemosensitive biopsies, suggesting repetitive platinum-based chemotherapy as an appropriate therapy for patients with IL-17-positive recurrences.	Platinum	131-139	interleukin 17A	Homo sapiens	20-25
23624523-12	2013	Higher frequency of IL-17-positive TICI might persist in recurrent tumor tissues of chemosensitive biopsies, suggesting repetitive platinum-based chemotherapy as an appropriate therapy for patients with IL-17-positive recurrences.	Platinum	131-139	interleukin 17A	Homo sapiens	203-208
23817417-6	2013	Importantly, treatment with celecoxib, a COX-2 inhibitor, resulted in significantly lower PGE2 and IL-17A, but not IFN-gamma, production.	Celecoxib	28-37	interleukin 17A	Homo sapiens	99-105
23998596-6	2013	The results showed that the proportions of blood Th17 cells and concentration of blood serum IL-17 and IFN-gamma increased in patients with SAA, compared with MAA and normal controls, but CD4(+) CD25(+) Foxp3(+) Treg cells obviously decreased in patients with SAA.	saa	140-143	interleukin 17A	Homo sapiens	93-98
23998596-7	2013	The concentrations of IL-17 and IFN-gamma significantly increased in culture supernatant of SAA group.	saa	92-95	interleukin 17A	Homo sapiens	22-27
23866118-0	2013	TNFalpha and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells.	Glucose	43-50	interleukin 17A	Homo sapiens	13-18
23772036-5	2013	Although IL-17 induced the coshift of Act1 and HuR to the polysomal fractions in a sucrose gradient, HuR deficiency reduced the ratio of translation-active/translation-inactive IL-17-induced chemokine mRNAs.	Sucrose	83-90	interleukin 17A	Homo sapiens	9-14
23883806-8	2013	RESULTS: After NAC, allergic subjects had a significant immediate response of nasal symptoms as well as a significant increase at 5 hours of IL-4, IL-10, and IL-17 and at 2, 5, and 24 hours significantly raising levels of eotaxin-3.	nac	15-18	interleukin 17A	Homo sapiens	158-163
23683514-10	2013	An antagonist of the ectonucleotidase CD39 reversed 1,25(OH)2D3-mediated inhibition of the IL-17A response.	25(oh)2d3	54-63	interleukin 17A	Homo sapiens	91-97
23607532-10	2013	In-vitro study demonstrated that IFX treatment could suppress IL-21, IL-17A and RORC expression in cultured CD biopsies.	Ifosfamide	33-36	interleukin 17A	Homo sapiens	69-75
23590758-6	2013	Such studies have shown that myeloid cells are required to induce the disease and IL-17-producing CD4(+) T cells may contribute to maintaining aldosterone-mediated hypertension.	Aldosterone	143-154	interleukin 17A	Homo sapiens	82-87
23797094-4	2013	The addition of N6-(1-iminoethyl)-l-lysine dihydrochloride (L-NIL), the iNOS inhibitor, significantly enhanced TH17 cell differentiation, and S-nitroso-N-acetylpenicillamine (SNAP), the NO donor, dosedependently reduced the percentage of IL-17-producing CD4+ T cells.	L-NIL	60-65	interleukin 17A	Homo sapiens	238-243
23039944-3	2013	However, it was also found that IL-17 was elevated in some patients with acetaminophen (APAP)-induced liver failure.	Acetaminophen	73-86	interleukin 17A	Homo sapiens	32-37
23039944-3	2013	However, it was also found that IL-17 was elevated in some patients with acetaminophen (APAP)-induced liver failure.	Acetaminophen	88-92	interleukin 17A	Homo sapiens	32-37
23039944-6	2013	To the authors" surprise, it was found that most of the IL-17 producing cells in the liver were T(H)17 cells, and they were increased within hours of APAP treatment.	Acetaminophen	150-154	interleukin 17A	Homo sapiens	56-61
28748127-7	2013	In addition, SE-positive females showed a significantly higher percentage of IL-17A-positive cells compared to SE-negative females.	Selenium	13-15	interleukin 17A	Homo sapiens	77-83
23472658-0	2013	IL-23/IL-17A axis correlates with the nitric oxide pathway in inflammatory bowel disease: immunomodulatory effect of retinoic acid.	Nitric Oxide	38-50	interleukin 17A	Homo sapiens	6-12
23472658-0	2013	IL-23/IL-17A axis correlates with the nitric oxide pathway in inflammatory bowel disease: immunomodulatory effect of retinoic acid.	Tretinoin	117-130	interleukin 17A	Homo sapiens	6-12
23797095-5	2013	Inhibition of NOS2 or cGMP-cGK signaling abolishes the de novo induction of Th17 cells and selectively suppresses IL-17 production by established Th17 cells isolated from OvCa patients.	Cyclic GMP	22-26	interleukin 17A	Homo sapiens	114-119
23778483-8	2013	CONCLUSIONS Our in vitro results demonstrated that hydroxychloroquine inhibits IL-6, IL-17 and IL-22 production and contributes to a better understanding of the mechanism of action of this medication.	Hydroxychloroquine	51-69	interleukin 17A	Homo sapiens	85-90
23767916-9	2013	IL-17 levels were significantly increased in the low dose group, while patients receiving high dose vitamin D had a heterogeneous IL-17 response.	Vitamin D	100-109	interleukin 17A	Homo sapiens	130-135
23767916-12	2013	CONCLUSION: Vitamin D supplementation to IFN-beta treated PwMS, at the doses used, seems safe and associated with dose-dependent changes in IL-17 serum levels, while not affecting IFN-beta related FLS.	Vitamin D	12-21	interleukin 17A	Homo sapiens	140-145
23692034-6	2013	In nickel-allergic patients, there was massive cellular infiltration dominated by CD4(+) T cells producing IL-17, IL-22 and IFN-gamma in nickel-challenged skin but not in vehicle-challenged skin.	Nickel	3-9	interleukin 17A	Homo sapiens	107-112
23692034-0	2013	CD4(+) T cells producing interleukin (IL)-17, IL-22 and interferon-gamma are major effector T cells in nickel allergy.	Nickel	103-109	interleukin 17A	Homo sapiens	25-44
23692034-7	2013	CONCLUSION: CD4(+) T cells producing IL-17, IL-22 and IFN-gamma are important effector cells in the eczematous reactions of nickel-induced allergic contact dermatitis in humans.	Nickel	124-130	interleukin 17A	Homo sapiens	37-42
23506849-5	2013	The paquinimod-induced amelioration correlated with reduced priming of antigen-specific CD4(+) T cells and reduced frequency of IFN-gamma- and IL-17-producing cells in draining lymph nodes.	paquinimod	4-14	interleukin 17A	Homo sapiens	143-148
22915623-0	2013	Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-alpha on endothelial cells.	Simvastatin	0-11	interleukin 17A	Homo sapiens	72-77
22915623-3	2013	The aim of this study was to assess whether simvastatin modulates the vascular effects of interleukin (IL)-17, an emerging actor in atherosclerosis.	Simvastatin	44-55	interleukin 17A	Homo sapiens	90-109
22915623-4	2013	METHODS: The effect of simvastatin was assessed in human umbilical vein endothelial cells treated by IL-17 alone or combined with tumour necrosis factor (TNF)-alpha, with or without mevalonate, an inhibitor of simvastatin.	Simvastatin	23-34	interleukin 17A	Homo sapiens	101-106
22915623-7	2013	RESULTS: Simvastatin decreased IL-17-induced IL-6, IL-8, CX3CL-1, RANTES mRNA and CX3CL-1 and CCL20 production.	Simvastatin	9-20	interleukin 17A	Homo sapiens	31-36
22915623-8	2013	Simvastatin restored the level of IL-33 mRNA which was decreased by IL-17.	Simvastatin	0-11	interleukin 17A	Homo sapiens	68-73
22915623-11	2013	Simvastatin enhanced the expression of CD39 and thrombomodulin mRNA initially reduced by IL-17 and TNF-alpha combination.	Simvastatin	0-11	interleukin 17A	Homo sapiens	89-94
22915623-12	2013	Simvastatin suppressed IL-17-induced endothelial cells invasion.	Simvastatin	0-11	interleukin 17A	Homo sapiens	23-28
22915623-14	2013	Finally, simvastatin had an additive effect with infliximab to decrease the effect of the combination of IL-17 and TNF-alpha on IL-6 mRNA expression.	Simvastatin	9-20	interleukin 17A	Homo sapiens	105-110
23562757-6	2013	In contrast, as compared with control, the secretion of IL-12p40, IL-23 and IL-6 was lower from AEE-DCs and 2Ph-CDs and allogeneic CD4(+) T cells co-cultured with these DCs secreted lower levels of IFN-gamma and IL-10 but the same levels of IL-17.	aspirin eugenol ester	96-99	interleukin 17A	Homo sapiens	241-246
23160983-0	2013	Glucocorticoid receptor-beta up-regulation and steroid resistance induction by IL-17 and IL-23 cytokine stimulation in peripheral mononuclear cells.	Steroids	47-54	interleukin 17A	Homo sapiens	79-84
23613503-8	2013	IL-17A expression in CRS was positively correlated with symptom severity, endoscopic findings and radiological appearance.	3-cresol	21-24	interleukin 17A	Homo sapiens	0-6
23613503-9	2013	CONCLUSIONS: Expression of IL-17A was higher in Chinese patients with CRS than in controls, and was associated with infiltrating inflammatory cells, symptom severity, endoscopic findings and radiological appearance.	3-cresol	70-73	interleukin 17A	Homo sapiens	27-33
23416458-5	2013	Higher levels of IL-17 and IFN-gamma were produced by stimulation with PMA/Ionomycin compared to anti-CD3/anti-CD28.	Tetradecanoylphorbol Acetate	71-74	interleukin 17A	Homo sapiens	17-22
23416458-5	2013	Higher levels of IL-17 and IFN-gamma were produced by stimulation with PMA/Ionomycin compared to anti-CD3/anti-CD28.	Ionomycin	75-84	interleukin 17A	Homo sapiens	17-22
23416458-8	2013	Furthermore the dose response curve for PMA/Ionomycin differed for IL-10 compared to IL-17 and IFN-gamma as it was biphasic with no IL-10 production at higher PMA/Ionomycin concentrations.	Tetradecanoylphorbol Acetate	40-43	interleukin 17A	Homo sapiens	85-90
23416458-8	2013	Furthermore the dose response curve for PMA/Ionomycin differed for IL-10 compared to IL-17 and IFN-gamma as it was biphasic with no IL-10 production at higher PMA/Ionomycin concentrations.	Ionomycin	44-53	interleukin 17A	Homo sapiens	85-90
23415729-8	2013	RESULTS: In the LB group, biopsies showed a significant presence of IL-17+ cells/mm2 of lamina propria compared with the stable, acute A-grade/chronic rejection and infection groups (p < 0.0001).	lb	16-18	interleukin 17A	Homo sapiens	68-73
23415729-10	2013	Azithromycin reduced both %BAL neutrophilia and IL-17+ cells (both p = 0.016) in the LB group.	Azithromycin	0-12	interleukin 17A	Homo sapiens	48-53
23415729-10	2013	Azithromycin reduced both %BAL neutrophilia and IL-17+ cells (both p = 0.016) in the LB group.	lb	85-87	interleukin 17A	Homo sapiens	48-53
23415729-13	2013	Moreover, azithromycin significantly decreased the number of IL-17+ cells in the airway wall, which may further explain its effect on BAL neutrophilia.	Azithromycin	10-22	interleukin 17A	Homo sapiens	61-66
23626544-3	2013	Interestingly, immunohistochemical staining revealed that prominent CD163(+) proinflammatory macrophages and IL-17-producing cells were infiltrating around plasma cells, which might suggest the reason for the therapeutic effect of topical tacrolimus on PLC.	Tacrolimus	239-249	interleukin 17A	Homo sapiens	109-114
23421940-11	2013	Most importantly, treatment with STAT3 inhibitor reversed the protective effect of IL-17 on FLSs apoptosis induced by sodium nitroprusside (SNP).	Nitroprusside	118-138	interleukin 17A	Homo sapiens	83-88
23868508-1	2013	The aim of this study was to investigate the role of vitamin A on RORgammat and IL-17 gene expression in multiple sclerotic patients.	Vitamin A	53-62	interleukin 17A	Homo sapiens	80-85
23868508-4	2013	The results of this study show that vitamin A downregulates IL-17 and RORgammat gene expression.	Vitamin A	36-45	interleukin 17A	Homo sapiens	60-65
23274801-0	2013	IL-17 level in patients with Dengue virus infection & its association with severity of illness.	Adenosine Monophosphate	53-56	interleukin 17A	Homo sapiens	0-5
23190888-7	2013	Significant correlations were found between SE induced upregulation of mRNA expression for ifn-gamma, il-17, il-22, ip-10, and serum level of antistreptolysin O in psoriatic patients.	Selenium	44-46	interleukin 17A	Homo sapiens	102-107
23628048-8	2013	It is concluded that the serum levels of all cytokines from the patients after NAHSCT increased significantly, in which the levels of IL-2, IL-4 and IL-17 increased early, but the level of INF-gamma changed late.	nahsct	79-85	interleukin 17A	Homo sapiens	149-154
23628053-8	2013	In response to phytohemagglutinin (PHA, 1 microg/ml), PBMNC from SpA patients secreted more IL-17 than that from healthy control [(573.95 +- 171.68) pg/ml vs (115.53 +- 40.41) pg/ml (P < 0.01)].	pbmnc	54-59	interleukin 17A	Homo sapiens	92-97
23331973-5	2013	In secondary mixed lymphocyte cultures, CsA dramatically decreased donor-specific IFN-gamma production, enhanced IL-17 production and did not affect IL-13.	Cyclosporine	40-43	interleukin 17A	Homo sapiens	113-118
23608554-8	2013	Decreased levels of TNF-alpha, IL-1beta and IL-17 were found in hydroxyurea-treated patients.	Hydroxyurea	64-75	interleukin 17A	Homo sapiens	44-49
23422488-4	2013	The percentage of both IFN-gamma- and IL-17-producing Th17/Th1-like cells was significantly higher in the pSS, as compared to the control group, whereas that of Th2 cells was lower.	pss	106-109	interleukin 17A	Homo sapiens	38-43
22904262-8	2013	Notably, IL-17-producing DN T cells from SS patients, but not from healthy controls, were strongly resistant to the in vitro effect of dexamethasone.	Dexamethasone	135-148	interleukin 17A	Homo sapiens	9-14
23590971-6	2013	Treatments with inhibitors of caspase-1 and Stat3 reduce the Fas-signal-associated induction of RORgammat, IL-17A, and IL-17F, as well as the phosphorylation of Stat3.	ammonium ferrous sulfate	61-64	interleukin 17A	Homo sapiens	107-113
23160983-7	2013	IL17, IL-23 and IL2 + 4 stimulations significantly hampered Dexamethasone-inhibition of proliferation (Dex EC(50) for: IL-17A + F = 251 nM; IL-23 = 435 nM; IL2 + 4 = 950 nM; Medium = 90 nM).	Dexamethasone	60-73	interleukin 17A	Homo sapiens	0-4
23160983-7	2013	IL17, IL-23 and IL2 + 4 stimulations significantly hampered Dexamethasone-inhibition of proliferation (Dex EC(50) for: IL-17A + F = 251 nM; IL-23 = 435 nM; IL2 + 4 = 950 nM; Medium = 90 nM).	Dexamethasone	60-73	interleukin 17A	Homo sapiens	119-125
23160983-7	2013	IL17, IL-23 and IL2 + 4 stimulations significantly hampered Dexamethasone-inhibition of proliferation (Dex EC(50) for: IL-17A + F = 251 nM; IL-23 = 435 nM; IL2 + 4 = 950 nM; Medium = 90 nM).	Dextromethorphan	60-63	interleukin 17A	Homo sapiens	0-4
23160983-7	2013	IL17, IL-23 and IL2 + 4 stimulations significantly hampered Dexamethasone-inhibition of proliferation (Dex EC(50) for: IL-17A + F = 251 nM; IL-23 = 435 nM; IL2 + 4 = 950 nM; Medium = 90 nM).	Dextromethorphan	60-63	interleukin 17A	Homo sapiens	119-125
23160983-8	2013	IL2 + 4 and IL17A + F but not IL-23, significantly hampered Dexamethasone-induced apoptosis (1400 and 320 nM Dex, respectively).	Dexamethasone	60-73	interleukin 17A	Homo sapiens	12-17
23160983-8	2013	IL2 + 4 and IL17A + F but not IL-23, significantly hampered Dexamethasone-induced apoptosis (1400 and 320 nM Dex, respectively).	Dextromethorphan	60-63	interleukin 17A	Homo sapiens	12-17
23160983-9	2013	Dexamethasone"s trans-activation of GILZ and trans-repression of NF-kB-driven IL-6 expression were both inhibited by IL2 + 4; IL17 + IL23 antagonized Dex trans-repression in PBMC from asthmatics.	Dexamethasone	0-13	interleukin 17A	Homo sapiens	126-130
23160983-9	2013	Dexamethasone"s trans-activation of GILZ and trans-repression of NF-kB-driven IL-6 expression were both inhibited by IL2 + 4; IL17 + IL23 antagonized Dex trans-repression in PBMC from asthmatics.	Dextromethorphan	0-3	interleukin 17A	Homo sapiens	126-130
23160983-10	2013	CONCLUSIONS: GR-beta up-regulation by IL-17/IL-23 cytokines is associated with induced steroid insensitivity in PBMCs, observed as diminished Dexamethasone"s effects on cell proliferation, apoptosis and gene regulation.	Steroids	87-94	interleukin 17A	Homo sapiens	38-43
23160983-10	2013	CONCLUSIONS: GR-beta up-regulation by IL-17/IL-23 cytokines is associated with induced steroid insensitivity in PBMCs, observed as diminished Dexamethasone"s effects on cell proliferation, apoptosis and gene regulation.	Dexamethasone	142-155	interleukin 17A	Homo sapiens	38-43
23409930-4	2013	On further investigation, we observe a marked reduction in retinoid-related orphan nuclear receptor (RORgammat; Th17 lineage specific transcription factor) binding at IL-17 promoter in HIV patients with high viremia (pVL>10,000 copies/mL) in contrast to relatively low viremic patients which indicate the magnitude of viral copy number on RORgammat binding at IL-17 promoter.	Retinoids	59-67	interleukin 17A	Homo sapiens	167-172
23409930-4	2013	On further investigation, we observe a marked reduction in retinoid-related orphan nuclear receptor (RORgammat; Th17 lineage specific transcription factor) binding at IL-17 promoter in HIV patients with high viremia (pVL>10,000 copies/mL) in contrast to relatively low viremic patients which indicate the magnitude of viral copy number on RORgammat binding at IL-17 promoter.	Retinoids	59-67	interleukin 17A	Homo sapiens	363-368
23164666-2	2013	Differentiation of Th1 and Th17 subsets is mainly regulated by interleukins (ILs) secreted from dendritic cells (DCs) and the ability of inorganic arsenic to impair interferon-gamma and IL-17 secretion by interfering with the physiology of DCs is unknown.	Arsenic	147-154	interleukin 17A	Homo sapiens	186-191
23164666-7	2013	Finally, differentiation of monocytes with non-cytotoxic concentrations of As(III) subsequently reduces the ability of activated DCs to stimulate the release of interferon-gamma and IL-17 from Th cells.	as(iii)	75-82	interleukin 17A	Homo sapiens	182-187
23184956-0	2013	Pyroglutamate and O-linked glycan determine functional production of anti-IL17A and anti-IL22 peptide-antibody bispecific genetic fusions.	Pyrrolidonecarboxylic Acid	0-13	interleukin 17A	Homo sapiens	74-79
24078927-0	2013	Synthesis of a novel thiazolidinedione and evaluation of its modulatory effect on IFN- gamma , IL-6, IL-17A, and IL-22 production in PBMCs from rheumatoid arthritis patients.	2,4-thiazolidinedione	21-38	interleukin 17A	Homo sapiens	101-107
23710436-5	2013	CONCLUSIONS: The present study demonstrated that 1,25(OH)2D3 reduced the production of RANKL and the secretion of TNF- alpha , IL-17, and IL-6 in PBMCs of RA patients, which indicated that 1,25(OH)2D3 might be able to decrease damage of cartilage and bone in RA patients by regulating the expression of RANKL signaling pathway and pathway-associated cytokines.	(oh)2d3	53-60	interleukin 17A	Homo sapiens	127-132
24489536-4	2013	To compare the effect of narrow band ultraviolet B (NB-UVB) and methotrexate (MTX) therapy on serum levels of IL-17 and IL-23 in psoriatic patients.	Methotrexate	64-76	interleukin 17A	Homo sapiens	110-115
24489536-4	2013	To compare the effect of narrow band ultraviolet B (NB-UVB) and methotrexate (MTX) therapy on serum levels of IL-17 and IL-23 in psoriatic patients.	Methotrexate	78-81	interleukin 17A	Homo sapiens	110-115
23184956-0	2013	Pyroglutamate and O-linked glycan determine functional production of anti-IL17A and anti-IL22 peptide-antibody bispecific genetic fusions.	o-linked glycan	18-33	interleukin 17A	Homo sapiens	74-79
23184956-5	2013	When a glutamine residue was introduced at the N terminus, which can be cyclized to form pyroglutamate in mammalian cells, the IL17A neutralization activity of the fusion protein was restored.	Glutamine	7-16	interleukin 17A	Homo sapiens	127-132
23184956-5	2013	When a glutamine residue was introduced at the N terminus, which can be cyclized to form pyroglutamate in mammalian cells, the IL17A neutralization activity of the fusion protein was restored.	Pyrrolidonecarboxylic Acid	89-102	interleukin 17A	Homo sapiens	127-132
23184956-6	2013	Interestingly, the mass spectroscopic analysis of the purified fusion protein revealed an unexpected O-linked glycosylation modification at threonine 5 of the anti-IL17A peptide.	Threonine	140-149	interleukin 17A	Homo sapiens	164-169
23573194-4	2013	The effect of Budesonide and Formoterol was tested "in vitro" on IL-17A, RORgamma(t) and FOXP3 expression in cultured T-lymphocytes from mild-moderate asthma/persistent rhinitis patients, and on nasal and bronchial epithelial cells stimulated with NW and Ss from mild-moderate asthma/persistent rhinitis.	Formoterol Fumarate	29-39	interleukin 17A	Homo sapiens	65-71
22983163-7	2013	The assay was validated by performing dose-response testing of rapamycin and cyclosporine A, which had previously been reported to inhibit IL-17, and determining, for the first time, their in vitro potencies (IC(50)s of 80 +- 23 pM and 223 +- 52 nM, respectively).	Sirolimus	63-72	interleukin 17A	Homo sapiens	139-144
22983163-7	2013	The assay was validated by performing dose-response testing of rapamycin and cyclosporine A, which had previously been reported to inhibit IL-17, and determining, for the first time, their in vitro potencies (IC(50)s of 80 +- 23 pM and 223 +- 52 nM, respectively).	Cyclosporine	77-91	interleukin 17A	Homo sapiens	139-144
23533402-6	2013	Conversely, TCDD treatment led to epigenetic modification of IL-17A and conversion of Treg to Th17 T cells.	Polychlorinated Dibenzodioxins	12-16	interleukin 17A	Homo sapiens	61-67
23880957-6	2013	RESULTS: TNFalpha, LPS and poly(I:C) induced an increase in IL-17RA in RA-FLS, whereas TNFalpha, TNFalpha plus IL-17 and poly(I:C) enhanced IL-17RC transcripts in FLS.	poly	27-31	interleukin 17A	Homo sapiens	60-65
23555696-3	2013	The cytokine IL-17A has been recently identified as a potent inducer of several AMP in keratinocytes.	Adenosine Monophosphate	80-83	interleukin 17A	Homo sapiens	13-19
23555696-6	2013	This combination was more effective in inducing RNase 7 than the combination of IL-17A/TNF-alpha, a combination previously identified as a strong inducer of psoriasis-related immune response genes including several AMP.	Adenosine Monophosphate	215-218	interleukin 17A	Homo sapiens	80-86
23555696-10	2013	Similarly as seen with RNase 7, treatment of keratinocytes with IL-17A/IFN-gamma revealed also a synergistic induction of gene expression of the AMP human beta-defensin (hBD)-2 and -3 as well as the S100 protein psoriasin (S100A7) indicating that the combination of IL-17A/IFN-gamma is a potent inducer of various AMP classes in general.	Adenosine Monophosphate	145-148	interleukin 17A	Homo sapiens	64-70
23555696-10	2013	Similarly as seen with RNase 7, treatment of keratinocytes with IL-17A/IFN-gamma revealed also a synergistic induction of gene expression of the AMP human beta-defensin (hBD)-2 and -3 as well as the S100 protein psoriasin (S100A7) indicating that the combination of IL-17A/IFN-gamma is a potent inducer of various AMP classes in general.	Adenosine Monophosphate	314-317	interleukin 17A	Homo sapiens	64-70
23573194-8	2013	Budesonide with Formoterol reduced IL-17A and RORgamma(t), while increased FOXP3 in cultured T-lymphocytes from mild-moderate asthma/persistent rhinitis, and reduced the IL-8 release mediated by IL-17A present in NW and Ss from mild-moderate asthma/persistent rhinitis in nasal and bronchial epithelial cells.	Budesonide	0-10	interleukin 17A	Homo sapiens	35-41
23573194-8	2013	Budesonide with Formoterol reduced IL-17A and RORgamma(t), while increased FOXP3 in cultured T-lymphocytes from mild-moderate asthma/persistent rhinitis, and reduced the IL-8 release mediated by IL-17A present in NW and Ss from mild-moderate asthma/persistent rhinitis in nasal and bronchial epithelial cells.	Budesonide	0-10	interleukin 17A	Homo sapiens	195-201
23573194-8	2013	Budesonide with Formoterol reduced IL-17A and RORgamma(t), while increased FOXP3 in cultured T-lymphocytes from mild-moderate asthma/persistent rhinitis, and reduced the IL-8 release mediated by IL-17A present in NW and Ss from mild-moderate asthma/persistent rhinitis in nasal and bronchial epithelial cells.	Formoterol Fumarate	16-26	interleukin 17A	Homo sapiens	35-41
23573194-8	2013	Budesonide with Formoterol reduced IL-17A and RORgamma(t), while increased FOXP3 in cultured T-lymphocytes from mild-moderate asthma/persistent rhinitis, and reduced the IL-8 release mediated by IL-17A present in NW and Ss from mild-moderate asthma/persistent rhinitis in nasal and bronchial epithelial cells.	Formoterol Fumarate	16-26	interleukin 17A	Homo sapiens	195-201
23573194-9	2013	Finally, Budesonide with Formoterol reduced IL-17A levels in P and Ss, CD4(+)IL-17A(+)T-cells, in naive children with mild-moderate asthma/persistent rhinitis after 12 weeks of treatment.	Budesonide	9-19	interleukin 17A	Homo sapiens	44-50
23573194-9	2013	Finally, Budesonide with Formoterol reduced IL-17A levels in P and Ss, CD4(+)IL-17A(+)T-cells, in naive children with mild-moderate asthma/persistent rhinitis after 12 weeks of treatment.	Budesonide	9-19	interleukin 17A	Homo sapiens	77-83
23573194-9	2013	Finally, Budesonide with Formoterol reduced IL-17A levels in P and Ss, CD4(+)IL-17A(+)T-cells, in naive children with mild-moderate asthma/persistent rhinitis after 12 weeks of treatment.	Formoterol Fumarate	25-35	interleukin 17A	Homo sapiens	44-50
23573194-9	2013	Finally, Budesonide with Formoterol reduced IL-17A levels in P and Ss, CD4(+)IL-17A(+)T-cells, in naive children with mild-moderate asthma/persistent rhinitis after 12 weeks of treatment.	Formoterol Fumarate	25-35	interleukin 17A	Homo sapiens	77-83
23505568-6	2013	IL-17A production was found to be preferentially sensitive to inhibition of the PI3K/mTOR pathway, while prostaglandin EP receptor agonists, including PGE2, increased IL-17A concentrations.	Dinoprostone	151-155	interleukin 17A	Homo sapiens	167-173
23489689-7	2013	The level of IL-10 produced by the treated cells was also enhanced, whereas the expression of IL-17 was prominently attenuated, which could be offset by anti-Jagged-1 antibody or DAPT.	dapt	179-183	interleukin 17A	Homo sapiens	94-99
23437201-0	2013	Significance and suppression of redundant IL17 responses in acute allograft rejection by bioinformatics based drug repositioning of fenofibrate.	Fenofibrate	132-143	interleukin 17A	Homo sapiens	42-46
23437201-7	2013	A combined IL17/IFN-y suppressive role was predicted for the antilipidemic drug Fenofibrate.	Fenofibrate	80-91	interleukin 17A	Homo sapiens	11-21
23437201-8	2013	To assess the immunregulatory action of Fenofibrate, we conducted in-vitro treatment of anti-CD3/CD28 stimulated human peripheral blood cells (PBMC), and, as predicted, Fenofibrate reduced IL17 and IFN-gamma gene expression in stimulated PMBC.	Fenofibrate	169-180	interleukin 17A	Homo sapiens	189-193
23437201-9	2013	In-vivo Fenofibrate treatment of an experimental rodent model of cardiac AR reduced infiltration of total leukocytes, reduced expression of IL17/IFN-y and their pathway related genes in allografts and recipients" spleens, and extended graft survival by 21 days (p<0.007).	Fenofibrate	8-19	interleukin 17A	Homo sapiens	140-150
23308194-0	2013	The microbial capsular polysaccharide galactoxylomannan inhibits IL-17A production in circulating T cells from rheumatoid arthritis patients.	Polysaccharides	23-37	interleukin 17A	Homo sapiens	65-71
23326479-9	2013	Additionally, DON significantly induced the expression of genes involved in the differentiation of Th17 cells (STAT3, IL-17A, IL-6, IL-1beta) at the expenses of the pathway of regulatory T cells (Treg) (FoxP3, RALDH1).	deoxynivalenol	14-17	interleukin 17A	Homo sapiens	118-124
23069765-0	2013	Unexpected mucin-type O-glycosylation and host-specific N-glycosylation of human recombinant interleukin-17A expressed in a human kidney cell line.	Nitrogen	56-57	interleukin 17A	Homo sapiens	93-108
23069765-1	2013	The T helper cell-derived cytokine interleukin-17A (IL-17A) is a variably glycosylated disulfide-linked homodimer of 34-38 kDa.	Disulfides	87-96	interleukin 17A	Homo sapiens	35-50
23069765-1	2013	The T helper cell-derived cytokine interleukin-17A (IL-17A) is a variably glycosylated disulfide-linked homodimer of 34-38 kDa.	Disulfides	87-96	interleukin 17A	Homo sapiens	52-58
23069765-2	2013	Its polypeptide monomer contains one canonical N-glycosylation site at Asn68, and human recombinant IL-17A was partly N-glycosylated when expressed in human kidney (HEK293) cells as a fusion protein with a melittin signal sequence and an N-terminal hexahistidine tag.	Nitrogen	118-119	interleukin 17A	Homo sapiens	100-106
23069765-2	2013	Its polypeptide monomer contains one canonical N-glycosylation site at Asn68, and human recombinant IL-17A was partly N-glycosylated when expressed in human kidney (HEK293) cells as a fusion protein with a melittin signal sequence and an N-terminal hexahistidine tag.	His-His-His-His-His-His	249-262	interleukin 17A	Homo sapiens	100-106
23069765-4	2013	The mass spectrum of IL-17A monomer also included peaks shifted by +948 Da from the respective masses of unglycosylated and N-glycosylated polypeptides.	Nitrogen	124-125	interleukin 17A	Homo sapiens	21-27
23069765-7	2013	Therefore, the kidney host cell line not only imposed its characteristic pattern of N-glycosylation on recombinant IL-17A but additionally created an O-glycosylation not known to be present in the T cell-derived cytokine.	Nitrogen	84-85	interleukin 17A	Homo sapiens	115-121
23308194-0	2013	The microbial capsular polysaccharide galactoxylomannan inhibits IL-17A production in circulating T cells from rheumatoid arthritis patients.	galactoxylomannan	38-55	interleukin 17A	Homo sapiens	65-71
23308194-5	2013	GalXM immunomodulating effect on apoptosis and signal transduction pathway involved in IL-17A production was evaluated on T cells.	galactoxylomannan	0-5	interleukin 17A	Homo sapiens	87-93
23308194-8	2013	GalXM induced consistent impairment of IL-17A production and inhibition of STAT3, which was hyperactivated in RA.	galactoxylomannan	0-5	interleukin 17A	Homo sapiens	39-45
24049650-3	2012	Immunohistochemical techniques were used to examine the accumulation of the proinflammatory cytokine IL-17 in forty (n = 40) formalin-fixed, paraffin-embedded oesophageal archived specimens across a range of endoscopic diagnostic categories, and a highly significant difference was found, where P <= 0.001, in IL-17 expression (Kruskall Wallis and Mann-Whitney U) between all the cell types examined.	Formaldehyde	125-133	interleukin 17A	Homo sapiens	101-106
24049650-3	2012	Immunohistochemical techniques were used to examine the accumulation of the proinflammatory cytokine IL-17 in forty (n = 40) formalin-fixed, paraffin-embedded oesophageal archived specimens across a range of endoscopic diagnostic categories, and a highly significant difference was found, where P <= 0.001, in IL-17 expression (Kruskall Wallis and Mann-Whitney U) between all the cell types examined.	Paraffin	141-149	interleukin 17A	Homo sapiens	101-106
23124208-7	2012	Previous data from our group identified cAMP-responsive element modulator alpha (CREMalpha), which is up-regulated in SLE T cells, as a key regulator of epigenetic patterns and gene transcription, e.g. that of IL2 and IL17 genes.	Cyclic AMP	40-44	interleukin 17A	Homo sapiens	218-222
23071273-7	2012	Mechanistic analysis revealed that the enhancing effect of IL-17 production by basophils in T(EM) involved the ERK1/2 signaling pathway, occurred in a contact-independent manner, and was partially mediated by histamine via H(2) and H(4) histamine receptors.	Histamine	209-218	interleukin 17A	Homo sapiens	59-64
22954486-0	2012	Celastrol inhibits interleukin-17A-stimulated rheumatoid fibroblast-like synoviocyte migration and invasion through suppression of NF-kappaB-mediated matrix metalloproteinase-9 expression.	celastrol	0-9	interleukin 17A	Homo sapiens	19-34
22814427-8	2012	PGI(2) analogues (iloprost, treprostinil and beraprost) significantly increased IL-17A and IL-22 in vitro while decreasing IFNgamma production both in SSc and HD PBMC.	Epoprostenol	0-6	interleukin 17A	Homo sapiens	80-86
22814427-8	2012	PGI(2) analogues (iloprost, treprostinil and beraprost) significantly increased IL-17A and IL-22 in vitro while decreasing IFNgamma production both in SSc and HD PBMC.	Iloprost	18-26	interleukin 17A	Homo sapiens	80-86
22814427-8	2012	PGI(2) analogues (iloprost, treprostinil and beraprost) significantly increased IL-17A and IL-22 in vitro while decreasing IFNgamma production both in SSc and HD PBMC.	treprostinil	28-40	interleukin 17A	Homo sapiens	80-86
22814427-8	2012	PGI(2) analogues (iloprost, treprostinil and beraprost) significantly increased IL-17A and IL-22 in vitro while decreasing IFNgamma production both in SSc and HD PBMC.	beraprost	45-54	interleukin 17A	Homo sapiens	80-86
22898922-5	2012	IL-17A and IL-17F-induced proliferation of ASMCs was dependent on ERK1/2 MAPK pathway, while IL-22-induced proliferation involved both ERK1/2 MAPK and NF-kappaB pathways.	asmcs	43-48	interleukin 17A	Homo sapiens	0-6
22802109-6	2012	RESULTS: Combined administration of ETN/MTX significantly inhibited the proliferation of T lymphocytes, decreased serum IL-6, TNF-alpha, IL-1beta, RANKL and macrophage supernatant IL-17, LT-alpha, increased serum IFN-gamma and macrophage supernatant IL-10.	Methotrexate	40-43	interleukin 17A	Homo sapiens	180-185
22796894-1	2012	BACKGROUND & AIMS: IL-17 secreting CD4 (Th17) and CD8 (Tc17) T cells have been implicated in immune-mediated liver diseases, but the molecular basis for their recruitment and positioning within the liver is unknown.	Adenosine Monophosphate	12-15	interleukin 17A	Homo sapiens	23-28
22736020-9	2012	FOXP3+ mucosal CD4+ T cells from both IBD and control specimens were able to make IL-17A in vitro after phorbol myristate acetate (PMA) and ionomycin stimulation, but these cells did not preferentially express Deltaexon2.	Tetradecanoylphorbol Acetate	104-129	interleukin 17A	Homo sapiens	82-88
22736020-9	2012	FOXP3+ mucosal CD4+ T cells from both IBD and control specimens were able to make IL-17A in vitro after phorbol myristate acetate (PMA) and ionomycin stimulation, but these cells did not preferentially express Deltaexon2.	Tetradecanoylphorbol Acetate	131-134	interleukin 17A	Homo sapiens	82-88
22736020-9	2012	FOXP3+ mucosal CD4+ T cells from both IBD and control specimens were able to make IL-17A in vitro after phorbol myristate acetate (PMA) and ionomycin stimulation, but these cells did not preferentially express Deltaexon2.	Ionomycin	140-149	interleukin 17A	Homo sapiens	82-88
23019580-0	2012	cAMP response element modulator alpha controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus.	Cyclic AMP	0-4	interleukin 17A	Homo sapiens	55-60
22954486-6	2012	Results showed that treatment of RA-FLSs with celastrol suppressed the IL-17A-induced migration and invasion abilities of the cells.	celastrol	46-55	interleukin 17A	Homo sapiens	71-77
22954486-7	2012	In addition, celastrol inhibited IL-17A-induced matrix metalloproteinase (MMP)-9 mRNA and protein expression, and the proteolytic activity of MMP-9 in RA-FLSs.	celastrol	13-22	interleukin 17A	Homo sapiens	33-39
22954486-9	2012	In conclusion, celastrol can inhibit IL-17A-induced migration and invasion by suppressing NF-kappaB-mediated MMP-9 expression in RA-FLSs.	celastrol	15-24	interleukin 17A	Homo sapiens	37-43
22521469-6	2012	RESULTS: CLA significantly suppressed the ability of peripheral blood CD4+ and CD8+ T cell subsets to produce IFN-gamma, TNF-alpha and IL-17 and lymphoproliferation at week 12.	Linoleic Acids, Conjugated	9-12	interleukin 17A	Homo sapiens	135-140
22972933-4	2012	Dendritic cells treated with LPS and 3-methyladenine secreted enhanced levels of both IL-1beta and IL-23, and supernatants from these cells stimulated the innate secretion of IL-17, IFN-gamma, and IL-22 by gammadelta T cells.	3-methyladenine	37-52	interleukin 17A	Homo sapiens	175-180
22914361-3	2012	Here, the ex vivo phenotype of CD4(+) and CD8(+) T cells and the frequency and phenotype of gamma interferon (IFN-gamma)- and interleukin 17 (IL-17)-producing cells elicited in short-term and long-term cultures following CFP-10 and purified protein derivative (PPD) stimulation were determined in noninfected persons (non-TBi), latently infected persons (LTBi), and patients with active tuberculosis (ATB).	Thioacetazone	322-325	interleukin 17A	Homo sapiens	142-147
22683003-6	2012	Sirtinol treatment (a known SIRT1 inhibitor) or SIRT1 knockdown by small interfering RNA blocked LPS-stimulated IL-17 and IL-23 expression.	sirtinol	0-8	interleukin 17A	Homo sapiens	112-117
22531062-10	2012	The protein kinase C (PKC)beta/Erk1/2/NF-kappaB (Nuclear Factor kappaappa B) pathway was involved in the development of myocardial fibrosis and IL-17 contributed to cardiac fibrosis following EAM via this pathway.	molibresib	192-195	interleukin 17A	Homo sapiens	144-149
22698519-5	2012	METHODS: The effect of IL-17-induced supernatants on human ASMC migration was investigated.	asmc	59-63	interleukin 17A	Homo sapiens	23-28
22698519-8	2012	RESULTS: IL-17-induced supernatants promoted ASMC migration.	asmc	45-49	interleukin 17A	Homo sapiens	9-14
22698519-11	2012	CONCLUSION: These findings suggest that IL-17-induced GROs can be an important mediator of ASMC migration and therefore might contribute to the pathogenesis of airway remodeling in asthmatic patients.	asmc	91-95	interleukin 17A	Homo sapiens	40-45
22280420-9	2012	Role of cytokines such as TNF-alpha, IL-17 or IL-6 and their links to superoxide and hydrogen peroxide production are discussed.	Superoxides	70-80	interleukin 17A	Homo sapiens	37-42
22281165-2	2012	INCB018424, a small molecule inhibitor of JAK1 and JAK2, inhibits cytokine-induced JAK/signal transducers and activators of transcription signaling and the resultant production of inflammatory proteins (eg, IL-17).	ruxolitinib	0-10	interleukin 17A	Homo sapiens	207-212
22851696-3	2012	Recently, inducible IkappaB kinase (IKKi) has been shown to phosphorylate Act1 on Ser 311 to mediate IL-17-induced mRNA stability.	Serine	82-85	interleukin 17A	Homo sapiens	101-106
22690919-0	2012	Upregulation of stromal cell-derived factor by IL-17 and IL-18 via a phosphatidylinositol 3-kinase-dependent pathway.	Phosphatidylinositols	69-89	interleukin 17A	Homo sapiens	47-52
23351387-7	2012	Significant difference in IL-17 level was observed between NAC/ibuprofen combination group and placebo (p = 0.043).	Acetylcysteine	59-62	interleukin 17A	Homo sapiens	26-31
23351387-7	2012	Significant difference in IL-17 level was observed between NAC/ibuprofen combination group and placebo (p = 0.043).	Ibuprofen	63-72	interleukin 17A	Homo sapiens	26-31
22700697-1	2012	In a screen for small-molecule inhibitors of retinoid acid-related orphan receptor gamma (RORgamma), we fortuitously discovered that a class of aryl amide compounds behaved as functional activators of the interleukin 17 (IL-17) reporter in Jurkat cells.	aryl amide	144-154	interleukin 17A	Homo sapiens	205-219
22700697-1	2012	In a screen for small-molecule inhibitors of retinoid acid-related orphan receptor gamma (RORgamma), we fortuitously discovered that a class of aryl amide compounds behaved as functional activators of the interleukin 17 (IL-17) reporter in Jurkat cells.	aryl amide	144-154	interleukin 17A	Homo sapiens	221-226
22542425-2	2012	We recently showed high serum levels of interleukin (IL)-17 in patients with gonococcal infection and we hypothesized that Neisseria gonorrhoeae could exploit a PGE2 mediated mechanism to promote IL-17 production.	Dinoprostone	161-165	interleukin 17A	Homo sapiens	40-59
22542425-2	2012	We recently showed high serum levels of interleukin (IL)-17 in patients with gonococcal infection and we hypothesized that Neisseria gonorrhoeae could exploit a PGE2 mediated mechanism to promote IL-17 production.	Dinoprostone	161-165	interleukin 17A	Homo sapiens	196-201
22542425-5	2012	N. gonorrhoeae stimulated DC induce a robust IL-17 production by memory CD4(+) T cells and this function correlates with PGE2 production.	Dinoprostone	121-125	interleukin 17A	Homo sapiens	45-50
23028326-4	2012	Despite this difference, mangabey NKT lymphocytes were functionally distinct from both macaque species in their ability to secrete significantly more IFN-gamma, IL-13, and IL-17 in response to CD1d/alpha-galactosylceramide stimulation.	alpha-galactosylceramide	198-222	interleukin 17A	Homo sapiens	172-177
22993666-1	2012	AIM: To assess vitamin D in hepatitis C patients and its relationship to interleukin (IL)-23, IL-17, and macrophage chemoattractant protein-1 (MCP-1).	Vitamin D	15-24	interleukin 17A	Homo sapiens	94-99
22993666-20	2012	IL-23, IL-17, and MCP-1 were markedly increased in HCV-infected patients in comparison to controls.A significant negative correlation between vitamin D and IL-17 and -23 and MCP-1 was detected.	Vitamin D	142-151	interleukin 17A	Homo sapiens	156-169
22435970-8	2012	However, levels of IL-17 (P<0.0001) after isotretinoin treatment were higher than those of the control group, despite a significant decline after treatment.	Isotretinoin	45-57	interleukin 17A	Homo sapiens	19-24
22435970-10	2012	CONCLUSIONS: This study shows that isotretinoin treatment significantly decreases TNF, IL-4, IL-17 and IFN-gamma levels in patients with acne.	Isotretinoin	35-47	interleukin 17A	Homo sapiens	93-98
22314659-1	2012	BACKGROUND: This pilot study aimed to assess whether the perioperative infusion of donor bone marrow cells (DBMC) in renal allograft recipients can affect the appearance of peripheral regulatory T-cell subsets and the profile of cytokine-producing cells [interferon-gamma (IFN-gamma), interleukin (IL)-17 and IL-10] 2 years after transplantation.	4,6-Di-tert-butyl-m-cresol	108-112	interleukin 17A	Homo sapiens	285-304
22836084-0	2012	Delivery of IL-12p40 ameliorates DSS-induced colitis by suppressing IL-17A expression and inflammation in the intestinal mucosa.	dss	33-36	interleukin 17A	Homo sapiens	68-74
22836084-6	2012	Our results demonstrate that IL-12p40 delivery ameliorates DSS-induced colitis by suppressing IL-17A production and inflammation in the intestinal mucosa, providing an effective new therapeutic strategy for IBDs.	dss	59-62	interleukin 17A	Homo sapiens	94-100
22563781-13	2012	Especially, IL-17 and IL-32 expressing B cells (Br17 & Br32) are present.	Adenosine Monophosphate	54-57	interleukin 17A	Homo sapiens	12-17
22672991-4	2012	Treg cells from IND present suppressive activity, although the mechanism is not IL-10 or CTLA-4 dependent and are able to produce augmented levels of IL-17, IL-10 and granzyme B being its frequency correlated with percentage of Annexin V(+) CD4(+)-cells.	indole	16-19	interleukin 17A	Homo sapiens	150-155
22415432-6	2012	After stimulation with PMA and ionomycin, gammadelta T cells from HBV-ACLF patients produced the greatest amount of TNF-alpha or IL-17 among the three groups.	Tetradecanoylphorbol Acetate	23-26	interleukin 17A	Homo sapiens	129-134
22805469-11	2012	LPS pre-treatment enhanced SEB-induced IL-5, IL-13 and IL-17A production in diclofenac-treated DNPCs, while addition of PGE(2)  inhibited IL-5, IL-13 and IFN-gamma production.	Diclofenac	76-86	interleukin 17A	Homo sapiens	55-61
22805469-11	2012	LPS pre-treatment enhanced SEB-induced IL-5, IL-13 and IL-17A production in diclofenac-treated DNPCs, while addition of PGE(2)  inhibited IL-5, IL-13 and IFN-gamma production.	dnpcs	95-100	interleukin 17A	Homo sapiens	55-61
22415432-6	2012	After stimulation with PMA and ionomycin, gammadelta T cells from HBV-ACLF patients produced the greatest amount of TNF-alpha or IL-17 among the three groups.	Ionomycin	31-40	interleukin 17A	Homo sapiens	129-134
21691744-0	2012	Methotrexate attenuates the Th17/IL-17 levels in peripheral blood mononuclear cells from healthy individuals and RA patients.	Methotrexate	0-12	interleukin 17A	Homo sapiens	33-38
21691744-6	2012	The augmentation of IL-17 at the mRNA and protein levels was significantly inhibited when PBMC cultures were preincubated with MTX.	Methotrexate	127-130	interleukin 17A	Homo sapiens	20-25
21691744-7	2012	Compared with PBMCs of healthy donors, PBMCs of RA patients produced higher levels of IL-17, and this increase in IL-17 levels was more inhibited by MTX pretreatment.	Methotrexate	149-152	interleukin 17A	Homo sapiens	86-91
21691744-7	2012	Compared with PBMCs of healthy donors, PBMCs of RA patients produced higher levels of IL-17, and this increase in IL-17 levels was more inhibited by MTX pretreatment.	Methotrexate	149-152	interleukin 17A	Homo sapiens	114-119
21691744-8	2012	MTX inhibited IL-17 at the mRNA level in a dose-dependent manner, but not at the protein level, in both PBMCs of healthy donors and RA patients.	Methotrexate	0-3	interleukin 17A	Homo sapiens	14-19
21691744-10	2012	MTX dose dependently suppressed the production of IL-17 at the mRNA level by PBMCs from healthy donors and RA patients.	Methotrexate	0-3	interleukin 17A	Homo sapiens	50-55
21691744-11	2012	Suppression of IL-17 by MTX may contribute to its potent anti-inflammatory role in RA therapy.	Methotrexate	24-27	interleukin 17A	Homo sapiens	15-20
22617429-0	2012	Inorganic arsenic represses interleukin-17A expression in human activated Th17 lymphocytes.	inorganic arsenic	0-17	interleukin 17A	Homo sapiens	28-43
22211698-7	2012	These results suggest that the IL-17-induced pro-inflammatory reaction is enhanced by the activation of PAR2 in keratinocytes, and that the effect of PAR2 is differentially modulated by cyclosporine A, the active form of vitamin D(3)  and glucocorticoids.	Cyclosporine	186-200	interleukin 17A	Homo sapiens	31-36
22211698-7	2012	These results suggest that the IL-17-induced pro-inflammatory reaction is enhanced by the activation of PAR2 in keratinocytes, and that the effect of PAR2 is differentially modulated by cyclosporine A, the active form of vitamin D(3)  and glucocorticoids.	Vitamin D	221-230	interleukin 17A	Homo sapiens	31-36
22607938-12	2012	Several other cytokines and inflammation markers in tears, including MMP-9, IL-15, IL-17A, and IL-12p70, were markedly reduced in the tofacitinib 0.005% QD group but not the vehicle group.	tofacitinib	134-145	interleukin 17A	Homo sapiens	83-89
22579702-0	2012	Tacrolimus potently inhibits human osteoclastogenesis induced by IL-17 from human monocytes alone and suppresses human Th17 differentiation.	Tacrolimus	0-10	interleukin 17A	Homo sapiens	65-70
22579702-4	2012	The present study was undertaken to assess the effect of tacrolimus on IL-17-induced human osteoclastogenesis and human Th17 differentiation.	Tacrolimus	57-67	interleukin 17A	Homo sapiens	71-76
22579702-10	2012	Tacrolimus potently inhibited IL-17-induced osteoclastogenesis from human monocytes and osteoclast activation.	Tacrolimus	0-10	interleukin 17A	Homo sapiens	30-35
22579702-11	2012	Addition of tacrolimus also reduced production of IL-17 in human activated T cells stimulated with IL-23.	Tacrolimus	12-22	interleukin 17A	Homo sapiens	50-55
22579702-12	2012	Interestingly, the population of human IL-17(+)IFN-gamma(-) CD4 T cells or IL-17(+)TNF-alpha(+) CD4 T cells were decreased by adding of tacrolimus.	Tacrolimus	136-146	interleukin 17A	Homo sapiens	39-44
22579702-12	2012	Interestingly, the population of human IL-17(+)IFN-gamma(-) CD4 T cells or IL-17(+)TNF-alpha(+) CD4 T cells were decreased by adding of tacrolimus.	Tacrolimus	136-146	interleukin 17A	Homo sapiens	75-80
22579702-13	2012	The present study demonstrates that the inhibitory effect of tacrolimus on IL-17-induced osteoclastogenesis from human monocytes.	Tacrolimus	61-71	interleukin 17A	Homo sapiens	75-80
22579702-14	2012	Tacrolimus also inhibited expression of IL-17 or TNF-alpha by reducing the proportion of Th17, suggesting that therapeutic effect on Th17-associated disease such as RA, inflammatory bowel disease, multiple sclerosis, psoriasis, or allograft rejection.	Tacrolimus	0-10	interleukin 17A	Homo sapiens	40-45
22669715-12	2012	Treatment with corticosteroids and cyclosporine A (CsA) resolved the intraocular inflammation in association with an upregulation of IL-27 and a downregulation of IL-17.	Cyclosporine	35-49	interleukin 17A	Homo sapiens	163-168
22669715-12	2012	Treatment with corticosteroids and cyclosporine A (CsA) resolved the intraocular inflammation in association with an upregulation of IL-27 and a downregulation of IL-17.	Cyclosporine	51-54	interleukin 17A	Homo sapiens	163-168
22343219-0	2012	Glycosphingolipids mediate pneumocystis cell wall beta-glucan activation of the IL-23/IL-17 axis in human dendritic cells.	Glycosphingolipids	0-18	interleukin 17A	Homo sapiens	86-91
22343219-0	2012	Glycosphingolipids mediate pneumocystis cell wall beta-glucan activation of the IL-23/IL-17 axis in human dendritic cells.	beta-Glucans	50-61	interleukin 17A	Homo sapiens	86-91
22343219-5	2012	Accordingly, we further observe that PCBG-stimulated human DCs interact with lymphocytes to drive the secretion of IL-17 and IL-22, both Th17-produced cytokines.	S-(1,2,3,4,4-Pentachloro-1,3-butadienyl)glutathione	37-41	interleukin 17A	Homo sapiens	115-120
22343219-8	2012	These data strongly support the idea that the beta-glucan surface components of Pneumocystis drive the activation of the IL-23/IL-17 axis during this infection, through a glycosphingolipid-initiated mechanism.	beta-Glucans	46-57	interleukin 17A	Homo sapiens	127-132
22343219-8	2012	These data strongly support the idea that the beta-glucan surface components of Pneumocystis drive the activation of the IL-23/IL-17 axis during this infection, through a glycosphingolipid-initiated mechanism.	Glycosphingolipids	171-188	interleukin 17A	Homo sapiens	127-132
22504663-3	2012	Peripheral blood mononuclear cells (PBMCs) isolated from Swedish adults produced IL-17A after stimulation with WCA, with the pneumolysoid PdT and with the protein required for cell separation in group B streptococci (PcsB).	wca	111-114	interleukin 17A	Homo sapiens	81-87
22147632-0	2012	The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells.	tofacitinib	18-29	interleukin 17A	Homo sapiens	93-107
22147632-5	2012	RESULTS: Tofacitinib treatment of CD4+ T cells originating from synovium and peripheral blood inhibited the production of interleukin-17 (IL-17) and interferon-gamma (IFNgamma) in a dose-dependent manner, affecting both proliferation and transcription, but had no effect on IL-6 and IL-8 production.	tofacitinib	9-20	interleukin 17A	Homo sapiens	122-136
22147632-5	2012	RESULTS: Tofacitinib treatment of CD4+ T cells originating from synovium and peripheral blood inhibited the production of interleukin-17 (IL-17) and interferon-gamma (IFNgamma) in a dose-dependent manner, affecting both proliferation and transcription, but had no effect on IL-6 and IL-8 production.	tofacitinib	9-20	interleukin 17A	Homo sapiens	138-143
22147632-9	2012	CONCLUSION: Tofacitinib directly suppressed the production of IL-17 and IFNgamma and the proliferation of CD4+ T cells, resulting in inhibition of IL-6 production by RASFs and IL-8 production by CD14+ cells and decreased cartilage destruction.	tofacitinib	12-23	interleukin 17A	Homo sapiens	62-80
22350510-6	2012	Zinc aspartate suppressed proliferation as well as IL-2, IL-10 and IL-17 production in stimulated human T cells and mouse splenocytes.	zinc-bis(hydrogenaspartate)	0-14	interleukin 17A	Homo sapiens	67-72
22416258-11	2012	Taken together, the present findings suggest that analysis of the expansion of CD4(+)IFN-gamma(+)IL-17(+) T lymphocytes in peripheral blood of TB patients might be used as an indicator of the clinical outcome in active TB.	Terbium	143-145	interleukin 17A	Homo sapiens	97-102
22527432-4	2012	RESULTS: IL17A, the hallmark of TH17, was consistently seen before and after thalidomide treatment, confirming the TH17 subset to be involved in ENL and potentially up-regulated by thalidomide.	Thalidomide	181-192	interleukin 17A	Homo sapiens	9-14
22444300-7	2012	The proportions of steroid-resistant rejection, incomplete recovery and recurrent ATCMR were higher in the IL-17 high group than in the FOXP3 high group (all indicators, P < 0 05).	Steroids	19-26	interleukin 17A	Homo sapiens	107-112
22548790-12	2012	In addition, both Th17 frequency and plasm IL-17A levels positively correlated with ALT (r = 0.33,p = 0.01 Vs r = 0.29, p = 0.04) and total bilirubin levels (r = 0.72,p<0.0001 Vs r = 0.53, p = 0.0001) in these chronic HBV-infected subjects.	Bilirubin	140-149	interleukin 17A	Homo sapiens	43-49
21993883-9	2012	Additionally, IL-17A induced MAPK (ERK1/2 but not p38 MAPK or JNK) activation, and pharmacological inhibitors of MEK1/2 (U0126) but not of p38 MAPK (SB203580) or JNK (SP600125), significantly blocked the IL-17A-mediated G-CSF release.	U 0126	121-126	interleukin 17A	Homo sapiens	14-20
22370611-0	2012	Vitamin D deficiency is associated with increased IL-17 and TNFalpha levels in patients with chronic heart failure.	Vitamin D	0-9	interleukin 17A	Homo sapiens	50-55
22353714-4	2012	Global transcriptional profiling reveals that IL-17A induces artificial nutrient starvation conditions in Candida albicans, resulting in a downregulation of the target of rapamycin signalling pathway and in an increase in autophagic responses and intracellular cAMP.	Sirolimus	171-180	interleukin 17A	Homo sapiens	46-52
22353714-4	2012	Global transcriptional profiling reveals that IL-17A induces artificial nutrient starvation conditions in Candida albicans, resulting in a downregulation of the target of rapamycin signalling pathway and in an increase in autophagic responses and intracellular cAMP.	Cyclic AMP	261-265	interleukin 17A	Homo sapiens	46-52
21979002-7	2012	RESULTS: IL-22, IL-23 and IL-17 were significantly increased at both protein and mRNA levels in the inflamed salivary glands of patients with pSS.	pss	142-145	interleukin 17A	Homo sapiens	26-31
22236010-7	2012	Senescent cells and CD4(+) /IL-17A(+) cells were increased among graft biopsies in subjects receiving cyclosporin A (CsA) compared to those under belatacept treatment.	Cyclosporine	102-115	interleukin 17A	Homo sapiens	28-34
22236010-7	2012	Senescent cells and CD4(+) /IL-17A(+) cells were increased among graft biopsies in subjects receiving cyclosporin A (CsA) compared to those under belatacept treatment.	Cyclosporine	117-120	interleukin 17A	Homo sapiens	28-34
22219320-3	2012	In cultured ECs, IL-17 increased expression of eNOS, eNOS phosphorylation at Ser(1177), and NO production.	Serine	77-80	interleukin 17A	Homo sapiens	17-22
22442208-7	2012	In those patients who had not received immunosuppressive treatment before biopsy, serum creatinine levels were positively correlated with tubulointerstitial IL-17(+) neutrophils as well as IL-17(+) T cells.	Creatinine	88-98	interleukin 17A	Homo sapiens	157-162
22442208-7	2012	In those patients who had not received immunosuppressive treatment before biopsy, serum creatinine levels were positively correlated with tubulointerstitial IL-17(+) neutrophils as well as IL-17(+) T cells.	Creatinine	88-98	interleukin 17A	Homo sapiens	189-194
22460142-5	2012	In vitro experiments indicated that the effects of tofacitinib were mediated through suppression of interleukin 17 (IL-17) and interferon gamma production and proliferation of CD4 T cells, presumably Th1 and Th17.	tofacitinib	51-62	interleukin 17A	Homo sapiens	100-114
22460142-5	2012	In vitro experiments indicated that the effects of tofacitinib were mediated through suppression of interleukin 17 (IL-17) and interferon gamma production and proliferation of CD4 T cells, presumably Th1 and Th17.	tofacitinib	51-62	interleukin 17A	Homo sapiens	116-121
22058222-4	2012	Interleukin-17A-producing cells were analyzed in formalin-fixed, paraffin-embedded spleen and lymph node sections using immunohistochemistry and immunofluorescence.	Formaldehyde	49-57	interleukin 17A	Homo sapiens	0-15
22058222-4	2012	Interleukin-17A-producing cells were analyzed in formalin-fixed, paraffin-embedded spleen and lymph node sections using immunohistochemistry and immunofluorescence.	Paraffin	65-73	interleukin 17A	Homo sapiens	0-15
22664499-1	2012	BACKGROUND & OBJECTIVES: The interleukin (IL)-17 producing T-helper cells have been linked to pathogenesis of autoimmunity and mostly investigated in rheumatoid arthritis (RA).	Adenosine Monophosphate	12-15	interleukin 17A	Homo sapiens	33-52
22664499-4	2012	The values obtained for IL-17 in pSS patients were also associated with the patients" clinical characteristics, particularly the rheumatoid factor (RF) and total antinuclear antibodies (tANA) levels.	pss	33-36	interleukin 17A	Homo sapiens	24-29
22664499-5	2012	RESULTS: Serum concentrations of IL-17 were significantly (P<0.01) higher in patients with pSS (12.9 +- 28.0 pg/ml) as compared to those obtained in healthy individuals (0.2 +- 0.6 pg/ml), but not as high as the values obtained for the patients with RA (34.5 +- 56.2 pg/ml).	pss	94-97	interleukin 17A	Homo sapiens	33-38
22664499-6	2012	The mean IL-17 levels were significantly (P<0.05) higher in the pSS patients positive for rheumatoid factor (20.3 +- 33.3 pg/ml) than in RF-negatives (0.3 +- 0.6 pg/ml).	pss	67-70	interleukin 17A	Homo sapiens	9-14
22664499-9	2012	INTERPRETATION & CONCLUSIONS: The findings of this study showed that there was increased IL-17 and NO production in patients with primary SS, especially if they had associated elevated rheumatoid factor and antinuclear antibody values.	Adenosine Monophosphate	16-19	interleukin 17A	Homo sapiens	93-98
22065093-1	2012	OBJECTIVES: To identify relationships between vitamin D serum levels and the presence of autoantibodies directed against vitamin D and levels of interleukin(IL)-17 and IL-23 in patients with systemic lupus erythematosus (SLE).	Vitamin D	46-55	interleukin 17A	Homo sapiens	145-163
22541095-9	2012	Serum VEGF and IL-17 levels significantly decreased in MM patients after treatment, and the serum levels of VEGF and IL-17 was much lower in MM patients treated with VAD regimen than those in patients treated with BD regimen.	VAD I protocol	166-169	interleukin 17A	Homo sapiens	117-122
22417709-11	2012	CONCLUSIONS: Our data demonstrate that TLR2 ligation induces the production of IL-23/IL-17 via IL-6, STAT3 and NF-kB pathway in pSS.	pss	128-131	interleukin 17A	Homo sapiens	85-90
22118820-11	2012	The ear thickness in ACD model and the expression of IL-17 and IL-23; PASI score and TEWL values in psoriatic plaque like model were significantly less (p < 0.001) for SPN compared to control gel.	spn	171-174	interleukin 17A	Homo sapiens	53-58
21828034-5	2012	We demonstrated that IL-17A-induced IL-8 production is normally sensitive to GCs, while IL-17A pre-treatment significantly reduced the sensitivity of TNF-alpha-induced IL-8 production to budesonide.	Budesonide	187-197	interleukin 17A	Homo sapiens	88-94
21369944-0	2012	Anti-inflammatory effect of resveratrol and polydatin by in vitro IL-17 modulation.	Resveratrol	28-39	interleukin 17A	Homo sapiens	66-71
21369944-0	2012	Anti-inflammatory effect of resveratrol and polydatin by in vitro IL-17 modulation.	polydatin	44-53	interleukin 17A	Homo sapiens	66-71
21369944-5	2012	We have investigated the effects of resveratrol and polydatin on the in vitro production of IL-17 in a model of inflammation in vitro.	Resveratrol	36-47	interleukin 17A	Homo sapiens	92-97
21369944-5	2012	We have investigated the effects of resveratrol and polydatin on the in vitro production of IL-17 in a model of inflammation in vitro.	polydatin	52-61	interleukin 17A	Homo sapiens	92-97
21993883-9	2012	Additionally, IL-17A induced MAPK (ERK1/2 but not p38 MAPK or JNK) activation, and pharmacological inhibitors of MEK1/2 (U0126) but not of p38 MAPK (SB203580) or JNK (SP600125), significantly blocked the IL-17A-mediated G-CSF release.	pyrazolanthrone	167-175	interleukin 17A	Homo sapiens	14-20
22063299-2	2012	Interleukin (IL)-17-producing T cells (Th17 cells) represent a newly defined major CD4(+) T-cell subset, having been identified in psoriatic plaques and in acute skin lesions of atopic dermatitis where histamine is also present in high concentrations.	Histamine	202-211	interleukin 17A	Homo sapiens	0-19
23383400-2	2012	Increased serum levels of IL6 and IL17A have been detected in sporadic ALS (sALS) patients when compared to healthy controls.	sals	76-80	interleukin 17A	Homo sapiens	34-39
22063299-8	2012	Stimulation with histamine or a H4R agonist increased the production of IL-17 and induced activating protein-1 in Th17 cells.	Histamine	17-26	interleukin 17A	Homo sapiens	72-77
21968742-10	2012	Ex vivo targeting of synovial mast cells with the c-Kit inhibitor imatinib mesylate significantly decreased the production of IL-17 as well as other proinflammatory cytokines in synovial tissue cultures.	Imatinib Mesylate	66-83	interleukin 17A	Homo sapiens	126-131
23507624-3	2012	This study intends to determine the effects of isoproterenol (ISO; beta-agonist) and propranolol (PRO; beta-antagonist) on the production of IFN-gamma, IL-4, and IL-17.	Isoproterenol	47-60	interleukin 17A	Homo sapiens	162-167
23507624-3	2012	This study intends to determine the effects of isoproterenol (ISO; beta-agonist) and propranolol (PRO; beta-antagonist) on the production of IFN-gamma, IL-4, and IL-17.	Propranolol	85-96	interleukin 17A	Homo sapiens	162-167
22262980-3	2012	Comparison of the expression of IL-17, IL-23 and receptors of IL-17, IL-23 in MSG of patients with pSS with probable preclinical pSS, and with nonautoimmune sicca syndrome showed significant differences between three groups.	pss	99-102	interleukin 17A	Homo sapiens	32-37
22262980-3	2012	Comparison of the expression of IL-17, IL-23 and receptors of IL-17, IL-23 in MSG of patients with pSS with probable preclinical pSS, and with nonautoimmune sicca syndrome showed significant differences between three groups.	pss	129-132	interleukin 17A	Homo sapiens	32-37
23226926-7	2012	Moreover, GAgP group showed lower ratios of IL-11/IL-17 when compared to GCP group.	gagp	10-14	interleukin 17A	Homo sapiens	50-55
22056360-5	2012	We further showed that EGCG reduced production of interferon-gamma, IL-17, IL-6, IL-1beta, and tumor necrosis factor-alpha; decreased types 1 and 17 helper T cells (Th1 and Th17, respectively); and increased regulatory T-cell populations in lymph nodes, the spleen, and the central nervous system.	epigallocatechin gallate	23-27	interleukin 17A	Homo sapiens	68-73
23097974-7	2012	The SLE phenotypes are characterized by double CD negativity ( CD3 +/-, CD4-) caused by abnormal level of IL-2 and IL-17.	Cadmium	47-49	interleukin 17A	Homo sapiens	115-120
22724038-9	2012	In functional assays, TSLA stimulated the secretion of IL-17 and IL-23 from PBMCs of PKDL patients, while recIL-17 enhanced the production of TNF-alpha as well as nitric oxide (NO) in PKDL compared to control (TNF-alpha, P = 0.0002; NO, P = 0.0013).	tsla	22-26	interleukin 17A	Homo sapiens	55-60
22952917-6	2012	PBMCs from patients with ASA produce typically less IL-13, IL-7, IL-17 and MIG, and more MIP-1beta and IL-8, as compared to PBMCs from patients without ASA.	Aspirin	25-28	interleukin 17A	Homo sapiens	65-70
23284753-4	2012	We found that dmLT enhanced the production of IL-17A by peripheral blood mononuclear cells in response to all antigens tested.	dmlt	14-18	interleukin 17A	Homo sapiens	46-52
23284753-5	2012	dmLT had comparable effects on IL-17A responses to PPD as the single mutant LT(R192G) adjuvant, which has demonstrated clinical adjuvant activity in humans.	dmlt	0-4	interleukin 17A	Homo sapiens	31-37
23284753-6	2012	Neutralisation of IL-1beta and IL-23, but not IL-6, suppressed the IL-17A-enhancing effect of dmLT.	dmlt	94-98	interleukin 17A	Homo sapiens	67-73
23284753-7	2012	Furthermore, CD4+ T cells produced higher levels of IL-17A when stimulated with monocytes pulsed with PPD and dmLT compared to PPD alone, supporting an important role of antigen presenting cells in enhancing IL-17A responses.	dmlt	110-114	interleukin 17A	Homo sapiens	52-58
23284753-7	2012	Furthermore, CD4+ T cells produced higher levels of IL-17A when stimulated with monocytes pulsed with PPD and dmLT compared to PPD alone, supporting an important role of antigen presenting cells in enhancing IL-17A responses.	dmlt	110-114	interleukin 17A	Homo sapiens	208-214
23284753-8	2012	dmLT also potentiated mitogen-induced IL-17A and IL-13 production.	dmlt	0-4	interleukin 17A	Homo sapiens	38-44
23056446-9	2012	In the presence of anti-PD-L1, PGN induced secretion of IFN-gamma and IL-17 in total CCR6(+) cells, while nickel triggered secretion of IFN-gamma and IL-17 exclusively in CCR6(+)/CCR4(+) cells.	Nickel	106-112	interleukin 17A	Homo sapiens	150-155
22018702-4	2011	1,25-dihydroxyvitamin D inhibited proliferation and suppressed secretion of IFN-gamma and IL-17, irrespective of T cell origin and HLA restriction.	1,25-dihydroxyvitamin D	0-23	interleukin 17A	Homo sapiens	90-95
22025620-3	2011	In this report, we provide evidence that CREMalpha physically binds to a cAMP-responsive element, CRE (-111/-104), within the proximal human IL17A promoter and increases its activity.	Cyclic AMP	73-77	interleukin 17A	Homo sapiens	141-146
21723567-9	2011	Moreover, activated Vitamin D enhanced the development of IL-10 producing cells, and reduced the number of IL-6 and IL-17 secreting cells.	Vitamin D	20-29	interleukin 17A	Homo sapiens	116-121
22123380-0	2011	IL-13 and IL-17A gene polymorphisms in Japanese patients with aspirin-exacerbated respiratory disease.	Aspirin	62-69	interleukin 17A	Homo sapiens	10-16
21996014-10	2011	Time course study showed that increased IL-8 production in the BALF initiated at 6 weeks, but decreased IL-17 production started at 10 weeks following CS exposure.	Cesium	151-153	interleukin 17A	Homo sapiens	104-109
21912264-7	2011	Furthermore, with the addition of the NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B) and extracellular signal-regulated kinase inhibitors pyrrolidine dithiocarbamate and PD98059, the IL-17-induced CCL2 mRNA level was significantly compromised.	pyrrolidine dithiocarbamic acid	160-187	interleukin 17A	Homo sapiens	205-210
21964192-10	2011	RESULTS: Using mixed leukocytes reaction we demonstrated for the first time that both Art-C and PBrazil significantly inhibited the alloreactive CD4 T cell proliferation, activation, and suppressed the expressions of IL-2, IFN-gamma and IL-17 in these alloreactive CD4 T cells.	pbrazil	96-103	interleukin 17A	Homo sapiens	237-242
21964025-5	2011	Costimulation of primary human fibroblasts with IL-17 greatly enhanced respiratory syncytial virus-induced or synthetic dsRNA-based viral mimic polyinosinic:polycytidylic acid-induced expression of proinflammatory genes without affecting expression of IFN-beta-stimulated or IFN-stimulated genes.	Poly C	157-175	interleukin 17A	Homo sapiens	48-53
21985374-6	2011	In vitro, HepG2 cells cultured in the presence of free fatty acids (FFA; oleic acid and palmitic acid) for 24 h and IL-17 developed steatosis via insulin-signalling pathway interference.	Fatty Acids, Nonesterified	50-66	interleukin 17A	Homo sapiens	116-121
21985374-6	2011	In vitro, HepG2 cells cultured in the presence of free fatty acids (FFA; oleic acid and palmitic acid) for 24 h and IL-17 developed steatosis via insulin-signalling pathway interference.	Fatty Acids, Nonesterified	68-71	interleukin 17A	Homo sapiens	116-121
21985374-6	2011	In vitro, HepG2 cells cultured in the presence of free fatty acids (FFA; oleic acid and palmitic acid) for 24 h and IL-17 developed steatosis via insulin-signalling pathway interference.	Oleic Acid	73-83	interleukin 17A	Homo sapiens	116-121
21985375-5	2011	Simvastatin arrested phytohaemaglutinin (PHA)-induced T cells at the G0/G1 phase, inhibiting T helper type 1 (Th1), Th2, interleukin (IL)-10 and IL-17A cytokine secretion in both patients and healthy control groups.	Simvastatin	0-11	interleukin 17A	Homo sapiens	145-151
21955625-7	2011	Among children with ETB, those with neurologic involvement exhibited more significantly diminished Ag-driven IFN-gamma and IL-17 production.	etb	20-23	interleukin 17A	Homo sapiens	123-128
21818055-7	2011	Accordingly, renal transplant patients treated with MPA in combination with minimized dose of tacrolimus tended to have lower circulating IL-17 levels than patients treated with tacrolimus alone given at conventional dose.	Mycophenolic Acid	52-55	interleukin 17A	Homo sapiens	138-143
22211683-5	2012	Ingestion of HFM-P induced an inflammatory response mediated by TNF-alpha (p < 0.001), IL-6 (p < 0.001) and IL-17 (p < 0.01).	hfm-p	13-18	interleukin 17A	Homo sapiens	114-119
22408746-4	2011	IL-17 increased the suppressive function of MDSCs on T cells through the upregulation of Arg, IDO, and COX2.	Arginine	89-92	interleukin 17A	Homo sapiens	0-5
21716128-8	2011	T-cell polarization function was investigated by measuring interferon gamma, interleukin 13 (IL-13), and IL-17A production by T cells cocultured with iloprost-treated MDDCs.	Iloprost	150-158	interleukin 17A	Homo sapiens	105-111
21716128-12	2011	Iloprost suppressed the LPS-induced expression of costimulatory molecules, including CD80, CD86, CD40, and HLA-DR. Iloprost-treated MDDCs increased IL-17A production by T cells.	Iloprost	0-8	interleukin 17A	Homo sapiens	148-154
21716128-12	2011	Iloprost suppressed the LPS-induced expression of costimulatory molecules, including CD80, CD86, CD40, and HLA-DR. Iloprost-treated MDDCs increased IL-17A production by T cells.	Iloprost	115-123	interleukin 17A	Homo sapiens	148-154
21716128-12	2011	Iloprost suppressed the LPS-induced expression of costimulatory molecules, including CD80, CD86, CD40, and HLA-DR. Iloprost-treated MDDCs increased IL-17A production by T cells.	mddcs	132-137	interleukin 17A	Homo sapiens	148-154
21943782-3	2011	Compared with the placebo plus MTX group, serum levels of IL-17, IFN-gamma, IL-21 and IL-1beta significantly decreased, the percentages of Th17 cells and Th1 cells were lower and the percentage of Treg cells was higher after receiving Anakinra combined with MTX treatment.	Methotrexate	31-34	interleukin 17A	Homo sapiens	58-63
22338221-5	2011	The percentage of IL-17 before and after HAART were 1.90 +/- 0.9% vs. 4.65 +/- 1.48% respectively in HIV/TB group patients (P < 0.01).	Terbium	105-107	interleukin 17A	Homo sapiens	18-23
21841134-5	2011	Neutralization of IL-17A in vivo promoted the resolution of bleomycin-induced acute inflammation, attenuated pulmonary fibrosis, and increased survival.	Bleomycin	60-69	interleukin 17A	Homo sapiens	18-24
21841134-6	2011	Additionally, IL-17A antagonism inhibited silica-induced chronic inflammation and pulmonary fibrosis.	Silicon Dioxide	42-48	interleukin 17A	Homo sapiens	14-20
21841134-9	2011	Administration of 3-methylamphetamine, an autophagy inhibitor, reversed the therapeutic efficacy of IL-17A antagonism in pulmonary fibrosis.	3-methylamphetamine	18-37	interleukin 17A	Homo sapiens	100-106
21856936-4	2011	We report that simvastatin, one of the most hydrophobic statins with good CNS penetration, inhibited Th17 cell differentiation and IL-17A, IL-17F, IL-21, and IL-22 secretion in in vitro-differentiated naive CD4(+) T cells from RR MS patients.	Simvastatin	15-26	interleukin 17A	Homo sapiens	131-137
21856936-8	2011	Selective inhibition of geranylgeranylated RhoA-associated kinase replicated the effect of simvastatin on the inhibition of IRF4 expression and IL-17A, IL-17F, IL-21, and IL-22 secretion, presenting a promising new therapeutic approach for this disabling disease.	Simvastatin	91-102	interleukin 17A	Homo sapiens	144-150
21751146-7	2011	In contrast, granulomas and DFN contained mainly CD68+, CD163+/- and expressed more IL-17, IL-18, IL-23, CCL19, and CXCL11 than non-granulomatous cells.	DFN	28-31	interleukin 17A	Homo sapiens	84-89
21746882-2	2011	The active form of vitamin D, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], has a direct repressive effect on the expression of IL-17A in both human and mouse T cells.	Vitamin D	19-28	interleukin 17A	Homo sapiens	128-134
21746882-2	2011	The active form of vitamin D, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], has a direct repressive effect on the expression of IL-17A in both human and mouse T cells.	1,25-dihydroxyvitamin D	30-53	interleukin 17A	Homo sapiens	128-134
21906467-0	2011	[Effect of curcumin on IL-17-induced nitric oxide production and expression of iNOS in human keratinocytes].	Curcumin	11-19	interleukin 17A	Homo sapiens	23-28
21906467-0	2011	[Effect of curcumin on IL-17-induced nitric oxide production and expression of iNOS in human keratinocytes].	Nitric Oxide	37-49	interleukin 17A	Homo sapiens	23-28
21906467-1	2011	AIM: To investigate the effect of curcumin on IL-17-induced NO production, mRNA and protein expression of iNOS in human keratinocyte cell lines(HaCaT cells).	Curcumin	34-42	interleukin 17A	Homo sapiens	46-51
21906467-5	2011	Curcumin decreased IL-17 induced NO production and the iNOS expression at mRNA (P<0.01) and protein (P<0.01) levels significantly.	Curcumin	0-8	interleukin 17A	Homo sapiens	19-24
21906467-6	2011	CONCLUSION: Curcumin down-regulates IL-17-induced NO secretions and iNOS expression in HaCaT cells, thus provides a theoretical basis for the treatment of inflammatory diseases of skin related to keratinocytes.	Curcumin	12-20	interleukin 17A	Homo sapiens	36-41
21818055-7	2011	Accordingly, renal transplant patients treated with MPA in combination with minimized dose of tacrolimus tended to have lower circulating IL-17 levels than patients treated with tacrolimus alone given at conventional dose.	Tacrolimus	94-104	interleukin 17A	Homo sapiens	138-143
21646474-3	2011	Optimal doxorubicin treatment outcome also requires both interleukin (IL)-1beta and IL-17 cytokines, as blockade of IL-1beta/IL-1R or IL-17A/IL-17Ralpha signaling abrogated the therapeutic effect.	Doxorubicin	8-19	interleukin 17A	Homo sapiens	84-89
21884514-1	2011	Prostaglandin E2 (PGE2), interleukin (IL)-23, and IL-1beta (beta) propagate inflammatory bowel disease (IBD) by enhancing the development and function of IL-17 producing CD4(+) T helper (Th17) cells.	Dinoprostone	0-16	interleukin 17A	Homo sapiens	154-159
21884514-1	2011	Prostaglandin E2 (PGE2), interleukin (IL)-23, and IL-1beta (beta) propagate inflammatory bowel disease (IBD) by enhancing the development and function of IL-17 producing CD4(+) T helper (Th17) cells.	Dinoprostone	18-22	interleukin 17A	Homo sapiens	154-159
21884514-5	2011	PGE2 and IL-23 plus IL-1beta synergistically induced early IL-17A secretion from CD161(+) CD4(+) memory T cells and the selective enrichment of IL-17A(+) CD161(+) CD4(+) memory T cells in culture.	Dinoprostone	0-4	interleukin 17A	Homo sapiens	59-65
21884514-5	2011	PGE2 and IL-23 plus IL-1beta synergistically induced early IL-17A secretion from CD161(+) CD4(+) memory T cells and the selective enrichment of IL-17A(+) CD161(+) CD4(+) memory T cells in culture.	Dinoprostone	0-4	interleukin 17A	Homo sapiens	144-150
21645256-9	2011	The use of steroids and monoclonal antibodies reduced IL-17 expression, JAK2 phosphorylation and C4d deposition in acute ABMR patients.	Steroids	11-19	interleukin 17A	Homo sapiens	54-59
21804617-0	2011	IL-17A in LCH: systemic biomarker, local factor, or none of the above?	lithocholyl-N-hydroxysuccinimide	10-13	interleukin 17A	Homo sapiens	0-6
21639870-8	2011	The PMA/ionomycin and HBcAg -stimulated up-regulation of IL-17 production by CD4+ T cells could be reversed by a neutralizing antibody against IL-6R.	Ionomycin	8-17	interleukin 17A	Homo sapiens	57-62
22779186-6	2011	RESULT: Cell proliferation, intracellular expression of IL-17 and IL-17 secretion were inhibited by triptolide in a dose-dependent manner.	triptolide	100-110	interleukin 17A	Homo sapiens	56-61
21181220-14	2011	Significant positive correlation was observed between IL-17 and IL-1beta (r = 0.38, p < 0.005), IL-17 and IL-6 (r = 0.659, p < 0.0001), and IL-1beta and IL-6 (r = 0.391, p < 0.0001) in ReA and uSpA group.	uspa	202-206	interleukin 17A	Homo sapiens	54-59
21484436-0	2011	Grape seed proanthocyanidin extract inhibits interleukin-17-induced interleukin-6 production via MAPK pathway in human pulmonary epithelial cells.	proanthocyanidin	11-27	interleukin 17A	Homo sapiens	45-59
21484436-1	2011	This study was aimed to investigate the effect of grape seed proanthocyanidin extract (GSPE) on interleukin-17 (IL-17)-induced interleukin-6 (IL-6) production in A549 human pulmonary epithelial cells.	proanthocyanidin	61-77	interleukin 17A	Homo sapiens	96-110
21484436-1	2011	This study was aimed to investigate the effect of grape seed proanthocyanidin extract (GSPE) on interleukin-17 (IL-17)-induced interleukin-6 (IL-6) production in A549 human pulmonary epithelial cells.	proanthocyanidin	61-77	interleukin 17A	Homo sapiens	112-117
21555999-5	2011	Here, we demonstrate both in vitro and in vivo on primary psoriatic lesions that pharmacological inhibitors of ERKs as well as hydrogen sulfide not only reduce the basal expression and secretion of IL-8, but also interfere with IL-17- and IL-22-induced IL-8 production.	Hydrogen Sulfide	127-143	interleukin 17A	Homo sapiens	228-233
22779186-6	2011	RESULT: Cell proliferation, intracellular expression of IL-17 and IL-17 secretion were inhibited by triptolide in a dose-dependent manner.	triptolide	100-110	interleukin 17A	Homo sapiens	66-71
21330350-7	2011	Addition of IL-23 to zoledronate enhanced the expression of IFN-gamma and generated a distinct, IFN-gamma-negative, neonatal Vgamma9Vdelta2 T cell population producing IL-17.	Zoledronic Acid	21-32	interleukin 17A	Homo sapiens	168-173
21781514-11	2011	After glucocorticosteroid therapy, the percentage of eosinophils and neutrophils, the levels of IL-17 and SDF-1 decreased significantly in all patients (all P < 0.01), while the percentage of sputum neutrophils and the levels of IL-17 and SDF-1 in uncontrolled patients increased significantly compared with the controlled and partly controlled groups (all P < 0.05).	glucocorticosteroid	6-25	interleukin 17A	Homo sapiens	96-101
21781514-11	2011	After glucocorticosteroid therapy, the percentage of eosinophils and neutrophils, the levels of IL-17 and SDF-1 decreased significantly in all patients (all P < 0.01), while the percentage of sputum neutrophils and the levels of IL-17 and SDF-1 in uncontrolled patients increased significantly compared with the controlled and partly controlled groups (all P < 0.05).	glucocorticosteroid	6-25	interleukin 17A	Homo sapiens	232-237
21530487-0	2011	IL-17A increases ADP-induced platelet aggregation.	Adenosine Diphosphate	17-20	interleukin 17A	Homo sapiens	0-6
21530487-6	2011	Pre-incubation with IL-17A increased ADP-, but not collagen-induced platelet aggregation and accelerated CD62P expression and exposure of fibrinogen binding sites.	Adenosine Diphosphate	37-40	interleukin 17A	Homo sapiens	20-26
20667562-11	2011	With respect to individual components of MS, TGF-beta and IL-17 showed a significant association with blood pressure and blood glucose even after adjusting for age and sex.	Glucose	127-134	interleukin 17A	Homo sapiens	58-63
21489641-5	2011	After high-dose intravenous methylprednisolone (IVMP) therapy, memory Th17 proportion and IL-17A and IL-23 levels were decreased.	Methylprednisolone	28-46	interleukin 17A	Homo sapiens	90-96
21489641-5	2011	After high-dose intravenous methylprednisolone (IVMP) therapy, memory Th17 proportion and IL-17A and IL-23 levels were decreased.	ivmp	48-52	interleukin 17A	Homo sapiens	90-96
21441909-7	2011	At high concentrations, digoxin is toxic for human cells, but non-toxic synthetic derivatives 20,22-dihydrodigoxin-21,23-diol and digoxin-21-salicylidene specifically inhibited induction of IL-17 in human CD4(+) T cells.	Digoxin	24-31	interleukin 17A	Homo sapiens	190-195
21441909-7	2011	At high concentrations, digoxin is toxic for human cells, but non-toxic synthetic derivatives 20,22-dihydrodigoxin-21,23-diol and digoxin-21-salicylidene specifically inhibited induction of IL-17 in human CD4(+) T cells.	20,22-dihydrodigoxin-21,23-diol	94-125	interleukin 17A	Homo sapiens	190-195
21441909-7	2011	At high concentrations, digoxin is toxic for human cells, but non-toxic synthetic derivatives 20,22-dihydrodigoxin-21,23-diol and digoxin-21-salicylidene specifically inhibited induction of IL-17 in human CD4(+) T cells.	digoxin-21-salicylidene	130-153	interleukin 17A	Homo sapiens	190-195
21345484-10	2011	The p38 MAPK inhibitor BIRB0796 inhibited the migration induced by IL-17A and IL-17F.	birb0796	23-31	interleukin 17A	Homo sapiens	67-73
21461217-9	2011	IL-17 was significantly increased in patients with high fluorescein staining scores.	Fluorescein	56-67	interleukin 17A	Homo sapiens	0-5
21143255-10	2011	Furthermore, ethanol-treated cells alone or in combination with LPS had significantly fewer IL-17- and IFN-gamma-secreting CD4+ T cells but constant proportion of Treg cells when compared to control cells.	Ethanol	13-20	interleukin 17A	Homo sapiens	92-97
20933009-0	2011	Grape seed proanthocyanidin extract (GSPE) differentially regulates Foxp3(+) regulatory and IL-17(+) pathogenic T cell in autoimmune arthritis.	proanthocyanidin	11-27	interleukin 17A	Homo sapiens	92-97
21342445-4	2011	Upon CD3/CD28 stimulation, mycophenolic acid inhibited T cell IL-17, IFN-gamma and TNF-alpha production but not IL-2 production.	Mycophenolic Acid	27-44	interleukin 17A	Homo sapiens	62-67
21479174-7	2011	Both IL-17A and IL-17F significantly decreased the transepithelial electrical resistance (TER) of the ARPE-19 monolayer and increased the diffusion rate of fluorescein isothiocyanate (FITC)-dextran.	Fluorescein-5-isothiocyanate	156-182	interleukin 17A	Homo sapiens	5-11
21479174-7	2011	Both IL-17A and IL-17F significantly decreased the transepithelial electrical resistance (TER) of the ARPE-19 monolayer and increased the diffusion rate of fluorescein isothiocyanate (FITC)-dextran.	Fluorescein-5-isothiocyanate	184-188	interleukin 17A	Homo sapiens	5-11
21479174-7	2011	Both IL-17A and IL-17F significantly decreased the transepithelial electrical resistance (TER) of the ARPE-19 monolayer and increased the diffusion rate of fluorescein isothiocyanate (FITC)-dextran.	Dextrans	190-197	interleukin 17A	Homo sapiens	5-11
21139574-10	2011	The addition of the anti-CD40L antibody to treated celiac biopsies significantly inhibited the PT-gliadin-induced production of IFN-gamma and IL-17, and mucosal T-bet.	Platinum	95-97	interleukin 17A	Homo sapiens	142-147
21150855-12	2011	We found that IL-17 cytokine levels were higher in patients anesthetized with sevoflurane and fentanyl.	Sevoflurane	78-89	interleukin 17A	Homo sapiens	14-19
21150855-12	2011	We found that IL-17 cytokine levels were higher in patients anesthetized with sevoflurane and fentanyl.	Fentanyl	94-102	interleukin 17A	Homo sapiens	14-19
20674388-3	2011	The denatured recombinant human IL-17A variant was refolded in 20 mM Tris-HCl, pH 9.0, 500 mM arginine, 500 mM guanidine HCl, 15% glycerol, 1 mM cystamine, and 5 mM cysteine at 2-8 C for 40 h. The refolded IL-17A variant was subsequently purified using a combination of cation-exchange, reversed-phase and fluoroapatite chromatography.	Tris hydrochloride	69-77	interleukin 17A	Homo sapiens	32-38
21440743-10	2011	DBMI patients showed significantly lower levels of serum TGF-beta1 and IL-17 compared with normal subjects (P=.05 and P=.06, respectively).	dbmi	0-4	interleukin 17A	Homo sapiens	71-76
21130040-2	2011	At 0.03 muM to 1 muM, lenalidomide enhanced generation of IL-2 and IFN-gamma by T cell receptor-stimulated T cells of young subjects up to respective maximum increases of 17-fold and three-fold, but at 0.3 muM and 1 muM suppressed IL-17 generation.	Lenalidomide	22-34	interleukin 17A	Homo sapiens	231-236
21283546-6	2011	Rhamnolipid mediated shuttle across the outer skin barrier was not restricted to flagellin since rhamnolipids enable psoriasin expression by the cytokines IL-17 and IL-22 after topical application on human skin.	rhamnolipid	97-109	interleukin 17A	Homo sapiens	155-160
22282962-7	2011	Nigericin and valinomycin decreased the concentrations of interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, interleukin (IL)-10, and IL-17 in the culture medium with IC50 values less than 0.01 ng/ml.	Nigericin	0-9	interleukin 17A	Homo sapiens	142-147
22282962-7	2011	Nigericin and valinomycin decreased the concentrations of interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, interleukin (IL)-10, and IL-17 in the culture medium with IC50 values less than 0.01 ng/ml.	Valinomycin	14-25	interleukin 17A	Homo sapiens	142-147
20674388-3	2011	The denatured recombinant human IL-17A variant was refolded in 20 mM Tris-HCl, pH 9.0, 500 mM arginine, 500 mM guanidine HCl, 15% glycerol, 1 mM cystamine, and 5 mM cysteine at 2-8 C for 40 h. The refolded IL-17A variant was subsequently purified using a combination of cation-exchange, reversed-phase and fluoroapatite chromatography.	fluorapatite	306-319	interleukin 17A	Homo sapiens	32-38
20731586-6	2011	The levels of IL-15(+) and IL-17(+) cells and the amount of fibrosis were higher in the DMP group than in the other groups (P <0.05).	dmp	88-91	interleukin 17A	Homo sapiens	27-32
21294864-9	2011	RESULTS: Exogenous addition of IL-17 dramatically enhanced the spontaneous production of IL-6 and prostaglandin E2 (PGE2) by the ST-derived inflammatory cells, while it had no effect on the production of tumor necrosis factor (TNF)-alpha and macrophage colony-stimulating factor (M-CSF).	Dinoprostone	98-114	interleukin 17A	Homo sapiens	31-36
21294864-9	2011	RESULTS: Exogenous addition of IL-17 dramatically enhanced the spontaneous production of IL-6 and prostaglandin E2 (PGE2) by the ST-derived inflammatory cells, while it had no effect on the production of tumor necrosis factor (TNF)-alpha and macrophage colony-stimulating factor (M-CSF).	Dinoprostone	116-120	interleukin 17A	Homo sapiens	31-36
21294864-11	2011	On the other hand, IL-17 enhanced pannus-like tissue growth, the production of TNF-alpha and M-CSF and the development of osteoclastic activity in the presence of indomethacin, an inhibitor of endogenous prostanoid production, while exogenous addition of PGE1 suppressed their activities.	Indomethacin	163-175	interleukin 17A	Homo sapiens	19-24
21294864-11	2011	On the other hand, IL-17 enhanced pannus-like tissue growth, the production of TNF-alpha and M-CSF and the development of osteoclastic activity in the presence of indomethacin, an inhibitor of endogenous prostanoid production, while exogenous addition of PGE1 suppressed their activities.	Prostaglandins	204-214	interleukin 17A	Homo sapiens	19-24
21294864-11	2011	On the other hand, IL-17 enhanced pannus-like tissue growth, the production of TNF-alpha and M-CSF and the development of osteoclastic activity in the presence of indomethacin, an inhibitor of endogenous prostanoid production, while exogenous addition of PGE1 suppressed their activities.	Alprostadil	255-259	interleukin 17A	Homo sapiens	19-24
21294864-12	2011	CONCLUSIONS: The present study suggests that IL-17 induces negative feedback regulation through the induction of PGE2, while it stimulates proinflammatory pathways such as inflammatory cytokine production, pannus growth and osteoclastogenesis in RA.	Dinoprostone	113-117	interleukin 17A	Homo sapiens	45-50
20868777-3	2011	We assessed the optimal dose of alfacalcidol that could normalize the elevated levels of IFN-gamma expressed by the CD4+Th1 cells and the IL-17 expressed by Th17 cells.	alfacalcidol	32-44	interleukin 17A	Homo sapiens	138-143
20674388-3	2011	The denatured recombinant human IL-17A variant was refolded in 20 mM Tris-HCl, pH 9.0, 500 mM arginine, 500 mM guanidine HCl, 15% glycerol, 1 mM cystamine, and 5 mM cysteine at 2-8 C for 40 h. The refolded IL-17A variant was subsequently purified using a combination of cation-exchange, reversed-phase and fluoroapatite chromatography.	Arginine	94-102	interleukin 17A	Homo sapiens	32-38
20674388-3	2011	The denatured recombinant human IL-17A variant was refolded in 20 mM Tris-HCl, pH 9.0, 500 mM arginine, 500 mM guanidine HCl, 15% glycerol, 1 mM cystamine, and 5 mM cysteine at 2-8 C for 40 h. The refolded IL-17A variant was subsequently purified using a combination of cation-exchange, reversed-phase and fluoroapatite chromatography.	Guanidine	111-124	interleukin 17A	Homo sapiens	32-38
20674388-3	2011	The denatured recombinant human IL-17A variant was refolded in 20 mM Tris-HCl, pH 9.0, 500 mM arginine, 500 mM guanidine HCl, 15% glycerol, 1 mM cystamine, and 5 mM cysteine at 2-8 C for 40 h. The refolded IL-17A variant was subsequently purified using a combination of cation-exchange, reversed-phase and fluoroapatite chromatography.	Glycerol	130-138	interleukin 17A	Homo sapiens	32-38
20674388-3	2011	The denatured recombinant human IL-17A variant was refolded in 20 mM Tris-HCl, pH 9.0, 500 mM arginine, 500 mM guanidine HCl, 15% glycerol, 1 mM cystamine, and 5 mM cysteine at 2-8 C for 40 h. The refolded IL-17A variant was subsequently purified using a combination of cation-exchange, reversed-phase and fluoroapatite chromatography.	Cystamine	145-154	interleukin 17A	Homo sapiens	32-38
20674388-3	2011	The denatured recombinant human IL-17A variant was refolded in 20 mM Tris-HCl, pH 9.0, 500 mM arginine, 500 mM guanidine HCl, 15% glycerol, 1 mM cystamine, and 5 mM cysteine at 2-8 C for 40 h. The refolded IL-17A variant was subsequently purified using a combination of cation-exchange, reversed-phase and fluoroapatite chromatography.	Cysteine	165-173	interleukin 17A	Homo sapiens	32-38
20936708-10	2010	IL-17 activated NF-kappaB by p65 phosphorylation at serine 536 and nuclear translocation.	Serine	52-58	interleukin 17A	Homo sapiens	0-5
21050771-9	2011	CONCLUSIONS: Infestation of Demodex mites induces change of tear cytokine levels, IL-17 especially, which cause inflammation of the lid margin and ocular surface.	Bilirubin	28-41	interleukin 17A	Homo sapiens	82-87
21131367-0	2011	IL-23-dependent and -independent enhancement pathways of IL-17A production by lactic acid.	Lactic Acid	78-89	interleukin 17A	Homo sapiens	57-63
21131367-3	2011	Recently, we reported that tumor-derived lactic acid enhances the toll-like receptor (TLR) ligand-mediated expression of IL-23, leading to increased IL-17A production.	Lactic Acid	41-52	interleukin 17A	Homo sapiens	149-155
21131367-5	2011	Even without TLR ligand stimulation, lactic acid enhanced antigen-dependent IL-17A production from splenocytes in an IL-23-dependent manner.	Lactic Acid	37-48	interleukin 17A	Homo sapiens	76-82
21131367-6	2011	Here, we show that macrophages and effector/memory CD4(+) T cells are the primary cell types involved in the ability of lactic acid to boost IL-17A production.	Lactic Acid	120-131	interleukin 17A	Homo sapiens	141-147
21131367-8	2011	CD40 ligand-CD40 interactions were involved in the up-regulation of IL-17A by lactic acid through IL-12/23p40 production.	Lactic Acid	78-89	interleukin 17A	Homo sapiens	68-74
21115236-0	2011	Histamine modulates the responsiveness of keratinocytes to IL-17 and TNF-alpha through the H1-receptor.	Histamine	0-9	interleukin 17A	Homo sapiens	59-64
22162626-7	2011	Inhibition of Erk1/2 with PD98059 decreased the expression of the tested three inflammatory mediators when using low doses of IL-17A (0-10 ng/ml) but not at higher concentrations.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	26-33	interleukin 17A	Homo sapiens	126-132
21337007-3	2011	Molecular modeling in this review shows that IL-17s may adopt a "cysteine knot" fold commonly seen in nerve growth factor (NGF) and other neurotrophins.	Cysteine	65-73	interleukin 17A	Homo sapiens	45-50
20849904-8	2010	LL-37 enhanced IFN-gamma, IL-4, IL-13, and TNF-alpha secretion from CD3/CD28-stimulated T cells, suppressed TNF-alpha, IL-1beta, IL-6, and IL-10 secretion from lipopolysaccharide-stimulated monocytes, and IL-17, IL-22, IL-1beta, IL-6, and IL-10 secretion from CD3/CD28-stimulated T cells.	Cathelicidin	0-5	interleukin 17A	Homo sapiens	205-210
20849904-12	2010	In both groups, negative feedback by LL-37 on IL-17 may exist.	Cathelicidin	37-42	interleukin 17A	Homo sapiens	46-51
21062492-5	2010	The spinal cords of sALS (n = 8), but not control subjects (n = 4), were infiltrated by interleukin-1beta- (IL-1beta-), and tumor necrosis factor-alpha-positive macrophages (co-localizing with neurons), IL-17A-positive CD8 cells, and IL-17A-positive mast cells.	sals	20-24	interleukin 17A	Homo sapiens	203-209
21062492-5	2010	The spinal cords of sALS (n = 8), but not control subjects (n = 4), were infiltrated by interleukin-1beta- (IL-1beta-), and tumor necrosis factor-alpha-positive macrophages (co-localizing with neurons), IL-17A-positive CD8 cells, and IL-17A-positive mast cells.	sals	20-24	interleukin 17A	Homo sapiens	234-240
20847291-5	2010	Here we show that during alpha-galactosylceramide (alphaGalCer)-induced hepatitis in mice, a model of hepatitis driven by specific activation of the innate immune system via NKT cells within the liver, NK1.1+ and CD4+ iNKT cells rapidly produce IL-17 and are the main IL-17-producing cells within the liver.	alpha-galactosylceramide	25-49	interleukin 17A	Homo sapiens	245-250
20847291-5	2010	Here we show that during alpha-galactosylceramide (alphaGalCer)-induced hepatitis in mice, a model of hepatitis driven by specific activation of the innate immune system via NKT cells within the liver, NK1.1+ and CD4+ iNKT cells rapidly produce IL-17 and are the main IL-17-producing cells within the liver.	alpha-galactosylceramide	25-49	interleukin 17A	Homo sapiens	268-273
20847291-5	2010	Here we show that during alpha-galactosylceramide (alphaGalCer)-induced hepatitis in mice, a model of hepatitis driven by specific activation of the innate immune system via NKT cells within the liver, NK1.1+ and CD4+ iNKT cells rapidly produce IL-17 and are the main IL-17-producing cells within the liver.	alpha-galactosylceramide	51-62	interleukin 17A	Homo sapiens	245-250
20847291-5	2010	Here we show that during alpha-galactosylceramide (alphaGalCer)-induced hepatitis in mice, a model of hepatitis driven by specific activation of the innate immune system via NKT cells within the liver, NK1.1+ and CD4+ iNKT cells rapidly produce IL-17 and are the main IL-17-producing cells within the liver.	alpha-galactosylceramide	51-62	interleukin 17A	Homo sapiens	268-273
20817120-6	2010	Allogeneic CD4(+)T cells in co-culture with loxoribine-treated MoDCs proliferated more strongly, at lower DC/CD4(+)T-cell ratio (1:80), and secreted significantly higher levels of IL-17 and IFN-gamma compared to the cultures with control MoDCs.	loxoribine	44-54	interleukin 17A	Homo sapiens	180-185
20386089-9	2010	The VDR agonist elocalcitol partially reverts COX-2 and IL-8 mRNA upregulation induced by a pro-inflammatory cytokine mixture (IL-17, interferon-gamma, tumor necrosis factor-alpha) and inhibits cell migration in urethral cells.	BXL628	16-27	interleukin 17A	Homo sapiens	127-132
20965150-5	2010	CP-690550 efficiently inhibited IL-17 production from memory T cells in vitro and partly suppressed infarct volume increase after I/R.	tofacitinib	0-9	interleukin 17A	Homo sapiens	32-37
20716219-5	2010	Both NB-UVB and PUVA treatment gave, at T3, a significant decrease in TNF-alpha and IL-23; IL-22 and IL-17 decreased significantly at T6; all parameters and Psoriasis Area and Severity Index decreased significantly at T12.	puva	16-20	interleukin 17A	Homo sapiens	101-106
19847432-0	2010	The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients.	Methotrexate	30-42	interleukin 17A	Homo sapiens	82-87
19847432-1	2010	Objective of the study is to assess the effects of adalimumab and MTX therapy on peripheral Th17 cells and IL-17/IL-6 secretion in RA patients.	Methotrexate	66-69	interleukin 17A	Homo sapiens	107-112
20615161-8	2010	Alfacalcidol improved the Th17/nTreg imbalance, as it inhibited the IL-17 expression of Th17 cells, and increased the number of nTregs.	alfacalcidol	0-12	interleukin 17A	Homo sapiens	68-73
21438292-3	2010	In the Pd-sensitized women, with high basal values of cytokine release, the 10(-5) M Pd salt (but not Pd nanoparticles) inhibited IL-10 and IL-17 release.	pd salt	85-92	interleukin 17A	Homo sapiens	140-145
21438292-3	2010	In the Pd-sensitized women, with high basal values of cytokine release, the 10(-5) M Pd salt (but not Pd nanoparticles) inhibited IL-10 and IL-17 release.	Palladium	85-87	interleukin 17A	Homo sapiens	140-145
20706985-3	2010	We found that the high affinity and stable AHR-ligand dioxin as well as the natural AHR-ligand 6-formylinolo[3,2-b] carbazole induced the downstream AHR-target cytochrome P450A1, and without affecting IFN-gamma, they enhanced IL-22 while simultaneously decreasing IL-17A production by CD4(+) T cells.	Dioxins	54-60	interleukin 17A	Homo sapiens	264-270
20310011-11	2010	RESULTS: In vitro, 4SC-101 is a potent inhibitor of human DHODH, inhibits lymphocyte proliferation, and uniquely blocks phytohemagglutinin-stimulated IL-17 production by lymphocytes.	vidofludimus	19-26	interleukin 17A	Homo sapiens	150-155
21487509-7	2010	We demonstrate that RA containing PLGA nanoparticles suppress IL-17 production and ROR-gamma(t) expression in T cells polarized towards the Th17 phenotype in vitro with similar potency to that of free drug.	Tretinoin	20-22	interleukin 17A	Homo sapiens	62-67
20601897-8	2010	Only in the infliximab + MTX group that the frequency of T(H)17 cells and concentration of IL-17 decreased.	Methotrexate	25-28	interleukin 17A	Homo sapiens	91-96
20545708-13	2010	Dexamethasone significantly decreased the IL-17-induced IL-6 expression in cells from normal individuals but not in those from asthmatics (P< or =0.05).	Dexamethasone	0-13	interleukin 17A	Homo sapiens	42-47
20545708-14	2010	CONCLUSION: Evidence of an increased GR-beta expression in epithelial cells following IL-17 stimulation suggests a possible role for Th17-associated cytokines in the mechanism of steroid hypo-responsiveness in asthmatic subjects.	Steroids	179-186	interleukin 17A	Homo sapiens	86-91
20706985-3	2010	We found that the high affinity and stable AHR-ligand dioxin as well as the natural AHR-ligand 6-formylinolo[3,2-b] carbazole induced the downstream AHR-target cytochrome P450A1, and without affecting IFN-gamma, they enhanced IL-22 while simultaneously decreasing IL-17A production by CD4(+) T cells.	6-formylinolo[3,2-b] carbazole	95-125	interleukin 17A	Homo sapiens	264-270
20615550-9	2010	In addition, triptolide (20ng/ml) in vitro was able to down-regulate the IL-6/STAT3 pathway and reduce IL-17 expression in cultured colonic explants from patients with Crohn"s disease (CD).	triptolide	13-23	interleukin 17A	Homo sapiens	103-108
20624941-7	2010	In addition, we show that these latter 5-hydroxytryptophan metabolites inhibit IL-17 production.	5-Hydroxytryptophan	39-58	interleukin 17A	Homo sapiens	79-84
20022135-3	2010	The expression of IL-17 was measured by immunohistochemistry in 52 paraffin-embedded tissues with non-small cell lung cancer.	Paraffin	67-75	interleukin 17A	Homo sapiens	18-23
20067801-9	2010	EGCG and DHA, which significantly inhibited both IL-17 and TNF-alpha expression, appeared particularly interesting.	epigallocatechin gallate	0-4	interleukin 17A	Homo sapiens	49-54
20067801-9	2010	EGCG and DHA, which significantly inhibited both IL-17 and TNF-alpha expression, appeared particularly interesting.	Docosahexaenoic Acids	9-12	interleukin 17A	Homo sapiens	49-54
20060887-6	2010	Addition of Abeta-specific Th2 cells suppressed the Abeta-induced IFN-gamma production by Th1 cells and IL-17 production by Th17 cells with glia as the APC.	UNII-042A8N37WH	12-17	interleukin 17A	Homo sapiens	104-109
20597929-0	2010	Nickel (Ni) allergic patients with complications to Ni containing joint replacement show preferential IL-17 type reactivity to Ni.	Nickel	0-6	interleukin 17A	Homo sapiens	102-107
20399285-0	2010	Downregulation of IL-17 and IFN-gamma in the optic nerve by beta-elemene in experimental autoimmune encephalomyelitis.	beta-elemene	60-72	interleukin 17A	Homo sapiens	18-23
20039781-5	2010	The IL-17 levels were elevated in 60% of patients with IDILI, but also in a similar number of patients with acetaminophen-induced ALF and occasionally in patients with viral hepatitis.	Acetaminophen	108-121	interleukin 17A	Homo sapiens	4-9
20375992-6	2010	Mycophenolic acid delayed myeloid recovery after bone marrow transplantation and decreased the percentage of IL-17-producing T cells in the spleen and thymus, and inhibited IL-17 production in human and mouse T cells in vitro.	Mycophenolic Acid	0-17	interleukin 17A	Homo sapiens	109-114
20375992-6	2010	Mycophenolic acid delayed myeloid recovery after bone marrow transplantation and decreased the percentage of IL-17-producing T cells in the spleen and thymus, and inhibited IL-17 production in human and mouse T cells in vitro.	Mycophenolic Acid	0-17	interleukin 17A	Homo sapiens	173-178
20089077-10	2010	The IL-17-induced C3 mRNA expression was blocked by p42/44 mitogen-activated protein kinase (MAPK) inhibitors (PD98059 and U0216) and a p38 MAPK inhibitor (SB203580).	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	111-118	interleukin 17A	Homo sapiens	4-9
20089077-10	2010	The IL-17-induced C3 mRNA expression was blocked by p42/44 mitogen-activated protein kinase (MAPK) inhibitors (PD98059 and U0216) and a p38 MAPK inhibitor (SB203580).	u0216	123-128	interleukin 17A	Homo sapiens	4-9
20089077-10	2010	The IL-17-induced C3 mRNA expression was blocked by p42/44 mitogen-activated protein kinase (MAPK) inhibitors (PD98059 and U0216) and a p38 MAPK inhibitor (SB203580).	SB 203580	156-164	interleukin 17A	Homo sapiens	4-9
20298731-6	2010	The tvDTH response to TT was inhibited by anti-interferon-gamma, whereas the tvDTH response to collagen V was inhibited by anti-IL-17 antibody, mimicking the cytokine bias of adult human T cells to these antigens.	tvdth	77-82	interleukin 17A	Homo sapiens	128-133
20091246-4	2010	GSNO attenuated EAE disease by reducing the production of IL17 (from Th(i) or Th17 cells) and the infiltration of CD4 T cells into the central nervous system without affecting the levels of Th1 (IFN gamma) and Th2 (IL4) immune responses.	S-Nitrosoglutathione	0-4	interleukin 17A	Homo sapiens	58-62
19428234-10	2010	Moreover, tryptophan reduced the expression of the pro-inflammatory cytokines tumor necrosis factor-alpha, interleukin (IL)-6, interferon (IFN)-gamma, IL-12p40, IL-1beta and IL-17, as well as IL-8 and intracellular adhesion molecule-1, and resulted in increased expression of apoptosis initiators caspase-8 and Bax.	Tryptophan	10-20	interleukin 17A	Homo sapiens	174-179
20508866-3	2010	This study was designed to investigate the influence of cyclosporine A (CsA) on IL-17 production by peripheral blood mononuclear cells (PBMCs) from BD patients in vitro and in vivo.	Cyclosporine	56-70	interleukin 17A	Homo sapiens	80-85
20508866-3	2010	This study was designed to investigate the influence of cyclosporine A (CsA) on IL-17 production by peripheral blood mononuclear cells (PBMCs) from BD patients in vitro and in vivo.	Cyclosporine	72-75	interleukin 17A	Homo sapiens	80-85
20002791-6	2010	This effect was mediated through the propensity of A. fumigatus to metabolize tryptophan and release kynurenine, which modulates the inflammatory response through inhibition of IL-17 production.	Tryptophan	78-88	interleukin 17A	Homo sapiens	177-182
20002791-6	2010	This effect was mediated through the propensity of A. fumigatus to metabolize tryptophan and release kynurenine, which modulates the inflammatory response through inhibition of IL-17 production.	Kynurenine	101-111	interleukin 17A	Homo sapiens	177-182
20351184-6	2010	The NF-kappaB pathway inhibitor BAY-11, JNK inhibitor JNKi II, and p38 inhibitor SB203580 suppressed the synergistic effect of IL-6 and IL-17 on IL-6 expression.	bay-11	32-38	interleukin 17A	Homo sapiens	136-141
20351184-6	2010	The NF-kappaB pathway inhibitor BAY-11, JNK inhibitor JNKi II, and p38 inhibitor SB203580 suppressed the synergistic effect of IL-6 and IL-17 on IL-6 expression.	SB 203580	81-89	interleukin 17A	Homo sapiens	136-141
20045653-6	2010	Following stimulation with phorbol ester and ionomycin, PBMCs taken from MS patients in relapse developed a more inflammatory profile than those taken from controls or non-relapse patients, with greater expression of CD154, IL-17 and dual expression of IL-17/IFN-gamma.	Phorbol Esters	27-40	interleukin 17A	Homo sapiens	224-229
20045653-6	2010	Following stimulation with phorbol ester and ionomycin, PBMCs taken from MS patients in relapse developed a more inflammatory profile than those taken from controls or non-relapse patients, with greater expression of CD154, IL-17 and dual expression of IL-17/IFN-gamma.	Phorbol Esters	27-40	interleukin 17A	Homo sapiens	253-258
20045653-6	2010	Following stimulation with phorbol ester and ionomycin, PBMCs taken from MS patients in relapse developed a more inflammatory profile than those taken from controls or non-relapse patients, with greater expression of CD154, IL-17 and dual expression of IL-17/IFN-gamma.	Ionomycin	45-54	interleukin 17A	Homo sapiens	224-229
20045653-6	2010	Following stimulation with phorbol ester and ionomycin, PBMCs taken from MS patients in relapse developed a more inflammatory profile than those taken from controls or non-relapse patients, with greater expression of CD154, IL-17 and dual expression of IL-17/IFN-gamma.	Ionomycin	45-54	interleukin 17A	Homo sapiens	253-258
20487634-3	2010	In cultures without LPS, IL-10 and IL-17 release from PBMCs was inhibited by Pd salt, while Pd nanoparticles inhibited TNF-alpha and IL-17 release.	pd salt	77-84	interleukin 17A	Homo sapiens	35-40
20487634-3	2010	In cultures without LPS, IL-10 and IL-17 release from PBMCs was inhibited by Pd salt, while Pd nanoparticles inhibited TNF-alpha and IL-17 release.	Palladium	77-79	interleukin 17A	Homo sapiens	35-40
20487634-4	2010	In LPS-stimulated cultures, release of IFN-gamma, TNF-alpha, IL-10 and IL-17 was inhibited by Pd salt, whereas IFN-gamma release was enhanced and TNF-alpha and IL-17 release was inhibited by Pd nanoparticles.	pd salt	94-101	interleukin 17A	Homo sapiens	71-76
20487634-4	2010	In LPS-stimulated cultures, release of IFN-gamma, TNF-alpha, IL-10 and IL-17 was inhibited by Pd salt, whereas IFN-gamma release was enhanced and TNF-alpha and IL-17 release was inhibited by Pd nanoparticles.	Palladium	94-96	interleukin 17A	Homo sapiens	71-76
20159692-4	2010	RESULTS: Compared with the control group, high-concentration FK506 (20 ng/ml) significantly inhibited the secretions of IL-2, IL-6, IL-12, IL-17, IFN-gamma, TNF-alpha, GM-CSF and G-CSF.	Tacrolimus	61-66	interleukin 17A	Homo sapiens	139-144
20098669-10	2010	Furthermore, we demonstrated an unprecedented immunosuppressive effect of AEA on IL-17 production, a typical cytokine that is released from the unique CD4+ T-cell subset T-helper 17.	anandamide	74-77	interleukin 17A	Homo sapiens	81-86
20508866-11	2010	In vitro, CsA significantly inhibited the production of IL-17 and IFN-gamma by PBMCs activated with anti-CD3 and anti-CD28 antibodies or phorbol 12-myristate,13-acetate and ionomycin in BD patients with active uveitis.	Cyclosporine	10-13	interleukin 17A	Homo sapiens	56-61
20508866-13	2010	CONCLUSIONS: Our findings showed that CsA can significantly inhibit the intraocular inflammation of BD patients and the expression of IL-17 and IFN-gamma in vivo and in vitro.	Cyclosporine	38-41	interleukin 17A	Homo sapiens	134-139
20508866-14	2010	The results suggested that the inhibitory effect of CsA on uveitis in BD patients may be partially mediated through inhibiting the production of IL-17 and IFN-gamma.	Cyclosporine	52-55	interleukin 17A	Homo sapiens	145-150
19896472-8	2010	KR62980 also decreased goblet cell hyperplasia in the airway and mucous cell metaplasia in nasal epithelium, concurrent with decreases of allergic Th2 cytokines and IL-17 in the draining lymph node.	1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester	0-7	interleukin 17A	Homo sapiens	165-170
20127054-13	2010	The present results provided evidence that the genetic polymorphisms of IL-17A, and MIF-794-CATT repeat are associated with CIHM status in the gastric cancer.	cihm	124-128	interleukin 17A	Homo sapiens	72-78
20012175-6	2010	Furthermore, both of the B cell activities in AVMC and DCM groups were elevated and positively correlated to serum IL-17 (R = 0.66, P < 0.01) and IL-4 (R = 0.47, P < 0.05) respectively, with no correlation to INF-gamma.	avmc	46-50	interleukin 17A	Homo sapiens	115-120
20159692-6	2010	CONCLUSION: FK506 effectively inhibits the secretion of proinflammatory cytokines including IL-6, IFN-gamma and TNF-alpha and also the secretion of IL-2, IL-12, IL-17, GM-CSF and G-CSF.	Tacrolimus	12-17	interleukin 17A	Homo sapiens	161-166
19566585-10	2010	There was also a significant positive correlation between the allergen-induced IL-17 and SMS in whole study group (r = 0.38, p = 0.039) and especially the 200,000 SQ-U dose-treated group (r = 0.74, p = 0.027) at 2 yr. Allergen-induced FOXP3 mRNA expression was significantly increased in the 200,000 SQ-U dose-treated children after two study years as compared with baseline (p = 0.016) and placebo-treated children (p = 0.028).	sms	89-92	interleukin 17A	Homo sapiens	79-84
20056108-4	2010	We found that transfecting TE-5 and TE-9 cells with REG I Ialpha and Ibeta led to significantly increased expression of interleukin (IL)-6 mRNA and protein, but it had little or no effect on expression of IL-2, IL-4, IL-5, IL-10, IL-12, IL-13, IL-17A, interferon-gamma, tumor necrosis factor-alpha, granulocyte-colony stimulating factor or transforming growth factor-beta1.	ibeta	69-74	interleukin 17A	Homo sapiens	244-250
19807734-7	2010	The expression level of IL-17 was correlated closely with clinical parameters such as haematuria, blood urea nitrogen level, SLE Disease Activity Index scores in both glomeruli and interstitium, urine protein level in glomeruli and serum creatinine and creatinine clearance levels in interstitium.	Urea	104-108	interleukin 17A	Homo sapiens	24-29
19807734-7	2010	The expression level of IL-17 was correlated closely with clinical parameters such as haematuria, blood urea nitrogen level, SLE Disease Activity Index scores in both glomeruli and interstitium, urine protein level in glomeruli and serum creatinine and creatinine clearance levels in interstitium.	Nitrogen	109-117	interleukin 17A	Homo sapiens	24-29
19807734-7	2010	The expression level of IL-17 was correlated closely with clinical parameters such as haematuria, blood urea nitrogen level, SLE Disease Activity Index scores in both glomeruli and interstitium, urine protein level in glomeruli and serum creatinine and creatinine clearance levels in interstitium.	Creatinine	238-248	interleukin 17A	Homo sapiens	24-29
19807734-7	2010	The expression level of IL-17 was correlated closely with clinical parameters such as haematuria, blood urea nitrogen level, SLE Disease Activity Index scores in both glomeruli and interstitium, urine protein level in glomeruli and serum creatinine and creatinine clearance levels in interstitium.	Creatinine	253-263	interleukin 17A	Homo sapiens	24-29
19746420-6	2010	Interestingly, when incubated with conditioned media of HCECs irritated by polyI:C or TNF-alpha, CD4(+) T cells displayed increased mRNA levels of IL-17A, IL-17F, IL-22, CCL-20, and STAT3, increased IL-17 protein in the supernatant, and increased numbers of IL-17-producing T cells (Th17 cells).	Poly I	75-80	interleukin 17A	Homo sapiens	147-153
19746420-6	2010	Interestingly, when incubated with conditioned media of HCECs irritated by polyI:C or TNF-alpha, CD4(+) T cells displayed increased mRNA levels of IL-17A, IL-17F, IL-22, CCL-20, and STAT3, increased IL-17 protein in the supernatant, and increased numbers of IL-17-producing T cells (Th17 cells).	Poly I	75-80	interleukin 17A	Homo sapiens	147-152
19746420-6	2010	Interestingly, when incubated with conditioned media of HCECs irritated by polyI:C or TNF-alpha, CD4(+) T cells displayed increased mRNA levels of IL-17A, IL-17F, IL-22, CCL-20, and STAT3, increased IL-17 protein in the supernatant, and increased numbers of IL-17-producing T cells (Th17 cells).	Poly I	75-80	interleukin 17A	Homo sapiens	155-160
19835883-7	2009	The IL-17A is a disulfide-linked homodimer that is similar in structure to IL-17F, adopting a cystine-knot fold.	Disulfides	16-25	interleukin 17A	Homo sapiens	4-10
19835883-7	2009	The IL-17A is a disulfide-linked homodimer that is similar in structure to IL-17F, adopting a cystine-knot fold.	Cystine	94-101	interleukin 17A	Homo sapiens	4-10
19835883-14	2009	The observed interaction site between CAT-2200 and IL-17A is consistent with data from hydrogen/deuterium exchange mass spectrometry and mutagenesis approaches.	Hydrogen	87-95	interleukin 17A	Homo sapiens	51-57
19835883-14	2009	The observed interaction site between CAT-2200 and IL-17A is consistent with data from hydrogen/deuterium exchange mass spectrometry and mutagenesis approaches.	Deuterium	96-105	interleukin 17A	Homo sapiens	51-57
19846875-5	2009	Nicotine reduced T cell proliferation in response to an encephalitogenic Ag, as well as the production of Th1 (TNF-alpha and IFN-gamma) and Th17 cytokines (IL-17, IL-17F, IL-21, and IL-22).	Nicotine	0-8	interleukin 17A	Homo sapiens	156-161
19950293-7	2009	FLS proliferation stimulated by SF, Cyr61, and interleukin-17 (IL-17) was measured by thymidine incorporation.	Thymidine	86-95	interleukin 17A	Homo sapiens	63-68
19740775-7	2009	Anti-CD3/CD28-stimulated IBD LPMCs produced higher IL17 amounts compared to controls.	lpmcs	29-34	interleukin 17A	Homo sapiens	51-55
19933854-3	2009	Priming of influenza hemagglutinin (HA)-specific naive CD4 T cells with HA peptide and the TLR2 agonist Pam3CysK in vivo resulted in a high frequency of activated HA-specific CD4 T cells that predominantly produced IL-2 and IL-17, whereas priming with HA peptide and the TLR4 agonist LPS yielded a lower frequency of HA-specific CD4 T cells and predominant IFN-gamma producers.	pam3cysk	104-112	interleukin 17A	Homo sapiens	224-229
19543237-3	2009	Here, we report that T-cell-produced IL-17 can induce proliferation of human bone marrow-derived mesenchymal stem cells (hMSCs) in a manner dependent on the generation of reactive oxygen species (ROS).	Reactive Oxygen Species	171-194	interleukin 17A	Homo sapiens	37-42
19950293-7	2009	FLS proliferation stimulated by SF, Cyr61, and interleukin-17 (IL-17) was measured by thymidine incorporation.	Thymidine	86-95	interleukin 17A	Homo sapiens	47-61
19769778-6	2009	RESULTS: A significant reduction in IL-17 production and Th17 cells count in PBMCs was found in patients with MS after IVMP treatment.	ivmp	119-123	interleukin 17A	Homo sapiens	36-41
19769778-7	2009	Moreover, the expression of IL-17, IL-23R and RORc mRNA decreased significantly after IVMP treatment.	ivmp	86-90	interleukin 17A	Homo sapiens	28-33
18957484-0	2009	Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway.	Leflunomide	61-72	interleukin 17A	Homo sapiens	41-46
18957484-8	2009	Likewise, leflunomide, cyclosporin A and FK-506 all inhibited IL-17 production in IL-15-activated PBL.	Leflunomide	10-21	interleukin 17A	Homo sapiens	62-67
18957484-8	2009	Likewise, leflunomide, cyclosporin A and FK-506 all inhibited IL-17 production in IL-15-activated PBL.	Cyclosporine	23-36	interleukin 17A	Homo sapiens	62-67
18957484-8	2009	Likewise, leflunomide, cyclosporin A and FK-506 all inhibited IL-17 production in IL-15-activated PBL.	Tacrolimus	41-47	interleukin 17A	Homo sapiens	62-67
18957484-11	2009	CONCLUSION: Inhibition of the JAK/STAT pathway may represent an additional effect of leflunomide in chronic polyarthritis because it impairs certain events that control proinflammatory TNF and IL-17 cytokine production.	Leflunomide	85-96	interleukin 17A	Homo sapiens	193-198
19477911-10	2009	RA treatment up-regulated FOXP3 expression and down-regulated IL-17 expression in colon biopsies of patients and in colon tissues and MLN of mice with colitis compared with controls.	Radium	0-2	interleukin 17A	Homo sapiens	62-67
19863676-9	2009	Interestingly, SIV infection was associated with an increase in Tc-17 responses (IL-17(+)CD8(+) T cells) suggesting to a skewing in the ratio of Th-17: Tc-17 cells from a predominantly Th-17 phenotype to a predominantly Tc-17 phenotype.	tc-17	64-69	interleukin 17A	Homo sapiens	81-86
19863676-9	2009	Interestingly, SIV infection was associated with an increase in Tc-17 responses (IL-17(+)CD8(+) T cells) suggesting to a skewing in the ratio of Th-17: Tc-17 cells from a predominantly Th-17 phenotype to a predominantly Tc-17 phenotype.	Technetium	64-66	interleukin 17A	Homo sapiens	81-86
19762486-3	2009	Stimulation of CD56+ cells containing both DCs and abundant gammadelta T cells with zoledronate and interleukin-2 (IL-2) resulted in the rapid expansion of gammadelta T cells as well as in IFN-gamma, TNF-alpha, and IL-1beta but not in IL-4, IL-10, or IL-17 production.	Zoledronic Acid	84-95	interleukin 17A	Homo sapiens	251-256
19543237-3	2009	Here, we report that T-cell-produced IL-17 can induce proliferation of human bone marrow-derived mesenchymal stem cells (hMSCs) in a manner dependent on the generation of reactive oxygen species (ROS).	Reactive Oxygen Species	196-199	interleukin 17A	Homo sapiens	37-42
19543237-4	2009	Rac1 GTPase and NADPH oxidase 1 (Nox1) are activated by IL-17 to produce ROS, which in turn stimulates hMSC proliferation.	Reactive Oxygen Species	73-76	interleukin 17A	Homo sapiens	56-61
19623255-7	2009	All vitamin D analogs tested blocked IL-17A induced HBD2 expression by increasing IkappaB-alpha protein and inhibition of NF-kappaB signaling.	Vitamin D	4-13	interleukin 17A	Homo sapiens	37-43
19748983-0	2009	TLR3 ligand polyinosinic:polycytidylic acid induces IL-17A and IL-21 synthesis in human Th cells.	polyinosinic	12-24	interleukin 17A	Homo sapiens	52-58
19748983-0	2009	TLR3 ligand polyinosinic:polycytidylic acid induces IL-17A and IL-21 synthesis in human Th cells.	Poly C	25-43	interleukin 17A	Homo sapiens	52-58
19748983-6	2009	We investigated the expression of IL-17A and IL-21 in human CD4+ T cells in response to stimulation with the TLR3 ligand polyinosinic:polycytidylic acid (poly(I:C)) and the TLR9 ligand CpG.	polyinosinic	121-133	interleukin 17A	Homo sapiens	34-40
19748983-6	2009	We investigated the expression of IL-17A and IL-21 in human CD4+ T cells in response to stimulation with the TLR3 ligand polyinosinic:polycytidylic acid (poly(I:C)) and the TLR9 ligand CpG.	Poly C	134-152	interleukin 17A	Homo sapiens	34-40
19748983-7	2009	We discovered that poly(I:C) induced synthesis of both IL-17A and IL-21.	poly	19-23	interleukin 17A	Homo sapiens	55-61
19625644-9	2009	Additionally, the influence of microbial stimulation was demonstrated with TLR3 and TLR7/8 agonists inducing a Th1 response, whereas TLR2 or dectin stimulation of moDCs enhanced the IL-17 response.	dectin	141-147	interleukin 17A	Homo sapiens	182-187
19861249-8	2009	CONCLUSIONS: The mouse model of VMC in the chronic phase and DCM patients express high levels of IL-17, which may contribute to the transition from VMC to DCM.	2-methoxy-4-(1-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-4-phenyl-1H-imidazol-5-yl)phenol	32-35	interleukin 17A	Homo sapiens	97-102
19861249-8	2009	CONCLUSIONS: The mouse model of VMC in the chronic phase and DCM patients express high levels of IL-17, which may contribute to the transition from VMC to DCM.	2-methoxy-4-(1-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-4-phenyl-1H-imidazol-5-yl)phenol	148-151	interleukin 17A	Homo sapiens	97-102
19700754-8	2009	Furthermore, the Th17-centric cytokines IL-17, IL-6, IL-23, and IL-12 were significantly elevated in pSS plasma.	pss	101-104	interleukin 17A	Homo sapiens	40-45
19648266-8	2009	A concentration-dependent reduction in T-bet expression and production of IFN-gamma, IL-2, IL-17, but not IL-8, was observed in IBD LPMC and biopsy specimens treated with the CRAC inhibitor.	lpmc	132-136	interleukin 17A	Homo sapiens	91-96
19701202-6	2009	Antibody-mediated blockade of interleukin-17 (IL-17) as well as the receptor for IL-23, a key cytokine amplifying T(H)17 responses, inhibits ETBF-induced colitis, colonic hyperplasia and tumor formation.	etbf	141-145	interleukin 17A	Homo sapiens	30-44
19701202-6	2009	Antibody-mediated blockade of interleukin-17 (IL-17) as well as the receptor for IL-23, a key cytokine amplifying T(H)17 responses, inhibits ETBF-induced colitis, colonic hyperplasia and tumor formation.	etbf	141-145	interleukin 17A	Homo sapiens	46-51
19542431-4	2009	This study demonstrates that the activation of human iNKT cells by their specific ligand alpha-galactosylceramide enhances IL-12p70 while inhibiting the IL-23 production by monocyte-derived dendritic cells, and in turn down-regulating the IL-17 production by memory CD4(+) Th cells.	alpha-galactosylceramide	89-113	interleukin 17A	Homo sapiens	239-244
19428338-7	2009	IL-17A up-regulates cyclooxygenase (COX)-2 gene expression and thereby increases the level of prostaglandin (PG) E(2) in differentiated adipocyes.	Prostaglandins E	94-114	interleukin 17A	Homo sapiens	0-6
19428338-8	2009	The suppression of anti-adipogenic PGE(2) by COX inhibitors such as aspirin and NS-398 partially blocked the effect of IL-17A on adipocyte differentiation in hBM-MSCs.	Prostaglandins E	35-38	interleukin 17A	Homo sapiens	119-125
19428338-8	2009	The suppression of anti-adipogenic PGE(2) by COX inhibitors such as aspirin and NS-398 partially blocked the effect of IL-17A on adipocyte differentiation in hBM-MSCs.	Aspirin	68-75	interleukin 17A	Homo sapiens	119-125
19428338-8	2009	The suppression of anti-adipogenic PGE(2) by COX inhibitors such as aspirin and NS-398 partially blocked the effect of IL-17A on adipocyte differentiation in hBM-MSCs.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	80-86	interleukin 17A	Homo sapiens	119-125
19494326-3	2009	We provide evidence that metformin attenuates the induction of EAE by restricting the infiltration of mononuclear cells into the CNS, down-regulating the expression of proinflammatory cytokines (IFN-gamma, TNF-alpha, IL-6, IL-17, and inducible NO synthase (iNOS)), cell adhesion molecules, matrix metalloproteinase 9, and chemokine (RANTES).	Metformin	25-34	interleukin 17A	Homo sapiens	223-228
19384872-6	2009	Moreover, PGE2 promoted the selective enrichment of IL-17-producing cells by differentially modulating the proliferation of memory T-cell subsets in vitro.	Dinoprostone	10-14	interleukin 17A	Homo sapiens	52-57
19380384-3	2009	To address these issues, we examined the effect of simvastatin and inhibitors for protein farnesylation and geranylgeranylation on the differentiation of IL-17-producing T cells (T(h)17 cells) and Foxp3(+) CD4(+) T cells.	Simvastatin	51-62	interleukin 17A	Homo sapiens	154-159
19321461-12	2009	Moreover, activated Vitamin D enhanced the development of IL-10 producing cells, and reduced the number of IL-6 and IL-17 secreting cells.	Vitamin D	20-29	interleukin 17A	Homo sapiens	116-121
19200788-7	2009	In vitro experiments showed that CsA and dexamethasone could decrease the frequencies of Th1 and Th17 cells and inhibit IL-17 and IFN-gamma production.	Cyclosporine	33-36	interleukin 17A	Homo sapiens	120-125
19200788-7	2009	In vitro experiments showed that CsA and dexamethasone could decrease the frequencies of Th1 and Th17 cells and inhibit IL-17 and IFN-gamma production.	Dexamethasone	41-54	interleukin 17A	Homo sapiens	120-125
19384872-0	2009	Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFN-gamma production by memory CD4+ T cells.	Dinoprostone	0-16	interleukin 17A	Homo sapiens	59-64
19384872-4	2009	TCR triggering in the presence of PGE2 increased IL-17 and reduced IFN-gamma production by freshly isolated memory T cells or T-cell clones.	Dinoprostone	34-38	interleukin 17A	Homo sapiens	49-54
19273625-5	2009	Furthermore, PGE2 synergizes with IL-1beta and IL-23 to drive retinoic acid receptor-related orphan receptor (ROR)-gammat, IL-17, IL-17F, CCL20, and CCR6 expression, which is consistent with the reported Th17 phenotype.	Dinoprostone	13-17	interleukin 17A	Homo sapiens	123-128
19260856-3	2009	METHOD OF STUDY: The present study investigated the in vitro effect of IL-17 on progesterone and human chorionic gonadotropin (hCG) secretion by JEG-3 cells.	Progesterone	80-92	interleukin 17A	Homo sapiens	71-76
19373578-10	2009	IL-17 rather than IFN-gamma plays a crucial role in the development of EAU, and that antagonism of IL-17 could be useful for the treatment of human intraocular autoimmune diseases.	Water	71-74	interleukin 17A	Homo sapiens	0-5
19273625-7	2009	Furthermore, PGE2 is required for IL-17 production in the presence of antigen-presenting cells.	Dinoprostone	13-17	interleukin 17A	Homo sapiens	34-39
19318315-5	2009	In addition, the stimulation of IL-6 production by IL-17 in MSC cultures and co-cultures is enhanced by low O2 concentration.	Oxygen	108-110	interleukin 17A	Homo sapiens	51-56
19074559-6	2009	Exposure of HBE monolayers to IL-17A for 48 h induced a novel forskolin-stimulated bicarbonate secretion in addition to forskolin-stimulated chloride secretion and resulted in alkalinization of liquid on the mucosal surface of polarized cells.	Bicarbonates	83-94	interleukin 17A	Homo sapiens	30-36
19318315-0	2009	Low O2 concentrations enhance the positive effect of IL-17 on the maintenance of erythroid progenitors during co-culture of CD34+ and mesenchymal stem cells.	Oxygen	4-6	interleukin 17A	Homo sapiens	53-58
21794634-6	2009	The hyperfunction of TH17 cells is associated with diseases as reumatoid arthritis, due to the hypersecretion of the proinflammatory citoquine IL17.	citoquine	133-142	interleukin 17A	Homo sapiens	143-147
19074559-0	2009	Interleukin-17A induces bicarbonate secretion in normal human bronchial epithelial cells.	Bicarbonates	24-35	interleukin 17A	Homo sapiens	0-15
19074559-6	2009	Exposure of HBE monolayers to IL-17A for 48 h induced a novel forskolin-stimulated bicarbonate secretion in addition to forskolin-stimulated chloride secretion and resulted in alkalinization of liquid on the mucosal surface of polarized cells.	Colforsin	62-71	interleukin 17A	Homo sapiens	30-36
19074559-6	2009	Exposure of HBE monolayers to IL-17A for 48 h induced a novel forskolin-stimulated bicarbonate secretion in addition to forskolin-stimulated chloride secretion and resulted in alkalinization of liquid on the mucosal surface of polarized cells.	Colforsin	120-129	interleukin 17A	Homo sapiens	30-36
19074559-6	2009	Exposure of HBE monolayers to IL-17A for 48 h induced a novel forskolin-stimulated bicarbonate secretion in addition to forskolin-stimulated chloride secretion and resulted in alkalinization of liquid on the mucosal surface of polarized cells.	Chlorides	141-149	interleukin 17A	Homo sapiens	30-36
19074559-7	2009	IL-17A-induced bicarbonate secretion was cystic fibrosis transmembrane conductance regulator (CFTR)-dependent, mucosal chloride-dependent, partially Na(+)-dependent, and sensitive to serosal, but not mucosal, stilbene inhibition.	Bicarbonates	15-26	interleukin 17A	Homo sapiens	0-6
19074559-7	2009	IL-17A-induced bicarbonate secretion was cystic fibrosis transmembrane conductance regulator (CFTR)-dependent, mucosal chloride-dependent, partially Na(+)-dependent, and sensitive to serosal, but not mucosal, stilbene inhibition.	Chlorides	119-127	interleukin 17A	Homo sapiens	0-6
19074559-7	2009	IL-17A-induced bicarbonate secretion was cystic fibrosis transmembrane conductance regulator (CFTR)-dependent, mucosal chloride-dependent, partially Na(+)-dependent, and sensitive to serosal, but not mucosal, stilbene inhibition.	Stilbenes	209-217	interleukin 17A	Homo sapiens	0-6
19074559-8	2009	These data suggest that IL-17A modulates epithelial bicarbonate secretion and implicate a mechanism by which airway surface liquid pH changes may be abnormal in cystic fibrosis.	Bicarbonates	52-63	interleukin 17A	Homo sapiens	24-30
19114665-14	2009	In vivo challenge with the yeast cell wall product zymosan rapidly induced IL-17 production in these cells.	Zymosan	51-58	interleukin 17A	Homo sapiens	75-80
19138532-3	2009	The results revealed that DEX nonspecifically and dose-dependently inhibited the production of 12 cytokines (IL-2, IFN-gamma, TNF-alpha, IL-8, IL-1beta, IL-17, IL-4, IL-5, IL-6, IL-10, IL-13, and G-CSF).	Dexamethasone	26-29	interleukin 17A	Homo sapiens	153-158
18986691-9	2009	Inflamed skin of nickel-challenged allergic individuals contained infiltrating neutrophils and cells expressing IL-17, IL-22, CCR6, and IL-22R.	Nickel	17-23	interleukin 17A	Homo sapiens	112-117
19019941-0	2009	Inhibitory effect of rapamycin and dexamethasone on production of IL-17 and IFN-gamma in Vogt-Koyanagi-Harada patients.	Dexamethasone	35-48	interleukin 17A	Homo sapiens	66-71
19019941-1	2009	AIMS: To evaluate the effect of rapamycin (RAPA) and dexamethasone (DEX) on the production of IL-17 and IFN-gamma by peripheral blood mononuclear cells (PBMCs) from Vogt-Koyanagi-Harada (VKH) patients and healthy individuals.	Dexamethasone	53-66	interleukin 17A	Homo sapiens	94-99
19019941-1	2009	AIMS: To evaluate the effect of rapamycin (RAPA) and dexamethasone (DEX) on the production of IL-17 and IFN-gamma by peripheral blood mononuclear cells (PBMCs) from Vogt-Koyanagi-Harada (VKH) patients and healthy individuals.	Dexamethasone	68-71	interleukin 17A	Homo sapiens	94-99
19019941-7	2009	DEX inhibited the production of both IL-17 and IFN-gamma by approximately 70%.	Dexamethasone	0-3	interleukin 17A	Homo sapiens	37-42
19019941-8	2009	CONCLUSIONS: This study indicates that both RAPA and DEX inhibit the production of IL-17 and IFN-gamma by PBMCs.	Sirolimus	44-48	interleukin 17A	Homo sapiens	83-88
19019941-8	2009	CONCLUSIONS: This study indicates that both RAPA and DEX inhibit the production of IL-17 and IFN-gamma by PBMCs.	Dexamethasone	53-56	interleukin 17A	Homo sapiens	83-88
19019941-9	2009	RAPA is much stronger in inhibiting the production of IL-17 than DEX.	Sirolimus	0-4	interleukin 17A	Homo sapiens	54-59
19056110-6	2009	RESULTS: Approximately 10% of APT-infiltrating T cells secreted IL-17 after phorbol 12-myristate 13-acetate (PMA)/ionomycin stimulation.	Tetradecanoylphorbol Acetate	76-107	interleukin 17A	Homo sapiens	64-69
19056110-6	2009	RESULTS: Approximately 10% of APT-infiltrating T cells secreted IL-17 after phorbol 12-myristate 13-acetate (PMA)/ionomycin stimulation.	Tetradecanoylphorbol Acetate	109-112	interleukin 17A	Homo sapiens	64-69
19056110-6	2009	RESULTS: Approximately 10% of APT-infiltrating T cells secreted IL-17 after phorbol 12-myristate 13-acetate (PMA)/ionomycin stimulation.	Ionomycin	114-123	interleukin 17A	Homo sapiens	64-69
18804287-0	2008	Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis.	Glatiramer Acetate	66-84	interleukin 17A	Homo sapiens	18-23
19910679-0	2009	Catechins inhibit CCL20 production in IL-17A-stimulated human gingival fibroblasts.	Catechin	0-9	interleukin 17A	Homo sapiens	38-44
19910679-5	2009	EGCG and ECG prevented IL-17A-mediated CCL20 production in HGFs.	epigallocatechin gallate	0-4	interleukin 17A	Homo sapiens	23-29
19910679-5	2009	EGCG and ECG prevented IL-17A-mediated CCL20 production in HGFs.	epicatechin gallate	9-12	interleukin 17A	Homo sapiens	23-29
19910679-7	2009	EGCG and ECG prevented IL-17A-induced phosphorylation of p38 MAPK and ERK in HGFs.	epigallocatechin gallate	0-4	interleukin 17A	Homo sapiens	23-29
19910679-7	2009	EGCG and ECG prevented IL-17A-induced phosphorylation of p38 MAPK and ERK in HGFs.	epicatechin gallate	9-12	interleukin 17A	Homo sapiens	23-29
19050268-0	2008	IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes.	Cholecalciferol	16-26	interleukin 17A	Homo sapiens	0-6
19050268-9	2008	These results suggest that increased IL-17A in psoriatic skin increases cathelicidin through a vitamin D(3)-, Act1-, and MEK-ERK-dependent mechanism.	Vitamin D	95-104	interleukin 17A	Homo sapiens	37-43
18804287-3	2008	We demonstrate that GA downregulates the expression of both IL-17 and IL-6 in two different EAE models.	Glatiramer Acetate	20-22	interleukin 17A	Homo sapiens	60-65
18687303-0	2008	A selective phosphodiesterase 4 (PDE4) inhibitor Zl-n-91 suppresses IL-17 production by human memory Th17 cells.	FFPM	49-56	interleukin 17A	Homo sapiens	68-73
18698005-3	2008	In the presence of exogenous PGE(2), peripheral blood mononuclear cells produced higher interleukin-17 (IL-17), C-C chemokine ligand 20 (CCL20)/macrophage inflammatory protein 3alpha (MIP-3alpha), CXC chemokine ligand 8 (CXCL8)/IL-8, and lower interferon-gamma and IL-22 levels than in control cultures.	Prostaglandins E	29-32	interleukin 17A	Homo sapiens	88-102
18698005-3	2008	In the presence of exogenous PGE(2), peripheral blood mononuclear cells produced higher interleukin-17 (IL-17), C-C chemokine ligand 20 (CCL20)/macrophage inflammatory protein 3alpha (MIP-3alpha), CXC chemokine ligand 8 (CXCL8)/IL-8, and lower interferon-gamma and IL-22 levels than in control cultures.	Prostaglandins E	29-32	interleukin 17A	Homo sapiens	104-109
18698005-4	2008	Exogenous PGE(2) and IL-23 synergized in inducing IL-17, whereas indomethacin and IL-23 blockade drastically reduced IL-17 but not interferon-gamma production.	Prostaglandins E	10-13	interleukin 17A	Homo sapiens	50-55
18698005-4	2008	Exogenous PGE(2) and IL-23 synergized in inducing IL-17, whereas indomethacin and IL-23 blockade drastically reduced IL-17 but not interferon-gamma production.	Indomethacin	65-77	interleukin 17A	Homo sapiens	117-122
18698005-6	2008	PGE(2) doubled the frequency of CD4+ T cells producing IL-17 and within the CD4+ subset enhanced C-C chemokine receptor 6 (CCR6) and CCR4 while decreasing CXC chemokine receptor 3 (CXCR3) expression.	Prostaglandins E	0-3	interleukin 17A	Homo sapiens	55-60
18698005-9	2008	These results identify PGE(2) and IL-23 as participating in the expansion of CD4+ T cells endowed with high IL-17 production capacity, which in turn favors monocyte production of mediators important for host defense and tissue destruction.	Prostaglandins E	23-26	interleukin 17A	Homo sapiens	108-113
18941244-8	2008	The p38 and ERK pathway inhibitors SB203580 and U0126 reversed the repressive effect of IL-17 on CXCL10 mRNA abundance and promoter activity and also reversed the inductive effect of IL-17 on CXCL8 mRNA, indicating that MAPK signaling mediates both the transcriptional repression of CXCL10 and the stabilization of CXCL8 mRNA by IL-17.	SB 203580	35-43	interleukin 17A	Homo sapiens	88-93
18941244-8	2008	The p38 and ERK pathway inhibitors SB203580 and U0126 reversed the repressive effect of IL-17 on CXCL10 mRNA abundance and promoter activity and also reversed the inductive effect of IL-17 on CXCL8 mRNA, indicating that MAPK signaling mediates both the transcriptional repression of CXCL10 and the stabilization of CXCL8 mRNA by IL-17.	SB 203580	35-43	interleukin 17A	Homo sapiens	183-188
18692909-5	2008	Rivastigmine decreased the reactivity of encephalitogenic T-cells and the production of pro-inflammatory cytokines (TNF-alpha, IFN-gamma and IL-17) without affecting IL-10 production.	Rivastigmine	0-12	interleukin 17A	Homo sapiens	141-146
18941244-8	2008	The p38 and ERK pathway inhibitors SB203580 and U0126 reversed the repressive effect of IL-17 on CXCL10 mRNA abundance and promoter activity and also reversed the inductive effect of IL-17 on CXCL8 mRNA, indicating that MAPK signaling mediates both the transcriptional repression of CXCL10 and the stabilization of CXCL8 mRNA by IL-17.	SB 203580	35-43	interleukin 17A	Homo sapiens	183-188
18941244-8	2008	The p38 and ERK pathway inhibitors SB203580 and U0126 reversed the repressive effect of IL-17 on CXCL10 mRNA abundance and promoter activity and also reversed the inductive effect of IL-17 on CXCL8 mRNA, indicating that MAPK signaling mediates both the transcriptional repression of CXCL10 and the stabilization of CXCL8 mRNA by IL-17.	U 0126	48-53	interleukin 17A	Homo sapiens	88-93
18941244-8	2008	The p38 and ERK pathway inhibitors SB203580 and U0126 reversed the repressive effect of IL-17 on CXCL10 mRNA abundance and promoter activity and also reversed the inductive effect of IL-17 on CXCL8 mRNA, indicating that MAPK signaling mediates both the transcriptional repression of CXCL10 and the stabilization of CXCL8 mRNA by IL-17.	U 0126	48-53	interleukin 17A	Homo sapiens	183-188
18941244-8	2008	The p38 and ERK pathway inhibitors SB203580 and U0126 reversed the repressive effect of IL-17 on CXCL10 mRNA abundance and promoter activity and also reversed the inductive effect of IL-17 on CXCL8 mRNA, indicating that MAPK signaling mediates both the transcriptional repression of CXCL10 and the stabilization of CXCL8 mRNA by IL-17.	U 0126	48-53	interleukin 17A	Homo sapiens	183-188
18941244-9	2008	The EGFR kinase inhibitor AG1478 partially reversed the effects of IL-17 on CXCL8 and CXCL10 mRNA, demonstrating a role for EGFR in downstream IL-17 signaling.	RTKI cpd	26-32	interleukin 17A	Homo sapiens	67-72
18941244-9	2008	The EGFR kinase inhibitor AG1478 partially reversed the effects of IL-17 on CXCL8 and CXCL10 mRNA, demonstrating a role for EGFR in downstream IL-17 signaling.	RTKI cpd	26-32	interleukin 17A	Homo sapiens	143-148
18617638-7	2008	When an histone deacetylase (HDAC) inhibitor trichostatin A (TSA) was evaluated, we found a profound negative effect on the emergence of IL-17-producing cells from Tregs, implying that Treg differentiation into IL-17-producing cells depends on histone/protein deacetylase activity.	trichostatin A	45-59	interleukin 17A	Homo sapiens	137-142
18617638-7	2008	When an histone deacetylase (HDAC) inhibitor trichostatin A (TSA) was evaluated, we found a profound negative effect on the emergence of IL-17-producing cells from Tregs, implying that Treg differentiation into IL-17-producing cells depends on histone/protein deacetylase activity.	trichostatin A	45-59	interleukin 17A	Homo sapiens	211-216
18617638-7	2008	When an histone deacetylase (HDAC) inhibitor trichostatin A (TSA) was evaluated, we found a profound negative effect on the emergence of IL-17-producing cells from Tregs, implying that Treg differentiation into IL-17-producing cells depends on histone/protein deacetylase activity.	trichostatin A	61-64	interleukin 17A	Homo sapiens	137-142
18617638-7	2008	When an histone deacetylase (HDAC) inhibitor trichostatin A (TSA) was evaluated, we found a profound negative effect on the emergence of IL-17-producing cells from Tregs, implying that Treg differentiation into IL-17-producing cells depends on histone/protein deacetylase activity.	trichostatin A	61-64	interleukin 17A	Homo sapiens	211-216
18786233-11	2008	Our findings demonstrate the IL23/IL17 axis to be involved in the pathophysiology of BOS potentially triggering the IL8-mediated neutrophilia.	N-[4-(Aminosulfonyl)phenyl]-2-Mercaptobenzamide	85-88	interleukin 17A	Homo sapiens	34-38
18063670-5	2008	IL17 (IL17A) positive T cells were identified by a flow cytometer after ex vivo stimulation with phorbol myristate acetate and ionomycin.	Tetradecanoylphorbol Acetate	97-122	interleukin 17A	Homo sapiens	0-4
18063670-5	2008	IL17 (IL17A) positive T cells were identified by a flow cytometer after ex vivo stimulation with phorbol myristate acetate and ionomycin.	Tetradecanoylphorbol Acetate	97-122	interleukin 17A	Homo sapiens	6-11
18063670-5	2008	IL17 (IL17A) positive T cells were identified by a flow cytometer after ex vivo stimulation with phorbol myristate acetate and ionomycin.	Ionomycin	127-136	interleukin 17A	Homo sapiens	0-4
18063670-5	2008	IL17 (IL17A) positive T cells were identified by a flow cytometer after ex vivo stimulation with phorbol myristate acetate and ionomycin.	Ionomycin	127-136	interleukin 17A	Homo sapiens	6-11
18586117-4	2008	Highlighting the inflammatory profile in CIU found in ASST positive, is the enhanced B-cell proliferative responsiveness and increased IL-17 secretion levels.	n-cyclohexyl-n'-(4-iodophenyl)urea	41-44	interleukin 17A	Homo sapiens	135-140
18586117-7	2008	Our findings support the concept of immunologic dysregulation in CIU, revealing a systemic inflammatory profile associated with disturbed cytokine production by T cells, mainly related to IL-17 and IL-10 production.	n-cyclohexyl-n'-(4-iodophenyl)urea	65-68	interleukin 17A	Homo sapiens	188-193
18417374-9	2008	IL-17- and tumor necrosis factor-alpha (TNF-alpha)-induced NO and PGE(2) production was also inhibited by TSA and BA.	Dinoprostone	66-72	interleukin 17A	Homo sapiens	0-38
18417374-9	2008	IL-17- and tumor necrosis factor-alpha (TNF-alpha)-induced NO and PGE(2) production was also inhibited by TSA and BA.	trichostatin A	106-109	interleukin 17A	Homo sapiens	0-38
18417374-9	2008	IL-17- and tumor necrosis factor-alpha (TNF-alpha)-induced NO and PGE(2) production was also inhibited by TSA and BA.	Butyric Acid	114-116	interleukin 17A	Homo sapiens	0-38
18687303-3	2008	In the present study, we assessed the effect of a selective PDE4 inhibitor Zl-n-91 on IL-17 production by PBMCs and by purified CD4(+) T cells following stimulation.	FFPM	75-82	interleukin 17A	Homo sapiens	86-91
18687303-4	2008	The results for the first time demonstrated that the addition of Zl-n-91 into cell cultures of PBMCs and purified CD4(+) T cells could result in the suppression of IL-17 production at the protein and mRNA levels.	zl-n	65-69	interleukin 17A	Homo sapiens	164-169
18511701-10	2008	CONCLUSIONS: One mechanism of IFN-gamma protection against IPS is negative regulation of the expansion of pathogenic IL-17A-producing CD4(+) T cells through interaction with the IFN-gamma receptor on the pulmonary parenchymal cell population.	IPS	59-62	interleukin 17A	Homo sapiens	117-123
18687303-5	2008	Further analysis indicated that Zl-n-91 had a direct inhibitory effect on the IL-17 production by memory Th17 cells via the suppression of activation, proliferation and division of CD4(+) T cells.	FFPM	32-39	interleukin 17A	Homo sapiens	78-83
18687303-6	2008	Our data suggested that Zl-n-91 might have beneficial effects in the treatment of IL-17-related autoimmune diseases.	zl-n	24-28	interleukin 17A	Homo sapiens	82-87
18424069-0	2008	Cyclosporin A inhibits the production of IL-17 by memory Th17 cells from healthy individuals and patients with rheumatoid arthritis.	Cyclosporine	0-13	interleukin 17A	Homo sapiens	41-46
18434325-7	2008	RORgammat-mediated IL-17A promoter activation was suppressed by forced expression of Foxp3.	rorgammat	0-9	interleukin 17A	Homo sapiens	19-25
18512782-9	2008	IL-17 production was completely abrogated by anti-IL-1 or IL-1 receptor antagonist and partially inhibited by anti-IL-6, anti-IL-2, or exogenous retinoic acid, but not by anti-tumor necrosis factor alpha.	Tretinoin	145-158	interleukin 17A	Homo sapiens	0-5
18424069-5	2008	The addition of CsA into cell cultures significantly inhibited the IL-17 production by Th17 cells at protein and at mRNA levels.	Cyclosporine	16-19	interleukin 17A	Homo sapiens	67-72
18424069-6	2008	Compared to the PBMCs from normal individuals, PBMCs from the patients with RA produced higher levels of IL-17 that was also significantly inhibited by CsA both at protein and at mRNA levels.	Cyclosporine	152-155	interleukin 17A	Homo sapiens	105-110
18424069-8	2008	Taken together, these results demonstrated that CsA suppressed the IL-17 production and inhibited the Th17 cells differentiation from both healthy individuals and patients with RA.	Cyclosporine	48-51	interleukin 17A	Homo sapiens	67-72
18453621-0	2008	Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes.	Simvastatin	0-11	interleukin 17A	Homo sapiens	21-26
18490716-0	2008	Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway.	Lactic Acid	15-26	interleukin 17A	Homo sapiens	42-47
18490716-9	2008	These results suggest that rather than just being a terminal metabolite, lactic acid is a proinflammatory mediator that is secreted by tumor cells to activate the IL-23/IL-17 proinflammatory pathway but not the Th1 pathway.	Lactic Acid	73-84	interleukin 17A	Homo sapiens	169-174
18390695-6	2008	Recent data support a view in which IL-23/IL-17 antagonistic strategies, including the administration of synthetic kynurenines, could represent a new means of harnessing progressive or potentially harmful inflammation.	Kynurenine	115-126	interleukin 17A	Homo sapiens	42-47
18390697-3	2008	These rapid IL-6-independent IL-17 producers were identified as predominantly DX5(+) TCRbeta(+) NKT cells, and a comparable response could be found using the invariant NKT-specific ligand alpha-galactosylceramide.	alpha-galactosylceramide	188-212	interleukin 17A	Homo sapiens	29-34
18390697-8	2008	Importantly, in vivo administration of alpha-galactosylceramide triggered a rapid IL-17 response in the spleen.	alpha-galactosylceramide	39-63	interleukin 17A	Homo sapiens	82-87
18200064-3	2008	We localized Th17 cells predominantly to the dermis of psoriasis skin lesions, confirmed that IL-17 mRNA increased with disease activity, and demonstrated that IL-17 mRNA expression normalized with cyclosporine therapy.	Cyclosporine	198-210	interleukin 17A	Homo sapiens	160-165
18453621-0	2008	Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes.	Simvastatin	0-11	interleukin 17A	Homo sapiens	59-64
18453621-0	2008	Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes.	Simvastatin	0-11	interleukin 17A	Homo sapiens	59-64
18453621-4	2008	Simvastatin also induced IFN-gamma, IL-4, and IL-27 production in monocytes, which together inhibited IL-17 transcription and secretion in CD4(+) T cells.	Simvastatin	0-11	interleukin 17A	Homo sapiens	102-107
18453621-6	2008	Furthermore, simvastatin directly inhibited the expression of retinoic acid-related orphan nuclear hormone receptor C, a transcription factor that controls IL-17 production in CD4(+) T cells.	Simvastatin	13-24	interleukin 17A	Homo sapiens	156-161
17909455-1	2008	IL-17 is a cytokine produced by a newly identified T-cell subpopulation (THl7/THIL-17).	thl7	73-77	interleukin 17A	Homo sapiens	0-5
18262659-3	2008	The culture study showed reduced IL-12, IL-17, IFN-gamma, GM-CSF, TNF-alpha and MIP-1beta, and elevated IL-10 in the PBMC from patients who received tacrolimus, which suggests inhibition of T cells and macrophages, and enhancement of type 1 regulatory T cells.	Tacrolimus	149-159	interleukin 17A	Homo sapiens	40-45
18200634-9	2008	Consistently, blockade of IL-23 in cultures of LPMC from Hp-infected patients reduced Stat3 activation and IL-17 production.	lpmc	47-51	interleukin 17A	Homo sapiens	107-112
18164424-3	2008	Treatment with IL-17 upregulated the microglial production of IL-6, macrophage inflammatory protein-2, nitric oxide, adhesion molecules, and neurotrophic factors.	Nitric Oxide	103-115	interleukin 17A	Homo sapiens	15-20
18203812-8	2008	Simvastatin attenuated effects of both IL-17 and TGF-beta.	Simvastatin	0-11	interleukin 17A	Homo sapiens	39-44
18203812-9	2008	We have demonstrated the ability of simvastatin to attenuate release of airway neutrophilic and remodeling mediators and to inhibit their upregulation by TGF-beta and IL-17.	Simvastatin	36-47	interleukin 17A	Homo sapiens	167-172
17921324-12	2007	IL-17 induced p38 MAPK and ERK1/2 activation, and inhibition by SB-203580 and PD-98059 blunted IL-17-mediated transcription factor activation and MMP-1 expression.	SB 203580	64-73	interleukin 17A	Homo sapiens	95-100
18423430-3	2008	Administration of alpha-galactosylceramide (alpha-GalCer), a strong agonist of NKT cells, induces rapid IL-17 production by a small population of NKT cells, mostly belonging to a population different from that of IL-4- and IFN-gamma-producing NKT cells.	alpha-galactosylceramide	18-42	interleukin 17A	Homo sapiens	104-109
18395796-5	2008	IL-17s from the oyster, sea urchin, trout and human, contained conserved cysteine residues found in all forms of IL-17 in mammals.	Cysteine	73-81	interleukin 17A	Homo sapiens	0-5
17996694-2	2007	Using MACS-purified CD4 cells, we found that rapamycin and cyclosporine A (CsA) potently inhibited the TGFbeta and IL-6-induced generation of IL-17-producing cells.	Sirolimus	45-54	interleukin 17A	Homo sapiens	142-147
17996694-2	2007	Using MACS-purified CD4 cells, we found that rapamycin and cyclosporine A (CsA) potently inhibited the TGFbeta and IL-6-induced generation of IL-17-producing cells.	Cyclosporine	59-73	interleukin 17A	Homo sapiens	142-147
17996694-2	2007	Using MACS-purified CD4 cells, we found that rapamycin and cyclosporine A (CsA) potently inhibited the TGFbeta and IL-6-induced generation of IL-17-producing cells.	Cyclosporine	75-78	interleukin 17A	Homo sapiens	142-147
18484192-3	2008	In addition to the statin-mediated effect on the monocyte cytokine production, which regulates Th17 cell differentiation, simvastatin directly inhibits IL-17 production in CD4+ cells, which may collectively inhibit the autoimmune response in multiple sclerosis (MS), a central nervous system (CNS) inflammatory demyelinating disease.	Simvastatin	122-133	interleukin 17A	Homo sapiens	152-157
17921324-12	2007	IL-17 induced p38 MAPK and ERK1/2 activation, and inhibition by SB-203580 and PD-98059 blunted IL-17-mediated transcription factor activation and MMP-1 expression.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	78-86	interleukin 17A	Homo sapiens	0-5
17921324-12	2007	IL-17 induced p38 MAPK and ERK1/2 activation, and inhibition by SB-203580 and PD-98059 blunted IL-17-mediated transcription factor activation and MMP-1 expression.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	78-86	interleukin 17A	Homo sapiens	95-100
18219763-6	2007	IL-17 binding to an IL-17 receptor expressed on epithelial, endothelial, and fibroblastic stromal cells triggers the activation of transcription factor NF-kappaB and mitogen-activated protein kinase (p-38), which in turn results in the secretion of IL-1, TNF-alpha, IL-6, IL-8, or prostaglandin E2.	Dinoprostone	281-297	interleukin 17A	Homo sapiens	0-5
17921324-9	2007	IL-17-stimulated type I collagenase activity was inhibited by the MMP inhibitor GM-6001 and by siRNA-mediated MMP-1 knockdown.	N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide	80-87	interleukin 17A	Homo sapiens	0-5
17921324-10	2007	IL-17 stimulated activator protein-1 [AP-1 (c-Fos, c-Jun, and Fra-1)], NF-kappaB (p50 and p65), and CCAAT enhancer-binding protein (C/EBP)-beta DNA binding and reporter gene activities, effects attenuated by antisense oligonucleotides, siRNA-mediated knockdown, or expression of dominant-negative signaling proteins.	Oligonucleotides	218-234	interleukin 17A	Homo sapiens	0-5
17785852-6	2007	Using a tetracycline-regulated transgene in HeLa cells, we determined that IL-17 treatment alone promoted stabilization of KC mRNA in the absence of TNF-alpha.	Tetracycline	8-20	interleukin 17A	Homo sapiens	75-80
17652082-8	2007	IL-17 stimulated p38 MAPK and ERK1/2 activation, and SB203580 and PD98059 blunted IL-17-mediated NF-kappaB and C/EBP activation and CRP transcription.	SB 203580	53-61	interleukin 17A	Homo sapiens	82-87
17652082-8	2007	IL-17 stimulated p38 MAPK and ERK1/2 activation, and SB203580 and PD98059 blunted IL-17-mediated NF-kappaB and C/EBP activation and CRP transcription.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	66-73	interleukin 17A	Homo sapiens	82-87
17652082-9	2007	These results, confirmed in primary human hepatocytes and CASMC, demonstrate for the first time that IL-17 is a potent inducer of CRP expression via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation and suggest that IL-17 may mediate chronic inflammation, atherosclerosis, and thrombosis.	casmc	58-63	interleukin 17A	Homo sapiens	101-106
18219763-6	2007	IL-17 binding to an IL-17 receptor expressed on epithelial, endothelial, and fibroblastic stromal cells triggers the activation of transcription factor NF-kappaB and mitogen-activated protein kinase (p-38), which in turn results in the secretion of IL-1, TNF-alpha, IL-6, IL-8, or prostaglandin E2.	Dinoprostone	281-297	interleukin 17A	Homo sapiens	20-25
17694576-3	2007	We now show that, in the context of TGF-beta signalling, all-trans retinoic acid (ATRA) leads to increased induction of CD4(+) T cells expressing the Treg specification factor forkhead box protein P3 (FoxP3) and decreased frequency of cells expressing IL-17, even in the presence of IL-6.	Tretinoin	67-80	interleukin 17A	Homo sapiens	252-257
17694576-3	2007	We now show that, in the context of TGF-beta signalling, all-trans retinoic acid (ATRA) leads to increased induction of CD4(+) T cells expressing the Treg specification factor forkhead box protein P3 (FoxP3) and decreased frequency of cells expressing IL-17, even in the presence of IL-6.	Tretinoin	82-86	interleukin 17A	Homo sapiens	252-257
17548652-0	2007	The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23-->IL-17 axis.	Dinoprostone	30-46	interleukin 17A	Homo sapiens	125-130
17618562-4	2007	By the induction of Isopropyl-beta-D-Thiogalacto-Pyranoside (IPTG), recombinant IL-17/His protein was effectively expressed in E.coli M15.	Isopropyl Thiogalactoside	20-59	interleukin 17A	Homo sapiens	80-85
17618562-4	2007	By the induction of Isopropyl-beta-D-Thiogalacto-Pyranoside (IPTG), recombinant IL-17/His protein was effectively expressed in E.coli M15.	Isopropyl Thiogalactoside	61-65	interleukin 17A	Homo sapiens	80-85
17613395-3	2007	This prospective study aims to assess: (1) the possible role of IL-17 as a link between LTx clinical outcomes (such as infection, acute rejection and BOS) and airway immunopathologic measures from endobronchial biopsy (EBB) and bronchoalveolar lavage (BAL); and (2) any differences in IL-17 production between ERL and azathioprine (AZA)-based immunosuppression.	Azathioprine	318-330	interleukin 17A	Homo sapiens	64-69
17613395-3	2007	This prospective study aims to assess: (1) the possible role of IL-17 as a link between LTx clinical outcomes (such as infection, acute rejection and BOS) and airway immunopathologic measures from endobronchial biopsy (EBB) and bronchoalveolar lavage (BAL); and (2) any differences in IL-17 production between ERL and azathioprine (AZA)-based immunosuppression.	Azathioprine	332-335	interleukin 17A	Homo sapiens	64-69
17548652-4	2007	We found that PGE(2), a major lipid mediator released in inflammatory conditions, shifts the IL-12/IL-23 balance in DCs in favor of IL-23, and propose that high levels of PGE(2) exacerbate the inflammatory process in inflammatory bowel disease through the IL-23-->IL-17 axis.	Prostaglandins E	14-17	interleukin 17A	Homo sapiens	267-272
17548652-4	2007	We found that PGE(2), a major lipid mediator released in inflammatory conditions, shifts the IL-12/IL-23 balance in DCs in favor of IL-23, and propose that high levels of PGE(2) exacerbate the inflammatory process in inflammatory bowel disease through the IL-23-->IL-17 axis.	Prostaglandins E	171-174	interleukin 17A	Homo sapiens	267-272
17548652-5	2007	We assessed the effects of PGE(2) on IL-12, IL-27, and IL-23 and found that PGE(2) promotes IL-23, inhibits IL-12 and IL-27 expression and release from stimulated DCs, and subsequently induces IL-17 production in activated T cells.	Prostaglandins E	76-79	interleukin 17A	Homo sapiens	193-198
17548652-7	2007	In vivo, we assessed the effects of PGE analogs in an experimental model for inflammatory bowel disease and found that the exacerbation of clinical symptoms and histopathology correlated with an increase in IL-23 and IL-17, a decrease in IL-12p35 expression in colon and mesenteric lymph nodes, and a substantial increase in the number of infiltrating neutrophils and of CD4(+)IL-17(+) T cells in the colonic tissue.	Prostaglandins E	36-39	interleukin 17A	Homo sapiens	217-222
17548652-7	2007	In vivo, we assessed the effects of PGE analogs in an experimental model for inflammatory bowel disease and found that the exacerbation of clinical symptoms and histopathology correlated with an increase in IL-23 and IL-17, a decrease in IL-12p35 expression in colon and mesenteric lymph nodes, and a substantial increase in the number of infiltrating neutrophils and of CD4(+)IL-17(+) T cells in the colonic tissue.	Prostaglandins E	36-39	interleukin 17A	Homo sapiens	377-382
17277312-1	2007	Interleukin-17 (IL-17)-producing helper T (TH) cells, named as TH(IL-17), TH17, or inflammatory TH (THi), have been recently identified as a novel effector lineage.	2-acetyl-4(5)-tetrahydroxybutylimidazole	100-103	interleukin 17A	Homo sapiens	0-14
17470641-4	2007	NK1.1(neg) iNKT cells produce IL-17 upon synthetic (alpha-galactosylceramide [alpha-GalCer] or PBS-57), as well as natural (lipopolysaccharides or glycolipids derived from Sphingomonas wittichii and Borrelia burgdorferi), ligand stimulation.	alpha-galactosylceramide	52-76	interleukin 17A	Homo sapiens	30-35
17470641-4	2007	NK1.1(neg) iNKT cells produce IL-17 upon synthetic (alpha-galactosylceramide [alpha-GalCer] or PBS-57), as well as natural (lipopolysaccharides or glycolipids derived from Sphingomonas wittichii and Borrelia burgdorferi), ligand stimulation.	alpha-galactosylceramide	78-90	interleukin 17A	Homo sapiens	30-35
17452998-2	2007	Recently a novel subset of TH cells, termed TH(IL-17), TH17 or inflammatory TH (THi), has been identified as critical mediators of tissue inflammation.	2-acetyl-4(5)-tetrahydroxybutylimidazole	80-83	interleukin 17A	Homo sapiens	27-30
17425422-8	2007	With PMA/ionomycin stimulation, the percent IL-17 expression in CD4(+) cells (median) was 1.45 versus 0.65 (p< 0.0001) and in CD4() T cells it was 1.0 versus 0.12 (p< 0.0001).	Tetradecanoylphorbol Acetate	5-8	interleukin 17A	Homo sapiens	44-49
17425422-8	2007	With PMA/ionomycin stimulation, the percent IL-17 expression in CD4(+) cells (median) was 1.45 versus 0.65 (p< 0.0001) and in CD4() T cells it was 1.0 versus 0.12 (p< 0.0001).	Ionomycin	9-18	interleukin 17A	Homo sapiens	44-49
17425422-10	2007	IL-17 expression was further inducible by PMA/ionomycin stimulation in vitro only in CD4(+) T cells.	Tetradecanoylphorbol Acetate	42-45	interleukin 17A	Homo sapiens	0-5
17425422-10	2007	IL-17 expression was further inducible by PMA/ionomycin stimulation in vitro only in CD4(+) T cells.	Ionomycin	46-55	interleukin 17A	Homo sapiens	0-5
17277312-1	2007	Interleukin-17 (IL-17)-producing helper T (TH) cells, named as TH(IL-17), TH17, or inflammatory TH (THi), have been recently identified as a novel effector lineage.	2-acetyl-4(5)-tetrahydroxybutylimidazole	100-103	interleukin 17A	Homo sapiens	16-21
17277312-1	2007	Interleukin-17 (IL-17)-producing helper T (TH) cells, named as TH(IL-17), TH17, or inflammatory TH (THi), have been recently identified as a novel effector lineage.	2-acetyl-4(5)-tetrahydroxybutylimidazole	100-103	interleukin 17A	Homo sapiens	96-99
17240458-1	2007	ThIL-17 (IL-17+/IFN-gamma-) cell lines are significantly more encephalitogenic than Th1 (IL-17-/IFN-gamma+) cell lines in adoptive transfer EAE models.	thil	0-4	interleukin 17A	Homo sapiens	9-25
17218320-5	2007	Histone H3 acetylation and Lys-4 tri-methylation were specifically associated with IL-17 and IL-17F gene promoters in THi lineage.	Lysine	27-30	interleukin 17A	Homo sapiens	83-88
17218320-5	2007	Histone H3 acetylation and Lys-4 tri-methylation were specifically associated with IL-17 and IL-17F gene promoters in THi lineage.	2-acetyl-4(5)-tetrahydroxybutylimidazole	118-121	interleukin 17A	Homo sapiens	83-88
17218320-9	2007	In summary, our results demonstrate for the first time that THi cell differentiation is associated with epigenetic changes in the IL-17-IL-17F locus, which suggests novel mechanisms in T cell functional regulation.	2-acetyl-4(5)-tetrahydroxybutylimidazole	60-63	interleukin 17A	Homo sapiens	130-135
17470641-4	2007	NK1.1(neg) iNKT cells produce IL-17 upon synthetic (alpha-galactosylceramide [alpha-GalCer] or PBS-57), as well as natural (lipopolysaccharides or glycolipids derived from Sphingomonas wittichii and Borrelia burgdorferi), ligand stimulation.	Lead	95-98	interleukin 17A	Homo sapiens	30-35
17228364-4	2007	In vitro exposure of HPMCs to IL-17A resulted in a time- and dose-dependent release of G-CSF.	hpmcs	21-26	interleukin 17A	Homo sapiens	30-36
17161467-0	2007	Cyclosporine A inhibits IL-15-induced IL-17 production in CD4+ T cells via down-regulation of PI3K/Akt and NF-kappaB.	Cyclosporine	0-14	interleukin 17A	Homo sapiens	38-43
17161467-1	2007	Cyclosporine A (CSA) has various biological effects on T cells, including inhibition of interleukin (IL)-15-induced IL-17 production in CD4+ T cells from patients with rheumatoid arthritis (RA).	Cyclosporine	0-14	interleukin 17A	Homo sapiens	116-121
17161467-10	2007	Moreover PI3K/Akt inhibitor, NF-kappaB inhibitor, and FK506 significantly inhibited IL-15-induced IL-17 production in CD4+ T cells.	Tacrolimus	54-59	interleukin 17A	Homo sapiens	98-103
17061983-0	2007	Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells.	Macrolides	0-10	interleukin 17A	Homo sapiens	19-23
17061983-0	2007	Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells.	8-epi-prostaglandin F2alpha	40-53	interleukin 17A	Homo sapiens	19-23
17061983-7	2007	IL17-induced IL8 production was decreased by both erythromycin and azithromycin.	Erythromycin	50-62	interleukin 17A	Homo sapiens	0-4
17061983-7	2007	IL17-induced IL8 production was decreased by both erythromycin and azithromycin.	Azithromycin	67-79	interleukin 17A	Homo sapiens	0-4
17061983-11	2007	We conclude that macrolides (but not steroids/immunosuppressive agents) inhibit IL17-induced IL8 production in human primary airway smooth muscle cells via a reduction in MAPK activation and 8-isoprostane production.	Macrolides	17-27	interleukin 17A	Homo sapiens	80-84
17061983-11	2007	We conclude that macrolides (but not steroids/immunosuppressive agents) inhibit IL17-induced IL8 production in human primary airway smooth muscle cells via a reduction in MAPK activation and 8-isoprostane production.	8-epi-prostaglandin F2alpha	191-204	interleukin 17A	Homo sapiens	80-84
16772307-6	2007	Such effects of IL-17 were completely blocked by inhibitors of phosphatidylinositol (PI)-kinase/Akt, nuclear factor (NF)-kappaB and p38 mitogen-activated protein kinase (MAPK).	Phosphatidylinositols	63-83	interleukin 17A	Homo sapiens	16-21
17214584-5	2006	PGE2 is also produced in response to proinflammatory cytokines, which in turn negatively regulates both IL-17 and TNF-alpha expression and TNF/IL-1-induced activation of fibroblast-like synoviocytes through EP2/EP4 receptors, resulting in the modulation of proinflammatory cascades.	Dinoprostone	0-4	interleukin 17A	Homo sapiens	104-109
16859642-4	2006	The mitogenic effect of IL-17A on tracheal epithelial cells was confirmed with Calcein-AM assay.	calcein AM	79-89	interleukin 17A	Homo sapiens	24-30
17083726-9	2006	High sputum IL-8 and IL-17A mRNA levels were also found in moderate-to-severe (persistent) asthmatics on inhaled steroid treatment.	Steroids	113-120	interleukin 17A	Homo sapiens	21-27
16443681-9	2006	Furthermore, hydrogen peroxide treatment led to a greater accumulation of several inflammatory cytokines (IL-6, IL-7, IL-16, and IL-17) and increased necrosis in older cells.	Hydrogen Peroxide	13-30	interleukin 17A	Homo sapiens	129-134
16951370-5	2006	Moreover, IL-17A significantly induced eotaxin-1/CCL11 release and mRNA expression, an effect that was abrogated with cycloheximide and actinomycin D treatment.	Cycloheximide	118-131	interleukin 17A	Homo sapiens	10-16
16951370-5	2006	Moreover, IL-17A significantly induced eotaxin-1/CCL11 release and mRNA expression, an effect that was abrogated with cycloheximide and actinomycin D treatment.	Dactinomycin	136-149	interleukin 17A	Homo sapiens	10-16
16543723-0	2006	The active form of leflunomide, HMR1726, facilitates TNF-alpha and IL-17 induced MMP-1 and MMP-3 expression.	Leflunomide	19-30	interleukin 17A	Homo sapiens	67-72
16543723-0	2006	The active form of leflunomide, HMR1726, facilitates TNF-alpha and IL-17 induced MMP-1 and MMP-3 expression.	teriflunomide	32-39	interleukin 17A	Homo sapiens	67-72
16543723-1	2006	BACKGROUND/AIMS: To elucidate the influence and mode of action of HMR1726 (the active metabolite of leflunomide) on TNF-alpha and IL-17 activated metalloproteinases expression in synoviocytes.	teriflunomide	66-73	interleukin 17A	Homo sapiens	130-135
16543723-1	2006	BACKGROUND/AIMS: To elucidate the influence and mode of action of HMR1726 (the active metabolite of leflunomide) on TNF-alpha and IL-17 activated metalloproteinases expression in synoviocytes.	Leflunomide	100-111	interleukin 17A	Homo sapiens	130-135
16543723-4	2006	RESULTS: Microarray analyses revealed that the addition of HMR1726 (50 microM) to TNF-alpha and IL-17- stimulated synoviocytes induced gene expression of metallo-proteinases, especially MMP-1 and -3 in comparison to activated synoviocytes in the absence of leflunomide.	Leflunomide	257-268	interleukin 17A	Homo sapiens	96-101
15836713-11	2005	These findings suggest that COX-2 expression and prostaglandin synthesis might be regulated by both T-cell-derived factor (IL-17) and bacterial products (LPS) in the inflamed mucosa.	Prostaglandins	49-62	interleukin 17A	Homo sapiens	123-128
17427151-5	2006	Levels of IL-17A are elevated in sputum of asthmatic patients and correlate with airway hyperresponsiveness to methacholine.	Methacholine Chloride	111-123	interleukin 17A	Homo sapiens	10-16
17427151-10	2006	It is thought, that the character of the immunological response evoked by different cytokines of IL-17 family depends on the differences between the spatial structure of their fragments including disulfide bridges and that these differences determine their receptor interactions and biological functions.	Disulfides	196-205	interleukin 17A	Homo sapiens	97-102
15982617-7	2005	RESULTS: Western blotting clearly demonstrated that p38 MAPK, JNK and p42/p44 ERK were activated by IL-17 in HASMC.	hasmc	109-114	interleukin 17A	Homo sapiens	100-105
15982617-8	2005	Using SB203580, a specific inhibitor of p38 MAPK, we detected a concentration-dependent inhibition of IL-17--induced IL-8 production with a maximal decrease of 63 +/- 5% (n=8, p<0.01).	SB 203580	6-14	interleukin 17A	Homo sapiens	102-107
15982617-9	2005	Curcumin, a specific inhibitor of JNK, also concentration-dependently reduced IL-17--induced IL-8 production, with a maximal decrease of 82+/-4% (n=8, p<0.01).	Curcumin	0-8	interleukin 17A	Homo sapiens	78-83
15982617-11	2005	Pyrrolydine dithiocarbamate (PDTC), an inhibitor of NF-kappaB, caused a 70+/-5% (n=8, p<0.01) decrease in IL-17--induced IL-8 production.	pyrrolydine dithiocarbamate	0-27	interleukin 17A	Homo sapiens	109-114
15982617-11	2005	Pyrrolydine dithiocarbamate (PDTC), an inhibitor of NF-kappaB, caused a 70+/-5% (n=8, p<0.01) decrease in IL-17--induced IL-8 production.	prolinedithiocarbamate	29-33	interleukin 17A	Homo sapiens	109-114
15982617-12	2005	CONCLUSIONS: We found that IL-17 induces activation of p38MAPK, JNK and p42/p44ERK in HASMC.	hasmc	86-91	interleukin 17A	Homo sapiens	27-32
15982617-13	2005	We also found that p38MAPK, JNK, p42/p44 ERK and NF-kappaB play an important role in IL-17--induced IL-8 production in HASMC in vitro.	hasmc	119-124	interleukin 17A	Homo sapiens	85-90
15893694-6	2005	Furthermore, IL-17 induction of CXCL-8 mRNA and protein release from ASM cells was abrogated by transcriptional inhibitor actinomycin D.	Dactinomycin	122-135	interleukin 17A	Homo sapiens	13-18
15843470-3	2005	IL-6 production induced by IL-1, TNF-alpha, and IL-17 was specifically inhibited by the c-jun NH(2)-terminal kinase (JNK) inhibitor SP600125, but not by a selective inhibitor of p38 MAPK, and was moderately increased when the ERK1/2 pathway was inhibited.	pyrazolanthrone	132-140	interleukin 17A	Homo sapiens	48-53
16198312-3	2005	Proliferation and apoptosis in response to IL-17 was monitored in HIEC (cell counts, [(3)H]thymidine incorporation method, and annexinV-PI-apoptosis assay).	Thymidine	91-100	interleukin 17A	Homo sapiens	43-48
16198312-3	2005	Proliferation and apoptosis in response to IL-17 was monitored in HIEC (cell counts, [(3)H]thymidine incorporation method, and annexinV-PI-apoptosis assay).	annexinv-pi	127-138	interleukin 17A	Homo sapiens	43-48
16275389-10	2005	The COX-2 inhibitor NS398 counteracted the effects of IL-17, and prostaglandin E(2) prevented counteraction by NS398.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	20-25	interleukin 17A	Homo sapiens	54-59
16275389-11	2005	IL-17 alone or synergistically with TNF-alpha increased prostaglandin E(2) release from keratinocytes, and the increase was suppressed by NS398.	Dinoprostone	56-74	interleukin 17A	Homo sapiens	0-5
16003000-0	2005	Carbon monoxide inhibits IL-17-induced IL-6 production through the MAPK pathway in human pulmonary epithelial cells.	Carbon Monoxide	0-15	interleukin 17A	Homo sapiens	25-30
16003000-3	2005	As a cytoprotective and anti-inflammatory gaseous molecule, carbon monoxide (CO) may also regulate IL-17-induced inflammatory responses in pulmonary cells.	Carbon Monoxide	60-75	interleukin 17A	Homo sapiens	99-104
16003000-3	2005	As a cytoprotective and anti-inflammatory gaseous molecule, carbon monoxide (CO) may also regulate IL-17-induced inflammatory responses in pulmonary cells.	Carbon Monoxide	77-79	interleukin 17A	Homo sapiens	99-104
16003000-8	2005	Furthermore, in the presence of U0126 and PD-98059, selective inhibitors of MEK1/2, IL-17-induced IL-6 production was significantly attenuated.	U 0126	32-37	interleukin 17A	Homo sapiens	84-89
16003000-8	2005	Furthermore, in the presence of U0126 and PD-98059, selective inhibitors of MEK1/2, IL-17-induced IL-6 production was significantly attenuated.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	42-50	interleukin 17A	Homo sapiens	84-89
15640148-2	2005	We have investigated the potential immunomodulatory properties of prostaglandin E2 (PGE2) by examining the molecular mechanism by which the eicosanoid suppresses T-cell-derived interleukin-17 (IL-17)-induced TNF-alpha mRNA expression and protein synthesis in human macrophages and rheumatoid arthritis-affected synovial fibroblasts.	Dinoprostone	66-82	interleukin 17A	Homo sapiens	177-191
15640148-2	2005	We have investigated the potential immunomodulatory properties of prostaglandin E2 (PGE2) by examining the molecular mechanism by which the eicosanoid suppresses T-cell-derived interleukin-17 (IL-17)-induced TNF-alpha mRNA expression and protein synthesis in human macrophages and rheumatoid arthritis-affected synovial fibroblasts.	Dinoprostone	66-82	interleukin 17A	Homo sapiens	193-198
15640148-2	2005	We have investigated the potential immunomodulatory properties of prostaglandin E2 (PGE2) by examining the molecular mechanism by which the eicosanoid suppresses T-cell-derived interleukin-17 (IL-17)-induced TNF-alpha mRNA expression and protein synthesis in human macrophages and rheumatoid arthritis-affected synovial fibroblasts.	Dinoprostone	84-88	interleukin 17A	Homo sapiens	177-191
15640148-2	2005	We have investigated the potential immunomodulatory properties of prostaglandin E2 (PGE2) by examining the molecular mechanism by which the eicosanoid suppresses T-cell-derived interleukin-17 (IL-17)-induced TNF-alpha mRNA expression and protein synthesis in human macrophages and rheumatoid arthritis-affected synovial fibroblasts.	Eicosanoids	140-150	interleukin 17A	Homo sapiens	177-191
15640148-2	2005	We have investigated the potential immunomodulatory properties of prostaglandin E2 (PGE2) by examining the molecular mechanism by which the eicosanoid suppresses T-cell-derived interleukin-17 (IL-17)-induced TNF-alpha mRNA expression and protein synthesis in human macrophages and rheumatoid arthritis-affected synovial fibroblasts.	Eicosanoids	140-150	interleukin 17A	Homo sapiens	193-198
15640148-6	2005	PGE2 suppression of IL-17-induced ATF-2/c-Jun transactivation and DNA binding was dependent on Egr-1-mediated inhibition of induced c-Jun expression.	Dinoprostone	0-4	interleukin 17A	Homo sapiens	20-25
15987479-3	2005	MMP-3 and MMP-13 gene expression induced by IL-1beta, TNF-alpha and IL-17 was downregulated by mithramycin in human chondrosarcoma SW1353 cells and in primary human and bovine femoral head chondrocytes.	Plicamycin	95-106	interleukin 17A	Homo sapiens	68-73
16277680-4	2005	Recently, we reported that tumour necrosis factor (TNF)-alpha, IL-1alpha, IL-1beta and IL-17 enhance Cyp7b mRNA expression and induce a concomitant increase in the formation of 7alpha-OH-DHEA by fibroblast-like synoviocytes (FLS) from rheumatoid arthritis patients.	7-hydroxydehydroepiandrosterone	177-191	interleukin 17A	Homo sapiens	87-92
18033994-7	2004	It is suggested, that IL-17 stimulates osteoblasts to synthesis of prostaglandin E2 (PGE2) and expression of receptor gene NF - kappa ss (RANK), which induces osteclastogenesis.	Dinoprostone	67-83	interleukin 17A	Homo sapiens	22-27
15642134-12	2005	IL-17 production by activated RA PBMC is completely or partly blocked in the presence of the NF-kappaB inhibitor pyrrolidine dithiocarbamate and the PI3K/Akt inhibitor wortmannin and LY294002, respectively.	ra pbmc	30-37	interleukin 17A	Homo sapiens	0-5
15642134-12	2005	IL-17 production by activated RA PBMC is completely or partly blocked in the presence of the NF-kappaB inhibitor pyrrolidine dithiocarbamate and the PI3K/Akt inhibitor wortmannin and LY294002, respectively.	pyrrolidine dithiocarbamic acid	113-140	interleukin 17A	Homo sapiens	0-5
15642134-12	2005	IL-17 production by activated RA PBMC is completely or partly blocked in the presence of the NF-kappaB inhibitor pyrrolidine dithiocarbamate and the PI3K/Akt inhibitor wortmannin and LY294002, respectively.	Wortmannin	168-178	interleukin 17A	Homo sapiens	0-5
15642134-12	2005	IL-17 production by activated RA PBMC is completely or partly blocked in the presence of the NF-kappaB inhibitor pyrrolidine dithiocarbamate and the PI3K/Akt inhibitor wortmannin and LY294002, respectively.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	183-191	interleukin 17A	Homo sapiens	0-5
15229940-10	2004	The upregulation of synoviocyte COX-2 expression by supernatants from stimulated T cells was partially inhibited by addition of neutralizing antibodies against IL-17 or TNF-a or by treatment of T cells with cyclosporin A prior to stimulation.	Cyclosporine	207-220	interleukin 17A	Homo sapiens	160-165
15229940-12	2004	T cell derived IL-17, especially in combination with TNF-a, may contribute to ongoing inflammation through its effects on COX-2 expression and PGE2 production.	Dinoprostone	143-147	interleukin 17A	Homo sapiens	15-20
18033994-7	2004	It is suggested, that IL-17 stimulates osteoblasts to synthesis of prostaglandin E2 (PGE2) and expression of receptor gene NF - kappa ss (RANK), which induces osteclastogenesis.	Dinoprostone	85-89	interleukin 17A	Homo sapiens	22-27
15022319-8	2004	T cells, in turn, responded to FLS stimulation by secreting higher amounts of IL-17 and IFN gamma in coculture.	CHEMBL1232769	31-34	interleukin 17A	Homo sapiens	78-83
15134897-3	2004	After stimulation with a wide range of doses of IL-17, fibroblasts produced more amount of various kinds of angiogenic factors including NO, HGF, MCP-1, KC, MIP-2, PGE1, PGE2 and VEGF in a dose-dependent manner.	Alprostadil	164-168	interleukin 17A	Homo sapiens	48-53
15134897-3	2004	After stimulation with a wide range of doses of IL-17, fibroblasts produced more amount of various kinds of angiogenic factors including NO, HGF, MCP-1, KC, MIP-2, PGE1, PGE2 and VEGF in a dose-dependent manner.	Dinoprostone	170-174	interleukin 17A	Homo sapiens	48-53
15134897-8	2004	These results indicate that IL-17 up-regulates elaboration of various proangiogenic factors, and modulates macrophage-derived TNF-alpha-induced production of KC, MIP-2, PGE2 and VEGF by fibroblasts.	Dinoprostone	169-173	interleukin 17A	Homo sapiens	28-33
14984588-6	2004	IL-17 is able to induce expression of pro-inflammatory cytokines and stimulate release of eicosanoids by monocytes and synoviocytes.	Eicosanoids	90-101	interleukin 17A	Homo sapiens	0-5
14734137-7	2004	RESULTS: IL-17 produced a concentration-dependent increase in 8-isoprostane with a maximum of 136.5 +/- 15.5 pg/ml with IL-17 (10 ng/ml, p < 0.001, n = 12, vs unstimulated cells).	8-epi-prostaglandin F2alpha	62-75	interleukin 17A	Homo sapiens	9-14
14734137-7	2004	RESULTS: IL-17 produced a concentration-dependent increase in 8-isoprostane with a maximum of 136.5 +/- 15.5 pg/ml with IL-17 (10 ng/ml, p < 0.001, n = 12, vs unstimulated cells).	8-epi-prostaglandin F2alpha	62-75	interleukin 17A	Homo sapiens	120-125
14734137-8	2004	N-acetylcysteine (NAC) was able to decrease IL-17-induced 8-isoprostane production, with a maximum decrease of 59.3 +/- 9% (p < 0.001, n = 12) with 10 mmol/liter of N-acetylcysteine, which also decreased IL-17-induced IL-8 production in a concentration-dependent manner (with maximum inhibition of 86.3% when combined with NAC 10 mmol/liter as compared with IL-17 alone).	Acetylcysteine	0-16	interleukin 17A	Homo sapiens	44-49
14734137-8	2004	N-acetylcysteine (NAC) was able to decrease IL-17-induced 8-isoprostane production, with a maximum decrease of 59.3 +/- 9% (p < 0.001, n = 12) with 10 mmol/liter of N-acetylcysteine, which also decreased IL-17-induced IL-8 production in a concentration-dependent manner (with maximum inhibition of 86.3% when combined with NAC 10 mmol/liter as compared with IL-17 alone).	Acetylcysteine	0-16	interleukin 17A	Homo sapiens	207-212
14734137-8	2004	N-acetylcysteine (NAC) was able to decrease IL-17-induced 8-isoprostane production, with a maximum decrease of 59.3 +/- 9% (p < 0.001, n = 12) with 10 mmol/liter of N-acetylcysteine, which also decreased IL-17-induced IL-8 production in a concentration-dependent manner (with maximum inhibition of 86.3% when combined with NAC 10 mmol/liter as compared with IL-17 alone).	Acetylcysteine	0-16	interleukin 17A	Homo sapiens	207-212
14734137-8	2004	N-acetylcysteine (NAC) was able to decrease IL-17-induced 8-isoprostane production, with a maximum decrease of 59.3 +/- 9% (p < 0.001, n = 12) with 10 mmol/liter of N-acetylcysteine, which also decreased IL-17-induced IL-8 production in a concentration-dependent manner (with maximum inhibition of 86.3% when combined with NAC 10 mmol/liter as compared with IL-17 alone).	Acetylcysteine	18-21	interleukin 17A	Homo sapiens	44-49
14734137-8	2004	N-acetylcysteine (NAC) was able to decrease IL-17-induced 8-isoprostane production, with a maximum decrease of 59.3 +/- 9% (p < 0.001, n = 12) with 10 mmol/liter of N-acetylcysteine, which also decreased IL-17-induced IL-8 production in a concentration-dependent manner (with maximum inhibition of 86.3% when combined with NAC 10 mmol/liter as compared with IL-17 alone).	Acetylcysteine	18-21	interleukin 17A	Homo sapiens	207-212
14734137-8	2004	N-acetylcysteine (NAC) was able to decrease IL-17-induced 8-isoprostane production, with a maximum decrease of 59.3 +/- 9% (p < 0.001, n = 12) with 10 mmol/liter of N-acetylcysteine, which also decreased IL-17-induced IL-8 production in a concentration-dependent manner (with maximum inhibition of 86.3% when combined with NAC 10 mmol/liter as compared with IL-17 alone).	Acetylcysteine	18-21	interleukin 17A	Homo sapiens	207-212
14734137-8	2004	N-acetylcysteine (NAC) was able to decrease IL-17-induced 8-isoprostane production, with a maximum decrease of 59.3 +/- 9% (p < 0.001, n = 12) with 10 mmol/liter of N-acetylcysteine, which also decreased IL-17-induced IL-8 production in a concentration-dependent manner (with maximum inhibition of 86.3% when combined with NAC 10 mmol/liter as compared with IL-17 alone).	8-epi-prostaglandin F2alpha	58-71	interleukin 17A	Homo sapiens	44-49
14734137-8	2004	N-acetylcysteine (NAC) was able to decrease IL-17-induced 8-isoprostane production, with a maximum decrease of 59.3 +/- 9% (p < 0.001, n = 12) with 10 mmol/liter of N-acetylcysteine, which also decreased IL-17-induced IL-8 production in a concentration-dependent manner (with maximum inhibition of 86.3% when combined with NAC 10 mmol/liter as compared with IL-17 alone).	Acetylcysteine	168-184	interleukin 17A	Homo sapiens	44-49
14734137-8	2004	N-acetylcysteine (NAC) was able to decrease IL-17-induced 8-isoprostane production, with a maximum decrease of 59.3 +/- 9% (p < 0.001, n = 12) with 10 mmol/liter of N-acetylcysteine, which also decreased IL-17-induced IL-8 production in a concentration-dependent manner (with maximum inhibition of 86.3% when combined with NAC 10 mmol/liter as compared with IL-17 alone).	Acetylcysteine	326-329	interleukin 17A	Homo sapiens	44-49
14734137-9	2004	CONCLUSIONS: We demonstrated that human airway smooth muscle cells, when stimulated with IL-17, are able to produce 8-isoprostane, which could be inhibited by adding N-acetylcysteline, and which was also able to decrease IL-17-induced IL-8 production.	8-epi-prostaglandin F2alpha	116-129	interleukin 17A	Homo sapiens	89-94
14734137-9	2004	CONCLUSIONS: We demonstrated that human airway smooth muscle cells, when stimulated with IL-17, are able to produce 8-isoprostane, which could be inhibited by adding N-acetylcysteline, and which was also able to decrease IL-17-induced IL-8 production.	8-epi-prostaglandin F2alpha	116-129	interleukin 17A	Homo sapiens	221-226
14734137-9	2004	CONCLUSIONS: We demonstrated that human airway smooth muscle cells, when stimulated with IL-17, are able to produce 8-isoprostane, which could be inhibited by adding N-acetylcysteline, and which was also able to decrease IL-17-induced IL-8 production.	n-acetylcysteline	166-183	interleukin 17A	Homo sapiens	89-94
12875719-8	2003	The increase in IgG, anti-dsDNA and IL-6 protein levels induced by IL-17 was dose-dependent and could be completely blocked by IL-17 monoclonal antibody mIgG(28) and partially blocked by dexamethasone.	Dexamethasone	187-200	interleukin 17A	Homo sapiens	67-72
12772186-8	2003	IL-17 mRNA expression could be shown for activated BPH-T-cells and to some extend for BPH-EC.	bph-ec	86-92	interleukin 17A	Homo sapiens	0-5
12746433-3	2003	In preliminary work, recombinant human (rh) IL-17 stimulated a rapid (5-15 min), substantial (>8-fold), and sustained (>24 h) increase in COX-2 mRNA, protein, and prostaglandin E2 release.	Dinoprostone	169-185	interleukin 17A	Homo sapiens	44-49
12814161-0	2003	Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine.	Methacholine Chloride	71-83	interleukin 17A	Homo sapiens	0-14
14515359-8	2003	Moreover, antibody neutralization of CTLA-4, GITR, IL-10, or IL-17 completely reversed Treg-induced suppression.	treg	87-91	interleukin 17A	Homo sapiens	61-66
14520110-0	2003	IL-11 and IL-17 expression in nasal polyps: relationship to collagen deposition and suppression by intranasal fluticasone propionate.	Fluticasone	110-132	interleukin 17A	Homo sapiens	10-15
12875719-8	2003	The increase in IgG, anti-dsDNA and IL-6 protein levels induced by IL-17 was dose-dependent and could be completely blocked by IL-17 monoclonal antibody mIgG(28) and partially blocked by dexamethasone.	Dexamethasone	187-200	interleukin 17A	Homo sapiens	127-132
12297109-5	2002	Using reverse transcriptase-polymerase chain reaction (RT-PCR), immunoprecipitation and western blot analysis, we report that the early signalling events triggered by the hIL-17 involved tyrosyl phosphorylation of proteins and increased the levels of IL-6, IL-8 and MCP-1 in a dose-dependent manner.	cyclo(tyrosyl-tyrosyl)	187-194	interleukin 17A	Homo sapiens	171-177
12661990-7	2003	Conditioned cell medium from bronchial epithelial cells co-stimulated with hIL-17 plus TNF-alpha prolonged survival (trypan blue exclusion) of human neutrophils in vitro and this effect was blocked by an anti-GM-CSF antibody.	Trypan Blue	117-128	interleukin 17A	Homo sapiens	75-81
12823853-7	2003	The mitogen-activated protein kinase p38 seems to be necessary for the regulation of TSG-6 expression by IL-17, as shown by inhibition with SB203580.	SB 203580	140-148	interleukin 17A	Homo sapiens	105-110
12825130-7	2003	A c-Jun/activating protein-1 (AP-1) inhibitor, curcumin, reduced the IL-17-, IL-1beta-, and TNF-alpha-induced MMP-3 mRNA expression, and mitogen-activated protein (MAP) kinase inhibitors (U0126, PD098059, and SB203580) also blocked MMP-3 secretion.	Curcumin	47-55	interleukin 17A	Homo sapiens	69-74
12825130-7	2003	A c-Jun/activating protein-1 (AP-1) inhibitor, curcumin, reduced the IL-17-, IL-1beta-, and TNF-alpha-induced MMP-3 mRNA expression, and mitogen-activated protein (MAP) kinase inhibitors (U0126, PD098059, and SB203580) also blocked MMP-3 secretion.	U 0126	188-193	interleukin 17A	Homo sapiens	69-74
12825130-7	2003	A c-Jun/activating protein-1 (AP-1) inhibitor, curcumin, reduced the IL-17-, IL-1beta-, and TNF-alpha-induced MMP-3 mRNA expression, and mitogen-activated protein (MAP) kinase inhibitors (U0126, PD098059, and SB203580) also blocked MMP-3 secretion.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	195-203	interleukin 17A	Homo sapiens	69-74
12825130-7	2003	A c-Jun/activating protein-1 (AP-1) inhibitor, curcumin, reduced the IL-17-, IL-1beta-, and TNF-alpha-induced MMP-3 mRNA expression, and mitogen-activated protein (MAP) kinase inhibitors (U0126, PD098059, and SB203580) also blocked MMP-3 secretion.	SB 203580	209-217	interleukin 17A	Homo sapiens	69-74
12180737-0	2002	Interleukin 17 induced nitric oxide suppresses matrix synthesis and protects cartilage from matrix breakdown.	Nitric Oxide	23-35	interleukin 17A	Homo sapiens	0-14
12180737-6	2002	Treatment of articular cartilage explants with dexamethasone or anti-LIF blocked NO production by IL-17, but not by IL-1alpha.	Dexamethasone	47-60	interleukin 17A	Homo sapiens	98-103
12297109-6	2002	Tyrosyl phosphorylation of proteins was induced by IL-17 in 1 min and peaked in 5 min.	cyclo(tyrosyl-tyrosyl)	0-7	interleukin 17A	Homo sapiens	51-56
11966773-9	2002	The inhibitors genistein (tyrosine kinase inhibitor) and calphostin C (inhibitor of protein kinase C) reduced significantly the IL-17-stimulated mRNA expression of IL-8, GRO-alpha and GRO-beta in SFC, whereas PD98059 (inhibitor of MEK-1/2) was without effect.	Genistein	15-24	interleukin 17A	Homo sapiens	128-133
11843064-4	2002	The expression of IL-17 receptor (R) was analyzed by Northern blot and a binding assay using 125I-labeled IL-17.	Iodine-125	93-97	interleukin 17A	Homo sapiens	18-23
11843064-4	2002	The expression of IL-17 receptor (R) was analyzed by Northern blot and a binding assay using 125I-labeled IL-17.	Iodine-125	93-97	interleukin 17A	Homo sapiens	106-111
11777983-7	2002	EMSAs demonstrated that IL-17, IL-1beta, and TNF-alpha induced NF-kappaB activation within 1.5 h after stimulation, and a blockade of NF-kappaB activation by the pyrrolidine derivative of dithiocarbamate and tosyl-phe-chloromethylketone markedly reduced the IL-17-, IL-1beta-, or TNF-alpha-induced IL-6 gene expression.	pyrrolidine	162-173	interleukin 17A	Homo sapiens	24-29
11777983-7	2002	EMSAs demonstrated that IL-17, IL-1beta, and TNF-alpha induced NF-kappaB activation within 1.5 h after stimulation, and a blockade of NF-kappaB activation by the pyrrolidine derivative of dithiocarbamate and tosyl-phe-chloromethylketone markedly reduced the IL-17-, IL-1beta-, or TNF-alpha-induced IL-6 gene expression.	pyrrolidine	162-173	interleukin 17A	Homo sapiens	258-263
11777983-7	2002	EMSAs demonstrated that IL-17, IL-1beta, and TNF-alpha induced NF-kappaB activation within 1.5 h after stimulation, and a blockade of NF-kappaB activation by the pyrrolidine derivative of dithiocarbamate and tosyl-phe-chloromethylketone markedly reduced the IL-17-, IL-1beta-, or TNF-alpha-induced IL-6 gene expression.	Dithiocarbamate	188-203	interleukin 17A	Homo sapiens	24-29
11777983-7	2002	EMSAs demonstrated that IL-17, IL-1beta, and TNF-alpha induced NF-kappaB activation within 1.5 h after stimulation, and a blockade of NF-kappaB activation by the pyrrolidine derivative of dithiocarbamate and tosyl-phe-chloromethylketone markedly reduced the IL-17-, IL-1beta-, or TNF-alpha-induced IL-6 gene expression.	Dithiocarbamate	188-203	interleukin 17A	Homo sapiens	258-263
11777983-7	2002	EMSAs demonstrated that IL-17, IL-1beta, and TNF-alpha induced NF-kappaB activation within 1.5 h after stimulation, and a blockade of NF-kappaB activation by the pyrrolidine derivative of dithiocarbamate and tosyl-phe-chloromethylketone markedly reduced the IL-17-, IL-1beta-, or TNF-alpha-induced IL-6 gene expression.	tosyl-phe-chloromethylketone	208-236	interleukin 17A	Homo sapiens	24-29
11777983-8	2002	Furthermore, IL-17, IL-1beta, and TNF-alpha induced a rapid activation of extracellular signal-related kinase p42/44 and p38 MAPKs, and specific MAPK inhibitors (SB203580, PD98059, and U0216) significantly reduced IL-17-, IL-1beta-, or TNF-alpha-induced IL-6 secretion, indicating the role of MAPKs in the induction of IL-6.	SB 203580	162-170	interleukin 17A	Homo sapiens	13-18
11777983-8	2002	Furthermore, IL-17, IL-1beta, and TNF-alpha induced a rapid activation of extracellular signal-related kinase p42/44 and p38 MAPKs, and specific MAPK inhibitors (SB203580, PD98059, and U0216) significantly reduced IL-17-, IL-1beta-, or TNF-alpha-induced IL-6 secretion, indicating the role of MAPKs in the induction of IL-6.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	172-179	interleukin 17A	Homo sapiens	13-18
12016129-9	2002	MAPK inhibitors (SB-203580, PD-98059, and U-0126) significantly reduced the IL-17-induced IL-6 and chemokine secretion.	SB 203580	17-26	interleukin 17A	Homo sapiens	76-81
12016129-9	2002	MAPK inhibitors (SB-203580, PD-98059, and U-0126) significantly reduced the IL-17-induced IL-6 and chemokine secretion.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	28-36	interleukin 17A	Homo sapiens	76-81
12016129-9	2002	MAPK inhibitors (SB-203580, PD-98059, and U-0126) significantly reduced the IL-17-induced IL-6 and chemokine secretion.	U 0126	42-48	interleukin 17A	Homo sapiens	76-81
11966773-9	2002	The inhibitors genistein (tyrosine kinase inhibitor) and calphostin C (inhibitor of protein kinase C) reduced significantly the IL-17-stimulated mRNA expression of IL-8, GRO-alpha and GRO-beta in SFC, whereas PD98059 (inhibitor of MEK-1/2) was without effect.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	209-216	interleukin 17A	Homo sapiens	128-133
11966773-10	2002	Pharmacological drugs used in therapy of RA, such as cyclosporin and methotrexate, induced a fourfold increase of IL-17R mRNA expression and augmented the IL-17-stimulated IL-8 expression.	Cyclosporine	53-64	interleukin 17A	Homo sapiens	114-119
11966773-10	2002	Pharmacological drugs used in therapy of RA, such as cyclosporin and methotrexate, induced a fourfold increase of IL-17R mRNA expression and augmented the IL-17-stimulated IL-8 expression.	Methotrexate	69-81	interleukin 17A	Homo sapiens	114-119
11966773-9	2002	The inhibitors genistein (tyrosine kinase inhibitor) and calphostin C (inhibitor of protein kinase C) reduced significantly the IL-17-stimulated mRNA expression of IL-8, GRO-alpha and GRO-beta in SFC, whereas PD98059 (inhibitor of MEK-1/2) was without effect.	calphostin C	57-69	interleukin 17A	Homo sapiens	128-133
12171537-5	2002	This evidence suggests that pharmacotherapeutical modulation of neutrophilic airway inflammation can be achieved using several different strategies, including inhibition of IL-17 production by cAMP elevating agents or certain nuclear factor inhibitors, neutralization of released IL-17 protein by specific anti-IL-17-antibodies, blockade of the IL-17 receptor as well as inhibition of certain MAP kinases mediating the post receptor effects of IL-17 in airway cells.	Cyclic AMP	193-197	interleukin 17A	Homo sapiens	173-178
11692108-6	2001	A selective MAP kinase kinase inhibitor, PD98059, inhibited IL-17-induced IL-6 and IL-8.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	41-48	interleukin 17A	Homo sapiens	60-65
12677240-2	2002	IL-17 stimulates epithelial, endothelial and fibroblastic stromal cells to secrete several cytokines such as IL-6, IL-8 and granulocyte colony-stimulating factor, as well as prostoglandin E2.	prostoglandin e2	174-190	interleukin 17A	Homo sapiens	0-5
11592370-10	2001	The combination of IL-1beta and TNFalpha had an additive effect on PGE2 production, while addition of IL-17 to TNFalpha or IL-1beta synergistically enhanced PGE2 production.	Dinoprostone	157-161	interleukin 17A	Homo sapiens	102-107
11574464-0	2001	IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding.	Cystine	15-22	interleukin 17A	Homo sapiens	0-5
11574464-3	2001	Unexpectedly, the crystal structure of IL-17F reveals that IL-17 family members adopt a monomer fold typical of cystine knot growth factors, despite lacking the disulfide responsible for defining the canonical "knot" structure.	Cystine	112-119	interleukin 17A	Homo sapiens	39-44
11574464-3	2001	Unexpectedly, the crystal structure of IL-17F reveals that IL-17 family members adopt a monomer fold typical of cystine knot growth factors, despite lacking the disulfide responsible for defining the canonical "knot" structure.	Disulfides	161-170	interleukin 17A	Homo sapiens	39-44
11544464-11	2001	IL-17 did enhance the production of pro-fibrotic cytokines (IL-6 and IL-11) by fibroblasts, and this was inhibited by dexamethasone.	Dexamethasone	118-131	interleukin 17A	Homo sapiens	0-5
11692212-8	2001	In human renal biopsy samples, the IL-17 antigen could be found scattered around in the borderline changed rejected renal allografts without evidence of a serum creatinine increase, but was undetectable both in normal controls and in renal transplant tissue without signs of rejection.	Creatinine	161-171	interleukin 17A	Homo sapiens	35-40
11592370-11	2001	Inhibition of NO production by 1400W significantly increased IL-1beta-stimulated PGE2 production, and inhibition of PGE2 production by the COX-2 inhibitor N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide significantly increased IL-17-stimulated NO production.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	155-209	interleukin 17A	Homo sapiens	234-239
11327240-0	2001	Modulation of TIMP-1 synthesis by antiinflammatory cytokines and prostaglandin E2 in interleukin 17 stimulated human monocytes/macrophages.	Dinoprostone	65-81	interleukin 17A	Homo sapiens	85-99
11325811-9	2001	The IL-17-induced release of IL-6 and IL-8 was concentration-dependently inhibited by SB202190 and by PD98059 in bronchial epithelial cells without affecting cell proliferation or survival.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	102-109	interleukin 17A	Homo sapiens	4-9
11446747-4	2001	Moreover, HE inhibits the production of nitric oxide (NO) by IL-1beta- or IL-17-stimulated normal human chondrocytes.	Nitric Oxide	40-52	interleukin 17A	Homo sapiens	74-79
11327240-1	2001	OBJECTIVE: To examine the regulation of tissue inhibitor of metalloproteinase 1 (TIMP-1) synthesis by interleukin 17 (IL-17) stimulated human monocytes/macrophages in primary culture in the presence of prostaglandin E2 (PGE2) and antiinflammatory cytokines, and to compare this with the regulation of matrix metalloproteinase (MMP-9) production.	Dinoprostone	202-218	interleukin 17A	Homo sapiens	102-116
11327240-1	2001	OBJECTIVE: To examine the regulation of tissue inhibitor of metalloproteinase 1 (TIMP-1) synthesis by interleukin 17 (IL-17) stimulated human monocytes/macrophages in primary culture in the presence of prostaglandin E2 (PGE2) and antiinflammatory cytokines, and to compare this with the regulation of matrix metalloproteinase (MMP-9) production.	Dinoprostone	202-218	interleukin 17A	Homo sapiens	118-123
11327240-1	2001	OBJECTIVE: To examine the regulation of tissue inhibitor of metalloproteinase 1 (TIMP-1) synthesis by interleukin 17 (IL-17) stimulated human monocytes/macrophages in primary culture in the presence of prostaglandin E2 (PGE2) and antiinflammatory cytokines, and to compare this with the regulation of matrix metalloproteinase (MMP-9) production.	Dinoprostone	220-224	interleukin 17A	Homo sapiens	102-116
11327240-1	2001	OBJECTIVE: To examine the regulation of tissue inhibitor of metalloproteinase 1 (TIMP-1) synthesis by interleukin 17 (IL-17) stimulated human monocytes/macrophages in primary culture in the presence of prostaglandin E2 (PGE2) and antiinflammatory cytokines, and to compare this with the regulation of matrix metalloproteinase (MMP-9) production.	Dinoprostone	220-224	interleukin 17A	Homo sapiens	118-123
10684990-4	2000	Imipenem inhibited IL2-dependent proliferation of activated CD4(+) and CD8(+) T-cell clones, and an inhibition was also detected for IL7-, IL12-, IL15-, IL16- and IL17-dependent clonal proliferation.	Imipenem	0-8	interleukin 17A	Homo sapiens	163-167
11263774-8	2001	The inhibitory effect of PPARgamma activation was not restricted to IL-1beta, since TNFalpha- and IL-17-induced NO and MMP-13 production were also inhibited by 15d-PGJ2.	15-deoxy-delta(12,14)-prostaglandin J2	160-168	interleukin 17A	Homo sapiens	98-103
11062734-9	2000	When injected into the tail vein, however, the number of metastatic nodules in the lungs of CHO/IL-17-injected mice was significantly smaller than that of CHO- or CHO/neo-injected mice.	cho	92-95	interleukin 17A	Homo sapiens	96-101
10817568-6	2000	IL-17-induced MMP-9 production in human monocyte/ macrophages was dependent on endogenous prostaglandin E2 synthesis and related to autocrine stimulation by TNFalpha, but was IL-1beta independent.	Dinoprostone	90-106	interleukin 17A	Homo sapiens	0-5
10853869-5	2000	The IL-17-induced neutrophil recruitment is mediated via induced CXC chemokine release through steroid-sensitive mechanisms and is modulated by release of endogenous tachykinins.	Steroids	95-102	interleukin 17A	Homo sapiens	4-9
11327240-6	2001	Exogenous PGE2, cAMP, and cAMP-mimetics completely inhibited both basal and IL-17 induced MMP-9 synthesis, while only IL-17 induced TIMP-1 synthesis was abrogated.	Dinoprostone	10-14	interleukin 17A	Homo sapiens	76-81
11327240-6	2001	Exogenous PGE2, cAMP, and cAMP-mimetics completely inhibited both basal and IL-17 induced MMP-9 synthesis, while only IL-17 induced TIMP-1 synthesis was abrogated.	Cyclic AMP	16-20	interleukin 17A	Homo sapiens	76-81
11327240-6	2001	Exogenous PGE2, cAMP, and cAMP-mimetics completely inhibited both basal and IL-17 induced MMP-9 synthesis, while only IL-17 induced TIMP-1 synthesis was abrogated.	Cyclic AMP	26-30	interleukin 17A	Homo sapiens	76-81
11474253-4	2001	Murine Meth-A fibrosarcoma cells were transfected with the hIL-17 gene using the lipofectin method.	1,2-dielaidoylphosphatidylethanolamine	81-91	interleukin 17A	Homo sapiens	59-65
11067941-10	2000	Exposure of HPMC to IL-17 led to a dose- and time-dependent induction of GROalpha mRNA and protein.	hydroxypropylmethylcellulose-lactose matrix	12-16	interleukin 17A	Homo sapiens	20-25
11053480-10	2000	Stimulation of TEC with CD40L results in activation of NF-kappaB and induction of cytokine production by IL-17 and CD40L is prevented by addition of the NF-kappaB inhibitor pyrrolidine dithiocarbamate.	pyrrolidine dithiocarbamic acid	173-200	interleukin 17A	Homo sapiens	105-110
10833473-6	2000	Inhibition of ERK activation with the MEK inhibitor PD98059 blocked IL-17 as well as basal development of tight junctions in T84 cells.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	52-59	interleukin 17A	Homo sapiens	68-73
10679127-0	2000	High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism.	Cyclosporine	100-113	interleukin 17A	Homo sapiens	15-20
10679127-0	2000	High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism.	Cyclosporine	100-113	interleukin 17A	Homo sapiens	79-84
10679127-2	2000	In the present study, we hypothesized that elevated in the joints of rheumatoid arthritis, but not osteoarthritis, patients, IL-15 may exert its proinflammatory properties via the induction of IL-17, a cytokine known to stimulate synoviocytes to release several mediators of inflammation including IL-6, IL-8, GM-CSF and PGE2.	Dinoprostone	321-325	interleukin 17A	Homo sapiens	193-198
10679127-5	2000	Among tested factors, LPS and TNF-alpha failed, IL-15 and IL-2 were equipotent, and PMA + ionomycin was far more efficient in the induction of IL-17 secretion by PBMCs isolated from healthy blood donors.	Ionomycin	90-99	interleukin 17A	Homo sapiens	143-148
10679127-6	2000	Interestingly, synovial fluid cells, in contrast to PBMCs isolated from patients with rheumatoid arthritis, but not osteoarthritis, respond to PMA + ionomycin with much lower, comparable to IL-15-triggered IL-17 secretion.	Tetradecanoylphorbol Acetate	143-146	interleukin 17A	Homo sapiens	206-211
10679127-7	2000	Moreover, PMA + ionomycin-triggered IL-17 secretion is completely or partially blocked in the presence of low doses of cyclosporin A or high doses of methylprednisolone, respectively.	Tetradecanoylphorbol Acetate	10-13	interleukin 17A	Homo sapiens	36-41
10679127-7	2000	Moreover, PMA + ionomycin-triggered IL-17 secretion is completely or partially blocked in the presence of low doses of cyclosporin A or high doses of methylprednisolone, respectively.	Ionomycin	16-25	interleukin 17A	Homo sapiens	36-41
10679127-7	2000	Moreover, PMA + ionomycin-triggered IL-17 secretion is completely or partially blocked in the presence of low doses of cyclosporin A or high doses of methylprednisolone, respectively.	Cyclosporine	119-132	interleukin 17A	Homo sapiens	36-41
10679127-7	2000	Moreover, PMA + ionomycin-triggered IL-17 secretion is completely or partially blocked in the presence of low doses of cyclosporin A or high doses of methylprednisolone, respectively.	Methylprednisolone	150-168	interleukin 17A	Homo sapiens	36-41
10679127-9	2000	Thus, our results suggest for the first time that IL-15 may represent a physiological trigger that via cyclosporin A and steroid sensitive pathways leads to the overproduction of IL-17 in the joints of rheumatoid arthritis patients.	Cyclosporine	103-116	interleukin 17A	Homo sapiens	179-184
10679127-9	2000	Thus, our results suggest for the first time that IL-15 may represent a physiological trigger that via cyclosporin A and steroid sensitive pathways leads to the overproduction of IL-17 in the joints of rheumatoid arthritis patients.	Steroids	121-128	interleukin 17A	Homo sapiens	179-184
10334935-7	1999	These findings provide the first evidence that the mechanism of IL-17 signaling involves rapid tyrosine phosphorylation and activation of raf-1 serine/threonine kinase.	Tyrosine	95-103	interleukin 17A	Homo sapiens	64-69
10555036-0	1999	Mitogen-activated protein kinase and nuclear factor kappaB together regulate interleukin-17-induced nitric oxide production in human osteoarthritic chondrocytes: possible role of transactivating factor mitogen-activated protein kinase-activated proten kinase (MAPKAPK).	Nitric Oxide	100-112	interleukin 17A	Homo sapiens	77-91
10555036-7	1999	The cAMP mimetics, 3-isobutyl-1-methyl xanthine plus forskolin, completely blocked IL-17-induced NO production.	Cyclic AMP	4-8	interleukin 17A	Homo sapiens	83-88
10555036-7	1999	The cAMP mimetics, 3-isobutyl-1-methyl xanthine plus forskolin, completely blocked IL-17-induced NO production.	1-Methyl-3-isobutylxanthine	19-47	interleukin 17A	Homo sapiens	83-88
10555036-7	1999	The cAMP mimetics, 3-isobutyl-1-methyl xanthine plus forskolin, completely blocked IL-17-induced NO production.	Colforsin	53-62	interleukin 17A	Homo sapiens	83-88
10555036-8	1999	KT-5720, genistein, and Calphostin C, inhibitors of protein kinase A (PKA), tyrosine kinase, and protein kinase C, respectively, reduced the IL-17-induced NO production by 72%, 56%, and 42%, respectively.	Genistein	9-18	interleukin 17A	Homo sapiens	141-146
10555036-11	1999	Specific protein kinase inhibitors for MEK-1/2 (PD98059), p38 (SB202190), and nuclear factor kappaB (NF-kappaB) (pyrrolidine dithiocarbamate) each markedly decreased the IL-17-increased iNOS level and NO production.	pyrrolidine dithiocarbamic acid	113-140	interleukin 17A	Homo sapiens	170-175
10580807-4	1999	Using a competitive RT-PCR, we examined the IL-17-induced IkappaB-alpha mRNA expression in glioblastoma cells, and we examined IL-17 up-regulated IkappaB-alpha mRNA expression in a dose- and time-dependent fashion with a maximum time between 1 and 3 h. This induction could be inhibited by Calphostin C (protein kinase C inhibitor) and genistein (tyrosine kinase inhibitor).	calphostin C	290-302	interleukin 17A	Homo sapiens	127-132
10580807-4	1999	Using a competitive RT-PCR, we examined the IL-17-induced IkappaB-alpha mRNA expression in glioblastoma cells, and we examined IL-17 up-regulated IkappaB-alpha mRNA expression in a dose- and time-dependent fashion with a maximum time between 1 and 3 h. This induction could be inhibited by Calphostin C (protein kinase C inhibitor) and genistein (tyrosine kinase inhibitor).	Genistein	336-345	interleukin 17A	Homo sapiens	127-132
10446984-1	1999	Interleukin (IL) 17 is a proinflammatory cytokine secreted mainly by activated human memory CD4 T cells that induces IL-6, IL-8, and nitric oxide.	Nitric Oxide	133-145	interleukin 17A	Homo sapiens	0-19
10228105-7	1999	Inhalation of peptidase inhibitors (phosphoramidon plus captopril) potentiated the effect of both hIL-17 and rIL-1beta.	phosphoramidon	36-50	interleukin 17A	Homo sapiens	98-104
10228105-7	1999	Inhalation of peptidase inhibitors (phosphoramidon plus captopril) potentiated the effect of both hIL-17 and rIL-1beta.	Captopril	56-65	interleukin 17A	Homo sapiens	98-104
10228105-8	1999	Inhalation of a neutral endopeptidase inhibitor (phosphoramidon) alone also increased the neutrophil count for hIL-17, whereas an angiotensin-converting enzyme inhibitor (captopril) alone did not.	phosphoramidon	49-63	interleukin 17A	Homo sapiens	111-117
10225978-3	1999	Direct interaction between osteoclast progenitors and osteoblasts was required for IL-17-induced osteoclastogenesis, which was completely inhibited by adding indomethacin or NS398, a selective inhibitor of cyclooxgenase-2 (COX-2).	Indomethacin	158-170	interleukin 17A	Homo sapiens	83-88
10225978-3	1999	Direct interaction between osteoclast progenitors and osteoblasts was required for IL-17-induced osteoclastogenesis, which was completely inhibited by adding indomethacin or NS398, a selective inhibitor of cyclooxgenase-2 (COX-2).	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	174-179	interleukin 17A	Homo sapiens	83-88
10225978-4	1999	Adding IL-17 increased prostaglandin E2 (PGE2) synthesis in cocultures of bone marrow cells and osteoblasts and in single cultures of osteoblasts, but not in single cultures of bone marrow cells.	Dinoprostone	23-39	interleukin 17A	Homo sapiens	7-12
10225978-4	1999	Adding IL-17 increased prostaglandin E2 (PGE2) synthesis in cocultures of bone marrow cells and osteoblasts and in single cultures of osteoblasts, but not in single cultures of bone marrow cells.	Dinoprostone	41-45	interleukin 17A	Homo sapiens	7-12
10225978-10	1999	These findings suggest that IL-17 first acts on osteoblasts, which stimulates both COX-2-dependent PGE2 synthesis and ODF gene expression, which in turn induce differentiation of osteoclast progenitors into mature osteoclasts, and that IL-17 is a crucial cytokine for osteoclastic bone resorption in RA patients.	Dinoprostone	99-103	interleukin 17A	Homo sapiens	28-33
10328864-2	1999	Our data showed that IL-17 mRNA was highly expressed in memory human peripheral CD8(+)45RO+T cells and CD4(+)45RO+T cells when peripheral blood mononuclear cells were first stimulated with ionomycin/PMA.	Ionomycin	189-198	interleukin 17A	Homo sapiens	21-26
10335518-3	1999	In situ hybridisation with synthetic oligonucleotide probes was adopted to detect and enumerate IL-17 mRNA expressing mononuclear cells (MNC) in blood and cerebrospinal fluid (CSF) from patients with MS and control individuals.	Oligonucleotides	37-52	interleukin 17A	Homo sapiens	96-101
10328864-2	1999	Our data showed that IL-17 mRNA was highly expressed in memory human peripheral CD8(+)45RO+T cells and CD4(+)45RO+T cells when peripheral blood mononuclear cells were first stimulated with ionomycin/PMA.	Tetradecanoylphorbol Acetate	199-202	interleukin 17A	Homo sapiens	21-26
10328864-3	1999	IL-17 expression in memory CD8(+)T cells required accessory signals since culture of ionomycin/PMA-activated CD8(+)45RO+T cells alone did not result to IL-17 expression.	Ionomycin	85-94	interleukin 17A	Homo sapiens	0-5
10328864-5	1999	IL-17 and interferon gamma(IFN-gamma) mRNA were both inhibited in the presence of PGE2 or the cAMP analogue (dibutyryl-cAMP), while the anti-inflammatory cytokine IL-10 was highly increased.	Dinoprostone	82-86	interleukin 17A	Homo sapiens	0-5
10328864-5	1999	IL-17 and interferon gamma(IFN-gamma) mRNA were both inhibited in the presence of PGE2 or the cAMP analogue (dibutyryl-cAMP), while the anti-inflammatory cytokine IL-10 was highly increased.	Cyclic AMP	94-98	interleukin 17A	Homo sapiens	0-5
10328864-5	1999	IL-17 and interferon gamma(IFN-gamma) mRNA were both inhibited in the presence of PGE2 or the cAMP analogue (dibutyryl-cAMP), while the anti-inflammatory cytokine IL-10 was highly increased.	dibutyryl	109-118	interleukin 17A	Homo sapiens	0-5
10328864-5	1999	IL-17 and interferon gamma(IFN-gamma) mRNA were both inhibited in the presence of PGE2 or the cAMP analogue (dibutyryl-cAMP), while the anti-inflammatory cytokine IL-10 was highly increased.	Cyclic AMP	119-123	interleukin 17A	Homo sapiens	0-5
10328864-10	1999	However, we suggest that PGE2 may be more efficient in blocking both IL-17 and IFN-gamma expression in already primed memory T cells, rather than in suppressing naive T cells that could represent a significant source of IL-10.	Dinoprostone	25-29	interleukin 17A	Homo sapiens	69-74
9886425-0	1999	IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha.	Nickel	21-27	interleukin 17A	Homo sapiens	0-5
9886425-2	1999	In this study, we investigated whether hapten-specific T cells isolated from patients with allergic contact dermatitis (ACD) to nickel produce IL-17 and the effects of IL-17 alone or in combination with IFN-gamma or TNF-alpha on the immune activation of keratinocytes.	Nickel	128-134	interleukin 17A	Homo sapiens	143-148
9878122-0	1998	Regulation of IL-17, IFN-gamma and IL-10 in human CD8(+) T cells by cyclic AMP-dependent signal transduction pathway.	Cyclic AMP	68-78	interleukin 17A	Homo sapiens	14-19
9886425-3	1999	Skin affected with ACD to nickel and skin-derived, nickel-specific CD4+ T cell lines expressed IFN-gamma, TNF-alpha, and IL-17 mRNAs.	Nickel	51-57	interleukin 17A	Homo sapiens	121-126
9886425-4	1999	Four of seven nickel-specific CD4+ T cell clones positive for the skin-homing receptor, cutaneous lymphocyte-associated Ag, were shown to corelease IL-17, IFN-gamma, and TNF-alpha.	Nickel	14-20	interleukin 17A	Homo sapiens	148-153
9878122-3	1998	Expression of IL-17 mRNA in CD8(+) T cell was induced by prior activation of PBMC for 18 h with Ca2+ ionophore and phorbol myristate acetate (PMA).	PBMC	77-81	interleukin 17A	Homo sapiens	14-19
9878122-3	1998	Expression of IL-17 mRNA in CD8(+) T cell was induced by prior activation of PBMC for 18 h with Ca2+ ionophore and phorbol myristate acetate (PMA).	Tetradecanoylphorbol Acetate	115-140	interleukin 17A	Homo sapiens	14-19
9878122-3	1998	Expression of IL-17 mRNA in CD8(+) T cell was induced by prior activation of PBMC for 18 h with Ca2+ ionophore and phorbol myristate acetate (PMA).	Tetradecanoylphorbol Acetate	142-145	interleukin 17A	Homo sapiens	14-19
9765276-2	1998	Stimulation of normal human articular chondrocytes with IL-17 induced nitric oxide (NO) production, concomitant with an increase in transcripts and de novo translation products of the inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) genes.	Nitric Oxide	70-82	interleukin 17A	Homo sapiens	56-61
9765276-6	1998	IL-17 effects on NO release, as well as iNOS, COX-2, and IL-6 protein expression, were inhibited by the anti-inflammatory drug dexamethasone.	Dexamethasone	127-140	interleukin 17A	Homo sapiens	0-5
9765276-7	1998	Importantly, dexamethasone blunted IL-17-dependent activation of MAP kinases, suggesting a mechanistic relationship between these activities and the aforementioned gene expression responses.	Dexamethasone	13-26	interleukin 17A	Homo sapiens	35-40
9518462-3	1998	The hIL-17 produced in Pichia had the correct N-terminus of natural mature hIL-17 and a glycosylation pattern similar to hIL-17 produced in mammalian cells; both Pichia and human cells add approximately 5 kDa of sugars via N-linked glycosylation and both express a mixture of the glycosylated and nonglycosylated forms.	Sugars	212-218	interleukin 17A	Homo sapiens	4-10
9518462-3	1998	The hIL-17 produced in Pichia had the correct N-terminus of natural mature hIL-17 and a glycosylation pattern similar to hIL-17 produced in mammalian cells; both Pichia and human cells add approximately 5 kDa of sugars via N-linked glycosylation and both express a mixture of the glycosylated and nonglycosylated forms.	Nitrogen	46-47	interleukin 17A	Homo sapiens	4-10
33775443-7	2021	In addition, in experimental models of hypertension, blocking IL-17A by genetic strategies, or using neutralising antibodies, lowers blood pressure by acting on the vascular wall and tubule sodium transport and reduces damage to target organs.	Sodium	190-196	interleukin 17A	Homo sapiens	62-68
9182915-0	1997	Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage.	Nitric Oxide	32-44	interleukin 17A	Homo sapiens	0-14
9182915-1	1997	OBJECTIVE: To examine the effect of human interleukin-17 (IL-17) on nitric oxide (NO) production in human osteoarthritis (OA) cartilage under ex vivo conditions.	Nitric Oxide	68-80	interleukin 17A	Homo sapiens	42-56
9182915-1	1997	OBJECTIVE: To examine the effect of human interleukin-17 (IL-17) on nitric oxide (NO) production in human osteoarthritis (OA) cartilage under ex vivo conditions.	Nitric Oxide	68-80	interleukin 17A	Homo sapiens	58-63
9182915-4	1997	RESULTS: IL-17 augmented the spontaneous production of nitric oxide.	Nitric Oxide	55-67	interleukin 17A	Homo sapiens	9-14
9182915-6	1997	CONCLUSION: IL-17 augments nitric oxide production in OA cartilage via nuclear factor kappaB activation, but independently of IL-1beta signaling.	Nitric Oxide	27-39	interleukin 17A	Homo sapiens	12-17
8676080-4	1996	Although devoid of direct effects on cells of hematopoietic origin, hIL-17 and the product of its viral counterpart, ORF13, stimulate epithelial, endothelial, and fibroblastic cells to secrete cytokines such as IL-6, IL-8, and granulocyte-colony-stimulating factor, as well as prostaglandin E2.	Dinoprostone	277-293	interleukin 17A	Homo sapiens	68-74
33771372-7	2021	Production of IL-17 decreased after empagliflozin treatment, while IL-10 was enhanced in the EMPA+ group.	empagliflozin	36-49	interleukin 17A	Homo sapiens	14-19
33780033-9	2021	Vitamin K2 alone tended to suppress the secretion of IL-17, IFN-gamma and TNF-alpha from the activated PBMCs of RA patients with smaller influences on the cytokine productions from healthy PBMCs.	Vitamin K 2	0-10	interleukin 17A	Homo sapiens	53-58
33810258-1	2021	BACKGROUND: Seven weeks of high-dose vitamin D treatment decreases intestinal IL17A and IFN-gamma mRNA expression in active Crohn"s disease (CD).	Vitamin D	37-46	interleukin 17A	Homo sapiens	78-83
33807944-3	2021	PDE4 blocking can lead to increased levels of intracellular cAMP, which results in down-regulation of inflammatory responses by reducing the expression of tumor necrosis factor (TNF), interleukin (IL)-23, IL-17, interferon-gamma, while increasing regulatory cytokines, such as IL-10.	Cyclic AMP	60-64	interleukin 17A	Homo sapiens	205-210
33766235-5	2021	Previous studies demonstrated that IL-23 and IL-17 increased in IBD, which lead to an imbalance between Tregs and auto-reactive T cells to exacerbate the inflammatory pathological damage of the intestinal mucosa.	tregs	104-109	interleukin 17A	Homo sapiens	45-50
33235720-3	2021	The present study aimed to determine the value of interleukin (IL)-17 and IL-22 in predicting the severity and outcomes of PC in trauma patients.	pc	123-125	interleukin 17A	Homo sapiens	50-69
29600943-11	2018	Daily prednisone dose had an inverse association with lower serum IL-4, IL6, IL-17A, IL-17E, IL-22 and IL-23.	Prednisone	6-16	interleukin 17A	Homo sapiens	77-83
33032016-4	2020	At the same time, E3 stimulated production of IL-10 and inhibited secretion of IL-17.	e3	18-20	interleukin 17A	Homo sapiens	79-84
32795656-9	2020	CAF+TRI+CGA had the most pronounced effects on decreasing hepatic pro-inflammatory IL-17 and NFkappaB, contributing to reduce CD68-positive macrophage number, stellate cell activation, and collagen deposition.	trigonelline	4-7	interleukin 17A	Homo sapiens	83-88
28840844-7	2017	The IL-17A levels were significantly correlated with those of IL-4, IL-25, IL-10, and IFN-gamma in patients with uncontrolled asthma, and the patients with the highest levels of all the above cytokines were refractory to high-dose of inhaled corticosteroid therapy and have a history of acute exacerbation within 1 year, requiring systemic steroid therapy.	Steroids	249-256	interleukin 17A	Homo sapiens	4-10
34894724-4	2022	In this exploratory, post-hoc substudy, it was hypothesized that 1-year intervention with the MR antagonist spironolactone lowers IL-17A and related cytokines and reduces epithelial injury in kidney transplant recipients.	Spironolactone	108-122	interleukin 17A	Homo sapiens	130-136
25638413-0	2015	A77 1726, the active metabolite of leflunomide, attenuates lupus nephritis by promoting the development of regulatory T cells and inhibiting IL-17-producing double negative T cells.	Leflunomide	35-46	interleukin 17A	Homo sapiens	141-146
26017791-4	2015	METHODS: Systemic sclerosis patient-derived dermal vascular smooth muscle cells were incubated with various dosages of tanshinone IIA in the presence of interleukin-17A or the serum of systemic sclerosis patients.	tanshinone	119-133	interleukin 17A	Homo sapiens	153-168
26017791-9	2015	RESULTS: Our data demonstrate that tanshinone IIA exerts an inhibitory effect on interleukin-17A-induced systemic sclerosis patient-derived dermal vascular smooth muscle cell proliferation, collagen synthesis and migration.	tanshinone	35-45	interleukin 17A	Homo sapiens	81-96
34929209-11	2022	Overall, we identified PKM2/p-Stat3/IL-17A axis participates in the hematotoxicity of benzene, and targeting PKM2 has certain therapeutic implications in hematologic diseases.	Benzene	86-93	interleukin 17A	Homo sapiens	36-42
34894724-3	2022	Aldosterone promotes T-helper-17 (Th-17) lymphocyte differentiation and IL-17A production through the mineralocorticoid receptor (MR).	Aldosterone	0-11	interleukin 17A	Homo sapiens	72-78
34237339-7	2022	In vitro Th17 cell differentiation of naive CD4+ cells from psoriatic patients markedly induced IL-17A expression under increased NaCl concentrations.	Sodium Chloride	130-134	interleukin 17A	Homo sapiens	96-102
34979203-4	2022	Our results showed that BPS exposure significantly increased the production of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and interleukin-17A (IL-17A).	bis(4-hydroxyphenyl)sulfone	24-27	interleukin 17A	Homo sapiens	191-206
34979203-4	2022	Our results showed that BPS exposure significantly increased the production of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and interleukin-17A (IL-17A).	bis(4-hydroxyphenyl)sulfone	24-27	interleukin 17A	Homo sapiens	208-214
34929480-7	2022	Further, POH treatment has decreased the pro-inflammatory serum cytokine levels such as IL-6, IL-12/23, TNF-alpha and IL-1beta and also reduced the expression levels of various inflammatory proteins, COX-2, iNOS, IL-17A, IL-22, NF-kB and STAT3 evidenced by Immunoblotting studies from skin samples.	perillyl alcohol	9-12	interleukin 17A	Homo sapiens	213-219
34543449-6	2022	In MS patients, lenabasum also reduced activation marker CD25 and inhibited IL-2 production from both T cell subsets and IFN-gamma and IL-17 from committed Th1 and Th17 cells, respectively.	lenabasum	16-25	interleukin 17A	Homo sapiens	135-140
34776280-1	2022	The ligand binding domain (LBD) of retinoid-related orphan nuclear receptor gammat (RORgammat) has been exploited as a promising target for the new small molecule therapeutics to cure autoimmune diseases via modulating the IL-17 and IL-22 production by Th17 cells.	Retinoids	35-43	interleukin 17A	Homo sapiens	223-228
34801521-9	2022	In cells from aviremic individuals living with HIV-1, the HDAC1-3 inhibitor, suberohydroxamic acid (SBHA), reduced secretion of pro-inflammatory cytokines TNF-alpha, IL-5, IL-2r, and IL-17 but did not significantly reactivate latent HIV-1 when combined with Ingenol-3,20-dibenzoate.	suberoyl bis-hydroxamic acid	77-98	interleukin 17A	Homo sapiens	183-188
34801521-9	2022	In cells from aviremic individuals living with HIV-1, the HDAC1-3 inhibitor, suberohydroxamic acid (SBHA), reduced secretion of pro-inflammatory cytokines TNF-alpha, IL-5, IL-2r, and IL-17 but did not significantly reactivate latent HIV-1 when combined with Ingenol-3,20-dibenzoate.	suberoyl bis-hydroxamic acid	100-104	interleukin 17A	Homo sapiens	183-188
34673156-10	2022	In addition, the increased expression of IL-17A and IL-22 cooperatively enhanced the mRNA expression of AMPs which response to F-induced microbiota perturbations.	Adenylyl sulfate	104-108	interleukin 17A	Homo sapiens	41-47
34544076-7	2022	RESULTS: Serum 25(OH)D negatively correlated with serum IL-17, the platelet/lymphocyte ratio, and TSH receptor antibody.	25(oh)d	15-22	interleukin 17A	Homo sapiens	56-61
34755269-11	2022	After colchicine treatment, patients had higher BUN and lower serum levels of IL-8, IL-12p70, and IL-17A.	Colchicine	6-16	interleukin 17A	Homo sapiens	98-104
34808482-0	2022	The protective effects of allopurinol against IL-17A-induced inflammatory response in mast cells.	Allopurinol	26-37	interleukin 17A	Homo sapiens	46-52
34808482-7	2022	We found that the production of inflammatory factors, PGE2, and COX-2 was significantly elevated in IL-17A-treated mast cells, accompanied by the activation of the iNOS/NO axis and the elevated secretion of ROS.	Dinoprostone	54-58	interleukin 17A	Homo sapiens	100-106
34808482-7	2022	We found that the production of inflammatory factors, PGE2, and COX-2 was significantly elevated in IL-17A-treated mast cells, accompanied by the activation of the iNOS/NO axis and the elevated secretion of ROS.	ros	207-210	interleukin 17A	Homo sapiens	100-106
34808482-9	2022	Mechanistically, the activated JNK/AP-1 and NF-kappaB pathways in IL-17A-treated mast cells were dramatically suppressed by the introduction of allopurinol.	Allopurinol	144-155	interleukin 17A	Homo sapiens	66-72
34808482-10	2022	Taken together, our data reveal that allopurinol significantly alleviated the IL-17A-induced inflammatory response in mast cells.	Allopurinol	37-48	interleukin 17A	Homo sapiens	78-84
34874211-2	2022	The objective of this study was to determine the effect of occupational co-exposure to Pb and Cd on the blood levels of selected immune-modulatory cytokines related to T helper (Th), that is, Th1, interleukin-2 (IL-2), Th2, (IL-4 and IL-10), and Th17, (IL-17) cells.	Cadmium	94-96	interleukin 17A	Homo sapiens	253-258
34874211-8	2022	While IL-2 levels were highest among the low Pb and Cd group, the IL-17 levels were highest among individuals with higher Cd levels.	Cadmium	122-124	interleukin 17A	Homo sapiens	66-71
34719371-5	2021	In particular, ALA is able to reduce inflammasome activity, the pro-inflammatory cytokine levels, such as TNF-alpha, IL-1beta, IL-6, IL-18 and IL-17, interferon (INF)-gamma as well as the production of Vascular and Intercellular cell adhesion protein (VCAM-1 and ICAM-1).	Thioctic Acid	15-18	interleukin 17A	Homo sapiens	143-148
34975894-9	2021	Interestingly, some DAMs, such as L-tryptophan and sphingosine 1-phosphate, showed an evident negative correlation with changes in the level of TNF-alpha and IL-17, while tightly positively correlating with altered concentrations of anti-inflammatory cytokines and chemokines, such as MIP-1alpha and RANTES.	Tryptophan	34-46	interleukin 17A	Homo sapiens	158-163
34992498-10	2021	Overexpression of miR-766-3p promoted keratinocyte proliferation and IL-17A and IL-22 secretion.	mir-766-3p	18-28	interleukin 17A	Homo sapiens	69-75
34953015-7	2022	The results show that GMSC-Exo has the same or stronger effects compared with GMSC in inhibiting IL-17A and promoting IL-10, reducing incidences and bone erosion of arthritis, via inhibiting IL-17RA-Act1-TRAF6-NF-kappaB signal pathway.	gmsc	22-26	interleukin 17A	Homo sapiens	97-103
34953015-7	2022	The results show that GMSC-Exo has the same or stronger effects compared with GMSC in inhibiting IL-17A and promoting IL-10, reducing incidences and bone erosion of arthritis, via inhibiting IL-17RA-Act1-TRAF6-NF-kappaB signal pathway.	gmsc	78-82	interleukin 17A	Homo sapiens	97-103
34975894-9	2021	Interestingly, some DAMs, such as L-tryptophan and sphingosine 1-phosphate, showed an evident negative correlation with changes in the level of TNF-alpha and IL-17, while tightly positively correlating with altered concentrations of anti-inflammatory cytokines and chemokines, such as MIP-1alpha and RANTES.	sphingosine 1-phosphate	51-74	interleukin 17A	Homo sapiens	158-163
34970568-10	2021	BHB may exert inhibitory effects also on IL-17 and intermittent fasting improved the clinical manifestations of psoriatic arthritis.	3-Hydroxybutyric Acid	0-3	interleukin 17A	Homo sapiens	41-46
34970256-0	2021	Treatment With Cladribine Selects IFNgamma+IL17+ T Cells in RRMS Patients - An In Vitro Study.	Cladribine	15-25	interleukin 17A	Homo sapiens	43-47
34872498-12	2021	Of note, we confirmed that GS2018 induced Th17 cell differentiation in PBLCs and persistently increased the expression levels of IL17A.	GS2018	27-33	interleukin 17A	Homo sapiens	129-134
34944509-11	2021	High doses of vitamin D supplementation led to a significant decrease in pro-inflammatory cytokines (IFN- , TNF-alpha, IL-1beta, IL-6, IL-8, and IL-17) and high-sensitivity C-reactive protein (hsCRP), whereas the production of anti-inflammatory cytokines (IL-10, IL-5) was up-regulated.	Vitamin D	14-23	interleukin 17A	Homo sapiens	145-150
34872498-13	2021	In turn, the replication of GS2018 was inhibited by IL17A.	GS2018	28-34	interleukin 17A	Homo sapiens	52-57
34943042-10	2021	Furthermore, hydrogen peroxide addition was observed to mimic, in vitro, the SOD-1 effect on IL-17 production.	Hydrogen Peroxide	13-30	interleukin 17A	Homo sapiens	93-98
34899944-11	2021	Conclusion: The possible mechanisms of the components of the Zhishi-Baizhu herb pair in treating gastric cancer might be related to luteolin and naringenin, which intervened with the targets AKT1, MMP9, IL-6, CCND1, BCL2, MTOR, and MDM2, and are linked with the PI3K-Akt and IL-17 signaling pathways.	naringenin	145-155	interleukin 17A	Homo sapiens	275-280
34509039-2	2021	We aimed to compare mRNA expression of RORgammat and IL-17 in paraffin-embedded blocks of OLP and CLP lesions with normal oral mucosa (NOM), and also its correlation with hematologic parameters.	Paraffin	62-70	interleukin 17A	Homo sapiens	53-58
34719112-4	2021	For the first time, this paper reviews the evidence from in vitro and in vivo experimental models to explore the anti-inflammatory effects of BBR in periodontitis and exhibits that BBR has the high potency to exert anti-inflammatory effects by reducing expression and secretion of pro-inflammatory mediators including TNF-alpha, IL-1beta, IL-17, RANKL, MMP-2, MMP-9 and MCP-1.	Berberine	181-184	interleukin 17A	Homo sapiens	339-344
34218304-8	2021	Rupatadine significantly reduced all measured parameters (P < 0.05) except for IL-17 and CLU.	rupatadine	0-10	interleukin 17A	Homo sapiens	79-84
34741349-10	2021	The enriched KEGG pathway mainly included the HIF-1 signaling pathway, NOD-like receptor signaling pathway, ferroptosis, IL-17 signaling pathway, central carbon metabolism in cancer, PPAR signaling pathway, PD-L1 expression, and PD-1 checkpoint pathway in cancer.	kegg	13-17	interleukin 17A	Homo sapiens	121-126
34879788-4	2021	Generalized estimating equation was used to evaluate the association between exposure to PM2.5 and NO2 and the following serum cytokine levels on the 7 days preceding clinical assessment and serum collection: MCP1, IL-6, IL-8, IL-10, IL-17, IFN-alpha, and TNF-alpha.	pm2.5	89-94	interleukin 17A	Homo sapiens	234-239
34879788-4	2021	Generalized estimating equation was used to evaluate the association between exposure to PM2.5 and NO2 and the following serum cytokine levels on the 7 days preceding clinical assessment and serum collection: MCP1, IL-6, IL-8, IL-10, IL-17, IFN-alpha, and TNF-alpha.	Nitrogen Dioxide	99-102	interleukin 17A	Homo sapiens	234-239
34624807-9	2021	CONCLUSION: This systematic review broadly reports that, in contrast to other classes of phytochemicals, flavonoids have the greatest therapeutic potential against arthritis by modulating the expression of pro-inflammatory TNF-alpha, IL-1beta, IL-6, IL-8, and IL-17, as well as anti-inflammatory IL-2 and IL-10 cytokines, through the suppression of dynamic inflammatory biomarkers.	Flavonoids	105-115	interleukin 17A	Homo sapiens	260-265
34546593-10	2021	In PI vs PM, significantly higher REL was found for Hey 1, TNF-alpha, IL-17, IL-1beta, IL-6 and RANKL.	pipermethystine	9-11	interleukin 17A	Homo sapiens	70-75
34825313-10	2022	Delphinidin also significantly decreased IL-17+ CD4+ T cells in all tested subjects, with marginal effect on the increase of IL-10-producing T regulatory subsets.	delphinidin	0-11	interleukin 17A	Homo sapiens	41-46
34554306-4	2021	Serum levels were determined by Human IL-17A Platinum ELISA kit.	Platinum	45-53	interleukin 17A	Homo sapiens	38-44
34906298-6	2021	The changes of Th17 cell proportion and IL-17 expression were observed after adding methylation inhibitor 5-Aza-2"-deoxycytidine (5-Aza-dC) to CD4+ T cells.	Decitabine	106-128	interleukin 17A	Homo sapiens	40-45
34906298-6	2021	The changes of Th17 cell proportion and IL-17 expression were observed after adding methylation inhibitor 5-Aza-2"-deoxycytidine (5-Aza-dC) to CD4+ T cells.	Azacitidine	130-135	interleukin 17A	Homo sapiens	40-45
34906298-12	2021	After the addition of 5-Aza-dC in CD4+ T cells, the expression of miR-146a-3p was increased and the expression of IL-17 mRNA was decreased, and in the supernatant, the level of IL-17 was decreased and the proportion of Th17 cells was significantly reduced.	Azacitidine	22-27	interleukin 17A	Homo sapiens	114-119
34906298-12	2021	After the addition of 5-Aza-dC in CD4+ T cells, the expression of miR-146a-3p was increased and the expression of IL-17 mRNA was decreased, and in the supernatant, the level of IL-17 was decreased and the proportion of Th17 cells was significantly reduced.	Azacitidine	22-27	interleukin 17A	Homo sapiens	177-182
34899697-0	2021	Tetracyclines Diminish In Vitro IFN-gamma and IL-17-Producing Adaptive and Innate Immune Cells in Multiple Sclerosis.	Tetracyclines	0-13	interleukin 17A	Homo sapiens	46-51
34899697-7	2021	They also decreased IL-17+ T and NKT cells following PMA and Ionomycin-stimulation.	Tetradecanoylphorbol Acetate	53-56	interleukin 17A	Homo sapiens	20-25
34899697-7	2021	They also decreased IL-17+ T and NKT cells following PMA and Ionomycin-stimulation.	Ionomycin	61-70	interleukin 17A	Homo sapiens	20-25
34899697-9	2021	Conclusion: Tetracyclines can in vitro suppress IFN-gamma and IL-17- producing cells from MS patients, and this may explain their potential therapeutic effect in vivo.	Tetracyclines	12-25	interleukin 17A	Homo sapiens	62-67
34825387-0	2022	The effects of mannuronic acid on IL-1beta, IL-17A, STAT1 and STAT3 gene expression and TLR2 and TLR4 molecules in multiple sclerosis.	mannuronic acid	15-30	interleukin 17A	Homo sapiens	44-50
34880863-8	2021	The 4 most promising peptides were synthesized, and the peptides with and without incorporation into glucan particles induced CD4+ and CD8+ T cell proliferation and produced a Th1 and Th17 response marked by the secretion of high levels of IFN-gamma, IL-17 and IL-2.	Glucans	101-107	interleukin 17A	Homo sapiens	251-256
34807506-0	2021	METTL3/14 and IL-17 signaling contribute to CEBPA-DT enhanced oral cancer cisplatin resistance.	Cisplatin	74-83	interleukin 17A	Homo sapiens	14-19
34807506-9	2021	CEBPA-DT overexpression could inhibit the activity of IL-17 signaling, resulting in the homeostasis breakdown of immune infiltration and cytokine release.	Thymidine	6-8	interleukin 17A	Homo sapiens	54-59
34807506-11	2021	CONCLUSIONS: Our results suggest that CEBPA-DT might regulate OSCC chemoresistance through BHLHB9 gene manipulated by METTL3/METTL14 as well as through IL-17 signaling inhibition, which may contribute to the assessment of potential therapeutic targets in OSCC chemoresistance.	cebpa-dt	38-46	interleukin 17A	Homo sapiens	152-157
34741215-3	2021	The subsequent hypothetical case study applies these principles to a specific example HC-12, based loosely on anti-TNFalpha and anti-IL-17A bispecific molecules previously in development, structured as an example immunogenicity risk assessment for submission to health authorities.	hc-12	86-91	interleukin 17A	Homo sapiens	133-139
34835109-5	2021	MPA treatment reduced the replication of both tested HIV-1 strains as well as the production of the mediators of inflammation IL-1beta, IL-17A and CCL5, but not CCL20, in a similar way to DEX, whereas P4 had no effect on HIV-1 replication.	Medroxyprogesterone Acetate	0-3	interleukin 17A	Homo sapiens	136-142
34774955-7	2022	Pyrogallol, pyridoxine, and N-acetylputrescine were positively associated with IL-17A levels.	Pyrogallol	0-10	interleukin 17A	Homo sapiens	79-85
34774955-7	2022	Pyrogallol, pyridoxine, and N-acetylputrescine were positively associated with IL-17A levels.	N-acetylputrescine	28-46	interleukin 17A	Homo sapiens	79-85
34749650-9	2021	Kyoto encyclopedia of genes and genomes (KEGG) enrichment showed that signaling pathways, such as tumor necrosis factor (TNF), Jak, Toll-like receptor and IL-17, were altered after DI treatment.	dimethyl itaconate	181-183	interleukin 17A	Homo sapiens	155-160
34748646-12	2022	RGRN-305 treatment resulted in pronounced inhibition of the IL-23, TNFalpha, and IL-17A signaling pathways and normalization of both histological changes and psoriatic lesion gene expression profiles in patients responding to treatment.	rgrn-305	0-8	interleukin 17A	Homo sapiens	81-87
34539828-4	2021	ALA/DHLA reduce the levels of pro-inflammatory cytokines (IL-1beta, IL-6, IL-8 and IL-17), while increasing the secretion of anti-inflammatory cytokines (IL-10).	Thioctic Acid	0-3	interleukin 17A	Homo sapiens	83-88
34539828-4	2021	ALA/DHLA reduce the levels of pro-inflammatory cytokines (IL-1beta, IL-6, IL-8 and IL-17), while increasing the secretion of anti-inflammatory cytokines (IL-10).	dihydrolipoic acid	4-8	interleukin 17A	Homo sapiens	83-88
34698528-0	2021	Tetramethylpyrazine Alleviates Tight Junction Disruption of Bronchial Mucosal Epithelial Cells Caused by Interleukin-17 via Inhibiting Nuclear Factor-kappaB-p65/Tumor Necrosis Factor-alpha Signaling Pathway.	tetramethylpyrazine	0-19	interleukin 17A	Homo sapiens	105-119
34698528-5	2021	Here, we demonstrated the protective effects of TMP on bronchial mucosal epithelial injury induced by IL-17.	tetramethylpyrazine	48-51	interleukin 17A	Homo sapiens	102-107
34698528-7	2021	TMP obviously rescued IL-17-induced occludin and ZO-1 downregulation.	tetramethylpyrazine	0-3	interleukin 17A	Homo sapiens	22-27
34698528-8	2021	Mechanically, TMP substantially suppressed NF-kappaB-p65 activation and NF-kappaB-p65-induced TNF-alpha production in bronchial mucosal epithelial cells caused by IL-17.	tetramethylpyrazine	14-17	interleukin 17A	Homo sapiens	163-168
34698528-9	2021	Taken together, this study indicates that TMP has a protective effect on bronchial mucosal epithelial cell injury due to IL-17 induction by inhibiting the NF-kappaB-p65/TNF-alpha signaling pathway.	tetramethylpyrazine	42-45	interleukin 17A	Homo sapiens	121-126
34541720-7	2021	Serum levels of IFN-gamma (p = .52) and IL-17 (p = .11) decreased, while IL-4 (p = .12) and TGF-beta (p = .14) increased in the nano-curcumin group compared with placebo on day 14.	Curcumin	133-141	interleukin 17A	Homo sapiens	40-45
34764759-7	2021	Furthermore, the findings revealed that 4-HI also improved the levels of other neurotransmitters (Ach, DOPA, GABA, glutamate); inflammatory cytokines (TNF-alpha, IL-1beta, IL-17), and oxidative stress markers (MDA, nitrite, LDH, AchE, SOD, CAT, GPx, GSH) in the brain when evaluated after Day 35.	4-hydroxyisoleucine	40-44	interleukin 17A	Homo sapiens	172-177
34760922-14	2021	A positive correlation between IL-6 or IL-17A and STAT3 and negative correlation between SOCS3 and STAT3 were shown, suggesting that the IL-6/STAT3 pathway may be involved in OVA + ozone-induced corticosteroid-resistant airway inflammation.	Ozone	181-186	interleukin 17A	Homo sapiens	39-45
34757278-8	2021	Also, at both time points of before and after plasmapheresis, serum levels of IL-1, IL-6, IFN-gamma and IL-17 were inversely correlated to blood oxygen saturation.	Oxygen	145-151	interleukin 17A	Homo sapiens	104-109
34768873-8	2021	Graphene exposure (10 microg/mL) for 24 h significantly increased levels of pro-inflammatory cytokines IFNgamma, IL-8, IL-17, IL-6, IL-9, MIP-1alpha, and Eotaxin.	Graphite	0-8	interleukin 17A	Homo sapiens	119-124
34768873-9	2021	Collectively, these results indicated that graphene may activate the STAT3-IL23-IL17 response axis.	Graphite	43-51	interleukin 17A	Homo sapiens	80-84
34733276-6	2021	Furthermore, we found significantly increased plasma levels of IL-6, IL-12, IL-17, IL-18, stem cell factor (SCF), and IL-21/IL-23 in SLE patients compared to healthy controls, and those levels positively correlated with the plasma levels of 17beta-estradiol.	Estradiol	241-257	interleukin 17A	Homo sapiens	76-81
34733276-8	2021	In vitro treatment of PBMCs from either SLE patients or healthy controls with 17beta-estradiol at physiological concentration (~50 pg/ml) also significantly increased secretion of many pro-inflammatory cytokines and chemokines (IL-6, IL-12, IL-17, IL-8, IFN-gamma; MIP1alpha, and MIP1beta) in both groups.	Estradiol	78-94	interleukin 17A	Homo sapiens	241-246
34379099-10	2021	Treatment with RORgammat small molecule inhibitor SR1001 increased the expression of occludin, decreased the apoptotic rate of HCT-116 cells, and decreased the concentrations of Th17 and IL-17.	SR1001	50-56	interleukin 17A	Homo sapiens	187-192
34675572-6	2021	The study participants with the highest IL-17A (Q4) levels had higher TC, DBP, and low-density lipoprotein cholesterol (LDL-C) values than those the other groups.	Technetium	70-72	interleukin 17A	Homo sapiens	40-46
34259316-8	2021	Compared with those in the DSS group, the expressions of IL-1beta, IL-6, IL-17, and TNF-alpha in the DSS+DHA and DSS+5-aminosalicylic acid (5-ASA) groups were decreased, while the expressions of IL-4 and IL-10 were significantly upregulated.	dss	27-30	interleukin 17A	Homo sapiens	73-78
34689174-5	2021	In particular, the activated endothelium releases reactive oxygen species and interleukin (IL)-6 which in turn stimulate transformation of monocytes to become antigen presenting cells and produce cytokines like IL-1beta and IL-23, which further affect T cell function to produce IL-17A.	Reactive Oxygen Species	50-73	interleukin 17A	Homo sapiens	279-285
34101628-12	2021	IL-17A significantly decreased both IL-32 beta/gamma/epsilon mRNA and cell-associated IL-32 protein levels induced upon TNF-alpha and Poly I:C triggering.	Poly I	134-140	interleukin 17A	Homo sapiens	0-6
34101628-12	2021	IL-17A significantly decreased both IL-32 beta/gamma/epsilon mRNA and cell-associated IL-32 protein levels induced upon TNF-alpha and Poly I:C triggering.	Carbon	141-142	interleukin 17A	Homo sapiens	0-6
34365090-7	2021	Exposure to butyrate potently inhibited CD4 T cell activation, proliferation, and cytokine (IFNgamma, IL-17) production in a concentration dependent manner.	Butyrates	12-20	interleukin 17A	Homo sapiens	102-107
34817126-1	2021	OBJECTIVES: To evaluate the serum and salivary levels of IL-1beta, IL-6, IL-17A, TNF-alpha, IL-4 and, IL-10 in patients with Oral Lichen Planus (OLP) treated with Photobiomodulation (PBM) and clobetasol propionate 0.05%.	pbm	183-186	interleukin 17A	Homo sapiens	73-79
34817126-1	2021	OBJECTIVES: To evaluate the serum and salivary levels of IL-1beta, IL-6, IL-17A, TNF-alpha, IL-4 and, IL-10 in patients with Oral Lichen Planus (OLP) treated with Photobiomodulation (PBM) and clobetasol propionate 0.05%.	Clobetasol	192-213	interleukin 17A	Homo sapiens	73-79
34640589-0	2021	IL-17 Promotes Nitric Oxide Production in Non-Small-Cell Lung Cancer.	Nitric Oxide	15-27	interleukin 17A	Homo sapiens	0-5
34640589-2	2021	Inflammatory cytokines and Th cells, including Th17, are now emerging as being involved in NSCLC pathways, thus postulating a role of IL-17 in tumour angiogenesis by stimulating the vascular endothelial growth factor and the release of nitric oxide.	Nitric Oxide	236-248	interleukin 17A	Homo sapiens	134-139
34640589-8	2021	Significant correlations were found between FeNO 50 mL/s and IL-17, IL-1 and VEGF.	flubendiamide	44-48	interleukin 17A	Homo sapiens	61-66
34369213-9	2021	Furthermore, suPAR was positively correlated with Th1 cell proportion, Th17 cell proportion, IFN-gamma, IL-17 and TNF-alpha.	supar	13-18	interleukin 17A	Homo sapiens	104-109
34314911-0	2021	P300 inhibition improves cell apoptosis and cognition impairment induced by sevoflurane through regulating IL-17A activation.	Sevoflurane	76-87	interleukin 17A	Homo sapiens	107-113
34314911-6	2021	P300 inhibitor C646 could reduce the apoptosis induced by Sev through decreasing IL-17A avtivity.	C646	15-19	interleukin 17A	Homo sapiens	81-87
34314911-7	2021	Furthermore, IL-17A expression was up-regulated after neurons were transfected with P300 expression plasmid and IL-17A expression was down-regulated after neurons were incubated with P300 inhibitor C646.	C646	198-202	interleukin 17A	Homo sapiens	13-19
34314911-7	2021	Furthermore, IL-17A expression was up-regulated after neurons were transfected with P300 expression plasmid and IL-17A expression was down-regulated after neurons were incubated with P300 inhibitor C646.	C646	198-202	interleukin 17A	Homo sapiens	112-118
34664816-10	2021	However, non-significant variations in the IL-1beta and IL-17 levels suggest an alternative way of NAC effectiveness without influencing the measured cytokines.	Acetylcysteine	99-102	interleukin 17A	Homo sapiens	56-61
34580601-9	2021	The shared targets between Resveratrol targets and SARS-CoV-2 mainly involved the IL-17 signaling pathway, NF-kappa B signaling pathway, and TNF signaling pathway.	Resveratrol	27-38	interleukin 17A	Homo sapiens	82-87
34595177-0	2021	HIF1alpha Regulates IL17 Signaling Pathway Influencing Sensitivity of Taxane-Based Chemotherapy for Breast Cancer.	taxane	70-76	interleukin 17A	Homo sapiens	20-24
34595177-10	2021	Experiments in vitro verified that HIF1alpha/IL-17 pathway influences paclitaxel sensitivity to BC cells.	Paclitaxel	70-80	interleukin 17A	Homo sapiens	45-50
34521933-6	2021	Moreover, at the mRNA level of genes associated with the early inflammatory response characteristic for Ps (CAMP, CCL20, DEFB4A, PIK3CA, S100A7, and S100A9) and key cellular signalling (MTORC1 and TFEB), we showed that this isoflavone attenuated the increased response of IL-17A- and TNF-alpha-related pathways.	Isoflavones	224-234	interleukin 17A	Homo sapiens	272-278
34676030-0	2021	Imidazo(1,2-b)pyridazines as IL-17A Inhibitors for Treating Psoriasis, Rheumatoid Arthritis, and Multiple Sclerosis.	imidazo(1,2-b)pyridazines	0-25	interleukin 17A	Homo sapiens	29-35
34532040-7	2021	In GCA patients, Treg were unable to control Teff proliferation and induced ~50% increase in the amount of IL-17+ Teff, which was improved after in vitro blockade of the IL-6 pathway by tocilizumab.	treg	17-21	interleukin 17A	Homo sapiens	107-112
34511884-9	2021	Moreover, KEGG analysis indicated that the anti-pancreatic cancer effect of ZJP was mediated by multiple pathways, such as the PI3K-AKT, IL-17, TNF, HIF-1, and P53 signaling pathways.	zjp	76-79	interleukin 17A	Homo sapiens	137-142
34153674-6	2021	Experimentally, resolvins, maresins, and lipoxins downregulate the cytokine expression of the IL-23/IL-17 axis and inhibition of mitogen-activated protein kinases and nuclear factor kappa-light-chain-enhancer of activated B (NF-kappaB) cell signaling transduction pathways.	Lipoxins	41-49	interleukin 17A	Homo sapiens	100-105
34259316-8	2021	Compared with those in the DSS group, the expressions of IL-1beta, IL-6, IL-17, and TNF-alpha in the DSS+DHA and DSS+5-aminosalicylic acid (5-ASA) groups were decreased, while the expressions of IL-4 and IL-10 were significantly upregulated.	dss	101-104	interleukin 17A	Homo sapiens	73-78
34259316-8	2021	Compared with those in the DSS group, the expressions of IL-1beta, IL-6, IL-17, and TNF-alpha in the DSS+DHA and DSS+5-aminosalicylic acid (5-ASA) groups were decreased, while the expressions of IL-4 and IL-10 were significantly upregulated.	artenimol	105-108	interleukin 17A	Homo sapiens	73-78
34259316-8	2021	Compared with those in the DSS group, the expressions of IL-1beta, IL-6, IL-17, and TNF-alpha in the DSS+DHA and DSS+5-aminosalicylic acid (5-ASA) groups were decreased, while the expressions of IL-4 and IL-10 were significantly upregulated.	dss	113-116	interleukin 17A	Homo sapiens	73-78
34259316-8	2021	Compared with those in the DSS group, the expressions of IL-1beta, IL-6, IL-17, and TNF-alpha in the DSS+DHA and DSS+5-aminosalicylic acid (5-ASA) groups were decreased, while the expressions of IL-4 and IL-10 were significantly upregulated.	Mesalamine	117-138	interleukin 17A	Homo sapiens	73-78
34259316-8	2021	Compared with those in the DSS group, the expressions of IL-1beta, IL-6, IL-17, and TNF-alpha in the DSS+DHA and DSS+5-aminosalicylic acid (5-ASA) groups were decreased, while the expressions of IL-4 and IL-10 were significantly upregulated.	5-Aminosalicylic acid	140-145	interleukin 17A	Homo sapiens	73-78
34429055-4	2021	Dopamine suppressed IL-17, IFN-gamma, GM-CSF, and IL-21 production by stimulated SD4+ T-cells in both groups.	Dopamine	0-8	interleukin 17A	Homo sapiens	20-25
34403509-12	2021	RAP group showed a decrease IL-17A levels in advanced stages of the periodontal disease.	3-(4-(reduced 3-pyridine aldehyde-adenine dinucleotide))pyruvate	0-3	interleukin 17A	Homo sapiens	28-34
34483911-8	2021	The o/w emulsion together with BECC438 provided the best protective efficacy, which correlated with high levels of opsonophagocytic killing and IL-17A secretion, thereby reducing the lung burden among all the vaccinated groups tested.	becc438	31-38	interleukin 17A	Homo sapiens	144-150
34484234-6	2021	In addition, RSA-P patients had higher proportion of IL-17A-secreting but not IL-4-secreting Vdelta2+ cells compared to the control groups.	rsa-p	13-18	interleukin 17A	Homo sapiens	53-59
34483908-6	2021	Results: Under the stimulation of tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma), DHA inhibited the proliferation of HaCaT cells and significantly affected the mRNA expression levels of IFN-gamma, interleukin (IL), IL-17A and IL-23.	artenimol	108-111	interleukin 17A	Homo sapiens	241-247
34483908-8	2021	DHA restored the expression of IFN-gamma, IL-17A, and IL-23 in skins, as well as a decrease of cytokines and chemokines in skin supernatant.	artenimol	0-3	interleukin 17A	Homo sapiens	42-48
34429055-6	2021	In contrast, blockade of D2-like dopaminergic receptor by sulpiride decreased dopamine"s inhibitory effect on IL-17 secretion in both groups and GM-CSF and IL-21 production in MS patients.	Sulpiride	58-67	interleukin 17A	Homo sapiens	110-115
34429055-6	2021	In contrast, blockade of D2-like dopaminergic receptor by sulpiride decreased dopamine"s inhibitory effect on IL-17 secretion in both groups and GM-CSF and IL-21 production in MS patients.	Dopamine	78-86	interleukin 17A	Homo sapiens	110-115
34429055-8	2021	Finally, activation of D2-like dopaminergic receptor with a specific agonist quinpirole decreased IL-17, IFN-gamma, and GM-CSF production in both groups.	Quinpirole	77-87	interleukin 17A	Homo sapiens	98-103
34385542-7	2021	Neutralization of IL-17 with the IL-17 inhibitor plumbagin (PB) reduced the effects of IL-34.	plumbagin	49-58	interleukin 17A	Homo sapiens	18-23
34385542-7	2021	Neutralization of IL-17 with the IL-17 inhibitor plumbagin (PB) reduced the effects of IL-34.	plumbagin	49-58	interleukin 17A	Homo sapiens	33-38
34385542-7	2021	Neutralization of IL-17 with the IL-17 inhibitor plumbagin (PB) reduced the effects of IL-34.	plumbagin	60-62	interleukin 17A	Homo sapiens	18-23
34385542-7	2021	Neutralization of IL-17 with the IL-17 inhibitor plumbagin (PB) reduced the effects of IL-34.	plumbagin	60-62	interleukin 17A	Homo sapiens	33-38
34385542-9	2021	PB-mediated inhibition of IL-17A also decreased the expression of IL-6, TNF-alpha, HIF-1alpha and VEGF in RA-FLSs.	plumbagin	0-2	interleukin 17A	Homo sapiens	26-32
34408814-6	2021	Results: H2S triggered the secretion of the pro-inflammatory IFN-gamma, IL-6, IL-17, TNF-alpha, IL-12p40, and IL-12p70, while the reverse was seen for IL-1Ra.	Deuterium	9-12	interleukin 17A	Homo sapiens	78-83
34166230-5	2021	TNFalpha+IL-17 markedly increased ASL pH by upregulating pendrin, an apical Cl-/HCO3- exchanger.	Bicarbonates	80-84	interleukin 17A	Homo sapiens	9-14
34314383-3	2021	Our data show that curcumol significantly inhibits proliferation and induces cell cycle arrest in NHEK cells stimulated with proinflammatory cytokines (IL-1alpha, IL-17A, IL-22, oncostatin M, and TNF-alpha; mix M5).	curcumol	19-27	interleukin 17A	Homo sapiens	163-169
34320346-0	2021	Prostaglandin E2 amplifies IL-17 production by gammadelta T cells during barrier inflammation.	Dinoprostone	0-16	interleukin 17A	Homo sapiens	27-32
34451823-5	2021	In addition, Pitavastatin suppressed the IL-10 and IL-17 production of stimulated T cells.	pitavastatin	13-25	interleukin 17A	Homo sapiens	51-56
34367977-8	2021	RNA-seq and pathway analysis of cisplatin-affected genes revealed enrichment of G2/M cell cycle regulation and DNA repair pathways in parental and OlaR MDA-MB-468 cells whereas parental and OlaR SUM1315 cells showed enrichment of inflammatory stress response pathways associated with TNFR1/2, TWEAK and IL-17 signaling.	Cisplatin	32-41	interleukin 17A	Homo sapiens	303-308
34335262-7	2021	The generation of Th17 cells in colitis was significantly inhibited by aucuboside and accompanied by the suppression of IL-17 expression.	aucubin	71-81	interleukin 17A	Homo sapiens	120-125
34233192-5	2021	Our data reveal that these microbiota-derived metabolites, particularly propionate, reduce IL-17 and IL-22 production by intestinal gammadelta T cells.	Propionates	72-82	interleukin 17A	Homo sapiens	91-96
34233192-6	2021	Propionate acts directly on gammadelta T cells to inhibit their production of IL-17 in a histone deacetylase-dependent manner.	Propionates	0-10	interleukin 17A	Homo sapiens	78-83
34233192-7	2021	Moreover, the production of IL-17 by human IL-17-producing gammadelta T cells from patients with inflammatory bowel disease (IBD) is regulated by propionate.	Propionates	146-156	interleukin 17A	Homo sapiens	28-33
34233192-7	2021	Moreover, the production of IL-17 by human IL-17-producing gammadelta T cells from patients with inflammatory bowel disease (IBD) is regulated by propionate.	Propionates	146-156	interleukin 17A	Homo sapiens	43-48
34085740-13	2021	Serum BPA levels correlated with IL-23 (r = 0.807; P = .001) and IL-17A (r = 0.743; P = .001).	bisphenol A	6-9	interleukin 17A	Homo sapiens	65-71
34085740-14	2021	The multivariate analysis revealed an independent significant contribution of BPA and bacterial-DNA to serum levels of IL-23 and IL-17A.	bisphenol A	78-81	interleukin 17A	Homo sapiens	129-135
34249502-18	2021	TNF, IL-17 and JAK-STAT signaling pathways might be more significant for cisplatin-resistance.	Cisplatin	73-82	interleukin 17A	Homo sapiens	5-10
34430345-7	2021	Results: We have found reduced activity of TNF (normalized enrichment score: 2.03), IL-17 (normalized enrichment score: 1.93), MAPK (normalized enrichment score: 1.51), and relaxin signaling pathways (normalized enrichment score: 1.42) in the samples obtained after platinum-based therapy.	Platinum	266-274	interleukin 17A	Homo sapiens	84-89
34445513-0	2021	A Michael Acceptor Analogue, SKSI-0412, Down-Regulates Inflammation and Proliferation Factors through Suppressing Signal Transducer and Activator of Transcription 3 Signaling in IL-17A-Induced Human Keratinocyte.	sksi-0412	29-38	interleukin 17A	Homo sapiens	178-184
34445513-4	2021	We hypothesized that the SKSI-0412 can inhibit interleukin (IL)-17A-induced inflammation in keratinocytes.	sksi-0412	25-34	interleukin 17A	Homo sapiens	47-67
34445513-5	2021	The introduction of IL-17A increased the phosphorylation of STAT3 in keratinocytes, whereas the inactivation of STAT3 by SKSI-0412 reduced IL-17A-induced STAT3 phosphorylation and IkappaBzeta expression.	sksi-0412	121-130	interleukin 17A	Homo sapiens	139-145
34445513-8	2021	Based on these results, we suggest targeting STAT3 with SKSI-0412 as a novel therapeutic strategy to regulate IL-17A-induced psoriatic inflammation in keratinocytes.	sksi-0412	56-65	interleukin 17A	Homo sapiens	110-116
34409142-5	2021	Immunohistochemical staining proved a predominant infiltration of CD4+ T cells and the corresponding IL-17A response to metal.	Metals	120-125	interleukin 17A	Homo sapiens	101-107
34409142-6	2021	We conclude that neck-rim impingement may lead to the development of adverse local tissue reaction (periarticular mass and osteolysis) due to a metal hypersensitivity with the production of proinflammatory cytokines (IL-17A) by CD4+ T cells even in ceramic-on-ceramic total hip arthroplasty.	Metals	144-149	interleukin 17A	Homo sapiens	217-223
34421897-7	2021	Flow cytometry suggested that the Y287N mutation might reduce the expression of IL-17 of Th17 cells in peripheral blood mononuclear cells stimulated by phorbol myristate acetate and ionomycin.	Tetradecanoylphorbol Acetate	152-177	interleukin 17A	Homo sapiens	80-85
34421897-7	2021	Flow cytometry suggested that the Y287N mutation might reduce the expression of IL-17 of Th17 cells in peripheral blood mononuclear cells stimulated by phorbol myristate acetate and ionomycin.	Ionomycin	182-191	interleukin 17A	Homo sapiens	80-85
34376972-4	2021	We hypothesize that intravenous lidocaine attenuates surgical stress and reduces serum IL-17 levels during video-assisted thoracic surgery (VATS) for NSCLC.	Lidocaine	32-41	interleukin 17A	Homo sapiens	87-92
34376972-9	2021	Results: The lidocaine group had lower serum IL-17 at 24 hours postoperatively compared with the control group (23.0 +- 5.8 pg/mL vs 27.3 +- 8.2 pg/mL, difference (95% CI) = -4.3 (-8.4 to -0.2) pg/mL; P = 0.038).	Lidocaine	13-22	interleukin 17A	Homo sapiens	45-50
34376972-10	2021	The lidocaine group also had reduced serum IL-17 (difference (95% CI) = -4.6 (-8.7 to -0.5) pg/mL), serum cortisol (difference (95% CI) = -37 (-73 to -2) ng/mL), and pain scores (difference (95% CI) = -0.7 (-1.3 to -0.1) points) at PACU discharge.	Lidocaine	4-13	interleukin 17A	Homo sapiens	43-48
34376972-12	2021	Conclusion: Intravenous lidocaine was associated with reduced serum IL-17 and cortisol following VATS procedures in early-stage NSCLC patients.	Lidocaine	24-33	interleukin 17A	Homo sapiens	68-73
34218389-9	2021	Bupropion reduced IL-17A, TNFalpha, and IL-1beta protein levels in the cultures.	Bupropion	0-9	interleukin 17A	Homo sapiens	18-24
34218389-10	2021	Nonetheless, bupropion increased IL-1beta (P < 0.0001), TNFalpha (P < 0.0001), and IL-17A (P < 0.05) mRNA levels.	Bupropion	13-22	interleukin 17A	Homo sapiens	83-89
34410877-0	2021	Diacerein Alone and in Combination with Infliximab Suppresses the Combined Proinflammatory Effects of IL-17A, IL-22, Oncostatin M, IL-1A, and TNF-alpha in Keratinocytes: A Potential Therapeutic Option in Psoriasis.	diacerein	0-9	interleukin 17A	Homo sapiens	102-108
34334139-5	2021	These actions of sodium, potassium and magnesium and other minerals, trace elements and vitamins are likely to be secondary to their action on pro-inflammatory cytokines IL-6, TNF-alpha and IL-17 and metabolism of essential fatty acids that may account for their involvement in the pathobiology of insulin resistance, T2DM, HTN and autoimmune diseases.	Sodium	17-23	interleukin 17A	Homo sapiens	190-195
34334139-5	2021	These actions of sodium, potassium and magnesium and other minerals, trace elements and vitamins are likely to be secondary to their action on pro-inflammatory cytokines IL-6, TNF-alpha and IL-17 and metabolism of essential fatty acids that may account for their involvement in the pathobiology of insulin resistance, T2DM, HTN and autoimmune diseases.	Potassium	25-34	interleukin 17A	Homo sapiens	190-195
34334139-5	2021	These actions of sodium, potassium and magnesium and other minerals, trace elements and vitamins are likely to be secondary to their action on pro-inflammatory cytokines IL-6, TNF-alpha and IL-17 and metabolism of essential fatty acids that may account for their involvement in the pathobiology of insulin resistance, T2DM, HTN and autoimmune diseases.	Magnesium	39-48	interleukin 17A	Homo sapiens	190-195
34146944-0	2021	Glutamine metabolism is essential for the production of IL-17A in gammadelta T cells and skin inflammation.	Glutamine	0-9	interleukin 17A	Homo sapiens	56-62
34146944-4	2021	Here, we identified glutamine metabolism as a critical regulator for the generation of IL-17-producing gammadelta T cells.	Glutamine	20-29	interleukin 17A	Homo sapiens	87-92
34146944-6	2021	Pharmaceutical blocking of glutamine impaired IL-17 production in gammadelta T cells both in vitro and in vivo.	Glutamine	27-36	interleukin 17A	Homo sapiens	46-51
34146944-7	2021	Mechanism studies further revealed that genes downregulated upon glutamine deprivation enriched in IL-17 and IL-23/STAT3 signaling pathways.	Glutamine	65-74	interleukin 17A	Homo sapiens	99-104
34584877-11	2021	Cytokine IL-4, IL-5, IL-6, IL-8, IL-13, and IL-17 in BALF were significantly different in the high FeNO, low FeNO, and control groups (all P<0.05).	feno	99-103	interleukin 17A	Homo sapiens	44-49
34202367-10	2021	However, CVNE reduced the levels of the pro-inflammatory cytokines IL-2, IL-17, and IFN-gamma at 50 microM.	cvne	9-13	interleukin 17A	Homo sapiens	73-78
34100601-0	2021	Macrolide Inspired Macrocycles as Modulators of the IL-17A/IL-17RA Interaction.	Macrolides	0-9	interleukin 17A	Homo sapiens	52-58
34100601-5	2021	Therefore, this paper is focused on the macrolide inspired macrocycles as potential IL-17A/IL-17RA modulators and covers the molecular design, synthesis, and in vitro profiling.	Macrolides	40-49	interleukin 17A	Homo sapiens	84-90
34234776-17	2021	IPA showed that these metabolites are connected to IL17 signaling, TGF-B signaling, and IL10 signaling, which are related closely to Th17 and Treg pathway.	treg	142-146	interleukin 17A	Homo sapiens	51-55
34284852-5	2021	During 3-6 months of treatment, compared with baseline, the PEG-IFN group showed a significant decrease in interferon-gamma (IFN-gamma), interleukin-17A (IL-17A), interleukin-6(IL-6), interleukin-10(IL-10), and transforming growth factor beta (TGF-beta) ( P < 0.001) and a significant increase in interferon-alpha 2(IFN-alpha2) ( P < 0.001).	peg-ifn	60-67	interleukin 17A	Homo sapiens	137-152
34284852-5	2021	During 3-6 months of treatment, compared with baseline, the PEG-IFN group showed a significant decrease in interferon-gamma (IFN-gamma), interleukin-17A (IL-17A), interleukin-6(IL-6), interleukin-10(IL-10), and transforming growth factor beta (TGF-beta) ( P < 0.001) and a significant increase in interferon-alpha 2(IFN-alpha2) ( P < 0.001).	peg-ifn	60-67	interleukin 17A	Homo sapiens	154-160
34284852-7	2021	After 3 months, the levels of IFN-alpha2, IL-17A, and tumor necrosis factor-alpha(TNF-alpha) in the PEG-IFN group were significantly higher than those in the ETV group ( P < 0.01).	peg-ifn	100-107	interleukin 17A	Homo sapiens	42-48
34284852-7	2021	After 3 months, the levels of IFN-alpha2, IL-17A, and tumor necrosis factor-alpha(TNF-alpha) in the PEG-IFN group were significantly higher than those in the ETV group ( P < 0.01).	entecavir	158-161	interleukin 17A	Homo sapiens	42-48
34211461-7	2021	Metformin increased the levels of SMILE, AMPK, and Foxp3 but decreased the number of interleukin (IL)-17-producing T cells among PBMCs from patients with UC.	Metformin	0-9	interleukin 17A	Homo sapiens	85-104
34211477-0	2021	Retinoic Acid: A New Old Friend of IL-17A in the Immune Pathogeny of Liver Fibrosis.	Tretinoin	0-13	interleukin 17A	Homo sapiens	35-41
34211477-4	2021	Retinoic acid (active metabolite of vitamin A) is able to regulate the differentiation of IL-17A+/IL-22-producing cells as well as the expression of profibrotic markers.	Tretinoin	0-13	interleukin 17A	Homo sapiens	90-96
34211477-4	2021	Retinoic acid (active metabolite of vitamin A) is able to regulate the differentiation of IL-17A+/IL-22-producing cells as well as the expression of profibrotic markers.	Vitamin A	36-45	interleukin 17A	Homo sapiens	90-96
34221070-13	2021	The relevant pathways of CKZI against asthma mainly include IL-17, NF-kappa B, HIF-1, calcium, and PI3K-Akt signaling pathways.	ckzi	25-29	interleukin 17A	Homo sapiens	60-65
34149863-13	2021	SCDP key active ingredients are mainly quercetin, wogonin, baicalein, acacetin, oroxylin A, and beta-sitosterol, which function mainly by regulating targets, such as PTGS2, CASP3, TP53, IL-6, TNF, and AKT1, and are associated with multiple signaling pathways as pathways in cancer, PI3K-Akt signaling pathway, apoptosis, IL-17 signaling pathways.	scdp	0-4	interleukin 17A	Homo sapiens	321-326
34204678-8	2021	By contrast, tamoxifen decreased both CD8+ and B220+ populations in the spleen and decreased the serum levels of IL-2, IL-6, and IL-17.	Tamoxifen	13-22	interleukin 17A	Homo sapiens	129-134
34082814-14	2021	Furthermore, our data suggest that IL-17A is not dominant in this T cell-SF activation loop but that a multiple T cell cytokine inhibitor, such as 1,25(OH)2D3, is able to suppress CCR6+ memTh subpopulation-driven SF activation.	Calcitriol	147-158	interleukin 17A	Homo sapiens	35-41
34149863-13	2021	SCDP key active ingredients are mainly quercetin, wogonin, baicalein, acacetin, oroxylin A, and beta-sitosterol, which function mainly by regulating targets, such as PTGS2, CASP3, TP53, IL-6, TNF, and AKT1, and are associated with multiple signaling pathways as pathways in cancer, PI3K-Akt signaling pathway, apoptosis, IL-17 signaling pathways.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	80-90	interleukin 17A	Homo sapiens	321-326
34149863-13	2021	SCDP key active ingredients are mainly quercetin, wogonin, baicalein, acacetin, oroxylin A, and beta-sitosterol, which function mainly by regulating targets, such as PTGS2, CASP3, TP53, IL-6, TNF, and AKT1, and are associated with multiple signaling pathways as pathways in cancer, PI3K-Akt signaling pathway, apoptosis, IL-17 signaling pathways.	gamma-sitosterol	96-111	interleukin 17A	Homo sapiens	321-326
34446953-9	2021	Further, a highly significant negative correlation (Correlation Coefficient: -0.668) was noted between serum IL-17 and 25(OH) D levels along with disease severity in acne patients (P value < 0.001).	25(oh) d	119-127	interleukin 17A	Homo sapiens	109-114
34084198-9	2021	Meanwhile, treated cells with PCN G expressed decreased levels of IFN-gamma (difference = 8.0; 0.49-1.07; P = 0.001) and IL-17A (difference = 2.2; 0.05-0.75; P <= 0.05) genes comparing to unstimulated cell by PCN-G. GATA3 genes expression levels downregulated by PCN G after 72 h of incubation by PBMCs (difference = 1.1; 0.77-0.88; P = 0.035).	Pregnenolone Carbonitrile	30-33	interleukin 17A	Homo sapiens	121-127
34737829-2	2021	Objective  To determine the relation between interleukin-17 (IL-17) serum level and reactive oxygen species (ROS) serum levels in children suffering from OME and to disclose if any variation occurs in the level of IL-17 Will affect the ROS and antioxidant equilibrium in the serum, which indicates the entire body"s reaction to OME.	Reactive Oxygen Species	84-107	interleukin 17A	Homo sapiens	45-59
34737829-2	2021	Objective  To determine the relation between interleukin-17 (IL-17) serum level and reactive oxygen species (ROS) serum levels in children suffering from OME and to disclose if any variation occurs in the level of IL-17 Will affect the ROS and antioxidant equilibrium in the serum, which indicates the entire body"s reaction to OME.	Reactive Oxygen Species	84-107	interleukin 17A	Homo sapiens	61-66
34737829-2	2021	Objective  To determine the relation between interleukin-17 (IL-17) serum level and reactive oxygen species (ROS) serum levels in children suffering from OME and to disclose if any variation occurs in the level of IL-17 Will affect the ROS and antioxidant equilibrium in the serum, which indicates the entire body"s reaction to OME.	Reactive Oxygen Species	109-112	interleukin 17A	Homo sapiens	45-59
34737829-2	2021	Objective  To determine the relation between interleukin-17 (IL-17) serum level and reactive oxygen species (ROS) serum levels in children suffering from OME and to disclose if any variation occurs in the level of IL-17 Will affect the ROS and antioxidant equilibrium in the serum, which indicates the entire body"s reaction to OME.	Reactive Oxygen Species	109-112	interleukin 17A	Homo sapiens	61-66
34737829-2	2021	Objective  To determine the relation between interleukin-17 (IL-17) serum level and reactive oxygen species (ROS) serum levels in children suffering from OME and to disclose if any variation occurs in the level of IL-17 Will affect the ROS and antioxidant equilibrium in the serum, which indicates the entire body"s reaction to OME.	Reactive Oxygen Species	236-239	interleukin 17A	Homo sapiens	214-219
34737829-11	2021	Conclusion  In the present study, there is a reasonable role of the IL-17 pathway in OME pathogenesis through an increase in ROS levels.	Reactive Oxygen Species	125-128	interleukin 17A	Homo sapiens	68-73
34349088-11	2021	Crocetin treatment significantly increased survival, attenuated myocardial necrotic lesions, reduced CVB3 replication and expression of ROCK2 and IL-17 in the infected hearts.	crocetin	0-8	interleukin 17A	Homo sapiens	146-151
35398417-4	2022	Here, we evaluated the associations between PM10, NO2 and O3 exposure (on the day of the blood sample collection and on the day before, and the mean annual residential level) and levels of the inflammatory biomarkers high-sensitivity C-reactive protein (hsCRP), interleukin (IL)-1beta, IL-6, IL-8, IL-10, IL-17A, IL-22, and tumor necrosis factor alpha.	pm10	44-48	interleukin 17A	Homo sapiens	305-311
34091460-8	2021	Serum miR-221-3p was positively correlated with the expression levels of tumor necrosis factor-alpha, interleukin (IL)-17A, and IL-22.	mir-221-3p	6-16	interleukin 17A	Homo sapiens	102-122
35475923-2	2022	IL-17 is considered to induce neutrophilic inflammation in the lung, which is often observed in severe, steroid-resistant asthma-phenotypes.	Steroids	104-111	interleukin 17A	Homo sapiens	0-5
35504060-14	2022	Blocking the Th17/IL-17 related pathways with plumbagin abolished the effects of IL-35 on IL-1beta-stimulated SW1353 cells.	plumbagin	46-55	interleukin 17A	Homo sapiens	18-23
35183690-5	2022	In vitro, TNF-alpha treated HaCaT cells with or without Khasianine, were used to analyze the expression and cellular location of NF-kappaB p65, the expression of IL-17A and IL-33, and the binding intensity of NF-kappaB p65 on the promoter of IL-17A and IL-33 to understand the molecular mechanism of Khasianine mediated anti-inflammatory effect.	khasianine	56-66	interleukin 17A	Homo sapiens	162-168
35183690-5	2022	In vitro, TNF-alpha treated HaCaT cells with or without Khasianine, were used to analyze the expression and cellular location of NF-kappaB p65, the expression of IL-17A and IL-33, and the binding intensity of NF-kappaB p65 on the promoter of IL-17A and IL-33 to understand the molecular mechanism of Khasianine mediated anti-inflammatory effect.	khasianine	56-66	interleukin 17A	Homo sapiens	242-248
35183690-8	2022	Further studies in human keratinocytes demonstrated that Khasianine inhibited TNF-alpha-induced transcriptional activation (transactivation) of NF-kappaB p65 such as evicting NF-kappaB p65 binding from the promoter regions of IL-17A and IL-33 and preventing NF-kappaB nuclear translocation.	khasianine	57-67	interleukin 17A	Homo sapiens	226-232
34084198-9	2021	Meanwhile, treated cells with PCN G expressed decreased levels of IFN-gamma (difference = 8.0; 0.49-1.07; P = 0.001) and IL-17A (difference = 2.2; 0.05-0.75; P <= 0.05) genes comparing to unstimulated cell by PCN-G. GATA3 genes expression levels downregulated by PCN G after 72 h of incubation by PBMCs (difference = 1.1; 0.77-0.88; P = 0.035).	Pregnenolone Carbonitrile	263-266	interleukin 17A	Homo sapiens	121-127
35619309-11	2022	Treatment of dendrobine significantly reduced Foxp3, and increased the level of IL-17 in serum.	dendrobine	13-23	interleukin 17A	Homo sapiens	80-85
35148063-9	2022	After adjusting for other covariates, higher PM2.5-bound copper was significantly associated with increased levels of interleukin (IL)1beta, IL6, IL10, and IL17 levels.	Copper	57-63	interleukin 17A	Homo sapiens	156-160
35581429-10	2022	L-Selenomethionine could alleviate inflammation and abnormal apoptosis by inhibiting the IL-17/TNF-alpha/FADD axis.	Selenomethionine	0-18	interleukin 17A	Homo sapiens	89-94
35574720-7	2022	Enrichment analyses revealed that the IL-17 signaling pathway was associated with the therapeutic effects of kaempferol.	kaempferol	109-119	interleukin 17A	Homo sapiens	38-43
35580792-5	2022	Furthermore, we have previously elucidated that T-lymphocytes generate their own catecholamines, and strong associations exist between tyrosine hydroxylase (TH; the rate-limiting enzyme in the synthesis of catecholamines) and pro-inflammatory interleukin 17A (IL-17A) expression within purified T-lymphocytes in a rodent model of psychological trauma.	Catecholamines	81-95	interleukin 17A	Homo sapiens	243-258
35580792-5	2022	Furthermore, we have previously elucidated that T-lymphocytes generate their own catecholamines, and strong associations exist between tyrosine hydroxylase (TH; the rate-limiting enzyme in the synthesis of catecholamines) and pro-inflammatory interleukin 17A (IL-17A) expression within purified T-lymphocytes in a rodent model of psychological trauma.	Catecholamines	81-95	interleukin 17A	Homo sapiens	260-266
35580792-5	2022	Furthermore, we have previously elucidated that T-lymphocytes generate their own catecholamines, and strong associations exist between tyrosine hydroxylase (TH; the rate-limiting enzyme in the synthesis of catecholamines) and pro-inflammatory interleukin 17A (IL-17A) expression within purified T-lymphocytes in a rodent model of psychological trauma.	Catecholamines	206-220	interleukin 17A	Homo sapiens	243-258
35580792-5	2022	Furthermore, we have previously elucidated that T-lymphocytes generate their own catecholamines, and strong associations exist between tyrosine hydroxylase (TH; the rate-limiting enzyme in the synthesis of catecholamines) and pro-inflammatory interleukin 17A (IL-17A) expression within purified T-lymphocytes in a rodent model of psychological trauma.	Catecholamines	206-220	interleukin 17A	Homo sapiens	260-266
35580792-8	2022	RSDS characteristically increased tumor necrosis factor-alpha (TNFalpha), IL-6, IL-17A, and IL-22, however, IL-17A and IL-22 (TH17 produced cytokines) were selectively attenuated in circulation and in T-lymphocytes of THT-KO animals.	tetrahydrothiophene	218-221	interleukin 17A	Homo sapiens	108-114
35580792-9	2022	When activated ex vivo, secretion of IL-17A and IL-22 by THT-KO T-lymphocytes was also found to be reduced, but could be partially rescued with supplementation of norepinephrine specifically.	tetrahydrothiophene	57-60	interleukin 17A	Homo sapiens	37-43
35580792-9	2022	When activated ex vivo, secretion of IL-17A and IL-22 by THT-KO T-lymphocytes was also found to be reduced, but could be partially rescued with supplementation of norepinephrine specifically.	Norepinephrine	163-177	interleukin 17A	Homo sapiens	37-43
35592551-0	2022	Psoriasis Patients with Specific HLA-Cw Alleles and Lower Plasma IL-17 Level Show Improved Response to Topical Lindioil Treatment.	lindioil	111-119	interleukin 17A	Homo sapiens	65-70
35592551-8	2022	Conclusion: Our findings suggest that the presence of the HLA-Cw*06:02 or HLA-Cw*01:02 alleles and plasma IL-17 levels are predictive markers of treatment response to Lindioil ointment in patients with psoriasis.	lindioil	167-175	interleukin 17A	Homo sapiens	106-111
35603964-5	2022	By fusing the skin fibroblast membrane onto poly(lactic-co-glycolic) acid cores, these nanoparticles, termed fibroblast membrane-camouflaged nanoparticles (FNPs), are shown to effectively scavenge various profibrotic cytokines, including transforming growth factor-beta, interleukin (IL)-11, IL-13, and IL-17, thereby modulating the profibrotic microenvironment.	Polylactic Acid-Polyglycolic Acid Copolymer	44-73	interleukin 17A	Homo sapiens	303-308
35604916-13	2022	CONCLUSIONS: In the UTI- affected patients, the combination of the immune status of an individual and Ag43 status of the UPEC strain determined urine IL17 level in the analyzed group.	Tyrphostin A63	102-106	interleukin 17A	Homo sapiens	150-154
35618242-6	2022	Transcript levels of genes involved in the IL-17A, IL-1beta, MAP kinase, and NF-kappaB signaling pathways were increasingly dysregulated by PCB126 over time.	3,4,5,3',4'-pentachlorobiphenyl	140-146	interleukin 17A	Homo sapiens	43-49
35532103-0	2022	"In silico identification of ethoxy phthalimide pyrazole derivatives as IL-17A and IL-18 targeted gouty arthritis agents".	ethoxy phthalimide pyrazole	29-56	interleukin 17A	Homo sapiens	72-78
35532103-2	2022	In present study, we have combined molecular docking, molecular dynamics studies and MM-PBSA analysis to study the effectiveness of ethoxy phthalimide pyrazole derivatives (series 3a to 3e) as potential inhibitors against cytokines IL17A and IL18 as a druggable targets.	ethoxy phthalimide	132-150	interleukin 17A	Homo sapiens	232-237
35532103-4	2022	Compound 3e had the lowest binding energy with IL17A at -12.6 kcal/mol compared to control allopurinol (3.32 kcal/mol).	Allopurinol	91-102	interleukin 17A	Homo sapiens	47-52
35592501-0	2022	Retraction Notice to: FABP4 facilitates inflammasome activation to induce the Treg/Th17 imbalance in preeclampsia via forming a positive feedback with IL-17A.	treg	78-82	interleukin 17A	Homo sapiens	151-157
35218793-0	2022	Lower antidepressant response to fluoxetine is associated with anxiety-like behavior, hippocampal oxidative imbalance, and increase on peripheral IL-17 and IFN-gamma levels.	Fluoxetine	33-43	interleukin 17A	Homo sapiens	146-151
35218793-9	2022	Our findings suggest that a redox imbalance in the hippocampus, combined with increased levels of peripheral IL-17 and INF-gamma, may be involved with an impaired response to fluoxetine.	Fluoxetine	175-185	interleukin 17A	Homo sapiens	109-114
35225420-5	2022	The resulting Abetaz-linked GlcNAc is a close mimic of native N-GlcNAc and could be installed on various proteins, including IL-17A and RNase A.	Acetylglucosamine	28-34	interleukin 17A	Homo sapiens	125-131
35225420-5	2022	The resulting Abetaz-linked GlcNAc is a close mimic of native N-GlcNAc and could be installed on various proteins, including IL-17A and RNase A.	n-glcnac	62-70	interleukin 17A	Homo sapiens	125-131
35255378-7	2022	A strong positive correlation of GSS score was noted with IL-17(r = 0.7), IL-6 (r = 0.7), IL-1b (r = 0.7), and IL-33 (r = 0.6).	gss	33-36	interleukin 17A	Homo sapiens	58-63
35514988-9	2022	LPE decreased the serum levels of antibodies, immunoglobulins, and complements 4 weeks after the first replacement, with decreased levels of interleukin (IL)-17A and interferon (IFN)-gamma and increased level of IL-10.	LPC-ETHER	0-3	interleukin 17A	Homo sapiens	141-161
35528611-7	2022	Subsequently, through RNA pull-down, RNA-binding protein immunoprecipitation (RIP), and dual luciferase reporter assay, we found that STAT4-AS1 could inhibit the binding of retinoid-related orphan receptor-gammat (RORgammat) protein with an IL-17A promoter after binding with RORgammat protein.	Retinoids	173-181	interleukin 17A	Homo sapiens	241-247
35528524-8	2022	According to bioinformatics analysis, the mechanisms of KTC treatment for PCOS could be linked to IL-17 signaling route, p53 signaling pathway, HIF-1 signaling pathway, etc.	5-ethyl-4-methoxy-2-phenylquinoline	56-59	interleukin 17A	Homo sapiens	98-103
35492074-10	2022	The in vitro results demonstrated that the combination of morphine and ketamine may decrease CD4+ percentage, CD4+/CD8+ ratio, and the levels of IFN-gamma, IL-2, and IL-17 via the JAK3/STAT5 pathway.	Morphine	58-66	interleukin 17A	Homo sapiens	166-171
35492074-10	2022	The in vitro results demonstrated that the combination of morphine and ketamine may decrease CD4+ percentage, CD4+/CD8+ ratio, and the levels of IFN-gamma, IL-2, and IL-17 via the JAK3/STAT5 pathway.	Ketamine	71-79	interleukin 17A	Homo sapiens	166-171
35441257-8	2022	Nicotine elevated the expression of pro-inflammatory cytokines TNF-alpha, IL-1beta, IL-6, IL-8, and IL-17 and decreased the anti-inflammatory IL-10 in HGFs at 24 and 72 h. Boric acid at 100 ng/mL in the medium prevented the changes induced by nicotine alone.	Nicotine	0-8	interleukin 17A	Homo sapiens	100-105
35460727-9	2022	Increased uric acid levels were positively correlated with mucosal neutrophil numbers and IFN-gamma, IL-17A, IL-1beta, and IL-8 mRNA levels.	Uric Acid	10-19	interleukin 17A	Homo sapiens	101-107
35603405-14	2022	Both KEGG and GSEA analyses results indicated that IL-17 and NOD-like receptor signaling pathways were enriched in down-regulated marker genes.	gsea	14-18	interleukin 17A	Homo sapiens	51-56
35447164-8	2022	Some dietary conditions, such as high salt intake, have been shown to change the intestinal microbiome composition, stimulating the immune branch of the gut-brain axis through the production of inflammatory cytokines, such as IL-17, which can stimulate the brain immune system.	Salts	38-42	interleukin 17A	Homo sapiens	226-231
35551580-12	2022	IL-17 level was shown to be significantly correlated with TBUT(r = - 0.25, P = 0.014) and Schirmer I test (r = - 0.21, P = 0.018).	tbut	58-62	interleukin 17A	Homo sapiens	0-5
35015114-7	2022	In retinal ischemia reperfusion injury, curcumin downregulates IL-17, IL-23, NFKB, STAT-3, MCP-1 and JNK.	Curcumin	40-48	interleukin 17A	Homo sapiens	63-68
35277788-6	2022	Positive correlations were found between IL-1beta and fasting blood sugar and between creatinine levels and IL-17, HbA1c%, and sodium levels.	Creatinine	86-96	interleukin 17A	Homo sapiens	108-113
35457132-7	2022	Additionally, pretreatment with palmitic acid and leptin enhanced IL-17A-mediated c-Jun N-terminal kinase phosphorylation.	Palmitic Acid	32-45	interleukin 17A	Homo sapiens	66-72
35346673-0	2022	IL-17A Mediates Pyroptosis via ERK Pathway and Contributes to Steroid Resistance in CRSwNP.	Steroids	62-69	interleukin 17A	Homo sapiens	0-6
35437353-10	2022	KEGG pathway analysis revealed that overexpressed genes were enriched in the IL-17 and cytokine-cytokine receptor interaction pathways.	kegg	0-4	interleukin 17A	Homo sapiens	77-82
35404942-0	2022	Exposure to arsenic and level of Vitamin D influence the number of Th17 cells and production of IL-17A in human peripheral blood mononuclear cells in adults.	Arsenic	12-19	interleukin 17A	Homo sapiens	96-102
35404942-0	2022	Exposure to arsenic and level of Vitamin D influence the number of Th17 cells and production of IL-17A in human peripheral blood mononuclear cells in adults.	Vitamin D	33-42	interleukin 17A	Homo sapiens	96-102
35404942-6	2022	Likewise, UAs, DMA+3/+5 and MMA+3/+5 were associated with diminished production of IL-17A among non-smoking males.	N-myristoyl-alaninol	15-18	interleukin 17A	Homo sapiens	83-89
35404942-6	2022	Likewise, UAs, DMA+3/+5 and MMA+3/+5 were associated with diminished production of IL-17A among non-smoking males.	mma	28-31	interleukin 17A	Homo sapiens	83-89
35404942-9	2022	Collectively, we find that exposure to As via drinking water is associated with alterations in Th17 numbers and IL-17A production, and that these associations may be modified by Vitamin D status.	Arsenic	39-41	interleukin 17A	Homo sapiens	112-118
35404942-9	2022	Collectively, we find that exposure to As via drinking water is associated with alterations in Th17 numbers and IL-17A production, and that these associations may be modified by Vitamin D status.	Water	55-60	interleukin 17A	Homo sapiens	112-118
35410224-3	2022	This study aimed to assess the effect of a Th17-stimulating cytokine environment and of IL-17A-inhibition on phenotype plasticity and suppressive function of Treg derived from JIA patients.	treg	158-162	interleukin 17A	Homo sapiens	88-94
35217429-6	2022	Sperm exposed to different concentrations of IFNgamma, IL-17A and IL-1beta, or a combination of them, for either 1 or 3 h showed significantly increased levels of mitochondrial ROS production and reduced motility and viability with respect to sperm incubated with vehicle.	ros	177-180	interleukin 17A	Homo sapiens	55-61
35217429-9	2022	In conclusion, our results indicate that IFNgamma, IL-17A and IL-1beta per se impair sperm motility and decreases viability by triggering increased mitochondrial ROS production and inducing sperm apoptosis.	ros	162-165	interleukin 17A	Homo sapiens	51-57
35363433-6	2022	In the arsenic-exposed group, the upregulation of METTL3 exacerbated the increase in cytokine levels (IL-6, IL-17, and IL-10), which was associated with the upregulation of keratins (Krt1 and Krt10).	Arsenic	7-14	interleukin 17A	Homo sapiens	108-113
35480154-14	2022	The diverse TCs had distinct bacterial commensal networks, whereas the common TCs were linked by specific bacteria to serum IL-17A and TBA.	Technetium	78-81	interleukin 17A	Homo sapiens	124-130
35419071-18	2022	DHJSD treatment of AS-related pathways mainly involved the IL-17 signaling pathway, the TNF signaling pathway, and the rheumatoid arthritis signaling pathway.	dhjsd	0-5	interleukin 17A	Homo sapiens	59-64
35363433-3	2022	In human keratinocytes, arsenite increased the levels of m6 A methylation by upregulating the RNA methyltransferase like 3 (METTL3), mediating the disordered secretion of indicators that reflect inflammatory homeostasis (IL-6, IL-17, and IL-10).	arsenite	24-32	interleukin 17A	Homo sapiens	227-232
35165166-4	2022	Inhibition of P2X4 receptor with the specific antagonist 5-BDBD and small interfering RNA inhibited the development of Th17 cells and the production of IL-17 by effector Th17 cells stimulated via the CD3/CD28 pathway.	5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro(3,2-e)-1,4-diazepin-2-one	57-63	interleukin 17A	Homo sapiens	152-157
35426800-7	2022	Treatment with TPL significantly decreased the expression of circRNA 0003353, suppressed the viability and migration ability, decreased the expressions of IL-6 and IL-17, and increased the expression IL-4 in cultured RA-FLS in a time-dependent manner (P < 0.01).	triptolide	15-18	interleukin 17A	Homo sapiens	164-169
35330265-8	2022	Blood samples of 14 and 10 patients in the beta-glucan and control groups, respectively, were obtained before and after the treatment, and the enzyme-linked immunosorbent assay (ELISA) was performed to measure the serum concentration of the IL-4, IL-17, and IFN-gamma cytokines.	beta-Glucans	43-54	interleukin 17A	Homo sapiens	247-252
35099003-0	2022	Paeonol enhances treatment of fluconazole and amphotericin B against oropharyngeal candidiasis (OPC) through HIF-1alpha related IL-17 signaling.	paeonol	0-7	interleukin 17A	Homo sapiens	128-133
35099003-0	2022	Paeonol enhances treatment of fluconazole and amphotericin B against oropharyngeal candidiasis (OPC) through HIF-1alpha related IL-17 signaling.	Fluconazole	30-41	interleukin 17A	Homo sapiens	128-133
35293350-7	2022	Patients carrying AG genotype (rs2275913, IL-17A) had a significantly higher risk of steroid-dependent response (69.1% of SD VS 46.4% of SS; OR=2.58, p=0.014).	Steroids	85-92	interleukin 17A	Homo sapiens	42-48
35346673-13	2022	Moreover, IL-17A-induced pyroptosis contributes to steroid resistance by affecting glucocorticoid receptor (GR)alpha and GRbeta expression, and the inhibition of pyroptotic proteins partially abolished IL-17A-induced steroid resistance in hNECs.	Steroids	51-58	interleukin 17A	Homo sapiens	10-16
35346673-13	2022	Moreover, IL-17A-induced pyroptosis contributes to steroid resistance by affecting glucocorticoid receptor (GR)alpha and GRbeta expression, and the inhibition of pyroptotic proteins partially abolished IL-17A-induced steroid resistance in hNECs.	Steroids	217-224	interleukin 17A	Homo sapiens	10-16
35346673-13	2022	Moreover, IL-17A-induced pyroptosis contributes to steroid resistance by affecting glucocorticoid receptor (GR)alpha and GRbeta expression, and the inhibition of pyroptotic proteins partially abolished IL-17A-induced steroid resistance in hNECs.	Steroids	217-224	interleukin 17A	Homo sapiens	202-208
35372072-11	2022	Network pharmacological results showed that the active ingredient luteolin, quercetin, licochalcone a, and kaempferol and the effective targets prostaglandin-endoperoxide synthase 2 (PTGS2), matrix metallopeptidase 9 (MMP9), and C-C motif chemokine ligand 2 (CCL2) were related to the interleukin-17 (IL-17) and tumor necrosis factor (TNF) pathway.	Quercetin	76-85	interleukin 17A	Homo sapiens	285-299
35372072-11	2022	Network pharmacological results showed that the active ingredient luteolin, quercetin, licochalcone a, and kaempferol and the effective targets prostaglandin-endoperoxide synthase 2 (PTGS2), matrix metallopeptidase 9 (MMP9), and C-C motif chemokine ligand 2 (CCL2) were related to the interleukin-17 (IL-17) and tumor necrosis factor (TNF) pathway.	Quercetin	76-85	interleukin 17A	Homo sapiens	301-306
35372072-11	2022	Network pharmacological results showed that the active ingredient luteolin, quercetin, licochalcone a, and kaempferol and the effective targets prostaglandin-endoperoxide synthase 2 (PTGS2), matrix metallopeptidase 9 (MMP9), and C-C motif chemokine ligand 2 (CCL2) were related to the interleukin-17 (IL-17) and tumor necrosis factor (TNF) pathway.	licochalcone A	87-101	interleukin 17A	Homo sapiens	285-299
35372072-11	2022	Network pharmacological results showed that the active ingredient luteolin, quercetin, licochalcone a, and kaempferol and the effective targets prostaglandin-endoperoxide synthase 2 (PTGS2), matrix metallopeptidase 9 (MMP9), and C-C motif chemokine ligand 2 (CCL2) were related to the interleukin-17 (IL-17) and tumor necrosis factor (TNF) pathway.	licochalcone A	87-101	interleukin 17A	Homo sapiens	301-306
35372072-11	2022	Network pharmacological results showed that the active ingredient luteolin, quercetin, licochalcone a, and kaempferol and the effective targets prostaglandin-endoperoxide synthase 2 (PTGS2), matrix metallopeptidase 9 (MMP9), and C-C motif chemokine ligand 2 (CCL2) were related to the interleukin-17 (IL-17) and tumor necrosis factor (TNF) pathway.	kaempferol	107-117	interleukin 17A	Homo sapiens	285-299
35372072-11	2022	Network pharmacological results showed that the active ingredient luteolin, quercetin, licochalcone a, and kaempferol and the effective targets prostaglandin-endoperoxide synthase 2 (PTGS2), matrix metallopeptidase 9 (MMP9), and C-C motif chemokine ligand 2 (CCL2) were related to the interleukin-17 (IL-17) and tumor necrosis factor (TNF) pathway.	kaempferol	107-117	interleukin 17A	Homo sapiens	301-306
35372072-15	2022	Luteolin and quercetin may be the core active ingredients of QYSLS in the treatment of EGFRI-related adverse skin reactions, and their therapeutic effects are potentially mediated through PTGS2, CCL2, and MMP9 in the IL-17 and TNF signaling pathway.	Luteolin	0-8	interleukin 17A	Homo sapiens	217-222
35372072-15	2022	Luteolin and quercetin may be the core active ingredients of QYSLS in the treatment of EGFRI-related adverse skin reactions, and their therapeutic effects are potentially mediated through PTGS2, CCL2, and MMP9 in the IL-17 and TNF signaling pathway.	Quercetin	13-22	interleukin 17A	Homo sapiens	217-222
35350754-11	2022	Furthermore, bioenrichment analysis revealed that the TNF signaling pathway and IL-17 signaling pathway may be potential key pathways for baicalin to treat CS.	baicalin	138-146	interleukin 17A	Homo sapiens	80-85
35099003-0	2022	Paeonol enhances treatment of fluconazole and amphotericin B against oropharyngeal candidiasis (OPC) through HIF-1alpha related IL-17 signaling.	Amphotericin B	46-60	interleukin 17A	Homo sapiens	128-133
35099003-10	2022	Meanwhile, compared with the infected EC109 cells treated with a single drug, PAE plus FLU or AmB significantly inhibited the mRNA and protein expression of HIF-1alpha, IL-17A, and IL-23.	Amphotericin B	94-97	interleukin 17A	Homo sapiens	169-175
35099003-11	2022	Taken together, the possible mechanism of PAE plus FLU or AmB can be attributed to the regulation of hypoxia-associated IL-17 signaling in OPC treatment.	Amphotericin B	58-61	interleukin 17A	Homo sapiens	120-125
35218301-12	2022	CONCLUSION: Vitamin D maybe an alternative to acitretin in the treatment of congenital ichthyosis where it reduces the expression of RORgammat and IL-17.	Vitamin D	12-21	interleukin 17A	Homo sapiens	147-152
35218301-12	2022	CONCLUSION: Vitamin D maybe an alternative to acitretin in the treatment of congenital ichthyosis where it reduces the expression of RORgammat and IL-17.	Acitretin	46-55	interleukin 17A	Homo sapiens	147-152
35080634-7	2022	RESULTS: We found that chronic clozapine treatment in patients with schizophrenia resulted in the abnormal expression of serum cytokines, such as IL-2, IL-6, IL-17, and TNF-alpha, compared with the healthy controls.	Clozapine	31-40	interleukin 17A	Homo sapiens	158-163
35166073-4	2022	METHODS: IL-17A production from 5 sorted peripheral blood cell populations, namely MAITs, gammadelta T-cells, CD4+T-cells, CD8+T-cells and neutrophils was evaluated pre- and post-stimulation with PMA, the calcium ionophore A23187 and beta1,3 glucan.	Tetradecanoylphorbol Acetate	196-199	interleukin 17A	Homo sapiens	9-15
35152822-5	2022	The findings showed that H-GA significantly inhibited expression of interleukin 17 A in the dermis, and interleukin IL-23 in the epidermis, compared with Cur raw drug powder (RDP), whereas L-GA had no significant effect on the expression.	h-ga	25-29	interleukin 17A	Homo sapiens	68-84
35225298-9	2022	Curcumin-treated groups, with and without PZQ, resulted in higher significant Immunoreactivity score (IRS) for Bcl-2-associated X (BAX) and lower Interleukine- 17A (IL-17A), and Human epidermal growth factor (EGF), compared to the control.	Curcumin	0-8	interleukin 17A	Homo sapiens	146-163
35225298-9	2022	Curcumin-treated groups, with and without PZQ, resulted in higher significant Immunoreactivity score (IRS) for Bcl-2-associated X (BAX) and lower Interleukine- 17A (IL-17A), and Human epidermal growth factor (EGF), compared to the control.	Curcumin	0-8	interleukin 17A	Homo sapiens	165-171
35225298-9	2022	Curcumin-treated groups, with and without PZQ, resulted in higher significant Immunoreactivity score (IRS) for Bcl-2-associated X (BAX) and lower Interleukine- 17A (IL-17A), and Human epidermal growth factor (EGF), compared to the control.	Praziquantel	42-45	interleukin 17A	Homo sapiens	146-163
35225298-9	2022	Curcumin-treated groups, with and without PZQ, resulted in higher significant Immunoreactivity score (IRS) for Bcl-2-associated X (BAX) and lower Interleukine- 17A (IL-17A), and Human epidermal growth factor (EGF), compared to the control.	Praziquantel	42-45	interleukin 17A	Homo sapiens	165-171
35225298-10	2022	However, PZQ revealed a lower mean IRS value in BAX, higher IL-17A and EGF in the periovulatory granuloma.	Praziquantel	9-12	interleukin 17A	Homo sapiens	60-66
35270196-3	2022	These include antipsoriatic activities which we demonstrated in silico by modelling the interaction of apiin, guanosine and hyperoside, a few main river plant metabolites, with NF-kB, IL-17 and IL-36, which are recognized targets involved in psoriasis disease.	apiin	103-108	interleukin 17A	Homo sapiens	184-189
35270196-3	2022	These include antipsoriatic activities which we demonstrated in silico by modelling the interaction of apiin, guanosine and hyperoside, a few main river plant metabolites, with NF-kB, IL-17 and IL-36, which are recognized targets involved in psoriasis disease.	Guanosine	110-119	interleukin 17A	Homo sapiens	184-189
35270196-3	2022	These include antipsoriatic activities which we demonstrated in silico by modelling the interaction of apiin, guanosine and hyperoside, a few main river plant metabolites, with NF-kB, IL-17 and IL-36, which are recognized targets involved in psoriasis disease.	hyperoside	124-134	interleukin 17A	Homo sapiens	184-189
35166073-4	2022	METHODS: IL-17A production from 5 sorted peripheral blood cell populations, namely MAITs, gammadelta T-cells, CD4+T-cells, CD8+T-cells and neutrophils was evaluated pre- and post-stimulation with PMA, the calcium ionophore A23187 and beta1,3 glucan.	Calcium	205-212	interleukin 17A	Homo sapiens	9-15
35166073-4	2022	METHODS: IL-17A production from 5 sorted peripheral blood cell populations, namely MAITs, gammadelta T-cells, CD4+T-cells, CD8+T-cells and neutrophils was evaluated pre- and post-stimulation with PMA, the calcium ionophore A23187 and beta1,3 glucan.	Calcimycin	223-229	interleukin 17A	Homo sapiens	9-15
35166073-4	2022	METHODS: IL-17A production from 5 sorted peripheral blood cell populations, namely MAITs, gammadelta T-cells, CD4+T-cells, CD8+T-cells and neutrophils was evaluated pre- and post-stimulation with PMA, the calcium ionophore A23187 and beta1,3 glucan.	Glucans	242-248	interleukin 17A	Homo sapiens	9-15
35103990-4	2022	Prior studies have linked the cyclooxygenase 2 (COX2)-driven prostaglandin E2 (PGE2) pathway to IL-17 expression.	Dinoprostone	61-77	interleukin 17A	Homo sapiens	96-101
35103990-4	2022	Prior studies have linked the cyclooxygenase 2 (COX2)-driven prostaglandin E2 (PGE2) pathway to IL-17 expression.	Dinoprostone	79-83	interleukin 17A	Homo sapiens	96-101
35103990-5	2022	Here, we report that an immune-activating PDT regimen (imPDT) induces COX2/PGE2 expression in TDLNs, whereby IL-17 expression is facilitated without corresponding effects on the expression of RORgammat, the transcriptional driver of the canonical IL-17 pathway.	Dinoprostone	75-79	interleukin 17A	Homo sapiens	109-114
35103990-6	2022	Pharmacologic inhibition with NS398, a COX2 inhibitor, was utilized to demonstrate that imPDT-induced COX2 regulates RORgammat-independent expression of IL-17 by B cells and neutrophil entry into TDLNs.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	30-35	interleukin 17A	Homo sapiens	153-158
35072213-6	2022	RESULTS: Azithromycin decreased the secretion of interleukin (IL) 4, IL-5, IL-13, and IL-17A from PBMCs, as well as the production of IL-4 and IL-8 by CD4+ and CD8+ T cells.	Azithromycin	9-21	interleukin 17A	Homo sapiens	86-92
35140700-13	2021	Both frequencies of mono-sialylated and disialylated N-glycans were increased by IL-21 and IL-17A with decreased frequency of asialylation, and the expression of beta-galactoside alpha-2,6-sialyltransferase 1 was upregulated by IL-21 and IL-17A.	n-glycans	53-62	interleukin 17A	Homo sapiens	91-97
35140700-13	2021	Both frequencies of mono-sialylated and disialylated N-glycans were increased by IL-21 and IL-17A with decreased frequency of asialylation, and the expression of beta-galactoside alpha-2,6-sialyltransferase 1 was upregulated by IL-21 and IL-17A.	n-glycans	53-62	interleukin 17A	Homo sapiens	238-244
34843183-2	2022	In preclinical studies, spironolactone suppresses pro-hypertensive interleukin 17A (IL-17A).	Spironolactone	24-38	interleukin 17A	Homo sapiens	67-82
34843183-2	2022	In preclinical studies, spironolactone suppresses pro-hypertensive interleukin 17A (IL-17A).	Spironolactone	24-38	interleukin 17A	Homo sapiens	84-90
34843183-4	2022	We tested the hypothesis that spironolactone-induced antihypertensive effects are associated with suppression of IL-17A and related cytokines.	Spironolactone	30-44	interleukin 17A	Homo sapiens	113-119
35291613-7	2022	Results: A significant relationship was detected between IL-2 (p< 0.001), IL-17 (p< 0.001) levels and serum creatinine concentrations.	Creatinine	108-118	interleukin 17A	Homo sapiens	74-79
35291613-8	2022	The significant increase of IL-2 and IL-17 levels were also paralleled with a significant increase in serum urea (p< 0.001), and urine albumin (p< 0.001) concentrations respectively.	Urea	108-112	interleukin 17A	Homo sapiens	37-42
35291613-10	2022	The significant increase of IL-2 and IL-17 is associated with significantly high concentrations of creatinine, serum urea and urine albumin suggesting that these interleukins may be used as targets for future biomarkers and molecular therapy.	Creatinine	99-109	interleukin 17A	Homo sapiens	37-42
35291613-10	2022	The significant increase of IL-2 and IL-17 is associated with significantly high concentrations of creatinine, serum urea and urine albumin suggesting that these interleukins may be used as targets for future biomarkers and molecular therapy.	Urea	117-121	interleukin 17A	Homo sapiens	37-42
35072213-7	2022	The combination of azithromycin and budesonide suppressed inflammatory response by inhibition of IL-4, IL-5, IL-8, IL-13, IL-17A, IL-33, thymic stromal lymphopoietin (TSLP), macrophage migration inhibitory factor (MIF) release from PBMCs and by reduction of the percentage of IL-4-, IL-8-, interferon gamma- and tumor necrosis factor a-expressing CD4+ and CD8+ T cells.	Budesonide	36-46	interleukin 17A	Homo sapiens	122-128
35072213-8	2022	The inhibitory effect of azithromycin combined with budesonide on IL-4, IL-5, IL-8, IL-17A, TSLP production by PBMCs, as well as IL-4 and IL-8 production by T helper cells and cytotoxic T lymphocytes was significantly greater than the effect of budesonide alone.	Azithromycin	25-37	interleukin 17A	Homo sapiens	84-90
35072213-8	2022	The inhibitory effect of azithromycin combined with budesonide on IL-4, IL-5, IL-8, IL-17A, TSLP production by PBMCs, as well as IL-4 and IL-8 production by T helper cells and cytotoxic T lymphocytes was significantly greater than the effect of budesonide alone.	Budesonide	52-62	interleukin 17A	Homo sapiens	84-90
35064870-3	2022	The results show that arsenic can induce the hypermethylation of 6 sites in the Foxp3 promoter by upregulating the expression of recombinant DNA Methyltransferase 1 (Dnmt1) mRNA, leading to the downregulation of Foxp3 mRNA, Tregs, and interleukin 10 (IL-10, anti-inflammatory cytokine) levels, and increased the levels of interleukin 17 (IL-17, pro-inflammatory cytokine) in the peripheral blood of patients with arsenic poisoning.	Arsenic	22-29	interleukin 17A	Homo sapiens	322-336
35064870-3	2022	The results show that arsenic can induce the hypermethylation of 6 sites in the Foxp3 promoter by upregulating the expression of recombinant DNA Methyltransferase 1 (Dnmt1) mRNA, leading to the downregulation of Foxp3 mRNA, Tregs, and interleukin 10 (IL-10, anti-inflammatory cytokine) levels, and increased the levels of interleukin 17 (IL-17, pro-inflammatory cytokine) in the peripheral blood of patients with arsenic poisoning.	Arsenic	22-29	interleukin 17A	Homo sapiens	338-343
35127485-0	2021	Neutralizing Anti-IL-17A Antibody Demonstrates Preclinical Activity Enhanced by Vinblastine in Langerhans Cell Histiocytosis.	Vinblastine	80-91	interleukin 17A	Homo sapiens	18-24
35127485-9	2021	Interestingly, the in vitro combination of low-dose vinblastine with neutralizing anti-IL-17A antibodies killed Mo-DCs from LCH patients.	Vinblastine	52-63	interleukin 17A	Homo sapiens	87-93
35042454-13	2022	KEGG enrichment analysis and GSEA revealed that the estrogen and IL-17 signaling pathways were significantly upregulated in the high S100A2 expression group, in which estrogen response, JAK-STAT3, K-Ras, and TNFalpha/NF-kappaB were differentially enriched.	gsea	29-33	interleukin 17A	Homo sapiens	65-70
35087596-13	2022	Finally, we found wogonin, the key compound in SMS, might play a pivotal role on Toll-like receptor, IL-17, TNF, osteoclast differentiation, and apoptosis signaling pathways through interacting with four key targets.	wogonin	18-25	interleukin 17A	Homo sapiens	101-106
35054851-2	2022	This study aimed to clarify the role of the beta2-adrenoreceptor in the norepinephrine-mediated modulation of interleukin-17 (IL-17) and interferon-gamma (IFN-gamma) production, which play a critical pathogenetic role in MS. CD4+ T cells obtained from twenty-five relapsing-remitting MS patients and sixteen healthy subjects were cultured ex vivo with norepinephrine and/or beta2-adrenoreceptor antagonist or agonist, followed by a cytokine production analysis using ELISA.	Norepinephrine	72-86	interleukin 17A	Homo sapiens	110-124
35054851-2	2022	This study aimed to clarify the role of the beta2-adrenoreceptor in the norepinephrine-mediated modulation of interleukin-17 (IL-17) and interferon-gamma (IFN-gamma) production, which play a critical pathogenetic role in MS. CD4+ T cells obtained from twenty-five relapsing-remitting MS patients and sixteen healthy subjects were cultured ex vivo with norepinephrine and/or beta2-adrenoreceptor antagonist or agonist, followed by a cytokine production analysis using ELISA.	Norepinephrine	72-86	interleukin 17A	Homo sapiens	126-131
35054851-2	2022	This study aimed to clarify the role of the beta2-adrenoreceptor in the norepinephrine-mediated modulation of interleukin-17 (IL-17) and interferon-gamma (IFN-gamma) production, which play a critical pathogenetic role in MS. CD4+ T cells obtained from twenty-five relapsing-remitting MS patients and sixteen healthy subjects were cultured ex vivo with norepinephrine and/or beta2-adrenoreceptor antagonist or agonist, followed by a cytokine production analysis using ELISA.	Norepinephrine	352-366	interleukin 17A	Homo sapiens	110-124
35054851-2	2022	This study aimed to clarify the role of the beta2-adrenoreceptor in the norepinephrine-mediated modulation of interleukin-17 (IL-17) and interferon-gamma (IFN-gamma) production, which play a critical pathogenetic role in MS. CD4+ T cells obtained from twenty-five relapsing-remitting MS patients and sixteen healthy subjects were cultured ex vivo with norepinephrine and/or beta2-adrenoreceptor antagonist or agonist, followed by a cytokine production analysis using ELISA.	Norepinephrine	352-366	interleukin 17A	Homo sapiens	126-131
35054851-3	2022	Norepinephrine suppressed IL-17 and IFN-gamma production by the anti-CD3/anti-CD28-microbead-stimulated CD4+ T cells in both groups.	Norepinephrine	0-14	interleukin 17A	Homo sapiens	26-31
35054851-4	2022	Blockade of the beta2-adrenoreceptor with the specific antagonist ICI 118.551 enhanced norepinephrine-mediated IL-17 suppression but decreased its inhibitory effect on IFN-gamma production in MS patients.	Norepinephrine	87-101	interleukin 17A	Homo sapiens	111-116
35054851-8	2022	These data illustrate the inhibitory effect of norepinephrine on IL-17 and IFN-gamma production by CD4+ T cells in MS.	Norepinephrine	47-61	interleukin 17A	Homo sapiens	65-70
35006038-0	2022	Dihydroartemisinin targets fibroblast growth factor receptor 1 (FGFR1) to inhibit interleukin 17A (IL-17A)-induced hyperproliferation and inflammation of keratinocytes.	artenimol	0-18	interleukin 17A	Homo sapiens	82-97
35006038-0	2022	Dihydroartemisinin targets fibroblast growth factor receptor 1 (FGFR1) to inhibit interleukin 17A (IL-17A)-induced hyperproliferation and inflammation of keratinocytes.	artenimol	0-18	interleukin 17A	Homo sapiens	99-105
35006038-8	2022	The results showed that DHA obviously inhibited IL-17A-induced hyperproliferation, migration and expression of inflammatory factors in HaCaT cells.	artenimol	24-27	interleukin 17A	Homo sapiens	48-54
35006038-9	2022	Furthermore, FGFR1 was highly expressed in IL-17A-induced HaCaT cells, and DHA inhibited its expression.	artenimol	75-78	interleukin 17A	Homo sapiens	43-49
35006038-10	2022	However, the inhibitory effect of DHA on IL-17A-induced HaCaT cells was reversed after the addition of FGFR1 agonist.	artenimol	34-37	interleukin 17A	Homo sapiens	41-47
35006038-11	2022	In conclusion, DHA could inhibit IL-17A-induced hyperproliferation and inflammation of keratinocytes by targeting FGFR1, which also provided a new target for the treatment of psoriasis.	artenimol	15-18	interleukin 17A	Homo sapiens	33-39
35072213-7	2022	The combination of azithromycin and budesonide suppressed inflammatory response by inhibition of IL-4, IL-5, IL-8, IL-13, IL-17A, IL-33, thymic stromal lymphopoietin (TSLP), macrophage migration inhibitory factor (MIF) release from PBMCs and by reduction of the percentage of IL-4-, IL-8-, interferon gamma- and tumor necrosis factor a-expressing CD4+ and CD8+ T cells.	Azithromycin	19-31	interleukin 17A	Homo sapiens	122-128
33968184-3	2021	The potential effect of apatinib on IL-17 expression levels in the development of gastric carcinoma has been rarely reported.	apatinib	24-32	interleukin 17A	Homo sapiens	36-41
34000471-3	2021	Fluoxetine and 5-HT suppressed IL-17, IFN-gamma and GM-CSF production by stimulated SD4+ T-cells in both groups.	Fluoxetine	0-10	interleukin 17A	Homo sapiens	31-36
34000471-3	2021	Fluoxetine and 5-HT suppressed IL-17, IFN-gamma and GM-CSF production by stimulated SD4+ T-cells in both groups.	Serotonin	15-19	interleukin 17A	Homo sapiens	31-36
33968184-0	2021	Apatinib inhibits gastric carcinoma development by regulating the expression levels of IL-17 via the Bax/Bcl-2 signaling pathway.	apatinib	0-8	interleukin 17A	Homo sapiens	87-92
33968184-11	2021	Conversely, apatinib treatment significantly inhibited the proliferative and invasive abilities of HGC-27 cells, but promoted cell apoptosis in the IL-17 and IL-17-apatinib groups..	apatinib	12-20	interleukin 17A	Homo sapiens	148-153
33968184-11	2021	Conversely, apatinib treatment significantly inhibited the proliferative and invasive abilities of HGC-27 cells, but promoted cell apoptosis in the IL-17 and IL-17-apatinib groups..	apatinib	12-20	interleukin 17A	Homo sapiens	158-163
33968184-11	2021	Conversely, apatinib treatment significantly inhibited the proliferative and invasive abilities of HGC-27 cells, but promoted cell apoptosis in the IL-17 and IL-17-apatinib groups..	apatinib	164-172	interleukin 17A	Homo sapiens	158-163
33968184-13	2021	The findings indicated that apatinib may inhibit gastric carcinoma development by regulating IL-17 expression via the Bax/Bcl-2 signaling pathway.	apatinib	28-36	interleukin 17A	Homo sapiens	93-98
34040108-4	2021	JNJ-61803534 inhibited IL-17A production in human CD4+ T cells under Th17 differentiation conditions, but did not inhibit IFNgamma production under Th1 differentiation conditions, and had no impact on in vitro differentiation of regulatory T cells (Treg), nor on the suppressive activity of natural Tregs.	jnj-61803534	0-12	interleukin 17A	Homo sapiens	23-29
34058750-7	2021	The analysis indicated that quercetin could inhibit cytokines release, alleviate excessive immune responses and eliminate inflammation, through NF-kappaB, IL-17 and Toll-like receptor signaling pathway.	Quercetin	28-37	interleukin 17A	Homo sapiens	155-160
34022896-15	2021	CONCLUSION: These data strongly suggest that both IL-17 and IL-22 are required for Th2-low endotype associated biology and that a RORgammat inhibitor may provide improved clinical benefit in a severe asthma sub-population of patients by blocking both IL-17 and IL-22 biology compared with blocking IL-17 alone.	th2	83-86	interleukin 17A	Homo sapiens	50-55
34044769-8	2021	However, when glycyrrhizin was added at the same time, the proliferation of IL-17A-HaCaT cells increased, and the expression of STAT3, p-STAT3, and a-STAT3 reduced.	Glycyrrhizic Acid	14-26	interleukin 17A	Homo sapiens	76-82
34044769-10	2021	CONCLUSIONS: Together, these results indicated that glycyrrhizin improved psoriasis by inhibiting the expression of IL-17A and IFN-gamma in vivo and suppressed the proliferation of IL-17A-HaCaT cells and the expression of STAT3, p-STAT3, and a-STAT3 by upregulating SIRT1 in vitro.	Glycyrrhizic Acid	52-64	interleukin 17A	Homo sapiens	116-122
34044769-10	2021	CONCLUSIONS: Together, these results indicated that glycyrrhizin improved psoriasis by inhibiting the expression of IL-17A and IFN-gamma in vivo and suppressed the proliferation of IL-17A-HaCaT cells and the expression of STAT3, p-STAT3, and a-STAT3 by upregulating SIRT1 in vitro.	Glycyrrhizic Acid	52-64	interleukin 17A	Homo sapiens	181-187
33999692-8	2021	Celastrol treatment inhibited the production of both IL-23 and IL-17 in PBMCs of SO patients in a dose-dependent manner.	celastrol	0-9	interleukin 17A	Homo sapiens	63-68
33999692-9	2021	In PBMCs isolated from SO patients and healthy controls, the administration of recombinant human IL-23 (rIL-23) enhanced the production of IL-17, which was then suppressed by co-stimulation with celastrol.	celastrol	195-204	interleukin 17A	Homo sapiens	139-144
33999692-11	2021	Conclusions: Celastrol can reduce the production of IL-17 in PBMCs of SO patients.	celastrol	13-22	interleukin 17A	Homo sapiens	52-57
33982373-7	2022	The results showed that butyrate could significantly reduce pro-inflammatory cytokines (IL-17A, IFN-gamma, TNF- alpha) in the ileum and colon while promoting IL-10 expression in the colon.	Butyrates	24-32	interleukin 17A	Homo sapiens	88-94
34054818-7	2021	The adjuvant dmLT significantly enhanced SEB- and PHA-induced IL-17A, but not IFN-gamma responses, in PBMCs from both infants and adults.	dmlt	13-17	interleukin 17A	Homo sapiens	62-68
34054553-11	2021	However, inflammation-associated genes induced by TNF/IL17 were attenuated at low oxygen concentration.	Oxygen	82-88	interleukin 17A	Homo sapiens	54-58
34025642-10	2021	In vitro studies, hyperforin reduced the expression and secretion of IL-17A in gammadelta T cells, and suppressed the activation of MAPK/STAT3 pathways in human keratinocyte HaCaT cells and gammadelta T cells.	hyperforin	18-28	interleukin 17A	Homo sapiens	69-75
33125075-8	2021	Particularly, robust release of IL-17 suggested that these early developing tissue-type MCTCs could play a central role in tumor immunity.	mctcs	88-93	interleukin 17A	Homo sapiens	32-37
33556876-0	2021	The suppression of IL-17 production from T cells by gallate-type procyanidin is mediated by selectively inhibiting cytokine production from dendritic cells.	procyanidin	65-76	interleukin 17A	Homo sapiens	19-24
33516071-16	2021	The gene enrichment analysis implied that TP and Levofloxacin probably benefited patients with HPS by modulating pathways associated with the AGE-RAGE signaling pathway, the TNF signaling pathway, the HIF-1 signaling pathway, the VEGF signaling pathway, and the IL-17 signaling pathway, Rheumatoid arthritis, Fluid shear stress, and atherosclerosis.	tp	42-44	interleukin 17A	Homo sapiens	262-267
33516071-16	2021	The gene enrichment analysis implied that TP and Levofloxacin probably benefited patients with HPS by modulating pathways associated with the AGE-RAGE signaling pathway, the TNF signaling pathway, the HIF-1 signaling pathway, the VEGF signaling pathway, and the IL-17 signaling pathway, Rheumatoid arthritis, Fluid shear stress, and atherosclerosis.	Levofloxacin	49-61	interleukin 17A	Homo sapiens	262-267
33556876-3	2021	Procyanidin B2 3,3""-di-O-gallate (PCB2DG) contained in grape seeds markedly suppressed interleukin (IL)-17 production from spleen cells but not CD4+ T cells.	procyanidin B2-3,3'-di-O-gallate	0-33	interleukin 17A	Homo sapiens	88-107
33556876-3	2021	Procyanidin B2 3,3""-di-O-gallate (PCB2DG) contained in grape seeds markedly suppressed interleukin (IL)-17 production from spleen cells but not CD4+ T cells.	procyanidin B2-3,3'-di-O-gallate	35-41	interleukin 17A	Homo sapiens	88-107
33556876-4	2021	The aim of this study was to elucidate the mechanisms by which PCB2DG suppresses IL-17.	procyanidin B2-3,3'-di-O-gallate	63-69	interleukin 17A	Homo sapiens	81-86
33556876-5	2021	Our results showed that PCB2DG suppressed the production of IL-17, tumor necrosis factor (TNF)-alpha, IL-1beta, and IL-6 with the suppression of transcription factors expression.	procyanidin B2-3,3'-di-O-gallate	24-30	interleukin 17A	Homo sapiens	60-65
33556876-8	2021	These results suggested that PCB2DG first modulated TNF-alpha production by CD4+ T cells and then suppressed IL-1beta secretion from DCs, resulting in decreased IL-17 production.	procyanidin B2-3,3'-di-O-gallate	29-35	interleukin 17A	Homo sapiens	161-166
32955700-9	2021	CONCLUSION: Serum IL-1beta, IL-6, and IL-17A serve as indicators for predicting clinical response to celecoxib in AS patients, which may assist with the optimization of personalized treatment.	Celecoxib	101-110	interleukin 17A	Homo sapiens	38-44
33908659-6	2021	The DM-AMI group showed the highest expression levels of TANK-binding kinase 1 (TBK1), hypoxia-inducible factor 1alpha (HIF-1alpha), and interleukin (IL)-17 and the lowest expression level of IL-10, followed by the non-DM-AMI group and the SCHD group (P < .05).	dm-ami	4-10	interleukin 17A	Homo sapiens	137-156
33908659-7	2021	THP-1 cell studies showed that BAY87-2243 (a HIF-1alpha inhibitor) reversed the increase in IL-17 and decrease in IL-10 expression induced by hyperglycemia.	1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine	31-41	interleukin 17A	Homo sapiens	92-97
32955700-0	2021	Interleukin-1beta, interleukin-6, and interleukin-17A as indicators reflecting clinical response to celecoxib in ankylosing spondylitis patients.	Celecoxib	100-109	interleukin 17A	Homo sapiens	38-53
33611057-0	2021	Indirubin attenuates IL-17A-induced CCL20 expression and production in keratinocytes through repressing TAK1 signaling pathway.	indirubin	0-9	interleukin 17A	Homo sapiens	21-27
33611057-7	2021	Indirubin treatment strongly inhibited CCL20 expression and secretion in IL-17A stimulated HaCaT cells.	indirubin	0-9	interleukin 17A	Homo sapiens	73-79
33475942-5	2021	IFN-beta-induced STAT1 phosphorylation/dephosphorylation levels and PMA/ionomycin-stimulated intracellular IL-17A/IFN-gamma production in CD4+ T cells were evaluated.	Ionomycin	72-81	interleukin 17A	Homo sapiens	107-113
33191068-10	2021	KEGG pathway analysis enrichment revealed two pathways: signaling pathway- IL-17 and signaling pathway- TNF.	kegg	0-4	interleukin 17A	Homo sapiens	75-80
33617042-0	2021	First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis.	cjm112	109-115	interleukin 17A	Homo sapiens	82-88
33899926-5	2021	Tofacitinib down-regulated inflammatory cytokines by stimulated B (IL-6 and TNF-alpha) and T (IFN-gamma, IL-17, or TNF-alpha) cells in the short term while a significant reduction of IL-17 and IL-6 levels in PBMC supernatant was also observed.	tofacitinib	0-11	interleukin 17A	Homo sapiens	105-110
33995403-3	2021	Further, parallel pathways of induction of IL-17-producing cells with Th9 phenotype have to be distinguished from exclusively Th9-inductive mechanisms.	TH9	70-73	interleukin 17A	Homo sapiens	43-48
33899926-5	2021	Tofacitinib down-regulated inflammatory cytokines by stimulated B (IL-6 and TNF-alpha) and T (IFN-gamma, IL-17, or TNF-alpha) cells in the short term while a significant reduction of IL-17 and IL-6 levels in PBMC supernatant was also observed.	tofacitinib	0-11	interleukin 17A	Homo sapiens	183-188
33038226-8	2021	Monocytes exposed to high salt stimulated IL-17A production from autologous CD4+ and CD8+ T cells.	Salts	26-30	interleukin 17A	Homo sapiens	42-48
33981320-0	2021	gammadelta T/Interleukin-17A Contributes to the Effect of Maresin Conjugates in Tissue Regeneration 1 on Lipopolysaccharide-Induced Cardiac Injury.	7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid	58-65	interleukin 17A	Homo sapiens	13-28
33849528-9	2021	Additionally, the results clarified that ICA significantly inhibited the migration, invasion capacity, and expression levels of TGF-beta1, TNF-alpha, IL-6, IL-17A, IL-10 in SiHa cells.	icariin	41-44	interleukin 17A	Homo sapiens	156-162
33871822-7	2021	We further showed that the catecholaminergic neurotransmitter norepinephrine exerted a pro-inflammatory function by enhancing the expression of IL-17 cytokines.	Norepinephrine	62-76	interleukin 17A	Homo sapiens	144-149
33508280-9	2021	In addition, COP treatment remarkably suppressed the levels of colonic myeloperoxidase (MPO), adhesion molecules and pro-inflammatory cytokines (TNF-alpha, IFN-gamma, IL-1beta, IL-6 and IL-17), while enhanced IL-10 and TGF-beta.	coptisine	13-16	interleukin 17A	Homo sapiens	186-191
33835051-0	2021	Clinical effects of ursodeoxycholic acid on patients with ulcerative colitis may improve via the regulation of IL-23-IL-17 axis and the changes of the proportion of intestinal microflora.	Ursodeoxycholic Acid	20-40	interleukin 17A	Homo sapiens	117-122
33835051-6	2021	At post-treatment week 4, IL-23 and IL-17 levels were significantly lower in the UDCA + Mesalazine group compared to those in the Mesalazine group (both P < 0.038).	Mesalamine	88-98	interleukin 17A	Homo sapiens	36-41
33835051-6	2021	At post-treatment week 4, IL-23 and IL-17 levels were significantly lower in the UDCA + Mesalazine group compared to those in the Mesalazine group (both P < 0.038).	Ursodeoxycholic Acid	81-85	interleukin 17A	Homo sapiens	36-41
33639176-7	2021	Baricitinib did modulate other soluble factors besides IFN-gamma, significantly decreasing the spike-specific-response mediated by IL-17, IL-1beta, IL-6, TNF-alpha, IL-4, IL-13, IL-1ra, IL-10, GM-CSF, FGF, IP-10, MCP-1, MIP-1beta (p <= 0.0156).	baricitinib	0-11	interleukin 17A	Homo sapiens	131-136
33835051-9	2021	Conclusion: Additional UDCA could provide better therapeutic effects than mesalazine alone, possibly due to the change of IL-23 and IL-17 and the proportional distribution of intestinal microflora.	Ursodeoxycholic Acid	23-27	interleukin 17A	Homo sapiens	132-137
33996256-0	2021	FABP4 facilitates inflammasome activation to induce the Treg/Th17 imbalance in preeclampsia via forming a positive feedback with IL-17A.	treg	56-60	interleukin 17A	Homo sapiens	129-135
33996256-0	2021	FABP4 facilitates inflammasome activation to induce the Treg/Th17 imbalance in preeclampsia via forming a positive feedback with IL-17A.	th17	61-65	interleukin 17A	Homo sapiens	129-135
33996256-10	2021	In conclusion, FABP4 facilitates inflammasome activation to induce the imbalance of Treg/Th17 in PE via forming a positive feedback with IL-17A.	treg	84-88	interleukin 17A	Homo sapiens	137-143
33179273-8	2021	Further investigation demonstrated that interleukin (IL)-17 and tumor necrosis factor (TNF)-alpha exerted synergistic effects in airway epithelial cells by upregulating the expression of six transmembrane epithelial antigens of prostate 4 (STEAP4), a metalloreductase that reduces extracellular copper ions from the cupric state to the cuprous state and facilitates copper uptake.	Copper	295-301	interleukin 17A	Homo sapiens	40-59
33179273-8	2021	Further investigation demonstrated that interleukin (IL)-17 and tumor necrosis factor (TNF)-alpha exerted synergistic effects in airway epithelial cells by upregulating the expression of six transmembrane epithelial antigens of prostate 4 (STEAP4), a metalloreductase that reduces extracellular copper ions from the cupric state to the cuprous state and facilitates copper uptake.	Copper	366-372	interleukin 17A	Homo sapiens	40-59
33179273-12	2021	Our data suggest a novel IL-17/TNF-alpha-TRAF4-STEAP4 axis that regulates copper homeostasis.	Copper	74-80	interleukin 17A	Homo sapiens	25-30
33915703-7	2021	Moreover, in co-culture with allogeneic T cells, DCs loaded with PAM-lysates increased the proportion of cytotoxic IFN-gamma+ granzyme A+ CD8+ T cells and IL-17A-producing T cells and preserved the Th1 response.	pam-lysates	65-76	interleukin 17A	Homo sapiens	155-161
33648937-5	2021	In contrast, CDDO-Im inhibits IL-17A response in multiple sclerosis patient-derived PBMCs.	1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole	13-20	interleukin 17A	Homo sapiens	30-36
33549556-8	2021	Spironolactone reduced biomarkers of collagen metabolism (e.g., COL1A1, MMP-2); brain natriuretic peptide; and biomarkers related to metabolic processes (e.g., PAPPA), inflammation, and thrombosis (e.g., IL17A, VEGF, and urokinase).	Spironolactone	0-14	interleukin 17A	Homo sapiens	204-209
33518366-9	2021	Furthermore, the percentages of IL-17-producing CD4+ T cells and IFN-gamma-producing CD8+ T cells were significantly higher in patients with AAV than in HCs (p = 0.014, p = 0.008).	CHEMBL2031461	141-144	interleukin 17A	Homo sapiens	32-37
33518366-13	2021	DN T cells represent a T-lymphocyte subset that produces inflammatory cytokines (IFN-gamma, IL-4 and IL-17) and is absolutely elevated in patients with AAV.	CHEMBL2031461	152-155	interleukin 17A	Homo sapiens	101-106
33119735-6	2021	Of note, IL-17A deficiency abolished the skin phenotype and treatment using the JAK inhibitor tofacitinib not only prevented onset, but also improved the skin manifestations even after onset.	tofacitinib	94-105	interleukin 17A	Homo sapiens	9-15
33549903-10	2021	PGE2 blockade significantly reduced percentage and proliferation of T CD4+IL-17+ (p = 0.003, p = 0.0018), T CD4+ IFN-gamma+ (p = 0.002, p = 0.0022) and T CD4+IL-17+ IFN-gamma+ (p = 0.004, p = 0.02) cells.	Dinoprostone	0-4	interleukin 17A	Homo sapiens	74-79
33549903-10	2021	PGE2 blockade significantly reduced percentage and proliferation of T CD4+IL-17+ (p = 0.003, p = 0.0018), T CD4+ IFN-gamma+ (p = 0.002, p = 0.0022) and T CD4+IL-17+ IFN-gamma+ (p = 0.004, p = 0.02) cells.	Dinoprostone	0-4	interleukin 17A	Homo sapiens	158-163
33796569-2	2021	This study aimed to investigate the effect of intracellular calcium (Cai) handling and VA susceptibility by IL-17.	Calcium	60-67	interleukin 17A	Homo sapiens	108-113
33869300-8	2021	We first demonstrated that the number and function of circulating EPCs are reduced in the AAD group, which may be partly related to upregulated plasma IL-6 and IL-17.	L-2-Aminoadipic acid	90-93	interleukin 17A	Homo sapiens	160-165
33796569-8	2021	Conclusions: IL-17 enhanced CaiTD and APD alternans through disturbances in calcium handling, which may increase VA susceptibility.	Calcium	76-83	interleukin 17A	Homo sapiens	13-18
33747110-12	2021	Animal experiment indicated that QDD decreased serum concentrations of alanine aminotransferase (ALT), aspartate aminotransferase (AST), endotoxin (ET), and IL-17 and increased prothrombin time activity (PTA) level.	QDD	33-36	interleukin 17A	Homo sapiens	157-162
33547171-0	2021	Functional Analysis of Immune Signature Genes in Th1* Memory Cells Links ISOC1 and Pyrimidine Metabolism to IFN-gamma and IL-17 Production.	pyrimidine	83-93	interleukin 17A	Homo sapiens	122-127
33690729-18	2021	However, further investigations are necessary to confirm the observations and conclusions drawn from the presented data after metformin administration, especially for proteins that were regulated in a favorable way, i.e. AKT3, CCND2, CD63, CD81, GFAP, IL5, IL17A, IRF4, PI3, and VTCN1.	Metformin	126-135	interleukin 17A	Homo sapiens	257-262
33666761-3	2021	IL-17A promotes an increase in blood pressure through multiple mechanisms including inhibiting endothelial nitric oxide production, increasing reactive oxygen species formation, promoting vascular fibrosis, and enhancing renal sodium retention and glomerular injury.	Nitric Oxide	107-119	interleukin 17A	Homo sapiens	0-6
33666761-3	2021	IL-17A promotes an increase in blood pressure through multiple mechanisms including inhibiting endothelial nitric oxide production, increasing reactive oxygen species formation, promoting vascular fibrosis, and enhancing renal sodium retention and glomerular injury.	Oxygen	152-158	interleukin 17A	Homo sapiens	0-6
33666761-3	2021	IL-17A promotes an increase in blood pressure through multiple mechanisms including inhibiting endothelial nitric oxide production, increasing reactive oxygen species formation, promoting vascular fibrosis, and enhancing renal sodium retention and glomerular injury.	Sodium	227-233	interleukin 17A	Homo sapiens	0-6
33666761-4	2021	IL-17A production from Th17 cells is increased by high salt conditions in vitro and in vivo.	Salts	55-59	interleukin 17A	Homo sapiens	0-6
33666761-5	2021	There is also emerging data linking salt, the gut microbiome, and intestinal T cell IL-17A production.	Salts	36-40	interleukin 17A	Homo sapiens	84-90
33737877-10	2020	Thiamine-treated DC patients showed significant lowering in IL-17 and increase in the IL-22 levels.	Thiamine	0-8	interleukin 17A	Homo sapiens	60-65
33727775-16	2021	Positive correlations were detected between BG and IL-17 in the CD (r: 0.737; P = 0.001) and the UC group (r: 0.574; P = 0.005), and between BG and interferon-gamma in the CD group (r: 0.597; P = 0.015).	(1----3)-beta-d-glucan	44-46	interleukin 17A	Homo sapiens	51-56
33737877-13	2020	Thiamine, a very safe drug even at very high doses, could be repurposed for treating the Th17 mediated IL-17 immune storm, and the subsequent neurological symptoms observed in COVID-19.	Thiamine	0-8	interleukin 17A	Homo sapiens	103-108
32550719-1	2021	Background/Aims: The present study aimed to investigate whether tocotrienol regulates interleukin 17 (IL-17)-induced osteoclastogenesis in rheumatoid arthritis (RA).	Tocotrienols	64-75	interleukin 17A	Homo sapiens	86-100
33650164-0	2021	Durable remissions of guttate psoriasis following short courses of IL-17 inhibitors.	guttate	22-29	interleukin 17A	Homo sapiens	67-72
33448323-10	2021	SA-beta-gal staining results indicated that the presence of apremilast suppressed IL-17-induced cellular senescence.	2-(2-quinolinyl)-1H-indene--1,3(2H)-dione-6'-sulfonic acid	0-11	interleukin 17A	Homo sapiens	82-87
33404125-2	2021	Tumor necrosis factor (TNF)-alpha/interleukin (IL)-23/IL-17 inflammatory pathway may be involved in the pathogenesis of PPP, and the skin lesions manifest the enhanced expression of IL-8 in keratinocytes and increased levels of antimicrobial peptide cathelicidin, leucine leucine-37 in vesicles/pustules.	Leucine	264-271	interleukin 17A	Homo sapiens	54-59
32438447-6	2021	RESULTS: In psoriasis patients treated with DMF we observed an increase in the frequency of Treg cells and a decrease in Th17 lineage cells and associated cytokines IL-17, IL-22 and GM-CSF.	Dimethyl Fumarate	44-47	interleukin 17A	Homo sapiens	165-170
32550719-1	2021	Background/Aims: The present study aimed to investigate whether tocotrienol regulates interleukin 17 (IL-17)-induced osteoclastogenesis in rheumatoid arthritis (RA).	Tocotrienols	64-75	interleukin 17A	Homo sapiens	102-107
32550719-2	2021	Methods: We evaluated the effect of tocotrienol on IL-17-induced receptor activator of nuclear factor kappa B ligand (RANKL) production using RA fibroblast-like synoviocyte (FLS), together with real-time polymerase chain reaction and enzyme-linked immunosorbent assay.	Tocotrienols	36-47	interleukin 17A	Homo sapiens	51-56
32550719-3	2021	Osteoclast differentiation was confirmed after culturing IL-17-treated RA FLS and Th17 cells with tocotrienol and monocytes.	Tocotrienols	98-109	interleukin 17A	Homo sapiens	57-62
32550719-5	2021	Results: We found that IL-17 stimulated FLS to produce RANKL and tocotrienol decreased this IL-17-induced RANKL production.	Tocotrienols	65-76	interleukin 17A	Homo sapiens	92-97
32550719-6	2021	Tocotrienol decreased the IL-17-induced activation of mammalian target of rapamycin, extracellular signal-regulated kinase, and inhibitor of kappa B-alpha.	Tocotrienols	0-11	interleukin 17A	Homo sapiens	26-31
32550719-7	2021	When monocytes were incubated with IL-17, RANKL, IL-17-treated FLS or Th17 cells, osteoclasts were differentiated and tocotrienol decreased this osteoclast differentiation.	Tocotrienols	118-129	interleukin 17A	Homo sapiens	35-40
32550719-7	2021	When monocytes were incubated with IL-17, RANKL, IL-17-treated FLS or Th17 cells, osteoclasts were differentiated and tocotrienol decreased this osteoclast differentiation.	Tocotrienols	118-129	interleukin 17A	Homo sapiens	49-54
32550719-8	2021	Tocotrienol reduced Th17 cell differentiation and the production of IL-17 and sRANKL; however, tocotrienol did not affect Treg cell differentiation.	Tocotrienols	0-11	interleukin 17A	Homo sapiens	68-73
32550719-9	2021	Conclusions: Tocotrienol inhibited IL-17- activated RANKL production in RA FLS and IL-17-activated osteoclast formation.	Tocotrienols	13-24	interleukin 17A	Homo sapiens	35-40
32550719-9	2021	Conclusions: Tocotrienol inhibited IL-17- activated RANKL production in RA FLS and IL-17-activated osteoclast formation.	Tocotrienols	13-24	interleukin 17A	Homo sapiens	83-88
33577335-0	2021	Probing N-Glycan Functions in Human Interleukin-17A Based on Chemically Synthesized Homogeneous Glycoforms.	n-glycan	8-16	interleukin 17A	Homo sapiens	36-51
33577335-3	2021	Here we report our synthesis and evaluation of homogeneously glycosylated interleukin-17A (IL-17A), based on a synthetic approach combining solid-phase synthesis of (glyco)peptides, chemoenzymatic glycan modification on segments, and chemical ligations.	Polysaccharides	197-203	interleukin 17A	Homo sapiens	74-89
33577335-6	2021	Further surface plasmon resonance (SPR) and hydrogen/deuterium exchange mass spectroscopic experiments confirm that the evaluated complex type N-glycan impedes the binding between IL-17A and its receptor IL-17RA.	Hydrogen	44-52	interleukin 17A	Homo sapiens	180-186
33577335-6	2021	Further surface plasmon resonance (SPR) and hydrogen/deuterium exchange mass spectroscopic experiments confirm that the evaluated complex type N-glycan impedes the binding between IL-17A and its receptor IL-17RA.	Deuterium	53-62	interleukin 17A	Homo sapiens	180-186
33577335-3	2021	Here we report our synthesis and evaluation of homogeneously glycosylated interleukin-17A (IL-17A), based on a synthetic approach combining solid-phase synthesis of (glyco)peptides, chemoenzymatic glycan modification on segments, and chemical ligations.	Polysaccharides	197-203	interleukin 17A	Homo sapiens	91-97
33577335-6	2021	Further surface plasmon resonance (SPR) and hydrogen/deuterium exchange mass spectroscopic experiments confirm that the evaluated complex type N-glycan impedes the binding between IL-17A and its receptor IL-17RA.	n-glycan	143-151	interleukin 17A	Homo sapiens	180-186
33577335-5	2021	A comparison of three IL-17A glycoforms in a normal human dermal fibroblast (NHDF) assay reveals dose-dependent interleukin-6-inducing activities in all cases, wherein the glycoform with sialyl undecasaccharides displays much weaker stimulatory effect than that of the GlcNAc- or GlcNAc(beta1 4)GlcNAc-modified proteins.	undecasaccharides	194-211	interleukin 17A	Homo sapiens	22-28
33577335-5	2021	A comparison of three IL-17A glycoforms in a normal human dermal fibroblast (NHDF) assay reveals dose-dependent interleukin-6-inducing activities in all cases, wherein the glycoform with sialyl undecasaccharides displays much weaker stimulatory effect than that of the GlcNAc- or GlcNAc(beta1 4)GlcNAc-modified proteins.	Acetylglucosamine	269-275	interleukin 17A	Homo sapiens	22-28
33577335-5	2021	A comparison of three IL-17A glycoforms in a normal human dermal fibroblast (NHDF) assay reveals dose-dependent interleukin-6-inducing activities in all cases, wherein the glycoform with sialyl undecasaccharides displays much weaker stimulatory effect than that of the GlcNAc- or GlcNAc(beta1 4)GlcNAc-modified proteins.	Acetylglucosamine	280-286	interleukin 17A	Homo sapiens	22-28
33577335-5	2021	A comparison of three IL-17A glycoforms in a normal human dermal fibroblast (NHDF) assay reveals dose-dependent interleukin-6-inducing activities in all cases, wherein the glycoform with sialyl undecasaccharides displays much weaker stimulatory effect than that of the GlcNAc- or GlcNAc(beta1 4)GlcNAc-modified proteins.	Acetylglucosamine	280-286	interleukin 17A	Homo sapiens	22-28
33669652-3	2021	DMF treatment decreased the proliferation of T cells and the production of IL-17A and GM-CSF.	Dimethyl Fumarate	0-3	interleukin 17A	Homo sapiens	75-81
33595097-1	2022	BACKGROUND AND PURPOSE: Recent biochemical and pharmacological studies have reported that in several tissues and cell types, microsomal prostaglandin E2 synthase (mPGES) and peroxisome proliferator-activated receptor-gamma (PPAR-gamma) expression are modulated by a variety of inflammatory factors and stimuli Considering that very little is known about the biological effects promoted by IL-17 in the context of mPGES-1/PPAR-gamma modulation, we sought to investigate the contribution of this unique cytokine on this integrated pathway during the onset of inflammation.	Dinoprostone	136-152	interleukin 17A	Homo sapiens	389-394
33595097-6	2022	KEY RESULTS: PF 9184 and Troglitazone, in a time and dose-dependent manner, were shown to significantly modulate leukocyte infiltration, myeloperoxidase activity, and the expression of COX-2/mPGES-1, NF-kB/IkB-alpha and mPTGDS-1/PPAR-gamma induced by IL-17.	N-(3',4'-dichlorobiphenyl-4-yl)-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide	13-20	interleukin 17A	Homo sapiens	251-256
33595097-6	2022	KEY RESULTS: PF 9184 and Troglitazone, in a time and dose-dependent manner, were shown to significantly modulate leukocyte infiltration, myeloperoxidase activity, and the expression of COX-2/mPGES-1, NF-kB/IkB-alpha and mPTGDS-1/PPAR-gamma induced by IL-17.	Troglitazone	25-37	interleukin 17A	Homo sapiens	251-256
33788463-10	2021	CONCLUSION: Thunder-fire moxibustion combined with mifepristone could significantly improve dysmenorrhea symptoms, shorten dysmenorrhea time and promote atrophy of ovarian heterotopic cyst in patients with ovarian chocolate cyst dysmenorrhea of kidney deficiency and blood stasis, and the mechanism may be related to the reduction of serum levels of TGF-beta1 and IL-17.	Mifepristone	51-63	interleukin 17A	Homo sapiens	364-369
33592002-12	2021	Finally, sulforaphane significantly inhibited the production of IL-6, TNF-alpha, and IL-17 by human peripheral blood mononuclear cells stimulated with an anti-CD3 monoclonal antibody in a dose-dependent manner.	sulforaphane	9-21	interleukin 17A	Homo sapiens	85-90
33573560-8	2021	In enrichment analysis, it was found that the NF- kappaB, toll-like receptors and IL-17 signaling pathway were mainly involved in TP for these cancers.	triptolide	130-132	interleukin 17A	Homo sapiens	82-87
33614471-11	2020	GSEA analysis indicated ENDOU down-stream pathways like DNA replication, mismatch repair, cell cycle and IL-17 signaling pathway.	gsea	0-4	interleukin 17A	Homo sapiens	105-110
33568922-8	2021	IL-17A was positively correlated with triglyceride (TG) level and low-density lipoprotein cholesterol (LDL-C) (P=0.011, r=0.303; P=0.043, r=0.242, respectively).	Triglycerides	38-50	interleukin 17A	Homo sapiens	0-6
33568922-8	2021	IL-17A was positively correlated with triglyceride (TG) level and low-density lipoprotein cholesterol (LDL-C) (P=0.011, r=0.303; P=0.043, r=0.242, respectively).	Triglycerides	52-54	interleukin 17A	Homo sapiens	0-6
33568922-9	2021	Additionally, IL-17A was negatively correlated with high-density lipoprotein cholesterol (HDL-C) level (P=0.036, r=-0.251).	Cholesterol	77-88	interleukin 17A	Homo sapiens	14-20
33383445-6	2021	The results showed that IL-23R and IL-17A were upregulated to different degrees and reached the highest levels with both stimuli, indicating that IL-23 induced PBMCs to secrete PGE2, which further boosted the proportion of IL-23R+CD4+T cells to promote IL-17A secretion.	Dinoprostone	177-181	interleukin 17A	Homo sapiens	35-41
32926407-9	2021	Osmotic controls L-glucose and D-mannose demonstrate that induction of IL-17A is a substance-independent, tonicity-dose-dependent process.	Glucose	19-26	interleukin 17A	Homo sapiens	71-77
32926407-9	2021	Osmotic controls L-glucose and D-mannose demonstrate that induction of IL-17A is a substance-independent, tonicity-dose-dependent process.	Mannose	31-40	interleukin 17A	Homo sapiens	71-77
32926407-11	2021	Blockade of reactive-oxygen species (ROS) prevented IL-17A induction in response to PD-range glucose.	Reactive Oxygen Species	12-35	interleukin 17A	Homo sapiens	52-58
32926407-11	2021	Blockade of reactive-oxygen species (ROS) prevented IL-17A induction in response to PD-range glucose.	Reactive Oxygen Species	37-40	interleukin 17A	Homo sapiens	52-58
32926407-11	2021	Blockade of reactive-oxygen species (ROS) prevented IL-17A induction in response to PD-range glucose.	Glucose	93-100	interleukin 17A	Homo sapiens	52-58
33285073-9	2021	In PBMCs of AR patients, the levels of IL-17A and LC3-II were increased, and the levels of Foxp3 and P62 were decreased, while these changes could be reversed by glutathione.	Glutathione	162-173	interleukin 17A	Homo sapiens	39-45
33383445-6	2021	The results showed that IL-23R and IL-17A were upregulated to different degrees and reached the highest levels with both stimuli, indicating that IL-23 induced PBMCs to secrete PGE2, which further boosted the proportion of IL-23R+CD4+T cells to promote IL-17A secretion.	Dinoprostone	177-181	interleukin 17A	Homo sapiens	253-259
33383445-7	2021	Pretreatment with antagonists aimed at EP2/EP4 receptors diminished PGE2-induced upregulation of IL-23R and IL-17A.	Dinoprostone	68-72	interleukin 17A	Homo sapiens	108-114
33334656-0	2021	A novel role of IL-17A in contributing to the impaired suppressive function of Tregs in psoriasis.	tregs	79-84	interleukin 17A	Homo sapiens	16-22
32100582-6	2021	The levels of RAR-related orphan receptor (RORC) and IL-17A expression were also determined by quantitative real-time PCR.The results showed that Apigenin 3-Acetate inhibited Th17 cells proliferation (P value: 0.018) at 80 microM concentration after 48 hr.	apigenin 3-acetate	146-164	interleukin 17A	Homo sapiens	53-59
32100582-7	2021	Additionally, IL-17A gene expression significantly (P value&lt;= 0.0001) inhibited by Apigenin, Apigenin 3-Acetate and Methyl Prednisolone Acetate in 80 microM, 80 microM and 2.5 microM (selected dose in IC50 determination) respectively These results demonstrate that Acetate increases anti-inflammatory effects of Apigenin on Th17 cells.	3-acetate	105-114	interleukin 17A	Homo sapiens	14-20
33334656-14	2021	CONCLUSION: Our study implies a crucial role of IL-17A in mediating the dysfunction of the Treg suppressive function in psoriasis.	treg	91-95	interleukin 17A	Homo sapiens	48-54
33334656-4	2021	OBJECTIVE: To explore the effect and underlying mechanism of IL-17A on the suppressive function of Tregs and to evaluate the restoration of the suppressive function of Tregs in psoriasis during anti-IL-17A (secukinumab) treatment.	tregs	99-104	interleukin 17A	Homo sapiens	61-67
33334656-15	2021	Secukinumab, which neutralizes IL-17A signaling, restored the suppressive function of Tregs to exert its antipsoriatic effect.	tregs	86-91	interleukin 17A	Homo sapiens	31-37
32100582-7	2021	Additionally, IL-17A gene expression significantly (P value&lt;= 0.0001) inhibited by Apigenin, Apigenin 3-Acetate and Methyl Prednisolone Acetate in 80 microM, 80 microM and 2.5 microM (selected dose in IC50 determination) respectively These results demonstrate that Acetate increases anti-inflammatory effects of Apigenin on Th17 cells.	Methylprednisolone Acetate	119-146	interleukin 17A	Homo sapiens	14-20
33334656-10	2021	RESULTS: IL-17A blocked the suppressive function of Tregs, possibly by inhibiting the release of TGF-beta and promoting the production of IFN-gamma.	tregs	52-57	interleukin 17A	Homo sapiens	9-15
32100582-7	2021	Additionally, IL-17A gene expression significantly (P value&lt;= 0.0001) inhibited by Apigenin, Apigenin 3-Acetate and Methyl Prednisolone Acetate in 80 microM, 80 microM and 2.5 microM (selected dose in IC50 determination) respectively These results demonstrate that Acetate increases anti-inflammatory effects of Apigenin on Th17 cells.	Acetates	107-114	interleukin 17A	Homo sapiens	14-20
33436376-7	2021	RESULTS: cTfh increased with elevated expression of inducible T-cell costimulator (ICOS) in patients with MG. cTfh shifted to Th2 and Th17 over Th1 in MG. ICOShighcTfh produced significantly higher levels of interleukin (IL)-21, IL-4, and IL-17A than ICOSlow cTfh only in patients with MG.	ctfh	9-13	interleukin 17A	Homo sapiens	239-245
32890713-7	2021	Phytohaemagglutinin M (PHA-M) -elicited human peripheral blood mononuclear cells (PBMCs) were further applied to assess the suppressive activity of PePs on IFN-gamma and IL-17 production.	peps	148-152	interleukin 17A	Homo sapiens	170-175
33249060-5	2021	Consistent with known DHODH requirements for immunomodulatory cytokine production, PTC299 inhibited the production of interleukin (IL)-6, IL-17A (also called IL-17), IL-17 F, and vascular endothelial growth factor (VEGF) in tissue culture models.	6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole	83-89	interleukin 17A	Homo sapiens	138-144
33249060-5	2021	Consistent with known DHODH requirements for immunomodulatory cytokine production, PTC299 inhibited the production of interleukin (IL)-6, IL-17A (also called IL-17), IL-17 F, and vascular endothelial growth factor (VEGF) in tissue culture models.	6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole	83-89	interleukin 17A	Homo sapiens	138-143
33436376-7	2021	RESULTS: cTfh increased with elevated expression of inducible T-cell costimulator (ICOS) in patients with MG. cTfh shifted to Th2 and Th17 over Th1 in MG. ICOShighcTfh produced significantly higher levels of interleukin (IL)-21, IL-4, and IL-17A than ICOSlow cTfh only in patients with MG.	ctfh	110-114	interleukin 17A	Homo sapiens	239-245
33436376-7	2021	RESULTS: cTfh increased with elevated expression of inducible T-cell costimulator (ICOS) in patients with MG. cTfh shifted to Th2 and Th17 over Th1 in MG. ICOShighcTfh produced significantly higher levels of interleukin (IL)-21, IL-4, and IL-17A than ICOSlow cTfh only in patients with MG.	icoshighctfh	155-167	interleukin 17A	Homo sapiens	239-245
33436376-7	2021	RESULTS: cTfh increased with elevated expression of inducible T-cell costimulator (ICOS) in patients with MG. cTfh shifted to Th2 and Th17 over Th1 in MG. ICOShighcTfh produced significantly higher levels of interleukin (IL)-21, IL-4, and IL-17A than ICOSlow cTfh only in patients with MG.	ctfh	110-114	interleukin 17A	Homo sapiens	239-245
33505216-6	2021	The anti-inflammatory mechanism of GL and GA is realized via cytokines like interferon-gamma, tumor necrotizing factor-alpha, interleukin- (IL-) 1beta, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, and IL-17.	gl	35-37	interleukin 17A	Homo sapiens	194-199
33411100-6	2021	Based on the GO and KEGG pathway analysis, the most important dysregulated pathways were regulation of cell proliferation, biocarbonate transport, Wnt, and IL-17 signaling pathways, and nitrogen metabolism.	biocarbonate	123-135	interleukin 17A	Homo sapiens	156-161
33411100-6	2021	Based on the GO and KEGG pathway analysis, the most important dysregulated pathways were regulation of cell proliferation, biocarbonate transport, Wnt, and IL-17 signaling pathways, and nitrogen metabolism.	Nitrogen	186-194	interleukin 17A	Homo sapiens	156-161
33505216-6	2021	The anti-inflammatory mechanism of GL and GA is realized via cytokines like interferon-gamma, tumor necrotizing factor-alpha, interleukin- (IL-) 1beta, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, and IL-17.	Glycyrrhetinic Acid	42-44	interleukin 17A	Homo sapiens	194-199
33390552-10	2021	Vitamin K2 significantly inhibited the IL-17A, IL-10, and tumor necrosis factor alpha (TNF-alpha) production (p < 0.05), and increased the IL-2 production (p < 0.01) in the culture supernatant of atopic dermatitis PBMCs.	Vitamin K 2	0-10	interleukin 17A	Homo sapiens	39-45
33160017-0	2021	The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1beta and IL-18 secretion.	empagliflozin	20-33	interleukin 17A	Homo sapiens	45-60
33160017-4	2021	Supporting our hypotheses, exposure of cultured SMC to IL-17A promoted proliferation and migration via TRAF3IP2, TRAF3IP2-dependent superoxide and hydrogen peroxide production, NLRP3 expression, caspase-1 activation, and IL-1beta and IL-18 secretion.	Superoxides	132-142	interleukin 17A	Homo sapiens	55-61
33160017-4	2021	Supporting our hypotheses, exposure of cultured SMC to IL-17A promoted proliferation and migration via TRAF3IP2, TRAF3IP2-dependent superoxide and hydrogen peroxide production, NLRP3 expression, caspase-1 activation, and IL-1beta and IL-18 secretion.	Hydrogen Peroxide	147-164	interleukin 17A	Homo sapiens	55-61
33160017-6	2021	Importantly, SMC express SGLT2, and pre-treatment with EMPA attenuated IL-17A/TRAF3IP2-dependent oxidative stress, NLRP3 expression, caspase-1 activation, IL-1beta and IL-18 secretion, and SMC proliferation and migration.	empagliflozin	55-59	interleukin 17A	Homo sapiens	71-77
33160017-7	2021	Importantly, silencing SGLT2 attenuated EMPA-mediated inhibition of IL-17A-induced cytokine secretion and SMC proliferation and migration.	empagliflozin	40-44	interleukin 17A	Homo sapiens	68-74
32651310-0	2021	IL-17 predicts the effect of TACE combined with apatinib in hepatocellular carcinoma.	Chlorotrianisene	29-33	interleukin 17A	Homo sapiens	0-5
32651310-0	2021	IL-17 predicts the effect of TACE combined with apatinib in hepatocellular carcinoma.	apatinib	48-56	interleukin 17A	Homo sapiens	0-5
32651310-8	2021	Compared with adjuvant TACE alone, patients with low-expression of IL-17 treated combined with apatinib have a higher 5-year overall survival.	Chlorotrianisene	23-27	interleukin 17A	Homo sapiens	67-72
32516443-11	2021	Methotrexate treatment helps to decrease IL-9, IL-17 and VEGF levels, thereby limiting the disease progression and improving quality of life in psoriasis.	Methotrexate	0-12	interleukin 17A	Homo sapiens	47-52
32651310-8	2021	Compared with adjuvant TACE alone, patients with low-expression of IL-17 treated combined with apatinib have a higher 5-year overall survival.	apatinib	95-103	interleukin 17A	Homo sapiens	67-72
32651310-10	2021	CONCLUSION: IL-17 had a pivotal role in the invasion and angiogenesis of HCC and contribute to the selection of patients who may benefit from adjuvant TACE combined with apatinib.	Chlorotrianisene	151-155	interleukin 17A	Homo sapiens	12-17
32651310-10	2021	CONCLUSION: IL-17 had a pivotal role in the invasion and angiogenesis of HCC and contribute to the selection of patients who may benefit from adjuvant TACE combined with apatinib.	apatinib	170-178	interleukin 17A	Homo sapiens	12-17
33355284-3	2021	Cytoquines, such as IL-17, may be involved in the pathophysiology of psoriasis and inflammatory bowel diseases.	cytoquines	0-10	interleukin 17A	Homo sapiens	20-25
32767679-3	2021	The RORC2 inhibitor PF-06763809 has been hypothesized to inhibit IL-17A production in T-helper 17 (Th17) cells, thereby reducing psoriasis symptoms.	pf-06763809	20-31	interleukin 17A	Homo sapiens	65-71
32783069-8	2021	RESULTS: Stimulation with IL-17A induced STAT3 phosphorylation, which was inhibited by the pretreatment with JAK2 inhibitor AZD1480 or JAK1/3 inhibitor tofacitinib.	AZD 1480	124-131	interleukin 17A	Homo sapiens	26-32
32783069-8	2021	RESULTS: Stimulation with IL-17A induced STAT3 phosphorylation, which was inhibited by the pretreatment with JAK2 inhibitor AZD1480 or JAK1/3 inhibitor tofacitinib.	tofacitinib	152-163	interleukin 17A	Homo sapiens	26-32
33226450-7	2021	IL-17+ T cells were also down-regulated in polyps from patients treated with glucocorticoid steroids, and exhibited poly-functionality patterns in polyp tissues.	Steroids	92-100	interleukin 17A	Homo sapiens	0-5
33273977-3	2021	MTT and flow cytometry assays demonstrated that IL-17 promoted proliferation and inhibited apoptosis of HaCaT cells, while this effect was reversed following knockdown of TRAF3IP2 with lentiviral vectors.	monooxyethylene trimethylolpropane tristearate	0-3	interleukin 17A	Homo sapiens	48-53
32469071-0	2021	Retinoic Acid Is Elevated in the Mucosa of Patients With Active Ulcerative Colitis and Displays a Proinflammatory Role by Augmenting IL-17 and IFNgamma Production.	Tretinoin	0-13	interleukin 17A	Homo sapiens	133-138
32469071-2	2021	Our previous research highlighted that in the face of inflammatory conditions, RA plays a contrary role where it aggravates intestinal inflammation by promoting interferon (IFN) gamma and interleukin (IL)-17 differentiation in vitro.	Tretinoin	79-81	interleukin 17A	Homo sapiens	188-207
32469071-6	2021	Moreover, the raised RA levels in patients with active disease showed a positive correlation with proinflammatory cytokines (IL-17, IFNgamma) and a negative correlation with IL-10.	Tretinoin	21-23	interleukin 17A	Homo sapiens	125-130
33631989-7	2021	FK506 clearly decreased the numbers of Th17 cells and FoxP3+IL-17+ cells.	Tacrolimus	0-5	interleukin 17A	Homo sapiens	60-65
32951264-10	2021	In addition, crocin/crocetin at low concentrations caused an elevation in mRNA expression of anti-inflammatory cytokines (transforming growth factor-beta, interleukin-10 [IL-10], and IL-4), while at higher doses (25 and 50 microM) they led to lowering inflammatory cytokines (IL-1beta, IL-6, IL-17, and interferon gamma).	crocin	13-19	interleukin 17A	Homo sapiens	292-297
32791248-7	2021	T2 POS was positively associated with eosinophils, IgE, and FeNO, and negatively with AQLQ, sputum neutrophils, IL-17A, IL-8, and TNF-alpha.	t2 pos	0-6	interleukin 17A	Homo sapiens	112-118
32951264-10	2021	In addition, crocin/crocetin at low concentrations caused an elevation in mRNA expression of anti-inflammatory cytokines (transforming growth factor-beta, interleukin-10 [IL-10], and IL-4), while at higher doses (25 and 50 microM) they led to lowering inflammatory cytokines (IL-1beta, IL-6, IL-17, and interferon gamma).	crocetin	20-28	interleukin 17A	Homo sapiens	292-297
33176965-8	2021	RESULTS: BTX-B injection significantly suppressed PSI score and reduced the number of CD4+ T cells, CD11c+ dendritic cells, and the production of IL-17A/F in the lesional skin.	btx-b	9-14	interleukin 17A	Homo sapiens	146-154
32914717-0	2021	New oxazolidines inhibit the secretion of IFN-gamma and IL-17 by PBMCS from moderate to severe asthmatic patients.	oxazolidine	4-16	interleukin 17A	Homo sapiens	56-61
33310666-10	2021	Compared with the positive control group, human PBMCs treated with TM had lower levels of IL-17A, percentage of Th17 cells, levels of phospho-signal transducer and activator of transcription (p-STAT) 3 and phospho-nuclear transcription factor-kappaB (p-NF-kappaB), but higher levels of acetylated LDHA.	Thulium	67-69	interleukin 17A	Homo sapiens	90-96
32914717-3	2021	OBJECTIVE: The present study aimed to evaluate the IL-17A and IFN-gamma modulatory effect of two new oxazolidine derivatives (LPSF/NB-12 and -13) on mononucleated cells of patients with moderate and severe asthma.	lpsf	126-130	interleukin 17A	Homo sapiens	51-57
33290779-8	2021	Treatment with 6SA increases the secretion of IL-2, IL-12, GM-CSF, TNF-alpha and IFN-gamma and significantly reduces IL-10 and IL-17 secretion, suggesting that the reduction of regulatory T cells and tumor-associated macrophages contribute to the host control of tumor development.	anacardic acid	15-18	interleukin 17A	Homo sapiens	127-132
33045675-7	2021	CONCLUSION: Chromium picolinate significantly decreased TG, insulin, HOMA-IR, fetuin-A, the number of inflammatory factors, and increased QUICKI without changing FBS, HbA1C, TC, LDL, HDL, IL-17 levels and liver steatosis intensity in patients with NAFLD.	picolinic acid	12-31	interleukin 17A	Homo sapiens	188-193
33283480-8	2021	C-NP nanoparticles also stimulate the release of IL-lbeta, MCP-1, TNF-alpha, IL-8, IL-12p70, IL-17, IL-18, and IL-23 from MDM.	c-np	0-4	interleukin 17A	Homo sapiens	93-98
33371832-7	2021	Furthermore, NAC decreases TNF-alpha, IL-1beta, IL-6, IL-8, IL-10, and IL-17 serum levels in patients with sepsis, severe burns, acute liver failure, or peritoneal dialysis and may also reduce cytokine storm in COVID-19.	Acetylcysteine	13-16	interleukin 17A	Homo sapiens	71-76
33317849-8	2021	Although the mechanism(s) driving the increase in Th17-biased MAIT cells with reduced IFN-gamma production in tumor is not fully understood, recent studies have linked IL-17 response to dysfunctional mitochondria and reactive oxygen species (ROS) from the mitochondria.	Reactive Oxygen Species	217-240	interleukin 17A	Homo sapiens	168-173
33353437-5	2022	In the patient group, elevated levels of IFN-gamma, IL-17A, and IL-10 had a significant association with the serum levels of 25(OH)D, while the levels of TGF-beta, IL-6, and TNF-alpha showed an insignificant association.	25(oh)d	125-132	interleukin 17A	Homo sapiens	52-58
33317849-8	2021	Although the mechanism(s) driving the increase in Th17-biased MAIT cells with reduced IFN-gamma production in tumor is not fully understood, recent studies have linked IL-17 response to dysfunctional mitochondria and reactive oxygen species (ROS) from the mitochondria.	Reactive Oxygen Species	242-245	interleukin 17A	Homo sapiens	168-173
33376732-10	2020	Simiao powder components were predicted to exert their therapeutic effect on the AGE-RAGE signaling pathway in diabetic complications, IL-17 signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, and HIF-1 signaling pathway.	simiao powder	0-13	interleukin 17A	Homo sapiens	135-140
32860704-8	2020	NMR spectroscopy revealed changes in tumor lactate as a potential early biomarker for IL17/PD-1 combination efficacy.	Lactic Acid	43-50	interleukin 17A	Homo sapiens	86-90
33324092-10	2020	Intraarticular injection of the IFX-loaded F127-HA-PGA hydrogel could alleviate the expression of inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and interleukin-17 (IL-17), in the synovial fluid and cartilage as well as relieve pain and inhibit cartilage destruction in RA.	f127-ha-pga	43-54	interleukin 17A	Homo sapiens	227-241
33324092-10	2020	Intraarticular injection of the IFX-loaded F127-HA-PGA hydrogel could alleviate the expression of inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and interleukin-17 (IL-17), in the synovial fluid and cartilage as well as relieve pain and inhibit cartilage destruction in RA.	f127-ha-pga	43-54	interleukin 17A	Homo sapiens	243-248
33045867-8	2020	Moreover, vitexin decreased expression of interleukin-1beta (IL-1beta), IL-17A and ROS in melanocytes induced by H2O2.	Hydrogen Peroxide	113-117	interleukin 17A	Homo sapiens	72-78
33028712-0	2020	Estradiol enhances anti-viral CD4+ tissue-resident memory T cell responses following mucosal herpes simplex virus 2 vaccination through an IL-17-mediated pathway.	Estradiol	0-9	interleukin 17A	Homo sapiens	139-144
33045560-11	2020	Hence, they blocked IL-17A proinflammatory activity, which is consistent with the inhibition of the signalling of the IL-17A receptor by ligand CBG060392.	cbg060392	144-153	interleukin 17A	Homo sapiens	20-26
33045560-11	2020	Hence, they blocked IL-17A proinflammatory activity, which is consistent with the inhibition of the signalling of the IL-17A receptor by ligand CBG060392.	cbg060392	144-153	interleukin 17A	Homo sapiens	118-124
33157566-4	2020	The in vitro induction of IFN-gamma+ IL-17+ Th17 cells was performed adopting PHA and rIL-12.	ril-12	86-92	interleukin 17A	Homo sapiens	37-42
33463083-9	2020	Moreover, AM80 also inhibited IL-17 production by liver-infiltrating gamma delta  T cells isolated from animals suffering from BA.	tamibarotene	10-14	interleukin 17A	Homo sapiens	30-35
33265085-0	2020	Expression changes of IL-17 in zoledronic acid combined with PVP technology in the treatment of postmenopausal osteoporotic vertebral compression fracture and its predictive value of relapse.	Zoledronic Acid	31-46	interleukin 17A	Homo sapiens	22-27
33265085-1	2020	OBJECTIVE: To investigate the expression of interleukin-17 (IL-17) in zoledronic acid combined with PVP technology for patients with postmenopausal osteoporotic vertebral compression fracture (OVCF) and its predictive value for relapse.	Zoledronic Acid	70-85	interleukin 17A	Homo sapiens	44-58
33265085-1	2020	OBJECTIVE: To investigate the expression of interleukin-17 (IL-17) in zoledronic acid combined with PVP technology for patients with postmenopausal osteoporotic vertebral compression fracture (OVCF) and its predictive value for relapse.	Zoledronic Acid	70-85	interleukin 17A	Homo sapiens	60-65
33174023-6	2020	Transcriptional profile comparisons revealed that CDEL or CAMP stable expression in HSC-3 cells upregulated expression of genes involved in the IL-17-dependent pathway compared with the control.	Cyclic AMP	58-62	interleukin 17A	Homo sapiens	144-149
33463083-17	2020	In the study at hand, we demonstrate that treatment with AM80, a synthetic retinoid with superior pharmacological properties, effectively inhibits the IL-17 production of gamma delta T cells without generating systemic immunosuppression.	tamibarotene	57-61	interleukin 17A	Homo sapiens	151-156
33463083-17	2020	In the study at hand, we demonstrate that treatment with AM80, a synthetic retinoid with superior pharmacological properties, effectively inhibits the IL-17 production of gamma delta T cells without generating systemic immunosuppression.	Retinoids	75-83	interleukin 17A	Homo sapiens	151-156
33463083-18	2020	Although all-trans retinoic acid (ATRA) has been demonstrated to suppress differentiation of IL-17-producing conventional T-helper cells (Th17) in vitro, the therapeutic application of ATRA in vivo is limited by the compound"s potential side effects caused by its instability and lack of receptor specificity.	Tretinoin	19-32	interleukin 17A	Homo sapiens	93-98
33463083-18	2020	Although all-trans retinoic acid (ATRA) has been demonstrated to suppress differentiation of IL-17-producing conventional T-helper cells (Th17) in vitro, the therapeutic application of ATRA in vivo is limited by the compound"s potential side effects caused by its instability and lack of receptor specificity.	Tretinoin	34-38	interleukin 17A	Homo sapiens	93-98
33243748-0	2020	[IL-17A/lL-17RA reduces cisplatin sensitivity of ovarian cancer SKOV3 cells by regulating autophagy].	Cisplatin	24-33	interleukin 17A	Homo sapiens	1-7
32911021-5	2020	The use of an aryl hydrocarbon receptor (AhR) specific inhibitor demonstrated its involvement in this bisphenol-induced IL-17 production.	bis(4-hydroxyphenyl)sulfone	102-111	interleukin 17A	Homo sapiens	120-125
33266022-8	2020	RESULTS: High-dose vitamin D treatment alone and combined with infliximab decreased the IL17A, IFNgamma and IL10 expression.	Vitamin D	19-28	interleukin 17A	Homo sapiens	88-93
33243748-1	2020	OBJECTIVE: To investigate the effect of interleukin-17A (IL-17A) on chemosensitivity of ovarian cancer cells to cisplatin (DDP) and explore the mechanism in light of autophagy regulation.	Cisplatin	112-121	interleukin 17A	Homo sapiens	40-55
33266022-11	2020	CONCLUSIONS: High-dose vitamin D as monotherapy and combined with infliximab decreases IL17A, IFNgamma and IL-10 expression in mucosa within treatment groups.	Vitamin D	23-32	interleukin 17A	Homo sapiens	87-92
33243748-1	2020	OBJECTIVE: To investigate the effect of interleukin-17A (IL-17A) on chemosensitivity of ovarian cancer cells to cisplatin (DDP) and explore the mechanism in light of autophagy regulation.	Cisplatin	112-121	interleukin 17A	Homo sapiens	57-63
33243748-1	2020	OBJECTIVE: To investigate the effect of interleukin-17A (IL-17A) on chemosensitivity of ovarian cancer cells to cisplatin (DDP) and explore the mechanism in light of autophagy regulation.	Cisplatin	123-126	interleukin 17A	Homo sapiens	40-55
33243748-1	2020	OBJECTIVE: To investigate the effect of interleukin-17A (IL-17A) on chemosensitivity of ovarian cancer cells to cisplatin (DDP) and explore the mechanism in light of autophagy regulation.	Cisplatin	123-126	interleukin 17A	Homo sapiens	57-63
33243748-3	2020	MTT assay was used to observe the changes in proliferation of the treated cells and the effect of treatment with 100 ng/mL IL-17A for 24 h on DDP-induced apoptosis of SKOV3 cells.	Cisplatin	142-145	interleukin 17A	Homo sapiens	123-129
33243748-10	2020	Treatment with IL-17A significantly reduced the susceptibility of SKOV3 cells to cisplatin-induced apoptosis (P < 0.05).	Cisplatin	81-90	interleukin 17A	Homo sapiens	15-21
33294000-14	2020	Functional analysis indicated that these targets were closely related to pathophysiological processes and pathways such as biosynthetic and metabolic processes of prostaglandins and prostanoids, cytokine and chemokine activities, and the IL-17, TNF, Toll-like receptor, and nuclear factor-kappa B (NF-kappaB) signaling pathways.	Prostaglandins	182-193	interleukin 17A	Homo sapiens	238-243
33240608-12	2020	In untreated MS patients, acetate levels correlated inversely with CD4+ naive T cells (r =  - 0.550, p = 0.001) and directly with CD8+ IL-17+ cells (r = 0.557; p = 0.001).	Acetates	26-33	interleukin 17A	Homo sapiens	135-140
33203651-11	2021	T cells primed with laquinimod-treated monocytes differentiated significantly less into IL-17A-producing T helper (Th)-17 cells.	laquinimod	20-30	interleukin 17A	Homo sapiens	88-94
33240608-14	2020	In MS there exists a correlation between plasma acetate levels, EDSS and increased IL-17+ T cells.	Acetates	48-55	interleukin 17A	Homo sapiens	83-88
33115468-7	2020	As an inducer of ferroptosis, erastin inhibited HCC cell proliferation and progression, and it was showed to affect Th17 cell differentiation and IL-17 signaling pathway through bioinformatics analysis, indicating it a potential agent of cancer immunotherapy.	erastin	30-37	interleukin 17A	Homo sapiens	146-151
33147541-1	2020	BACKGROUND: The present study was aimed to evaluate the nano-curcumin supplementation on Th1/Th17 balance by assessment of gene expression and serum level of interferon gamma (IFN-gamma) and interleukin-17 (IL-17) in migraine patients.	Curcumin	61-69	interleukin 17A	Homo sapiens	191-205
33147541-1	2020	BACKGROUND: The present study was aimed to evaluate the nano-curcumin supplementation on Th1/Th17 balance by assessment of gene expression and serum level of interferon gamma (IFN-gamma) and interleukin-17 (IL-17) in migraine patients.	Curcumin	61-69	interleukin 17A	Homo sapiens	207-212
33147541-4	2020	RESULTS: Compared to placebo group, two month nano-curcumin supplementation led to a significant reduction in serum levels and expression of IL-17 mRNA (P = 0.006 & 0.04, respectively), while there was no statistical difference regarding serum levels and expression of IFN-gamma mRNA.	Curcumin	51-59	interleukin 17A	Homo sapiens	141-146
33147541-5	2020	CONCLUSION: Nano-curcumin supplementation in migraine patients led to a significant reduction in gene expression and plasma levels of IL-17 compared to control group.	Curcumin	17-25	interleukin 17A	Homo sapiens	134-139
32620467-5	2020	OBJECTIVE: The factors that can lead to RA includes inflammatory cascades, increased levels of (TNF-alpha) tumor necrosis factor alpha, IL-1b and IL-17 (interleukins) along with reduced levels of Nrf2 factors (nuclear factor-erythroid 2-related factor-2).	Radium	40-42	interleukin 17A	Homo sapiens	146-151
32696064-8	2020	With a limited number of studies available, IL-17A inhibitors exhibited remission rates of 15-21% for ASAS-PR and 11-16% for ASDAS-ID at week 16.	asas-pr	102-109	interleukin 17A	Homo sapiens	44-50
33023995-8	2020	Inhibition of Wnt signaling via ICG-001 resulted in significantly decreased nasal polypoid lesions (p<0.001), EMT-related markers (p=0.019 for E-cadherin and p=0.002 for vimentin) and the mRNA levels of IL-4 (p<0.001) and IL-17A (p=0.004) compared with the positive control group.	Indocyanine Green	32-35	interleukin 17A	Homo sapiens	222-228
32712400-9	2020	Moreover, monodansylcadaverine staining showed that cells treated with IL-17A had significantly fewer changes in their autophagic vacuoles compared to control-treated cells.	monodansylcadaverine	10-30	interleukin 17A	Homo sapiens	71-77
32860939-13	2020	Interestingly, AEA, but not 2-AG, was significantly, negatively correlated with interleukin (IL)-2 and IL-17a at six months follow-up.	aea	15-18	interleukin 17A	Homo sapiens	103-109
32536325-0	2020	Abstinent patients with alcohol use disorders show an altered plasma cytokine profile: Identification of both interleukin 6 and interleukin 17A as potential biomarkers of consumption and comorbid liver and pancreatic diseases.	Alcohols	24-31	interleukin 17A	Homo sapiens	128-143
32777075-10	2020	Amoxicillin-modified KP-2 and KP-3 peptide-specific CD4+ clones proliferated and secreted IFN-gamma, IL-10, perforin and/or IL-17/IL-22 in a dose-dependent manner and displayed no cross-reactivity with amoxicillin, unmodified peptide or with positional derivatives.	Amoxicillin	0-11	interleukin 17A	Homo sapiens	124-129
33091918-3	2021	Vitamin D has an immune-regulatory role and suppresses IL-17 production via direct transcriptional inhibition of IL-17 gene expression.	Vitamin D	0-9	interleukin 17A	Homo sapiens	55-60
33193433-7	2020	Further supporting an immune mechanism, CTX:SBA-15 treatment reduced both recruitment and proliferation of peripheral Th17 cells as well as diminished IL-17 expression and glial cells activation in the spinal cord in EAE animals when compared with CTX-treated EAE group.	SBA-15	44-50	interleukin 17A	Homo sapiens	151-156
33091918-3	2021	Vitamin D has an immune-regulatory role and suppresses IL-17 production via direct transcriptional inhibition of IL-17 gene expression.	Vitamin D	0-9	interleukin 17A	Homo sapiens	113-118
33091918-4	2021	OBJECTIVE: To explore the relationship of IL-17 and vitamin D levels with LP, and the possible inter-relationship between IL-17 and vitamin D.	Vitamin D	52-61	interleukin 17A	Homo sapiens	42-47
33091918-12	2021	However, a direct relationship between IL-17 and vitamin D deficiency could not be clarified.	Vitamin D	49-58	interleukin 17A	Homo sapiens	39-44
33044677-12	2021	had negative correlations with lysophospholipids metabolites, and three of them had also negative correlations with serum IL-17alpha.	Lysophospholipids	31-48	interleukin 17A	Homo sapiens	122-132
33132753-6	2020	We found that PB-MNC of SCD patients with or without ON presented significantly reduced TCD4+, TCD8+, and TCD4+ naive cell frequencies and increased frequency of circulating CD4+T cells able to simultaneously produce IFN-gamma +/IL4+ and IL-17+/IL4+ compared to healthy controls.	Lead	14-16	interleukin 17A	Homo sapiens	238-243
33060625-5	2020	Calcipotriol reduced T cell proliferation and production of IFN-gamma, granzyme B and IL-17, but increased IL-10 secretion.	calcipotriene	0-12	interleukin 17A	Homo sapiens	86-91
33117342-7	2020	Leonurine treatment had a direct recovery effect on the impaired balance and reduced the expression of TAZ and led to normalization of IL-17, IL-1beta, and TNF-alpha and IL-10.	leonurine	0-9	interleukin 17A	Homo sapiens	135-140
33377877-13	2020	On the other hand, IL-17 and IFN-gamma decreased after TACE in both groups, although not statistically significant.	Chlorotrianisene	55-59	interleukin 17A	Homo sapiens	19-24
33377877-15	2020	CONCLUSION: increased circulating Th1, Th17, and CD4+/IFN-gamma+/IL-17+ T cells were observed in HCC patients with complete or partial response to TACE.	Chlorotrianisene	147-151	interleukin 17A	Homo sapiens	65-70
32785828-0	2020	Immunomodulatory effect of diallyl sulfide on experimentally-induced benign prostate hyperplasia via the suppression of CD4+T/IL-17 and TGF-beta1/ERK pathways.	allyl sulfide	27-42	interleukin 17A	Homo sapiens	126-131
33911769-7	2020	Results: In comparison with healthy controls, TCDD-treated PBMCs and CD4+ T cells from patients with PS and AD showed an increase in AhR gene levels as well as significantly increased expression of AhR-related factors (such as AhR, CYP1A1, IL-17, and IL-22).	Polychlorinated Dibenzodioxins	46-50	interleukin 17A	Homo sapiens	240-245
32172331-9	2020	In addition, NaB decreased T regulatory cells and increased natural killer T cells and T helper 17 cells, accordingly decreased IL-10 and increased IL-17 secretion in CLM mice liver.	nab	13-16	interleukin 17A	Homo sapiens	148-153
32862457-9	2020	Collectively, our results demonstrated that Ca2+ -CaMK4-Akt/mTOR-IL-17A axis inhibition may serve as a promising therapeutic strategy for CP/CPPS.	cpps	141-145	interleukin 17A	Homo sapiens	65-71
33023123-5	2020	EVOO supplementation was associated with a reduction in body weight, waist circumference, body mass index (BMI), alanine transaminase and FLI, as well as interleukin (IL)-6, IL-17A, tumor necrosis factor-alpha and IL-1B, while IL-10 increased.	evoo	0-4	interleukin 17A	Homo sapiens	174-180
32702508-6	2020	We show that mother"s exposure to BPA increases proliferation of the spleen T helper 17 (Th17) cells and serum protein level of IL-17 in the offspring; however, VitD3 supplementation in mothers dose-dependently ameliorated these BPA-induced side effects on the immune system in the offspring as evidenced by attenuated upregulation of Th17 proliferation, and RORgammat, IL-17, IL-6, and IL-23 expressions in the offspring.	bisphenol A	34-37	interleukin 17A	Homo sapiens	128-133
32702508-6	2020	We show that mother"s exposure to BPA increases proliferation of the spleen T helper 17 (Th17) cells and serum protein level of IL-17 in the offspring; however, VitD3 supplementation in mothers dose-dependently ameliorated these BPA-induced side effects on the immune system in the offspring as evidenced by attenuated upregulation of Th17 proliferation, and RORgammat, IL-17, IL-6, and IL-23 expressions in the offspring.	bisphenol A	34-37	interleukin 17A	Homo sapiens	370-375
33090557-6	2020	Following ex vivo stimulation with phorbol myristate acetate/ionomycin, PSC patients showed significantly increased numbers of IL-17A-producing peripheral blood CD4+ T cells compared to PBC patients and healthy controls, indicating increased Th17 differentiation in vivo.	Tetradecanoylphorbol Acetate	35-60	interleukin 17A	Homo sapiens	127-133
33090557-6	2020	Following ex vivo stimulation with phorbol myristate acetate/ionomycin, PSC patients showed significantly increased numbers of IL-17A-producing peripheral blood CD4+ T cells compared to PBC patients and healthy controls, indicating increased Th17 differentiation in vivo.	Ionomycin	61-70	interleukin 17A	Homo sapiens	127-133
32627187-13	2020	Treating epithelia with IL-17 plus TNFalpha alkalinized ASL pH to ~7.0, increased paracellular HCO3 - permeability, and paracellular HCO3 - flux was negligible.	Bicarbonates	95-99	interleukin 17A	Homo sapiens	24-29
32725680-0	2020	Dexamethasone combined metronidazole on mammary duct ectasia and its relationship with serum IL-10 and IL-17.	Dexamethasone	0-13	interleukin 17A	Homo sapiens	103-108
32725680-0	2020	Dexamethasone combined metronidazole on mammary duct ectasia and its relationship with serum IL-10 and IL-17.	Metronidazole	23-36	interleukin 17A	Homo sapiens	103-108
32725680-1	2020	AIM: To explore the effect of dexamethasone combined with metronidazole in the treatment of mammary duct ectasia (MDE) and its relationship with changes in serum interleukin-10 (IL-10) and IL-17 expression.	Dexamethasone	30-43	interleukin 17A	Homo sapiens	189-194
32725680-1	2020	AIM: To explore the effect of dexamethasone combined with metronidazole in the treatment of mammary duct ectasia (MDE) and its relationship with changes in serum interleukin-10 (IL-10) and IL-17 expression.	Metronidazole	58-71	interleukin 17A	Homo sapiens	189-194
32173874-0	2020	Elevated Interleukin-17A expression in amlodipine-induced gingival overgrowth.	Amlodipine	39-49	interleukin 17A	Homo sapiens	9-24
32627187-13	2020	Treating epithelia with IL-17 plus TNFalpha alkalinized ASL pH to ~7.0, increased paracellular HCO3 - permeability, and paracellular HCO3 - flux was negligible.	Bicarbonates	133-137	interleukin 17A	Homo sapiens	24-29
32173874-5	2020	The aim of this study was to figure out the possible role of IL-17A in amlodipine-induced gingival overgrowth.	Amlodipine	71-81	interleukin 17A	Homo sapiens	61-67
33089034-6	2020	Consistent with this prediction, the PPARy antagonist T0070907 significantly increased HIV transcription (cell-associated HIV-RNA) and RORyt-mediated Th17 effector functions (IL-17A).	T 0070907	54-62	interleukin 17A	Homo sapiens	175-181
32173874-15	2020	Immunohistochemistry findings showed that IL-17A expression was increased in amlodipine samples (81.90%) compared with control samples (42.35%) (P < .001).	Amlodipine	77-87	interleukin 17A	Homo sapiens	42-48
32173874-18	2020	CONCLUSION: In this study, elevated IL-17A expression regardless of inflammation shows that amlodipine might cause an increase of IL-17A in gingival tissues.	Amlodipine	92-102	interleukin 17A	Homo sapiens	36-42
32173874-18	2020	CONCLUSION: In this study, elevated IL-17A expression regardless of inflammation shows that amlodipine might cause an increase of IL-17A in gingival tissues.	Amlodipine	92-102	interleukin 17A	Homo sapiens	130-136
32703116-15	2020	Regarding cytokine analysis, a negative correlation between daily caffeine consumption and serum level of IFNgamma was found (p = 0.03, r = -0.2); furthermore, patients with a high intake of caffeine showed lower serum levels of IFNalpha (p = 0.02), IL-17 (p = 0.01) and IL-6 (p = 0.003).	Caffeine	191-199	interleukin 17A	Homo sapiens	250-255
32871353-7	2020	Moreover, we found that circ_0003738 could bind to miR-562 to release the inhibition of target gene IL-17RA (IL-17 receptor A), thus promoting IL-17A signaling in psoriatic Tregs.	tregs	173-178	interleukin 17A	Homo sapiens	143-149
33062720-2	2020	CQ and HCQ are able to inhibit the production of cytokines such as interleukin- (IL-) 1, IL-2, IL-6, IL-17, and IL-22.	Chloroquine	0-2	interleukin 17A	Homo sapiens	101-106
33062720-2	2020	CQ and HCQ are able to inhibit the production of cytokines such as interleukin- (IL-) 1, IL-2, IL-6, IL-17, and IL-22.	Hydroxychloroquine	7-10	interleukin 17A	Homo sapiens	101-106
32660717-9	2020	After anaesthesia with propofol and remifentanil, IL17 (P=0.013), interferon gamma (P=0.003), and MICA (P=0.001) decreased, but IL6 (P=0.006) and L-selectin (P=0.001) increased.	Propofol	23-31	interleukin 17A	Homo sapiens	50-54
32886659-7	2020	In CS relative to OS, there were numerous differentially expressed genes including pro-inflammatory cytokines (IL17A, IL8, IL19, IL20 and OSM) and chemokines involved in immune cell activation and recruitment (CCL20, CCL27 and CXCL6).	Cesium	3-5	interleukin 17A	Homo sapiens	111-116
32484796-5	2020	The p38/MAPK pathway, involving NFAT5 and SGK1, regulated FoxP3 and IL-17A expression in high-NaCl conditions.	Sodium Chloride	94-98	interleukin 17A	Homo sapiens	68-74
32388860-5	2020	Exposure of peripheral Th17-Tregs (CD4+ CD25hi CD127lo CXCR3- CCR4+ CCR6+ ) to BMS-336 also inhibited IL-17A production and prevented inflammatory cytokine-induced destabilization, as evidenced by preserved FOXP3 expression and epigenetic status of the Treg-specific demethylation region.	tregs	28-33	interleukin 17A	Homo sapiens	102-108
32565006-0	2020	Predictive role of vitamin A serum concentration in psoriatic patients treated with IL-17 inhibitors to prevent skin and systemic fungal infections.	Vitamin A	19-28	interleukin 17A	Homo sapiens	84-89
32705251-0	2020	Shikonin inhibits CEBPD downregulation in IL-17-treated HaCaT cells and in an imiquimod-induced psoriasis model.	shikonin	0-8	interleukin 17A	Homo sapiens	42-47
32705251-3	2020	Shikonin, a natural naphthoquinone isolated from Lithospermum erythrorhizon, possesses anti-inflammatory and immunosuppressive properties and can suppress IL-17-induced vascular endothelial growth factor expression by inhibiting the JAK/STAT3 pathway.	shikonin	0-8	interleukin 17A	Homo sapiens	155-160
32705251-8	2020	Shikonin reversed IL-17-mediated downregulation of the tumor suppressor CEBPD in HaCaT cells.	shikonin	0-8	interleukin 17A	Homo sapiens	18-23
32808031-9	2020	Thus, our findings suggest that tofacitinib is quite effective in protecting from colitis by inhibition of a bundle of T cell derived cytokines like IL-5, IL-6, IL-9, IL-13 and IL-17A.	tofacitinib	32-43	interleukin 17A	Homo sapiens	177-183
32868758-12	2020	Our results thus show that the ionic environment typical in SLT impairs IL-17 immunity, but the intracellular pathways that mediate salt-driven Th17 polarisation are intact and in vitro IL-17 responses can be reinvigorated by increasing extracellular sodium concentration.	Sodium	251-257	interleukin 17A	Homo sapiens	186-191
32869036-16	2020	Discussion The Th17 mediated IL-17 proinflammatory response can potentially be attenuated by thiamine.	Thiamine	93-101	interleukin 17A	Homo sapiens	29-34
32497931-4	2020	These results suggest imbalanced Tfh cell regulation, further supported by increased frequencies of CD4 T cells co-producing IL-21/IL-17 and IL-17/IFN-gamma, and increased Tfh-supported IgG production.	tfh	33-36	interleukin 17A	Homo sapiens	131-136
32497931-4	2020	These results suggest imbalanced Tfh cell regulation, further supported by increased frequencies of CD4 T cells co-producing IL-21/IL-17 and IL-17/IFN-gamma, and increased Tfh-supported IgG production.	tfh	33-36	interleukin 17A	Homo sapiens	141-146
32793904-5	2020	Consistent with known DHODH requirements for immunomodulatory cytokine production, PTC299 inhibited the production of interleukin (IL)-6, IL-17A (also called IL-17), IL-17F, and vascular endothelial growth factor (VEGF) in tissue culture models.	6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole	83-89	interleukin 17A	Homo sapiens	138-144
32793904-5	2020	Consistent with known DHODH requirements for immunomodulatory cytokine production, PTC299 inhibited the production of interleukin (IL)-6, IL-17A (also called IL-17), IL-17F, and vascular endothelial growth factor (VEGF) in tissue culture models.	6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole	83-89	interleukin 17A	Homo sapiens	138-143
32403163-6	2020	Surprisingly, SR completely inhibited the differentiation of IL-17-producing cells and facilitated Treg generation in the inflammatory condition and had highly suppressive activity against T cell proliferation without Treg -specific demethylase region (TSDR) demethylation.	Strontium	14-16	interleukin 17A	Homo sapiens	61-66
32742398-11	2020	In addition, miR-510-3p was identified as the downstream target of MIR4435-2HG, and miR-510-3p directly targeted IL-17A.	mir-510-3p	84-94	interleukin 17A	Homo sapiens	113-119
32817992-4	2020	Results Tacrolimus significantly increased the expression of LIF, IL-10, and IL-17 and decreased the expression of IL-4, IFN-gamma, and the IFN-gamma/IL-10 ratio in RIF patients.	Tacrolimus	8-18	interleukin 17A	Homo sapiens	77-82
32380371-6	2020	Progesterone and dydrogesterone significantly down-regulated the secretion of the Th1 cytokines IFN-alpha and TNF-gamma, and the Th17 cytokine IL-17A, and IL-23.	Progesterone	0-12	interleukin 17A	Homo sapiens	143-149
32380371-6	2020	Progesterone and dydrogesterone significantly down-regulated the secretion of the Th1 cytokines IFN-alpha and TNF-gamma, and the Th17 cytokine IL-17A, and IL-23.	Dydrogesterone	17-31	interleukin 17A	Homo sapiens	143-149
32802141-8	2020	Shikonin significantly inhibited Der p 2-induced expression of interleukin (IL)-6, IL-9, and IL-17A; monocyte chemoattractant protein (MCP)-1; macrophage inflammatory protein (MIP)-1alpha; MIP-1beta; and Chemokine (C-C motif) ligand 5 (RANTES).	shikonin	0-8	interleukin 17A	Homo sapiens	93-99
32680482-0	2020	Combined signaling of NF-kappaB and IL-17 contributes to Mesenchymal stem cells-mediated protection for Paraquat-induced acute lung injury.	Paraquat	104-112	interleukin 17A	Homo sapiens	36-41
32774513-7	2020	In the second part of the study, the tissue expression of IL-17 was assessed in archival paraffin-embedded biopsy specimens from CLP (n = 14) against normal control tissues (n = 11) using immunohistochemical assays.	Paraffin	89-97	interleukin 17A	Homo sapiens	58-63
32680482-8	2020	CONCLUSION: This study not only reiterates the important role of NF-kappaB signaling and IL-17 signaling in the pathogenesis of PQ-induced toxicity, but also provides insight into a molecular basis of MSC administration for the treatment of PQ-induced toxicity.	Paraquat	128-130	interleukin 17A	Homo sapiens	89-94
32775222-6	2020	However, a significantly lower plasma IL-17A detection was obtained with E_41802 compared to the two other ELISAs.	e_41802	73-80	interleukin 17A	Homo sapiens	38-44
31036393-11	2020	CONCLUSION: Plant derived essential oils and related active compounds have potential therapeutic activity for the treatment of asthma by modulating the release of pro-inflammatory (TNF-alpha, IL-1beta, IL-8), Th17 (IL-17), anti-inflammatory (IL-10), Th1 (IFN-gamma, IL-2, IL-12) and Th2 (IL-4, IL-5, IL-6, IL-13) cytokines and the suppression of inflammatory cell accumulation.	Oils, Volatile	26-40	interleukin 17A	Homo sapiens	215-220
32793721-14	2020	IL-17a neutralizing antibody or JAK2 inhibitor AG490 can significantly inhibit the effects of CAFs on the migration, invasion, MMP2/9, TIMP1/2, and JAK2/STAT3 pathways of GC cells.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	47-52	interleukin 17A	Homo sapiens	0-6
32668224-3	2020	describe that interleukin-17 (IL-17) re-programs the urea cycle in keratinocytes increasing polyamines that stabilize RNA-Ag-complexes that upon cellular turnover activate dendritic cells, which amplify psoriasis inflammation.	Urea	53-57	interleukin 17A	Homo sapiens	14-28
32668224-3	2020	describe that interleukin-17 (IL-17) re-programs the urea cycle in keratinocytes increasing polyamines that stabilize RNA-Ag-complexes that upon cellular turnover activate dendritic cells, which amplify psoriasis inflammation.	Urea	53-57	interleukin 17A	Homo sapiens	30-35
32849611-10	2020	Pre-incubation with Dexamethasone (Dexa) led to a decrease in GR-alpha/GR-beta ratio in obese adipocytes which was further affected by IL-17A whereas Dexa led to an increase in GR-alpha/GR-beta ratio in lean adipocytes which was decreased in response to IL-17A.	Dexamethasone	20-33	interleukin 17A	Homo sapiens	135-141
32849611-10	2020	Pre-incubation with Dexamethasone (Dexa) led to a decrease in GR-alpha/GR-beta ratio in obese adipocytes which was further affected by IL-17A whereas Dexa led to an increase in GR-alpha/GR-beta ratio in lean adipocytes which was decreased in response to IL-17A.	Dexamethasone	20-33	interleukin 17A	Homo sapiens	254-260
32849611-10	2020	Pre-incubation with Dexamethasone (Dexa) led to a decrease in GR-alpha/GR-beta ratio in obese adipocytes which was further affected by IL-17A whereas Dexa led to an increase in GR-alpha/GR-beta ratio in lean adipocytes which was decreased in response to IL-17A.	Dexamethasone	20-24	interleukin 17A	Homo sapiens	135-141
32849611-10	2020	Pre-incubation with Dexamethasone (Dexa) led to a decrease in GR-alpha/GR-beta ratio in obese adipocytes which was further affected by IL-17A whereas Dexa led to an increase in GR-alpha/GR-beta ratio in lean adipocytes which was decreased in response to IL-17A.	Dexamethasone	20-24	interleukin 17A	Homo sapiens	254-260
32849611-10	2020	Pre-incubation with Dexamethasone (Dexa) led to a decrease in GR-alpha/GR-beta ratio in obese adipocytes which was further affected by IL-17A whereas Dexa led to an increase in GR-alpha/GR-beta ratio in lean adipocytes which was decreased in response to IL-17A.	Dexamethasone	35-39	interleukin 17A	Homo sapiens	135-141
32849611-10	2020	Pre-incubation with Dexamethasone (Dexa) led to a decrease in GR-alpha/GR-beta ratio in obese adipocytes which was further affected by IL-17A whereas Dexa led to an increase in GR-alpha/GR-beta ratio in lean adipocytes which was decreased in response to IL-17A.	Dexamethasone	35-39	interleukin 17A	Homo sapiens	254-260
32335141-0	2020	Ellipticine blocks synergistic effects of IL-17A and TNF-alpha in epithelial cells and alleviates severe acute pancreatitis-associated acute lung injury.	ellipticine	0-11	interleukin 17A	Homo sapiens	42-48
32335141-3	2020	However, it is still unknown whether ellipticine can inhibit IL-17A and TNF-alpha-mediated signaling and has treatment effect on PALI.	ellipticine	37-48	interleukin 17A	Homo sapiens	61-67
32335141-4	2020	Here, we reported that ellipticine significantly inhibited the production of pro-inflammatory cytokines and chemokines in pulmonary epithelial cell BEAS-2B treated with IL-17A and TNF-alpha, but not IL-17A or TNF-alpha alone.	ellipticine	23-34	interleukin 17A	Homo sapiens	169-175
32335141-5	2020	Meanwhile, ellipticine attenuated NF-kappaB and MAPKs activation in response to IL-17A and TNF-alpha treatment, inhibited Act1 and TRAF6-mediated NF-kappaB activation, and blocked the interaction of Act1 with TRAF6.	ellipticine	11-22	interleukin 17A	Homo sapiens	80-86
32335141-8	2020	Collectively, our findings indicate that ellipticine inhibits the synergistic effect of IL-17A and TNF-alpha by targeting on Act1 and TRAF6 interaction and is a potential therapeutic agent for the treatment of SAP/PALI.	ellipticine	41-52	interleukin 17A	Homo sapiens	88-94
32360069-4	2020	In vitro, seletalisib inhibited the production of pro-inflammatory cytokines, including IL-17A and IL-17F, from peripheral blood mononuclear cells (PBMCs), T helper 17 (Th17) cells as well as gammadelta-T cells and mucosal-associated invariant T cells.	seletalisib	10-21	interleukin 17A	Homo sapiens	88-94
32067249-10	2020	AZD0284 showed dose-dependent reduction of ex vivo stimulated IL-17A release after both single and multiple doses.	scyllitol	0-7	interleukin 17A	Homo sapiens	62-68
32067249-12	2020	CONCLUSIONS: AZD0284 was well tolerated, rapidly and dose-dependently absorbed, and reduced stimulated IL-17A release after single and multiple dosing.	scyllitol	13-20	interleukin 17A	Homo sapiens	103-109
32537005-7	2020	However, treatment with helenalin, a NF-kappaB inhibitor, decreased p65 phosphorylation, attenuated IL-17-induced podocyte apoptosis and suppressed the IL-17-activated Fas/FasL/caspase-8/caspase-3 apoptotic pathway.	helenalin	24-33	interleukin 17A	Homo sapiens	100-105
32537005-7	2020	However, treatment with helenalin, a NF-kappaB inhibitor, decreased p65 phosphorylation, attenuated IL-17-induced podocyte apoptosis and suppressed the IL-17-activated Fas/FasL/caspase-8/caspase-3 apoptotic pathway.	helenalin	24-33	interleukin 17A	Homo sapiens	152-157
32300908-11	2020	IL-17 was higher in subjects with fewer missing teeth if the following criteria were fulfilled: shorter prednisolone (< 5 mg) and methotrexate therapy, more swollen joints, longer morning stiffness.	Prednisolone	104-116	interleukin 17A	Homo sapiens	0-5
32713148-0	2020	Zytokine der IL-17-Familie bei der Psoriasis.	zytokine	0-8	interleukin 17A	Homo sapiens	13-18
32300908-11	2020	IL-17 was higher in subjects with fewer missing teeth if the following criteria were fulfilled: shorter prednisolone (< 5 mg) and methotrexate therapy, more swollen joints, longer morning stiffness.	Methotrexate	130-142	interleukin 17A	Homo sapiens	0-5
32602469-8	2020	CONCLUSION: Exposure to RF-EMF for 60 minutes at 5 cm distance causes a significant reduction in the number of CD4+ T cells, IL-2, IL-10 and IL-17a expressing T cells.	rf-emf	24-30	interleukin 17A	Homo sapiens	141-147
32590737-6	2020	In addition, ATO significantly reduced the levels of IFN-gamma (at 1, 2.5 and 5 mumol/L, P < .001), IL-4 (at 2.5 mumol/L, P = .009; at 5 mumol/L, P < .001), and IL-17 (at 2.5, P = .016; at 5 mumol/L, P < .001).	Arsenic Trioxide	13-16	interleukin 17A	Homo sapiens	161-166
32615662-0	2020	Increased miR-223-3p in Leukocytes Positively Correlated with IL-17A in Plasma of Asthmatic Patients.	mir-223-3p	10-20	interleukin 17A	Homo sapiens	62-68
32637034-6	2020	Indoximod increases the transcription of RORC while inhibiting transcription of FOXP3, thus favoring differentiation to IL-17-producing helper T cells and inhibiting the differentiation of regulatory T cells.	1-methyltryptophan	0-9	interleukin 17A	Homo sapiens	120-125
32655793-8	2020	Moreover, fingolimod suppressed the secretion of pro-inflammatory or inflammatory cytokines IL-17A, IL-6, and INF-gamma, but did not noticeably alter the secretion of immunosuppressive cytokines TGF-beta1 and IL-4.	Fingolimod Hydrochloride	10-20	interleukin 17A	Homo sapiens	92-98
32512720-6	2020	WGPH treatment reduced cell proliferation and the production of the Type 1 T helper (Th1) and Th17 pro-inflammatory cytokines IFN-gamma and IL-17, respectively.	wgph	0-4	interleukin 17A	Homo sapiens	140-145
32582751-2	2020	Among the phytonutrients, epidemiological and experimental studies show that dietary organosulfur compounds (OSC) play a significant role in preventing various human pathological progressions, including chronic inflammation, by decreasing inflammatory mediators such as nitric oxide (NO), prostaglandin (PG)E2, interleukin (IL)-1beta, IL-6, tumor necrosis factor (TNF)-alpha, and IL-17, which are all typical hallmarks of inflammation.	organosulfur compounds	85-107	interleukin 17A	Homo sapiens	380-385
31630153-10	2020	Cobitolimod inhibited IL17A and IL17F, but increased IL10 and FoxP3 expression in cultured intestinal UC T cells.	Cobitolimod	0-11	interleukin 17A	Homo sapiens	22-27
32565729-6	2020	We found that, in both the normal and ETEC-infected piglets, jejunal SIgA secretion and expression of some cytokines, such as IL-4, IL-13, and IL-17, were increased by GABA supplementation.	gamma-Aminobutyric Acid	168-172	interleukin 17A	Homo sapiens	143-148
32200408-11	2020	This IL-17A elevation was present in the total NIU group (p = 0.08) as well as a positive correlation between IL-17A levels and the absolute counts of memory Tregs (p = 0.013; R = 0.465).	NIU	47-50	interleukin 17A	Homo sapiens	5-11
31660620-7	2020	Meanwhile, IL-17A secretion and CCR6 co-expression levels in Tregs were significantly increased in active UC.	tregs	61-66	interleukin 17A	Homo sapiens	11-17
31660620-11	2020	These findings suggested that upregulated IL-17A secretion and CCR6 co-expression in Treg subsets may be related to the imbalance between Tregs and Th17 cells and associated with the disease activity in UC patients.	tregs	138-143	interleukin 17A	Homo sapiens	42-48
31630153-11	2020	Cobitolimod-mediated suppression of intestinal IL17+T cells was abrogated by IL10 blockade.	Cobitolimod	0-11	interleukin 17A	Homo sapiens	47-51
31630153-13	2020	Immunohistochemistry in intestinal biopsies of cobitolimod-treated UC patients indicated increased presence of IL10+mononuclear and regulatory T cells, as well as reduction of IL17+cells.	Cobitolimod	47-58	interleukin 17A	Homo sapiens	176-180
32509883-9	2020	As a novel finding, we demonstrate that human Treg injection led to a reduction of IL-17-secreting cells while promoting a relative increase in immunosuppressive FOXP3+ Treg in the human skin, indicating active immune regulation in controlling the local proinflammatory response.	treg	46-50	interleukin 17A	Homo sapiens	83-88
32478182-11	2020	Our results also showed that Majie Cataplasm and dexamethasone could inhibit the secretion of CGRP and the infiltration of T lymphocytes together with neutrophils in lung tissue and reduce expressions of CGRP mRNA, SP mRNA, IL-17 mRNA and IL-13 mRNA in lung tissue.	Dexamethasone	49-62	interleukin 17A	Homo sapiens	224-229
32489459-7	2020	Pretreatment of cells with U0126 could reverse the nuclear translocation of NF-kappaB/p50 and p65 and EMT induced by IL-17A.	U 0126	27-32	interleukin 17A	Homo sapiens	117-123
32670268-10	2020	Inhibition of autophagy using bafilomycin-A1 reduced PINK1 expression in NHBF and restored the IL-17 mediated changes in PINK1 to their basal levels in DHBF.	bafilomycin	30-41	interleukin 17A	Homo sapiens	95-100
32670268-11	2020	Bafilomycin-A1 also reversed the IL-17 associated fibrotic response in these fibroblasts, suggesting a role for IL-17 induced autophagy in the induction of fibrosis in bronchial fibroblasts.	bafilomycin	0-11	interleukin 17A	Homo sapiens	33-38
32670268-11	2020	Bafilomycin-A1 also reversed the IL-17 associated fibrotic response in these fibroblasts, suggesting a role for IL-17 induced autophagy in the induction of fibrosis in bronchial fibroblasts.	bafilomycin	0-11	interleukin 17A	Homo sapiens	112-117
32509883-10	2020	Consistent with the local control (skin), systemically (splenocytes), we observed that Treg injection led to lower frequencies of IFNgamma and IL-17A-expressing human T cells, while a trend towards enrichment of FOXP3+ Treg was observed.	treg	87-91	interleukin 17A	Homo sapiens	143-149
31138901-0	2020	Interleukin-17A polymorphisms predict the response and development of tolerance to FOLFOX chemotherapy in colorectal cancer treatment.	Folfox protocol	83-89	interleukin 17A	Homo sapiens	0-15
31643095-9	2020	The present study confirms a synergistic effect of osteocytes and IL-17 in the production of biochemical signals to stimulate the osteogenic differentiation of MSCs, which could be further promoted in the PCL 3D-scaffold.	starch polycaprolactone	205-208	interleukin 17A	Homo sapiens	66-71
32020710-5	2020	Our results indicated that paroxetine attenuates proinflammatory cytokine production (interleukin-1beta [IL-1beta], IL-17, and tumor necrosis factor-alpha) and increases expression of IL-10 and JAK2/STAT3 evidence for macrophages polarization to M2 subset and functional dendritic cells depletion.	Paroxetine	27-37	interleukin 17A	Homo sapiens	116-154
32051095-0	2020	Atorvastatin inhibits IL-17A, TNF, IL-6, and IL-10 in PBMC cultures from patients with severe rheumatoid arthritis.	atorvastatin	0-12	interleukin 17A	Homo sapiens	22-28
32051095-10	2020	RESULTS: Atorvastatin showed no toxicity at the tested doses in RA PBMC cultures, and at 10muM, it showed the most significant results, reducing IL-17A (p = 0.002), TNF (p = 0.002), and IL-6 (p = 0.008) supernatant levels.	atorvastatin	9-21	interleukin 17A	Homo sapiens	145-151
32349768-4	2020	Moreover, dimethyl itaconate (DMI), an itaconate derivative, inhibits IL-17-induced IkappaBsigma activation in keratinocytes and modulates IL-17-IkappaBsigma pathway-mediated skin inflammation in an animal model of psoriasis.	dimethyl itaconate	10-28	interleukin 17A	Homo sapiens	70-75
32122724-0	2020	Battling IL-17, the troublemaker in alcohol-induced hepatocellular carcinoma.	Alcohols	36-43	interleukin 17A	Homo sapiens	9-14
32048307-0	2020	The prostaglandin E2 increases the production of IL-17 and the expression of costimulatory molecules on gammadelta T cells in rheumatoid arthritis.	Dinoprostone	4-20	interleukin 17A	Homo sapiens	49-54
32048307-6	2020	After adding PGE2 to gammadelta T cells from RA patients, the IL-17A level increased accordingly, and the expression of the costimulatory molecules, CD80 and CD86 on these cells also increased.	Dinoprostone	13-17	interleukin 17A	Homo sapiens	62-68
32048307-7	2020	These results suggest that PEG2 can increase the production of IL-17A and the expression of CD80 and CD86 on gammadelta T cells in RA patients.	pentaerythritol poly(ethylene glycol) ether tetrasuccinimidyl glutarate	27-31	interleukin 17A	Homo sapiens	63-69
32349768-4	2020	Moreover, dimethyl itaconate (DMI), an itaconate derivative, inhibits IL-17-induced IkappaBsigma activation in keratinocytes and modulates IL-17-IkappaBsigma pathway-mediated skin inflammation in an animal model of psoriasis.	dimethyl itaconate	10-28	interleukin 17A	Homo sapiens	139-144
32349768-4	2020	Moreover, dimethyl itaconate (DMI), an itaconate derivative, inhibits IL-17-induced IkappaBsigma activation in keratinocytes and modulates IL-17-IkappaBsigma pathway-mediated skin inflammation in an animal model of psoriasis.	dimethyl itaconate	30-33	interleukin 17A	Homo sapiens	70-75
32349768-4	2020	Moreover, dimethyl itaconate (DMI), an itaconate derivative, inhibits IL-17-induced IkappaBsigma activation in keratinocytes and modulates IL-17-IkappaBsigma pathway-mediated skin inflammation in an animal model of psoriasis.	dimethyl itaconate	30-33	interleukin 17A	Homo sapiens	139-144
32349768-4	2020	Moreover, dimethyl itaconate (DMI), an itaconate derivative, inhibits IL-17-induced IkappaBsigma activation in keratinocytes and modulates IL-17-IkappaBsigma pathway-mediated skin inflammation in an animal model of psoriasis.	itaconic acid	19-28	interleukin 17A	Homo sapiens	70-75
32349768-4	2020	Moreover, dimethyl itaconate (DMI), an itaconate derivative, inhibits IL-17-induced IkappaBsigma activation in keratinocytes and modulates IL-17-IkappaBsigma pathway-mediated skin inflammation in an animal model of psoriasis.	itaconic acid	19-28	interleukin 17A	Homo sapiens	139-144
32351959-6	2020	In this study, we reported that high glucose-induced lncRNA-MIAT upregulation is responsible for proinflammatory IL-17 production in cardiomyocytes.	Glucose	37-44	interleukin 17A	Homo sapiens	113-118
32372631-10	2020	EP/HS oil treatment significantly inhibited the expression of RAPTOR, IFN-gamma, IL-17, and STAT3 genes and promoted the expression of RICTOR, IL-10, and FOXP3 genes.	ep/hs oil	0-9	interleukin 17A	Homo sapiens	81-86
32313725-10	2020	In conclusion, tumor-infiltrating IL17A+ cells were correlated with an elevated anti-tumor immunity in MIBC.	4-METHYL-2-PENTANOL	103-107	interleukin 17A	Homo sapiens	34-39
32322257-4	2020	These cells displayed the typical morphology and markers of astroglia, and were susceptible to the action of inflammatory mediators and BAF312, because expressing receptors for IL1, IL17, and S1P (namely S1P1 and S1P3).	siponimod	136-142	interleukin 17A	Homo sapiens	182-186
32169850-4	2020	To develop a novel gene-silencing agent that targets IL-23/IL-17 axis, we designed polyamide that specifically binds to the transcription factor c-Rel-binding site located in the promoter of IL-23p19 subunit.	Nylons	83-92	interleukin 17A	Homo sapiens	59-64
32251441-1	2020	BACKGROUND & AIMS: In our previous study, a Seesaw model was proposed for the fluctuation of crucial anti- (IL-10) and pro-inflammatory (Il-6 & IL-17A) cytokines through vitamin D3.	Cholecalciferol	170-180	interleukin 17A	Homo sapiens	144-150
32251441-7	2020	In addition, the plasma levels of IL-27, TGF-beta1, IL-10, IL-17A, and IL-6 significantly changed following the administration of vitamin D3.	Cholecalciferol	130-140	interleukin 17A	Homo sapiens	59-65
31838663-0	2020	Tacrolimus Inhibits TNF-alpha/IL-17A-Produced pro-Inflammatory Effect on Human Keratinocytes by Regulating IkappaBzeta.	Tacrolimus	0-10	interleukin 17A	Homo sapiens	30-36
31608649-0	2020	MiR-126 targets IL-17A to enhance proliferation and inhibit apoptosis in high-glucose-induced human retinal endothelial cells.	Glucose	78-85	interleukin 17A	Homo sapiens	16-22
31608649-3	2020	The results showed that expression of miR-126 and interleukin-17A (IL-17A) in high-glucose-induced HRECs was downregulated and upregulated, respectively.	Glucose	83-90	interleukin 17A	Homo sapiens	50-65
31608649-3	2020	The results showed that expression of miR-126 and interleukin-17A (IL-17A) in high-glucose-induced HRECs was downregulated and upregulated, respectively.	Glucose	83-90	interleukin 17A	Homo sapiens	67-73
31608649-8	2020	Altogether, miR-126 enhances proliferation and inhibits apoptosis in high-glucose-induced HRECs by activating the PI3K/AKT pathway, increasing survivinand decreasing Bax and caspase-3 expression by targeting IL-17A, suggesting that miR-126 may be a novel target for preventing DR.	Glucose	74-81	interleukin 17A	Homo sapiens	208-214
31838663-3	2020	This study aimed to investigate the potential regulatory effect of tacrolimus on TNF-alpha/ IL-17A-costimulated human keratinocytes in the mimic psoriatic microenvironment.	Tacrolimus	67-77	interleukin 17A	Homo sapiens	92-98
31838663-8	2020	Tacrolimus significantly inhibited TNF-alpha/IL-17A-induced IL-36gamma, CCL-20, IL-1beta, and S100-A9 expression at gene level and IL-36gamma and CCL-20 expression at protein level.	Tacrolimus	0-10	interleukin 17A	Homo sapiens	45-51
31838663-9	2020	We further discovered TNF-alpha/IL-17A induced significant IkappaBzeta mRNA and protein expression in NHKs, which could be inhibited by tacrolimus.	Tacrolimus	136-146	interleukin 17A	Homo sapiens	32-38
31838663-10	2020	Tacrolimus can inhibit pro-inflammatory synergistic action of TNF-alpha/IL-17A on human keratinocytes by regulating IkappaBzeta expression.	Tacrolimus	0-10	interleukin 17A	Homo sapiens	72-78
32210598-10	2020	Conclusion: This preliminary study of MPP in a pediatric population has shown that measurement of serum IL-17A may be a useful marker for the predictor of RMPP.	rmpp	155-159	interleukin 17A	Homo sapiens	104-110
32074467-10	2020	There was also a statistically positive linear association between TG and IL-17.	Triglycerides	67-69	interleukin 17A	Homo sapiens	74-79
32044269-14	2020	This study provides the first evidence that cyanidin can be used as IL-17/17RA signalling targeting therapeutic drug for the treatment of RA and this need to be investigated in RA patients.	cyanidin	44-52	interleukin 17A	Homo sapiens	68-73
32210598-8	2020	A serum IL-17A level above 10.8 pg/mL was a predictor for RMPP: area under the curve (AUC) 0.822; standard error (SE) 0.039; 95% confidence interval (CI) 0.746-0.897; diagnostic sensitivity and specificity of 77.8% and 77.1%, respectively.	rmpp	58-62	interleukin 17A	Homo sapiens	8-14
31465741-0	2020	A Zingerone Analog, Acetyl Zingerone, Bolsters Matrisome Synthesis, Inhibits Matrix Metallopeptidases, and Represses IL-17A Target Gene Expression.	zingerone	2-11	interleukin 17A	Homo sapiens	117-123
31887550-6	2020	Si-H19 significantly downregulated miR22-5p and upregulated miR675-5p expression; Si-H19 decreased the protein and mRNA expression of VDR and decreased the cytokine and mRNA levels of interleukin-17A (IL-17A) and IL-23.	Silicon	0-2	interleukin 17A	Homo sapiens	184-199
31887550-6	2020	Si-H19 significantly downregulated miR22-5p and upregulated miR675-5p expression; Si-H19 decreased the protein and mRNA expression of VDR and decreased the cytokine and mRNA levels of interleukin-17A (IL-17A) and IL-23.	Silicon	0-2	interleukin 17A	Homo sapiens	201-207
31887550-6	2020	Si-H19 significantly downregulated miR22-5p and upregulated miR675-5p expression; Si-H19 decreased the protein and mRNA expression of VDR and decreased the cytokine and mRNA levels of interleukin-17A (IL-17A) and IL-23.	Silicon	82-84	interleukin 17A	Homo sapiens	184-199
31887550-6	2020	Si-H19 significantly downregulated miR22-5p and upregulated miR675-5p expression; Si-H19 decreased the protein and mRNA expression of VDR and decreased the cytokine and mRNA levels of interleukin-17A (IL-17A) and IL-23.	Silicon	82-84	interleukin 17A	Homo sapiens	201-207
31901549-5	2020	The addition of IL-17A (25-100 mug) to human renal proximal tubular cells or renal fibroblasts caused an increase in fibronectin production and extracellular signal-regulated kinase (ERK)1/2 activation, which were reduced upon pretreatment with the ERK inhibitor U0126.	U 0126	263-268	interleukin 17A	Homo sapiens	16-22
31901549-8	2020	The administration of an anti-TGF-beta1 neutralizing antibody or TGF-beta1 receptor I inhibitor (SB431542) to cells abrogated the IL-17A-mediated increase of fibronectin production.	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	97-105	interleukin 17A	Homo sapiens	130-136
31901549-9	2020	IL-17A induced an increase in p-Smad2 and p-Smad3 expression at 7.5 min and 24 h and pretreatment with the anti-TGF-beta1 neutralizing antibody, and SB431542 reduced the IL-17A-stimulated increase of p-Smad2.	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	149-157	interleukin 17A	Homo sapiens	0-6
31901549-9	2020	IL-17A induced an increase in p-Smad2 and p-Smad3 expression at 7.5 min and 24 h and pretreatment with the anti-TGF-beta1 neutralizing antibody, and SB431542 reduced the IL-17A-stimulated increase of p-Smad2.	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	149-157	interleukin 17A	Homo sapiens	170-176
31327083-8	2020	DOXY group exhibited a significant increase in the levels of anti-inflammatory interleukin (IL)-10 and a reduction in IL-8, IFN-y, IL-6, and IL-17 (p &lt; 0.05), significant reduction in periodontal pathogens (p &lt; 0.05), and a lower mean percentage of HbA1C at 3 months (p &lt; 0.05).	Doxycycline	0-4	interleukin 17A	Homo sapiens	141-146
32194991-6	2020	To further reveal the mechanism involved, we examined how metformin treatment affected NLRP3 inflammasome activated by TNF-alpha and IL-17A stimulation.	Metformin	58-67	interleukin 17A	Homo sapiens	133-139
32194991-10	2020	Metformin treatment inhibited upregulation of IL-36gamma, CXCL1, CXCL2, CCL20, S100A7, S100A8 and S100A9 mRNA and protein levels induced by TNF-alpha and IL-17A stimulation.	Metformin	0-9	interleukin 17A	Homo sapiens	154-160
32180840-7	2020	One study reported mSASSS progression in patients with AS treated with secukinumab, an interleukin-17A inhibitor.	msasss	19-25	interleukin 17A	Homo sapiens	87-102
32383705-15	2020	As it was established the amount of bacteria producing short-chain fatty acids (SCFA) markedly decrease in T2-D, and treatment with SCFA reduced induction of TFN-alpha, IL-10 and IL-17 cytokines in contrast to IL-6, IFN-y and IL-22, without modification of their induction after using of SCFA.	Fatty Acids, Volatile	132-136	interleukin 17A	Homo sapiens	179-184
32383705-15	2020	As it was established the amount of bacteria producing short-chain fatty acids (SCFA) markedly decrease in T2-D, and treatment with SCFA reduced induction of TFN-alpha, IL-10 and IL-17 cytokines in contrast to IL-6, IFN-y and IL-22, without modification of their induction after using of SCFA.	Fatty Acids, Volatile	132-136	interleukin 17A	Homo sapiens	179-184
31465741-0	2020	A Zingerone Analog, Acetyl Zingerone, Bolsters Matrisome Synthesis, Inhibits Matrix Metallopeptidases, and Represses IL-17A Target Gene Expression.	acetyl zingerone	20-36	interleukin 17A	Homo sapiens	117-123
32121312-5	2020	Nevertheless, in cell cultures under strong inflammatory activation by poly (I:C), clozapine reduced the levels of IL-1alpha, IL-1beta, IL-2, and IL-17.	Clozapine	83-92	interleukin 17A	Homo sapiens	146-151
32863248-4	2020	The aim of this study is to compare the effects of serum vitamin D on serum IL 17 and pulmonary function test (FVC, FEV1, FEV1/FVC) before and after oral vitamin D supplementation.	Vitamin D	57-66	interleukin 17A	Homo sapiens	76-81
32114280-3	2020	We hypothesized that curcumin could inhibit interferon (IFN)-gamma and interleukin (IL)-17 production in peripheral blood mononuclear cells from patients with psoriasis and psoriatic arthritis (PsA).	Curcumin	21-29	interleukin 17A	Homo sapiens	71-90
32114280-9	2020	In conclusion, curcumin in vitro inhibits pro-inflammatory IFN-gamma and IL-17 production in psoriatic disease, and this may strengthen its role as a dietary immunosuppressant in patients with this disease.	Curcumin	15-23	interleukin 17A	Homo sapiens	73-78
32121312-6	2020	Risperidone and haloperidol both reduced the levels of IL-1alpha, IL-1beta, IL-2, and IL-17, and increased the levels of IL-6, IL-10, INF-gamma, and TNF-alpha.	Haloperidol	16-27	interleukin 17A	Homo sapiens	86-91
32121312-9	2020	Clozapine and CRID3 both reduced the IL-1alpha, IL-1beta, IL-2, and IL-17 levels.	Clozapine	0-9	interleukin 17A	Homo sapiens	68-73
32121312-9	2020	Clozapine and CRID3 both reduced the IL-1alpha, IL-1beta, IL-2, and IL-17 levels.	N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide	14-19	interleukin 17A	Homo sapiens	68-73
32121312-6	2020	Risperidone and haloperidol both reduced the levels of IL-1alpha, IL-1beta, IL-2, and IL-17, and increased the levels of IL-6, IL-10, INF-gamma, and TNF-alpha.	Risperidone	0-11	interleukin 17A	Homo sapiens	86-91
32076052-2	2020	Cefazolin, a safe, first-generation cephalosporin antibiotic, has been recently shown to specifically interact with interleukin 15 (IL-15) receptor subunit alpha (IL-15Ralpha) and to inhibit IL-15-dependent TNF-alpha and IL-17 synthesis.	Cefazolin	0-9	interleukin 17A	Homo sapiens	221-226
32106058-8	2020	We also found a decrease in the levels of IL-1beta, IL-6, IL-17, and IL-23 cytokines in the culture supernatant of digoxin treated PBMCs isolated from RA patients.	Digoxin	115-122	interleukin 17A	Homo sapiens	58-63
32076052-5	2020	In vitro, cefazolin decreased proliferation of PBMC (peripheral blood mononuclear cells) following IL-2, IL-4 and IL-15 stimulation, reduced production of IFN-gamma, IL-17 and TNF-alpha in IL-2- and IL-15-treated PBMC and in IL-15 stimulated natural killer (NK) cells, attenuated IL-4-dependent expression of CD11c in monocyte-derived dendritic cells and suppressed phosphorylation of JAK3 in response to IL-2 and IL-15 in PBMC, to IL-4 in TF-1 (erythroleukemic cell line) and to IL-21 in NK-92 (NK cell line).	Cefazolin	10-19	interleukin 17A	Homo sapiens	166-171
32056400-13	2020	In vitro, tocilizumab and 1,25(OH)2D treatment synergistically suppressed IL-17 production and osteoclastogenesis.	1,25(oh)2d	26-36	interleukin 17A	Homo sapiens	74-79
32056400-15	2020	Tocilizumab and 1,25(OH)2D synergistically suppress IL-17 production and osteoclast differentiation in RA patients.	1,25(oh)2d	16-26	interleukin 17A	Homo sapiens	52-57
32060280-0	2020	Inflammation mobilizes copper metabolism to promote colon tumorigenesis via an IL-17-STEAP4-XIAP axis.	Copper	23-29	interleukin 17A	Homo sapiens	79-84
32060280-3	2020	In this study, we report a axis by which inflammatory cytokines, such as IL-17, drive cellular copper uptake via the induction of a metalloreductase, STEAP4.	Copper	95-101	interleukin 17A	Homo sapiens	73-78
32060280-4	2020	IL-17-induced elevated intracellular copper level leads to the activation of an E3-ligase, XIAP, which potentiates IL-17-induced NFkappaB activation and suppresses the caspase 3 activity.	Copper	37-43	interleukin 17A	Homo sapiens	0-5
32060280-4	2020	IL-17-induced elevated intracellular copper level leads to the activation of an E3-ligase, XIAP, which potentiates IL-17-induced NFkappaB activation and suppresses the caspase 3 activity.	Copper	37-43	interleukin 17A	Homo sapiens	115-120
32060280-6	2020	In summary, this study reveals a IL-17-STEAP4-XIAP axis through which the inflammatory response induces copper uptake, promoting colon tumorigenesis.	Copper	104-110	interleukin 17A	Homo sapiens	33-38
32051339-4	2020	The level of circulating IL-17A positively correlated with the alcohol use in excessive drinkers and was further increased in patients with ALD as compared with healthy individuals.	Ethanol	63-70	interleukin 17A	Homo sapiens	25-31
32051339-5	2020	Our data suggest that IL-17A is a common mediator of excessive alcohol consumption and alcohol-induced liver/brain injury, and targeting IL-17A may provide a novel strategy for treatment of alcohol-induced pathology.	Ethanol	63-70	interleukin 17A	Homo sapiens	22-28
32111491-3	2020	Resveratrol triggers apoptosis of activated T cells and suppresses tumor necrosis factor-alpha (TNF-alpha), interleukin-17 (IL-17) and other pro-inflammatory molecules and inhibits expression of hypoxia inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) that may explain its anti-inflammatory actions.	Resveratrol	0-11	interleukin 17A	Homo sapiens	108-122
32051339-5	2020	Our data suggest that IL-17A is a common mediator of excessive alcohol consumption and alcohol-induced liver/brain injury, and targeting IL-17A may provide a novel strategy for treatment of alcohol-induced pathology.	Ethanol	87-94	interleukin 17A	Homo sapiens	22-28
32051339-5	2020	Our data suggest that IL-17A is a common mediator of excessive alcohol consumption and alcohol-induced liver/brain injury, and targeting IL-17A may provide a novel strategy for treatment of alcohol-induced pathology.	Ethanol	87-94	interleukin 17A	Homo sapiens	22-28
32051346-1	2020	IL-17A plays a critical role in the pathogenesis of steroid-resistant neutrophilic airway inflammation, which is a hallmark of severe asthma and chronic obstructive pulmonary disease (COPD).	Steroids	52-59	interleukin 17A	Homo sapiens	0-6
32051346-2	2020	Through RNA sequencing analysis of transcriptomes of human airway smooth muscle cells treated with IL-17A, dexamethasone (DEX, a synthetic glucocorticoid drug), alone or in combination, we identified a group of genes that are synergistically induced by IL-17A and DEX, including the neutrophil-promoting cytokine CSF3.	Dexamethasone	107-120	interleukin 17A	Homo sapiens	99-105
32051346-2	2020	Through RNA sequencing analysis of transcriptomes of human airway smooth muscle cells treated with IL-17A, dexamethasone (DEX, a synthetic glucocorticoid drug), alone or in combination, we identified a group of genes that are synergistically induced by IL-17A and DEX, including the neutrophil-promoting cytokine CSF3.	Dexamethasone	107-120	interleukin 17A	Homo sapiens	253-259
32051346-2	2020	Through RNA sequencing analysis of transcriptomes of human airway smooth muscle cells treated with IL-17A, dexamethasone (DEX, a synthetic glucocorticoid drug), alone or in combination, we identified a group of genes that are synergistically induced by IL-17A and DEX, including the neutrophil-promoting cytokine CSF3.	Dexamethasone	122-125	interleukin 17A	Homo sapiens	99-105
32051346-2	2020	Through RNA sequencing analysis of transcriptomes of human airway smooth muscle cells treated with IL-17A, dexamethasone (DEX, a synthetic glucocorticoid drug), alone or in combination, we identified a group of genes that are synergistically induced by IL-17A and DEX, including the neutrophil-promoting cytokine CSF3.	Dexamethasone	122-125	interleukin 17A	Homo sapiens	253-259
32051346-2	2020	Through RNA sequencing analysis of transcriptomes of human airway smooth muscle cells treated with IL-17A, dexamethasone (DEX, a synthetic glucocorticoid drug), alone or in combination, we identified a group of genes that are synergistically induced by IL-17A and DEX, including the neutrophil-promoting cytokine CSF3.	Dexamethasone	264-267	interleukin 17A	Homo sapiens	99-105
32051346-2	2020	Through RNA sequencing analysis of transcriptomes of human airway smooth muscle cells treated with IL-17A, dexamethasone (DEX, a synthetic glucocorticoid drug), alone or in combination, we identified a group of genes that are synergistically induced by IL-17A and DEX, including the neutrophil-promoting cytokine CSF3.	Dexamethasone	264-267	interleukin 17A	Homo sapiens	253-259
32051346-5	2020	Disruption of the IL-17A/DEX synergy by IL-17A inhibition with anti-IL-17A mAb or cyanidin-3-glucoside (C3G, a small-molecule IL-17A blocker) or depletion of CSF3 effectively rendered DEX sensitivity in type-17 preclinical models of neutrophilic airway diseases.	Dexamethasone	25-28	interleukin 17A	Homo sapiens	40-46
32051346-5	2020	Disruption of the IL-17A/DEX synergy by IL-17A inhibition with anti-IL-17A mAb or cyanidin-3-glucoside (C3G, a small-molecule IL-17A blocker) or depletion of CSF3 effectively rendered DEX sensitivity in type-17 preclinical models of neutrophilic airway diseases.	Dexamethasone	25-28	interleukin 17A	Homo sapiens	40-46
32051346-5	2020	Disruption of the IL-17A/DEX synergy by IL-17A inhibition with anti-IL-17A mAb or cyanidin-3-glucoside (C3G, a small-molecule IL-17A blocker) or depletion of CSF3 effectively rendered DEX sensitivity in type-17 preclinical models of neutrophilic airway diseases.	Dexamethasone	25-28	interleukin 17A	Homo sapiens	40-46
32051346-5	2020	Disruption of the IL-17A/DEX synergy by IL-17A inhibition with anti-IL-17A mAb or cyanidin-3-glucoside (C3G, a small-molecule IL-17A blocker) or depletion of CSF3 effectively rendered DEX sensitivity in type-17 preclinical models of neutrophilic airway diseases.	Dexamethasone	184-187	interleukin 17A	Homo sapiens	18-24
32011316-0	2020	Calcium channel Orai1 promotes lymphocyte IL-17 expression and progressive kidney injury.	Calcium	0-7	interleukin 17A	Homo sapiens	42-47
32111491-3	2020	Resveratrol triggers apoptosis of activated T cells and suppresses tumor necrosis factor-alpha (TNF-alpha), interleukin-17 (IL-17) and other pro-inflammatory molecules and inhibits expression of hypoxia inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) that may explain its anti-inflammatory actions.	Resveratrol	0-11	interleukin 17A	Homo sapiens	124-129
31856612-0	2020	Effects of guluronic acid, as a new NSAID with immunomodulatory properties on IL-17, RORgammat, IL-4 and GATA-3 gene expression in rheumatoid arthritis patients.	guluronic acid	11-25	interleukin 17A	Homo sapiens	78-83
32010251-10	2020	Allylestrenol combined with ritodrine can significantly reduce the expression levels of IL-17, IL-10 and IL-6 in TPTL, reduce adverse pregnancy conditions, prolong gestational weeks, and has higher safety and better application value.	Allylestrenol	0-13	interleukin 17A	Homo sapiens	88-93
32010251-10	2020	Allylestrenol combined with ritodrine can significantly reduce the expression levels of IL-17, IL-10 and IL-6 in TPTL, reduce adverse pregnancy conditions, prolong gestational weeks, and has higher safety and better application value.	Ritodrine	28-37	interleukin 17A	Homo sapiens	88-93
31876196-12	2020	When co-cultured with BPA-treated moDCs, cytokines (IFN-gamma, IL4, IL17, IL10) and transcription factors (T-bet, Gata3, RoR-gammat, Foxp3) of CD4+ T cells showed imbalance of Th1/Th2/Th17/Treg polarization, with Th1 and Th17 dominating.Conclusions: BPA altered the function of moDCs through ERalpha, including antigen capture, secretion of inflammatory factors, and ability to stimulate T cells, as well as accelerated the progression and further deterioration of pSS.	bisphenol A	22-25	interleukin 17A	Homo sapiens	68-72
31856612-3	2020	In this study, the effect of Guluronic Acid (G2013) as a novel non-steroidal anti-inflammatory drug (NSAID) with immunomodulatory effects was evaluated on IL-17, RORgammat, IL-4 and GATA-3 gene expression in RA patients.Methods: Fourteen patients with RA who had an inadequate response to conventional treatments were included in this clinical trial.	guluronic acid	29-43	interleukin 17A	Homo sapiens	155-160
31718798-0	2020	Dimethyl fumarate dampens IL-17-ACT1-TBK1 axis-mediated phosphorylation of Regnase-1 and suppresses IL-17-induced IkappaB-zeta expression.	Dimethyl Fumarate	0-17	interleukin 17A	Homo sapiens	26-31
31863921-7	2020	By contrast, inhibition of Notch signaling by DAPT can efficiently decrease Th17 cell response, downregulate the expression of Notch1, DLL4, IL-17 and the transcription of RORgammat, reduce Th17 levels and restore the CD4+/CD8+, Th17/Treg balance.	dapt	46-50	interleukin 17A	Homo sapiens	141-146
31975436-6	2020	Following ex vivo stimulation with PMA/Ionomycin, PSC patients showed significantly increased numbers of IL-17A-producing peripheral blood CD4+ T cells compared to PBC patients and healthy controls, indicating increased Th17 differentiation in vivo.	Ionomycin	39-48	interleukin 17A	Homo sapiens	105-111
31863918-0	2020	Acitretin inhibits IL-17A-induced IL-36 expression in keratinocytes by down-regulating IkappaBzeta.	Acitretin	0-9	interleukin 17A	Homo sapiens	19-25
31863918-8	2020	RESULTS: Acitretin significantly down-regulated expression of IL-36beta and IL-36gamma induced by IL-17A stimulation at both gene and protein levels in HaCaT cells.	Acitretin	9-18	interleukin 17A	Homo sapiens	98-104
31863918-11	2020	IL-17A stimulation induced significantly IkappaBzeta expression in HaCaT cells, which could be inhibited by acitretin.	Acitretin	108-117	interleukin 17A	Homo sapiens	0-6
31302689-0	2020	IgM anti-phosphorylcholine antibodies associate with senescent and IL-17+ T cells in SLE patients with a pro-inflammatory lipid profile.	Phosphorylcholine	9-26	interleukin 17A	Homo sapiens	67-72
31601712-3	2020	Pulmonary research has quickly incorporated this technology, from characterizing the IL-17 signature of steroid-unresponsive COPD patients [1] to discovering pathogen-host interactions of M. tuberculosis [2].	Steroids	104-111	interleukin 17A	Homo sapiens	85-90
31718798-0	2020	Dimethyl fumarate dampens IL-17-ACT1-TBK1 axis-mediated phosphorylation of Regnase-1 and suppresses IL-17-induced IkappaB-zeta expression.	Dimethyl Fumarate	0-17	interleukin 17A	Homo sapiens	100-105
31718798-7	2020	Intriguingly, this TBK1-mediated phosphorylation of Regnase-1 was suppressed by the addition of dimethyl fumarate (DMF), an electrophilic small molecule that has been used to treat IL-17-related autoimmune diseases.	Dimethyl Fumarate	96-113	interleukin 17A	Homo sapiens	181-186
31718798-7	2020	Intriguingly, this TBK1-mediated phosphorylation of Regnase-1 was suppressed by the addition of dimethyl fumarate (DMF), an electrophilic small molecule that has been used to treat IL-17-related autoimmune diseases.	Dimethyl Fumarate	115-118	interleukin 17A	Homo sapiens	181-186
31718798-9	2020	These results suggested that DMF is a small molecule that compromises IL-17-induced activation of the ACT1-TBK1 pathway, thereby inhibiting IL-17-induced mRNA stabilization.	Dimethyl Fumarate	29-32	interleukin 17A	Homo sapiens	70-75
31718798-9	2020	These results suggested that DMF is a small molecule that compromises IL-17-induced activation of the ACT1-TBK1 pathway, thereby inhibiting IL-17-induced mRNA stabilization.	Dimethyl Fumarate	29-32	interleukin 17A	Homo sapiens	140-145
31901076-0	2020	Erratum for Research Article "Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-beta" by J. Li, M. Ritelli, C. S. Ma, G. Rao, T. Habib, E. Corvilain, S. Bougarn, S. Cypowyj, L. Grodecka, R. Levy, V. Beziat, L. Shang, K. Payne, D. T. Avery, M. Migaud, S. Boucherit, S. Boughorbel, A. Guennoun, M. Chrabieh, F. Rapaport, B. Bigio, Y. Itan, B. Boisson, V. Cormier-Daire, D. Syx, F. Malfait, N.	Nitrogen	120-121	interleukin 17A	Homo sapiens	147-153
32256191-7	2020	Nonetheless, significant negative correlations between circulating IL-17A and ionized calcium levels (r = -0.294, P = 0.047) and urine calcium excretions (r = -0.300, P = 0.045) were found.	Calcium	86-93	interleukin 17A	Homo sapiens	67-73
32173487-8	2020	Pretreatment with oxidant, H2O2 led to attenuation of IL-17A levels along with increased oxidative stress in stimulated CD4+ T cells from ASD subjects.	Hydrogen Peroxide	27-31	interleukin 17A	Homo sapiens	54-60
31976312-11	2020	TRAF3-acetoacetate interaction may be involved in regulating inflammation in OA and RA by the NF-kappa B and IL-17 pathway.	Acetoacetates	6-18	interleukin 17A	Homo sapiens	109-114
31919709-5	2020	The receiver operating characteristic (ROC) plot showed that a combination consisting of IL-17 x SOFA &lt;=22.3 was a reliable predictive factor of the need for catecholamine treatment during HCO-CVVHD, with 82% sensitivity and 90% specificity, with the area under curve (AUC) of 0.843; p &lt; 0.001.	Catecholamines	161-174	interleukin 17A	Homo sapiens	89-94
32060887-4	2020	The IL-17 family itself comprises at least six members, IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (also called IL-25), and IL-17F, all of which are known to be secreted as disulfide-linked homo- or heterodimers.	Disulfides	169-178	interleukin 17A	Homo sapiens	4-9
31898238-5	2020	Third, MLN4924 inhibits the interaction between ACT1 (NF-kappaB activator 1) and TRAF6 (tumor necrosis factor receptor-associated factor 6) and attenuates IL-17A-mediated activation of NF-kappaB to reduce pulmonary inflammation.	pevonedistat	7-14	interleukin 17A	Homo sapiens	155-161
31782370-7	2020	In particular, polyphenols are able to decrease serum levels of interleukin (IL)-17, while increasing levels of IL-10.	Polyphenols	15-26	interleukin 17A	Homo sapiens	64-83
31606265-5	2020	RESULTS: Compared with cyclosporine and methotrexate, anti-IL-17A treatment resulted in a greater increase in GLS at 4 and 12 months after treatment (10% and 14% with anti-IL-17A vs 2% and 2% with cyclosporine vs 4% and 4% with methotrexate, respectively), GLSR, GLSR at early diastole (45% and 41% vs 5% and 4% vs 7% and 9%, respectively), and LV twisting (32% and 28% vs 6% and 8% vs 7% and 6%, respectively) (P &lt; 0.05).	Cyclosporine	197-209	interleukin 17A	Homo sapiens	59-65
31606265-5	2020	RESULTS: Compared with cyclosporine and methotrexate, anti-IL-17A treatment resulted in a greater increase in GLS at 4 and 12 months after treatment (10% and 14% with anti-IL-17A vs 2% and 2% with cyclosporine vs 4% and 4% with methotrexate, respectively), GLSR, GLSR at early diastole (45% and 41% vs 5% and 4% vs 7% and 9%, respectively), and LV twisting (32% and 28% vs 6% and 8% vs 7% and 6%, respectively) (P &lt; 0.05).	Methotrexate	228-240	interleukin 17A	Homo sapiens	59-65
31606265-10	2020	CONCLUSIONS: In psoriasis, inhibition of IL-17A results in a greater improvement of vascular and myocardial function compared with cyclosporine or methotrexate treatment, indicating a beneficial effect on overall cardiovascular function.	Cyclosporine	131-143	interleukin 17A	Homo sapiens	41-47
31472402-4	2020	TB-KDM individuals exhibit significantly higher levels of IFNgamma, IL-2, TNFalpha, IL-17A, IL-1alpha, IL-1beta and IL-6 in comparison to TB-NDM, TB alone and DM alone individuals.	Terbium	0-2	interleukin 17A	Homo sapiens	84-90
31472402-7	2020	TB-NDM individuals are also characterized by significantly diminished TB-antigen stimulated levels of IFNgamma, IL-2, TNFalpha, IL-17A, IL-17F, IL-1alpha, IL-1beta and/or IL-6 at pre-treatment and at 2  months of ATT and IFNgamma, IL-2, IL-1alpha and IL-1beta at post-treatment.	Terbium	0-2	interleukin 17A	Homo sapiens	128-134
31902928-5	2020	Regarding neutrophilic airway inflammation in steroid-resistant asthma, IL-17 derived from Th17 cells and IL-8 and tumor necrosis factor-alpha derived mainly from macrophages were reported to be involved in the pathogenesis.	Steroids	46-53	interleukin 17A	Homo sapiens	72-77
31623021-7	2020	The IL-17+ T cell subsets mainly included CD4+ (Th17, 60.0%) and CD8+ (Tc17, 30.0%), and both subsets were enhanced in the SNIP samples than controls.	Technetium	71-75	interleukin 17A	Homo sapiens	4-9
31670484-7	2020	The pooled estimate supported that IL-17A-197G/A and IL-17F-7488T/C polymorphisms were significantly associated with OA susceptibility in the overall population (IL-17A-197G/A: GG + GA vs AA, OR = 0.69, 95%CI 0.57-0.80; P < .001; IL-17F-7488T/C, TT + TC vs CC, OR = 0.46, 95%CI 0.29-0.71, P < .001).	Technetium	251-253	interleukin 17A	Homo sapiens	162-168
31087753-9	2020	Also, significant positive correlation was found between increase in SALT Score and serum levels of IL-2, IL-17A, and IL-23.	Salts	69-73	interleukin 17A	Homo sapiens	106-112
31670484-7	2020	The pooled estimate supported that IL-17A-197G/A and IL-17F-7488T/C polymorphisms were significantly associated with OA susceptibility in the overall population (IL-17A-197G/A: GG + GA vs AA, OR = 0.69, 95%CI 0.57-0.80; P < .001; IL-17F-7488T/C, TT + TC vs CC, OR = 0.46, 95%CI 0.29-0.71, P < .001).	Technetium	251-253	interleukin 17A	Homo sapiens	35-41
31675639-8	2020	We also found that monomethyl fumarate dampened T cell proliferation and reduced the frequency of TNF-alpha, IL-17 and IFN-gamma producing T cells.	citraconic acid	19-38	interleukin 17A	Homo sapiens	109-114
32544369-4	2020	In vivo, treatment with JNJ-61178104 resulted in dose-dependent inhibition of cellular influx in a human IL-17A/TNF-induced murine lung neutrophilia model and the inhibitory effects of JNJ-61178104 were more potent than the treatment with bivalent parental anti-TNF or anti-IL-17A antibodies.	jnj-61178104	24-36	interleukin 17A	Homo sapiens	105-111
33099553-3	2020	We analyzed the effects of collagen I (Col I), Col V, IL-6, and IL-17 on vascular remodeling and hemodynamics and its possible mechanisms of action in monocrotaline (MCT)-induced PAH.	Monocrotaline	166-169	interleukin 17A	Homo sapiens	64-69
31630418-7	2020	After blocking Act1/TRAF6/p38MAPK cascade and interfering AP-1 with Curcumin or c-Jun siRNA, CCL2 expression induced by IL-17 was significantly attenuated at both mRNA and protein levels.	Curcumin	68-76	interleukin 17A	Homo sapiens	120-125
31257245-5	2019	The children with RMPP had significantly higher BALF levels of IL-8, IL-17 and TNF-alpha than the children with GMPP (P&lt;0.05), and the elevated levels of IL-17 correlated with the focal size of the lung lesions (P&lt;0.05).	rmpp	18-22	interleukin 17A	Homo sapiens	69-74
31844089-0	2019	IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis.	dimethyl fumarate	34-51	interleukin 17A	Homo sapiens	0-5
31844089-4	2019	Mechanistically, DMF potentiates the PI3K-AKT-FOXO1-T-BET pathway, thereby limiting IL-17 and RORgammat expression as well as STAT5-signaling in a glutathione-dependent manner.	dimethyl fumarate	17-20	interleukin 17A	Homo sapiens	84-89
31748346-10	2019	Administration of exogenous rIL-23 to mice increased CVB3 pancreatitis through in vivo expansion of IL-17+gammadeltaT17 cells at 12 h postinfection.	ril-23	28-34	interleukin 17A	Homo sapiens	100-105
31051495-5	2019	RESULTS: Incubation of peripheral and intestinal T cells with 1,25(OH)2-vitD resulted in strongly reduced frequencies of pro-inflammatory CD4+ and CD8+ T cells producing IFNgamma, IL-17, IL-22, IL-9 and TNF.	1,25(oh)2-vitd	62-76	interleukin 17A	Homo sapiens	180-185
31708446-4	2019	SLC5A12-mediated lactate uptake into CD4+ T cells induces a reshaping of their effector phenotype, resulting in increased IL17 production via nuclear PKM2/STAT3 and enhanced fatty acid synthesis.	Lactic Acid	17-24	interleukin 17A	Homo sapiens	122-126
31520180-9	2019	The secreted levels of IL-8, TNF-alpha, IL-6 and IL-17A induced by silica particles were also significantly lower from CTGF siRNA-transfected cells than that from normal 16HBE cells (P &lt; 0.05).	Silicon Dioxide	67-73	interleukin 17A	Homo sapiens	49-55
31257245-5	2019	The children with RMPP had significantly higher BALF levels of IL-8, IL-17 and TNF-alpha than the children with GMPP (P&lt;0.05), and the elevated levels of IL-17 correlated with the focal size of the lung lesions (P&lt;0.05).	rmpp	18-22	interleukin 17A	Homo sapiens	157-162
31575437-5	2019	Furthermore, compared to direct anti-CD3/CD28 stimulation, PMMA preferentially stimulated the expression of IFNgamma and IL-17 but not the expression of IL-4 or TGFbeta.	Polymethyl Methacrylate	59-63	interleukin 17A	Homo sapiens	121-126
31679846-9	2019	In the SPL, enrofloxacin treatment increased the secretion of TGF-beta and IL-10 and decreased the secretion of IL-17A and IFN-gamma.	enrofloxacin	12-24	interleukin 17A	Homo sapiens	112-118
31703545-10	2019	In addition, U-As levels were seen to be negatively associated with PBMC formation of fractalkine and IL-7, and positively associated with that for IL-13, IL-17 and MIP-1alpha.	Arsenic	15-17	interleukin 17A	Homo sapiens	155-160
31520180-7	2019	The secretions of IL-8, TNF-alpha, IL-6 and IL-17A were also significantly increased by silica particles (P &lt; 0.05).	Silicon Dioxide	88-94	interleukin 17A	Homo sapiens	44-50
31631469-6	2019	The expression of TNF-alpha was downregulated during therapy, IL23A was upregulated during CsA treatment, while the expression of IFN-gamma and IL17 were higher after 42 days and lower after 84 days compared to 0 days of CsA treatment.	Cyclosporine	221-224	interleukin 17A	Homo sapiens	144-148
31752330-6	2019	A significant inverse correlation with IL-1beta (R = -0.78), TNF-alpha (R = -0.53), IL-6 (R = -0.42), IL-8 (R = -0.41), IL-17A (R = -0.31), LDL-cholesterol (R = -0.51), Apo-B (R = -0.57), total-cholesterol (R = -0.48), and triglycerides (R = -0.32) was shown.	Cholesterol	144-155	interleukin 17A	Homo sapiens	120-126
31752330-6	2019	A significant inverse correlation with IL-1beta (R = -0.78), TNF-alpha (R = -0.53), IL-6 (R = -0.42), IL-8 (R = -0.41), IL-17A (R = -0.31), LDL-cholesterol (R = -0.51), Apo-B (R = -0.57), total-cholesterol (R = -0.48), and triglycerides (R = -0.32) was shown.	Cholesterol	194-205	interleukin 17A	Homo sapiens	120-126
31752330-6	2019	A significant inverse correlation with IL-1beta (R = -0.78), TNF-alpha (R = -0.53), IL-6 (R = -0.42), IL-8 (R = -0.41), IL-17A (R = -0.31), LDL-cholesterol (R = -0.51), Apo-B (R = -0.57), total-cholesterol (R = -0.48), and triglycerides (R = -0.32) was shown.	Triglycerides	223-236	interleukin 17A	Homo sapiens	120-126
31752330-7	2019	Cluster analysis demonstrated that patients from cluster three, with the lowest 25(OH)D levels, presented the lowermost vitamin D intake, IL-10 (1.0 +- 0.9 pg/mL), and IL-12p70 (0.5 +- 0.4 pg/mL), but the highest TNF-alpha (9.1 +- 3.5 pg/mL), IL-8 (55.6 +- 117.1 pg/mL), IL-17A (3.5 +- 2.0 pg/mL), total-cholesterol (193.9 +- 61.4 mg/dL), LDL-cholesterol (127.7 +- 58.2 mg/dL), and Apo-B (101.4 +- 33.4 mg/dL) levels, compared with patients from cluster one.	25(oh)d	80-87	interleukin 17A	Homo sapiens	271-277
31475727-5	2019	The nadir in serum testosterone preceded the post-prandial increase in serum IL-6/IL-17 by several hours, suggesting that inflammation was unlikely the cause.	Testosterone	19-31	interleukin 17A	Homo sapiens	82-87
31257011-5	2019	RESULTS: Oral-tracheal administration of montelukast significantly attenuated total cells (P<.05), macrophages (P<.05), neutrophils (P<.01), lymphocytes (P<.001) and total protein levels in BAL (P<.05), as well as IL-6 (P<.05), CXCL1/KC (P<.05), IL-17 (P<.05) and TNF-alpha (P<.05).	montelukast	41-52	interleukin 17A	Homo sapiens	246-251
31518664-7	2019	In addition, IL-17 correlated negatively with HDL and positively with total cholesterol, LDL, triglycerides, VLDL, and glucose in the eutrophic ones, but not in the overweight individuals.	Cholesterol	76-87	interleukin 17A	Homo sapiens	13-18
31518664-7	2019	In addition, IL-17 correlated negatively with HDL and positively with total cholesterol, LDL, triglycerides, VLDL, and glucose in the eutrophic ones, but not in the overweight individuals.	Triglycerides	94-107	interleukin 17A	Homo sapiens	13-18
31518664-7	2019	In addition, IL-17 correlated negatively with HDL and positively with total cholesterol, LDL, triglycerides, VLDL, and glucose in the eutrophic ones, but not in the overweight individuals.	Glucose	119-126	interleukin 17A	Homo sapiens	13-18
31630084-0	2019	Serum and sputum levels of IL-17, IL-21, TNFalpha and mRNA expression of IL-17 in sulfur mustard lung tissue with long term pulmonary complications (28 years after sulfur mustard exposure).	Mustard Gas	82-96	interleukin 17A	Homo sapiens	73-78
31570180-0	2019	Predictive role of IL-17A/IL-10 ratio in persistent asthmatic patients on vitamin D supplement.	Vitamin D	74-83	interleukin 17A	Homo sapiens	19-25
31570180-4	2019	This study aims to investigate the role of IL-17A and IL-10 in predicting asthma control in case of Vit D supplementation.	Vitamin D	100-105	interleukin 17A	Homo sapiens	43-49
31570180-12	2019	Vit D supplementation reduces the serum IL-17A levels and elevates the serum IL-10 levels in persistent asthmatic patients.	Vitamin D	0-5	interleukin 17A	Homo sapiens	40-46
31570180-14	2019	The IL-17A/IL-10 ratio seems to be a possible predictive biomarker for asthma improvement in patients depending on Vit D supplementation.	Vitamin D	115-120	interleukin 17A	Homo sapiens	4-10
31630084-0	2019	Serum and sputum levels of IL-17, IL-21, TNFalpha and mRNA expression of IL-17 in sulfur mustard lung tissue with long term pulmonary complications (28 years after sulfur mustard exposure).	Mustard Gas	164-178	interleukin 17A	Homo sapiens	73-78
31630084-5	2019	In this study, we evaluate the serum and sputum levels of IL-17, IL-21, TNF-alpha, and mRNA expression of IL-17 in the lung tissue of the patients 28 years after SM exposure.	Mustard Gas	162-164	interleukin 17A	Homo sapiens	106-111
31444906-10	2019	The concentration of ACh and cholinesterase activity levels in PICF correlated with levels of IL-17A and MBL around implants 1 month post-placement in patients with GAgP.	Acetylcholine	21-24	interleukin 17A	Homo sapiens	94-100
31415242-0	2019	Calcium channel Orai1 promotes lymphocyte IL-17 expression and progressive kidney injury.	Calcium	0-7	interleukin 17A	Homo sapiens	42-47
30998987-6	2019	The patients with IL-17-high asthma were characterized by risk of frequent exacerbations, airway (sputum and mucosal) neutrophilia, decreased lung microbiota diversity, and urinary biomarker evidence of activation of the thromboxane B2 pathway.	Thromboxane B2	221-235	interleukin 17A	Homo sapiens	18-23
30998987-8	2019	CONCLUSION: The IL-17-high asthma phenotype, characterized by bronchial epithelial dysfunction and upregulated antimicrobial and inflammatory response, resembles the immunophenotype of psoriasis, including activation of the thromboxane B2 pathway, which should be considered a biomarker for this phenotype in further studies, including clinical trials targeting IL-17.	Thromboxane B2	224-238	interleukin 17A	Homo sapiens	16-21
31548328-0	2019	IL-4 and IL-17A Cooperatively Promote Hydrogen Peroxide Production, Oxidative DNA Damage, and Upregulation of Dual Oxidase 2 in Human Colon and Pancreatic Cancer Cells.	Hydrogen Peroxide	38-55	interleukin 17A	Homo sapiens	9-15
31361541-5	2019	Furthermore, IL-17A stimulation resulted in mRNA and protein expression of scavenger receptor (LOX-1) in phorbol 12-myristate 13-acetate (PMA)-activated U937 cells.	Tetradecanoylphorbol Acetate	105-136	interleukin 17A	Homo sapiens	13-19
31780862-6	2019	Serum IL-35 levels were significantly increased and serum levels of TNF-alpha, IL-17, IL-6, and IFN-gamma were significantly reduced in response to tofacitinib since week 4.	tofacitinib	148-159	interleukin 17A	Homo sapiens	79-84
31361541-5	2019	Furthermore, IL-17A stimulation resulted in mRNA and protein expression of scavenger receptor (LOX-1) in phorbol 12-myristate 13-acetate (PMA)-activated U937 cells.	Tetradecanoylphorbol Acetate	138-141	interleukin 17A	Homo sapiens	13-19
31361541-6	2019	Oil Red O also demonstrated that IL-17A enhanced foam cell formation by PMA-activated U937 cells induced by oxidized low-density lipoprotein (ox-LDL), and this enhancement of ox-LDL-induced foam cell formation in IL-17A-treated U937 cells was downregulated by transfection of LOX-1 siRNA.	oil red O	0-9	interleukin 17A	Homo sapiens	33-39
31361541-6	2019	Oil Red O also demonstrated that IL-17A enhanced foam cell formation by PMA-activated U937 cells induced by oxidized low-density lipoprotein (ox-LDL), and this enhancement of ox-LDL-induced foam cell formation in IL-17A-treated U937 cells was downregulated by transfection of LOX-1 siRNA.	oil red O	0-9	interleukin 17A	Homo sapiens	213-219
31353088-3	2019	This study describes the preclinical in vitro and in vivo characterization of GR1501, a human IL-17A-neutralizing IgG4 monoclonal antibody.	gr1501	78-84	interleukin 17A	Homo sapiens	94-100
30473441-6	2019	RESULTS: Fixed effect analysis of the WMD (95% CI) of the changes in gene expression showed that gene expression of the inflammatory (IL-17, IFN-gamma and T-bet) and anti-inflammatory (TGF-beta and FOXP3) cytokines significantly decreased and increased due to vitamin A supplementation in patients with autoimmune (Multiple sclerosis and atherosclerosis) diseases.	Vitamin A	260-269	interleukin 17A	Homo sapiens	134-139
31236602-9	2019	Sitagliptin with VitD3 was more effective in suppression of proliferation, decreasing of IL-17 and enhancing of IL-37 production.	Sitagliptin Phosphate	0-11	interleukin 17A	Homo sapiens	89-94
31377676-4	2019	RhIL-17A and rhIL-17F shared 96.8% and 93.9% amino acid sequence identity with human IL-17A (huIL-17A) and IL-17F (huIL-17F) respectively and the sequences also shared one N-glycosylation site and six conserved cysteine residues with huIL-17A and huIL-17F.	Nitrogen	172-173	interleukin 17A	Homo sapiens	2-8
31377676-4	2019	RhIL-17A and rhIL-17F shared 96.8% and 93.9% amino acid sequence identity with human IL-17A (huIL-17A) and IL-17F (huIL-17F) respectively and the sequences also shared one N-glycosylation site and six conserved cysteine residues with huIL-17A and huIL-17F.	Cysteine	211-219	interleukin 17A	Homo sapiens	2-8
31553732-11	2019	At the 12 months" time point, IL-17A levels of non-reactive subjects were significantly higher than either those of reactive or ambiguous subjects suggesting that IL-17A might be useful to determine the reactivity to BNZ treatment.	benzonidazole	217-220	interleukin 17A	Homo sapiens	30-36
31553732-11	2019	At the 12 months" time point, IL-17A levels of non-reactive subjects were significantly higher than either those of reactive or ambiguous subjects suggesting that IL-17A might be useful to determine the reactivity to BNZ treatment.	benzonidazole	217-220	interleukin 17A	Homo sapiens	163-169
31353088-4	2019	GR1501 binds human, rhesus and cynomolgus IL-17A with high affinity but does not bind to mouse IL-17A or other IL-17 family members.	gr1501	0-6	interleukin 17A	Homo sapiens	42-48
31492195-4	2019	RESULTS: The study showed that 50 mug/ml astilbin could inhibit the growth and reduce the accumulation of ROS in HaCaT cells stimulated by IL-17 and TNF-alpha.	astilbin	41-49	interleukin 17A	Homo sapiens	139-144
31551929-9	2019	Exposure to BPA significantly increased CD4+ T cells, IFNgamma, IL-17A, TLR4, caspase-1, and IL-1beta in the heart.	bisphenol A	12-15	interleukin 17A	Homo sapiens	64-70
31540162-7	2019	In addition, fisetin treatment significantly decreased the secretion of Th1/Th-17 pro-inflammatory cytokines, particularly IFN-gamma and IL-17A by 12-O-tetradecanolylphorbol 13-acetate (TPA)-stimulated NHEKs and anti-CD3/CD28-activated human PBMCs.	fisetin	13-20	interleukin 17A	Homo sapiens	137-143
31540162-7	2019	In addition, fisetin treatment significantly decreased the secretion of Th1/Th-17 pro-inflammatory cytokines, particularly IFN-gamma and IL-17A by 12-O-tetradecanolylphorbol 13-acetate (TPA)-stimulated NHEKs and anti-CD3/CD28-activated human PBMCs.	12-o-tetradecanolylphorbol 13-acetate	147-184	interleukin 17A	Homo sapiens	137-143
31540162-7	2019	In addition, fisetin treatment significantly decreased the secretion of Th1/Th-17 pro-inflammatory cytokines, particularly IFN-gamma and IL-17A by 12-O-tetradecanolylphorbol 13-acetate (TPA)-stimulated NHEKs and anti-CD3/CD28-activated human PBMCs.	Tetradecanoylphorbol Acetate	186-189	interleukin 17A	Homo sapiens	137-143
31455731-4	2019	REV-ERBalpha binds to ROR response elements (RORE) in Th17 cells and inhibits the expression of RORgammat-dependent genes including Il17a and Il17f Furthermore, elevated REV-ERBalpha expression or treatment with a synthetic REV-ERB agonist significantly delays the onset and impedes the progression of experimental autoimmune encephalomyelitis (EAE).	erbalpha	4-12	interleukin 17A	Homo sapiens	132-137
31492195-4	2019	RESULTS: The study showed that 50 mug/ml astilbin could inhibit the growth and reduce the accumulation of ROS in HaCaT cells stimulated by IL-17 and TNF-alpha.	ros	106-109	interleukin 17A	Homo sapiens	139-144
31221438-6	2019	Dexamethasone-treated TRIMEL/DCs inhibited allogeneic CD4+ T cell proliferation and cytokine release (IFNgamma, TNF-alpha and IL-17).	polyimide resin	22-28	interleukin 17A	Homo sapiens	126-131
30897215-0	2019	Leukotriene B4 receptors mediate the production of IL-17, thus contributing to neutrophil-dominant asthmatic airway inflammation.	Leukotrienes	0-11	interleukin 17A	Homo sapiens	51-56
30943138-9	2019	IL-23, cPLA2 and PI3K increase the production of CD11b+Gr1high myeloid subtype and calcium concentration, which promote the production of LTB4 and further accelerate IL-17 and TNF activation as well as calcium influx to conduce to osteoclastogenesis, resulting in aggregated bone damage.	Calcium	83-90	interleukin 17A	Homo sapiens	166-171
31173374-6	2019	We observed that while exposure to L braziliensis induced an inflammatory profile, as measured by the expression of granzyme A, IFN-gamma and IL-17, as well as a higher IFN/IL-10 ratio, exposure to L infantum led to a regulatory profile, as measured by lower IFN/IL-10 ratio and higher expression of CTLA-4.	braziliensis	37-49	interleukin 17A	Homo sapiens	142-147
31221438-6	2019	Dexamethasone-treated TRIMEL/DCs inhibited allogeneic CD4+ T cell proliferation and cytokine release (IFNgamma, TNF-alpha and IL-17).	Dexamethasone	0-13	interleukin 17A	Homo sapiens	126-131
31229737-5	2019	RESULTS: Here, Pam3C (TLR2) and LPS (TLR4) induced significant cell proliferation and IL-6, IL-17 and IL-21 production by CD4+ T-cells from NMOSD.	pam3c	15-20	interleukin 17A	Homo sapiens	92-97
31229737-8	2019	Finally, circulating levels of CD14, an indirect marker of microbial translocation, were positively correlated with IL-6, IL-17 and IL-21 release by Pam3C- and LPS-activated CD4+ T-cells.	pam3c	149-154	interleukin 17A	Homo sapiens	122-127
31455723-4	2019	Whereas SMs inhibited interleukin-17 (IL-17) production and ameliorated TH17 cell-driven inflammation, they stimulated IL-22 secretion.	Samarium	8-11	interleukin 17A	Homo sapiens	22-36
31164437-7	2019	Systemic corticosteroids, but not maintenance inhaled steroids resulted in improved symptom control and exacerbations concomitant with a reduction in functional ILC2s despite persistently elevated IL-17+ lymphoid cells.	Steroids	16-24	interleukin 17A	Homo sapiens	197-202
31455723-4	2019	Whereas SMs inhibited interleukin-17 (IL-17) production and ameliorated TH17 cell-driven inflammation, they stimulated IL-22 secretion.	Samarium	8-11	interleukin 17A	Homo sapiens	38-43
31475011-4	2019	Our results showed that zebularine restrained the expression of inflammatory cytokines IFN-gamma and IL-17 in both human and murine CD4+ T cells in vitro.	pyrimidin-2-one beta-ribofuranoside	24-34	interleukin 17A	Homo sapiens	101-106
31447768-9	2019	The protective effects by alphaCD147 treatment were associated with deceased lung inflammatory cell infiltration by reducing IL-17A expression in lung gammadelta T cells and attenuated bacterial load by enhancing IFN-gamma expression in the lung NK1.1+ cells and CD4+ T cells.	alphacd147	26-36	interleukin 17A	Homo sapiens	125-131
31375946-9	2019	The decreased ADA activity and the increase in A1 receptor expression may contribute to adenosine pro-tumor effects by increasing IL-6 and TNF-alpha and decreasing IL-17 and INF-gamma serum levels.	Adenosine	88-97	interleukin 17A	Homo sapiens	164-169
30657173-7	2019	The protein production of the proinflammatory cytokines TNF-alpha, interferon gamma, IL-1beta, IL-6 and IL-17A was significantly inhibited by adalimumab, infliximab, ustekinumab, prednisolone (all P &lt; 0 001) and rituximab (P = 0 0071), but not by secukinumab (P = 0 0663).	Prednisolone	179-191	interleukin 17A	Homo sapiens	104-110
31173888-6	2019	In AA-derived CD4+ T-cell cultures, 1,25(OH)2D3 was less efficient at inhibiting IL-5, IL-6 and IL-17 production, and up regulating IL-10 release, as those from healthy subjects.	Calcitriol	36-47	interleukin 17A	Homo sapiens	96-101
31069604-6	2019	DEX (1.000 nM) treatment in PBMC of SSc patients stimulated with anti-CD3 and anti-CD28 promoted a significant reduction in IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-gamma, TNF, IL-1beta (p &lt; 0.001 for all), and IL-17F (p = 0.023) cytokines levels.	Dexamethasone	0-3	interleukin 17A	Homo sapiens	149-155
31069604-8	2019	In PBMC from healthy volunteers, we observed that DEX treatment significantly reduced IL-4, IFN-gamma (p = 0.003 for both), IL-6, IL-10, IL-17A, and TNF (p = 0.002 for all) cytokines.	Dexamethasone	50-53	interleukin 17A	Homo sapiens	137-143
31102993-12	2019	Moreover, resveratrol could markedly downregulate the production of IL-17A and IL-22 and upregulate the secretion of IL-10 in CD4+ T cells in a time- and concentration-dependent manner.	Resveratrol	10-21	interleukin 17A	Homo sapiens	68-74
31011925-0	2019	Acute Lung Injury: IL-17A-Mediated Inflammatory Pathway and Its Regulation by Curcumin.	Curcumin	78-86	interleukin 17A	Homo sapiens	19-25
31331833-11	2019	ALP activity and Alizarin Red staining showed IL-13 and IL-17A dose-dependent osteoblast differentiation and mineralisation in vitro.	alizarin	17-29	interleukin 17A	Homo sapiens	56-62
31179646-8	2019	Urine IL-17A levels correlated positively with urine protein : creatinine index while serum IL-17 level correlated with the BILAG hematology score (all P &lt; 0.05).	Creatinine	63-73	interleukin 17A	Homo sapiens	6-12
31179646-8	2019	Urine IL-17A levels correlated positively with urine protein : creatinine index while serum IL-17 level correlated with the BILAG hematology score (all P &lt; 0.05).	Creatinine	63-73	interleukin 17A	Homo sapiens	6-11
31102993-13	2019	Mechanistic studies revealed that resveratrol exerted its beneficial function mainly through suppressing the AhR pathway, which led to the impaired expression of ROR-gammat and reduced secretion of IL-17A and IL-22, as well as enhanced expression of Foxp3 and augmented secretion of IL-10.	Resveratrol	34-45	interleukin 17A	Homo sapiens	198-204
31102993-14	2019	The induction of AhR by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in CD4+ T cells led to a Th17/Treg imbalance and the upregulation of IL-17A and IL-22, an effect that could be reversed by resveratrol treatment.	Polychlorinated Dibenzodioxins	24-59	interleukin 17A	Homo sapiens	136-142
31102993-14	2019	The induction of AhR by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in CD4+ T cells led to a Th17/Treg imbalance and the upregulation of IL-17A and IL-22, an effect that could be reversed by resveratrol treatment.	Polychlorinated Dibenzodioxins	61-65	interleukin 17A	Homo sapiens	136-142
31294563-7	2019	The OVA-Man group exhibited decreased concentrations of IL-4 (67.98 +- 3.11 pg/mL) and IL-17 (67.98 +- 3.11 pg/mL) and an increased concentration of IL-12 (336.70 +- 18.69 pg/mL, p &lt; 0.05) compared with the positive control.	ova-man	4-11	interleukin 17A	Homo sapiens	87-92
31418380-9	2019	The expression level of IL-17 and IL-18 in PBMNC of the ITP patients in newly diagnosed group was higher than that in the control group and the remission group(P&lt;0.	Inosine Triphosphate	56-59	interleukin 17A	Homo sapiens	24-29
31173199-6	2019	The supernatant of Huh7.5-IL17A cells promoted endothelial cell chemotaxis, which was attenuated by the C-X-C chemokine receptor type 2 (CXCR2) inhibitor SB225002.	SB 225002	154-162	interleukin 17A	Homo sapiens	26-31
30981079-0	2019	PPAR-gamma agonist pioglitazone protects against IL-17 induced intervertebral disc inflammation and degeneration via suppression of NF-kappaB signaling pathway.	Pioglitazone	19-31	interleukin 17A	Homo sapiens	49-54
31085243-0	2019	IL-17A-stimulated endothelial fatty acid beta-oxidation promotes tumor angiogenesis.	Fatty Acids	30-40	interleukin 17A	Homo sapiens	0-6
31085243-12	2019	Finally, IL-17A-induced angiogenesis was blocked when FAO was inhibited using etomoxir.	etomoxir	78-86	interleukin 17A	Homo sapiens	9-15
31396228-9	2019	Here, a strong inhibition of T cell proliferation and reduction of pro-inflammatory cytokines (IFNgamma, TNFalpha, TNFbeta, IL-17A, IL-2) were observable after pre-stimulation of hAACs with IFNgamma.	haacs	179-184	interleukin 17A	Homo sapiens	124-130
31379807-7	2019	Treatment with 1,25(OH)2D3 inhibited pro-inflammatory cytokines such as IL-17A, IL-17F, IL-22 and IFNgamma in memory CCR6+ Th cells from both healthy controls and RA patients.	Calcitriol	15-26	interleukin 17A	Homo sapiens	72-78
31295961-4	2019	After PB monocytes were co-cultured with IL-17-stimulated RA synovial fibroblasts in the presence of SKI306, osteoclast differentiation was assessed.	ski306	101-107	interleukin 17A	Homo sapiens	41-46
31172649-2	2019	The aim of this study was to explore the mechanism underlying CO2 fractional laser treatment of vitiligo by detecting the levels of Th1 cytokines (IL-2 and IFN-gamma), Th2 cytokines (IL-4 and IL-10), and Th17 cytokines (IL-17 and IL-23) in peripheral blood.	Carbon Dioxide	62-65	interleukin 17A	Homo sapiens	220-225
30957574-4	2019	Ongoing studies on other IL-17 inhibitors (bimekizumab, brodalumab and BCD-085) that are being developed are also summarized.	bcd-085	71-78	interleukin 17A	Homo sapiens	25-30
30981079-5	2019	This study was undertaken to investigate the potential therapeutic effect of pioglitazone, as a PPAR-gamma ligand, and its underlying molecular mechanism in IL-17-induced human intervertebral disc degeneration model in vitro.	Pioglitazone	77-89	interleukin 17A	Homo sapiens	157-162
30848861-0	2019	Omega-3 Polyunsaturated Fatty Acids Inhibit IL-17A Secretion through Decreased ICAM-1 Expression in T Cells Co-Cultured with Adipose-Derived Stem Cells Harvested from Adipose Tissues of Obese Subjects.	omega-3 polyunsaturated fatty acids	0-35	interleukin 17A	Homo sapiens	44-50
31028753-6	2019	With respect to cytokine inductions, APCs treated with either Sal-HA or Sal-M2e induced significantly (p &lt; .05) higher mRNA transcription levels of proinflammatory (IL-1beta, IL-6, IL-12 and IL-23), Th1 (IFN-gamma), Th17 (IL-17 and IL-21) and Th2 (IL-10 and TGF-beta) cytokines in T cells compared to Sal-NA or Salmonella alone treated APCs.	sal-ha	62-68	interleukin 17A	Homo sapiens	225-230
31028753-6	2019	With respect to cytokine inductions, APCs treated with either Sal-HA or Sal-M2e induced significantly (p &lt; .05) higher mRNA transcription levels of proinflammatory (IL-1beta, IL-6, IL-12 and IL-23), Th1 (IFN-gamma), Th17 (IL-17 and IL-21) and Th2 (IL-10 and TGF-beta) cytokines in T cells compared to Sal-NA or Salmonella alone treated APCs.	sal-m2e	72-79	interleukin 17A	Homo sapiens	225-230
31184998-6	2019	VTP-938 also reduced pulmonary production of IL-17 and airway neutrophilia when given during the allergen challenge of the model.	vtp-938	0-7	interleukin 17A	Homo sapiens	45-50
31184998-7	2019	Finally, in an environmentally relevant model of allergic responses to house dust extracts, VTP-938 suppressed production of IL-17 and neutrophilic inflammation, and also markedly diminished airway hyperresponsiveness.	vtp-938	92-99	interleukin 17A	Homo sapiens	125-130
31078066-6	2019	It has been revealed that pro-inflammatory cytokines such as IFN-gamma, TNF-alpha, TGF-beta, IL-17A, IL-27, IL-33 and thymic stromal lymphopoietin (TSLP) may contribute to steroid resistance in severe asthma and COPD.	Steroids	172-179	interleukin 17A	Homo sapiens	93-99
30776434-8	2019	Administration of anti-IL-17A monoclonal antibody improved hyperglycemia in patients with psoriasis and imiquimod-treated mice with psoriasiform features.	Imiquimod	104-113	interleukin 17A	Homo sapiens	23-29
31059089-3	2019	The genetic mutations and expression of IL-17 family members were investigated using the Catalogue of Somatic Mutations in Cancer (COSMIC), Oncomine, and cBio Cancer Genomics Portal (cBioPortal) databases.	oncomine	140-148	interleukin 17A	Homo sapiens	40-45
31284792-7	2019	Although the levels of IL-17 correlated positively with generation of ROS, myeloperoxidase, markers of protein damage and DAS28, IL-23 correlated positively only with protein damage, and negatively with free radical scavenging activity.	Reactive Oxygen Species	70-73	interleukin 17A	Homo sapiens	23-28
31260471-0	2019	LL-37 alone and in combination with IL17A enhances proinflammatory cytokine expression in parallel with hyaluronan metabolism in human synovial sarcoma cell line SW982-A step toward understanding the development of inflammatory arthritis.	Hyaluronic Acid	104-114	interleukin 17A	Homo sapiens	36-41
31260471-7	2019	In combination, LL-37 and IL17A significantly enhanced PTGS2, TNF, and HAS3 gene expression concomitantly with the elevation of their respective products, PGE2, TNF, and HA.	Dinoprostone	155-159	interleukin 17A	Homo sapiens	26-31
30876976-6	2019	Over expression of IL-17 can reverse si-visfatin suppressed cell proliferation and increased Dox sensitivity.	Doxorubicin	93-96	interleukin 17A	Homo sapiens	19-24
30876976-10	2019	The inhibitor of miR-135a can attenuate si-visfatin suppressed expression of IL-17 and proliferation of AML cells.	mir-135a	17-25	interleukin 17A	Homo sapiens	77-82
30848861-9	2019	In addition, ALA down-regulated Intercellular-Adhesion-Molecule-1 (ICAM-1) expression in both monocytes and ASCs, which resulted in decreased interactions between ob-ASCs and MNCs, and inhibition of IL-17A secretion.	alpha-Linolenic Acid	13-16	interleukin 17A	Homo sapiens	199-205
30848861-7	2019	ALA also inhibited IL-17A secretion mediated by adipocytes differentiated from ob-ASCs.	alpha-Linolenic Acid	0-3	interleukin 17A	Homo sapiens	19-25
31186764-0	2019	Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL-17.	apatinib	21-29	interleukin 17A	Homo sapiens	86-91
31186764-1	2019	Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on the levels of serum IL-17 were investigated.	apatinib	21-29	interleukin 17A	Homo sapiens	106-111
31186764-12	2019	In addition, apatinib can downregulate IL-17 expression, which is helpful in attenuating tumor proliferation and improving the clinical efficacy.	apatinib	13-21	interleukin 17A	Homo sapiens	39-44
31126019-5	2019	At meningitis diagnosis, stimulation with cryptococcal capsule component, glucuronoxylomannan (GXM) elicited consistently lower frequencies of CD4+ and CD8+ T cell memory subsets expressing intracellular cytokines (IL-2, IFN-gamma, and IL-17) among subjects who subsequently developed CM-IRIS.	glucuronoxylomannan	74-93	interleukin 17A	Homo sapiens	236-241
30852259-0	2019	Indole alkaloids indigodoles A-C from aerial parts of Strobilanthes cusia in the traditional Chinese medicine Qing Dai have anti-IL-17 properties.	Indole Alkaloids	0-16	interleukin 17A	Homo sapiens	129-134
30852259-5	2019	Indigodole C and tryptanthrin could significantly inhibit IL-17 production of Th17 cells.	indigodole c	0-12	interleukin 17A	Homo sapiens	58-63
30852259-5	2019	Indigodole C and tryptanthrin could significantly inhibit IL-17 production of Th17 cells.	tryptanthrine	17-29	interleukin 17A	Homo sapiens	58-63
30852259-6	2019	In addition, indigodole A and indirubin showed notably anti-IL-17 gene expression in dose-dependent effects without cytotoxicities toward Th17 and Jurkat cells, respectively.	indigodole a	13-25	interleukin 17A	Homo sapiens	60-65
30852259-6	2019	In addition, indigodole A and indirubin showed notably anti-IL-17 gene expression in dose-dependent effects without cytotoxicities toward Th17 and Jurkat cells, respectively.	indirubin	30-39	interleukin 17A	Homo sapiens	60-65
31159519-8	2019	Similarly,the protein levels as well as mRNA expression of IL-6 and IL-17 in patients with iron overload were significantly higher than those in non-iron overload group (P&lt;0.01 both in PB and BM).	Iron	91-95	interleukin 17A	Homo sapiens	68-73
31159519-9	2019	Conclusions: As hematopoietic regulators secreted by Th17 cells, the expression of IL-6 and IL-17 in MDS patients with iron overload are elevated.	Iron	119-123	interleukin 17A	Homo sapiens	92-97
31231373-11	2019	In addition, plasma IL-17 and IL-23 levels were elevated in acute gout, whereas protein levels of T-bet were downregulated in PBMCs from acute gout patients and intercritical gout treated with MSU crystals in vitro as well.	Uric Acid	193-196	interleukin 17A	Homo sapiens	20-25
31126019-5	2019	At meningitis diagnosis, stimulation with cryptococcal capsule component, glucuronoxylomannan (GXM) elicited consistently lower frequencies of CD4+ and CD8+ T cell memory subsets expressing intracellular cytokines (IL-2, IFN-gamma, and IL-17) among subjects who subsequently developed CM-IRIS.	glucuronoxylomannan	95-98	interleukin 17A	Homo sapiens	236-241
30988066-9	2019	DAPT treatment did not affect frequency of either circulating Tregs or Th17 cells, however, reduced FoxP3/RORgammat mRNA expression and interleukin (IL)-35/IL-17 production in purified CD4+ T cells from GC patients.	dapt	0-4	interleukin 17A	Homo sapiens	156-161
30902899-9	2019	injection of CCK8S suppressed the IMQ-induced psoriatic inflammation accompanied by reduced mRNA expression of IL-17, IL-22, and IL-6 but not of IL-23.	Imiquimod	34-37	interleukin 17A	Homo sapiens	111-116
30474934-7	2019	Treatment of experimental arthritis with ibudilast resulted in a reduction in IL-17-producing cells and inhibition of disease progression.	ibudilast	41-50	interleukin 17A	Homo sapiens	78-83
30615197-7	2019	Furthermore, MDL-101 significantly suppressed proliferation and IL-17 production of anti-CD3-activated effector/memory CD45RO+ CD4+ human CD4 T cells and promoted human Treg development.	mdl-101	13-20	interleukin 17A	Homo sapiens	64-69
31025232-13	2019	An irreversible inhibitor of ITK, ibrutinib, blocked ex vivo Th17 generation and IL-17A production, conversely augmented FOXP3 expression only at low doses in Treg cultures.	ibrutinib	34-43	interleukin 17A	Homo sapiens	81-87
30855208-6	2019	Treatment with sitagliptin plus VitD3 reduced the levels of IFN-gamma and IL-17 in both nonnephropathic and nephropathic patients compared with untreated patients.	Sitagliptin Phosphate	15-26	interleukin 17A	Homo sapiens	74-79
30623486-6	2019	Our results show that PZQ enhanced T-cell proliferation, increased secretion of IL-17 and IL-10 but had no effect on secretion of GM-CSF or IFNgamma.	Praziquantel	22-25	interleukin 17A	Homo sapiens	80-85
30517642-11	2019	Multivariate analyses revealed that the Th17 pathway [IL-17A (P = 0.001), IFN-gamma (P = 0.009), RORgammat (P = 0.003), IL-23R (P = 0.033), IL-21R (P = 0.019)], and Th2 pathway [IL-13 (P = 0.015), GATA3 (P = 0.012)] were associated with TAO.	th17	40-44	interleukin 17A	Homo sapiens	54-60
31080419-10	2019	Finally, plasma free thiol concentrations negatively correlated with biomarkers of inflammation, including hsCRP, SAA, IL-17A (all P &lt; 0.05), and VEGF.	Sulfhydryl Compounds	21-26	interleukin 17A	Homo sapiens	119-125
30962593-6	2019	Induction of the transcriptional co-activator IkappaBzeta via IL-17 signaling mediated increased glucose uptake and expression of the gene Cpt1a, encoding CPT1A, a rate-limiting enzyme of mitochondrial fatty acid oxidation.	Glucose	97-104	interleukin 17A	Homo sapiens	62-67
30962593-6	2019	Induction of the transcriptional co-activator IkappaBzeta via IL-17 signaling mediated increased glucose uptake and expression of the gene Cpt1a, encoding CPT1A, a rate-limiting enzyme of mitochondrial fatty acid oxidation.	Fatty Acids	202-212	interleukin 17A	Homo sapiens	62-67
31047104-10	2019	IL-17A levels were positively correlated with FeNO values in severe asthmatics with eosinophils>400 cells/mul.	flubendiamide	46-50	interleukin 17A	Homo sapiens	0-6
31024070-7	2019	Consistent with the human fertility studies, this investigation reveals a beneficial systemic use of tacrolimus (0.1 mg/kg) in promoting early pregnancy in individuals with PCOS and suggests the need for further research into the selective inhibition of IL17A as a plausibly alternative immunotherapeutic approach in the clinical management of infertile individuals with PCOS.	Tacrolimus	101-111	interleukin 17A	Homo sapiens	254-259
30855208-9	2019	These findings indicated that the sitagliptin plus VitD3 was more effective to reduce the increased proinflammatory IFN-gamma and IL-17 cytokines in T2DM patients.	Sitagliptin Phosphate	34-45	interleukin 17A	Homo sapiens	130-135
31084433-6	2019	Other shared functions of vitamin A and vitamin D include the support of innate lymphoid cells that produce IL-22, suppression of IFN-gamma and IL-17 by T cells, and induction of regulatory T cells in the mucosal tissues.	Vitamin A	26-35	interleukin 17A	Homo sapiens	144-149
31024518-8	2019	Additionally, the frequency of IL-17-expressing CD4+ T cells, predominately with single-positive IL-17+ and double-positive IL-2+/IL-17+ phenotypes, was higher in participants with active TB than in the other two groups.	Terbium	188-190	interleukin 17A	Homo sapiens	31-36
30929860-10	2019	Rintatolimod was predicted to make available substantial remission in a significant subset of subjects, in particular those with low levels of IL-1alpha, IL-17, and cortisol; intermediate levels of progesterone and FSH; and high estrogen levels.	poly(I).poly(c12,U)	0-12	interleukin 17A	Homo sapiens	154-159
30924030-1	2019	Tildrakizumab (tildrakizumab-asmn in the USA) [Ilumetri ; Ilumya ] is a humanized monoclonal antibody (mAb) that selectively targets the p19 subunit of interleukin (IL)-23, thereby inhibiting the IL-23/IL-17 axis, the signalling pathway primarily implicated in the immunopathogenesis of psoriasis.	asmn	29-33	interleukin 17A	Homo sapiens	202-207
31084433-6	2019	Other shared functions of vitamin A and vitamin D include the support of innate lymphoid cells that produce IL-22, suppression of IFN-gamma and IL-17 by T cells, and induction of regulatory T cells in the mucosal tissues.	Vitamin D	40-49	interleukin 17A	Homo sapiens	144-149
30907193-5	2019	Results: The production of IFN-gamma and IL-17 was increased in untreated (without sitagliptin and VitD3) nephropathic and non-nephropathic T2DM patients compared with healthy controls, whereas FOXP3 expression was decreased.	Sitagliptin Phosphate	83-94	interleukin 17A	Homo sapiens	41-46
30907193-8	2019	Conclusion: These data demonstrate that sitagliptin in combination with VitD3 may accelerate the process of T2DM treatment by exerting synergic anti-inflammatory effects on immune system through upregulation of FOXP3 and IL-37, and downregulation of RORgammat and BCL6 as well as IFN-gamma, IL-17 and IL-21 production.	Sitagliptin Phosphate	40-51	interleukin 17A	Homo sapiens	291-296
30907193-7	2019	Production of IL-17 and IL-21 and the expression of RORgammat and BCL6 was diminished in patients treated with combined sitagliptin and VitD3, whereas the production of IL-37 and FOXP3 expression were increased in the patients treated with sitagliptin or sitagliptin plus VitD3.	Sitagliptin Phosphate	120-131	interleukin 17A	Homo sapiens	14-19
30362152-0	2019	Loss of miR-146b-5p promotes T cell acute lymphoblastic leukemia migration and invasion via the IL-17A pathway.	mir-146b-5p	8-19	interleukin 17A	Homo sapiens	96-102
31135243-4	2019	Results &amp; conclusion: New biologics such as IL-17 antagonist or IL-23 antagonist show greater responses in bio-experienced patients and could even be used for patients in whom previous treatments failed.	Adenosine Monophosphate	9-12	interleukin 17A	Homo sapiens	48-53
30070012-8	2019	CONCLUSIONS: Deficiency of vitamin D3 accompanied with higher IL-17 in an inverse pattern may have a possible role in active acne vulgaris.	Cholecalciferol	27-37	interleukin 17A	Homo sapiens	62-67
30972071-8	2019	Using human keratinocytes cultured with supernatants from compound treated Th17 cells we showed that pharmacological inhibition of RORgammat translated to suppressed IL-17-regulated gene expression in keratinocyte cell cultures.	rorgammat	131-140	interleukin 17A	Homo sapiens	166-171
30799725-1	2019	Aim: This study aimed to investigate the effect of and mechanism involved in the IL-17 SNP on cyclosporine metabolism and outcomes of liver transplantation (LT).	Cyclosporine	94-106	interleukin 17A	Homo sapiens	81-86
30799725-7	2019	Cyclosporine concentration was associated with the different IL-17 genotype (p < 0.05).	Cyclosporine	0-12	interleukin 17A	Homo sapiens	61-66
30799725-11	2019	Conclusion: This study revealed the possible association of IL-17 G-197A with cyclosporine metabolism and transplant rejection after LT, which might be partly related to the upregulations of CYP3A4/5 dependent on PXR.	Cyclosporine	78-90	interleukin 17A	Homo sapiens	60-65
30922377-10	2019	RESULTS: The level of Il-17A in EBC significantly decreased in calcitriol group from 0,475 pg/mL (+- SD 0,515 pg/mL) to 0,384 pg/mL (+- SD 0,429 pg/mL) (p = 0,008); there was no change in cholecalciferol group (p = 0,074).	NSC638702	32-35	interleukin 17A	Homo sapiens	22-28
30922377-10	2019	RESULTS: The level of Il-17A in EBC significantly decreased in calcitriol group from 0,475 pg/mL (+- SD 0,515 pg/mL) to 0,384 pg/mL (+- SD 0,429 pg/mL) (p = 0,008); there was no change in cholecalciferol group (p = 0,074).	Calcitriol	63-73	interleukin 17A	Homo sapiens	22-28
30922377-10	2019	RESULTS: The level of Il-17A in EBC significantly decreased in calcitriol group from 0,475 pg/mL (+- SD 0,515 pg/mL) to 0,384 pg/mL (+- SD 0,429 pg/mL) (p = 0,008); there was no change in cholecalciferol group (p = 0,074).	Cholecalciferol	188-203	interleukin 17A	Homo sapiens	22-28
30922377-13	2019	CONCLUSIONS: Both analogs of vitamin D revealed their anti-inflammatory effect and reduced the level of Il-17A and Il-23 in the airway of CF patients with chronic P. aeruginosa infection.	Vitamin D	29-38	interleukin 17A	Homo sapiens	104-110
30295316-16	2019	Vitamin D inhibited IL-6 and IL-8 production stimulated by G-HSA or HSA + IL-1beta or IL-1beta + IL-17.	Vitamin D	0-9	interleukin 17A	Homo sapiens	97-102
30908540-7	2019	Digoxin was recently identified to selectively inhibit IL-17 production by antagonizing its transcription factor, retinoid-related orphan receptor gamma t (RORgammat).	Digoxin	0-7	interleukin 17A	Homo sapiens	55-60
30908540-8	2019	Digoxin inhibits RORgammat binding to IL-17 and Th17 associated genes, and suppresses IL-17 production in vitro in human and murine leukocytes and in vivo in rodent models of autoimmune disease.	Digoxin	0-7	interleukin 17A	Homo sapiens	38-43
30908540-8	2019	Digoxin inhibits RORgammat binding to IL-17 and Th17 associated genes, and suppresses IL-17 production in vitro in human and murine leukocytes and in vivo in rodent models of autoimmune disease.	Digoxin	0-7	interleukin 17A	Homo sapiens	86-91
30908540-8	2019	Digoxin inhibits RORgammat binding to IL-17 and Th17 associated genes, and suppresses IL-17 production in vitro in human and murine leukocytes and in vivo in rodent models of autoimmune disease.	rorgammat	17-26	interleukin 17A	Homo sapiens	38-43
30668316-8	2019	RESULTS: The results showed that terpenes have promising biological effects in relation to the treatment of arthritis, with the 24 terpenes identified in our survey being effective in the modulation of inflammatory mediators important to the physiopathology of arthritis, such as IL-6, IL-17, TNF-alpha, NFkappaB, and COX-2, among others.	Terpenes	131-139	interleukin 17A	Homo sapiens	286-291
30529000-8	2019	Furthermore, activation of IL-17A/IL-17R signaling in neutrophils of ASD subjects leads to upregulation of phospho-NFkappaB, IL-6 and NOX2/ROS, thus suggesting a compelling role of IL-17A in modulation of inflammation.	Reactive Oxygen Species	139-142	interleukin 17A	Homo sapiens	27-33
30849987-5	2019	Module-trait analysis identified that a module involved in microtubule bundle formation, drug metabolism-cytochrome P450, and IL-17 signaling pathway was negatively correlated with osteosarcoma and positively correlated with metastasis; a module involved in DNA replication was positively correlated with osteosarcoma; a module involved in cell junction was positively correlated with metastasis; and a module involved in heparin binding negatively correlated with osteosarcoma.	Heparin	422-429	interleukin 17A	Homo sapiens	126-131
31074416-10	2019	The levels of IL-2, IL-4, IL-10, IFN-gamma, and IL-17 correlated positively with the levels of serum creatinine.	Creatinine	101-111	interleukin 17A	Homo sapiens	48-53
30604628-7	2019	In addition, inhibiting Janus activated kinase (JAK) 2 by either siRNA or a selective pharmacological inhibitor, AZD1480-but not a JAK1/JAK3 selective inhibitor, tofacitinib-also significantly reduced this IL-17A-induced fibrogenic response.	AZD 1480	113-120	interleukin 17A	Homo sapiens	206-212
30549005-0	2019	The effect of anti-IL-17 treatment on the reaction to a nickel patch test in patients with allergic contact dermatitis.	Nickel	56-62	interleukin 17A	Homo sapiens	19-24
30638709-6	2019	Treatment ex vivo with TPC decreased the production of IL-1beta, IL-2, IL-5, IL-6, IL-9, IL-12(p70), IL-13, IL-17A, IL-18, IL-21, IL-22, IL-23, IFNgamma, TNFalpha, GM-CSF by CD3/CD28 activated PBMCs whereas it negligibly affected cell viability.	tpc	23-26	interleukin 17A	Homo sapiens	108-114
30873944-0	2019	Safety of the use of anti-IL17A treatment in a patient with certolizumab-induced sarcoidosis.	Certolizumab Pegol	60-72	interleukin 17A	Homo sapiens	26-31
30638709-8	2019	In inflamed TABs, treatment with TPC down-regulated the production of IL-1beta, IL-6, IL-13, IL-17A and CD68 gene expression.	tpc	33-36	interleukin 17A	Homo sapiens	93-99
30548981-5	2019	Also, while TT and TC+CC genotypes are equally prevalent in the lesions presenting low IFN/IL17 ratio, a significant decrease in polymorphic TC+CC genotypes was observed in lesions presenting intermediate and high IFN/IL17 ratio.	Technetium	19-21	interleukin 17A	Homo sapiens	91-95
30683702-4	2019	Rab35 knockdown showed that IL-17A-induced Rab35 activation was essential for protein kinase Calpha (PKCalpha) activation and phosphorylation of fascin at Ser39 in ASMCs, allowing F-actin to interact with myosin to form stress fibers and enhance the contraction induced by methacholine.	Methacholine Chloride	273-285	interleukin 17A	Homo sapiens	28-34
30683702-5	2019	PKCalpha inhibitor or Rab35 knockdown indeed substantially reduced IL-17A-induced stress fiber formation in ASMCs and attenuated IL-17A-enhanced, methacholine-induced contraction of airway smooth muscle.	asmcs	108-113	interleukin 17A	Homo sapiens	67-73
30683702-5	2019	PKCalpha inhibitor or Rab35 knockdown indeed substantially reduced IL-17A-induced stress fiber formation in ASMCs and attenuated IL-17A-enhanced, methacholine-induced contraction of airway smooth muscle.	Methacholine Chloride	146-158	interleukin 17A	Homo sapiens	129-135
30670307-4	2019	Recent studies have uncovered T helper type 17 skewing in ichthyotic skin, resembling psoriasis, and high frequencies of IL-17- and IL-22-expressing T cells in blood, correlating with severity and transepidermal water loss.	Water	212-217	interleukin 17A	Homo sapiens	121-126
30683702-4	2019	Rab35 knockdown showed that IL-17A-induced Rab35 activation was essential for protein kinase Calpha (PKCalpha) activation and phosphorylation of fascin at Ser39 in ASMCs, allowing F-actin to interact with myosin to form stress fibers and enhance the contraction induced by methacholine.	asmcs	164-169	interleukin 17A	Homo sapiens	28-34
31106538-5	2019	CONCLUSION: alpha-MMC can significantly inhibit the synthesis and secretion of cytokines such as IL-6, IL-17A and TNF-alpha in hepatocytes, which may become a side effect of its anti-tumor application.	alpha-mmc	12-21	interleukin 17A	Homo sapiens	103-109
29695840-4	2019	A deeper investigation of the microbe-derived metabolite, ascorbate, revealed its selective inhibition on activated human CD4+ effector T cells, including IL-17A-, IL-4-, and IFNgamma-producing cells.	Ascorbic Acid	58-67	interleukin 17A	Homo sapiens	155-161
30890498-10	2019	The results of ELISA and qRT-PCR revealed that metformin treatment obviously increased Foxp3 and TGF-beta expressions at both the protein and mRNA levels and significantly decreased the levels of ROR-gammat, IL-17 and TNF-alpha as well as IL-35 level in these patients.	Metformin	47-56	interleukin 17A	Homo sapiens	208-213
30838000-8	2019	Upon in vitro activation with PMA plus ionomycin or IL12 plus IL18, fewer MAIT cells isolated from the young adult group expressed IFN-gamma, IL17A and Granzyme B then cells from other age groups while the proportion of cells that expressed TNF-alpha was similar.	Tetradecanoylphorbol Acetate	30-33	interleukin 17A	Homo sapiens	142-147
30445620-8	2019	Their second and third patients received Azithromycin targeting IL-17A and showed clinical responses.	Azithromycin	41-53	interleukin 17A	Homo sapiens	64-70
30838000-8	2019	Upon in vitro activation with PMA plus ionomycin or IL12 plus IL18, fewer MAIT cells isolated from the young adult group expressed IFN-gamma, IL17A and Granzyme B then cells from other age groups while the proportion of cells that expressed TNF-alpha was similar.	Ionomycin	39-48	interleukin 17A	Homo sapiens	142-147
30563869-12	2019	Autophagy-mediated release of TF-bearing and IL-17A-bearing NETs provides a link between thromboinflammation and fibrosis in SLE and may account for the salutary effects of hydroxychloroquine.	Hydroxychloroquine	173-191	interleukin 17A	Homo sapiens	45-51
30828332-9	2019	Importantly, ex vivo exposure of ILC3 and ILC1 to fingolimod or SEW2871, another S1PR1 antagonist, reduced production of ILC3- and ILC1- associated cytokines GM-CSF, IL-22, IL-17, and IFN-gamma, respectively.	Fingolimod Hydrochloride	50-60	interleukin 17A	Homo sapiens	173-178
30828332-9	2019	Importantly, ex vivo exposure of ILC3 and ILC1 to fingolimod or SEW2871, another S1PR1 antagonist, reduced production of ILC3- and ILC1- associated cytokines GM-CSF, IL-22, IL-17, and IFN-gamma, respectively.	SEW2871	64-71	interleukin 17A	Homo sapiens	173-178
30717391-5	2019	In addition, Western blotting, reverse-transcription polymerase chain reaction (PCR), and real-time PCR analyses showed that loliolide enhanced the expression of the epidermal growth factor receptor signaling pathway (PI3K, AKT) and migration factors, such as K6, K16, and K17; keratinocyte growth factor; and inflammatory cytokines, such as interleukin (IL)-1, IL-17, and IL-22 expressed during the cellular scratching process, suggesting a putative wound-healing ability.	loliolide	125-134	interleukin 17A	Homo sapiens	362-367
30357602-4	2019	After 72 h of incubation of PBMCs from eRA patients with 1,25(OH)2D3, the levels of IFN- , TNF-alpha, IL-2, IL-6, and IL-17 significantly decreased compared to those of the control.	Calcitriol	57-68	interleukin 17A	Homo sapiens	118-123
30530046-5	2019	AZM and EM significantly inhibited IL-17A and CXCL-2 production in patients" PBLs (all P &lt; 0.05).	Azithromycin	0-3	interleukin 17A	Homo sapiens	35-41
30530046-8	2019	AZM and EM significantly decreased secreted IL-17A levels (P &lt; 0.05) in the primary CD4 + T cells of patients with DPB.	Azithromycin	0-3	interleukin 17A	Homo sapiens	44-50
30357602-9	2019	The present study demonstrated that 1,25(OH)2D3 inhibited the synthesis of specific cytokines: Th1 (IFN- ) and Th17 (IL-17, IL-22, IL-6, TNF-alpha) might upregulated Th2 cytokine (IL-4), which indicated the possible immunoregulatory roles and bone-sparing effects of 1,25(OH)2D3 in eRA through modulation of the Th1 and Th17 cytokine balance.	Calcitriol	36-47	interleukin 17A	Homo sapiens	117-122
30357602-9	2019	The present study demonstrated that 1,25(OH)2D3 inhibited the synthesis of specific cytokines: Th1 (IFN- ) and Th17 (IL-17, IL-22, IL-6, TNF-alpha) might upregulated Th2 cytokine (IL-4), which indicated the possible immunoregulatory roles and bone-sparing effects of 1,25(OH)2D3 in eRA through modulation of the Th1 and Th17 cytokine balance.	Calcitriol	267-278	interleukin 17A	Homo sapiens	117-122
30528394-0	2019	Elevated IL-17 levels and echocardiographic signs of preserved myocardial function in benznidazole-treated individuals with chronic Chagas" disease.	benzonidazole	86-98	interleukin 17A	Homo sapiens	9-14
30528394-4	2019	The treated group exhibited higher levels of IL-17 (median 142.45x1.22pg/ml, P=0.025), which was the only one significantly associated with Bz treatment, especially after adjusting for time of disease and NYHA class (P=0.024; OR 1.006, 95% CI 1.001-1.010).	Quinuclidinyl Benzilate	140-142	interleukin 17A	Homo sapiens	45-50
30528394-7	2019	CONCLUSION: The present findings suggest that the group of CCD patients treated with Bz displayed increased plasma levels of IL-17 and preserved myocardial function, reinforcing the idea that Bz treatment may be beneficial.	Quinuclidinyl Benzilate	85-87	interleukin 17A	Homo sapiens	125-130
30544066-6	2019	Our results showed that administration of GA significantly increased the expressions of IL-4, and IL-10, while down-regulated IL-1, IL-6, IL-12, IL-17, IL-23, TGF-beta and TNF-alpha expressions compared with a model control group in vitro and in vivo.	Gallic Acid	42-44	interleukin 17A	Homo sapiens	145-150
30528394-7	2019	CONCLUSION: The present findings suggest that the group of CCD patients treated with Bz displayed increased plasma levels of IL-17 and preserved myocardial function, reinforcing the idea that Bz treatment may be beneficial.	Quinuclidinyl Benzilate	192-194	interleukin 17A	Homo sapiens	125-130
32328572-8	2019	We found that the stiffness and traction force of HASMCs were enhanced along with the increases of IL-17A concentration and exposure time, and SDN treatment dose-dependently reduced these IL-17A-induced changes in cell mechanical properties.	SDN	143-146	interleukin 17A	Homo sapiens	188-194
30553912-5	2019	In addition, we found that the mRNA expression of IL-1beta, IL-6, IL-8 and IL-17A were markedly down-regulated by treatment with betulinic acid in TNF-alpha-induced RA FLSs.	betulinic acid	129-143	interleukin 17A	Homo sapiens	75-81
32328572-0	2019	Saponins of Dioscorea Nipponicae Inhibits IL-17A-Induced Changes in Biomechanical Behaviors of In Vitro Cultured Human Airway Smooth Muscle Cells.	Saponins	0-8	interleukin 17A	Homo sapiens	42-48
30472069-6	2019	We determined that tacrolimus profoundly suppressed CD4 and CD8 T cell proliferation and significantly suppressed Th1 and Th17 responses, as demonstrated by a reduced frequency of IFN-gamma, IL-2, and IL-17 producing CD4 T cells and reduced frequencies of IFN-gamma and IL-2 producing CD8 T cells.	Tacrolimus	19-29	interleukin 17A	Homo sapiens	201-206
30472069-7	2019	Tacrolimus also inhibits pathogenic Th17 cells coproducing IL-17 and IFN-gamma.	Tacrolimus	0-10	interleukin 17A	Homo sapiens	59-64
30640172-8	2019	We hypothesized that the mechanism of action probably involves TGF-beta, ERBB, or EHF, which would predict that geldanamycin would also revert IL-17-induced goblet cell metaplasia, a prediction confirmed by our experiments.	geldanamycin	112-124	interleukin 17A	Homo sapiens	143-148
30598515-4	2019	In addition, dexamethasone increased production of IL-17A, IL-17F, and IL-22, with the most striking enhancement in cells coproducing Th17-associated cytokines together with IL-10.	Dexamethasone	13-26	interleukin 17A	Homo sapiens	51-57
32328572-5	2019	Here, we evaluated the biomechanical effect of SDN on IL-17A-mediated changes of cultured human airway smooth muscle cells (HASMCs) in vitro.	SDN	47-50	interleukin 17A	Homo sapiens	54-60
32328572-9	2019	Furthermore, SDN alleviated IL-17A-mediated effects on HASMCs proliferation, migration, and cytoskeleton remodeling.	SDN	13-16	interleukin 17A	Homo sapiens	28-34
30693003-0	2018	Blockade of Store-Operated Calcium Entry Reduces IL-17/TNF Cytokine-Induced Inflammatory Response in Human Myoblasts.	Calcium	27-34	interleukin 17A	Homo sapiens	49-54
30674716-5	2019	Accordingly, calcipotriol treatment suppressed IL-36alpha/gamma expression in lesional skin from patients with plaque psoriasis, which was accompanied by a reduced IL-23/IL-17 expression.	calcipotriene	13-25	interleukin 17A	Homo sapiens	170-175
30596535-6	2019	We found that IL-17 stimulated RA-FLS to produce RANKL and quercetin decreased the IL-17-induced RANKL protein levels.	Quercetin	59-68	interleukin 17A	Homo sapiens	14-19
30596535-6	2019	We found that IL-17 stimulated RA-FLS to produce RANKL and quercetin decreased the IL-17-induced RANKL protein levels.	Quercetin	59-68	interleukin 17A	Homo sapiens	83-88
30596535-7	2019	Quercetin decreased the IL-17-produced activation of mammalian target of rapamycin, extracellular signal-regulated kinase and inhibitor of kappa B-alpha.	Quercetin	0-9	interleukin 17A	Homo sapiens	24-29
30596535-8	2019	When monocytes were stimulated with IL-17, macrophage colony-stimulating factor or RANKL, mature osteoclasts were formed, and quercetin decreased this osteoclastogenesis.	Quercetin	126-135	interleukin 17A	Homo sapiens	36-41
30596535-9	2019	When monocytes were cultured with IL-17-prestimulated RA-FLS or Th17 cells, osteoclasts were produced, and quercetin decreased this osteoclast differentiation.	Quercetin	107-116	interleukin 17A	Homo sapiens	34-39
30596535-10	2019	In Th17-differentiation conditions, quercetin suppressed Th17 cell and the production of IL-17, but quercetin did not affect Treg cells.	Quercetin	36-45	interleukin 17A	Homo sapiens	89-94
30596535-11	2019	Quercetin inhibits IL-17-stimulated RANKL production in RA-FLS and IL-17-stimulated osteoclast formation.	Quercetin	0-9	interleukin 17A	Homo sapiens	19-24
30596535-11	2019	Quercetin inhibits IL-17-stimulated RANKL production in RA-FLS and IL-17-stimulated osteoclast formation.	Quercetin	0-9	interleukin 17A	Homo sapiens	67-72
30693003-9	2018	IL-17 and/or TNFalpha increased the level of the ER stress marker Grp78, mitochondrial ROS and promoted SOCE activation by 2-fold (p < 0.01) in isolated myoblasts.	ros	87-90	interleukin 17A	Homo sapiens	0-5
30616547-2	2019	A subset of asthma patients also exhibits elevated IL-17, which is associated with greater disease severity, neutrophilic inflammation, and steroid resistance.	Steroids	140-147	interleukin 17A	Homo sapiens	51-56
30544018-1	2019	The purpose of this study was to evaluate the anti-inflammatory property of gelatin hydrogel containing cerium oxide nanoparticles coated with interleukin-17 Aptemer ([CeON@IL-17]).	ceric oxide	104-116	interleukin 17A	Homo sapiens	173-178
30616627-10	2019	TANs enhanced the migration, invasion and EMT of GC cells through the secretion of IL-17a, which activated the Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT3) pathway in GC cells, while deprivation of IL-17a using a neutralizing antibody or inhibition of the JAK2/STAT3 pathway with AG490 markedly reversed these TAN-induced phenotypes in GC cells induced by TANs.	tans	0-4	interleukin 17A	Homo sapiens	83-89
30666196-6	2018	Furthermore, analysis of the transcriptomes of Th17 cells cultured in the presence of digoxin revealed the induction of the expression of numerous Th17-specific genes, including IL17A/F, IL21, IL22, IL23R, CCR4, and CCR6.	Digoxin	86-93	interleukin 17A	Homo sapiens	178-183
30616627-10	2019	TANs enhanced the migration, invasion and EMT of GC cells through the secretion of IL-17a, which activated the Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT3) pathway in GC cells, while deprivation of IL-17a using a neutralizing antibody or inhibition of the JAK2/STAT3 pathway with AG490 markedly reversed these TAN-induced phenotypes in GC cells induced by TANs.	tans	0-4	interleukin 17A	Homo sapiens	232-238
30616627-10	2019	TANs enhanced the migration, invasion and EMT of GC cells through the secretion of IL-17a, which activated the Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT3) pathway in GC cells, while deprivation of IL-17a using a neutralizing antibody or inhibition of the JAK2/STAT3 pathway with AG490 markedly reversed these TAN-induced phenotypes in GC cells induced by TANs.	tans	390-394	interleukin 17A	Homo sapiens	83-89
30616627-12	2019	TANs produce IL-17a, which promotes EMT of GC cells through JAK2/STAT3 signalling.	tans	0-4	interleukin 17A	Homo sapiens	13-19
30951887-7	2019	Furthermore, the effects of IL-17A and IL-17F were reduced by downregulation of Act1 with siRNA and inhibition of NF-kappaB and MAPK pathways with BAY11-7082 and U0126, respectively.	3-(4-methylphenylsulfonyl)-2-propenenitrile	147-157	interleukin 17A	Homo sapiens	28-34
29934047-5	2019	RESULTS: CHF6001 inhibited IFNgamma, IL-2 and IL-17, but not IL-13, secretion from both mild and moderate asthma patient BAL cells; there was a greater effect on IFNgamma and IL-2 than IL-17.	3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoyloxy)ethyl)pyridine 1-oxide	9-16	interleukin 17A	Homo sapiens	46-51
29934047-5	2019	RESULTS: CHF6001 inhibited IFNgamma, IL-2 and IL-17, but not IL-13, secretion from both mild and moderate asthma patient BAL cells; there was a greater effect on IFNgamma and IL-2 than IL-17.	3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoyloxy)ethyl)pyridine 1-oxide	9-16	interleukin 17A	Homo sapiens	185-190
30383540-0	2019	An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup.	Steroids	60-67	interleukin 17A	Homo sapiens	21-27
31332998-8	2019	Comparison between omega-3 fatty acids and sublingual immunotherapy as regards ACT, PEFR, and FEV1and IL17A showed that omega-3 fatty acids treatment was better than sublingual immunotherapy in decreasing IL17A, but both were effective in decreasing PEFR, FEV1 and ACT.	Fatty Acids, Omega-3	120-139	interleukin 17A	Homo sapiens	205-210
30689515-5	2019	PTg induced significant antigen-specific CD4+ T cell activation and IL17 secretion than PTc.	Teniposide	0-3	interleukin 17A	Homo sapiens	68-72
30689515-6	2019	TLR agonist combinations improved PTg induced T cell-CD69 expression and IL17 secretion.	Teniposide	34-37	interleukin 17A	Homo sapiens	73-77
30353649-10	2019	LY294002 treatment also attenuated the IL-17A causing increases of protein levels of PI3K, AKT, MMP-2/9, Twist and the decreases of protein level of ZO-1 in the U87MG and U251 cells.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	interleukin 17A	Homo sapiens	39-45
30951887-7	2019	Furthermore, the effects of IL-17A and IL-17F were reduced by downregulation of Act1 with siRNA and inhibition of NF-kappaB and MAPK pathways with BAY11-7082 and U0126, respectively.	U 0126	162-167	interleukin 17A	Homo sapiens	28-34
31814545-5	2019	Some flavonoids exert anti-inflammatory effects through: Blockade of NF-kappaB, and NLRP3 inflammasome, inhibition of pro-inflammatory cytokine production, IL-1beta, IL-2, IL-6, TNF-alpha, IL-17A, down regulation of chemokines, and reduction of reactive oxygen and nitrogen species.	Flavonoids	5-15	interleukin 17A	Homo sapiens	189-195
30189151-6	2019	Topical CsA treatment induced a significant reduction in CD4 and IL-17 expressions (P &lt; 0.05); post-treatment levels were same as normals (P &gt; 0.05).	Cyclosporine	8-11	interleukin 17A	Homo sapiens	65-70
30279516-4	2019	We found that the combination of TNFalpha and IL-17 induced a dramatic upregulation of NOXO1 expression that was dependent on the activation of p38MAPK and JNK1/2, and resulted into an increase of NOX1 activity and ROS production.	Reactive Oxygen Species	215-218	interleukin 17A	Homo sapiens	46-51
30655852-0	2019	Interleukin-17 promotes the development of cisplatin resistance in colorectal cancer.	Cisplatin	43-52	interleukin 17A	Homo sapiens	0-14
30680297-13	2018	Quercetin could decrease pro-inflammatory cytokines and IL-17 production.	Quercetin	0-9	interleukin 17A	Homo sapiens	56-61
30130103-5	2018	This approach successfully identified 3-cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide as a potent and selective RORC2 inverse agonist, demonstrating good metabolic stability, oral bioavailability, and the ability to reduce IL-17 levels and skin inflammation in a preclinical in vivo animal model upon oral administration.	rorc2	178-183	interleukin 17A	Homo sapiens	289-294
30449598-5	2018	Increased production of IL-17A and IFN-gamma has been implicated in the pathogenesis of MS, epilepsy, and stroke, and these cytokines impact BBB integrity after 24 h. We here report that primary human brain microvascular endothelial cells expressed the EGFR and PAR2 receptors necessary to respond to zonulin, and that zonulin increased BBB permeability to a 40 kDa dextran tracer within 1 h. Moreover, both IL-17A and IFN-gamma also rapidly increased BBB and IEB permeability.	Dextrans	366-373	interleukin 17A	Homo sapiens	24-30
30388623-9	2018	Simultaneously blocking miR-125a and IL-17A might represent a new therapeutic strategy for GCTB.	gctb	91-95	interleukin 17A	Homo sapiens	37-43
30680297-11	2018	Conclusion: Our results indicated that the levels of IL-17, IL-33, and IL-6 in supernatants from patients" cultured T cells were increased after stimulation with HMGB-1 following employing quercetin.	Quercetin	189-198	interleukin 17A	Homo sapiens	53-58
30276559-8	2018	RESULTS: Increasing IL-17A level was found in NAEB group (29.65 +- 8.13 pg/ml), EA group (32.45 +- 3.22 pg/ml), and NEA group (29.62 +- 6.91 pg/ml) compared with the healthy control group (17.05 +- 10.30 pg/ml) (P &lt; 0.05, P &lt; 0.01, P &lt; 0.05, respectively).	naeb	46-50	interleukin 17A	Homo sapiens	20-26
30024651-4	2018	Moreover, IL-17A plasma levels were significantly higher in AR group; pretransplantation (Day-1 [D-1]): P = 0.00022 and posttransplantation (Day 7 [D7]): P &lt; 10-14 .	Argon	60-62	interleukin 17A	Homo sapiens	10-16
30422744-4	2018	We found that TQ treatment resulted in a significant upregulation of phagocytic activity, respiratory burst, the production of interleukin-2 (IL-2), IL-6, and IL-17 in NecrJCL-pulsed Mphi co-culture system, and, conversely, in downregulation of the production of IL-6, IL-17, nitric oxide (NO), and arginase activity in nonpulsed TQ-treated Mphis co-culture system.	thymoquinone	14-16	interleukin 17A	Homo sapiens	159-164
30422744-4	2018	We found that TQ treatment resulted in a significant upregulation of phagocytic activity, respiratory burst, the production of interleukin-2 (IL-2), IL-6, and IL-17 in NecrJCL-pulsed Mphi co-culture system, and, conversely, in downregulation of the production of IL-6, IL-17, nitric oxide (NO), and arginase activity in nonpulsed TQ-treated Mphis co-culture system.	thymoquinone	14-16	interleukin 17A	Homo sapiens	269-274
30276559-8	2018	RESULTS: Increasing IL-17A level was found in NAEB group (29.65 +- 8.13 pg/ml), EA group (32.45 +- 3.22 pg/ml), and NEA group (29.62 +- 6.91 pg/ml) compared with the healthy control group (17.05 +- 10.30 pg/ml) (P &lt; 0.05, P &lt; 0.01, P &lt; 0.05, respectively).	ea	80-82	interleukin 17A	Homo sapiens	20-26
30276559-8	2018	RESULTS: Increasing IL-17A level was found in NAEB group (29.65 +- 8.13 pg/ml), EA group (32.45 +- 3.22 pg/ml), and NEA group (29.62 +- 6.91 pg/ml) compared with the healthy control group (17.05 +- 10.30 pg/ml) (P &lt; 0.05, P &lt; 0.01, P &lt; 0.05, respectively).	N-Nitroso-N-ethylaniline	116-119	interleukin 17A	Homo sapiens	20-26
30276559-9	2018	The sputum IL-17A level was correlated with FENO (r = 0.44, P &lt; 0.01), FEV1/FVC% (r = - 0.38, P &lt; 0.05), MMEF%pred (r = - 0.34, P &lt; 0.05), and sputum neutrophil% (r = 0.33, P &lt; 0.05) in total.	flubendiamide	44-48	interleukin 17A	Homo sapiens	11-17
30533524-5	2018	Results: Vitamin D3 affected the levels of IL-17A, IL-10, and IL-6 among the 3 groups (p &lt; 0.001 for all).	Cholecalciferol	9-19	interleukin 17A	Homo sapiens	43-49
30815354-11	2019	Moreover, IMQ-induced inflammatory cytokines; Th1 cytokines (TNF-alpha, IFN-alpha, IFN-gamma,and IL-27) and Th17 cytokines (IL-17A and IL-23), in the serum and skin showed marked inhibition by hE-MSCs.	Imiquimod	10-13	interleukin 17A	Homo sapiens	124-130
30572991-8	2018	CONCLUSIONS: Vitamin A may protect residual pancreatic beta cell function, possibly by improving the abnormal secretion of IL-17 in children with T1DM.	Vitamin A	13-22	interleukin 17A	Homo sapiens	123-128
30479197-12	2018	CONCLUSIONS: Our findings suggest that initial targeted treatment with IL-17 inhibitors is the most effective treatment strategy for plaque psoriasis patients who have failed methotrexate and phototherapy.	Methotrexate	175-187	interleukin 17A	Homo sapiens	71-76
30533524-8	2018	Conclusions: Although supplementation with vitamin D3 reduced the mRNA expression levels of IL-17A and IL-6, it increased the mRNA expression level of IL-10 in all groups.	Cholecalciferol	43-53	interleukin 17A	Homo sapiens	92-98
30533524-10	2018	Of interest, in a deficiency state of serum vitamin D3, IL-17A expression had a positive feedback effect on the expression of IL-6.	Cholecalciferol	44-54	interleukin 17A	Homo sapiens	56-62
29855172-9	2018	CONCLUSION: Over the 12-week study period, dual inhibition of TNF and IL-17A with ABT-122 produced a safety profile consistent with that of adalimumb used for inhibition of TNF alone.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	82-85	interleukin 17A	Homo sapiens	70-76
30005016-8	2018	Thus, CD4/IL21 and CD4/IL17 T lymphocytes, as well as IL-21 and IL-17 expression and production were significantly augmented in HESN compared to healthy controls.	hesn	128-132	interleukin 17A	Homo sapiens	23-27
30005016-8	2018	Thus, CD4/IL21 and CD4/IL17 T lymphocytes, as well as IL-21 and IL-17 expression and production were significantly augmented in HESN compared to healthy controls.	hesn	128-132	interleukin 17A	Homo sapiens	64-69
30386121-10	2018	Moreover, the changes in IL-17A over the treatment period were significantly associated with vitamin D changes (beta=-0.04, SE=0.02, P=0.046).	Vitamin D	93-102	interleukin 17A	Homo sapiens	25-31
29855175-0	2018	Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	18-21	interleukin 17A	Homo sapiens	56-71
29855175-10	2018	CONCLUSION: Dual neutralization of TNF and IL-17A with ABT-122 had efficacy and safety that was similar to, and not broadly differentiated from, that of adalimumab over a 12-week treatment course in patients with PsA.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	55-58	interleukin 17A	Homo sapiens	43-49
29855175-1	2018	OBJECTIVE: To investigate the safety and efficacy of ABT-122, a tumor necrosis factor (TNF)- and interleukin-17A (IL-17A)-targeted dual variable domain immunoglobulin, in patients with active psoriatic arthritis (PsA) who have experienced an inadequate response to methotrexate.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	53-56	interleukin 17A	Homo sapiens	97-112
29855175-1	2018	OBJECTIVE: To investigate the safety and efficacy of ABT-122, a tumor necrosis factor (TNF)- and interleukin-17A (IL-17A)-targeted dual variable domain immunoglobulin, in patients with active psoriatic arthritis (PsA) who have experienced an inadequate response to methotrexate.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	53-56	interleukin 17A	Homo sapiens	114-120
30138619-9	2018	Treatment of cultured PBMCs with 10 ng of lipopolysaccharide induced NLRP3, caspase-1, ASC, IL-1beta, IL-17A, and IL-23 expression, which was marked suppressed by treatment with ascorbic acid.	Ascorbic Acid	178-191	interleukin 17A	Homo sapiens	102-108
30061014-9	2018	Inhibition of mTORC1 pathway with rapamycin, increase Tregs and decrease effector CD4+IFNgamma+, CD4+IL17+ and CD4+IL21+ T cells in patients with LVV.	Sirolimus	34-43	interleukin 17A	Homo sapiens	101-105
30032191-0	2018	Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	67-70	interleukin 17A	Homo sapiens	46-61
29665658-3	2018	The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor pravastatin can potentially be used to treat asthma in obese patients by inhibiting interleukin 17 (IL-17) expression.	Pravastatin	62-73	interleukin 17A	Homo sapiens	146-160
29665658-3	2018	The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor pravastatin can potentially be used to treat asthma in obese patients by inhibiting interleukin 17 (IL-17) expression.	Pravastatin	62-73	interleukin 17A	Homo sapiens	162-167
30405296-12	2018	Our findings suggest that the Jats of Haryana, North India, exhibiting high levels of homocysteine, might also carry the high IL-17A -pro-atherogenic marker, suggesting an increasing burden of pre-morbid condition.	Homocysteine	86-98	interleukin 17A	Homo sapiens	126-132
30405600-9	2018	BI119 significantly reduced IL17 and IL26 transcription in colonic and ileal CD biopsies and did not affect IL22.	bi119	0-5	interleukin 17A	Homo sapiens	28-32
30356256-7	2018	In addition irbesartan exerts an anti-inflammatory activity reducing Toll-like receptors (TLRs)-2 and -4 mRNA expression, TNF-alpha expression and activity (20%) and increasing the expression of the cytokine IL-17 (40%) (P&lt;0.05 vs hypoxia).	Irbesartan	12-22	interleukin 17A	Homo sapiens	208-213
30224514-5	2018	In this study, we have shown that polyinosinic:polycytidylic acid (polyI:C) and influenza A virus (IAV) infection increased IFN-lambda expression at mRNA and protein levels in primary cultures of normal human bronchial epithelial cells, whereas IL-17A attenuated polyI:C- or IAV-induced IFN-lambda expression.	polyinosinic:	34-47	interleukin 17A	Homo sapiens	245-251
30332475-7	2018	In this study, we report on the labeling of an anti-IL17 IgG1 model antibody with 14C propionate tag and its detection by CRDS using it as nanotracer (2.1 nCi or 77.7 Bq blended with the therapeutic dose) in a pharmacokinetics study in a preclinical species.	Carbon-14	82-85	interleukin 17A	Homo sapiens	52-56
30332475-9	2018	The derived concentration time profiles for anti-IL17 by CRDS were in concordance with the ones derived by AMS and gamma-counting of an 125I-labeled anti-IL17 radiotracer and were well described by a 2-compartment population pharmacokinetic model.	Iodine-125	136-140	interleukin 17A	Homo sapiens	49-53
30332475-9	2018	The derived concentration time profiles for anti-IL17 by CRDS were in concordance with the ones derived by AMS and gamma-counting of an 125I-labeled anti-IL17 radiotracer and were well described by a 2-compartment population pharmacokinetic model.	Iodine-125	136-140	interleukin 17A	Homo sapiens	154-158
30321197-0	2018	The small molecule rhodomyrtone suppresses TNF-alpha and IL-17A-induced keratinocyte inflammatory responses: A potential new therapeutic for psoriasis.	rhodomyrtone	19-31	interleukin 17A	Homo sapiens	57-63
30321197-4	2018	This study assessed the potential of rhodomyrtone for curtailing TNF/IL-17A-driven inflammation.	rhodomyrtone	37-49	interleukin 17A	Homo sapiens	69-75
30224514-5	2018	In this study, we have shown that polyinosinic:polycytidylic acid (polyI:C) and influenza A virus (IAV) infection increased IFN-lambda expression at mRNA and protein levels in primary cultures of normal human bronchial epithelial cells, whereas IL-17A attenuated polyI:C- or IAV-induced IFN-lambda expression.	Poly C	47-65	interleukin 17A	Homo sapiens	245-251
30224514-5	2018	In this study, we have shown that polyinosinic:polycytidylic acid (polyI:C) and influenza A virus (IAV) infection increased IFN-lambda expression at mRNA and protein levels in primary cultures of normal human bronchial epithelial cells, whereas IL-17A attenuated polyI:C- or IAV-induced IFN-lambda expression.	Poly I-C	67-74	interleukin 17A	Homo sapiens	245-251
30224514-7	2018	In Western blotting analysis, we demonstrated that polyI:C and IAV infection induced STAT1 phosphorylation in normal human bronchial epithelial cells, whereas IL-17A suppressed polyI:C- or IAV-mediated STAT1 phosphorylation.	Poly I	51-56	interleukin 17A	Homo sapiens	159-165
30224514-9	2018	SOCS1 small interfering RNA and SOCS3 small interfering RNA negated the inhibitory effect of IL-17A in polyI:C-induced IFN-lambda expression by restoring attenuated STAT1 phosphorylation.	Poly I-C	103-110	interleukin 17A	Homo sapiens	93-99
30291224-2	2018	IL-17A regulates airway inflammation, oxidative stress, and reduction of steroid sensitivity in chronic obstructive pulmonary disease (COPD).	Steroids	73-80	interleukin 17A	Homo sapiens	0-6
30321197-5	2018	Stimulating human skin organ cultures with TNF+IL-17A to model the skin inflammation in psoriasis, we found that rhodomyrtone significantly decreased inflammatory gene expression and the expression and secretion of inflammatory proteins, assessed by qRT-PCR, immunohistochemistry and ELISA assays respectively.	rhodomyrtone	113-125	interleukin 17A	Homo sapiens	47-53
30321197-6	2018	RNA-seq analysis of monolayer primary keratinocytes treated with IL-17A/TNF showed that rhodomyrtone inhibited 724/1587 transcripts &gt;2-fold altered by IL-17A/TNF (p&lt;0.01), a number of which were confirmed at the mRNA and protein level.	rhodomyrtone	88-100	interleukin 17A	Homo sapiens	65-71
30321197-6	2018	RNA-seq analysis of monolayer primary keratinocytes treated with IL-17A/TNF showed that rhodomyrtone inhibited 724/1587 transcripts &gt;2-fold altered by IL-17A/TNF (p&lt;0.01), a number of which were confirmed at the mRNA and protein level.	rhodomyrtone	88-100	interleukin 17A	Homo sapiens	154-160
30356853-7	2018	The vitamin D status was assessed according to the level of 25(OH)D. Results: Patients with combined endocrine disorders (DM and AIT) with a decreased vitamin D status had significantly increased background concentrations of Th1-type cytokines and reduced concentrations of Th2-type cytokines (IL-4 and IL-5), IL-10, and IL-17.	Vitamin D	151-160	interleukin 17A	Homo sapiens	321-326
30402507-3	2018	The aim of this study was to investigate the role of curcumin in modulating the expression of IL-17 and IDO in H. pylori-infected human gastric mucosa.	Curcumin	53-61	interleukin 17A	Homo sapiens	94-99
30402507-5	2018	In H. pylori-infected patients (n = 21), IL-17 was significantly lower, both in gastric biopsies (p = 0.0003) and culture supernatant (p = 0.0001) while IDO significantly increased (p &lt; 0.00001) in curcumin-treated sample compared with untreated samples.	Curcumin	201-209	interleukin 17A	Homo sapiens	41-46
30402507-6	2018	In a subgroup of H. pylori-infected patients (n = 15), samples treated with curcumin in addition to IDO inhibitor 1-methyl-L-tryptophan (1-MT) showed a higher expression of IL-17 compared with untreated samples and curcumin-treated alone (p &lt; 0.00001).	Curcumin	76-84	interleukin 17A	Homo sapiens	173-178
30402507-6	2018	In a subgroup of H. pylori-infected patients (n = 15), samples treated with curcumin in addition to IDO inhibitor 1-methyl-L-tryptophan (1-MT) showed a higher expression of IL-17 compared with untreated samples and curcumin-treated alone (p &lt; 0.00001).	1-Methyl-L-tryptophan	114-135	interleukin 17A	Homo sapiens	173-178
30402507-6	2018	In a subgroup of H. pylori-infected patients (n = 15), samples treated with curcumin in addition to IDO inhibitor 1-methyl-L-tryptophan (1-MT) showed a higher expression of IL-17 compared with untreated samples and curcumin-treated alone (p &lt; 0.00001).	Curcumin	215-223	interleukin 17A	Homo sapiens	173-178
30402507-7	2018	Curcumin downregulates IL-17 production through the induction of IDO in H. pylori-infected human gastric mucosa, suggesting its role in dampening H. pylori-induced immune-mediated inflammatory changes.	Curcumin	0-8	interleukin 17A	Homo sapiens	23-28
30291224-12	2018	IL-17A/IKKalpha signaling induced the mechanism of chromatin remodeling associated with acetyl-histone H3(Lys14) and TSLP production in bronchial epithelial cells.	acetyl-histone	88-102	interleukin 17A	Homo sapiens	0-6
29748971-0	2018	Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis.	tofacitinib	67-78	interleukin 17A	Homo sapiens	26-41
29748971-5	2018	AIM: To evaluate correlations between circulating IL-17A and clinical efficacy in patients with psoriasis treated with tofacitinib or etanercept.	tofacitinib	119-130	interleukin 17A	Homo sapiens	50-56
30022504-8	2018	Acetylcholine levels in saliva and GCF correlated positively with clinical markers of disease severity and with increased levels of IL-17A and IL-17F.	Acetylcholine	0-13	interleukin 17A	Homo sapiens	132-138
29928760-11	2018	In IL-17A-stimulated HaCaT cells, MES+HS treatment significantly lowered the mRNA expression of aggravation markers (S100A8, S100A9 and beta-defensin2).	2-(N-morpholino)ethanesulfonic acid	34-37	interleukin 17A	Homo sapiens	3-9
30007092-10	2018	PD98059, an ERK inhibitor, decreased IL-6 generation under low dose of IL-17 but not with high dose.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	0-7	interleukin 17A	Homo sapiens	71-76
29572822-9	2018	Moreover, MTX could significantly restore the immunosuppressive function of IL-17-secreting Tregs.	Methotrexate	10-13	interleukin 17A	Homo sapiens	76-81
30098001-0	2018	The selective ROCK2 inhibitor KD025 reduces IL-17 secretion in human peripheral blood mononuclear cells independent of IL-1 and IL-6.	KD025	30-35	interleukin 17A	Homo sapiens	44-49
30098001-3	2018	We reported here that the selective ROCK2 inhibitor KD025 significantly reduced in vitro production of IL-17 in unfractionated human peripheral blood mononuclear cells (PBMCs) stimulated with the dectin-1 agonist Candida albicans.	KD025	52-57	interleukin 17A	Homo sapiens	103-108
29879374-4	2018	We found that OEA, PEA, and eicosatrienoyl ethanolamide (ETEA) could directly inhibit both T-cell responses by reducing their production of TNF-alpha and IFN-gamma from CD8 T cells and TNF-alpha, IFN-gamma and IL-17 from CD4 T cells.	oleoylethanolamide	14-17	interleukin 17A	Homo sapiens	210-215
29879374-4	2018	We found that OEA, PEA, and eicosatrienoyl ethanolamide (ETEA) could directly inhibit both T-cell responses by reducing their production of TNF-alpha and IFN-gamma from CD8 T cells and TNF-alpha, IFN-gamma and IL-17 from CD4 T cells.	palmidrol	19-22	interleukin 17A	Homo sapiens	210-215
29879374-4	2018	We found that OEA, PEA, and eicosatrienoyl ethanolamide (ETEA) could directly inhibit both T-cell responses by reducing their production of TNF-alpha and IFN-gamma from CD8 T cells and TNF-alpha, IFN-gamma and IL-17 from CD4 T cells.	eicosatrienoyl ethanolamide	28-55	interleukin 17A	Homo sapiens	210-215
29879374-4	2018	We found that OEA, PEA, and eicosatrienoyl ethanolamide (ETEA) could directly inhibit both T-cell responses by reducing their production of TNF-alpha and IFN-gamma from CD8 T cells and TNF-alpha, IFN-gamma and IL-17 from CD4 T cells.	etea	57-61	interleukin 17A	Homo sapiens	210-215
30022504-11	2018	CONCLUSIONS: Elevated acetylcholine levels and reduced butyrylcholinesterase activity are clinically associated with periodontal diseases and elevated levels of IL-17A and IL-17F.	Acetylcholine	22-35	interleukin 17A	Homo sapiens	161-167
33435075-10	2018	Additionally, restimulated splenocytes from animals immunized with Ply-PhaC beads produced a balanced INF-gamma/IL-17A profile unlike animals immunized with soluble Ply.	phac	71-75	interleukin 17A	Homo sapiens	112-118
30127088-0	2018	Testosterone Decreases House Dust Mite-Induced Type 2 and IL-17A-Mediated Airway Inflammation.	Testosterone	0-12	interleukin 17A	Homo sapiens	58-64
30127088-4	2018	Therefore, we hypothesized that testosterone and AR signaling attenuate type 2 and IL-17A-mediated airway inflammation.	Testosterone	32-44	interleukin 17A	Homo sapiens	83-89
30127088-6	2018	Testosterone decreased and ovarian hormones increased HDM-induced eosinophilic and neutrophilic inflammation, IgE production, and airway hyperresponsiveness, as well as decreased the numbers of IL-13+ CD4 Th2 cells and IL-17A+ CD4 Th17 cells in the lung.	Testosterone	0-12	interleukin 17A	Homo sapiens	219-225
30214568-6	2018	Serum levels of IL-23R and IL-17 in serum of UBC patients and normal controls were detected by ELISA, and the correlations with clinical features of UBC were analyzed.	1-(2-amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione	45-48	interleukin 17A	Homo sapiens	27-32
30214568-10	2018	ROC curve was used to detect the diagnostic values of IL-23R and IL-17 protein for UBC.	1-(2-amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione	83-86	interleukin 17A	Homo sapiens	65-70
30214568-11	2018	Levels of IL-23R and IL-17 mRNA in UBC tissue were 3.26 and 2.65 times higher than those in adjacent tissue (P&lt;0.05), and serum levels of IL-23R and IL-17 protein in UBC patients were significantly higher than those in normal control group.	1-(2-amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione	35-38	interleukin 17A	Homo sapiens	21-26
30214568-11	2018	Levels of IL-23R and IL-17 mRNA in UBC tissue were 3.26 and 2.65 times higher than those in adjacent tissue (P&lt;0.05), and serum levels of IL-23R and IL-17 protein in UBC patients were significantly higher than those in normal control group.	1-(2-amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione	169-172	interleukin 17A	Homo sapiens	152-157
30214568-12	2018	Protein expression levels of IL-23R and IL-17 were correlated with clinical stage and lymph node metastasis in UBC patients (P&lt;0.05), and Cox hazard model showed that L-23R and IL-17 expression may be independent factors for UBC (P&lt;0.05), and high expression levels of IL-23R and IL-17 significantly shortened the OS and DFS (P&lt;0.05).	1-(2-amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione	111-114	interleukin 17A	Homo sapiens	40-45
30208917-8	2018	However, whereas phorbol 12-myristate 13-acetate/ionomycin stimulation induced the production of both interferon-gamma and IL-17 by breast duct MAIT cells, bacterially exposed breast carcinoma cells elicited a strongly IL-17-biased response.	Tetradecanoylphorbol Acetate	17-48	interleukin 17A	Homo sapiens	123-128
30208917-8	2018	However, whereas phorbol 12-myristate 13-acetate/ionomycin stimulation induced the production of both interferon-gamma and IL-17 by breast duct MAIT cells, bacterially exposed breast carcinoma cells elicited a strongly IL-17-biased response.	Ionomycin	49-58	interleukin 17A	Homo sapiens	123-128
30208917-8	2018	However, whereas phorbol 12-myristate 13-acetate/ionomycin stimulation induced the production of both interferon-gamma and IL-17 by breast duct MAIT cells, bacterially exposed breast carcinoma cells elicited a strongly IL-17-biased response.	Ionomycin	49-58	interleukin 17A	Homo sapiens	219-224
30214568-13	2018	Serum levels of IL-23R and IL-17 can be used to effectively diagnose clinical stage and lymph node metastasis of UBC patients, and the combined diagnosis has a higher sensitivity and specificity than the diagnosis using a single factor.	1-(2-amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione	113-116	interleukin 17A	Homo sapiens	27-32
30214568-15	2018	Detection of IL-23R and IL-17 levels has certain clinical significance in the diagnosis and prognosis of UBC.	1-(2-amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione	105-108	interleukin 17A	Homo sapiens	24-29
29981919-4	2018	Further, strophanthidin, digoxigenin and dihydroouabain upregulated IL17A and IL17F expression and enhanced IL17 secretion in Th17 human lymphocytes.	Strophanthidin	9-23	interleukin 17A	Homo sapiens	68-73
29981919-4	2018	Further, strophanthidin, digoxigenin and dihydroouabain upregulated IL17A and IL17F expression and enhanced IL17 secretion in Th17 human lymphocytes.	Strophanthidin	9-23	interleukin 17A	Homo sapiens	68-72
29981919-4	2018	Further, strophanthidin, digoxigenin and dihydroouabain upregulated IL17A and IL17F expression and enhanced IL17 secretion in Th17 human lymphocytes.	Digoxigenin	25-36	interleukin 17A	Homo sapiens	68-73
29981919-4	2018	Further, strophanthidin, digoxigenin and dihydroouabain upregulated IL17A and IL17F expression and enhanced IL17 secretion in Th17 human lymphocytes.	Digoxigenin	25-36	interleukin 17A	Homo sapiens	68-72
29981919-4	2018	Further, strophanthidin, digoxigenin and dihydroouabain upregulated IL17A and IL17F expression and enhanced IL17 secretion in Th17 human lymphocytes.	dihydroouabain	41-55	interleukin 17A	Homo sapiens	68-73
29981919-4	2018	Further, strophanthidin, digoxigenin and dihydroouabain upregulated IL17A and IL17F expression and enhanced IL17 secretion in Th17 human lymphocytes.	dihydroouabain	41-55	interleukin 17A	Homo sapiens	68-72
34025836-13	2021	In UC, higher vitamin D concentrations were associated with lower IL-17 concentrations.	Vitamin D	14-23	interleukin 17A	Homo sapiens	66-71
30171593-11	2018	Prostaglandin E2 induces IL-17A independent of IL-23 via IL-1beta and IL-6.	Dinoprostone	0-16	interleukin 17A	Homo sapiens	25-31
30537798-6	2018	We also showed that IFN-gamma+IL17+ co-producing CD8+ T cells were reduced in patients under fingolimod therapy.	Fingolimod Hydrochloride	93-103	interleukin 17A	Homo sapiens	30-34
29990694-8	2018	The rate of overall AEs was significantly higher (P &lt; 0.00001) in biologics targeting the IL-17 (RR 1.18, 95% CI 1.12-1.24, P &lt; 0.00001) compared to biologics targeting IL-23 (RR 0.97, 95% CI 0.91-1.04, P = 0.44), and with respect to one or more SAEs, no difference was seen between biologics targeting IL-17 and IL-23.	saes	252-256	interleukin 17A	Homo sapiens	93-98
29895377-8	2018	In contrast to cyclosporine A and dexamethasone, only zinc aspartate and rapamycin were capable of suppressing the proliferation and Th1 (IFN-gamma), Th2 (IL-5), and Th17 (IL-17) cytokine production of pre-activated T cells.	zinc-bis(hydrogenaspartate)	54-68	interleukin 17A	Homo sapiens	172-177
29895377-8	2018	In contrast to cyclosporine A and dexamethasone, only zinc aspartate and rapamycin were capable of suppressing the proliferation and Th1 (IFN-gamma), Th2 (IL-5), and Th17 (IL-17) cytokine production of pre-activated T cells.	Sirolimus	73-82	interleukin 17A	Homo sapiens	172-177
30049713-5	2018	Targeting surface-expressed PHBs on Th17 cells with ligands such as Vi polysaccharide (Typhim vaccine) inhibited CRAF-MAPK pathway, reduced interleukin (IL)-17 expression and ameliorated disease pathology with an increase in FOXP3+-expressing Tregs in an animal model for multiple sclerosis (MS).	Polysaccharides	71-85	interleukin 17A	Homo sapiens	140-159
30246694-0	2018	Vitamin D3 Induced Decrease in IL-17 and Malondialdehyde, and Increase in IL-10 and Total Antioxidant Capacity Levels in Patients with Irritable Bowel Syndrome.	Cholecalciferol	0-10	interleukin 17A	Homo sapiens	31-36
30246694-5	2018	RESULTS: Vitamin D supplementation significantly reduced the IL-17 and MDA serum levels (P&lt;0.05) and observably increased the TAC and IL-10 serum levels (P&lt;0.05), compared with the placebo group.	Vitamin D	9-18	interleukin 17A	Homo sapiens	61-66
30246694-6	2018	Comparing different bowel habit subtypes, we observed that it was only in diarrhea predominant IBS (IBS-D) that vitamin D supplementation was able to significantly reduce the serum levels of TNF-alpha and IL-17 (P&lt;0.05).	Vitamin D	112-121	interleukin 17A	Homo sapiens	205-210
30246694-8	2018	CONCLUSION: Vitamin D3 supplementation reduces the serum IL-17 and MDA levels, and augments the serum IL-10 and TAC levels in IBS patients, particularly in IBS-D subtype.	Cholecalciferol	12-22	interleukin 17A	Homo sapiens	57-62
30278529-13	2018	Serum levels of IL-8, TNF-alpha, IL-17A, LTB4 and CRP decreased significantly after YFN treatment compared to the placebo group (P &lt; 0.05).	yfn	84-87	interleukin 17A	Homo sapiens	33-39
30127914-7	2018	The results of the present study suggested that patients with AR have raised mitochondrial ROS levels, which may upregulate the expression of IL-1beta, affecting IL-17-production and serving a role in the pathogenesis of AR.	Reactive Oxygen Species	91-94	interleukin 17A	Homo sapiens	162-167
30174672-11	2018	We demonstrated that silibinin upregulated ERbeta expression, induced apoptosis, inhibited proliferation, and reduced expression of the pro-inflammatory cytokines IL-17 and TNF-alpha, through ERbeta binding, in T lymphocytes from female and male healthy donors.	Silybin	21-30	interleukin 17A	Homo sapiens	163-168
30537794-0	2018	Immunotherapeutic Effects of beta-D Mannuronic Acid on IL-4, GATA3, IL-17 and RORC Gene Expression in the PBMC of Patients with Inflammatory Bowel Diseases.	mannuronic acid	29-51	interleukin 17A	Homo sapiens	68-73
29979995-7	2018	IL-17 was negatively correlated with testosterone (r = -0.368, p = 0.018) and positively correlated with duration of disease (r = 0.382, p = 0.014) in bipolar disorder patients.	Testosterone	37-49	interleukin 17A	Homo sapiens	0-5
29400705-6	2018	Consistent with this, TAOK1 deficiency exacerbates colitis in the 2,4,6-trinitrobenzenesulfonic acid)-induced experimental model of inflammatory bowel disease, likely by its promotion of the IL-17-mediated signaling pathway.	Trinitrobenzenesulfonic Acid	66-100	interleukin 17A	Homo sapiens	191-196
29957387-0	2018	Decitabine induces regulatory T cells, inhibits the production of IFN-gamma and IL-17 and exerts preventive and therapeutic efficacy in rodent experimental autoimmune neuritis.	Decitabine	0-10	interleukin 17A	Homo sapiens	80-85
29846789-10	2018	However, IL-6, IL-12, IL-17 and IL-18 were significantly increased in pSS patients compared to controls.	pss	70-73	interleukin 17A	Homo sapiens	22-27
29512851-11	2018	Furthermore, the frequency of TIGIT+CD4+ T cells was significantly increased in patients with PV after 2 months of treatment with acitretin, with associated significant changes in IFN-gamma, IL-10and IL-17A plasma levels.	Acitretin	130-139	interleukin 17A	Homo sapiens	200-206
29852475-5	2018	Post-treatment evaluation of the nanocurcumin group revealed a significant decrease in Th17 associated parameters such as Th17 frequency (p = 0.029), expression levels of RORgammat (p &lt; 0.0001) and IL-17 (p = 0.0044) and also secretion level of IL-17 (p = 0.0011), but IL-23 mRNA expression levels and IL-23 concentration were not influenced by nanocurcumin.	nanocurcumin	33-45	interleukin 17A	Homo sapiens	201-206
29852475-5	2018	Post-treatment evaluation of the nanocurcumin group revealed a significant decrease in Th17 associated parameters such as Th17 frequency (p = 0.029), expression levels of RORgammat (p &lt; 0.0001) and IL-17 (p = 0.0044) and also secretion level of IL-17 (p = 0.0011), but IL-23 mRNA expression levels and IL-23 concentration were not influenced by nanocurcumin.	nanocurcumin	33-45	interleukin 17A	Homo sapiens	248-253
29808357-0	2018	IL-17A suppresses and curcumin up-regulates Akt expression upon bleomycin exposure.	Bleomycin	64-73	interleukin 17A	Homo sapiens	0-6
29808357-1	2018	Pro-inflammatory cytokine IL-17A modulates the expression of Akt in bleomycin (BLM) administered alveolar basal epithelial cells, the mechanism behind which remains unclear.	Bleomycin	68-77	interleukin 17A	Homo sapiens	26-32
29808357-1	2018	Pro-inflammatory cytokine IL-17A modulates the expression of Akt in bleomycin (BLM) administered alveolar basal epithelial cells, the mechanism behind which remains unclear.	Bleomycin	79-82	interleukin 17A	Homo sapiens	26-32
29808357-7	2018	Administrations of BLM and IL-17A to the alveolar basal epithelial cells showed significant down-regulation of Akt expression which was reversed by treatment with curcumin.	Curcumin	163-171	interleukin 17A	Homo sapiens	27-33
29808357-8	2018	BLM and IL-17A mediated inflammation was intervened effectively with curcumin.	Curcumin	69-77	interleukin 17A	Homo sapiens	8-14
30078983-9	2018	Results: The CE-CKC emulsions decreased inflammatory gene expression in LPS-stimulated PBMCs (IFN-gamma, IL-17A, CXCL-9, and TNFalpha) and LPS-stimulated HCE-2 cells (THBS1 and CCL2).	CKC	16-19	interleukin 17A	Homo sapiens	105-111
29800585-11	2018	The IL-17, MMP-9 and Caspase-3 were significantly (&lt;=0.05) higher in the cardiac muscle after chronic fluoride exposure.	Fluorides	105-113	interleukin 17A	Homo sapiens	4-9
30078983-10	2018	Both CE-CKC emulsions inhibited the secretion of IL-17 (from anti-CD3/anti-CD28-stimulated TCD4), TNFalpha, IFN-gamma, and IL-2 (from anti-CD3-/anti-CD28-stimulated PBMCs), and IL-6 and IL-8 (from LPS-stimulated HCE-2).	ce-ckc	5-11	interleukin 17A	Homo sapiens	49-54
29713730-6	2018	However, the molecular mechanism of IL-23, a key cytokine, and PGE2 in the development and perpetuation of IL-17 producing effector Th17 cells is poorly understood.	Dinoprostone	63-67	interleukin 17A	Homo sapiens	107-112
29715455-9	2018	The results showed nicotine reduced IL-17A and increased IL-4 produced by stimulated PBMCs.	Nicotine	19-27	interleukin 17A	Homo sapiens	36-42
29715455-10	2018	During Th17 differentiation conditions, nicotine reduced the levels of IL-17A and RORc, induced the phosphorylation of ERK1/2.	Nicotine	40-48	interleukin 17A	Homo sapiens	71-77
29150843-5	2018	RESULTS: Topical treatment with imiquimod induced a form of psoriasiform dermatitis reminiscent of the human disorder, characterized by thickened and scaly skin, psoriasiform epidermal hyperplasia, altered keratinocyte differentiation and cutaneous overexpression of interleukin-17A.	Imiquimod	32-41	interleukin 17A	Homo sapiens	267-282
29377102-2	2018	Recently, CT was reported to induce T helper type 17-skewing dendritic cells and activate interleukin-17A (IL-17A) production in CD4+ T cells through a cAMP-dependent pathway.	Cyclic AMP	152-156	interleukin 17A	Homo sapiens	107-113
29377102-3	2018	However, the underlying mechanism by which cAMP regulates IL-17A production in T cells is not completely defined.	Cyclic AMP	43-47	interleukin 17A	Homo sapiens	58-64
29377102-5	2018	We found that CT induced IL-17A production and IL-17A promoter activity in activated CD4+ T cells through a cAMP/PKA pathway.	Cyclic AMP	108-112	interleukin 17A	Homo sapiens	25-31
29980703-5	2018	We also characterised their effects in ex-vivo psoriasis PBMC and report that curcumin, but not carnosol, strongly reduces T cell proliferation and cytokine poly-functionality, with reduced expression of psoriatic cytokines IFNgamma, IL-17, GM-CSF and IL-22.	Curcumin	78-86	interleukin 17A	Homo sapiens	234-239
29377102-2	2018	Recently, CT was reported to induce T helper type 17-skewing dendritic cells and activate interleukin-17A (IL-17A) production in CD4+ T cells through a cAMP-dependent pathway.	Cyclic AMP	152-156	interleukin 17A	Homo sapiens	90-105
29377102-8	2018	Most interestingly, not only in CD4+ T cells, CT also enhanced cAMP/PKA-dependent IL-17A production and CREB phosphorylation in CD8+ T cells.	Cyclic AMP	63-67	interleukin 17A	Homo sapiens	82-88
29558805-5	2018	A higher activity of ganglioside Hp-s1 analogue on IL-17A transcript upregulation than ganglioside Hp-s1 was found.	Gangliosides	21-32	interleukin 17A	Homo sapiens	51-57
29377102-9	2018	In conclusion, our data suggest that CT induces an IL-17A-dominated immune microenvironment through the cAMP/PKA/CREB signalling pathway.	Cyclic AMP	104-108	interleukin 17A	Homo sapiens	51-57
31949707-5	2018	The aim of this research was to investigate whether the function of IL-17 influenced hepatocyte-induced H2O2.	Water	104-108	interleukin 17A	Homo sapiens	68-73
31949707-6	2018	We found that the expression of IL-17 was enhanced in hepatocyte-induced H2O2 and that IL-17 was down-regulated by siRNA.	Water	73-77	interleukin 17A	Homo sapiens	32-37
29749556-6	2018	Andrographolide decreased interferon gamma, interleukin (IL)-23 and IL-17A, however it increased IL-4 in a dose-dependent manner, as indicated by ELISA assay.	andrographolide	0-15	interleukin 17A	Homo sapiens	68-74
29933753-11	2018	At 6 h, CD8+ lymphocytes in NAIS produced more IL-17.	nais	28-32	interleukin 17A	Homo sapiens	47-52
29933753-15	2018	At 72 h, we found elevated plasma levels of IL-5, MCP-1, and IL-17 in NAIS.	nais	70-74	interleukin 17A	Homo sapiens	61-66
29933753-16	2018	By 1 month, plasma levels of IL-4, IL-12, and IL-17 decreased in NAIS but remained elevated in HIE.	nais	65-69	interleukin 17A	Homo sapiens	46-51
29558805-5	2018	A higher activity of ganglioside Hp-s1 analogue on IL-17A transcript upregulation than ganglioside Hp-s1 was found.	s1	36-38	interleukin 17A	Homo sapiens	51-57
29678878-5	2018	Here, we present the development of MT-6194, a bispecific antibody targeting both IL-6R and IL-17A that was developed with the FynomAb technology.	mt-6194	36-43	interleukin 17A	Homo sapiens	92-98
29545450-10	2018	RESULTS: In patients, HCQ plus prednisone treatment inhibited IL-17 production, gene expression, and Th17 cell differentiation.	Hydroxychloroquine	22-25	interleukin 17A	Homo sapiens	62-67
30042815-7	2018	Evidence for a correlation between circulating NOx and IL17 is already present in the literature, mostly from studies conducted under inflammatory conditions.	Nitric Oxide	47-50	interleukin 17A	Homo sapiens	55-59
30042815-8	2018	Our hypothesis is that such negative correlation can be attributed to an endogenous homeostatic system that IL17 production by the constitutively produced NOx from the vascular endothelium.	Nitric Oxide	155-158	interleukin 17A	Homo sapiens	108-112
29292524-8	2018	When stimulated with PMA/ionomycin, CD4+ T cells from women with EP presented significantly higher interferon (IFN)-gamma and interleukin (IL)-17 secretion, and lower transforming growth factor (TGF)-beta secretion.	Tetradecanoylphorbol Acetate	21-24	interleukin 17A	Homo sapiens	126-145
29292524-8	2018	When stimulated with PMA/ionomycin, CD4+ T cells from women with EP presented significantly higher interferon (IFN)-gamma and interleukin (IL)-17 secretion, and lower transforming growth factor (TGF)-beta secretion.	Ionomycin	25-34	interleukin 17A	Homo sapiens	126-145
30600949-7	2018	Circulating Th17 cells and serum IL17 levels were significantly decreased after successful Sofosbuvir-Ribavirin therapy (P &lt; 0.0001).	Sofosbuvir	91-101	interleukin 17A	Homo sapiens	33-37
30600949-7	2018	Circulating Th17 cells and serum IL17 levels were significantly decreased after successful Sofosbuvir-Ribavirin therapy (P &lt; 0.0001).	Ribavirin	102-111	interleukin 17A	Homo sapiens	33-37
29942355-10	2018	In this case, the expression of IL-17 mRNA in the colon mucosa greatly decreased after prednisolone treatment for EGE.	Prednisolone	87-99	interleukin 17A	Homo sapiens	32-37
29364523-1	2018	ABT-122 is an IgG1 dual-variable domain immunoglobulin that specifically blocks TNF-alpha and IL-17A.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	0-3	interleukin 17A	Homo sapiens	94-100
29545450-10	2018	RESULTS: In patients, HCQ plus prednisone treatment inhibited IL-17 production, gene expression, and Th17 cell differentiation.	Prednisone	31-41	interleukin 17A	Homo sapiens	62-67
29545450-15	2018	CONCLUSION: HCQ inhibited Th17 cell differentiation and IL-17 production both in vitro and in patients with SLE.	Hydroxychloroquine	12-15	interleukin 17A	Homo sapiens	56-61
29499168-1	2018	IL-17A is implicated in many aspects of pathogenesis of severe asthma, including inducing neutrophilic inflammation, airway hyperresponsiveness, steroid insensitivity and airway remodeling.	Steroids	145-152	interleukin 17A	Homo sapiens	0-6
29862305-0	2018	Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A3 Adenosine Receptor Agonist Piclidenoson.	N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine	90-102	interleukin 17A	Homo sapiens	14-19
29432814-0	2018	PI3K/AKT/mTOR activation and autophagy inhibition plays a key role in increased cholesterol during IL-17A mediated inflammatory response in psoriasis.	Cholesterol	80-91	interleukin 17A	Homo sapiens	99-105
29768427-3	2018	In the context of experimental RA, Cd addition has an anti-proliferative and anti-inflammatory effect when associated to IL-17/TNF-alpha stimulation, due to its accumulation in synoviocytes.	Cadmium	35-37	interleukin 17A	Homo sapiens	121-126
29768427-4	2018	The aim of this work was to evaluate if IL-1beta interaction with IL-17 also contributes to metal-import mechanisms and its effects on cell viability and inflammation.	Metals	92-97	interleukin 17A	Homo sapiens	66-71
29768427-8	2018	Metal import was lower with IL17/ IL-1beta in comparison to IL-17/TNF-alpha exposed-synoviocytes, as the expression of ZIP-8 and MT-1F was less induced.	Metals	0-5	interleukin 17A	Homo sapiens	28-32
29768427-10	2018	The IL-17/IL-1beta combination with Cd slightly reduced cell viability in comparison to the IL-17/TNF-alpha combination and resulted in a strong induction of IL-6 production.	Cadmium	36-38	interleukin 17A	Homo sapiens	4-9
29768427-11	2018	CONCLUSION: IL-17/TNF-alpha combination but not IL-17/IL-1beta combination mainly drives the accumulation of Cd in synoviocytes and its effects on cell viability and inflammation.	Cadmium	109-111	interleukin 17A	Homo sapiens	12-17
29740080-7	2018	IL-17 signaling restored early vascularized connective tissue formation and osteoclastogenesis induced by BMP-2 in ZOL-coated scaffolds.	Zoledronic Acid	115-118	interleukin 17A	Homo sapiens	0-5
29432814-8	2018	Herein, we also observed that inhibition of autophagy by IL-17A was accompanied by enhanced cellular cholesterol levels which in turn regulated the autophagic flux.	Cholesterol	101-112	interleukin 17A	Homo sapiens	57-63
29499168-6	2018	Pretreatment of ROS scavenger (NAC) significantly inhibited DEP-induced IL-17A mRNA expression.	ros	16-19	interleukin 17A	Homo sapiens	72-78
29499168-10	2018	These results indicate DEP stimulates IL-17A expression in airway epithelium through ROS/NF-kappaB pathway, and provide a possible link between traffic pollution exposure and IL-17A-related responses in severe allergic asthma patients.	ros	85-88	interleukin 17A	Homo sapiens	38-44
29740348-4	2018	Indeed, experimental data report the influence of sodium chloride on the differentiation of naive CD4+ T cells into IL-17 secreting T helper (Th) cells (Th17 cells), by a mechanism involving the serum glucocorticoid kinase-1 (SGK1) that promotes the expression of the IL-23 receptor (IL-23R).	Sodium Chloride	50-65	interleukin 17A	Homo sapiens	116-121
29463070-3	2018	However, the interaction between CS and IL-17A and the underlying molecular mechanisms have not been clarified.	Cesium	33-35	interleukin 17A	Homo sapiens	40-46
29483123-6	2018	In addition, preincubation with micafungin before exposure to human tissue macrophages enhanced the secretion of tumor necrosis factor alpha (TNF-alpha), interleukin-17A (IL-17A), and IL-10 cytokines.	Micafungin	32-42	interleukin 17A	Homo sapiens	154-169
29483123-6	2018	In addition, preincubation with micafungin before exposure to human tissue macrophages enhanced the secretion of tumor necrosis factor alpha (TNF-alpha), interleukin-17A (IL-17A), and IL-10 cytokines.	Micafungin	32-42	interleukin 17A	Homo sapiens	171-177
29374507-6	2018	Human astrocytes treated with IL17/TNF increases the nuclear translocation of NFkappaB, which is attenuated by pre-treatment with 7alpha25HC; 2.	7alpha25hc	130-140	interleukin 17A	Homo sapiens	30-34
29374507-7	2018	IL17/TNF increases cell impedance in human astrocytes, which is also attenuated by pre-treatment with 7alpha25HC; 3.	7alpha25hc	102-112	interleukin 17A	Homo sapiens	0-4
29679037-7	2018	Through in vitro experiments, we found that isoflavone extract can reduce IL-22, IL-17A, and TNF-alpha-induced MAPK, NF-kappaB, and JAK-STAT activation in normal human epidermal keratinocytes.	Isoflavones	44-54	interleukin 17A	Homo sapiens	81-87
29703987-5	2018	Our study showed inhibition of the staphylococcal enterotoxins A and B (SEA and SEB) response by Th22 (CD4+IL-22+IL-17A-IFN-gamma-) cells in AD patients.	th22	97-101	interleukin 17A	Homo sapiens	113-119
29679037-8	2018	At the mRNA level, we determined that isoflavone extract attenuated the increased response of the TNF-alpha-, IL-17A-, and IL-22- related pathways.	Isoflavones	38-48	interleukin 17A	Homo sapiens	110-116
30701852-8	2018	The highest content of the Il-17 was registered at patients with bronchial asthma and obesity as in comparison with indicators of patients with normal BMI, and with almost healthy that, perhaps, is the reason of low effect of steroid therapy at these patients.	Steroids	226-233	interleukin 17A	Homo sapiens	27-32
29703987-6	2018	In contrast, Tc22 (CD8+IL-22+IL-17A-IFN-gamma-) cells were less susceptible to the inhibitory effects of staphylococcal enterotoxins and exhibited an enhanced response to the bacterial stimuli.	tc22	13-17	interleukin 17A	Homo sapiens	29-35
29653697-4	2018	Here we have shown that IL-25, also highly expressed in the lesional skin of psoriasis patients, was regulated by IL-17 in murine skin of a imiquimod (IMQ)-induced psoriasis model.	Imiquimod	151-154	interleukin 17A	Homo sapiens	114-119
29337379-8	2018	However IL-17A had no direct effect on HMVEC-L function but it enhanced endothelial tube formation and cell migration through the production of angiogenic factors by NHBE and ASMC.	asmc	175-179	interleukin 17A	Homo sapiens	8-14
29113816-9	2018	HDAC2 regulated IL-17A production partially through modulation of CD4+ T cells during T helper 17 cell differentiation and retinoid-related orphan nuclear receptor gammat in airway epithelial cells.	Retinoids	123-131	interleukin 17A	Homo sapiens	16-22
29531163-4	2018	Our investigations revealed that anti-CD3/CD28-stimulated CD4+ T cells cultured in biotin-deficient medium secreted significantly enhanced levels of the proinflammatory cytokines IFN-gamma, TNF, and IL-17.	Biotin	83-89	interleukin 17A	Homo sapiens	199-204
29113816-2	2018	The goal of this study was to determine whether histone deacetylase (HDAC) 2 protects against cigarette smoke (CS)-induced airway remodeling through IL-17A-dependent mechanisms.	Cesium	111-113	interleukin 17A	Homo sapiens	149-155
29380034-6	2018	In the absence of an airway insult, we expected to find no evidence of airway inflammation; however, transcripts for several asthma-associated cytokines, including IL17A, IL1A, and IL8, were elevated in the tracheas of bethanechol-treated piglets.	Bethanechol	219-230	interleukin 17A	Homo sapiens	164-169
28735449-7	2018	The administration of omeprazole to the patients significantly increased Treg and IL-10 levels and reduced Th17 and IL-17 levels.	Omeprazole	22-32	interleukin 17A	Homo sapiens	116-121
28735449-8	2018	Omeprazole markedly increased the number of Foxp3-positive cells, decreased the number of RORgammat-positive cells and restored the balanced ratio of IL-10/IL-17 in the ulcer tissue.	Omeprazole	0-10	interleukin 17A	Homo sapiens	156-161
29431293-7	2018	Elevated IL-17A expression was observed in the high NOx exposure groups, within IL-17[G197G] (p = .0004).	nicotine 1-N-oxide	52-55	interleukin 17A	Homo sapiens	9-15
29431293-7	2018	Elevated IL-17A expression was observed in the high NOx exposure groups, within IL-17[G197G] (p = .0004).	nicotine 1-N-oxide	52-55	interleukin 17A	Homo sapiens	9-14
29540697-7	2018	Notably, the inhibition of bFGF-FGFR3-RSK2 signaling by kaempferol suppresses the proliferation and migration of RA FLSs and the release of activated T-cell-mediated inflammatory cytokines, such as IL-17, IL-21, and TNF-alpha.	kaempferol	56-66	interleukin 17A	Homo sapiens	198-203
29446486-0	2018	Interleukin-17A participates in podocyte injury by inducing IL-1beta secretion through ROS-NLRP3 inflammasome-caspase-1 pathway.	ros	87-90	interleukin 17A	Homo sapiens	0-15
29476557-4	2018	Eight databases were searched for original studies reporting the expression of IL-17 in patients with pSS and controls.	pss	102-105	interleukin 17A	Homo sapiens	79-84
29476557-8	2018	The expression of IL-17 is significantly increased in patients with pSS compared to controls.	pss	68-71	interleukin 17A	Homo sapiens	18-23
29476557-9	2018	Furthermore, patients with pSS without immunosuppressive treatment show markedly higher IL-17 levels.	pss	27-30	interleukin 17A	Homo sapiens	88-93
29476557-10	2018	In addition, patients with pSS with positive rheumatoid factors tend to express a higher level of IL-17 than patients with negative rheumatoid factors.	pss	27-30	interleukin 17A	Homo sapiens	98-103
29476557-11	2018	Negative correlations between IL-17 levels and ocular parameters are also found in patients with pSS.	pss	97-100	interleukin 17A	Homo sapiens	30-35
29476557-15	2018	These findings demonstrate the significance of IL-17 overexpression in patients with pSS and may provide insights for the development of therapeutic interventions targeting IL-17 for pSS.	pss	85-88	interleukin 17A	Homo sapiens	47-52
29253109-9	2018	AZA treatment markedly decreased the expressions of tumour necrosis factor-alpha, interleukin-12 (IL-12)/23p40 and IL-17 in colonic biopsy samples, as assessed by quantitative reverse transcription polymerase chain reaction.	Azacitidine	0-3	interleukin 17A	Homo sapiens	115-120
29476739-5	2018	Furthermore, suppression of autophagy with chloroquine (CQ) or 3-MA could significantly attenuate the enhanced osteoclastogenesis by a low level of IL-17A.	Chloroquine	43-54	interleukin 17A	Homo sapiens	148-154
29476739-5	2018	Furthermore, suppression of autophagy with chloroquine (CQ) or 3-MA could significantly attenuate the enhanced osteoclastogenesis by a low level of IL-17A.	Chloroquine	56-58	interleukin 17A	Homo sapiens	148-154
29476739-5	2018	Furthermore, suppression of autophagy with chloroquine (CQ) or 3-MA could significantly attenuate the enhanced osteoclastogenesis by a low level of IL-17A.	3-methyladenine	63-67	interleukin 17A	Homo sapiens	148-154
29686529-5	2018	DAPT treatment resulted in the obvious downregulation of Th17 cell percentage in cocultured CD4+ T cells, RORgammat and IL-17 mRNA levels, and IL-17 concentration in cell-free supernatant from cocultured CD4+ T cells of PV patients in a dose-dependent manner, while there was no significant influence on Treg cell percentage, Foxp3, and IL-10 expression, therefore leading to the recovery of Th17/Treg immune imbalance.	dapt	0-4	interleukin 17A	Homo sapiens	120-125
29693024-4	2018	The emergence of IL-17, a cytokine largely produced by Th17 cells, as a powerful proinflammatory stimulus which attenuates the induction of Tregs has prompted a series of studies investigating the role of flavonoids on Th17 cells in experimental models as well as human autoimmune diseases.	Flavonoids	205-215	interleukin 17A	Homo sapiens	17-22
29686529-5	2018	DAPT treatment resulted in the obvious downregulation of Th17 cell percentage in cocultured CD4+ T cells, RORgammat and IL-17 mRNA levels, and IL-17 concentration in cell-free supernatant from cocultured CD4+ T cells of PV patients in a dose-dependent manner, while there was no significant influence on Treg cell percentage, Foxp3, and IL-10 expression, therefore leading to the recovery of Th17/Treg immune imbalance.	dapt	0-4	interleukin 17A	Homo sapiens	143-148
29392570-6	2018	METHODS: We evaluated side-by-side in the same healthy donors two recently approved IL-17A selective antibodies, secukinumab and ixekizumab, along with adalimumab and ustekinumab, for their capacity to induce anti-drug related T cell responses in vitro and estimated their potential for developing ADAs in patients.	dSMP	298-302	interleukin 17A	Homo sapiens	84-90
29504099-1	2018	We studied the role of endogenous melatonin in the development and functioning of T cells that produce IL-17 (Th17) and regulatory T cells (Treg) during pregnancy.	Melatonin	34-43	interleukin 17A	Homo sapiens	103-108
29467858-7	2018	The frequencies of Th17, Tc17 and Treg cells, as well as the serum levels of IL-17, IL-23, IL-10 and TGF-beta1 were significantly elevated in patients with DTC compared with healthy Controls, whereas 131I therapy significantly decreased them.	dtc	156-159	interleukin 17A	Homo sapiens	77-82
29324259-9	2018	RESULTS: Higher serum vitamin D levels positively correlated with higher ratios of IL-4 + IL-10/IL-17A + TNF-alpha (r = 0.37, P &lt; .01), and IL-4 + IL-10/IL-6 + TNF-alpha (r = 0.32, P &lt; .01).	Vitamin D	22-31	interleukin 17A	Homo sapiens	96-102
29479352-5	2018	We investigated the effect of prednisolone treatment on the inflammatory cytokines TNF, IFN-gamma, IL-1beta, IL-6, and IL-17 and the regulatory cytokines IL-10 and TGF-beta in the skin lesion and blood of patients with ENL and compared with non-reactional LL patient controls.	Prednisolone	30-42	interleukin 17A	Homo sapiens	119-124
29066221-1	2018	1,25-dihydroxyvitaminD3 (1,25(OH)2D3), has potent anti-inflammatory effects, including suppression of IL-17 + and IFNgamma+ T cells implicated in rheumatoid arthritis (RA), but efficacy at the site of active disease is unclear.	1,25-dihydroxyvitamind3 (1,25(oh)2d3	0-36	interleukin 17A	Homo sapiens	102-107
29066221-6	2018	Further studies using stimulated CD4+ T cells sorted according to IL-17 and IFNgamma expression confirmed the ability of 1,25(OH)2D3 to suppress pre-existing cytokines.	Calcitriol	121-132	interleukin 17A	Homo sapiens	66-71
29066221-7	2018	However, 1,25(OH)2D3 was most effective at suppressing de novo IL-17 and IFNgamma induction.	Calcitriol	9-20	interleukin 17A	Homo sapiens	63-68
29286161-7	2018	At a concentration of 2.22 microM, astilbin decreased the mRNA expression levels of IL-6, IL-17A and IL-22 in lipopolysaccharide (LPS)-induced HaCaT cells by 89, 69.1 and 69.3%, respectively.	astilbin	35-43	interleukin 17A	Homo sapiens	90-96
29353760-8	2018	CLL patients requiring fludarabine based chemotherapy expressed higher levels of IL-6 and IL-17, while CLL patients with the lowest levels of IgA/IgM had higher levels of IL-6, but not IL-17.	fludarabine	23-34	interleukin 17A	Homo sapiens	90-95
29511440-0	2018	Andrographolide presents therapeutic effect on ulcerative colitis through the inhibition of IL-23/IL-17 axis.	andrographolide	0-15	interleukin 17A	Homo sapiens	98-103
29511440-8	2018	Enzyme-linked immunosorbent assay (ELISA), flow cytometry and western blotting analyses showed that andrographolide could decreased the levels of proinflammatory factors TNF-alpha, IL-1beta, IL-6 and IL-17A in the serum and in the colon tissues, reduced the percentages of Th17 cells in CD4+ cells, and suppressed the levels of IL-23, IL-17A, ROR-gammat (key transcription factor of Th17 cells) and p-STAT3 in the colon tissues.	andrographolide	100-115	interleukin 17A	Homo sapiens	200-206
29511440-8	2018	Enzyme-linked immunosorbent assay (ELISA), flow cytometry and western blotting analyses showed that andrographolide could decreased the levels of proinflammatory factors TNF-alpha, IL-1beta, IL-6 and IL-17A in the serum and in the colon tissues, reduced the percentages of Th17 cells in CD4+ cells, and suppressed the levels of IL-23, IL-17A, ROR-gammat (key transcription factor of Th17 cells) and p-STAT3 in the colon tissues.	andrographolide	100-115	interleukin 17A	Homo sapiens	335-341
29511440-13	2018	In conclusion, we demonstrated that andrographolide inhibited the activity of IL-23/IL-17 axis and down-stream pro-inflammatory factors so as to suppress inflammation response, resulting in the relieving of UC.	andrographolide	36-51	interleukin 17A	Homo sapiens	84-89
28730424-7	2018	After retinol stimulation, the concentration of IL-17 and IFN-gamma increased significantly in both groups.	Vitamin A	6-13	interleukin 17A	Homo sapiens	48-53
29198077-8	2018	In contrast, applying an inhibitor of mTOR pathway, temsirolimus, or silencing eIF4E neutralized the stimulation of IL-17 on LAT1.	temsirolimus	52-64	interleukin 17A	Homo sapiens	116-121
29160080-0	2018	Adjuvant Activity of Poly-epsilon-caprolactone/Chitosan Nanoparticles Characterized by Mast Cell Activation and IFN-gamma and IL-17 Production.	polycaprolactone	21-46	interleukin 17A	Homo sapiens	126-131
28902433-14	2018	Curcumin also regulated the BLM and IL-17A mediated changes in p53-PAI-1 expression.	Curcumin	0-8	interleukin 17A	Homo sapiens	36-42
28919446-4	2018	The results show that in vitro treatment with Modafinil increased Interferon (IFN)-gamma, Interleukin (IL)-2 and IL-17 production and CD25 expression by T cells.	Modafinil	46-55	interleukin 17A	Homo sapiens	113-118
28902433-0	2018	Curcumin alleviates IL-17A-mediated p53-PAI-1 expression in bleomycin-induced alveolar basal epithelial cells.	Curcumin	0-8	interleukin 17A	Homo sapiens	20-26
28902433-0	2018	Curcumin alleviates IL-17A-mediated p53-PAI-1 expression in bleomycin-induced alveolar basal epithelial cells.	Bleomycin	60-69	interleukin 17A	Homo sapiens	20-26
29397841-6	2018	The ratio of Th17 cells in peripheral blood and serum levels of IL-17 in patients with multiple myeloma after treatment with thalidomide were significantly lower than those before treatment, and the ratio of Treg cells and levels of IL-35 were significantly higher than those before treatment, and the ratio of Th17 / Treg cells was higher than that before treatment (P&lt;0.05).	Thalidomide	125-136	interleukin 17A	Homo sapiens	64-69
29397841-9	2018	The anti-MM mechanism of thalidomide may relate with the regulation of Th17 / Treg cell ratio and expression levels of IL-17 and IL-35.	Thalidomide	25-36	interleukin 17A	Homo sapiens	119-124
29237778-4	2018	PGE2 is also associated with modulation of autoimmunity through altering the IL-23/IL-17 axis and regulatory T cell (Treg) development.	Dinoprostone	0-4	interleukin 17A	Homo sapiens	83-88
29237778-8	2018	However, in contrast with CD4+ cells that were Ag primed in vivo, exogenous PGE2 inhibited proliferation and skewed IL-17A to IFN-gamma production under Th17 polarization of naive T cells in vitro.	Dinoprostone	76-80	interleukin 17A	Homo sapiens	116-122
29237778-10	2018	Furthermore, we uncover a coordination of autocrine and paracrine mPGES1-driven PGE2 production that impacts effector T cell IL-17A and IFN-gamma responses.	Dinoprostone	80-84	interleukin 17A	Homo sapiens	125-131
30243007-4	2018	The aim of the study was to determine quantitatively gene expression of IL-17 in peripheral blood mononuclear cells (PBMN) &amp; the level of IL-17 in the serum of asthmatic patients, to correlate the level of IL-17 with the severity of asthma and to compare between gene expression of IL-17 and its serum level.	Adenosine Monophosphate	124-127	interleukin 17A	Homo sapiens	72-77
29135055-4	2018	Irrespective of glycemic status, colostrum and blood cells treated with IL-4 and IL-17 increased superoxide release in the presence of enteropathogenic Escherichia coli (EPEC).	Superoxides	97-107	interleukin 17A	Homo sapiens	81-86
29734196-9	2018	Transfection of exogenous miR-135a mimic resulted in significant suppression of IL-17 secretion and subsequent inhibition of NPC cell proliferation.	mir-135a	26-34	interleukin 17A	Homo sapiens	80-85
29734196-12	2018	These findings suggested that downregulation of miR-135a may contribute to the development of NPC via the mechanism of IL-17 stimulation of proinflammatory cytokine expression.	mir-135a	48-56	interleukin 17A	Homo sapiens	119-124
28935156-9	2018	IL-17RA antibody treatment in vitro reversed IL-17A-induced increase in NFkappaB and iNOS/nitrotyrosine expression in monocytes isolated from ASD subjects.	3-nitrotyrosine	90-103	interleukin 17A	Homo sapiens	45-51
30134246-4	2018	METHODS: The biochemical properties of TAK-828F were evaluated using Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) binding assay, surface plasmon resonance (SPR) biosensor assay, cofactor recruitment assay, reporter assay, and IL-17 expression assay.	TAK-828F	39-47	interleukin 17A	Homo sapiens	244-249
29564062-12	2018	Enrichment of these clusters separately lead to carbohydrate metabolism, long chain fatty acid and regulation of JAK-STAT and IL-17 signaling pathways, respectively.	Carbohydrates	48-60	interleukin 17A	Homo sapiens	126-131
29564062-12	2018	Enrichment of these clusters separately lead to carbohydrate metabolism, long chain fatty acid and regulation of JAK-STAT and IL-17 signaling pathways, respectively.	long chain fatty acid	73-94	interleukin 17A	Homo sapiens	126-131
29030006-0	2018	Dexmedetomidine mitigate acute lung injury by inhibiting IL-17-induced inflammatory reaction.	Dexmedetomidine	0-15	interleukin 17A	Homo sapiens	57-62
29030006-2	2018	Previous studies demonstrated that intranasal injections of IL-17 resulted in pulmonary inflammation and lung damage, we therefore hypothesize that dexmedetomidine, a potent alpha2 adrenergic receptor agonist that shows anti-inflammation effects in several animal models of inflammation, would attenuate IL-17 induced lung injury.	Dexmedetomidine	148-163	interleukin 17A	Homo sapiens	60-65
29030006-2	2018	Previous studies demonstrated that intranasal injections of IL-17 resulted in pulmonary inflammation and lung damage, we therefore hypothesize that dexmedetomidine, a potent alpha2 adrenergic receptor agonist that shows anti-inflammation effects in several animal models of inflammation, would attenuate IL-17 induced lung injury.	Dexmedetomidine	148-163	interleukin 17A	Homo sapiens	304-309
29030006-6	2018	In every aspect of pulmonary inflammation investigated, dexmedetomidine significantly and dose-dependently attenuated the inflammatory effects of IL-17.	Dexmedetomidine	56-71	interleukin 17A	Homo sapiens	146-151
29030006-7	2018	Our results not only give a comprehensive description of the protective action of dexmedetomidine on IL-17 induced acute lung injury, but also provide insights to the underlying cellular and molecular mechanisms.	Dexmedetomidine	82-97	interleukin 17A	Homo sapiens	101-106
29894287-7	2018	RESULTS: Immunohistochemistry results showed that the average positive staining area percentage of IL-17 and MPO in the clopidogrel group was significantly higher than that in the ticagrelor group.	Clopidogrel	120-131	interleukin 17A	Homo sapiens	99-104
29894287-7	2018	RESULTS: Immunohistochemistry results showed that the average positive staining area percentage of IL-17 and MPO in the clopidogrel group was significantly higher than that in the ticagrelor group.	Ticagrelor	180-190	interleukin 17A	Homo sapiens	99-104
29155646-0	2018	Combination treatment of docosahexaenoic acid (DHA) and all-trans-retinoic acid (ATRA) inhibit IL-17 and RORgammat gene expression in PBMCs of patients with relapsing-remitting multiple sclerosis.	Docosahexaenoic Acids	25-45	interleukin 17A	Homo sapiens	95-100
29155646-0	2018	Combination treatment of docosahexaenoic acid (DHA) and all-trans-retinoic acid (ATRA) inhibit IL-17 and RORgammat gene expression in PBMCs of patients with relapsing-remitting multiple sclerosis.	Docosahexaenoic Acids	47-50	interleukin 17A	Homo sapiens	95-100
29155646-0	2018	Combination treatment of docosahexaenoic acid (DHA) and all-trans-retinoic acid (ATRA) inhibit IL-17 and RORgammat gene expression in PBMCs of patients with relapsing-remitting multiple sclerosis.	Tretinoin	56-79	interleukin 17A	Homo sapiens	95-100
29155646-0	2018	Combination treatment of docosahexaenoic acid (DHA) and all-trans-retinoic acid (ATRA) inhibit IL-17 and RORgammat gene expression in PBMCs of patients with relapsing-remitting multiple sclerosis.	Tretinoin	81-85	interleukin 17A	Homo sapiens	95-100
29155646-4	2018	This study investigated the effects of DHA and ATRA individually and in combination on IL-17 and RORgammat gene expression in peripheral blood mononuclear cells (PBMCs) of relapsing-remitting MS (RRMS) patients who were receiving interferon beta (IFN-beta).	Docosahexaenoic Acids	39-42	interleukin 17A	Homo sapiens	87-92
29155646-6	2018	RESULTS: The results showed that single treatment of ATRA (p = 0.05) could significantly decrease the expression of IL-17 gene and single treatment of ATRA (p = 0.04) and single treatment of DHA (p = 0.05) induced significant inhibition on the expression of RORgammat gene.	Tretinoin	53-57	interleukin 17A	Homo sapiens	116-121
29155646-7	2018	The suppressive effect of combined treatment with ATRA and DHA on IL-17 (p = 0.02) and RORgammat (p = 0.01) was also found significant showing that the combined treatments can have additive effects.	Tretinoin	50-54	interleukin 17A	Homo sapiens	66-71
29155646-7	2018	The suppressive effect of combined treatment with ATRA and DHA on IL-17 (p = 0.02) and RORgammat (p = 0.01) was also found significant showing that the combined treatments can have additive effects.	Docosahexaenoic Acids	59-62	interleukin 17A	Homo sapiens	66-71
29040636-1	2018	Background: Candida albicans, the most common human fungal pathogen, causes chronic mucosal infections in patients with inborn errors of IL-17 immunity that rely heavily on chronic, often lifelong, azole antifungal agents for treatment.	Azoles	198-203	interleukin 17A	Homo sapiens	137-142
29299028-9	2017	Along with the significant improvement of clinical symptoms, use of vitamin D increase FOXP3 gene expression and downregulation of IL-10, TGF-B, and FOXP3, IL-17, but these changes were not statistically significant.	Vitamin D	68-77	interleukin 17A	Homo sapiens	156-161
29271481-23	2017	Small molecules were associated with a higher chance of reaching PASI 90 compared to conventional systemic agents.At drug level, in terms of reaching PASI 90, all of the anti-IL17 agents and guselkumab (an anti-IL23 drug) were significantly more effective than the anti-TNF alpha agents infliximab, adalimumab, and etanercept, but not certolizumab.	Certolizumab Pegol	335-347	interleukin 17A	Homo sapiens	175-179
29273710-7	2017	On in-vitro analysis, potassium under Th17 polarizing conditions significantly inhibited IL-17 and interferon-[Formula: see text] expression while favoring the induction of FoxP3+ T cells.	Potassium	22-31	interleukin 17A	Homo sapiens	89-94
29270166-6	2017	The whole blood of the patient produced 35% less IFN-gamma compared to controls assessed by ELISA and flow cytometry, but IL-17 producing T cells from patient were almost absent in PBMC stimulated with PMA plus ionomycin.	Ionomycin	211-220	interleukin 17A	Homo sapiens	122-127
29068453-7	2017	Both IL-4 and IL-17A AUC values were significantly increased after an SFA high-fat meal intake, accompanied by water, but not by orange juice.	Water	111-116	interleukin 17A	Homo sapiens	14-20
29068453-9	2017	Also, IL-17A significantly increased at 3 h after an SFA high-fat meal intake accompanied by water, but not by orange juice.	Water	93-98	interleukin 17A	Homo sapiens	6-12
29270166-6	2017	The whole blood of the patient produced 35% less IFN-gamma compared to controls assessed by ELISA and flow cytometry, but IL-17 producing T cells from patient were almost absent in PBMC stimulated with PMA plus ionomycin.	Tetradecanoylphorbol Acetate	202-205	interleukin 17A	Homo sapiens	122-127
29029813-5	2017	Several basic and translational mechanisms of resistance to immune checkpoint blockers (ICBs) were discussed during the meeting: 1. the impact of tumor microenvironment on the activity of immune system; 2. strategies to inhibit the cross-talk between extracellular matrix and myeloid-derived suppressor cells (MDSC) in the preclinical setting; 3. microRNA expression as a biomarker and as a target of therapy in non-small cell lung cancer (NSCLC); 4. the significance of complement activation pathways in response to immune checkpoint inhibitors; 5. the immunosuppressive activity of the microbiota by inducing IL-17 producing cells; and 6. modulation of HLA antigens as possible markers of response to ICB therapy.	indole-2-carboxylic acid	88-91	interleukin 17A	Homo sapiens	611-616
28763100-9	2017	Conversely, Dectin-2 activation by alpha-mannan reproduced the uveitic phenotype of EAU sufficiently, in a process mediated by the Card9-coupled signalling axis and interleukin (IL)-17 production.	alpha-mannan	35-47	interleukin 17A	Homo sapiens	165-184
28941216-0	2017	Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- and Interleukin-17-Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	46-49	interleukin 17A	Homo sapiens	84-98
28941216-2	2017	ABT-122 is a novel dual variable domain immunoglobulin that selectively and simultaneously targets human TNF and IL-17A.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	0-3	interleukin 17A	Homo sapiens	113-119
28941216-13	2017	CONCLUSION: The results of these phase I studies suggest that dual neutralization of TNF and IL-17 with ABT-122 has characteristics acceptable for further exploration of therapeutic potential in TNF- and IL-17A-driven immune-mediated inflammatory diseases.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	104-107	interleukin 17A	Homo sapiens	93-98
28941216-13	2017	CONCLUSION: The results of these phase I studies suggest that dual neutralization of TNF and IL-17 with ABT-122 has characteristics acceptable for further exploration of therapeutic potential in TNF- and IL-17A-driven immune-mediated inflammatory diseases.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	104-107	interleukin 17A	Homo sapiens	204-210
28990053-8	2017	Treatment with the mitogen-activated protein kinase (MAPK) inhibitors, SB203580 and PD98059, significantly inhibited the effects of IL-17 on the gene and protein expression levels of FLG and IVL.	SB 203580	71-79	interleukin 17A	Homo sapiens	132-137
29285128-10	2017	The expression of inflammatory mediators such as IL-17, IL-6 and TNF-alpha in the aqueous humor of patients with secondary glaucoma after silicone oil tamponade significantly increased relative to patients without secondary glaucoma.	Silicone Oils	138-150	interleukin 17A	Homo sapiens	49-54
28990053-8	2017	Treatment with the mitogen-activated protein kinase (MAPK) inhibitors, SB203580 and PD98059, significantly inhibited the effects of IL-17 on the gene and protein expression levels of FLG and IVL.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	84-91	interleukin 17A	Homo sapiens	132-137
29201026-12	2017	Conclusion: Childhood obesity is an independent factor that is associated with an elevated frequency of circulating TH17 cells and higher expression of RORC- and IL-17A-mRNA after in vitro stimulation with Ionomycin.	Ionomycin	206-215	interleukin 17A	Homo sapiens	162-168
28982342-4	2017	RESULTS: Polyphenols were able to reduce the increased release of interferon-gamma and interleukin (IL)-4, while maintaining the equilibrium between IL-10 and IL-17.	Polyphenols	9-20	interleukin 17A	Homo sapiens	159-164
28692864-11	2017	In particular, serum IL-17 and IL-23 values positively correlated with serum total IgE levels (p&lt;0.05); serum total cholesterol levels (p&lt;0.001); serum LDL levels (p&lt;0.001); serum triglycerides levels (p&lt;0.05).	Cholesterol	119-130	interleukin 17A	Homo sapiens	21-26
29127315-9	2017	We found that infusion of GMSCs but not fibroblast cells significantly controlled blood glucose levels, delayed diabetes onset, ameliorated pathology scores in pancreas, and down-regulated production of IL-17 and IFN-gamma in CD4+ and CD8+ T cells in spleens, pancreatic lymph nodes (pLN) and other lymph nodes.	gmscs	26-31	interleukin 17A	Homo sapiens	203-208
28698115-0	2017	Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection.	Bupropion	57-66	interleukin 17A	Homo sapiens	0-14
28698115-2	2017	IL-17 putatively disrupts the blood brain barrier and affects dopamine synthesis whereas dopamine has been shown to decrease Th17 cell-mediated immune response.	Dopamine	62-70	interleukin 17A	Homo sapiens	0-5
28698115-8	2017	Higher baseline IL-17 level was associated with greater reduction in depression severity (effect size=0.78, p=0.008) in the bupropion-SSRI but not the other two treatment arms.	Bupropion	124-133	interleukin 17A	Homo sapiens	16-21
28698115-10	2017	CONCLUSION: Higher baseline levels of IL-17 are selectively associated with greater symptomatic reduction in depressed patients treated with bupropion-SSRI combination.	Bupropion	141-150	interleukin 17A	Homo sapiens	38-43
28692864-11	2017	In particular, serum IL-17 and IL-23 values positively correlated with serum total IgE levels (p&lt;0.05); serum total cholesterol levels (p&lt;0.001); serum LDL levels (p&lt;0.001); serum triglycerides levels (p&lt;0.05).	Triglycerides	189-202	interleukin 17A	Homo sapiens	21-26
28994166-10	2017	Tofacitinib suppresses the expression of IL-23, IL-17A, IL-17F, and IL-22 receptors during the stimulation of lymphocytes.	tofacitinib	0-11	interleukin 17A	Homo sapiens	48-54
29061714-0	2017	Correction: IL-33 Signaling Regulates Innate IL-17A and IL-22 Production via Suppression of Prostaglandin E2 during Lung Fungal Infection.	Dinoprostone	92-108	interleukin 17A	Homo sapiens	45-51
28938397-7	2017	IL-17A promotes TGF-beta-induced fibrosis in CD90+ OFs but impedes 15-deoxy-Delta12,14-prostaglandin J2-induced adipogenesis in CD90- OFs.	ofs	51-54	interleukin 17A	Homo sapiens	0-6
28938397-7	2017	IL-17A promotes TGF-beta-induced fibrosis in CD90+ OFs but impedes 15-deoxy-Delta12,14-prostaglandin J2-induced adipogenesis in CD90- OFs.	14-prostaglandin j2	84-103	interleukin 17A	Homo sapiens	0-6
29294541-0	2017	[Prediction of occupational allergic contact dermatitis induced by formaldehyde by IL17/IL22 secretion cell rest combined with patch test].	Formaldehyde	67-79	interleukin 17A	Homo sapiens	83-87
28926770-6	2017	In addition, 1,25(OH)2D3 promoted secretion of the anti-inflammatory cytokine, transforming Growth Factor beta1 (TGF-beta1) but suppressed pro-inflammatory cytokines such as interleukin-17 (IL-17).	Calcitriol	13-24	interleukin 17A	Homo sapiens	174-188
28926770-6	2017	In addition, 1,25(OH)2D3 promoted secretion of the anti-inflammatory cytokine, transforming Growth Factor beta1 (TGF-beta1) but suppressed pro-inflammatory cytokines such as interleukin-17 (IL-17).	Calcitriol	13-24	interleukin 17A	Homo sapiens	190-195
29254235-6	2017	After treatment with prednisone alone, proportions of Th17/CD4+ cells and levels of IL-17A were significantly lower than in control cells, and proportions of Treg/CD4+ cells and levels of IL-10 significantly higher than in controls (all P &lt; 0.01).	Prednisone	21-31	interleukin 17A	Homo sapiens	84-90
29254235-7	2017	Our results suggest that prednisone may improve pregnancy outcomes by restoring immunological homeostasis through up-regulation of STAT5 and FOXP3, induction of DIC differentiation into Treg cells, inhibition of DIC differentiation into Th17 cells, reduction of IL-17A secretion and induction of IL-10 secretion.	Prednisone	25-35	interleukin 17A	Homo sapiens	262-268
29294541-1	2017	Objective: To investigate the possible role of IL17-and IL22-secreting cells combined with patch test for the prediction of formaldehyde-induced occupational allergic contact dermatitis(OACD).	Formaldehyde	124-136	interleukin 17A	Homo sapiens	47-51
29294541-6	2017	The proportions of circulating CD3+CD8-IL17+ and CD3+CD8-IL22+ cells from patch-test(+) formaldehyde-exposed workers were significantly higher than that of patch-test(-)group, formaldehyde-exposed workers without skin lesions and non-exposed controls(P&lt;0.05).	Formaldehyde	88-100	interleukin 17A	Homo sapiens	39-43
29294541-13	2017	Conclusion: The proportions of circulating IL17+ and IL22+T cells(both CD8-and CD8+)are enhanced in formaldehyde-exposed workers at proposed OEL, possibly involved in the development of formaldehyde-induced OACD.The detection of IL17-and IL22-secreting cells combined with formaldehyde patch test help to screen the workers with allergy property and prevent OACD.	Formaldehyde	100-112	interleukin 17A	Homo sapiens	43-47
29294541-13	2017	Conclusion: The proportions of circulating IL17+ and IL22+T cells(both CD8-and CD8+)are enhanced in formaldehyde-exposed workers at proposed OEL, possibly involved in the development of formaldehyde-induced OACD.The detection of IL17-and IL22-secreting cells combined with formaldehyde patch test help to screen the workers with allergy property and prevent OACD.	Formaldehyde	100-112	interleukin 17A	Homo sapiens	229-233
29294541-13	2017	Conclusion: The proportions of circulating IL17+ and IL22+T cells(both CD8-and CD8+)are enhanced in formaldehyde-exposed workers at proposed OEL, possibly involved in the development of formaldehyde-induced OACD.The detection of IL17-and IL22-secreting cells combined with formaldehyde patch test help to screen the workers with allergy property and prevent OACD.	Formaldehyde	186-198	interleukin 17A	Homo sapiens	43-47
29294541-13	2017	Conclusion: The proportions of circulating IL17+ and IL22+T cells(both CD8-and CD8+)are enhanced in formaldehyde-exposed workers at proposed OEL, possibly involved in the development of formaldehyde-induced OACD.The detection of IL17-and IL22-secreting cells combined with formaldehyde patch test help to screen the workers with allergy property and prevent OACD.	Formaldehyde	186-198	interleukin 17A	Homo sapiens	229-233
29294541-13	2017	Conclusion: The proportions of circulating IL17+ and IL22+T cells(both CD8-and CD8+)are enhanced in formaldehyde-exposed workers at proposed OEL, possibly involved in the development of formaldehyde-induced OACD.The detection of IL17-and IL22-secreting cells combined with formaldehyde patch test help to screen the workers with allergy property and prevent OACD.	Formaldehyde	186-198	interleukin 17A	Homo sapiens	43-47
29294541-13	2017	Conclusion: The proportions of circulating IL17+ and IL22+T cells(both CD8-and CD8+)are enhanced in formaldehyde-exposed workers at proposed OEL, possibly involved in the development of formaldehyde-induced OACD.The detection of IL17-and IL22-secreting cells combined with formaldehyde patch test help to screen the workers with allergy property and prevent OACD.	Formaldehyde	186-198	interleukin 17A	Homo sapiens	229-233
29038767-13	2017	Regarding inflammatory factors, we observed significantly lower plasma levels of IL-17alpha (p &lt; 0.001), MIP-1alpha (p &lt; 0.001) and TGFalpha (p &lt; 0.05) in the cocaine group compared with the levels in the control group.	Cocaine	168-175	interleukin 17A	Homo sapiens	81-91
28978810-5	2017	Using a necrotic Mtb mouse model, we show that loss of Mtb virulence factors, such as phenolic glycolipids, decreases the production of the proinflammatory cytokine IL-17 (also referred to as IL-17A).	Glycolipids	95-106	interleukin 17A	Homo sapiens	165-170
28822915-0	2017	Immunomodulatory effects of M2000 (beta-D-Mannuronic acid) on TNF-alpha, IL-17 and FOXP3 gene expression in patients with inflammatory bowel disease.	mannuronic acid	35-57	interleukin 17A	Homo sapiens	73-78
28634033-0	2017	Nickel Sulfate Promotes IL-17A Producing CD4+ T Cells by an IL-23-Dependent Mechanism Regulated by TLR4 and Jak-STAT Pathways.	nickel sulfate	0-14	interleukin 17A	Homo sapiens	24-30
28592369-9	2017	CONCLUSIONS: Histamine stimulation influences the IL-17 pathway in psoriasis via the fourth histamine receptor subtype, H4R, on CD4+ T cells.	Histamine	13-22	interleukin 17A	Homo sapiens	50-55
28634033-7	2017	Moreover, nickel-treated monocyte-derived dendritic cells induced an increase in the percentage of IL-17A+ CD4+ T cells, an effect reduced by IL-23 neutralization.	Nickel	10-16	interleukin 17A	Homo sapiens	99-105
28935920-7	2017	Moreover, BAY treatment reversed the Abeta-induced changes in IL-22 and IL-17 and the ratio of Bax/Bcl-2.	2-(3,4-dimethoxybenzyl)-7-(1-(1-hydroxyethyl)-4-phenylbutyl)-5-methylimidazo(5,1-f)(1,2,4)triazin-4 (3H)-one	10-13	interleukin 17A	Homo sapiens	72-77
28664925-10	2017	Following stimulation, lymphocytes of ELS+ adolescents produced significantly more IL-2, IL-4, IFN-gamma, and IL-17 and engaged more MAPK ERK and NF-kappaB signaling.	N-[(2S,3S,4R)-3,4-dihydroxy-8-oxo-8-[(4-pentylphenyl)amino]-1-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}octan-2-yl]hexacosanamide	38-41	interleukin 17A	Homo sapiens	110-115
28931051-7	2017	Thus, in the context of bladder CIS, IL-17+ mast cells predict favourable outcome following BCG immunotherapy indicative of a novel mechanism of BCG immunotherapy in UBC and could form the basis of a stratified approach to treatment.	1-(2-amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione	166-169	interleukin 17A	Homo sapiens	37-42
29296528-8	2017	Furthermore, IL-17 potentiates the direct killing capability of neutrophils by enhancing the production of cytotoxic molecules, including reactive oxygen species (ROS), MPO, TNF-related apoptosis-inducing ligand (TRAIL), and IFN-gamma.	Reactive Oxygen Species	138-161	interleukin 17A	Homo sapiens	13-18
29296528-8	2017	Furthermore, IL-17 potentiates the direct killing capability of neutrophils by enhancing the production of cytotoxic molecules, including reactive oxygen species (ROS), MPO, TNF-related apoptosis-inducing ligand (TRAIL), and IFN-gamma.	Reactive Oxygen Species	163-166	interleukin 17A	Homo sapiens	13-18
28902929-6	2017	In the RSA group, 25(OH) D and TGF-beta were significantly decreased while IL-17 and IL-23 were significantly increased compared with the control group.	rabbit sperm membrane autoantigen	7-10	interleukin 17A	Homo sapiens	75-80
28398068-4	2017	Supplementation of HIV-positive subjects with L-GSH for 3 months resulted in a notable increase in the levels of IL-12, IL-2, and IFN-gamma, with a concomitant decrease in the levels of IL-6, IL-10, and free radicals, and stabilization in the levels of TGF-beta, IL-1, and IL-17, compared to their placebo counterparts.	l-gsh	46-51	interleukin 17A	Homo sapiens	273-278
28865459-8	2017	Using an in vitro keratinocyte assay, an IL-17-inhibitory effect was observed for tryptanthrin, a component of Indigo naturalis.	tryptanthrine	82-94	interleukin 17A	Homo sapiens	41-46
28526351-0	2017	Docosahexaenoyl serotonin emerges as most potent inhibitor of IL-17 and CCL-20 released by blood mononuclear cells from a series of N-acyl serotonins identified in human intestinal tissue.	Docosahexaenoyl Serotonin	0-25	interleukin 17A	Homo sapiens	62-67
28463086-0	2017	Vitamin D Counteracts an IL-23-Dependent IL-17A+IFN-gamma+ Response Driven by Urban Particulate Matter.	Vitamin D	0-9	interleukin 17A	Homo sapiens	41-57
28463086-10	2017	1,25(OH)2D3 counteracted the UPM-driven DC maturation and inhibited the frequency of IL-17A+IFN-gamma+ cells, most prominently when DCs were co-treated with the corticosteroid dexamethasone, while maintaining antiinflammatory IL-10 synthesis.	Dexamethasone	176-189	interleukin 17A	Homo sapiens	85-101
28526351-0	2017	Docosahexaenoyl serotonin emerges as most potent inhibitor of IL-17 and CCL-20 released by blood mononuclear cells from a series of N-acyl serotonins identified in human intestinal tissue.	n-acyl serotonins	132-149	interleukin 17A	Homo sapiens	62-67
28526351-2	2017	Recently we reported that one of the serotonin-fatty acid conjugates, docosahexaenoyl serotonin (DHA-5-HT), previously found in gut tissue of mouse and pig, attenuates the IL-23-IL-17 signaling axis in LPS-stimulated mice macrophages.	serotonin-fatty acid	37-57	interleukin 17A	Homo sapiens	178-183
28526351-2	2017	Recently we reported that one of the serotonin-fatty acid conjugates, docosahexaenoyl serotonin (DHA-5-HT), previously found in gut tissue of mouse and pig, attenuates the IL-23-IL-17 signaling axis in LPS-stimulated mice macrophages.	Docosahexaenoyl Serotonin	70-95	interleukin 17A	Homo sapiens	178-183
28526351-2	2017	Recently we reported that one of the serotonin-fatty acid conjugates, docosahexaenoyl serotonin (DHA-5-HT), previously found in gut tissue of mouse and pig, attenuates the IL-23-IL-17 signaling axis in LPS-stimulated mice macrophages.	9,9,10-trimethylacridan	97-102	interleukin 17A	Homo sapiens	178-183
28526351-5	2017	Furthermore, we tested these fatty acid conjugates for their ability to inhibit the release of IL-17 and CCL-20 by stimulated human peripheral blood mononuclear cells (PBMCs).	Fatty Acids	29-39	interleukin 17A	Homo sapiens	95-100
28526351-8	2017	These results underline the idea that DHA-5-HT is a gut-specific endogenously produced mediator with the capacity to modulate the IL-17/Th17 signaling response.	dehydroacetic acid	38-41	interleukin 17A	Homo sapiens	130-135
28988536-4	2017	Ghrelin at a concentration characteristic of the first half of pregnancy (trimesters I-II), in contrast, enhances aTreg formation and, in parallel, reduces the level aT 17 (that express CCR6) and the IL-17A production by aTh17.	Ghrelin	0-7	interleukin 17A	Homo sapiens	200-206
28710773-11	2017	TERB increased IL-17A from purified Th17 cells, which argues that TERB acts directly on Th17 cells.	Terbutaline	0-4	interleukin 17A	Homo sapiens	15-21
28710773-11	2017	TERB increased IL-17A from purified Th17 cells, which argues that TERB acts directly on Th17 cells.	Terbutaline	66-70	interleukin 17A	Homo sapiens	15-21
28697061-6	2017	CONCLUSIONS: Low-level formaldehyde exposure may increase circulating IL17-/IL22-producing T cells (CD8 and CD8), possibly involved in the development of human OACD.	Formaldehyde	23-35	interleukin 17A	Homo sapiens	70-74
28926857-0	2017	The Amelioration of Insulin Resistance in Salt Loading Subjects by Potassium Supplementation is Associated with a Reduction in Plasma IL-17A Levels.	Salts	42-46	interleukin 17A	Homo sapiens	134-140
28926857-0	2017	The Amelioration of Insulin Resistance in Salt Loading Subjects by Potassium Supplementation is Associated with a Reduction in Plasma IL-17A Levels.	Potassium	67-76	interleukin 17A	Homo sapiens	134-140
28926857-3	2017	The polarization of Th17 cells and enhanced IL-17A production induced by high salt might increase the risk of autoimmune/inflammatory diseases.	Salts	78-82	interleukin 17A	Homo sapiens	44-50
28926857-8	2017	Moreover, after salt loading, the plasma IL-17A concentrations increased significantly (4.2+-2.1 pg/mL to 9.7+-5.1 pg/mL; P&lt;0.01), whereas dropped considerably when dietary potassium was supplemented (9.7+-5.1 pg/mL to 2.0+-0.9 pg/mL; P&lt;0.001).	Salts	16-20	interleukin 17A	Homo sapiens	41-47
28926857-8	2017	Moreover, after salt loading, the plasma IL-17A concentrations increased significantly (4.2+-2.1 pg/mL to 9.7+-5.1 pg/mL; P&lt;0.01), whereas dropped considerably when dietary potassium was supplemented (9.7+-5.1 pg/mL to 2.0+-0.9 pg/mL; P&lt;0.001).	Potassium	176-185	interleukin 17A	Homo sapiens	41-47
28926857-9	2017	Statistically significant correlations were found between changes in HOMA-IR and changes in plasma IL-17A concentrations during the interventions (low- to high-salt: r=0.642, P&lt;0.01; high-salt to potassium supplementation: r=0.703, P&lt;0.01).	Salts	160-164	interleukin 17A	Homo sapiens	99-105
28926857-9	2017	Statistically significant correlations were found between changes in HOMA-IR and changes in plasma IL-17A concentrations during the interventions (low- to high-salt: r=0.642, P&lt;0.01; high-salt to potassium supplementation: r=0.703, P&lt;0.01).	Salts	191-195	interleukin 17A	Homo sapiens	99-105
28926857-9	2017	Statistically significant correlations were found between changes in HOMA-IR and changes in plasma IL-17A concentrations during the interventions (low- to high-salt: r=0.642, P&lt;0.01; high-salt to potassium supplementation: r=0.703, P&lt;0.01).	Potassium	199-208	interleukin 17A	Homo sapiens	99-105
28926857-11	2017	Conclusions The amelioration of salt-loading-induced IR by potassium supplementation in participants may be related to the reduction in plasma IL-17A concentration.	Salts	32-36	interleukin 17A	Homo sapiens	143-149
28926857-11	2017	Conclusions The amelioration of salt-loading-induced IR by potassium supplementation in participants may be related to the reduction in plasma IL-17A concentration.	Potassium	59-68	interleukin 17A	Homo sapiens	143-149
28831064-7	2017	Patients with SAA or NSAA had higher plasma IL-17A concentrations, which were negatively correlated with AA manifestations and the CD4+/CD8+ ratio.	saa	14-17	interleukin 17A	Homo sapiens	44-50
28858634-4	2017	Moreover, semen interleukin (IL)-17 and IL-18 levels in DM males were significantly higher than those in normal males (p&lt;0.05) and were positively correlated with blood glucose level and sperm DNA fragmentation index.	Glucose	172-179	interleukin 17A	Homo sapiens	16-35
28858634-5	2017	DM increased blood glucose levels, consequently inducing the abnormal expression of IL-17 and IL-18.	Glucose	19-26	interleukin 17A	Homo sapiens	84-89
28912678-0	2017	IL-17A Enhances Microglial Response to OGD by Regulating p53 and PI3K/Akt Pathways with Involvement of ROS/HMGB1.	ros	103-106	interleukin 17A	Homo sapiens	0-6
28912678-2	2017	An oxygen-glucose deprivation (OGD) model showed that IL-17A expression was significantly up-regulated in microglial cells.	oxygen-glucose	3-17	interleukin 17A	Homo sapiens	54-60
28912678-6	2017	These findings demonstrated that ROS might be located upstream of IL-17A and HMGB1 so that ROS can regulate HMGB1/IL-17A expression to affect the p53 and PI3K/Akt signaling pathways and therefore promote the occurrence of apoptosis in microglial cells.	ros	33-36	interleukin 17A	Homo sapiens	66-72
28912678-6	2017	These findings demonstrated that ROS might be located upstream of IL-17A and HMGB1 so that ROS can regulate HMGB1/IL-17A expression to affect the p53 and PI3K/Akt signaling pathways and therefore promote the occurrence of apoptosis in microglial cells.	ros	33-36	interleukin 17A	Homo sapiens	114-120
28912678-6	2017	These findings demonstrated that ROS might be located upstream of IL-17A and HMGB1 so that ROS can regulate HMGB1/IL-17A expression to affect the p53 and PI3K/Akt signaling pathways and therefore promote the occurrence of apoptosis in microglial cells.	ros	91-94	interleukin 17A	Homo sapiens	66-72
28912678-6	2017	These findings demonstrated that ROS might be located upstream of IL-17A and HMGB1 so that ROS can regulate HMGB1/IL-17A expression to affect the p53 and PI3K/Akt signaling pathways and therefore promote the occurrence of apoptosis in microglial cells.	ros	91-94	interleukin 17A	Homo sapiens	114-120
28595093-4	2017	IL-17A rs4711998 and IL-17F rs763780 may affect susceptibility to HBeAg+ CHB and response to PEG-IFNa-2alpha treatment.	Polyethylene Glycols	93-96	interleukin 17A	Homo sapiens	0-6
29156727-6	2017	Furthermore, the proportions of Th17 cells and serum IL-17 levels were higher in patients with stage III than stage I &amp; II MM patients, and those parameters were positively correlated with the expression of IRF4 in these cases.	Adenosine Monophosphate	119-122	interleukin 17A	Homo sapiens	53-58
28681115-5	2017	Results have already been obtained from phase 3 studies for tofacitinib, a Janus kinase inhibitor as well as for the antibodies brodalumab, bimekizumab and ABT-122 that inhibit the IL17-signaling pathway.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	156-159	interleukin 17A	Homo sapiens	181-185
27893617-6	2017	Recipient treatment with donor apoptotic 1-ethyl-3-(3"-dimethylaminopropyl)-carbodiimide-treated splenocytes significantly inhibited antidonor IL-17 response, and when combined with B cell depletion and a short course of rapamycin led to survival of pig islet xenografts beyond 100 days in approximately 65% recipients.	Ethyldimethylaminopropyl Carbodiimide	41-88	interleukin 17A	Homo sapiens	143-148
28639386-10	2017	SKP TxRs with rejection developed Abs to KSAgs and PSAgs demonstrated increased frequencies of kidney or pancreas SAg-specific IFN-gamma and IL-17-secreting cells with reduced IL-10, suggesting loss of peripheral tolerance to SAgs.	ksags	41-46	interleukin 17A	Homo sapiens	141-146
27927883-0	2017	Serum 25-OH vitamin D level in treatment-naive systemic lupus erythematosus patients: Relation to disease activity, IL-23 and IL-17.	25-oh vitamin d	6-21	interleukin 17A	Homo sapiens	126-131
27927883-1	2017	Objectives The aim of this study was to assess the vitamin D status in treatment-naive SLE patients and its association with clinical and laboratory markers of disease activity, including serum levels of IL-17 and IL-23.	Vitamin D	51-60	interleukin 17A	Homo sapiens	204-209
28690324-9	2017	However, BTZ treatment profoundly suppressed the donor T-cell-derived Th17 response and ameliorated the reduction in salivary secretion in IL-17-deficient recipient mice.	Bortezomib	9-12	interleukin 17A	Homo sapiens	139-144
28742830-9	2017	Metal import increased with IL-17/TNF-alpha exposure, through the enhanced ZIP-8 expression.	Metals	0-5	interleukin 17A	Homo sapiens	28-33
28260649-0	2017	Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.	Sorafenib	195-204	interleukin 17A	Homo sapiens	13-28
28260649-8	2017	CONCLUSION: A higher serum IL-17A level is a potential biomarker for predicting poor PFS in patients with HBV-related advanced HCC treated with sorafenib.	Sorafenib	144-153	interleukin 17A	Homo sapiens	27-33
28285360-0	2017	Kynurenic acid downregulates IL-17/1L-23 axis in vitro.	Kynurenic Acid	0-14	interleukin 17A	Homo sapiens	29-34
28456711-9	2017	In vitro, paeoniflorin significantly inhibited the mRNA expression of IL-6, IL-17A and IL-22 at both 2.08 and 10.41muM (p&lt;0.01), and paeoniflorin had a marginal effect on the protein expression of IL-17A and IL-6.	peoniflorin	10-22	interleukin 17A	Homo sapiens	76-82
28456711-9	2017	In vitro, paeoniflorin significantly inhibited the mRNA expression of IL-6, IL-17A and IL-22 at both 2.08 and 10.41muM (p&lt;0.01), and paeoniflorin had a marginal effect on the protein expression of IL-17A and IL-6.	peoniflorin	10-22	interleukin 17A	Homo sapiens	200-206
28285360-5	2017	In this study, we sought to explore the potential role of kynurenic acid (KynA), in modulating the expression of IL-23 and IL-17 by DCs and CD4+ cells, respectively.	Kynurenic Acid	58-72	interleukin 17A	Homo sapiens	123-128
28285360-5	2017	In this study, we sought to explore the potential role of kynurenic acid (KynA), in modulating the expression of IL-23 and IL-17 by DCs and CD4+ cells, respectively.	Kynurenic Acid	74-78	interleukin 17A	Homo sapiens	123-128
28500073-7	2017	Engaging TLR9 with CpG oligonucleotide contributes to the development of IL17A+ and IL-21+ populations.	CPG-oligonucleotide	19-38	interleukin 17A	Homo sapiens	73-78
28319417-10	2017	Our data suggest that suppression of IL-17 A production as one of the mechanisms underlying the beneficial effect of first-line disease-modifying treatments is stronger in glatiramer acetate than in interferon-beta.	Glatiramer Acetate	172-190	interleukin 17A	Homo sapiens	37-44
28319417-2	2017	The aim of the study was to determine the effect of interferon-beta and glatiramer acetate on serum concentrations of TNF-alpha and IL-17 A and their correlation with the degree of disability in clinically stable patients with relapsing-remitting MS. A cross-sectional, case-control study of 220 patients (68 treatment naive; 152 treated with interferon-beta or glatiramer acetate) and 99 clinically healthy age-gender-body mass index-matched subjects were performed.	Glatiramer Acetate	72-90	interleukin 17A	Homo sapiens	132-139
28444390-11	2017	Isoniazid which did not induce significant hepatocyte toxicity, compared with SMX-NO and flucloxacillin, stimulated the release of a panel of cytokines including the above and IFN-gamma, IL-12, IL-17A, IP-10, and IL-10.	Isoniazid	0-9	interleukin 17A	Homo sapiens	194-200
29029520-7	2017	In addition, in stratified analyses by cancer types, IL-17A overexpression was significantly associated with worse OS in hepatic carcinoma, but with improved OS in esophageal squamous cell carcinoma (ESCC).	Osmium	115-117	interleukin 17A	Homo sapiens	53-59
29029520-7	2017	In addition, in stratified analyses by cancer types, IL-17A overexpression was significantly associated with worse OS in hepatic carcinoma, but with improved OS in esophageal squamous cell carcinoma (ESCC).	Osmium	158-160	interleukin 17A	Homo sapiens	53-59
27746241-12	2017	Stimulation of primary bronchial epithelial cells with IL-17A enhanced mRNA expression of IL-17RA and increased release of IL-8, even in the presence of budesonide.	Budesonide	153-163	interleukin 17A	Homo sapiens	55-61
28680381-6	2017	CD11chi DC ablation resulted in the accumulation of IL-17+CD4+ Th17 cells in the CNS, thereby leading to lower ratio of Tregs to Th17 cells.	cd11chi	0-7	interleukin 17A	Homo sapiens	52-57
28498408-0	2017	Induction of IL-17 production from human peripheral blood CD4+ cells by asbestos exposure.	Asbestos	72-80	interleukin 17A	Homo sapiens	13-18
29163764-3	2017	We found that ketamine significantly diminished the frequency of IL-17-producers among CD4+ T cells stimulated under Th17-skewing conditions.	Ketamine	14-22	interleukin 17A	Homo sapiens	65-70
28498408-8	2017	However, subsequent re-stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin resulted in enhanced IL-17 production and expression, particularly in CD4+ surface CXCR3 positive cells.	Tetradecanoylphorbol Acetate	40-71	interleukin 17A	Homo sapiens	113-118
28498408-8	2017	However, subsequent re-stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin resulted in enhanced IL-17 production and expression, particularly in CD4+ surface CXCR3 positive cells.	Tetradecanoylphorbol Acetate	73-76	interleukin 17A	Homo sapiens	113-118
28498408-8	2017	However, subsequent re-stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin resulted in enhanced IL-17 production and expression, particularly in CD4+ surface CXCR3 positive cells.	Ionomycin	82-91	interleukin 17A	Homo sapiens	113-118
28404635-3	2017	In this article, we show that miR-24 drives the production of IFN-gamma and IL-17 in T cells at least in part through targeting TCF1, a transcription factor known for its role in limiting Th1 and Th17 immunity.	mir-24	30-36	interleukin 17A	Homo sapiens	76-81
27686093-2	2017	The cyclic AMP-responsive element modulator-alpha (CREMalpha) is a central mediator of T-cell pathogenesis, which contributes to increased IL-17 expression in patients with autoimmune disorders.	Cyclic AMP	4-14	interleukin 17A	Homo sapiens	139-144
27943400-5	2017	The injection of HMGB1 into the IMQ-treated skin further aggravated the psoriasis-like disease, enhanced the infiltration of CD3+ T cells, myeloperoxidase+ neutrophils and CD11c+ dendritic cells, increased the number of gammadelta T cells, and upregulated the mRNA expression of interleukin (IL)-6, tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma and IL-17 compared with the PBS injection.	Imiquimod	32-35	interleukin 17A	Homo sapiens	361-366
28111801-2	2017	OBJECTIVE: To evaluate the efficacy, safety and patient acceptability of 300 and 150 mg secukinumab - a fully human anti-interleukin-17A monoclonal antibody that has demonstrated efficacy in the treatment of patients with moderate-to-severe plaque psoriasis - self-administered by autoinjection.	secukinumab - a	88-103	interleukin 17A	Homo sapiens	121-136
28881647-8	2017	An inhibition of Th1/Th17 responses was observed as evidenced by a decreased production of IFN-gamma, IL-17, and a reduction of IFN-gamma/IL-17- producing CD4+ T cells following treatment with DAC.	Decitabine	193-196	interleukin 17A	Homo sapiens	102-107
27623446-5	2017	RESULTS: SF enhanced naive CD4+ T cell proliferation and IFN-gamma/IL-17 production in cell-contact and in part ICAM-1-/VCAM-1-dependent manner.	sf	9-11	interleukin 17A	Homo sapiens	67-72
28881647-8	2017	An inhibition of Th1/Th17 responses was observed as evidenced by a decreased production of IFN-gamma, IL-17, and a reduction of IFN-gamma/IL-17- producing CD4+ T cells following treatment with DAC.	Decitabine	193-196	interleukin 17A	Homo sapiens	138-143
28284336-2	2017	Here we show that PAR treatment inhibits the initiation of experimental autoimmune neuritis (EAN), suppresses the production of TNF-alpha, IFN-gamma, IL-1beta and IL-17, and decreases Th1 and Th17 cells at early time point.	parthenolide	18-21	interleukin 17A	Homo sapiens	163-168
28160571-6	2017	Importantly, the interaction between ganlyrin and SHP-1 leads to inhibition of STAT3 activation and to enhancement of TNF-alpha and IL-17 in inflammatory cells.	ganlyrin	37-45	interleukin 17A	Homo sapiens	132-137
28258191-7	2017	A corresponding increase in IL-4 and decrease in IFN-gamma and IL-17-expressing CD4+ T cells were observed in DMF-treated patients.	Dimethyl Fumarate	110-113	interleukin 17A	Homo sapiens	63-68
28379210-1	2017	AIM: The study has two aims: 1) to evaluate the association of IL-17 polymorphism rs2275913 with RA severity and 2) to evaluate if this particular SNP is associated with susceptibility for RA in Mexican patients.	Radium	97-99	interleukin 17A	Homo sapiens	63-68
28420140-7	2017	The expression of COX-2 and IL-17 were significantly lower in samples treated with OLE + EC-LPS compared with those treated with EC-LPS alone (0.80 +- 0.15 arbitrary units (a.u.)	ole + ec-lps	83-95	interleukin 17A	Homo sapiens	28-33
28420140-7	2017	The expression of COX-2 and IL-17 were significantly lower in samples treated with OLE + EC-LPS compared with those treated with EC-LPS alone (0.80 +- 0.15 arbitrary units (a.u.)	ec-lps	89-95	interleukin 17A	Homo sapiens	28-33
28469721-8	2017	IL-17A levels were elevated (20.3 pg/ml) in OSAHS group compared to healthy group (10.05 pg/ml).	osahs	44-49	interleukin 17A	Homo sapiens	0-6
28469721-10	2017	IL-17 levels were positively correlated with nocturia severity (r = 0.24; P = 0.03) and negatively correlated with mean O2 saturation (r = -0.42; P = 0.03).	Oxygen	120-122	interleukin 17A	Homo sapiens	0-5
28157396-7	2017	DAPT treatment reduced Th17 response by downregulation of RORgammat expression and interleukin (IL)-17/IL-22 secretion.	dapt	0-4	interleukin 17A	Homo sapiens	83-102
28065853-10	2017	Sitagliptin treatment induced a significantly (p&lt;0.05) decrease in IL-17 and IFN-gamma intracellular expression compared with PHA alone.	Sitagliptin Phosphate	0-11	interleukin 17A	Homo sapiens	70-75
28408801-0	2017	Effects of beta-d-mannuronic acid, as a novel non-steroidal anti-inflammatory medication within immunosuppressive properties, on IL17, RORgammat, IL4 and GATA3 gene expressions in rheumatoid arthritis patients.	mannuronic acid	11-33	interleukin 17A	Homo sapiens	129-133
28408801-3	2017	In this study, the effect of beta-d-mannuronic acid (M2000) as a novel non-steroidal anti-inflammatory drug (NSAID) with immunosuppressive and anti-inflammatory effects together with antioxidant effects was evaluated on IL17, RORgammat, IL4 and GATA3 gene expression in 12 RA patients.	mannuronic acid	29-51	interleukin 17A	Homo sapiens	220-224
28065853-11	2017	Also, the percentage of T CD4+IL-17+, T CD4+IFNgamma+ and T CD4+IL-4+ cells were significantly reduced (p&lt;0.05) by sitagliptin.	Sitagliptin Phosphate	118-129	interleukin 17A	Homo sapiens	30-35
28292332-5	2017	RESULTS: A significantly higher proportion of stimulated CD4+ and CD8+ T cells that produced IL-17 (Th17 and Tc17) was found in the BM of PGF patients than in the BM of GGF patients and HD, whereas the percentages of Tregs in PGF patients were comparable to those in GGF patients and HD, resulting in a dramatically elevated ratio of Th17 cells/Tregs in the BM of PGF patients relative to those in GGF patients.	Prostaglandins F	138-141	interleukin 17A	Homo sapiens	93-98
27714313-5	2017	There are several shared effects of vitamin D and UVR on T cells including inhibition of proliferation and suppression of IFN-gamma and IL-17 producing T cells.	Vitamin D	36-45	interleukin 17A	Homo sapiens	136-141
28292332-5	2017	RESULTS: A significantly higher proportion of stimulated CD4+ and CD8+ T cells that produced IL-17 (Th17 and Tc17) was found in the BM of PGF patients than in the BM of GGF patients and HD, whereas the percentages of Tregs in PGF patients were comparable to those in GGF patients and HD, resulting in a dramatically elevated ratio of Th17 cells/Tregs in the BM of PGF patients relative to those in GGF patients.	Prostaglandins F	226-229	interleukin 17A	Homo sapiens	93-98
28292332-5	2017	RESULTS: A significantly higher proportion of stimulated CD4+ and CD8+ T cells that produced IL-17 (Th17 and Tc17) was found in the BM of PGF patients than in the BM of GGF patients and HD, whereas the percentages of Tregs in PGF patients were comparable to those in GGF patients and HD, resulting in a dramatically elevated ratio of Th17 cells/Tregs in the BM of PGF patients relative to those in GGF patients.	Prostaglandins F	226-229	interleukin 17A	Homo sapiens	93-98
27998025-2	2017	The aim of this work is to To assess the efficacy of trichloroacetic acid (TCA) chemical peel, dermapen, and fractional CO2 laser in treatment of stable non-segmental vitiligo and to detect their effects on IL-17 and MMP-9 levels.	Trichloroacetic Acid	75-78	interleukin 17A	Homo sapiens	207-212
28278264-9	2017	The IND group presented substantially higher levels of IL-17A, median of 26.16 (3.66-48.33) as compared to both the CARD group, median of 13.89 (3.87-34.54) (P &lt;0.0001), and the NI group, median of 10.78 (6.23-22.26) (P &lt;0.0001).	indole	4-7	interleukin 17A	Homo sapiens	55-61
28278264-10	2017	The data analysis demonstrated that the IND group comprises a significantly greater proportion (P &lt;0.001) of high IL-17A producers (52.6%, 50 of 95 subjects) than do the other groups.	indole	40-43	interleukin 17A	Homo sapiens	117-123
28450958-0	2017	Upregulation of OLR1 and IL17A genes and their association with blood glucose and lipid levels in femoropopliteal artery disease.	Glucose	70-77	interleukin 17A	Homo sapiens	25-30
27765615-0	2017	Everolimus restrains the IL-17A-dependent osteoclast-like transdifferentiation of dendritic cells in multiple myeloma.	Everolimus	0-10	interleukin 17A	Homo sapiens	25-31
28184939-0	2017	Interleukin-17A promotes esophageal adenocarcinoma cell invasiveness through ROS-dependent, NF-kappaB-mediated MMP-2/9 activation.	Reactive Oxygen Species	77-80	interleukin 17A	Homo sapiens	0-15
28143790-10	2017	IL17A-152 G/A polymorphism was associated with an enhanced response to biologic and MTX treatment.	Methotrexate	84-87	interleukin 17A	Homo sapiens	0-5
28184939-5	2017	The effect of IL-17A on cell proliferation was measured by MTT assay.	monooxyethylene trimethylolpropane tristearate	59-62	interleukin 17A	Homo sapiens	14-20
28184939-10	2017	Furthermore, IL-17A treatment significantly upregulated the expression of MMP-2 and MMP-9, stimulated intracellular ROS production, increased IkappaB-alpha phosphorylation and NF-kappaB nuclear translocation.	Reactive Oxygen Species	116-119	interleukin 17A	Homo sapiens	13-19
28184939-11	2017	Nevertheless, IL-17A-induced expression of MMP-2/9 and OE19 cell invasiveness were both inhibited by pretreatment with N-acetyl-L-cysteine (NAC, a ROS scavenger) or pyrrolidine dithiocarbamate (PDTC, a NF-kappaB inhibitor).	Reactive Oxygen Species	147-150	interleukin 17A	Homo sapiens	14-20
28184939-11	2017	Nevertheless, IL-17A-induced expression of MMP-2/9 and OE19 cell invasiveness were both inhibited by pretreatment with N-acetyl-L-cysteine (NAC, a ROS scavenger) or pyrrolidine dithiocarbamate (PDTC, a NF-kappaB inhibitor).	pyrrolidine dithiocarbamic acid	165-192	interleukin 17A	Homo sapiens	14-20
28184939-11	2017	Nevertheless, IL-17A-induced expression of MMP-2/9 and OE19 cell invasiveness were both inhibited by pretreatment with N-acetyl-L-cysteine (NAC, a ROS scavenger) or pyrrolidine dithiocarbamate (PDTC, a NF-kappaB inhibitor).	pyrrolidine dithiocarbamic acid	194-198	interleukin 17A	Homo sapiens	14-20
28184939-12	2017	In conclusion, these findings demonstrate that IL-17A can promote the migration and invasiveness of EAC cells through ROS/NF-kappaB/MMP-2/9 signaling pathway activation, indicating that IL-17A may be a potential therapeutic target for EAC.	Reactive Oxygen Species	118-121	interleukin 17A	Homo sapiens	47-53
28184939-12	2017	In conclusion, these findings demonstrate that IL-17A can promote the migration and invasiveness of EAC cells through ROS/NF-kappaB/MMP-2/9 signaling pathway activation, indicating that IL-17A may be a potential therapeutic target for EAC.	Reactive Oxygen Species	118-121	interleukin 17A	Homo sapiens	186-192
28650331-8	2017	Th17 cells, CD4+ CD25+ Foxp3+ cells and their secretory proteins IL-17, TGF-beta and transcription factors were significantly increased in AL patients.	Aluminum	139-141	interleukin 17A	Homo sapiens	65-70
28077599-4	2017	Interestingly, BLT1 blockade with its specific antagonist U75302 in the acute injury phase (days 0-10 after BLM treatment) significantly attenuated lung fibrosis, which was accompanied by significant decreases in early infiltrating neutrophils and later infiltrating CD4+ T cells and the production of TGF-beta, IL-13, and IL-17A.	U 75302	58-64	interleukin 17A	Homo sapiens	323-329
28231856-12	2017	After fingolimod, slanDCs demonstrated reduced potential to induce interferon-gamma-expressing Th1 or IL-17-expressing Th17 cells and DC-dependent T cell proliferation in vitro and in fingolimod-treated patients.	slandcs	18-25	interleukin 17A	Homo sapiens	102-107
28337387-11	2017	IL-21 levels (44.46 +- 17.27 pg/ml) decreased with the severity of anemia (P &lt; 0.05), whereas IL-17 levels increased in children with SMA (12.25 +- 1.25 pg/ml) than in those with mild malaria anemia (MMA: 6.2 +- 5.25 pg/ml, P = 0.002).	sma	137-140	interleukin 17A	Homo sapiens	97-102
28229025-10	2017	IL17A, RORA and RORC mRNA expression was significantly increased in Th17 cells induced by the cytokine cocktail, and the induction was significantly inhibited by addition of rIL-35 (1 ng/mL).	ril-35	174-180	interleukin 17A	Homo sapiens	0-5
27995384-6	2017	In cross-sectional analyses, when tested for multiple comparison setting, a false discovery rate at 10%, a common pattern of correlations between CEUS Peak, AUC (BVI) and MTT parameters with the IL17A-F+IL23+ - IL17A-F+CD161+ - and IL17A-F+CD161+IL23+ CD4+ T cells subsets, as well as lack of correlation between both peak and AUC values and both CD4+T and CD4+IL23+ T cells, was observed.	monooxyethylene trimethylolpropane tristearate	171-174	interleukin 17A	Homo sapiens	195-200
28166724-10	2017	Concentration of IL-17 correlated with the disease activity score (DAS)-28, IL-6 and anti-LPS IgA levels.	lps	90-93	interleukin 17A	Homo sapiens	17-22
28166724-12	2017	Conditioned media with SF containing IL-17 induced anti-LPS IgA production by SFMCs which was independent of IL-6 activity.	lps	56-59	interleukin 17A	Homo sapiens	37-42
28356957-3	2017	Furthermore, the expression of autophagy-related proteins was induced by IL-17/IL-17R and autophagy was shown to induce resistance to oxaliplatin in HCC.	Oxaliplatin	134-145	interleukin 17A	Homo sapiens	73-78
27423437-7	2017	The aim of this study was to evaluate the effect of vitamin D supplementation on FoxP3 expression and IL-17A-producing T cells, through FoxP3+/IL-17A ratio.	Vitamin D	52-61	interleukin 17A	Homo sapiens	102-108
27423437-7	2017	The aim of this study was to evaluate the effect of vitamin D supplementation on FoxP3 expression and IL-17A-producing T cells, through FoxP3+/IL-17A ratio.	Vitamin D	52-61	interleukin 17A	Homo sapiens	143-149
27423437-13	2017	The FoxP3+/IL-17A ratio in SLE patients after 6 months of vitamin D supplementation was higher than that in the baseline (p &lt; 0.001).	Vitamin D	58-67	interleukin 17A	Homo sapiens	11-17
28356957-0	2017	Autophagy impacts on oxaliplatin-induced hepatocarcinoma apoptosis via the IL-17/IL-17R-JAK2/STAT3 signaling pathway.	Oxaliplatin	21-32	interleukin 17A	Homo sapiens	75-80
28356957-2	2017	The present study demonstrated that oxaliplatin was able to increase the levels of IL-17/IL-17R in hepatocellular carcinoma (HCC) patients and cells lines, and that it had important roles in reducing the susceptibility of the cells to oxaliplatin-induced apoptosis.	Oxaliplatin	36-47	interleukin 17A	Homo sapiens	83-88
28095433-4	2017	BJ-3105, a 6-alkoxypyridin-3-ol analog, inhibited IFN-gamma and IL-17 production from polyclonal CD4+ T cells and ovalbumin (OVA)-specific CD4+ T cells which were activated by T cell receptor (TCR) engagement.	BJ-3105	0-7	interleukin 17A	Homo sapiens	64-69
28114998-9	2017	RESULTS: Significant higher levels of IL-17 were found in CSF of dogs with SRMA A compared with SRMA T, other neurological disorders and healthy dogs (p &lt; 0.0001).	srma a	75-81	interleukin 17A	Homo sapiens	38-43
28114998-9	2017	RESULTS: Significant higher levels of IL-17 were found in CSF of dogs with SRMA A compared with SRMA T, other neurological disorders and healthy dogs (p &lt; 0.0001).	srma t	96-102	interleukin 17A	Homo sapiens	38-43
28095433-4	2017	BJ-3105, a 6-alkoxypyridin-3-ol analog, inhibited IFN-gamma and IL-17 production from polyclonal CD4+ T cells and ovalbumin (OVA)-specific CD4+ T cells which were activated by T cell receptor (TCR) engagement.	6-alkoxypyridin-3-ol	11-31	interleukin 17A	Homo sapiens	64-69
28717429-9	2017	The IL-17 concentrations were significantly decreased in patients treated with interferon-beta (IFN-beta), methylprednisolone or both drugs as compared with untreated MS patients (P &lt; 0.050, P &lt; 0.020 and P &lt; 0.050, respectively).	Methylprednisolone	107-125	interleukin 17A	Homo sapiens	4-9
28102734-7	2017	Recent evidences indicate that FLS-dependent effector molecules (toll-like receptors, nodal effector molecules, hypoxia-inducible factor, and IL-17) have emerged as important mediators of RA.	CHEMBL1232769	31-34	interleukin 17A	Homo sapiens	142-147
27666819-12	2017	Finally, mannan from baker"s yeast caused PsA-like arthritis and Ps-like skin lesions that were blocked by IL-17 treatment.	Mannans	9-15	interleukin 17A	Homo sapiens	107-112
28954273-4	2017	OBJECTIVE: To evaluate a possible regulatory effect of vitamin D on IL-17 and their relation to disease activity in vitiligo.	Vitamin D	55-64	interleukin 17A	Homo sapiens	68-73
27931518-0	2017	Vitamin C enhances the expression of IL17 in a Jmjd2-dependent manner.	Ascorbic Acid	0-9	interleukin 17A	Homo sapiens	37-41
27931518-3	2017	Here, we show that the expression of interleukin-17A (IL17) increases with the treatment of vitamin C but not with other antioxidants.	Ascorbic Acid	92-101	interleukin 17A	Homo sapiens	37-52
27931518-3	2017	Here, we show that the expression of interleukin-17A (IL17) increases with the treatment of vitamin C but not with other antioxidants.	Ascorbic Acid	92-101	interleukin 17A	Homo sapiens	54-58
27931518-5	2017	Rather, vitamin C reduced the trimethylation of histone H3 lysine 9 (H3K9me3) in the regulatory elements of the Il17 locus, and the effects of vitamin C were abrogated by knockdown of jumonji-C domain-containing protein 2 (jmjd2).	Ascorbic Acid	8-17	interleukin 17A	Homo sapiens	112-116
27931518-5	2017	Rather, vitamin C reduced the trimethylation of histone H3 lysine 9 (H3K9me3) in the regulatory elements of the Il17 locus, and the effects of vitamin C were abrogated by knockdown of jumonji-C domain-containing protein 2 (jmjd2).	Ascorbic Acid	143-152	interleukin 17A	Homo sapiens	112-116
27931518-6	2017	These results suggest that vitamin C can affect the expression of IL17 by modulating the histone demethylase activity.	Ascorbic Acid	27-36	interleukin 17A	Homo sapiens	66-70
28954273-7	2017	Multivariable regression was performed to evaluate the relationship between IL-17 and vitamin D levels with the demographic data on the patients, revealing a nonsignificant relationship (p &gt; 0.05).	Vitamin D	86-95	interleukin 17A	Homo sapiens	76-81
29120580-5	2017	IL17a serum level was significantly elevated in cirrhotic HCV infected patients who were positive for ICA than negative ICA (P &lt; 0.0001) and was significantly higher in type 2 diabetic than both non-diabetic patients (P=0.04) and controls (P=0.0005).	isocyanic acid	102-105	interleukin 17A	Homo sapiens	0-5
29120580-5	2017	IL17a serum level was significantly elevated in cirrhotic HCV infected patients who were positive for ICA than negative ICA (P &lt; 0.0001) and was significantly higher in type 2 diabetic than both non-diabetic patients (P=0.04) and controls (P=0.0005).	isocyanic acid	120-123	interleukin 17A	Homo sapiens	0-5
28707594-6	2017	Instead, this metal dramatically reduced production of IL-17 which was restored by the supplementation of polyphenols.	Metals	14-19	interleukin 17A	Homo sapiens	55-60
27883186-6	2017	Furthermore, lactate promotes the switch of CD4+ T cells to an IL-17+ subset, and reduces the cytolytic capacity of CD8+ T cells.	Lactic Acid	13-20	interleukin 17A	Homo sapiens	63-68
28707594-6	2017	Instead, this metal dramatically reduced production of IL-17 which was restored by the supplementation of polyphenols.	Polyphenols	106-117	interleukin 17A	Homo sapiens	55-60
27777066-11	2017	Topical application of psoralen liposomal gels on imiquimod induced psoriatic plaque model reduced the symptoms of psoriasis and levels of key psoriatic cytokines such as tumor necrosis factor-alpha, IL-17 and IL-22.	Ficusin	23-31	interleukin 17A	Homo sapiens	200-205
28165543-10	2017	The Th17 cell proportion and the level of IL-17 after treatment of the entecavir group were lower than those before treatment.	entecavir	71-80	interleukin 17A	Homo sapiens	42-47
27622920-6	2017	In this paper, we illustrate that treatment of human colon adenocarcinoma cells with TNF-alpha and IL-17, two pro-inflammatory cytokines, modifies LDH activity, causing a shift toward the A isoform which results in increased lactate production.	Lactic Acid	225-232	interleukin 17A	Homo sapiens	99-104
28165543-13	2017	It does not increase liver injury and the antiviral effects of entecavir may be related to inhibition of the expression of Th17 cells and effector molecules IL-17.	entecavir	63-72	interleukin 17A	Homo sapiens	157-162
27817918-11	2017	Basal tear levels of the proinflammatory cytokine interleukin 17A were significantly reduced in the krill oil group, compared with placebo, at day 90 (-27.1+-10.9 vs. 46.5+-30.4 pg/ml; P = 0.02).	krill oil	100-109	interleukin 17A	Homo sapiens	50-65
27817918-13	2017	Omega-3 EFAs in a predominantly phospholipid form (krill oil) may confer additional therapeutic benefit, with improvements in DED symptoms and lower basal tear levels of interleukin 17A, relative to placebo.	omega-3 efas	0-12	interleukin 17A	Homo sapiens	170-185
27817918-13	2017	Omega-3 EFAs in a predominantly phospholipid form (krill oil) may confer additional therapeutic benefit, with improvements in DED symptoms and lower basal tear levels of interleukin 17A, relative to placebo.	krill oil	51-60	interleukin 17A	Homo sapiens	170-185
27989874-9	2016	RESULTS: Ingestion of DT suppressed CD4+ T cell expression of IL-1beta and Il-8 (p&lt;0.05) and up-regulated the expression of IL-10 and the Treg/IL-17 ratio (p&lt;0.05) which was not shown in PL.	Thymidine	22-24	interleukin 17A	Homo sapiens	146-151
28514405-13	2017	In the patients who failed to achieve ASAS partial remission, the baseline and final serum concentrations of IL-17A were higher than in those who achieved the remission.	Aspirin	38-42	interleukin 17A	Homo sapiens	109-115
28090315-7	2016	Four genetic etiologies, AR IL-17 receptor A, IL-17 receptor C and ACT1 deficiencies, and AD IL-17F deficiency, are reported to underlie CMCD.	cmcd	137-141	interleukin 17A	Homo sapiens	28-33
27964715-13	2016	In the same way, PA reduced IL6, IFN-gamma, TNF-alpha and IL17A production in both concentration and IL2 only at 50 muM (in the presence of ConA).	palmitoleic acid	17-19	interleukin 17A	Homo sapiens	58-63
27590238-12	2016	BAY11-7082 and salubrinal significantly suppressed IL-17-driven intervertebral disc degeneration.	3-(4-methylphenylsulfonyl)-2-propenenitrile	0-10	interleukin 17A	Homo sapiens	51-56
27590238-12	2016	BAY11-7082 and salubrinal significantly suppressed IL-17-driven intervertebral disc degeneration.	salubrinal	15-25	interleukin 17A	Homo sapiens	51-56
27590238-0	2016	Salubrinal Suppresses IL-17-Induced Upregulation of MMP-13 and Extracellular Matrix Degradation Through the NF-kB Pathway in Human Nucleus Pulposus Cells.	salubrinal	0-10	interleukin 17A	Homo sapiens	22-27
27590238-3	2016	We then examined whether salubrinal, a known inhibitor of eIF2alpha dephosphorylation, inhibited the IL-17-induced changes mentioned above.	salubrinal	25-35	interleukin 17A	Homo sapiens	101-106
27590238-9	2016	Moreover, we employed salubrinal and a specific inhibitor of NF-kB (BAY11-7082) to evaluate their effects on IL-17-driven regulation of MMP-13 and the ECM, as well as on the activation of NF-kB.	salubrinal	22-32	interleukin 17A	Homo sapiens	109-114
27590238-9	2016	Moreover, we employed salubrinal and a specific inhibitor of NF-kB (BAY11-7082) to evaluate their effects on IL-17-driven regulation of MMP-13 and the ECM, as well as on the activation of NF-kB.	3-(4-methylphenylsulfonyl)-2-propenenitrile	68-78	interleukin 17A	Homo sapiens	109-114
28322833-2	2017	Here, we present fluorescence molecular tomography (FMT) data regarding the reversion of third generation co-cultured U87+DBTRG and patient-derived GBM tumor model after treatment with novel IL17A inhibitor named FLVM and FLVZ (organic derivatives of caffeic acid).	caffeic acid	251-263	interleukin 17A	Homo sapiens	191-196